U.S. patent application number 10/295833 was filed with the patent office on 2003-10-02 for kinase inhibitors.
Invention is credited to Abrams, Jason N., Diebold, Robert, Dinges, Jurgen, Fischer, John P., Gandhi, Virajkumar, Giranda, Vincent L., Gong, Jianchun, Hutchins, Charles, Li, Qun, Li, Tongmei, Packard, Garrick K., Rosenberg, Saul H., Song, Xiaohong, Stoll, Vincent S., Thomas, Sheela A., Woods, Keith W., Zhu, Gui-Dong.
Application Number | 20030187026 10/295833 |
Document ID | / |
Family ID | 29554492 |
Filed Date | 2003-10-02 |
United States Patent
Application |
20030187026 |
Kind Code |
A1 |
Li, Qun ; et al. |
October 2, 2003 |
Kinase inhibitors
Abstract
Compounds having the formula 1 are useful for inhibiting protein
kinases. Also disclosed are compositions which inhibit protein
kinases and methods of inhibiting protein kinases in a patient.
Inventors: |
Li, Qun; (Libertyville,
IL) ; Woods, Keith W.; (Libertyville, IL) ;
Zhu, Gui-Dong; (Gurnee, IL) ; Fischer, John P.;
(Longmont, CO) ; Gong, Jianchun; (Deerfield,
IL) ; Li, Tongmei; (Waukegan, IL) ; Gandhi,
Virajkumar; (Park City, IL) ; Thomas, Sheela A.;
(Libertyville, IL) ; Packard, Garrick K.; (San
Diego, CA) ; Song, Xiaohong; (Park City, IL) ;
Abrams, Jason N.; (Des Plaines, IL) ; Diebold,
Robert; (Waukegan, IL) ; Dinges, Jurgen;
(Grayslake, IL) ; Hutchins, Charles; (Green Oaks,
IL) ; Stoll, Vincent S.; (Libertyville, IL) ;
Rosenberg, Saul H.; (Grayslake, IL) ; Giranda,
Vincent L.; (Gurnee, IL) |
Correspondence
Address: |
STEVEN F. WEINSTOCK
ABBOTT LABORATORIES
100 ABBOTT PARK ROAD
DEPT. 377/AP6A
ABBOTT PARK
IL
60064-6008
US
|
Family ID: |
29554492 |
Appl. No.: |
10/295833 |
Filed: |
November 18, 2002 |
Related U.S. Patent Documents
|
|
|
|
|
|
Application
Number |
Filing Date |
Patent Number |
|
|
10295833 |
Nov 18, 2002 |
|
|
|
10023363 |
Dec 13, 2001 |
|
|
|
Current U.S.
Class: |
514/332 ;
514/252.03; 514/255.05; 514/275; 514/333; 544/238; 544/333;
544/405; 546/255; 546/256 |
Current CPC
Class: |
C07D 401/12 20130101;
C07D 403/14 20130101; C07D 471/04 20130101; C07D 475/02 20130101;
C07D 401/04 20130101; C07D 409/14 20130101; C07D 213/63 20130101;
C07D 401/14 20130101 |
Class at
Publication: |
514/332 ;
514/333; 514/252.03; 514/255.05; 514/275; 546/255; 546/256;
544/238; 544/405; 544/333 |
International
Class: |
C07D 41/14; C07D 43/02;
A61K 031/444; A61K 031/506; A61K 031/501; A61K 031/497 |
Claims
What is claimed is:
1. A compound of formula (I) 101or a therapeutically acceptable
salt thereof, wherein X is selected from the group consisting of
C(R.sup.8) and N; wherein R.sup.8 is selected from the group
consisting of hydrogen, alkyl, amino, carboxy, cyano, halo,
hydroxy, and amido; X' is selected from the group consisting of C
and N; Y is selected from the group consisting of C and N; Y' is
selected from the group consisting of C(R.sup.9) and N; wherein
R.sup.9 is selected from the group consisting of hydrogen and
-L.sup.2-L.sup.3(R.sup.3)(R.sup.6); Z is selected from the group
consisting of C and N; provided that 0, 1, or 2 of X, X', Y, Y',
and Z are N; L.sup.1 is selected from the group consisting of a
bond, --O--, --NR.sup.5--, alkenyl, alkynyl, --C(O)--, --S--,
--S(O)--, --S(O).sub.2--, --S(O).sub.2N(R.sup.5)--,
--N(R.sup.5)S(O).sub.2--, --C(R.sup.12).sub.2--,
--C(R.sup.12).sub.2N(R.sup.5)--, --N(R.sup.5)C(O)--, and
--C(O)N(R.sup.5)--; wherein each group is drawn with its left end
attached to R.sup.1 and its right end attached to the aromatic
ring; L.sup.2 is selected from the group consisting of a bond,
--O--, --C(R.sup.12).sub.2--, --S--, --N(R.sup.5)--,
--N(R.sup.5)C(O)--, and --C(O)N(R.sup.5)--; L.sup.3 is selected
from the group consisting of a bond, alkylidene and alkylene,
wherein the alkylidene and the alkylene are optionally substituted
with one or two substituents independently selected from the group
consisting of alkoxy, amino, cyano, and hydroxy; R.sup.1 is
selected from the group consisting of aryl, heteroaryl, and
heterocycle; R.sup.2 and R.sup.4 are independently absent or
selected from the group consisting of hydrogen, alkenyl, alkyl,
alkynyl, amino, aryl, arylalkynyl, cyano, cyanoalkenyl, halo,
heteroaryl, heterocycle, hydroxyalkyl, and nitro; or R.sup.2 and
L.sup.1, together with the carbon atoms to which they are attached,
form a ring selected from the group consisting of aryl, heteroaryl,
and heterocycle; or R.sup.4 and L.sup.2, together with the carbon
atoms to which they are attached, form a ring selected from the
group consisting of aryl, heteroaryl, and heterocycle; provided
that when L.sup.3 is alkylidene, R.sup.4 and L.sup.2, together with
the carbon atoms to which they are attached, form a ring selected
from the group consisting of aryl, heteroaryl, and heterocycle;
R.sup.3 is absent or selected from the group consisting of
hydrogen, aryl, arylalkoxy, arylalkylamino, arylalkylthio, aryloxy,
arylthio, cycloalkyl, heteroaryl, heteroarylalkoxy, heteroaryloxy,
and heterocycle; R.sup.6 is selected from the group consisting of
hydrogen, aryl, arylalkoxy, arylalkylamino, arylalkylthio, aryloxy,
arylthio, cycloalkyl, heteroaryl, heteroarylalkoxy, heteroaryloxy,
and heterocycle; provided that when L.sup.1 and L.sup.2 are bonds,
at least one of R.sup.3 and R.sup.6 is other than hydrogen; R.sup.5
is selected from the group consisting of hydrogen, alkyl,
alkylcarbonyl, alkylsulfonyl, arylcarbonyl, arylsulfonyl, and
heteroarylsulfonyl; R.sup.7 is absent or selected from the group
consisting of hydrogen, alkyl, cyanoalkenyl, and
-L.sup.2-L.sup.3(R.sup.3)(R.sup.6); or R.sup.7 and L.sup.1,
together with the carbon atoms to which they are attached, form a
ring selected from the group consisting of aryl, heteroaryl, and
heterocycle; and each R.sup.12 is selected from the group
consisting of hydrogen, alkenyl, alkyl, alkynyl, amino, aryl,
cyano, halo, heteroaryl, heterocycle, and nitro.
2. A compound of formula (II) 102or a therapeutically acceptable
salt thereof, wherein L.sup.1 is selected from the group consisting
of a bond, --O--, --N(R.sup.5)--, alkenyl, alkynyl,
--N(R.sup.5)C(O)--, and --C(O)N(R.sup.5)--; L.sup.2 is selected
from the group consisting of a bond, --O--, --N(R.sup.5)--,
--N(R.sup.5)C(O)--, and --C(O)N(R.sup.5)--; L.sup.3 is selected
from the group consisting of a bond, alkylidene, and alkylene,
wherein the alkylidene and the alkylene are optionally substituted
with one or two substituents independently selected from the group
consisting of amino, cyano, and hydroxy; R.sup.1 is selected from
the group consisting of aryl, heteroaryl, and heterocycle; R.sup.2
and R.sup.4 are independently selected from the group consisting of
hydrogen, alkenyl, alkynyl, arylalkynyl, amino, cyano,
cyanoalkenyl, halo, hydroxyalkyl, and heteroaryl; wherein the
heteroaryl is selected from the group consisting of furyl,
pyrazinyl, thiazolyl, and thienyl; or R.sup.2 and L.sup.1, together
with the carbon atoms to which they are attached, form a ring
selected from the group consisting of dihydropyrrolyl, pyrazolyl,
and phenyl; or R.sup.4 and L.sup.2, together with the carbon atoms
to which they are attached, form a ring selected from the group
consisting of dihydropyrrolyl, phenyl, pyridinyl, and pyrrolyl;
wherein the ring can be optionally substituted with oxo; provided
that when L.sup.3 is alkylidene, R.sup.4 and L.sup.2, together with
the carbon atoms to which they are attached, form a ring selected
from the group consisting of dihydropyrrolyl, phenyl, pyridinyl,
and pyrrolyl; wherein the ring can be optionally substituted with
oxo; R.sup.3 is absent or selected from the group consisting of
hydrogen, aryl, arylalkoxy, arylalkylthio, aryloxy, arylthio,
cycloalkyl, heteroaryl, heteroarylalkoxy, heteroaryloxy, and
heterocycle; R.sup.6 are independently selected from the group
consisting of hydrogen, aryl, arylalkoxy, arylalkylthio, aryloxy,
arylthio, cycloalkyl, heteroaryl, and heteroarylalkoxy,
heteroaryloxy, and heterocycle; provided that when L.sup.1 and
L.sup.2 are bonds, at least one of R.sup.3 and R.sup.6 is other
than hydrogen; R.sup.5 is selected from the group consisting of
hydrogen, alkyl, alkylcarbonyl, alkylsulfonyl, arylcarbonyl,
arylsulfonyl, and heteroarylsulfonyl; and X is selected from the
group consisting of C(R.sup.8) and N; wherein R.sup.8 is selected
from the group consisting of hydrogen, amino, carboxy, cyano, and
halo.
3. A compound of formula (III) 103or a therapeutically acceptable
salt thereof, wherein L.sup.1 is selected from the group consisting
of a bond, --O--, --N(R.sup.5)--, alkenyl, alkynyl, and
--N(R.sup.5)C(O)--; L.sup.2 is selected from the group consisting
of a bond, --O--, --N(R.sup.5)--, --N(R.sup.5)C(O)--, and
--C(O)N(R.sup.5)--; L.sup.3 is alkylene, wherein the alkylene is
substituted with one or two substituents independently selected
from the group consisting of amino and hydroxy; R.sup.1 is selected
from the group consisting of aryl, heteroaryl, and heterocycle;
R.sup.2 and R.sup.4 are independently selected from the group
consisting of hydrogen and halo; R.sup.3 and R.sup.6 are
independently selected from the group consisting of hydrogen, aryl,
arylalkoxy, and heteroaryl; provided that when L.sup.1 and L.sup.2
are bonds, at least one of R.sup.3 and R.sup.6 is other than
hydrogen; and R.sup.5 is selected from the group consisting of
hydrogen and alkyl.
4. The compound according to claim 1 wherein L.sup.1 is
alkenyl.
5. The compound according to claim 4 wherein Y' is C(R.sup.9)
wherein R.sup.9 is -L.sup.2-L.sup.3(R.sup.3)(R.sup.6) and wherein
L.sup.2 is --O--.
6. The compound according to claim 5 selected from the group
consisting of
N,N-dimethyl-N-[2-({5-[(E)-2-pyridin-4-ylvinyl]pyridin-3-yl}oxy)ethyl]ami-
ne;
(1S)-2-(1H-indol-3-yl)-1-[({5-[(E)-2-pyridin-4-ylvinyl]pyridin-3-yl}ox-
y)methyl]ethylamine;
(1R)-2-(1H-indol-3-yl)-1-[({5-[(E)-2-pyridin-4-ylviny-
l]pyridin-3-yl}oxy)methyl]ethylamine;
1-(1H-indol-3-yl)-3-({5-[(E)-2-pyrid-
in-4-ylvinyl]pyridin-3-yl}oxy)propan-2-ol;
(1S)-2-(1-benzothien-3-yl)-1-[(-
{5-[(E)-2-pyridin-4-ylvinyl]pyridin-3-yl}oxy)methyl]ethylamine;
(1S)-2,2-diphenyl-1-[({5-[(E)-2-pyridin-4-ylvinyl]pyridin-3-yl}oxy)methyl-
]ethylamine;
(1S)-1-{4-[(2,6-dichlorobenzyl)oxy]benzyl}-2-({5-[(E)-2-pyrid-
in-4-ylvinyl]pyridin-3-yl}oxy)ethylamine;
(1S)-2-(benzyloxy)-1-[({5-[(E)-2-
-pyridin-4-ylvinyl]pyridin-3-yl}oxy)methyl]ethylamine;
N,N-dimethyl-N-[(1S,2S)-1-methyl-2-phenyl-2-({5-[(E)-2-pyridin-4-ylvinyl]-
pyridin-3-yl}oxy)ethyl]amine;
(1S)-2-(2-naphthyl)-1-[({5-[(E)-2-pyridin-4--
ylvinyl]pyridin-3-y]}oxy)methyl]ethylamine;
(1S)-2-({2-chloro-5-[(E)-2-pyr-
idin-4-ylvinyl]pyridin-3-yl}oxy)-1-(1H-indol-3-ylmethyl)ethylamine;
(1S)-2-({6-chloro-5-[(E)-2-pyridin-4-ylvinyl]pyridin-3-yl}oxy)-1-(1H-indo-
l-3-ylmethyl)ethylamine;
(1S)-2-(1H-indol-3-yl)-1-[({5-[(Z)-2-pyridin-4-yl-
vinyl]pyridin-3-yl}oxy)methyl]ethylamine; and
N-[(2E)-3-(4-bromophenyl)pro-
p-2-enyl]-N-[2-({5-[(E)-2-pyridin-4-ylvinyl]pyridin-3-yl}oxy)ethyl]amine.
7. The compound according to claim 4 wherein Y' is C(R.sup.9)
wherein R.sup.9 is -L.sup.2-L.sup.3(R.sup.3)(R.sup.6) and whereein
L.sup.2 is selected from the group consisting of a bond,
--N(R.sup.5)--, --N(R.sup.5)C(O)--, and --C(O)N(R.sup.5)--.
8. The compound according to claim 7 selected from the group
consisting of
N-[(2S)-2-amino-3-(1H-indol-3-yl)propyl]-N-{5-[(E)-2-pyridin-4-ylvinyl]py-
ridin-3-yl}amine;
(2S)-2-amino-4-phenyl-N-{5-[(E)-2-pyridin-4-ylvinyl]pyri-
din-3-yl}butanamide;
N-(aminomethyl)-5-[(E)-2-pyridin-4-ylvinyl]nicotinami- de; and
(1R)-3-{6-chloro-5-[(E)-2-pyridin-4-ylvinyl]pyridin-3-yl}-1-(1H-in-
dol-3-ylmethyl)propylamine.
9. The compound according to claim 1 wherein L.sup.1 is a bond.
10. The compound according to claim 9 wherein Y' is C(R.sup.9)
wherein R.sup.9 is -L.sup.2-L.sup.3(R.sup.3)(R.sup.6) and wherein
L.sup.2 is --O--.
11. The compound according to claim 10 selected from the group
consisting of
4-(5-{[(2S)-2-amino-3-(1H-indol-3-yl)propyl]oxy}pyridin-3-yl)benzonitr-
ile;
(1S)-2-(1H-indol-3-yl)-1-{[(5-isoquinolin-6-ylpyridin-3-yl)oxy]methyl-
}ethylamine;
(1R)-2-(1H-indol-3-yl)-1-{[(5-quinolin-6-ylpyridin-3-yl)oxy]m-
ethyl}ethylamine;
(1S)-2-[(6-chloro-5-isoquinolin-6-ylpyridin-3-yl)oxy]-1--
(1H-indol-3-ylmethyl)ethylamine;
(1S)-2-[(2-chloro-5-isoquinolin-6-ylpyrid-
in-3-yl)oxy]-1-(1H-indol-3-ylmethyl)ethylamine;
5-(5-{[(2S)-2-amino-3-(1H--
indol-3-yl)propyl]oxy}pyridin-3-yl)-1H-isoindole-1,3(2H)-dione;
5-(5-{[(2S)-2-amino-3-(1H-indol-3-yl)propyl]oxy}pyridin-3-yl)isoindolin-1-
-one;
(1S)-2-[(5-cinnolin-6-ylpyridin-3-yl)oxy]-1-(1H-indol-3-ylmethyl)eth-
ylamine;
(1S)-2-{[5-(1H-indazol-5-yl)pyridin-3-yl]oxy}-1-(1H-indol-3-ylmet-
hyl)ethylamine;
5-(5-{[(2S)-2-amino-3-(1H-indol-3-yl)propyl]oxy}pyridin-3--
yl)-1,3-dihydro-2H-indol-2-one;
(1S)-2-{[5-(2,1,3-benzoxadiazol-5-yl)pyrid-
in-3-yl]oxy}-1-(1H-indol-3-ylmethyl)ethylamine;
(1S)-2-(1H-indol-3-yl)-1-{-
[(5-thieno[2,3-c]pyridin-2-ylpyridin-3-yl)oxy]methyl}ethylamine;
(3Z)-5-(5-{[(2S)-2-amino-3-(1H-indol-3-yl)propyl]oxy}pyridin-3-yl)-3-(1H--
pyrrol-2-ylmethylene)-1,3-dihydro-2H-indol-2-one; and
6-(5-{[(2R)-2-amino-3-(1H-indol-3-yl)propyl]oxy}pyridin-3-yl)-1,3-benzoth-
iazol-2(3H)-one.
12. The compound according to claim 9 wherein Y' is C(R.sup.9)
wherein R.sup.9 is -L.sup.2-L.sup.3(R.sup.3)(R.sup.6) and wherein
L.sup.2 is selected from the group consisting of a bond,
--N(R.sup.5)C(O)--, and --N(R.sup.5)--.
13. The compound according to claim 12 selected from the group
consisting of
(2S)-2-amino-3-(1H-indol-3-yl)-N-[5-(1,6-naphthyridin-2-yl)pyridin-3-y-
l]propanamide;
N-[(2S)-2-amino-3-(1H-indol-3-yl)propyl]-N-[5-(1,6-naphthyr-
idin-2-yl)pyridin-3-yl]amine;
(1R)-1-(1H-indol-3-ylmethyl)-3-(5-isoquinoli-
n-6-ylpyridin-3-yl)propylamine;
2-(1H-indol-3-yl)-2-(5-isoquinolin-6-ylpyr- idin-3-yl)ethanamine;
and 2-(1H-indol-3-yl)-3-(5-isoquinolin-6-ylpyridin-3-
-yl)propan-1-amine.
14. The compound according to claim 9 wherein Y' is C(R.sup.9)
wherein R.sup.9 is -L.sup.2-L.sup.3(R.sup.3)(R.sup.6) and wherein
L.sup.2 and R.sup.4, together with the atoms to which they are
attached, form a heterocycle ring.
15. The compound according to claim 14 which is
(3Z)-3-[(2S)-2-amino-3-(1H-
-indol-3-yl)propylidene]-5-isoquinolin-6-yl-1,3-dihydro-2H-pyrrolo[2,3-b]p-
yridin-2-one.
16. The compound according to claim 1 wherein L.sup.1 is selected
from the group consisting of alkynyl, --N(R.sup.5)C(O)--,
--N(R.sup.5)--, and --O--.
17. The compound according to claim 16 selected from the group
consisting of
(1S)-2-(1H-indol-3-yl)-1-({[5-(pyridin-4-ylethynyl)pyridin-3-yl]oxy}me-
thyl)ethylamine;
5-{[(2S)-2-amino-3-(1H-indol-3-yl)propyl]oxy}-N-pyridin-4-
-ylnicotinamide;
N.sup.4-(3-{[(2S)-2-amino-3-(1H-indol-3-yl)propyl]oxy}phe-
nyl)pyrimidine-2,4-diamine;
N-[(2S)-2-amino-3-(1H-indol-3-yl)propyl]-N'-is-
oquinolin-5-ylpyridine-3,5-diamine; and
N-[(2S)-2-amino-3-(1H-indol-3-yl)p-
ropyl]-N-[5-(isoquinolin-5-yloxy)pyridin-3-yl]amine.
18. The compound according to claim 1 wherein L.sup.1 and R.sup.2,
together with the atoms to which they are attached, form an aryl
ring.
19. The compound according to claim 18 which is
(1S)-2-(1H-indol-3-yl)-1-{-
[(6-pyridin-4-ylquinolin-3-yl)oxy]methyl}ethylamine.
20. The compound according to claim 1 selected from the group
consisting of 3-Butoxyl-5-[2-(4-pyridinyl)vinyl]pyridine;
3-Methoxyl-5-[2-(4-pyridin- yl)vinyl]pyridine;
S-3-[2-Amino-3-phenyl-propyloxyl]-5-[2-(4-pyridinyl)vin-
yl]pyridine hydrochloride;
3-[2-(1H-3-Indolyl)-ethoxyl]-5-[2-(4-pyridinyl)- vinyl]pyridine
hydrochloride; 3-[2-(1H-3-Indolyl)-propyloxyl]-5-[2-(4-pyri-
dinyl)vinyl]pyridine;
S-3-[2-Amino-3-(4-benzyloxylphenyl)-propyloxyl]-5-[2-
-(4-pyridinyl)vinyl]pyridine hydrochloride;
3-(Piperidin-4-yl)-5-[2-(4-pyr- idinyl)vinyl]pyridine;
R-3-{2-Amino-3-benzyloxypropyloxyl}-5-[2-(4-pyridin-
yl)vinyl]pyridine hydrochloride;
3-(1-Methyl-imidazole-4-methoxyl)-5-[2-(4-
-pyridinyl)vinyl]pyridine;
S-3-{2-Amino-3-[3-hydroxylphenyl]-propyloxyl}-5-
-[2-(4-pyridinyl)vinyl]pyridine trifluoroacetic acid salt;
S-3-{2-Amino-3-[3-cyanophenyl]-propyloxyl}-5-[2-(4-pyridinyl)vinyl]pyridi-
ne hydrochloride salt;
3-[-(4-Cyanobenzyl)-imidazole-4-methoxyl]-5-[2-(4-p-
yridinyl)vinyl]pyridine;
S-3-[2-Amino-3-(1-methyl-1H-3-indolyl)-propyloxyl-
]-5-[2-(4-pyridinyl)vinyl]pyridine hydrochloride salt;
S-3-[2-Dimethylamino-3-(1H-3-indolyl)-propyloxyl]-5-[2-(4-pyridinyl)vinyl-
]pyridine hydrochloride salt;
S-3-[2-Amino-3-(1-naphthyl)-propyloxyl]-5-[2-
-(4-pyridinyl)vinyl]pyridine hydrochloride salt;
3-(2-Aminoethoxyl)-5-[2-(- 4-pyridinyl)vinyl]pyridine
hydrochcloride salt; 3-(3-Aminopropyloxyl)-5-[2-
-(4-pyridinyl)vinyl]pyridine hydrochloride salt;
S-3-(2-Amino3-methylbutyl- oxyl)-5-[2-(4-pyridinyl)vinyl]pyridine
hydrochloride salt;
3-(i-Methyl-3-piperidinyloxyl)-5-[2-(4-pyridinyl)vinyl]pyridine
trifluoroacetic acid salt;
3-(2-Chlorobenzyl)-5-[2-(4-pyridinyl)vinyl]pyr- idine
trifluoroacetic acid salt;
3-(N-Benzyl-N-methylaminoethoxyl)-5-[2-(4-
-pyridinyl)vinyl]pyridine trifluoroacetic acid salt;
3-(6-(N,N-Dimathylamino)hexyloxyl)-5-[2-(4-pyridinyl)vinyl]pyridine
trifluoroacetic acid salt;
3-(2-Thiophenoxyl-ethoxyl)-5-[2-(4-pyridinyl)v- inyl]pyridine
trifluoroacetic acid salt; 3-(1-Methyl-3-pyrrolidinyloxyl)-5-
-[2-(4-pyridinyl)vinyl]pyridine trifluoroacetic acid salt;
3-[(1-Methyl-2-piperidinyl)methoxyl]-5-[2-(4-pyridinyl)vinyl]pyridine
trifluoroacetic acid salt;
3-(1-Pyridinyl-ethoxyl)-5-[2-(4-pyridinyl)viny- l]pyridine
trifluoroacetic acid salt; 4-{5-[(2S)-2-Amino-3-(1H-indol-3-yl)-
-propoxy]-pyridin-3-yl}-N-hydroxyl-benzamidine trifluoroacetic acid
salt;
4-{5-[(2S)-2-Amino-3-(1H-indol-3-yl)-propoxy]-pyridin-3-yl}-benzamidine
trifluoroacetic acid salt;
3-[(2S)-2-Amino-3-(1H-3-indolyl)-propyloxyl]-6-
-(3-pyridinyl)-quinoline;
3-[(2S)-2-Amino-3-(1H-3-indolyl)-propyloxyl]-6-(-
3-quinolinyl)-quinoline;
3-[(2S)-2-Amino-3-(1H-3-indolyl)-propyloxyl]-5-[2-
-(2-amino-4-pyridinyl)vinyl]pyridine trifluoroacetic acid salt;
5-[(2S)-2-(Amino-3-(1H-3-indolyl)-propyloxyl]-3-[2-(2-amino-4-pyridinyl)v-
inyl]-2-chloro-pyridine trifluoroacetic acid salt;
(1S)-1-(1H-Indol-3-ylme-
thyl)-2-(5-naphthalen-2-yl-pyridin-3-yloxy)-ethylamine;
(1S)-1-(1H-Indol-3-ylmethyl)-2-(5-isoquinolin-5-yl-pyridin-3-yloxy)-ethyl-
amine;
6-{5-[(2S)-2-Amino-3-(1H-indol-3-yl)-propoxy]-pyridin-3-yl}-2H-isoq-
uinolin-1-one;
(1S)-2-[5-(3-Chloro-isoquinolin-6-yl)-pyridin-3-yloxy]-1-(1-
H-indol-3-ylmethyl)-ethylamine;
(1S)-2-([3,4']Bipyridinyl-5-yloxy)-1-(1H-i-
ndol-3-ylmethyl)-ethylamine trifluoroacetic acid;
(1S)-1-(1H-Indol-3-ylmet-
hyl)-2-[5-(2-pyridin-2-yl-vinyl)-pyridin-3-yloxy]-ethylamine;
(1S)-1-(1H-Indol-3-ylmethyl)-2-(5-pyridin-3-ylethynyl-pyridin-3-yloxy)-et-
hylamine trifluoroacetic acid salt;
(1S)-2-[5-(2-Fluoro-pyridin-4-ylethyny-
l)-pyridin-3-yloxy]-1-(1H-indol-3-ylmethyl)-ethylamine
trifluoroacetic acid salt;
(1S)-4-{5-[2-Amino-3-(1H-indol-3-yl)-propoxy]-pyridin-3-ylethy-
nyl}-pyridin-2-ol trifluoroacetic acid salt;
(1S)-2-[6-Chloro-5-(1-chloro--
isoquinolin-6-yl)-pyridin-3-yloxy]-1-(1H-indol-3-ylmethyl)-ethylamine
trifluoroacetic acid salt;
Bis-[3-(4-Bromo-phenyl)-allyl]-{2-[5-(2-pyridi-
n-4-yl-vinyl)-pyridin-3-yloxy]-ethyl}-amine hydrochloride;
N.sup.4-[3-(2-Amino-ethoxy)-phenyl]-pyrimidine-2,4-diamine
hydrochloride;
trans-[4-(2-{5-[(2S)-2-Amino-3-(1H-indol-3-yl)-propylamino]-pyridin-3-yl}-
-vinyl)-pyrimidin-2-yl]-carbamic acid ethyl ester trifluoroacetic
acid salt;
1-Amino-6-{5-[(2S)-2-amino-3-(1H-indol-3-yl)-propoxy]-pyridin-3-yl}-
-isoquinoline trifluoroacetic acid salt;
6-{5-[(2S)-2-amino-3-(1H-indol-3--
yl)-propoxy]-pyridin-3-yl}-1-chloro-isoquinoline trifluoroacetic
acid salt;
(2S)-2-Amino-3-(1H-indol-3-yl)-N-[5-(2-pyridin-4-yl-vinyl)-pyridin--
3-yl]-propionamide;
(2S)-2-Amino-3-(naphtha-1-yl)-N-[5-(2-pyridin-4-yl-vin-
yl)-pyridin-3-yl]-propionamide hydrochloride;
(2S)-2-Amino-3-phenyl-N-[5-(-
2-pyridin-4-yl-vinyl)-pyridin-3-yl]-propionamide hydrochloride;
S-2-Amino-3-(imidazol-4-yl)-N-[5-(2-pyridin-4-yl-vinyl)-pyridin-3-yl]-pro-
pionamide hydrochloride;
(1R)-2-(1H-indol-3-yl)-1-{[(5-isoquinolin-6-ylpyr-
idin-3-yl)oxy]methyl}ethylamine;
(1S)-5-{5-[2-Amino-3-(1H-indol-3-yl)-prop-
oxy]-pyridin-3-yl}-1H-indazol-3-ylamine;
(1S)-6-{5-[2-Amino-3-(1H-indol-3--
yl)-propoxy]-pyridin-3-yl}-1H-indazol-3-ylamine;
2-Amino-N-[(1S)-1-(1H-ind-
ol-3-ylmethyl)-2-(5-isoquinolin-6-yl-pyridin-3-yloxy)-ethyl]-acetamide;
(2S)-2-Amino-N-[(S)-1-(1H-indol-3-ylmethyl)-2-(5-isoquinolin-6-yl-pyridin-
-3-yloxy)-ethyl]-propionamide;
2-Dimethylamino-N-[(1S)-1-(1H-indol-3-ylmet-
hyl)-2-(5-isoquinolin-6-yl-pyridin-3-yloxy)-ethyl]-acetamide;
(1S)-1-(1H-Indol-3-ylmethyl)-2-[5-(3-methyl-1H-indazol-5-yl)-pyridin-3-yl-
oxy]-ethylamine;
(1S)-1-(1H-Indol-3-ylmethyl)-2-{5-[3-(1H-pyrrol-2-yl)-1H--
indazol-5-yl]-pyridin-3-yloxy}-ethyl amine;
(1S)-1-(1H-Indol-3-ylmethyl)-2-
-[5-(3-phenyl-1H-indazol-5-yl)-pyridin-3-yloxy]-ethylamine;
(1S)-2-[5-(3-Cyclopropyl-1H-indazol-5-yl)-pyridin-3-yloxy]-1-(1H-indol-3--
ylmethyl)-ethyl amine;
(1S)-2-[5-(3-Ethyl-1H-indazol-5-yl)-pyridin-3-yloxy-
]-1-(1H-indol-3-ylmethyl)-ethylamine;
(1S)-1-(1H-Indol-3-ylmethyl)-2-{5-[3-
-(1-methyl-1H-imidazol-2-yl)-1H-indazol-5-yl]-pyridin-3-yloxy}-ethylamine;
(1S)-1-(1H-Indol-3-ylmethyl)-2-[5-(3-thiazol-2-yl-1H-indazol-5-yl)-pyridi-
n-3-yloxy]-ethylamine;
(1S)-2-{5-[3-(1H-Imidazol-2-yl)-1H-indazol-5-yl]-py-
ridin-3-yloxy}-1-(1H-indol-3-ylmethyl)-ethylamine;
(1S)-1-(1H-Indol-3-ylme-
thyl)-2-[5-(3-thiophen-2-yl-1H-indazol-5-yl)-pyridin-3-yloxy]-ethylamine;
(1S)-1-(1H-Indol-3-ylmethyl)-2-[5-(3-morpholin-4-yl-1H-indazol-5-yl)-pyri-
din-3-yloxy]-ethyl amine;
(1S)-2-[5-(1,3-Dimethyl-1H-indazol-5-yl)-pyridin-
-3-yloxy]-1-(1H-indol-3-ylmethyl)-ethylamine;
(1S)-1-(1H-Indol-3-ylmethyl)-
-2-[3-(3-methyl-1H-indazol-5-yl)-phenoxy]-ethylamine;
(1S)-1-(1H-Indol-3-ylmethyl)-2-{5-[3-(4-methyl-piperazin-1-yl)-1H-indazol-
-5-yl]-pyridin-3-yloxy}-ethylamine;
(1S)-(5-{5-[2-Amino-3-(1H-indol-3-yl)--
propoxy]-pyridin-3-yl}-1H-indazol-3-yl)-dimethyl-amine;
(1S)-(4-(5-(2-Amino-3-(1H-indol-3-yl)-propoxy)-pyridin-3-yl)-benzyl)-phen-
ylamine;
(1S)-(4-(5-(2-Amino-3-(1H-indol-3-yl)-propoxy)-pyridin-3-yl)-phen-
yl)-methanol;
(1S)-2-(5-(4-Fluoro-phenyl)-pyridin-3-yloxy)-1-(1H-indol-3-y-
lmethyl)-ethylamine;
(1S)-4-(5-(2-Amino-3-(1H-indol-3-yl)-propoxy)-pyridin-
-3-yl)-benzoic acid;
(1S)-2-(3-Bromo-5-isoquinolin-6-yl-phenoxyoxy)-1-(1H--
indol-3-ylmethyl)-ethylamine;
N4-(3-(5-(2-Amino-3-(1H-indol-3-yl)-propoxy)-
-pyridin-3-yl)-phenyl)-pyrimidine-2,4-diamine;
(1S)-3-(2-Amino-3-(1H-indol-
-3-yl)-propoxy)-5-isoquinolin-6-yl-phenylamine;
4-(5-Isoquinolin-6-yl-pyri- din-3-yl)-piperazine-1-carboxylic acid
tert-butyl ester; 6-(5-Piperazin-1-yl-pyridin-3-yl)-isoquinoline;
((2S)-2-Amino-5-(5-(2-ami-
no-3-(1H-indol-3-yl)-propoxy)-pyridin-3-yl)-phenyl-(3-chloro-phenyl-methan-
one;
(1S)-N-6-(3-(5-(2-Amino-3-(1H-indol-3-yl)-propoxy)-pyridin-3-yl)-phen-
yl)-9H-purine-2,6-diamine;
(3-(5-((2S)-2-Amino-3-(1H-indol-3-yl)-propoxy)--
pyridin-3-yl)-phenyl)-pyrimidin-2yl-amine;
(3-(5-((2S)-2-Amino-3-(1H-indol-
-3-yl)-propoxy)-pyridin-3-yl)-phenyl)-thiazol-2yl-amine;
N-(3-(5-((2S)-2-Amino-3-(1H-indol-3-yl)-propoxy)-pyridin-3-yl)-phenyl)-ac-
etamide;
6-(5-(4-(1H-Indol-3-ylmethyl)-piperazin-1-yl)-pyridin-3-yl)-isoqu-
inoline;
3-((2S)-2-Amino-3-(1H-indol-3-yl)-propoxy)-5-isoquinolin-6-yl-ben-
zoic acid;
4-(5-((2S)-2-Amino-3-(1H-indol-3-yl)-propoxy)-pyridin-3-yl)-phe-
nylamine;
N-(4-(5-((2S)-2-Amino-3-(1H-indol-3-yl)-propoxy)-pyridin-3-yl)-p-
henyl)-acetamide;
N6-(4-(5-((2S)-2-Amino-3-(1H-indol-3-yl)-propoxy)-pyridi-
n-3-yl)-phenyl)-9H-purine-2,6-diamine;
N4-(4-(5-((2S)-2-Amino-3-(1H-indol--
3-yl)-propoxy)-pyridin-3-yl)-phenyl)-pyrimidine-2,4-diamine;
(4-(5-((2S)-2-Amino-3-(1H-indol-3-yl)-propoxy)-pyridin-3-yl)-phenyl)-pyri-
midin-2-yl-amine;
3-((2S)-2-Amino-3-(1H-indol-3-yl)-propoxy)-5-isoquinolin-
-6-yl-benzonitrile;
5'-Benzyloxy-5-isoquinolin-6-yl-(3,3')bipyridinyl;
(7-(5-((2S)-2-Amino-3-(1H-indol-3-yl)-propoxy)-pyridin-3-yl)-pyrido(2,3-d-
)pyrimidin-4-yl)-phenyl-amine;
(7-(5-((2S)-2-Amino-3-(1H-indol-3-yl)-propo-
xy)-pyridin-3-yl)-pyrido(2,3-d)pyrimidin-4-yl)-ethyl-amine;
(7-(5-((2S)-2-Amino-3-(1H-indol-3-yl)-propoxy)-pyridin-3-yl)-pyrido(2,3-d-
)pyrimidin-4-yl)-benzyl-amine;
(1S)-1-(1H-Indol-3-ylmethyl)-2-(6-isoquinol-
in-6-yl-pyrazin-2-yloxy)-ethylamine;
(1S)-2-(5-isoquinolin-6-yl-pyridin-3-- yloxy)-1-phenyl-ethylamine;
(1S)-1-(1H-Indol-3-ylmethyl)-2-(6-(3-methyl-1H-
-indazol-5-yl)-pyrazin-2-yloxy)-ethylamine;
(1S)-1-Cyclohexylmethyl-2-(5-i-
soquinolin-6-yl-pyridin-3-yloxy)-ethylamine;
(1S)-1-Benzyl-2-(5-(3-methyl--
1H-indazol-5-yl)-pyridin-3-yloxy)-ethylamine;
(1S)-2-(5-(3-Methyl-1H-indaz-
ol-5-yl)-pyridin-3-yloxy)-1-phenyl-ethylamine;
(1S)-2-(5-(3-Methyl-1H-inda-
zol-5-yl)-pyridin-3-yloxy)-1-phenyl-ethylamine;
4-((2S)-2-Amino-3-(5-(3-me-
thyl-1H-indazol-5-yl)-pyridin-3-yloxy)propyl)-benzonitrile;
(1S)-2-(5-(3-Methyl-1H-indazol-5-yl)-pyridin-3-yloxy)-1-napthalen-2-ylmet-
hyl-ethylamine;
4-((2S)-2-Amino-3-(5-isoquinolin-6-yl-pyridin-3-yloxy-prop-
yl)-benzonitrile;
(1S)-2-(5-Isoquinolin-6-yl-pyridin-3-yloxy)-1-nanpthalen-
-2-ylmethyl)-ethylamine;
(1S)-1-Benzyl-2-(5-isoquinolin-6-yl-pyridin-3-ylo- xy)-ethylamine;
(1S)-1-(4-Fluoro-benzyl)-2-(5-(3-methyl-1H-indazol-5-yl)-p-
yridin-3-yloxy)-ethylamine;
(1S)-1-(4-Fluoro-benzyl)-2-(5-isoquinolin-6-yl-
-pyridin-3-yloxy)-ethylamine;
2-((2S)-2-Amino-3-(5-(3-methyl-1H-indazol-5--
yl)-pyridin-3-yloxy)-propyl)-benzonitrile;
2-((2S)-2-Amino-3-(5-isoquinoli-
n-6-yl)-pyridin-3-yloxy)-propyl)-benzonitrile; (1
s)-2-5-(3-methyl-1H-inda-
zol-5-yl)-pyridin-3-yloxy)-1-pyridin-4-ylmethyl-ethylamine;
(1S)-2-(5-Isoquinolin-6-yl-pyridin-3-yloxy)-1-pyridin-4-ylmethyl-ethylami-
ne;
(1S)-1-(4-Methyl-benzyl)-2-(5-(3-methyl-1H-indazol-5-yl)-pyridin-3-ylo-
xy)-ethylamine;
(1S)-2-(5-Isoquinolin-6-yl-pyridin-3-yloxy)-1-(4-methyl-be-
nzyl)-ethylamine;
(1S)-2-(5-(3-methyl-1H-indazol-5-yl)-pyridin-3-yloxy)-1--
quinolin-3-ylmethyl-ethylamine;
(1S)-2-(5-Isoquinolin-6-yl-pyridin-3-yloxy-
)-1-quinolin-3-ylmethyl-ethylamine;
(1R)-1-Benzyl-2-(5-(3-methyl-1H-indazo-
l-5-yl)-pyridin-3-yloxy)-ethylamine;
(1R)-1-Benzyl-2-(5-isoquinolin-6-yl-p- yridin-3-yloxy)-ethylamine;
4-((2S)-2-Amino-3-(5-(3-methyl-1H-indazol-5-yl-
)-pyridin-3-yloxy)-propyl)-phenol;
(1S)-1-(4-Benzyloxy-benzyl)-2-(5-(3-met-
hyl-1H-indazol-5-yl)-pyridin-3-yloxy)-ethylamine;
(1S)-1-(3-Methyl-benzyl)-
-2-(5-(3-methyl-1H-indazol-5-yl)-pyridin-3-yloxy)-ethylamine;
(1S)-1-(2-Methyl-benzyl)-2-(5-(3-methyl-1H-indazol-5-yl)-pyridin-3-yloxy)-
-ethylamine;
(1S)-2-(5-(3-methyl-1H-indazol-5-yl)-pyridin-3-yloxy)-1-(4-ni-
tro-benzyl)-ethylamine;
(1S)-1-(4-Methoxy-benzyl)-2-(5-(3-methyl-1H-indazo-
l-5-yl)-pyridin-3-yloxy)-ethylamine;
(1S)-1-Biphenyl-4-ylmethyl-2-(5-(3-me-
thyl-1H-indazol-5-yl)-pyridin-3-yloxy)-ethylamine;
(1S)-2-(5-(3-Methyl-1H--
indazol-5-yl)-pyridin-3-yloxy)-1-napthalen-1-ylmethyl-ethylamine;
(1S)-1-(3-Chloro-benzyl)-2-(5-(3-methyl-1H-indazol-5-yl)-pyridin-3-yloxy)-
-ethylamine;
3-((2S)-2-Amino-3-(5-(3-methyl-1H-indazol-5-yl)-pyridin-3-ylo-
xy)-propyl)-benzonitrile;
(1S)-1-(3,4-Difluoro-benzyl)-2-(5-(3-methyl-1H-i-
ndazol-5-yl)-pyridin-3-yloxy)-ethylamine;
(1S)-1-(3,4-Dimethoxy-benzyl)-2--
(5-(3-methyl-1H-indazol-5-yl)-pyridin-3-yloxy)-ethylamine;
(1S)-1-(3-Fluoro-benzyl)-2-(5-(3-methyl-1H-indazol-5-yl)-pyridin-3-yloxy)-
-ethylamine;
(1S)-2-(5-(3-methyl-1H-indazol-5-yl)-pyridin-3-yloxy)-1-(3-tr-
ifluoromethyl-benzyl)-ethylamine;
(1S)-1-(4-Ethoxy-benzyl)-2-[5-(3-methyl--
1H-indazol-5-yl)-pyridin-3-yloxy]-ethylamine;
(1S)-1-(4-tert-Butyl-benzyl)-
-2-(5-(3-methyl-1H-indazol-5-yl)-pyridin-3-yloxy)-ethylamine;
(1S)-1-(4-Methoxy-3-methyl-benzyl)-2-(5-(3-methyl-1H-indazol-5-yl)-pyridi-
n-3-yloxy)-ethylamine;
2-((2S)-2-Amino-3-(5-(3-methyl-1H-indazol-5-yl)-pyr-
idin-3-yloxy)-propyl)-4-methyl-phenol;
(1S)-1-Methyl-2-[5-(3-methyl-1H-ind-
azol-5-yl)-pyridin-3-yloxy]-ethylamine;
(.+-.)-1-(1H-Benzoimidazol-2-ylmet-
hyl)-2-(5-isoquinolin-6-yl-pyridin-3-yloxy)-ethylamine;
(.+-.)-1-(1H-Indazol-3-ylmethyl)-2-(5-isoquinolin-6-yl-pyridin-3-yloxy)-e-
thylamine;
(1S)-1-(2-Fluoro-benzyl)-2-[5-(3-methyl-1H-indazol-5-yl)-pyridi-
n-3-yloxy]-ethylamine;
(1S)-1-(2-Chloro-benzyl)-2-[5-(3-methyl-1H-indazol--
5-yl)-pyridin-3-yloxy]-ethylamine;
(1S)-2-[5-(3-Methyl-1H-indazol-5-yl)-py-
ridin-3-yloxy]-1-thiophen-2-ylmethyl-ethylamine;
(1R)-1-(1H-Indol-3-ylmeth-
yl)-2-[5-(3-methyl-1H-indazol-5-yl)-pyridin-3-yloxy]-ethylamine;
1-(4-Chloro-benzyl)-2-[5-(3-methyl-1H-indazol-5-yl)-pyridin-3-yloxy]-ethy-
lamine;
(1S)-2-[5-(3-Methyl-1H-indazol-5-yl)-pyridin-3-yloxy]-1-(4-pyrrol--
1-yl-benzyl)-ethylamine;
(1S)-1-(4-Methyl-benzylsulfanylmethyl)-2-[5-(3-me-
thyl-1H-indazol-5-yl)-pyridin-3-yloxy]-ethyl amine;
(1S)-2-[5-(3-Methyl-1H-indazol-5-yl)-pyridin-3-yloxy]-1-(2-trifluoromethy-
l-benzyl)-ethylamine;
(1R)-1-Benzyl-3-[5-(3-methyl-1H-indazol-5-yl)-pyridi-
n-3-yloxy]-propylamine;
(1R)-1-Benzyl-4-[5-(3-methyl-1H-indazol-5-yl)-pyri-
din-3-yloxy]-butylamine;
(1S)-1-[5-(3-Methyl-1H-indazol-5-yl)-pyridin-3-yl-
oxymethyl]-3-phenyl-propylamine;
(1S)-2-(5-Isoquinolin-6-yl-pyridin-3-ylox- y)-1-(1-methyl-I
1H-indol-3-ylmethyl)-ethylamine trifloroacetic acid salt;
(1S)-[1-(1H-Indol-3-ylmethyl)-2-(5-isoquinolin-6-yl-pyridin-3-yloxy)-ethy-
l]-dimethyl-amine;
(1S)-1-Benzo[b]thiophen-3-ylmethyl-2-[5-(3-methyl-1H-in-
dazol-5-yl)-pyridin-3-yloxy]-ethylamine;
(1S)-2-[5-(3-Methyl-1H-indazol-5--
yl)-pyridin-3-yloxy]-1-thiophen-3-ylmethyl-ethylamine;
(1S)-1-Benzyloxymethyl-2-(5-isoquinolin-6-yl-pyridin-3-yloxy)-ethylamine;
(1S)-1-Benzyloxymethyl-2-[5-(3-methyl-1H-indazol-5-yl)-pyridin-3-yloxy]-e-
thylamine;
(1S)-2-(5-Isoquinolin-6-yl-pyridin-3-yloxy)-1-(naphthalen-2-ylo-
xymethyl)-ethylamine;
(1S)-2-(5-Isoquinolin-6-yl-pyridin-3-yloxy)-1-(pyrid-
in-3-yloxymethyl)-ethylamine;
(1S)-2-(5-Isoquinolin-6-yl-pyridin-3-yloxy)--
1-(quinolin-7-yloxymethyl)-ethylamine;
(2S)-4-[2-Amino-3-(5-isoquinolin-6--
yl-pyridin-3-yloxy)-propoxy]-benzonitrile;
(2S)-N'-(5-(3-methyl-1H-indazol-
-5-yl)-pyridin-3-yl)-3-phenyl-propane-1,2-diamine;
(2S)-N-(2-Amino-3-pheny-
l-propyl)-N-[5-(3-methyl-1H-indazol-5-yl)-pyridin-3-yl]-methanesulfonamide-
;
(2S)-N-(2-Amino-3-phenyl-propyl)-N-[5-(3-methyl-1H-indazol-5-yl)-pyridin-
-3-yl]-benzenesulfonamide;
(2S)-N-(2-Amino-3-phenyl-propyl)-N-[5-(3-methyl-
-1H-indazol-5-yl)-pyridin-3-yl]-benzamide;
(2S)-N-(2-Amino-3-phenyl-propyl-
)-N-[5-(3-methyl-1H-indazol-5-yl)-pyridin-3-yl]-acetamide;
(2S)-3-[2-Amino-3-(1H-indol-3-yl)-propylidene]-5-isoquinolin-6-yl-1,3-dih-
ydro-indol-2-one;
(1S)-2-(5-Isoquinolin-6-yl-pyridin-3-yloxy)-1-(1-methyl--
1H-indol-3-ylmethyl)-ethylamine;
(1S)-1-(1H-Indol-3-ylmethyl)-2-[5-(1H-pyr-
rolo[2,3-b]pyridin-5-yl)-pyridin-3-yloxy]-ethylamine;
(1S)-2-{5-[2-(2-Fluoro-pyridin-4-yl)-vinyl]-pyridin-3-yloxy}-1-(1H-indol--
3-ylmethyl)-ethylamine;
(1S)-1-(1H-Indol-3-ylmethyl)-2-{5-[2-(2-methoxy-py-
ridin-4-yl)-vinyl]-pyridin-3-yloxy}-ethylamine;
(1S)-1-(1H-Indol-3-ylmethy-
l)-2-{5-[2-(2-phenoxy-pyridin-4-yl)-vinyl]-pyridin-3-yloxy}-ethylamine;
(1S)-2-{5-[2-(2-Benzylsulfanyl-pyridin-4-yl)-vinyl]-pyridin-3-yloxy}-1-(1-
H-indol-3-ylmethyl)-ethylamine;
[4-(2-{5-[(2S)-2-Amino-3-(1H-indol-3-yl)-p-
ropoxy]-pyridin-3-yl}-vinyl)-pyridin-2-yl]-cyclopropyl-amine;
[4-(2-{5-[(2S)-2-Amino-3-(1H-indol-3-yl)-propoxy]-pyridin-3-yl}-vinyl)-py-
ridin-2-yl]-benzyl-amine;
[4-(2-{5-[(2S)-2-Amino-3-(1H-indol-3-yl)-propoxy-
]-pyridin-3-yl}-vinyl)-pyridin-2-yl]-ethyl-amine;
[4-(2-{5-[(2S)-2-Amino-3-
-(1H-indol-3-yl)-propoxy]-pyridin-3-yl}-vinyl)-pyridin-2-yl]-methyl-amine;
(1S)-1-(1H-Indol-3-ylmethyl)-2-{5-[2-(2-indol-1-yl-pyridin-4-yl)-vinyl]-p-
yridin-3-yloxy}-ethylamine;
(.+-.)-2-[5-(3-Methyl-1H-indazol-5-yl)-pyridin-
-3-yloxy]-1-(2-methyl-1H-indol-3-ylmethyl)-ethylamine;
7-{5-[(2S)-2-Amino-3-(1H-indol-3-yl)-propoxy]-pyridin-3-yl}-quinazolin-2--
ylamine;
2-Phenyl-2-(3-pyridin-4-yl-1H-pyrazolo[3,4-b]pyridin-6-yl)-ethyla-
mine;
Naphthalen-2-yl-(3-pyridin-4-yl-1H-pyrazolo[3,4-b]pyridin-6-yl)-acet-
onitrile;
2-Naphthalen-2-yl-2-(3-pyridin-4-yl-1H-pyrazolo[3,4-b]pyridin-6--
yl)-ethylamine;
(3-Isoquinolin-6-yl-1H-pyrazolo[3,4-b]pyridin-6-yl)-phenyl-
-acetonitrile;
2-(3-Isoquinolin-6-yl-1H-pyrazolo[3,4-b]pyridin-6-yl)-2-phe-
nyl-ethylamine;
(1S)-1-Benzyl-2-(3-pyridin-4-yl-1H-pyrazolo[3,4-b]pyridin--
5-yloxy)-ethylamine;
2-Benzyl-3-[5-(3-methyl-1H-indazol-5-yl)-pyridin-3-yl-
oxy]-propylamine;
(1S)-1-(1H-Indol-3-ylmethyl)-2-(2-pyridin-4-yl-[1,7]naph-
thyridin-5-yloxy)-ethylamine;
(1R)-1-(1H-Indol-3-ylmethyl)-2-(2-pyridin-4--
yl-[1,7]naphthyridin-5-yloxy)-ethylamine;
(1S)-1-(1H-Indol-3-ylmethyl)-2-(-
5-isoquinolin-6-yl-pyridin-3-ylsulfanyl)-ethylamine;
(1S)-1-(1H-Indol-3-ylmethyl)-2-[5-(3-methyl-1H-indazol-5-yl)-pyridin-3-yl-
sulfanyl]-ethylamine;
(1S)-1-(4-Bromo-benzyl)-2-[5-(3-methyl-1H-indazol-5--
yl)-pyridin-3-yloxy]-ethylamine;
(1S)-1-(1H-Indol-3-ylmethyl)-2-[5-(2-meth-
yl-quinazolin-7-yl)-pyridin-3-yloxy]-ethylamine;
(1S)-1-(1H-Indol-3-ylmeth-
yl)-2-[5-(1H-indol-5-yl)-pyridin-3-yloxy]-ethylamine;
(1S)-1-(1H-Indol-3-ylmethyl)-2-{5-[4-(1H-tetrazol-5-yl)-phenyl]-pyridin-3-
-yloxy}-ethylamine;
(1S)-1-(1H-Indol-3-ylmethyl)-2-(5-isoquinolin-6-yl-pyr-
imidin-4-yloxy)-ethylamine;
(1S)-1-Benzyl-2-[3-(3-methyl-1H-indazol-5-yl)--
phenoxy]-ethylamine;
(1S)-1-Benzyl-2-[6-(3-methyl-1H-indazol-5-yl)-pyridin-
-2-yloxy]-ethylamine;
(1S)-2-[5-(3-Methyl-1H-indazol-5-yl)-pyridin-3-yloxy-
]-1-(4-thiophen-3-yl-benzyl)-ethylamine;
(1S)-1-(4-Iodo-benzyl)-2-[5-(3-me-
thyl-1H-indazol-5-yl)-pyridin-3-yloxy]-ethylamine;
[4-((2S)-2-Amino-3-phen-
yl-propoxy)-2-(3-methyl-1H-indazol-5-yl)-phenyl]-methanol;
(1S)-2-[5-(1H-Benzotriazol-5-yl)-pyridin-3-yloxy]-1-(1H-indol-3-ylmethyl)-
-ethylamine;
(1S)-2-[5-(1H-Benzotriazol-5-yl)-pyridin-3-yloxy]-1-benzyl-et-
hylamine;
(1S)-1-Benzyl-2-[5-(3-morpholin-4-yl-1H-indazol-5-yl)-pyridin-3--
yloxy]-ethylamine;
(1S)-1-Benzyl-2-{5-[3-(4-methyl-piperazin-1-yl)-1H-inda-
zol-5-yl]-pyridin-3-yloxy}-ethylamine;
(1S)-{5-[5-(2-Amino-3-phenyl-propox-
y)-pyridin-3-yl]-1H-indazol-3-yl}-dimethyl-amine;
(1S)-{5-[5-(2-Amino-3-ph-
enyl-propoxy)-pyridin-3-yl]-1H-indazol-3-yl}-(2-methoxy-ethyl)-amine;
{5-[5-((2S)-2-Amino-3-phenyl-propoxy)-pyridin-3-yl]-1H-indazol-3-yl}-(2-m-
orpholin-4-yl-ethyl)-amine;
5-[5-((2S)-2-Amino-3-phenyl-propoxy)-pyridin-3-
-yl]-1H-indazol-3-ylamine;
N-{5-[5-((2S)-2-Amino-3-phenyl-propoxy)-pyridin-
-3-yl]-1H-indazol-3-yl}-2,2,2-trifluoro-acetamide;
(2S)-2-Amino-N-[5-(3-me-
thyl-1H-indazol-5-yl)-pyridin-3-yl]-3-phenyl-propionamide;
(1S)-2-[5-(3-Benzyl-1H-indazol-5-yl)-pyridin-3-yloxy]-1-(1H-indol-3-ylmet-
hyl)-ethylamine;
(1S)-1-Benzyl-2-[5-(3-benzyl-1H-indazol-5-yl)-pyridin-3-y-
loxy]-ethylamine;
(1S)-2-[5-(3-Benzyl-1H-indazol-5-yl)-pyridin-3-yloxy]-1--
methyl-ethylamine;
(6-{5-[(2S)-2-Amino-3-(1H-indol-3-yl)-propoxy]-pyridin--
3-yl}-cinnolin-4-yl)-phenyl-amine;
(1S)-2-[5-(1H-Indazol-6-yl)-pyridin-3-y-
loxy]-1-(1H-indol-3-ylmethyl)-ethylamine;
5-{5-[(2S)-2-Amino-3-(1H-indol-3-
-yl)-propoxy]-pyridin-3-yl}-2,3-dihydro-isoindol-1-one;
6-{5-[(2S)-2-Amino-3-(1H-indol-3-yl)-propoxy]-pyridin-3-yl}-1H-cinnolin-4-
-one;
(1S)-1-(1H-Indol-3-ylmethyl)-2-[5-(4-phenyl-cinnolin-6-yl)-pyridin-3-
-yloxy]-ethylamine;
(6-{5-[(2S)-2-Amino-3-(1H-indol-3-yl)-propoxy]-pyridin-
-3-yl}-cinnolin-4-yl)-benzyl-amine;
(6-{5-[(2S)-2-Amino-3-(1H-indol-3-yl)--
propoxy]-pyridin-3-yl}-cinnolin-4-yl)-methyl-amine;
6-{5-[(2S)-2-Amino-3-(1H-indol-3-yl)-propoxy]-pyridin-3-yl}-cinnolin-4-yl-
amine;
[(3S)-3-(5-Isoquinolin-6-yl-pyridin-3-yloxymethyl)-1,2,3,4-tetrahyd-
ro-b-carbolin-9-yl]-methanol;
3-(5-Isoquinolin-6-yl-pyridin-3-yloxymethyl)-
-2,3,4,9-tetrahydro-1H-.quadrature.-carboline;
5-{5-[(2S)-2-Amino-3-(1H-in-
dol-3-yl)-propoxy]-pyridin-3-yl}-1H-indazole-3-carboxylic acid;
5-[5-((2S)-2-tert-Butoxycarbonylamino-3-hydroxy-propoxy)-pyridin-3-yl]-3--
methylindazole-1-carboxylic acid tert-butyl ester;
5-[5-((2S)-Aziridin-2-y-
lmethoxy)-pyridin-3-yl]-3-methyl-1H-indazole;
(1S)-2-[5-(3-Methyl-1H-indaz-
ol-5-yl)-pyridin-3-yloxy]-1-(3-trifluoromethoxy-benzyl)-ethylamine;
(1S)-1-(3,5-Dichloro-benzyl)-2-[5-(3-methyl-1H-indazol-5-yl)-pyridin-3-yl-
oxy]-ethylamine;
(1S)-1-(2,3-Dichloro-benzyl)-2-[5-(3-methyl-1H-indazol-5--
yl)-pyridin-3-yloxy]-ethylamine;
(1S)-1-Biphenyl-3-ylmethyl-2-[5-(3-methyl-
-1H-indazol-5-yl)-pyridin-3-yloxy]-ethylamine;
(1S)-1-(3-Chloro-4-fluoro-b-
enzyl)-2-[5-(3-methyl-1H-indazol-5-yl)-pyridin-3-yloxy]-ethylamine;
(1S)-1-(4-Chloro-3-fluoro-benzyl)-2-[5-(3-methyl-1H-indazol-5-yl)-pyridin-
-3-yloxy]-ethylamine;
(1S)-2-[5-(3-Methyl-1H-indazol-5-yl)-pyridin-3-yloxy-
]-1-(4-trifluoromethoxy-benzyl)-ethylamine;
(1S)-1-(2-Fluoro-4-trifluorome-
thyl-benzyl)-2-[5-(3-methyl-1H-indazol-5-yl)-pyridin-3-yloxy]-ethylamine;
(1S)-1-(3-Fluoro-5-trifluoromethyl-benzyl)-2-[5-(3-methyl-1H-indazol-5-yl-
)-pyridin-3-yloxy]-ethylamine;
(1S)-1-(2-Methoxy-benzyl)-2-[5-(3-methyl-1H-
-indazol-5-yl)-pyridin-3-yloxy]-ethylamine;
(3-{(2S)-2-Amino-3-[5-(3-methy-
l-1H-indazol-5-yl)-pyridin-3-yloxy]-propyl}-phenyl)-dimethyl-amine;
(1S)-1-(4-Chloro-2-methyl-benzyl)-2-[5-(3-methyl-1H-indazol-5-yl)-pyridin-
-3-yloxy]-ethylamine;
(1S)-1-(3-Iodo-benzyl)-2-[5-(3-methyl-1H-indazol-5-y-
l)-pyridin-3-yloxy]-ethylamine;
(1S)-(1S)-1-(3-Fluoro-4-methyl-benzyl)-2-[-
5-(3-methyl-1H-indazol-5-yl)-pyridin-3-yloxy]-ethylamine;
(1S)-1-(3-Fluoro-4-methoxy-benzyl)-2-[5-(3-methyl-1H-indazol-5-yl)-pyridi-
n-3-yloxy]-ethylamine;
(1S)-2-[6-Chloro-5-(3-methyl-1H-indazol-5-yl)-pyrid-
in-3-yloxy]-1-(3,4-dichloro-benzyl)-ethylamine;
(1S)-1-(2-Fluoro-6-trifluo-
romethyl-benzyl)-2-[5-(3-methyl-1H-indazol-5-yl)-pyridin-3-yloxy]-ethylami-
ne;
(1S)-1-(4-Fluoro-3-trifluoromethyl-benzyl)-2-[5-(3-methyl-1H-indazol-5-
-yl)-pyridin-3-yloxy]-ethylamine;
(1S)-1-Furan-2-ylmethyl-2-[5-(3-methyl-1-
H-indazol-5-yl)-pyridin-3-yloxy]-ethylamine;
(1S)-1-Benzofuran-2-ylmethyl--
2-[5-(3-methyl-1H-indazol-5-yl)-pyridin-3-yloxy]-ethylamine;
(1S)-1-(3-Fluoro-4-trifluoromethyl-benzyl)-2-[5-(3-methyl-1H-indazol-5-yl-
)-pyridin-3-yloxy]-ethylamine;
(1S)-1-(4-Chloro-3-methyl-benzyl)-2-[5-(3-m-
ethyl-1H-indazol-5-yl)-pyridin-3-yloxy]-ethylamine;
(1S)-1-Furan-3-ylmethyl-2-[5-(3-methyl-1H-indazol-5-yl)-pyridin-3-yloxy]--
ethylamine;
(1S)-1-(2-Fluoro-5-methyl-benzyl)-2-[5-(3-methyl-1H-indazol-5--
yl)-pyridin-3-yloxy]-ethylamine;
(1S)-1-(3-Chloro-5-fluoro-benzyl)-2-[5-(3-
-methyl-1H-indazol-5-yl)-pyridin-3-yloxy]-ethylamine;
(1S)-2-[5-(3-Methyl-1H-indazol-5-yl)-pyridin-3-yloxy]-1-(3,4,5-trifluoro--
benzyl)-ethylamine;
(1S)-1-(4-Fluoro-3-methyl-benzyl)-2-[5-(3-methyl-1H-in-
dazol-5-yl)-pyridin-3-yloxy]-ethylamine;
(1S)-1-(2,4-Dichloro-benzyl)-2-[5-
-(3-methyl-1H-indazol-5-yl)-pyridin-3-yloxy]-ethylamine;
(1S)-1-(4-Chloro-3-trifluoromethyl-benzyl)-2-[5-(3-methyl-1H-indazol-5-yl-
)-pyridin-3-yloxy]-ethylamine;
(1S)-2-[5-(3-Methyl-1H-indazol-5-yl)-pyridi-
n-3-yloxy]-1-(2-trifluoromethoxy-benzyl)-ethylamine;
(1S)-1-(2,5-Dimethoxy-benzyl)-2-[5-(3-methyl-1H-indazol-5-yl)-pyridin-3-y-
loxy]-ethylamine;
(1S)-2-[5-(3-Methyl-1H-indazol-5-yl)-pyridin-3-yloxy]-1--
(4-methylsulfanyl-benzyl)-ethylamine;
(1S)-1-(2-Cyclohexyl-benzyl)-2-[5-(3-
-methyl-1H-indazol-5-yl)-pyridin-3-yloxy]-ethylamine;
(1S)-1-(2,5-Dichloro-benzyl)-2-[5-(3-methyl-1H-indazol-5-yl)-pyridin-3-yl-
oxy]-ethylamine;
(1S)-1-(2,5-Dimethyl-benzyl)-2-[5-(3-methyl-1H-indazol-5--
yl)-pyridin-3-yloxy]-ethylamine;
(1S)-1-(2,3-Dimethyl-benzyl)-2-[5-(3-meth-
yl-1H-indazol-5-yl)-pyridin-3-yloxy]-ethylamine;
(1S)-1-(3,4-Dichloro-benz-
yl)-2-[5-(3-methyl-1H-indazol-5-yl)-pyridin-3-yloxy]-ethylamine;
(1S)-1-(2,4-Dimethyl-benzyl)-2-[5-(3-methyl-1H-indazol-5-yl)-pyridin-3-yl-
oxy]-ethylamine;
(1S)-1-(3-Fluoro-4-trifluoromethyl-benzyl)-2-[5-(3-methyl-
-1H-indazol-5-yl)-pyridin-3-yloxy]-ethylamine;
(1S)-1-(3,5-Dimethyl-benzyl-
)-2-[5-(3-methyl-1H-indazol-5-yl)-pyridin-3-yloxy]-ethylamine;
(1S)-1-Biphenyl-2-ylmethyl-2-[5-(3-methyl-1H-indazol-5-yl)-pyridin-3-ylox-
y]-ethylamine;
(1S)-1-(3,4-Dimethyl-benzyl)-2-[5-(3-methyl-1H-indazol-5-yl-
)-pyridin-3-yloxy]-ethylamine;
(1S)-1-(2,3-Difluoro-benzyl)-2-[5-(3-methyl-
-1H-indazol-5-yl)-pyridin-3-yloxy]-ethylamine;
(1S)-1-(2,5-Difluoro-benzyl-
)-2-[5-(3-methyl-1H-indazol-5-yl)-pyridin-3-yloxy]-ethylamine;
(1S)-1-(2,6-Dichloro-benzyl)-2-[5-(3-methyl-1H-indazol-5-yl)-pyridin-3-yl-
oxy]-ethylamine;
(1S)-1-(2,4-Difluoro-benzyl)-2-[5-(3-methyl-1H-indazol-5--
yl)-pyridin-3-yloxy]-ethylamine;
(1S)-1-(2,6-Dimethyl-benzyl)-2-[5-(3-meth-
yl-1H-indazol-5-yl)-pyridin-3-yloxy]-ethylamine;
(1S)-1-(2,3-Dihydro-benzo-
[1,4]dioxin-6-ylmethyl)-2-[5-(3-methyl-1H-indazol-5-yl)-pyridin-3-yloxy]-e-
thylamine;
(1S)-1-(3,5-Difluoro-benzyl)-2-[5-(3-methyl-1H-indazol-5-yl)-py-
ridin-3-yloxy]-ethylamine;
(1S)-1-(2,6-Difluoro-benzyl)-2-[5-(3-methyl-1H--
indazol-5-yl)-pyridin-3-yloxy]-ethylamine;
(1S)-1-Benzo[1,3]dioxol-5-ylmet-
hyl-2-[5-(3-methyl-1H-indazol-5-yl)-pyridin-3-yloxy]-ethylamine;
(1S)-1-(4-Fluoro-3-methyl-benzyl)-2-[5-(3-methyl-1H-indazol-5-yl)-pyridin-
-3-yloxy]-ethylamine;
(1S)-2-[5-(3-Methyl-1H-indazol-5-yl)-pyridin-3-yloxy-
]-1-(2,4,6-trimethyl-benzyl)-ethylamine;
(1S)-1-(2,4-Dimethoxy-benzyl)-2-[-
5-(3-methyl-1H-indazol-5-yl)-pyridin-3-yloxy]-ethylamine;
(1S)-2-[5-(3-Methyl-1H-indazol-5-yl)-pyridin-3-yloxy]-1-(4-trifluoromethy-
l-benzyl)-ethylamine;
(1S)-1-(5-Fluoro-2-methyl-benzyl)-2-[5-(3-methyl-1H--
indazol-5-yl)-pyridin-3-yloxy]-ethylamine;
(1S)-1-(3,5-Bis-trifluoromethyl-
-benzyl)-2-[5-(3-methyl-1H-indazol-5-yl)-pyridin-3-yloxy]-ethylamine;
(1S)-1-(4-Fluoro-2-methyl-benzyl)-2-[5-(3-methyl-1H-indazol-5-yl)-pyridin-
-3-yloxy]-ethylamine;
(1S)-1-(5-Fluoro-2-methoxy-benzyl)-2-[5-(3-methyl-1H-
-indazol-5-yl)-pyridin-3-yloxy]-ethylamine;
(1S)-2-[5-(3-Methyl-1H-indazol-
-5-yl)-pyridin-3-yloxy]-1-(2-methyl-naphthalen-1-ylmethyl)-ethylamine;
(1S)-1-(2,2-Difluoro-benzo[1,3]dioxol-4-ylmethyl)-2-[5-(3-methyl-1H-indaz-
ol-5-yl)-pyridin-3-yloxy]-ethylamine;
(1S)-1-(4-Fluoro-naphthalen-1-ylmeth-
yl)-2-[5-(3-methyl-1H-indazol-5-yl)-pyridin-3-yloxy]-ethylamine;
(1S)-2-[5-(3-Methyl-1H-indazol-5-yl)-pyridin-3-yloxy]-1-(2,2,3,3-tetraflu-
oro-2,3-dihydro-benzo[1,4]dioxin-6-ylmethyl)-ethylamine;
(1S)-2-[5-(3-Methyl-1H-indazol-5-yl)-pyridin-3-yloxy]-1-(4-methyl-naphtha-
len-1-ylmethyl)-ethylamine;
(1S)-2-[5-(3-Methyl-1H-indazol-5-yl)-pyridin-3-
-yloxy]-1-(2,4,6-trifluoro-benzyl)-ethylamine;
(1S)-2-[5-(3-Methyl-1H-inda-
zol-5-yl)-pyridin-3-yloxy]-1-(2,3,4-trifluoro-benzyl)-ethylamine;
(1S)-1-(4-Bromo-2-fluoro-benzyl)-2-[5-(3-methyl-1H-indazol-5-yl)-pyridin--
3-yloxy]-ethylamine;
(1S)-1-(4-Bromo-3-fluoro-benzyl)-2-[5-(3-methyl-1H-in-
dazol-5-yl)-pyridin-3-yloxy]-ethylamine;
(1S)-1-(2-Bromo-4,6-difluoro-benz- yl)-2-[5-(3-methyl-I
1H-indazol-5-yl)-pyridin-3-yloxy]-ethylamine;
(1S)-1-(4-Bromo-3-methyl-benzyl)-2-[5-(3-methyl-1H-indazol-5-yl)-pyridin--
3-yloxy]-ethylamine; (1S)-Bromo-benzyl)-2-[5-(3-methyl-I
1H-indazol-5-yl)-pyridin-3-yloxy]-ethylamine;
(1S)-1-(3-Methoxy-benzyl)-2-
-[5-(3-methyl-1H-indazol-5-yl)-pyridin-3-yloxy]-ethylamine;
(1S)-1-(3-Bromo-benzyl)-2-[5-(3-methyl-1H-indazol-5-yl)-pyridin-3-yloxy]--
ethylamine;
(1S)-1-(2-Methoxy-naphthalen-1-ylmethyl)-2-[5-(3-methyl-1H-ind-
azol-5-yl)-pyridin-3-yloxy]-ethylamine;
(1R)-1-(4-Chloro-benzyl)-2-[5-(3-m-
ethyl-1H-indazol-5-yl)-pyridin-3-yloxy]-ethylamine;
(1R)-1-Benzo[1,3]dioxol-5-ylmethyl-2-[5-(3-methyl-1H-indazol-5-yl)-pyridi-
n-3-yloxy]-ethylamine;
(1R)-1-(3-Fluoro-4-methyl-benzyl)-2-[5-(3-methyl-1H-
-indazol-5-yl)-pyridin-3-yloxy]-ethyl amine;
(1S)-1-Benzyl-2-[6-chloro-5-(-
3-methyl-1H-indazol-5-yl)-pyridin-3-yloxy]-ethylamine;
(1S)-1-(4-Bromo-benzyl)-2-[6-chloro-5-(3-methyl-1H-indazol-5-yl)-pyridin--
3-yloxy]-ethylamine;
(1S)-1-(4-Chloro-benzyl)-2-[6-chloro-5-(3-methyl-1H-i-
ndazol-5-yl)-pyridin-3-yloxy]-ethylamine;
(1S)-2-[6-Chloro-5-(3-methyl-1H--
indazol-5-yl)-pyridin-3-yloxy]-1-cyclohexylmethyl-ethylamine;
(1S)-2-[6-Chloro-5-(3-methyl-1H-indazol-5-yl)-pyridin-3-yloxy]-1-(2,6-dim-
ethyl-benzyl)-ethylamine;
(1S)-1-[6-Chloro-5-(3-methyl-1H-indazol-5-yl)-py-
ridin-3-yloxymethyl]-2-phenyl-propylamine;
(1S)-1-[6-Chloro-5-(3-methyl-1H-
-indazol-5-yl)-pyridin-3-yloxymethyl]-2,2-diphenyl-ethylamine;
(1S)-1-[5-(3-Methyl-1H-indazol-5-yl)-pyridin-3-yloxymethyl]-2-phenyl-prop-
ylamine;
(1S)-1-[5-(3-Methyl-1H-indazol-5-yl)-pyridin-3-yloxymethyl]-2,2-d-
iphenyl-ethylamine;
(1S)-3-Methyl-1-[5-(3-methyl-1H-indazol-5-yl)-pyridin--
3-yloxymethyl]-butylamine;
(1S)-2-[6-Chloro-5-(3-methyl-1H-indazol-5-yl)-p-
yridin-3-yloxy]-1-(1H-indol-3-ylmethyl)-ethylamine;
(1S)-2-(6-Chloro-5-thieno[2,3-c]pyridin-2-yl-pyridin-3-yloxy)-1-(1H-indol-
-3-ylmethyl)-ethylamine;
5-[(2S)-2-Amino-3-(1H-indol-3-yl)-propoxy]-3-isoq-
uinolin-6-yl-pyridine-2-carbonitrile;
(1S)-1-(1H-Indol-3-ylmethyl)-2-[5-(3-
-phenyl-isoquinolin-6-yl)-pyridin-3-yloxy]-ethylamine;
(1S)-2-[5-(3-Ethyl-isoquinolin-6-yl)-pyridin-3-yloxy]-1-(1H-indol-3-ylmet-
hyl)-ethylamine;
(1S)-1-(1H-Indol-3-ylmethyl)-2-[5-(3-pyridin-4-yl-isoquin-
olin-6-yl)-pyridin-3-yloxy]-ethylamine;
(1S)-2-[5-(3-Furan-2-yl-isoquinoli-
n-6-yl)-pyridin-3-yloxy]-1-(1H-indol-3-ylmethyl)-ethylamine;
(1S)-1-(1H-Indol-3-ylmethyl)-2-[5-(3-phenylethynyl-isoquinolin-6-yl)-pyri-
din-3-yloxy]-ethylamine;
(1S)-1-(1H-Indol-3-ylmethyl)-2-[5-(3-prop-1-ynyl--
isoquinolin-6-yl)-pyridin-3-yloxy]-ethylamine;
(1S)-1-(1H-Indol-3-ylmethyl-
)-2-[5-(3-vinyl-isoquinolin-6-yl)-pyridin-3-yloxy]-ethylamine;
(1S)-6-{5-[2-Amino-3-(1H-indol-3-yl)-propoxy]-pyridin-3-yl}-isoquinoline--
3-carbonitrile;
(1S)-1-(1H-Indol-3-ylmethyl)-2-(5-isoquinolin-6-yl-6-vinyl-
-pyridin-3-yloxy)-ethylamine;
(1S)-2-(6-Ethynyl-5-isoquinolin-6-yl-pyridin-
-3-yloxy)-1-(1H-indol-3-ylmethyl)-ethylamine;
(1S)-2-(6-Furan-2-yl-5-isoqu-
inolin-6-yl-pyridin-3-yloxy)-1-(1H-indol-3-ylmethyl)-ethylamine;
(1S)-1-(1H-Indol-3-ylmethyl)-2-(5-isoquinolin-6-yl-6-phenylethynyl-pyridi-
n-3-yloxy)-ethylamine;
6-{5-[(2S)-2-Amino-3-(1H-indol-3-yl)-propoxy]-pyrid-
in-3-yl}-isoquinolin-5-ylamine;
(1S)-1-(1H-Indol-3-ylmethyl)-2-[5-(8-methy-
l-isoquinolin-6-yl)-pyridin-3-yloxy]-ethylamine;
(1S)-2-[5-(4-Chloro-thien- o
[2,3-c]pyridin-2-yl)-pyridin-3-yloxy]-1-(1H-indol-3-ylmethyl)-ethylamine-
;
(1S)-1-(1H-Indol-3-ylmethyl)-2-[5-(4-phenyl-thieno[2,3-c]pyridin-2-yl)-p-
yridin-3-yloxy]-ethylamine;
(1S)-1-(1H-Indol-3-ylmethyl)-2-[5-(4-phenoxy-t-
hieno[2,3-c]pyridin-2-yl)-pyridin-3-yloxy]-ethylamine;
(1S)-1-(1H-Indol-3-ylmethyl)-2-[5-(4-vinyl-thieno[2,3-c]pyridin-2-yl)-pyr-
idin-3-yloxy]-ethylamine;
(1S)-2-[5-(4-Ethyl-thieno[2,3-c]pyridin-2-yl)-py-
ridin-3-yloxy]-1-(1H-indol-3-ylmethyl)-ethylamine;
(1S)-(2-{5-[2-Amino-3-(-
1H-indol-3-yl)-propoxy]-pyridin-3-yl}-thieno[2,3-c]pyridin-4-yl)-phenyl-am-
ine;
5-{5-[(2S)-2-Amino-3-(1H-indol-3-yl)-propoxy]-pyridin-3-yl}-3,3-diflu-
oro-1,3-dihydro-indol-2-one;
6-{5-[(2S)-2-Amino-3-(1H-indol-3-yl)-propoxy]-
-pyridin-3-yl}-3H-oxazolo[4,5-b]pyridin-2-one;
N1-(5-Isoquinolin-6-yl-pyri- din-3-yl)-ethane-1,2-diamine;
Naphthalene-2-sulfonic acid
(2-amino-ethyl)-(5-isoquinolin-6-yl-pyridin-3-yl)-amide;
Naphthalene-1-sulfonic acid
(2-amino-ethyl)-(5-isoquinolin-6-yl-pyridin-3- -yl)-amide;
5-Dimethylamino-naphthalene-1-sulfonic acid
(2-amino-ethyl)-(5-isoquinolin-6-yl-pyridin-3-yl)-amide;
Quinoline-5-sulfonic acid
(2-amino-ethyl)-(5-isoquinolin-6-yl-pyridin-3-y- l)-amide;
Biphenyl-4-sulfonic acid (2-amino-ethyl)-(5-isoquinolin-6-yl-pyr-
idin-3-yl)-amide; 1-Methyl-1 H-imidazole-4-sulfonic acid
(2-amino-ethyl)-(5-isoquinolin-6-yl-pyridin-3-yl)-amide;
3-Amino-2-[5-(3-methyl-1H-indazol-5-yl)-pyridin-3-yloxy]-propan-1-ol;
2-[5-(3-Methyl-1H-indazol-5-yl)-pyridin-3-yloxy]-3-phenoxy-propylamine;
2-[5-(3-Methyl-1H-indazol-5-yl)-pyridin-3-yloxy]-3-(naphthalen-2-yloxy)-p-
ropylamine;
3-(Biphenyl-4-yloxy)-2-[5-(3-methyl-1H-indazol-5-yl)-pyridin-3-
-yloxy]-propylamine;
2-[5-(3-Methyl-1H-indazol-5-yl)-pyridin-3-yloxy]-3-(q-
uinolin-7-yloxy)-propylamine;
2-[5-(3-Methyl-1H-indazol-5-yl)-pyridin-3-yl-
oxy]-3-(pyridin-4-yloxy)-propylamine;
2-[5-(3-Methyl-1H-indazol-5-yl)-pyri-
din-3-yloxy]-3-(naphthalen-1-yloxy)-propylamine;
3-{(2S)-2-Amino-3-[5-(3-m-
ethyl-1H-indazol-5-yl)-pyridin-3-yloxy]-propyl}-1H-indol-5-ol;
(1S)-1-(5-Methoxy-1H-indol-3-ylmethyl)-2-[5-(3-methyl-1H-indazol-5-yl)-py-
ridin-3-yloxy]-ethylamine;
(1S)-1-(5-Ethoxy-1H-indol-3-ylmethyl)-2-[5-(3-m-
ethyl-1H-indazol-5-yl)-pyridin-3-yloxy]-ethylamine;
(1S)-1-(5-Butoxy-1H-indol-3-ylmethyl)-2-[5-(3-methyl-1H-indazol-5-yl)-pyr-
idin-3-yloxy]-ethyl amine;
(1S)-1-(5-Isopropoxy-1H-indol-3-ylmethyl)-2-[5--
(3-methyl-1H-indazol-5-yl)-pyridin-3-yloxy]-ethylamine;
3-(1H-Indol-3-yl)-2-[5-(3-methyl-1H-indazol-5-yl)-pyridin-3-yloxy]-propan-
-1-ol;
3-(1H-Indol-3-yl)-2-[5-(3-methyl-1H-indazol-5-yl)-pyridin-3-yloxy]--
propylamine; Naphthalene-2-sulfonic acid
(2-amino-ethyl)-[5-(3-methyl-1H-i-
ndazol-5-yl)-pyridin-3-yl]-amide; Biphenyl-4-sulfonic acid
(2-amino-ethyl)-[5-(3-methyl-1H-indazol-5-yl)-pyridin-3-yl]-amide;
5-{5-[(2S)-2-Amino-3-(1H-indol-3-yl)-propoxy]-pyridin-3-yl}-3-isopropylid-
ene-1,3-dihydro-indol-2-one;
5-{5-[(2S)-2-Amino-3-(1H-indol-3-yl)-propoxy]-
-pyridin-3-yl}-3-(1H-imidazol-2-ylmethylene)-1,3-dihydro-indol-2-one;
5-{5-[2-Amino-3-(1H-indol-3-yl)-propoxy]-pyridin-3-yl}-3-pyridin-2-ylmeth-
ylene-1,3-dihydro-indol-2-one;
5-{5-[(2S)-2-Amino-3-(1H-indol-3-yl)-propox-
y]-pyridin-3-yl}-3-furan-2-ylmethylene-1,3-dihydro-indol-2-one;
5-{5-[(2S)-2-Amino-3-(1H-indol-3-yl)-propoxy]-pyridin-3-yl}-3-(5-methyl-f-
uran-2-ylmethylene)-1,3-dihydro-indol-2-one;
5-{5-[(2S)-2-Amino-3-(1H-indo-
l-3-yl)-propoxy]-pyridin-3-yl}-3-(4,5-dimethyl-furan-2-ylmethylene)-1,3-di-
hydro-indol-2-one;
5-{5-[(2S)-2-Amino-3-(1H-indol-3-yl)-propoxy]-pyridin-3-
-yl}-3-thiophen-2-ylmethylene-1,3-dihydro-indol-2-one;
5-{5-[(2S)-2-Amino-3-(1H-indol-3-yl)-propoxy]-pyridin-3-yl}-3-(1-methyl-1-
H-pyrrol-2-ylmethylene)-1,3-dihydro-indol-2-one;
5-{5-[(2S)-2-Amino-3-(1H--
indol-3-yl)-propoxy]-pyridin-3-yl}-3-(1H-indol-3-ylmethylene)-1,3-dihydro--
indol-2-one;
5-{5-[(2S)-2-Amino-3-(1H-indol-3-yl)-propoxy]-pyridin-3-yl}-3-
-(1-phenyl-1H-pyrrol-3-ylmethylene)-1,3-dihydro-indol-2-one;
5-{5-[(2S)-2-Amino-3-(1H-indol-3-yl)-propoxy]-pyridin-3-yl}-3-pyridin-3-y-
lmethylene-1,3-dihydro-indol-2-one;
5-{5-[(2S)-2-Amino-3-(1H-indol-3-yl)-p-
ropoxy]-pyridin-3-yl}-3-(1H-pyrrol-3-ylmethylene)-1,3-dihydro-indol-2-one;
5-{5-[(2S)-2-Amino-3-(1H-indol-3-yl)-propoxy]-pyridin-3-yl}-3-(tetrahydro-
-pyran-4-ylidene)-1,3-dihydro-indol-2-one;
5-{5-[(2S)-2-Amino-3-(1H-indol--
3-yl)-propoxy]-pyridin-3-yl}-3-(4-ethyl-3,5-dimethyl-1H-pyrrol-2-ylmethyle-
ne)-1,3-dihydro-indol-2-one;
5-{5-[(2S)-2-Amino-3-(1H-indol-3-yl)-propoxy]-
-pyridin-3-yl}-3-cyclopropylmethylene-1,3-dihydro-indol-2-one;
5-{5-[(2S)-2-Amino-3-(1H-indol-3-yl)-propoxy]-pyridin-3-yl}-3-pyrrolidin--
2-ylmethylene-1,3-dihydro-indol-2-one;
5-(5-{5-[(2S)-2-Amino-3-(1H-indol-3-
-yl)-propoxy]-pyridin-3-yl}-2-oxo-1,2-dibydro-indol-3-ylidenemethyl)-furan-
-2-carboxylic acid;
5-{5-[(2S)-2-Amino-3-(1H-indol-3-yl)-propoxy]-pyridin--
3-yl}-3-benzylidene-1,3-dihydro-indol-2-one;
5-{5-[(2S)-2-Amino-3-(1H-indo-
l-3-yl)-propoxy]-pyridin-3-yl}-1H-indole-2,3-dione 3-oxime;
(1S)-2-(5-Benzo[b]thiophen-2-yl-6-furan-2-yl-pyridin-3-yloxy)-1-(1H-indol-
-3-ylmethyl)-ethylamine;
(1S)-2-(5-Benzo[b]thiophen-2-yl-6-vinyl-pyridin-3-
-yloxy)-1-(1H-indol-3-ylmethyl)-ethylamine;
(1S)-2-(5-Benzo[b]thiophen-2-y-
l-6-thiophen-2-yl-pyridin-3-yloxy)-1-(1H-indol-3-ylmethyl)-ethylamine;
(1S)-2-(5-Benzo[b]thiophen-2-yl-6-thiazol-2-yl-pyridin-3-yloxy)-1-(1H-ind-
ol-3-ylmethyl)-ethylamine;
(1S)-2-(5-Benzo[b]thiophen-2-yl-6-pyrazin-2-yl--
pyridin-3-yloxy)-1-(1H-indol-3-ylmethyl)-ethylamine;
{5-[(2S)-2-Amino-3-(1H-indol-3-yl)-propoxy]-3-benzo[b]thiophen-2-yl-pyrid-
in-2-yl}-phenyl-amine;
{5-[(2S)-2-Amino-3-(1H-indol-3-yl)-propoxy]-3-benzo-
[b]thiophen-2-yl-pyridin-2-yl}-pyridin-3-yl-amine;
6-{5-[(2S)-2-Amino-3-(1-
H-indol-3-yl)-propoxy]-pyridin-3-yl}-3H-benzooxazol-2-one;
1-Benzoimidazol-1-ylmethyl-2-[5-(3-methyl-1H-indazol-5-yl)-pyridin-3-ylox-
y]-ethylamine;
2-[5-(3-Methyl-1H-indazol-5-yl)-pyridin-3-yloxy]-1-morpholi-
n-4-ylmethyl-ethylamine;
5-[5-((2S)-2-Amino-3-phenyl-propoxy)-pyridin-3-yl-
]-1,3-dihydro-indol-2-one;
5-[5-((2S)-2-Amino-3-phenyl-propoxy)-pyridin-3--
yl]-3-(1H-pyrrol-2-ylmethylene)-1,3-dihydro-indol-2-one;
5-[5-((2S)-2-Amino-3-phenyl-propoxy)-pyridin-3-yl]-3-furan-2-ylmethylene--
1,3-dihydro-indol-2-one;
(1S)-1-Benzoimidazol-1-ylmethyl-2-[5-(3-methyl-1H-
-indazol-5-yl)-pyridin-3-yloxy]-ethylamine;
3-{3-[(2S)-2-Amino-3-(1H-indol-
-3-yl)-propoxy]-5-isoquinolin-6-yl-pyridin-4-yl}-acrylonitrile;
(1S)-1-(1H-Indol-3-ylmethyl)-2-(5-isoquinolin-6-yl-4-methyl-pyridin-3-ylo-
xy)-ethylamine;
5-{5-[(2S)-2-Amino-3-(1H-indol-3-yl)-propoxy]-pyridin-3-yl-
}-3-methyl-1,3-dihydro-indol-2-one;
5-{5-[(2S)-2-Amino-3-(1H-indol-3-yl)-p-
ropoxy]-pyridin-3-yl}-3,3-dimethyl-1,3-dihydro-indol-2-one;
5-{5-[(2S)-2-Amino-3-(1H-indol-3-yl)-propoxy]-pyridin-3-yl}-1,3,3-trimeth-
yl-1,3-dihydro-indol-2-one;
5-{5-[(2S)-2-Amino-3-(1H-indol-3-yl)-propoxy]--
pyridin-3-yl}-3-ethyl-1,3-dihydro-indol-2-one; and
5-{5-[(2S)-2-Amino-3-(1-
H-indol-3-yl)-propoxy]-pyridin-3-yl}-3-benzyl-1,3-dihydro-indol-2-one.
21. A pharmaceutical composition comprising a compound of claim 1,
or a therapeutically acceptable salt thereof, in combination with a
pharmaceutically acceptable carrier.
22. A method of inhibiting protein kinases in a patient in
recognized need of such treatment comprising administering to the
patient a therapeutically acceptable amount of a compound of claim
1, or a therapeutically acceptable salt thereof.
Description
[0001] This application is a continuation-in-part of U.S. patent
application Ser. No. 10/023,363, filed Dec. 13, 2001, which is
hereby incorporated by reference.
TECHNICAL FIELD
[0002] The present invention relates to compounds which are useful
for inhibiting protein kinases, methods of making the compounds,
compositions containing the compounds, and methods of treatment
using the compounds.
BACKGROUND OF THE INVENTION
[0003] Protein kinases have been clearly shown to be important in
the progression of many disease states that are induced by the
inappropriate proliferation of cells. These kinases are often found
to be up-regulated in many hyperproliferative states such as
cancer. These kinases may be important in cell signaling, where
their inappropriate activation induces cells to proliferate (e.g.
EGFR, ERBB2, VEGFR, FGFR, PDGFR, c-Met, IGF-1R, RET, TIE2).
Alternatively, they may be involved in signal transduction within
cells (e.g. c-Src, PKC, Akt, PKA, c-Abl, PDK-1). Often these signal
transduction genes are recognized proto-oncogenes. Many of these
kinases control cell cycle progression near the G1-S transition
(e.g. Cdk2, Cdk4), at the G2-M transition (e.g. Wee1, Myt1, Chk1,
Cdc2) or at the spindle checkpoint (Plk, Aurora1 or 2, Bub1 or 3).
Furthermore, kinases are intimately linked to the DNA damage
response (e.g. ATM, ATR, Chk1, Chk2). Disregulation of these
cellular functions; cell signaling, signal transduction, cell cycle
control, and DNA repair, are all hallmarks of hyperproliferative
diseases, particularly cancer. It is therefore likely that
pharmacological modulation of one or more kinases would be useful
in slowing or stopping disease progression in these diseases.
SUMMARY OF THE INVENTION
[0004] In its principle embodiment the present invention provides a
compound of formula (I) 2
[0005] or a therapeutically acceptable salt thereof, wherein
[0006] X is selected from the group consisting of C(R.sup.8) and N;
wherein R.sup.8 is selected from the group consisting of hydrogen,
alkyl, amino, carboxy, cyano, halo, hydroxy, and amido;
[0007] X' is selected from the group consisting of C and N;
[0008] Y is selected from the group consisting of C and N;
[0009] Y' is selected from the group consisting of C(R.sup.9) and
N; wherein R.sup.9 is selected from the group consisting of
hydrogen and -L.sup.2-L.sup.3(R.sup.3)(R.sup.6);
[0010] Z is selected from the group consisting of C and N;
[0011] provided that 0, 1, or 2 of X, X', Y, Y', and Z are N;
[0012] L.sup.1 is selected from the group consisting of a bond,
--O--, --NR.sup.5--, alkenyl, alkynyl, --C(O)--, --S--, --S(O)--,
--S(O).sub.2--, --S(O).sub.2N(R.sup.5)--, --N(R.sup.5)S(O).sub.2--,
--C(R.sup.12).sub.2--, --C(R.sup.12).sub.2N(R.sup.5)--,
--N(R.sup.5)C(O)--, and --C(O)N(R.sup.5)--; wherein each group is
drawn with its left end attached to R.sup.1 and its right end
attached to the aromatic ring;
[0013] L.sup.2 is selected from the group consisting of a bond,
--O--, --C(R.sup.12).sub.2--, --S--, --N(R.sup.5)--,
--N(R.sup.5)C(O)--, and --C(O)N(R.sup.5)--;
[0014] L.sup.3 is selected from the group consisting of a bond,
alkylidene and alkylene, wherein the alkylidene and the alkylene
are optionally substituted with one or two substituents
independently selected from the group consisting of alkoxy, amino,
cyano, and hydroxy;
[0015] R.sup.1 is selected from the group consisting of aryl,
heteroaryl, and heterocycle;
[0016] R.sup.2 and R.sup.4 are independently absent or selected
from the group consisting of hydrogen, alkenyl, alkyl, alkynyl,
amino, aryl, arylalkynyl, cyano, cyanoalkenyl, halo, heteroaryl,
heterocycle, hydroxyalkyl, and nitro; or
[0017] R.sup.2 and L.sup.1, together with the carbon atoms to which
they are attached, form a ring selected from the group consisting
of aryl, heteroaryl, and heterocycle; or
[0018] R.sup.4 and L.sup.2, together with the carbon atoms to which
they are attached, form a ring selected from the group consisting
of aryl, heteroaryl, and heterocycle; provided that when L.sup.3 is
alkylidene, R.sup.4 and L.sup.2, together with the carbon atoms to
which they are attached, form a ring selected from the group
consisting of aryl, heteroaryl, and heterocycle;
[0019] R.sup.3 is absent or selected from the group consisting of
hydrogen, aryl, arylalkoxy, arylalkylamino, arylalkylthio, aryloxy,
arylthio, cycloalkyl, heteroaryl, heteroarylalkoxy, heteroaryloxy,
and heterocycle;
[0020] R.sup.6 is selected from the group consisting of hydrogen,
aryl, arylalkoxy, arylalkylamino, arylalkylthio, aryloxy, arylthio,
cycloalkyl, heteroaryl, heteroarylalkoxy, heteroaryloxy, and
heterocycle;
[0021] provided that when L.sup.1 and L.sup.2 are bonds, at least
one of R.sup.3 and R.sup.6 is other than hydrogen;
[0022] R.sup.5 is selected from the group consisting of hydrogen,
alkyl, alkylcarbonyl, alkylsulfonyl, arylcarbonyl, arylsulfonyl,
and heteroarylsulfonyl;
[0023] R.sup.7 is absent or selected from the group consisting of
hydrogen, alkyl, cyanoalkenyl, and
-L.sup.2-L.sup.3(R.sup.3)(R.sup.6); or
[0024] R.sup.7 and L.sup.1, together with the carbon atoms to which
they are attached, form a ring selected from the group consisting
of aryl, heteroaryl, and heterocycle; and
[0025] each R.sup.12 is selected from the group consisting of
hydrogen, alkenyl, alkyl, alkynyl, amino, aryl, cyano, halo,
heteroaryl, heterocycle, and nitro.
[0026] In another embodiment the present invention provides a
compound of formula (II) 3
[0027] or a therapeutically acceptable salt thereof, wherein
[0028] L.sup.1 is selected from the group consisting of a bond,
--O--, --N(R.sup.5)--, alkenyl, alkynyl, --N(R.sup.5)C(O)--, and
--C(O)N(R.sup.5)--;
[0029] L.sup.2 is selected from the group consisting of a bond,
--O--, --N(R.sup.5)--, --N(R.sup.5)C(O)--, and
--C(O)N(R.sup.5)--;
[0030] L.sup.3 is selected from the group consisting of a bond,
alkylidene, and alkylene, wherein the alkylidene and the alkylene
are optionally substituted with one or two substituents
independently selected from the group consisting of amino, cyano,
and hydroxy;
[0031] R.sup.1 is selected from the group consisting of aryl,
heteroaryl, and heterocycle;
[0032] R.sup.2 and R.sup.4 are independently selected from the
group consisting of hydrogen, alkenyl, alkynyl, arylalkynyl, amino,
cyano, cyanoalkenyl, halo, hydroxyalkyl, and heteroaryl; wherein
the heteroaryl is selected from the group consisting of furyl,
pyrazinyl, thiazolyl, and thienyl; or
[0033] R.sup.2 and L.sup.1, together with the carbon atoms to which
they are attached, form a ring selected from the group consisting
of dihydropyrrolyl, pyrazolyl, and phenyl; or
[0034] R.sup.4 and L.sup.2, together with the carbon atoms to which
they are attached, form a ring selected from the group consisting
of dihydropyrrolyl, phenyl, pyridinyl, and pyrrolyl; wherein the
ring can be optionally substituted with oxo;
[0035] provided that when L.sup.3 is alkylidene, R.sup.4 and
L.sup.2, together with the carbon atoms to which they are attached,
form a ring selected from the group consisting of dihydropyrrolyl,
phenyl, pyridinyl, and pyrrolyl; wherein the ring can be optionally
substituted with oxo;
[0036] R.sup.3 is absent or selected from the group consisting of
hydrogen, aryl, arylalkoxy, arylalkylthio, aryloxy, arylthio,
cycloalkyl, heteroaryl, heteroarylalkoxy, heteroaryloxy, and
heterocycle;
[0037] R.sup.6 are independently selected from the group consisting
of hydrogen, aryl, arylalkoxy, arylalkylthio, aryloxy, arylthio,
cycloalkyl, heteroaryl, and heteroarylalkoxy, heteroaryloxy, and
heterocycle;
[0038] provided that when L.sup.1 and L.sup.2 are bonds, at least
one of R.sup.3 and R.sup.6 is other than hydrogen;
[0039] R.sup.5 is selected from the group consisting of hydrogen,
alkyl, alkylcarbonyl, alkylsulfonyl, arylcarbonyl, arylsulfonyl,
and heteroarylsulfonyl; and
[0040] X is selected from the group consisting of C(R.sup.8) and N;
wherein R.sup.8 is selected from the group consisting of hydrogen,
amino, carboxy, cyano, and halo.
[0041] In another embodiment the present invention provides a
compound of formula (III) 4
[0042] or a therapeutically acceptable salt thereof, wherein
[0043] L.sup.1 is selected from the group consisting of a bond,
--O--, --N(R.sup.5)--, alkenyl, alkynyl, and
--N(R.sup.5)C(O)--;
[0044] L.sup.2 is selected from the group consisting of a bond,
--O--, --N(R.sup.5)--, --N(R.sup.5)C(O)--, and
--C(O)N(R.sup.5)--;
[0045] L.sup.3 is alkylene, wherein the alkylene is substituted
with one or two substituents independently selected from the group
consisting of amino and hydroxy;
[0046] R.sup.1 is selected from the group consisting of aryl,
heteroaryl, and heterocycle;
[0047] R.sup.2 and R.sup.4 are independently selected from the
group consisting of hydrogen and halo;
[0048] R.sup.3 and R.sup.6 are independently selected from the
group consisting of hydrogen, aryl, arylalkoxy, and heteroaryl;
provided that when L.sup.1 and L.sup.2 are bonds, at least one of
R.sup.3 and R.sup.6 is other than hydrogen; and
[0049] R.sup.5 is selected from the group consisting of hydrogen
and alkyl.
[0050] In another embodiment, the present invention provides a
compound of formula (I) wherein X is selected from the group
consisting of C(R.sup.8) and N, wherein R.sup.8 is selected from
the group consisting of hydrogen, alkyl, amino, carboxy, cyano,
halo, hydroxy, and amido; X' is selected from the group consisting
of C and N; Y is C; Y' is C(R.sup.9), wherein R.sup.9 is
-L.sup.2-L.sup.3(R.sup.3)(R.sup.6); Z is C; L.sup.1 is alkenyl;
L.sup.2 is selected from the group consisting of a bond, --O--,
--C(R.sup.12).sub.2--, --S--, --N(R.sup.5)--, --N(R.sup.5)C(O)--,
and --C(O)N(R.sup.5)--; L.sup.3 is a bond or selected from the
group consisting of alkylidene and alkylene, wherein the alkylidene
and the alkylene are optionally substituted with one or two
substituents independently selected from the group consisting of
alkoxy, amino, cyano, and hydroxy; R.sup.1 is selected from the
group consisting of aryl, heteroaryl, and heterocycle; R.sup.2 and
R.sup.4 are independently absent or selected from the group
consisting of hydrogen, alkenyl, alkyl, alkynyl, amino, aryl,
arylalkynyl, cyano, cyanoalkenyl, halo, heteroaryl, heterocycle,
hydroxyalkyl, and nitro; R.sup.3 is absent or selected from the
group consisting of hydrogen, aryl, arylalkoxy, arylalkylamino,
arylalkylthio, aryloxy, arylthio, cycloalkyl, heteroaryl,
heteroarylalkoxy, heteroaryloxy, and heterocycle; R.sup.6 is
selected from the group consisting of hydrogen, aryl, arylalkoxy,
arylalkylamino, arylalkylthio, aryloxy, arylthio, cycloalkyl,
heteroaryl, heteroarylalkoxy, heteroaryloxy, and heterocycle;
R.sup.5 is selected from the group consisting of hydrogen, alkyl,
alkylcarbonyl, alkylsulfonyl, arylcarbonyl, arylsulfonyl, and
heteroarylsulfonyl; R.sup.7 is absent or selected from the group
consisting of hydrogen, alkyl, and cyanoalkenyl; and each R.sup.12
is selected from the group consisting of hydrogen, alkenyl, alkyl,
alkynyl, amino, aryl, cyano, halo, heteroaryl, heterocycle, and
nitro.
[0051] In another embodiment, the present invention provides a
compound of formula (I) wherein X is selected from the group
consisting of C(R.sup.8) and N, wherein R.sup.8 is selected from
the group consisting of hydrogen, alkyl, amino, carboxy, cyano,
halo, hydroxy, and amido; X' is selected from the group consisting
of C and N; Y is C; Y' is C(R.sup.9), wherein R.sup.9 is
-L.sup.2-L.sup.3(R.sup.3)(R.sup.6); Z is C; L.sup.1 is alkenyl;
L.sup.2 is --O--; L.sup.3 is alkylene, wherein the alkylene is
optionally substituted with one substituent selected from the group
consisting of alkoxy, amino, cyano, and hydroxy; R.sup.1 is
selected from the group consisting of aryl, heterocycle, and
heteroaryl; R.sup.2 and R.sup.4 are independently selected from the
group consisting of hydrogen, alkenyl, alkynyl, arylalkynyl, amino,
cyano, cyanoalkenyl, halo, hydroxyalkyl, and heteroaryl, wherein
the heteroaryl is selected from the group consisting of furyl,
pyrazinyl, thiazolyl, and thienyl; R.sup.3 is hydrogen; R.sup.6 is
selected from the group consisting of hydrogen, aryl, arylalkoxy,
arylalkylamino, arylalkylthio, aryloxy, arylthio, cycloalkyl,
heteroaryl, heteroarylalkoxy, heteroaryloxy, and heterocycle; and
R.sup.7 is absent or selected from the group consisting of
hydrogen, alkyl, and cyanoalkenyl.
[0052] In another embodiment, the present invention provides a
compound of formula (I) wherein X is selected from the group
consisting of C(R.sup.8) and N, wherein R.sup.8 is selected from
the group consisting of hydrogen, alkyl, amino, carboxy, cyano,
halo, hydroxy, and amido; X' is selected from the group consisting
of C and N; Y is C; Y' is C(R.sup.9), wherein R.sup.9 is
-L.sup.2-L.sup.3(R.sup.3)(R.sup.6); Z is C; L.sup.1 is alkenyl;
L.sup.2 is --O--; L.sup.1 is alkenyl; L.sup.2 is --O--; L.sup.3 is
alkylene, wherein the alkylene is optionally substituted with one
substituent selected from the group consisting of alkoxy, amino,
cyano, and hydroxy; R.sup.1 is heteroaryl; R.sup.2 and R.sup.4 are
independently selected from the group consisting of hydrogen,
alkenyl, alkynyl, arylalkynyl, amino, cyano, cyanoalkenyl, halo,
hydroxyalkyl, and heteroaryl, wherein the heteroaryl is selected
from the group consisting of furyl, pyrazinyl, thiazolyl, and
thienyl; R.sup.3 is hydrogen; R.sup.6 is selected from the group
consisting of hydrogen, aryl, arylalkoxy, arylalkylamino,
arylalkylthio, aryloxy, arylthio, cycloalkyl, heteroaryl,
heteroarylalkoxy, heteroaryloxy, and heterocycle; and R.sup.7 is
absent or selected from the group consisting of hydrogen, alkyl,
and cyanoalkenyl.
[0053] In another embodiment, the present invention provides a
compound of formula (I) wherein X is N; X' is C; Y is C; Y' is
C(R.sup.9), wherein R.sup.9 is -L.sup.2-L.sup.3(R.sup.3)(R.sup.6);
Z is C; L.sup.1 is alkenyl; L.sup.2 is --O--; L.sup.3 is alkylene,
wherein the alkylene is optionally substituted with one substituent
selected from the group consisting of alkoxy, amino, cyano, and
hydroxy; R.sup.1 is heteroaryl; R.sup.2 and R.sup.4 are
independently selected from the group consisting of hydrogen,
alkenyl, alkynyl, arylalkynyl, amino, cyano, cyanoalkenyl, halo,
hydroxyalkyl, and heteroaryl, wherein the heteroaryl is selected
from the group consisting of furyl, pyrazinyl, thiazolyl, and
thienyl; R.sup.3 is hydrogen; R.sup.6 is heteroaryl; and R.sup.7 is
hydrogen.
[0054] In another embodiment, the present invention provides a
compound of formula (I) wherein X is N; and X' is C; Y is C; Y' is
C(R.sup.9), wherein R.sup.9 is -L.sup.2-L.sup.3(R.sup.3)(R.sup.6);
Z is C; L.sup.1 is alkenyl; L.sup.2 is --O--; L.sup.3 is alkylene,
wherein the alkylene is optionally substituted with one substituent
selected from the group consisting of alkoxy, amino, cyano, and
hydroxy; R.sup.1 is heteroaryl; R.sup.2 and R.sup.4 are
independently selected from the group consisting of hydrogen,
alkenyl, alkynyl, arylalkynyl, amino, cyano, cyanoalkenyl, halo,
hydroxyalkyl, and heteroaryl, wherein the heteroaryl is selected
from the group consisting of furyl, pyrazinyl, thiazolyl, and
thienyl; R.sup.3 is hydrogen; R.sup.6 is aryl; and R.sup.7 is
hydrogen.
[0055] In another embodiment, the present invention provides a
compound of formula (I) wherein X is selected from the group
consisting of C(R.sup.8) and N, wherein R.sup.8 is selected from
the group consisting of hydrogen, alkyl, amino, carboxy, cyano,
halo, hydroxy, and amido; and X' is selected from the group
consisting of C and N; Y is C; Y' is C(R.sup.9), wherein R.sup.9 is
-L.sup.2-L.sup.3(R.sup.3)(R.sup.6); Z is C; L.sup.1 is alkenyl;
L.sup.2 is --O--; L.sup.3 is a bond; R.sup.1 is heteroaryl; R.sup.2
and R.sup.4 are independently selected from the group consisting of
hydrogen, alkenyl, alkynyl, arylalkynyl, amino, cyano,
cyanoalkenyl, halo, hydroxyalkyl, and heteroaryl, wherein the
heteroaryl is selected from the group consisting of furyl,
pyrazinyl, thiazolyl, and thienyl; R.sup.3 is absent; R.sup.6 is
heterocycle; and R.sup.7 is absent or selected from the group
consisting of hydrogen, alkyl, and cyanoalkenyl.
[0056] In another embodiment, the present invention provides a
compound of formula (I) wherein X is N; X' is C; Y is C; Y' is
C(R.sup.9), wherein R.sup.9 is -L.sup.2-L.sup.3(R.sup.3)(R.sup.6);
Z is C; L.sup.1 is alkenyl; L.sup.2 is --O--; L.sup.3 is a bond;
R.sup.1 is heteroaryl; R.sup.2 and R.sup.4 are hydrogen; R.sup.3 is
absent; R.sup.6 is heterocycle; and R.sup.7 is hydrogen.
[0057] In another embodiment, the present invention provides a
compound of formula (I) wherein X is selected from the group
consisting of C(R.sup.8) and N, wherein R.sup.8 is selected from
the group consisting of hydrogen, alkyl, amino, carboxy, cyano,
halo, hydroxy, and amido; X' is selected from the group consisting
of C and N; Y is C; Y' is C(R.sup.9), wherein R.sup.9 is
-L.sup.2-L.sup.3(R.sup.3)(R.sup.6); Z is C; L.sup.1 is alkenyl;
L.sup.2 is --N(R.sup.5)C(O)--; L.sup.3 is alkylene, wherein the
alkylene is optionally substituted with one substituent selected
from the group consisting of alkoxy, amino, cyano, and hydroxy;
R.sup.1 is selected from the group consisting of aryl, heterocycle,
and heteroaryl; R.sup.2 and R.sup.4 are independently selected from
the group consisting of hydrogen, alkenyl, alkynyl, arylalkynyl,
amino, cyano, cyanoalkenyl, halo, hydroxyalkyl, and heteroaryl,
wherein the heteroaryl is selected from the group consisting of
furyl, pyrazinyl, thiazolyl, and thienyl; R.sup.3 is hydrogen;
R.sup.6 is selected from the group consisting of hydrogen, aryl,
arylalkoxy, arylalkylamino, arylalkylthio, aryloxy, arylthio,
cycloalkyl, heteroaryl, heteroarylalkoxy, heteroaryloxy, and
heterocycle; and R.sup.7 is absent or selected from the group
consisting of hydrogen, alkyl, and cyanoalkenyl.
[0058] In another embodiment, the present invention provides a
compound of formula (I) wherein X is N; and X' is C; Y is C; Y' is
C(R.sup.9), wherein R.sup.9 is -L.sup.2-L.sup.3(R.sup.3)(R.sup.6);
Z is C; L.sup.1 is alkenyl; L.sup.2 is --N(R.sup.5)C(O)--; L.sup.3
is alkylene, wherein the alkylene is optionally substituted with
one substituent selected from the group consisting of alkoxy,
amino, cyano, and hydroxy; R.sup.1 is heteroaryl; R.sup.2 and
R.sup.4 are independently selected from the group consisting of
hydrogen, alkenyl, alkynyl, arylalkynyl, amino, cyano,
cyanoalkenyl, halo, hydroxyalkyl, and heteroaryl, wherein the
heteroaryl is selected from the group consisting of furyl,
pyrazinyl, thiazolyl, and thienyl; R.sup.3 is hydrogen; R.sup.6 is
heteroaryl; and R.sup.7 is hydrogen.
[0059] In another embodiment, the present invention provides a
compound of formula (I) wherein X is N; X' is C; Y is C; Y' is
C(R.sup.9), wherein R.sup.9 is -L.sup.2-L.sup.3(R.sup.3)(R.sup.6);
Z is C; L.sup.1 is alkenyl; L.sup.2 is --N(R.sup.5)C(O)--; L.sup.3
is alkylene, wherein the alkylene is optionally substituted with
one substituent selected from the group consisting of alkoxy,
amino, cyano, and hydroxy; R.sup.1 is heteroaryl; R.sup.2 and
R.sup.4 are independently selected from the group consisting of
hydrogen, alkenyl, alkynyl, arylalkynyl, amino, cyano,
cyanoalkenyl, halo, hydroxyalkyl, and heteroaryl, wherein the
heteroaryl is selected from the group consisting of furyl,
pyrazinyl, thiazolyl, and thienyl; R.sup.3 is hydrogen; R.sup.6 is
aryl; and R.sup.7 is hydrogen.
[0060] In another embodiment, the present invention provides a
compound of formula (I) wherein X is selected from the group
consisting of C(R.sup.8) and N, wherein R.sup.8 is selected from
the group consisting of hydrogen, alkyl, amino, carboxy, cyano,
halo, hydroxy, and amido; X' is selected from the group consisting
of C and N; Y is C; Y' is C(R.sup.9), wherein R.sup.9 is
-L.sup.2-L.sup.3(R.sup.3)(R.sup.6); Z is C; L.sup.1 is alkynyl;
L.sup.2 is selected from the group consisting of a bond, --O--,
--C(R.sup.12).sub.2--, --S--, --N(R.sup.5)--, --N(R.sup.5)C(O)--,
and --C(O)N(R.sup.5)--; L.sup.3 is a bond or selected from the
group consisting of alkylidene and alkylene, wherein the alkylidene
and the alkylene are optionally substituted with one or two
substituents independently selected from the group consisting of
alkoxy, amino, cyano, and hydroxy; R.sup.1 is selected from the
group consisting of aryl, heteroaryl, and heterocycle; R.sup.2 and
R.sup.4 are independently selected from the group consisting of
hydrogen, alkenyl, alkyl, alkynyl, amino, aryl, arylalkynyl, cyano,
cyanoalkenyl, halo, heteroaryl, heterocycle, hydroxyalkyl, and
nitro; R.sup.3 is absent or selected from the group consisting of
hydrogen, aryl, arylalkoxy, arylalkylamino, arylalkylthio, aryloxy,
arylthio, cycloalkyl, heteroaryl, heteroarylalkoxy, heteroaryloxy,
and heterocycle; R.sup.6 is selected from the group consisting of
hydrogen, aryl, arylalkoxy, arylalkylamino, arylalkylthio, aryloxy,
arylthio, cycloalkyl, heteroaryl, heteroarylalkoxy, heteroaryloxy,
and heterocycle; R.sup.5 is selected from the group consisting of
hydrogen, alkyl, alkylcarbonyl, alkylsulfonyl, arylcarbonyl,
arylsulfonyl, and heteroarylsulfonyl; R.sup.7 is absent or selected
from the group consisting of hydrogen, alkyl, and cyanoalkenyl; and
each R.sup.12 is selected from the group consisting of hydrogen,
alkenyl, alkyl, alkynyl, amino, aryl, cyano, halo, heteroaryl,
heterocycle, and nitro.
[0061] In another embodiment, the present invention provides a
compound of formula (I) wherein X is selected from the group
consisting of C(R.sup.8) and N, wherein R.sup.8 is selected from
the group consisting of hydrogen, alkyl, amino, carboxy, cyano,
halo, hydroxy, and amido; X' is selected from the group consisting
of C and N; Y is C; Y' is C(R.sup.9), wherein R.sup.9 is
-L.sup.2-L.sup.3(R.sup.3)(R.sup.6); Z is C; L.sup.1 is alkynyl;
L.sup.2 is --O--; L.sup.3 is alkylene, wherein the alkylene is
optionally substituted with one substituent selected from the group
consisting of alkoxy, amino, cyano, and hydroxy; R.sup.1 is
selected from the group consisting of aryl, heterocycle, and
heteroaryl; R.sup.2 and R.sup.4 are independently selected from the
group consisting of hydrogen, alkenyl, alkynyl, arylalkynyl, amino,
cyano, cyanoalkenyl, halo, hydroxyalkyl, and heteroaryl, wherein
the heteroaryl is selected from the group consisting of furyl,
pyrazinyl, thiazolyl, and thienyl; R.sup.3 is hydrogen; R.sup.6 is
selected from the group consisting of hydrogen, aryl, arylalkoxy,
arylalkylamino, arylalkylthio, aryloxy, arylthio, cycloalkyl,
heteroaryl, heteroarylalkoxy, heteroaryloxy, and heterocycle; and
R.sup.7 is absent or selected from the group consisting of
hydrogen, alkyl, and cyanoalkenyl.
[0062] In another embodiment, the present invention provides a
compound of formula (I) wherein X is selected from the group
consisting of C(R.sup.8) and N, wherein R.sup.8 is selected from
the group consisting of hydrogen, alkyl, amino, carboxy, cyano,
halo, hydroxy, and amido; X' is selected from the group consisting
of C and N; Y is C; Y' is C(R.sup.9), wherein R.sup.9 is
-L.sup.2-L.sup.3(R.sup.3)(R.sup.6); Z is C; L.sup.1 is a bond;
L.sup.2 is selected from the group consisting of a bond, --O--,
--C(R.sup.12).sub.2--, --S--, --N(R.sup.5)--, --N(R.sup.5)C(O)--,
and --C(O)N(R.sup.5)--; L.sup.3 is a bond or selected from the
group consisting of alkylidene and alkylene, wherein the alkylidene
and the alkylene are optionally substituted with one or two
substituents independently selected from the group consisting of
alkoxy, amino, cyano, and hydroxy; R.sup.1 is selected from the
group consisting of aryl, heteroaryl, and heterocycle; R.sup.2 and
R.sup.4 are independently selected from the group consisting of
hydrogen, alkenyl, alkyl, alkynyl, amino, aryl, arylalkynyl, cyano,
cyanoalkenyl, halo, heteroaryl, heterocycle, hydroxyalkyl, and
nitro; R.sup.3 is absent or selected from the group consisting of
hydrogen, aryl, arylalkoxy, arylalkylamino, arylalkylthio, aryloxy,
arylthio, cycloalkyl, heteroaryl, heteroarylalkoxy, heteroaryloxy,
and heterocycle; R.sup.6 is selected from the group consisting of
hydrogen, aryl, arylalkoxy, arylalkylamino, arylalkylthio, aryloxy,
arylthio, cycloalkyl, heteroaryl, heteroarylalkoxy, heteroaryloxy,
and heterocycle; R.sup.5 is selected from the group consisting of
hydrogen, alkyl, alkylcarbonyl, alkylsulfonyl, arylcarbonyl,
arylsulfonyl, and heteroarylsulfonyl; R.sup.7 is absent or selected
from the group consisting of hydrogen, alkyl, and cyanoalkenyl; and
each R.sup.12 is selected from the group consisting of hydrogen,
alkenyl, alkyl, alkynyl, amino, aryl, cyano, halo, heteroaryl,
heterocycle, and nitro.
[0063] In another embodiment, the present invention provides a
compound of formula (I) wherein X is selected from the group
consisting of C(R.sup.8) and N, wherein R.sup.8 is selected from
the group consisting of hydrogen, alkyl, amino, carboxy, cyano,
halo, hydroxy, and amido; and X' is selected from the group
consisting of C and N; Y is C; Y' is C(R.sup.9), wherein R.sup.9 is
-L.sup.2-L.sup.3(R.sup.3)(R.sup.6); Z is C; L.sup.1 is a bond;
L.sup.2 is --O--; L.sup.3 is alkylene, wherein the alkylene is
optionally substituted with one substituent selected from the group
consisting of alkoxy, amino, cyano, and hydroxy; R.sup.1 is
selected from the group consisting of aryl, heterocycle, and
heteroaryl; R.sup.2 and R.sup.4 are independently selected from the
group consisting of hydrogen, alkenyl, alkynyl, arylalkynyl, amino,
cyano, cyanoalkenyl, halo, hydroxyalkyl, and heteroaryl, wherein
the heteroaryl is selected from the group consisting of furyl,
pyrazinyl, thiazolyl, and thienyl; R.sup.3 is hydrogen; R.sup.6 is
selected from the group consisting of hydrogen, aryl, arylalkoxy,
arylalkylamino, arylalkylthio, aryloxy, arylthio, cycloalkyl,
heteroaryl, heteroarylalkoxy, heteroaryloxy, and heterocycle; and
R.sup.7 is absent or selected from the group consisting of
hydrogen, alkyl, and cyanoalkenyl.
[0064] In another embodiment, the present invention provides a
compound of formula (I) wherein X is N; X' is C; Y is C; Y' is
C(R.sup.9), wherein R.sup.9 is -L.sup.2-L.sup.3(R.sup.3)(R.sup.6);
Z is C; L.sup.1 is a bond; L.sup.2 is --O--; L.sup.3 is alkylene,
wherein the alkylene is optionally substituted with one substituent
selected from the group consisting of alkoxy, amino, cyano, and
hydroxy; R.sup.1 is heteroaryl; R.sup.2 and R.sup.4 are
independently selected from the group consisting of hydrogen,
alkenyl, alkynyl, arylalkynyl, amino, cyano, cyanoalkenyl, halo,
hydroxyalkyl, and heteroaryl, wherein the heteroaryl is selected
from the group consisting of furyl, pyrazinyl, thiazolyl, and
thienyl; R.sup.3 is hydrogen; R.sup.6 is aryl; and R.sup.7 is
hydrogen.
[0065] In another embodiment, the present invention provides a
compound of formula (I) wherein X is N; X' is C; Y is C; Y' is
C(R.sup.9), wherein R.sup.9 is -L.sup.2-L.sup.3(R.sup.3)(R.sup.6);
Z is C; L.sup.1 is a bond; L.sup.2 is --O--; L.sup.3 is alkylene,
wherein the alkylene is optionally substituted with one substituent
selected from the group consisting of alkoxy, amino, cyano, and
hydroxy; R.sup.1 is heteroaryl; R.sup.2 and R.sup.4 are
independently selected from the group consisting of hydrogen,
alkenyl, alkynyl, arylalkynyl, amino, cyano, cyanoalkenyl, halo,
hydroxyalkyl, and heteroaryl, wherein the heteroaryl is selected
from the group consisting of furyl, pyrazinyl, thiazolyl, and
thienyl; R.sup.3 is hydrogen; R.sup.6 is heteroaryl; and R.sup.7 is
hydrogen.
[0066] In another embodiment, the present invention provides a
compound of formula (I) wherein X is selected from the group
consisting of C(R.sup.8) and N, wherein R.sup.8 is hydrogen; X' is
N; Y is C; Y' is C(R.sup.9), wherein R.sup.9 is
-L.sup.2-L.sup.3(R.sup.3)(R.sup.6); Z is C; L.sup.1 is a bond;
L.sup.2 is --O--; L.sup.3 is alkylene, wherein the alkylene is
optionally substituted with one substituent selected from the group
consisting of alkoxy, amino, cyano, and hydroxy; R.sup.1 is
heteroaryl; R.sup.2 and R.sup.4 are independently selected from the
group consisting of hydrogen, alkenyl, alkynyl, arylalkynyl, amino,
cyano, cyanoalkenyl, halo, hydroxyalkyl, and heteroaryl, wherein
the heteroaryl is selected from the group consisting of furyl,
pyrazinyl, thiazolyl, and thienyl; R.sup.3 is hydrogen; R.sup.6 is
heteroaryl; and R.sup.7 is absent.
[0067] In another embodiment, the present invention provides a
compound of formula (I) wherein X is N; X' is C; Y is N; Y' is
C(R.sup.9), wherein R.sup.9 is -L.sup.2-L.sup.3(R.sup.3)(R.sup.6);
Z is C; L.sup.1 is a bond; L.sup.2 is --O--; L.sup.3 is alkylene,
wherein the alkylene is optionally substituted with one substituent
selected from the group consisting of alkoxy, amino, cyano, and
hydroxy; R.sup.1 is heteroaryl; R.sup.2 is absent; R.sup.4 is
selected from the group consisting of hydrogen, alkenyl, alkynyl,
arylalkynyl, amino, cyano, cyanoalkenyl, halo, hydroxyalkyl, and
heteroaryl, wherein the heteroaryl is selected from the group
consisting of furyl, pyrazinyl, thiazolyl, and thienyl; R.sup.3 is
hydrogen; R.sup.6 is aryl; and R.sup.7 is hydrogen.
[0068] In another embodiment, the present invention provides a
compound of formula (I) wherein X is N; X' is C; Y is N; Y' is
C(R.sup.9), wherein R.sup.9 is -L.sup.2-L.sup.3(R.sup.3)(R.sup.6);
Z is C; L.sup.1 is a bond; L.sup.2 is --O--; L.sup.3 is alkylene,
wherein the alkylene is optionally substituted with one substituent
selected from the group consisting of alkoxy, amino, cyano, and
hydroxy; R.sup.1 is heteroaryl; R.sup.2 is absent; R.sup.4 is
selected from the group consisting of hydrogen, alkenyl, alkynyl,
arylalkynyl, amino, cyano, cyanoalkenyl, halo, hydroxyalkyl, and
heteroaryl, wherein the heteroaryl is selected from the group
consisting of furyl, pyrazinyl, thiazolyl, and thienyl; R.sup.3 is
hydrogen; R.sup.6 is heteroaryl; and R.sup.7 is hydrogen.
[0069] In another embodiment, the present invention provides a
compound of formula (I) wherein X is C(R.sup.8), wherein R.sup.8 is
hydrogen; X' is C; Y is N; Y' is C(R.sup.9), wherein R.sup.9 is
-L.sup.2-L.sup.3(R.sup.3)- (R.sup.6); Z is C; L.sup.1 is a bond;
L.sup.2 is --O--; L.sup.3 is alkylene, wherein the alkylene is
optionally substituted with one substituent selected from the group
consisting of alkoxy, amino, cyano, and hydroxy; R.sup.1 is
heteroaryl; R.sup.2 is absent; R.sup.4 is selected from the group
consisting of hydrogen, alkenyl, alkynyl, arylalkynyl, amino,
cyano, cyanoalkenyl, halo, hydroxyalkyl, and heteroaryl, wherein
the heteroaryl is selected from the group consisting of furyl,
pyrazinyl, thiazolyl, and thienyl; R.sup.3 is hydrogen; R.sup.6 is
aryl; and R.sup.7 is hydrogen.
[0070] In another embodiment, the present invention provides a
compound of formula (I) wherein X is C(R.sup.8), wherein R.sup.8 is
hydrogen; X' is C; Y is N; Y' is C(R.sup.9), wherein R is
-L.sup.2-L.sup.3(R.sup.3)(R.sup- .6); Z is C; L.sup.1 is a bond;
L.sup.2 is --O--; L.sup.3 is alkylene, wherein the alkylene is
optionally substituted with one substituent selected from the group
consisting of alkoxy, amino, cyano, and hydroxy; R.sup.1 is
heteroaryl; R.sup.2 is absent; R.sup.4 is selected from the group
consisting of hydrogen, alkenyl, alkynyl, arylalkynyl, amino,
cyano, cyanoalkenyl, halo, hydroxyalkyl, and heteroaryl, wherein
the heteroaryl is selected from the group consisting of furyl,
pyrazinyl, thiazolyl, and thienyl; R.sup.3 is hydrogen; R.sup.6 is
heteroaryl; and R.sup.7 is hydrogen.
[0071] In another embodiment, the present invention provides a
compound of formula (I) wherein X is C(R.sup.8), wherein R.sup.8 is
hydrogen; X' is C; Y is N; Y' is C(R.sup.9), wherein R.sup.9 is
-L.sup.2-L.sup.3(R.sup.3)- (R.sup.6); Z is N; L.sup.1 is a bond;
L.sup.2 is --O--; L.sup.3 is alkylene, wherein the alkylene is
optionally substituted with one substituent selected from the group
consisting of alkoxy, amino, cyano, and hydroxy; R.sup.1 is
heteroaryl; R.sup.4 is absent; R.sup.2 is selected from the group
consisting of hydrogen, alkenyl, alkynyl, arylalkynyl, amino,
cyano, cyanoalkenyl, halo, hydroxyalkyl, and heteroaryl, wherein
the heteroaryl is selected from the group consisting of furyl,
pyrazinyl, thiazolyl, and thienyl; R.sup.3 is hydrogen; R.sup.6 is
aryl; and R.sup.7 is hydrogen.
[0072] In another embodiment, the present invention provides a
compound of formula (I) wherein X is C(R.sup.8), wherein R.sup.8 is
hydrogen; X' is C; Y is N; Y' is C(R.sup.9), wherein R.sup.9 is
-L.sup.2-L.sup.3(R.sup.3)- (R.sup.6); Z is N; L.sup.1 is a bond;
L.sup.2 is --O--; L.sup.3 is alkylene, wherein the alkylene is
optionally substituted with one substituent selected from the group
consisting of alkoxy, amino, cyano, and hydroxy; R.sup.1 is
heteroaryl; R.sup.4 is absent; R.sup.2 is selected from the group
consisting of hydrogen, alkenyl, alkynyl, arylalkynyl, amino,
cyano, cyanoalkenyl, halo, hydroxyalkyl, and heteroaryl, wherein
the heteroaryl is selected from the group consisting of furyl,
pyrazinyl, thiazolyl, and thienyl; R.sup.3 is hydrogen; R.sup.6 is
heteroaryl; and R.sup.7 is hydrogen.
[0073] In another embodiment, the present invention provides a
compound of formula (I) wherein X is N; X' is C; Y is N; Y' is
C(R.sup.9), wherein R.sup.9 is -L.sup.2-L.sup.3(R.sup.3)(R.sup.6);
Z is N; L.sup.1 is a bond; L.sup.2 is --O--; L.sup.3 is alkylene,
wherein the alkylene is optionally substituted with one substituent
selected from the group consisting of alkoxy, amino, cyano, and
hydroxy; R.sup.1 is heteroaryl; R.sup.4 is absent; R.sup.2 is
selected from the group consisting of hydrogen, alkenyl, alkynyl,
arylalkynyl, amino, cyano, cyanoalkenyl, halo, hydroxyalkyl, and
heteroaryl, wherein the heteroaryl is selected from the group
consisting of furyl, pyrazinyl, thiazolyl, and thienyl; R.sup.3 is
hydrogen; R.sup.6 is aryl; and R.sup.7 is hydrogen.
[0074] In another embodiment, the present invention provides a
compound of formula (I) wherein X is N; X' is C; Y is N; Y' is
C(R.sup.9), wherein R.sup.9 is -L.sup.2-L.sup.3(R.sup.3)(R.sup.6);
Z is N; L.sup.1 is a bond; L.sup.2 is --O--; L.sup.3 is alkylene,
wherein the alkylene is optionally substituted with one substituent
selected from the group consisting of alkoxy, amino, cyano, and
hydroxy; R.sup.1 is heteroaryl; R.sup.4 is absent; R.sup.2 is
selected from the group consisting of hydrogen, alkenyl, alkynyl,
arylalkynyl, amino, cyano, cyanoalkenyl, halo, hydroxyalkyl, and
heteroaryl, wherein the heteroaryl is selected from the group
consisting of furyl, pyrazinyl, thiazolyl, and thienyl; R.sup.3 is
hydrogen; R.sup.6 is heteroaryl; and R.sup.7 is hydrogen.
[0075] In another embodiment, the present invention provides a
compound of formula (I) wherein X is selected from the group
consisting of C(R.sup.8) and N, wherein R.sup.8 is selected from
the group consisting of hydrogen, alkyl, amino, carboxy, cyano,
halo, hydroxy, and amido; X' is selected from the group consisting
of C and N; Y is C; Y' is C(R.sup.9), wherein R.sup.9 is
-L.sup.2-L.sup.3(R.sup.3)(R.sup.6); Z is --C--; L.sup.1 is a bond;
L.sup.2 is --N(R.sup.5)--; L.sup.3 is alkylene, wherein the
alkylene is optionally substituted with one substituent selected
from the group consisting of alkoxy, amino, cyano, and hydroxy;
R.sup.1 is selected from the group consisting of aryl, heterocycle,
and heteroaryl; R.sup.2 and R.sup.4 are independently selected from
the group consisting of hydrogen, alkenyl, alkynyl, arylalkynyl,
amino, cyano, cyanoalkenyl, halo, hydroxyalkyl, and heteroaryl,
wherein the heteroaryl is selected from the group consisting of
furyl, pyrazinyl, thiazolyl, and thienyl; R.sup.3 is hydrogen;
R.sup.5 is selected from the group consisting of hydrogen, alkyl,
alkylcarbonyl, alkylsulfonyl, arylcarbonyl, arylsulfonyl, and
heteroarylsulfonyl; R.sup.6 is selected from the group consisting
of hydrogen, aryl, arylalkoxy, arylalkylamino, arylalkylthio,
aryloxy, arylthio, cycloalkyl, heteroaryl, heteroarylalkoxy,
heteroaryloxy, and heterocycle; and R.sup.7 is absent or selected
from the group consisting of hydrogen, alkyl, and cyanoalkenyl.
[0076] In another embodiment, the present invention provides a
compound of formula (I) wherein X is N; X' is C; Y is C; Y' is
C(R.sup.9), wherein R.sup.9 is -L.sup.2-L.sup.3(R.sup.3)(R.sup.6);
Z is C; L.sup.1 is a bond; L.sup.2 is --N(R.sup.5)--; L.sup.3 is
alkylene, wherein the alkylene is optionally substituted with one
substituent selected from the group consisting of alkoxy, amino,
cyano, and hydroxy; R.sup.1 is heteroaryl; R.sup.2 and R.sup.4 are
independently selected from the group consisting of hydrogen,
alkenyl, alkynyl, arylalkynyl, amino, cyano, cyanoalkenyl, halo,
hydroxyalkyl, and heteroaryl, wherein the heteroaryl is selected
from the group consisting of furyl, pyrazinyl, thiazolyl, and
thienyl; R.sup.3 is hydrogen; R.sup.5 is selected from the group
consisting of hydrogen, alkyl, alkylcarbonyl, alkylsulfonyl,
arylcarbonyl, arylsulfonyl, and heteroarylsulfonyl; R.sup.6 is
heteroaryl; and R.sup.7 is hydrogen.
[0077] In another embodiment, the present invention provides a
compound of formula (I) wherein X is N; X' is C; Y is C; Y' is
C(R.sup.9), wherein R.sup.9 is -L.sup.2-L.sup.3(R.sup.3)(R.sup.6);
Z is C; L.sup.1 is a bond; L.sup.2 is --N(R.sup.5)--; L.sup.3 is
alkylene, wherein the alkylene is optionally substituted with one
substituent selected from the group consisting of alkoxy, amino,
cyano, and hydroxy; R.sup.1 is heteroaryl; R.sup.2 and R.sup.4 are
independently selected from the group consisting of hydrogen,
alkenyl, alkynyl, arylalkynyl, amino, cyano, cyanoalkenyl, halo,
hydroxyalkyl, and heteroaryl, wherein the heteroaryl is selected
from the group consisting of furyl, pyrazinyl, thiazolyl, and
thienyl; R.sup.3 is hydrogen; R.sup.5 is selected from the group
consisting of hydrogen, alkyl, alkylcarbonyl, alkylsulfonyl,
arylcarbonyl, arylsulfonyl, and heteroarylsulfonyl; R.sup.6 is
aryl; and R.sup.7 is hydrogen.
[0078] In another embodiment, the present invention provides a
compound of formula (I) wherein X is selected from the group
consisting of C(R.sup.8) and N, wherein R.sup.8 is selected from
the group consisting of hydrogen, alkyl, amino, carboxy, cyano,
halo, hydroxy, and amido; X' is selected from the group consisting
of C and N; Y is C; Y' is C(R.sup.9), wherein R.sup.9 is
-L.sup.2-L.sup.3(R.sup.3)(R.sup.6); Z is C; L.sup.1 is a bond;
L.sup.2 is --N(R.sup.5)C(O)--; L.sup.3 is alkylene, wherein the
alkylene is optionally substituted with one substituent selected
from the group consisting of alkoxy, amino, cyano, and hydroxy;
R.sup.1 is selected from the group consisting of aryl, heterocycle,
and heteroaryl; R.sup.2 and R.sup.4 are independently selected from
the group consisting of hydrogen, alkenyl, alkynyl, arylalkynyl,
amino, cyano, cyanoalkenyl, halo, hydroxyalkyl, and heteroaryl,
wherein the heteroaryl is selected from the group consisting of
furyl, pyrazinyl, thiazolyl, and thienyl; R.sup.3 is hydrogen;
R.sup.6 is selected from the group consisting of hydrogen, aryl,
arylalkoxy, arylalkylamino, arylalkylthio, aryloxy, arylthio,
cycloalkyl, heteroaryl, heteroarylalkoxy, heteroaryloxy, and
heterocycle; and R.sup.7 is absent or selected from the group
consisting of hydrogen, alkyl, and cyanoalkenyl.
[0079] In another embodiment, the present invention provides a
compound of formula (I) wherein X is N; X' is C; Y is C; Y' is
C(R.sup.9), wherein R.sup.9 is -L.sup.2-L.sup.3(R.sup.3)(R.sup.6);
Z is C; L.sup.1 is a bond; L.sup.2 is --N(R.sup.5)C(O)--; L.sup.3
is alkylene, wherein the alkylene is optionally substituted with
one substituent selected from the group consisting of alkoxy,
amino, cyano, and hydroxy; R.sup.1 is heteroaryl; R.sup.2 and
R.sup.4 are independently selected from the group consisting of
hydrogen, alkenyl, alkynyl, arylalkynyl, amino, cyano,
cyanoalkenyl, halo, hydroxyalkyl, and heteroaryl, wherein the
heteroaryl is selected from the group consisting of furyl,
pyrazinyl, thiazolyl, and thienyl; R.sup.3 is hydrogen; R.sup.6 is
heteroaryl; and R.sup.7 is hydrogen.
[0080] In another embodiment, the present invention provides a
compound of formula (I) wherein X is N; X' is C; Y is C; Y' is
C(R.sup.9), wherein R.sup.9 is -L.sup.2-L.sup.3(R.sup.3)(R.sup.6);
Z is C; L.sup.1 is a bond; L.sup.2 is --N(R.sup.5)C(O)--; L.sup.3
is alkylene, wherein the alkylene is optionally substituted with
one substituent selected from the group consisting of alkoxy,
amino, cyano, and hydroxy; R.sup.1 is heteroaryl; R.sup.2 and
R.sup.4 are independently selected from the group consisting of
hydrogen, alkenyl, alkynyl, arylalkynyl, amino, cyano,
cyanoalkenyl, halo, hydroxyalkyl, and heteroaryl, wherein the
heteroaryl is selected from the group consisting of furyl,
pyrazinyl, thiazolyl, and thienyl; R.sup.3 is hydrogen; R.sup.6 is
aryl; and R.sup.7 is hydrogen.
[0081] In another embodiment, the present invention provides a
compound of formula (I) wherein X is selected from the group
consisting of C(R.sup.8) and N, wherein R.sup.8 is selected from
the group consisting of hydrogen, alkyl, amino, carboxy, cyano,
halo, hydroxy, and amido; X' is selected from the group consisting
of C and N; Y is C; Y' is C(R.sup.9), wherein R.sup.9 is
-L.sup.2-L.sup.3(R.sup.3)(R.sup.6); Z is C; L.sup.1 is
--N(R.sup.5)--; L.sup.2 is selected from the group consisting of a
bond, --O--, --C(R.sup.12).sub.2--, --S--, --N(R.sup.5)--,
--N(R.sup.5)C(O)--, and --C(O)N(R.sup.5)--; L.sup.3 is a bond or
selected from the group consisting of alkylidene and alkylene,
wherein the alkylidene and the alkylene are optionally substituted
with one or two substituents independently selected from the group
consisting of alkoxy, amino, cyano, and hydroxy; R.sup.1 is
selected from the group consisting of aryl, heteroaryl, and
heterocycle; R.sup.2 and R.sup.4 are independently selected from
the group consisting of hydrogen, alkenyl, alkyl, alkynyl, amino,
aryl, arylalkynyl, cyano, cyanoalkenyl, halo, heteroaryl,
heterocycle, hydroxyalkyl, and nitro; R.sup.3 is absent or selected
from the group consisting of hydrogen, aryl, arylalkoxy,
arylalkylamino, arylalkylthio, aryloxy, arylthio, cycloalkyl,
heteroaryl, heteroarylalkoxy, heteroaryloxy, and heterocycle;
R.sup.6 is selected from the group consisting of hydrogen, aryl,
arylalkoxy, arylalkylamino, arylalkylthio, aryloxy, arylthio,
cycloalkyl, heteroaryl, heteroarylalkoxy, heteroaryloxy, and
heterocycle; R.sup.5 is selected from the group consisting of
hydrogen, alkyl, alkylcarbonyl, alkylsulfonyl, arylcarbonyl,
arylsulfonyl, and heteroarylsulfonyl; R.sup.7 is absent or selected
from the group consisting of hydrogen, alkyl, and cyanoalkenyl; and
each R.sup.12 is selected from the group consisting of hydrogen,
alkenyl, alkyl, alkynyl, amino; aryl, cyano, halo, heteroaryl,
heterocycle, and nitro.
[0082] In another embodiment, the present invention provides a
compound of formula (I) wherein X is selected from the group
consisting of C(R.sup.8) and N, wherein R.sup.8 is selected from
the group consisting of hydrogen, alkyl, amino, carboxy, cyano,
halo, hydroxy, and amido; X' is selected from the group consisting
of C and N; Y is C; Y' is C(R.sup.9), wherein R.sup.9 is
-L.sup.2-L.sup.3(R.sup.3)(R.sup.6); Z is C; L.sup.1 is
--N(R.sup.5)--; L.sup.2 is --O--; L.sup.3 is alkylene, wherein the
alkylene is optionally substituted with one substituent selected
from the group consisting of alkoxy, amino, cyano, and hydroxy;
R.sup.1 is selected from the group consisting of aryl, heterocycle,
and heteroaryl; R.sup.2 and R.sup.4 are independently selected from
the group consisting of hydrogen, alkenyl, alkynyl, arylalkynyl,
amino, cyano, cyanoalkenyl, halo, hydroxyalkyl, and heteroaryl,
wherein the heteroaryl is selected from the group consisting of
furyl, pyrazinyl, thiazolyl, and thienyl; R.sup.3 is hydrogen;
R.sup.5 is selected from the group consisting of hydrogen, alkyl,
alkylcarbonyl, alkylsulfonyl, arylcarbonyl, arylsulfonyl, and
heteroarylsulfonyl; R.sup.6 is selected from the group consisting
of hydrogen, aryl, arylalkoxy, arylalkylamino, arylalkylthio,
aryloxy, arylthio, cycloalkyl, heteroaryl, heteroarylalkoxy,
heteroaryloxy, and heterocycle; and R.sup.7 is absent or selected
from the group consisting of hydrogen, alkyl, and cyanoalkenyl.
[0083] In another embodiment, the present invention provides a
compound of formula (I) wherein X is N; X' is C; Y is C; Y' is
C(R.sup.9), wherein R.sup.9 is -L.sup.2-L.sup.3(R.sup.3)(R.sup.6);
Z is C; L.sup.1 is --N(R.sup.5)--; L.sup.2 is --O--; L.sup.3 is
alkylene, wherein the alkylene is optionally substituted with one
substituent selected from the group consisting of alkoxy, amino,
cyano, and hydroxy; R.sup.1 is selected from the group consisting
of aryl, heterocycle, and heteroaryl; R.sup.2 and R.sup.4 are
independently selected from the group consisting of hydrogen,
alkenyl, alkynyl, arylalkynyl, amino, cyano, cyanoalkenyl, halo,
hydroxyalkyl, and heteroaryl, wherein the heteroaryl is selected
from the group consisting of furyl, pyrazinyl, thiazolyl, and
thienyl; R.sup.3 is hydrogen; R.sup.5 is selected from the group
consisting of hydrogen, alkyl, alkylcarbonyl, alkylsulfonyl,
arylcarbonyl, arylsulfonyl, and heteroarylsulfonyl; R.sup.6 is
heteroaryl; and R.sup.7 is hydrogen.
[0084] In another embodiment, the present invention provides a
compound of formula (I) wherein X is N; X' is C; Y is C; Y' is
C(R.sup.9), wherein R.sup.9 is L.sup.1-L.sup.3(R.sup.3)(R.sup.6); Z
is C; L.sup.1 is --N(R.sup.5)--; L.sup.2 is --O--; L.sup.3 is
alkylene, wherein the alkylene is optionally substituted with one
substituent selected from the group consisting of alkoxy, amino,
cyano, and hydroxy; R.sup.1 is selected from the group consisting
of aryl, heterocycle, and heteroaryl; R.sup.2 and R.sup.4 are
independently selected from the group consisting of hydrogen,
alkenyl, alkynyl, arylalkynyl, amino, cyano, cyanoalkenyl, halo,
hydroxyalkyl, and heteroaryl, wherein the heteroaryl is selected
from the group consisting of furyl, pyrazinyl, thiazolyl, and
thienyl; R.sup.3 is hydrogen; R.sup.5 is selected from the group
consisting of hydrogen, alkyl, alkylcarbonyl, alkylsulfonyl,
arylcarbonyl, arylsulfonyl, and heteroarylsulfonyl; R.sup.6 is
aryl; and R.sup.7 is hydrogen.
[0085] In another embodiment, the present invention provides a
compound of formula (I) wherein X is selected from the group
consisting of C(R.sup.8) and N, wherein R.sup.8 is selected from
the group consisting of hydrogen, alkyl, amino, carboxy, cyano,
halo, hydroxy, and amido; X' is selected from the group consisting
of C and N; Y is C; Y' is C(R.sup.9), wherein R.sup.9 is
-L.sup.2-L.sup.3(R.sup.3)(R.sup.6); Z is C; L.sup.1 is a bond;
L.sup.2 is a bond; L.sup.3 is a bond; R.sup.2 and R.sup.4 are
independently selected from the group consisting of hydrogen,
alkenyl, alkynyl, arylalkynyl, amino, cyano, cyanoalkenyl, halo,
hydroxyalkyl, and heteroaryl, wherein the heteroaryl is selected
from the group consisting of furyl, pyrazinyl, thiazolyl, and
thienyl; R.sup.3 is absent; R.sup.6 is heterocycle; and R.sup.7 is
absent or selected from the group consisting of hydrogen, alkyl,
and cyanoalkenyl.
[0086] In another embodiment, the present invention provides a
compound of formula (I) wherein X is selected from the group
consisting of C(R.sup.8) and N; wherein R.sup.8 is selected from
the group consisting of hydrogen, alkyl, amino, carboxy, cyano,
halo, hydroxy, and amido; X' is selected from the group consisting
of C and N; Y is C; Y' is C(R.sup.9), wherein R.sup.9 is
-L.sup.2-L.sup.3(R.sup.3)(R.sup.6); Z is C; L.sup.1 is selected
from the group consisting of a bond, --O--, --N(R.sup.5)--,
alkenyl, alkynyl, --C(O)--, --S--, --S(O)--, --S(O).sub.2--,
--S(O).sub.2N(R.sup.5)--, --N(R.sup.5)S(O).sub.2--,
--C(R.sup.12).sub.2--, --C(R.sup.12).sub.2N(R.sup.5)--,
--N(R.sup.5)C(O)--, and --C(O)N(R.sup.5)--, wherein each group is
drawn with its left end attached to R.sup.1 and its right end
attached to the aromatic ring; L.sup.3 is alkylidene, wherein the
alkylidene is optionally substituted with one or two substituents
independently selected from the group consisting of alkoxy, amino,
cyano, and hydroxy; R.sup.1 is selected from the group consisting
of aryl, heteroaryl, and heterocycle; R.sup.4 and L.sup.2, together
with the carbon atoms to which they are attached, form a ring
selected from the group consisting of aryl, heteroaryl, and
heterocycle; R.sup.3 is absent or selected from the group
consisting of hydrogen, aryl, arylalkoxy, arylalkylamino,
arylalkylthio, aryloxy, arylthio, cycloalkyl, heteroaryl,
heteroarylalkoxy, heteroaryloxy, and heterocycle; R.sup.6 is
selected from the group consisting of hydrogen, aryl, arylalkoxy,
arylalkylamino, arylalkylthio, aryloxy, arylthio, cycloalkyl,
heteroaryl, heteroarylalkoxy, heteroaryloxy, and heterocycle;
R.sup.5 is selected from the group consisting of hydrogen, alkyl,
alkylcarbonyl, alkylsulfonyl, arylcarbonyl, arylsulfonyl, and
heteroarylsulfonyl; R.sup.7 is absent or selected from the group
consisting of hydrogen, alkyl, and cyanoalkenyl; and each R.sup.12
is selected from the group consisting of hydrogen, alkenyl, alkyl,
alkynyl, amino, aryl, cyano, halo, heteroaryl, heterocycle, and
nitro.
[0087] In another embodiment, the present invention provides a
compound of formula (1) wherein X is selected from the group
consisting of C(R.sup.8) and N, wherein R.sup.8 is hydrogen; X' is
C; Y is C; Y' is C(R.sup.9), wherein R.sup.9 is
-L.sup.2-L.sup.3(R.sup.3)(R.sup.6); Z is C; L.sup.1 is a bond;
L.sup.3 is alkylidene, wherein the alkylidene is substituted with
one substituent selected from the group consisting of alkoxy,
amino, cyano, and hydroxy; R.sup.1 is heteroaryl wherein the
heteroaryl is isoquinolinyl; R.sup.4 and L.sup.2, together with the
carbon atoms to which they are attached, form a heterocycle wherein
the heterocycle is pyrrolidinyl substituted with oxo; R.sup.3 is
hydrogen; R.sup.6 is heteroaryl, wherein the heteroaryl is indolyl;
and R.sup.7 is hydrogen.
[0088] In another embodiment, the present invention provides a
compound of formula (I) wherein X is selected from the group
consisting of C(R.sup.8) and N; wherein R.sup.8 is selected from
the group consisting of hydrogen, alkyl, amino, carboxy, cyano,
halo, hydroxy, and amido; and X' is selected from the group
consisting of C and N; Y is C; Y' is C(R.sup.9), wherein R.sup.9 is
-L.sup.2-L.sup.3(R.sup.3)(R.sup.6); Z is C; R.sup.2 and L.sup.1,
together with the carbon atoms to which they are attached, form a
ring that is aryl wherein the aryl ring is phenyl; L.sup.2 is
--O--; L.sup.3 is alkylene, wherein the alkylene is optionally
substituted with one substituent selected from the group consisting
of alkoxy, amino, cyano, and hydroxy; R.sup.1 is heteroaryl;
R.sup.3 is absent; R.sup.6 is heteroaryl; and R.sup.7 is absent or
selected from the group consisting of hydrogen, alkyl, and
cyanoalkenyl.
[0089] In another embodiment, the present invention provides a
compound of formula (I) wherein X is N; X' is C; Y is C; Y' is
C(R.sup.9), wherein R.sup.9 is -L.sup.2-L.sup.3(R.sup.3)(R.sup.6);
Z is C; R.sup.2 and L.sup.1, together with the carbon atoms to
which they are attached, form a ring that is aryl wherein the aryl
ring is phenyl; L.sup.2 is --O--; L.sup.3 is alkylene, wherein the
alkylene is optionally substituted with one substituent selected
from the group consisting of alkoxy, amino, cyano, and hydroxy;
R.sup.1 is heteroaryl; R.sup.3 is absent; R.sup.6 is heteroaryl;
and R.sup.7 is hydrogen.
[0090] In another embodiment, the present invention provides a
compound of formula (I) wherein X is N; X' is C; Y is C; Y' is
C(R.sup.9), wherein R.sup.9 is -L.sup.2-L.sup.3(R.sup.3)(R.sup.6);
Z is C; R.sup.2 and L.sup.1, together with the carbon atoms to
which they are attached, form a ring that is aryl wherein the aryl
ring is phenyl; L.sup.2 is --O--; L.sup.3 is alkylene, wherein the
alkylene is optionally substituted with one substituent selected
from the group consisting of alkoxy, amino, cyano, and hydroxy;
R.sup.1 is heteroaryl; R.sup.3 is absent; R.sup.6 is aryl; and
R.sup.7 is hydrogen.
[0091] In another embodiment, the present invention provides a
compound of formula (I) wherein X is selected from the group
consisting of C(R.sup.8) and N; wherein R.sup.8 is selected from
the group consisting of hydrogen, alkyl, amino, carboxy, cyano,
halo, hydroxy, and amido; X' is selected from the group consisting
of C and N; Y is C; Y' is C(R.sup.9), wherein R.sup.9 is
-L.sup.2-L.sup.3(R.sup.3)(R.sup.6); Z is C; R.sup.2 and L.sup.1,
together with the carbon atoms to which they are attached, form a
ring that is heteroaryl wherein the heteroaryl is pyrazolyl;
L.sup.2 is a bond; L.sup.3 is alkylene, wherein the alkylene is
optionally substituted with one substituent selected from the group
consisting of alkoxy, amino, cyano, and hydroxy; R.sup.1 is
selected from the group consisting of aryl, heterocycle, and
heteroaryl; R.sup.3 is hydrogen; R.sup.6 is selected from the group
consisting of aryl, heterocycle, and heteroaryl; and R.sup.7 is
absent or selected from the group consisting of hydrogen, alkyl,
and cyanoalkenyl.
[0092] In another embodiment, the present invention provides a
compound of formula (I) wherein X is C(R.sup.8), wherein R.sup.8 is
hydrogen; X' is N; Y is C; Y' is C(R.sup.9), wherein R.sup.9 is
-L.sup.2-L.sup.3(R.sup.3)- (R.sup.6); Z is C; R.sup.2 and L.sup.1,
together with the carbon atoms to which they are attached, form a
ring that is heteroaryl wherein the heteroaryl is pyrazolyl;
L.sup.2 is a bond; L.sup.3 is alkylene, wherein the alkylene is
optionally substituted with one substituent selected from the group
consisting of alkoxy, amino, cyano, and hydroxy; R.sup.1 is
heteroaryl; R.sup.3 is hydrogen; R.sup.6 is aryl; and R.sup.7 is
absent.
[0093] In another embodiment, the present invention provides a
compound of formula (I) wherein X is C(R.sup.8), wherein R.sup.8 is
hydrogen; X' is N; Y is C; Y' is C(R.sup.9), wherein R.sup.9 is
-L.sup.2-L.sup.3(R.sup.3)- (R.sup.6); Z is C; R.sup.2 and L.sup.1,
together with the carbon atoms to which they are attached, form a
ring that is heteroaryl wherein the heteroaryl is pyrazolyl;
L.sup.2 is a bond; L.sup.3 is alkylene, wherein the alkylene is
optionally substituted with one substituent selected from the group
consisting of alkoxy, amino, cyano, and hydroxy; R.sup.1 is aryl;
R.sup.3 is hydrogen; R.sup.6 is aryl; and R.sup.7 is absent.
[0094] In another embodiment, the present invention provides a
compound of formula (I) wherein X is selected from the group
consisting of C(R.sup.8) and N; wherein R.sup.8 is selected from
the group consisting of hydrogen, alkyl, amino, carboxy, cyano,
halo, hydroxy, and amido; X is C; Y is C; Y' is C(R.sup.9), wherein
R.sup.9 is -L.sup.2-L.sup.3(R.sup.3)(R.sup.6); Z is C; R.sup.7 and
L.sup.1, together with the carbon atoms to which they are attached,
form a ring selected from the group consisting aryl, heteroaryl and
heterocycle; L.sup.2 is --O--; L.sup.3 is alkylene, wherein the
alkylene is optionally substituted with one substituent selected
from the group consisting of alkoxy, amino, cyano, and hydroxy;
R.sup.1 is selected from the group consisting of aryl, heterocycle,
and heteroaryl; R.sup.3 is hydrogen; and R.sup.6 is selected from
the group consisting of aryl, heterocycle, and heteroaryl.
[0095] In another embodiment, the present invention provides a
compound of formula (I) wherein X is N; and X' is C; Y is C; Y' is
C(R.sup.9), wherein R.sup.9 is -L.sup.2-L.sup.3(R.sup.3)(R.sup.6);
Z is C; R.sup.7 and L.sup.1, together with the carbon atoms to
which they are attached, form a ring that is a heteroaryl wherein
the heteroaryl is pyridinyl; L.sup.2 is --O--; L.sup.3 is alkylene,
wherein the alkylene is optionally substituted with one substituent
selected from the group consisting of alkoxy, amino, cyano, and
hydroxy; R.sup.1 is heteroaryl; R.sup.3 is hydrogen; and R.sup.6 is
heteroaryl.
[0096] In another embodiment, the present invention provides a
compound of formula (I) wherein X is N; and X' is C; Y is C; Y' is
C(R.sup.9), wherein R.sup.9 is -L.sup.2-L.sup.3(R.sup.3)(R.sup.6);
Z is C; R.sup.7 and L.sup.1, together with the carbon atoms to
which they are attached, form a ring that is a heteroaryl wherein
the heteroaryl is pyridinyl; L.sup.2 is --O--; L.sup.3 is alkylene,
wherein the alkylene is optionally substituted with one substituent
selected from the group consisting of alkoxy, amino, cyano, and
hydroxy; R.sup.1 is heteroaryl; R.sup.3 is hydrogen; and R.sup.6 is
aryl.
[0097] In another embodiment the invention provides a
pharmaceutical composition comprising a compound of formula (I), or
a therapeutically acceptable salt thereof, in combination with a
pharmaceutically acceptable carrier.
[0098] In another embodiment the invention provides a method of
inhibiting protein kinases in a patient in recognized need of such
treatment comprising administering to the patient a therapeutically
acceptable amount of a compound of formula (I), or a
therapeutically acceptable salt thereof.
DETAILED DESCRIPTION OF THE INVENTION
[0099] As used in the present specification the following terms
have the meanings indicated:
[0100] The term "alkenyl," as used herein, refers to a group
derived from a straight or branched chain hydrocarbon of up to six
atoms containing at least one double bond.
[0101] The term "alkoxy," as used herein, refers to an alkyl group
attached to the parent molecular moiety through an oxygen atom.
[0102] The term "alkoxyalkyl," as used herein, refers to an alkoxy
group attached to the parent molecular moiety through an alkyl
group.
[0103] The term "alkoxycarbonyl," as used herein, refers to an
alkoxy group attached to the parent molecular moiety through an
alkyl group.
[0104] The term "alkyl," as used herein, refers to a group derived
from a straight or branched chain saturated hydrocarbon of one to
six atoms.
[0105] The term "alkylene," as used herein, refers to a divalent
group derived from a straight or branched chain saturated
hydrocarbon of one to six atoms.
[0106] The term "alkylcarbonyl," as used herein, refers to an alkyl
group attached to the parent molecular moiety through a carbonyl
group.
[0107] The term "alkylidene," as used herein, refers to an alkenyl
group in which one carbon atom of the carbon-carbon double bond
belongs to the moiety to which the alkenyl group is attached.
[0108] The term "alkylsulfonyl," as used herein, refers to an alkyl
group attached to the parent molecular moiety through a sulfonyl
group.
[0109] The term "alkynyl," as used herein, refers to a group
derived from a straight or branched chain hydrocarbon of two to six
atoms containing at least one triple bond.
[0110] The term "amido," as used herein, refers to an amino group
attached to the parent molecular moiety through a carbonyl
group.
[0111] The term "amino," as used herein, refers to
--NR.sup.aR.sup.b, wherein R.sup.a and R.sup.b are independently
selected from the group consisting of hydrogen, alkenyl, alkoxy,
alkoxyalkyl, alkoxycarbonyl, alkyl, alkylcarbonyl, aryl,
arylalkenyl, arylalkyl, cycloalkyl, haloalkylcarbonyl,
(NR.sup.cR.sup.d)alkylcarbonyl, heteroaryl, heteroarylalkenyl,
heteroarylalkyl, heterocycle, (heterocycle)alkenyl, and
(heterocycle)alkyl, wherein the aryl, the aryl part of the
arylalkenyl, the arylalkyl, the heteroaryl, the heteroaryl part of
the heteroarylalkenyl and the heteroarylalkyl, the heterocycle, and
the heterocycle part of the (heterocycle)alkenyl and the
(heterocycle)alkyl can be optionally substituted with one, two,
three, four, or five substituents independently selected from the
group consisting of alkenyl, alkoxy, alkoxyalkyl, alkyl, cyano,
halo, haloalkoxy, haloalkyl, hydroxy, hydroxyalkyl, nitro, and
oxo.
[0112] The term "aminoalkyl," as used herein, refers to an amino
group attached to the parent molecular moiety through an alkyl
group.
[0113] The term "aryl," as used herein, refers to a phenyl group,
or a bicyclic or tricyclic fused ring system wherein one or more of
the fused rings is a phenyl group. Bicyclic fused ring systems are
exemplified by a phenyl group fused to a cycloalkyl group, as
defined herein, or another phenyl group. Tricyclic fused ring
systems are exemplified by a bicyclic fused ring system fused to a
cycloalkyl group, as defined herein, or another phenyl group.
Representative examples of aryl include, but are not limited to,
anthracenyl, azulenyl, fluorenyl, indanyl, indenyl, naphthyl,
phenyl, and tetrahydronaphthyl. The aryl groups of the present
invention can be optionally substituted with one, two, three, four,
or five substituents independently selected from the group
consisting of alkenyl, alkoxy, alkoxyalkyl, alkoxycarbonyl, alkyl,
alkylcarbonyl, alkylthio, amino, aminoalkyl, a second aryl group,
arylalkoxy, arylalkyl, arylcarbonyl, carboxy, cyano, cycloalkyl,
halo, haloalkoxy, haloalkyl, heteroaryl, heteroarylalkoxy,
heteroarylalkyl, heterocycle, (heterocycle)alkoxy,
(heterocycle)alkyl, hydroxy, hydroxyalkyl, nitro, oxo,
--C(.dbd.NOH)NH.sub.2, --C(.dbd.NH)NH.sub.2; wherein the second
aryl group, the aryl part of the arylalkoxy, the arylalkyl, and the
arylcarbonyl, the heteroaryl, the heteroaryl part of the
heteroarylalkoxy and the heteroarylalkyl, the heterocycle, and the
heterocycle part of the (heterocycle)alkoxy and the
(heterocycle)alkyl can be further optionally substituted with one,
two, three, four, or five substituents independently selected from
the group consisting of alkenyl, alkoxy, alkyl, halo, haloalkoxy,
haloalkyl, hydroxy, hydroxyalkyl, and nitro.
[0114] The term "arylalkenyl," as used herein, refers to an aryl
group attached to the parent molecular moiety through an alkenyl
group.
[0115] The term "arylalkoxy," as used herein, refers to an aryl
group attached to the parent molecular moiety through an alkoxy
group.
[0116] The term "arylalkyl," as used herein, refers to an aryl
group attached to the parent molecular moiety through an alkyl
group.
[0117] The term "arylalkylamino," as used herein, refers to an
arylalkyl group attached to the parent molecular moiety through a
nitrogen atom, wherein the nitrogen atom is substituted with
hydrogen.
[0118] The term "arylalkylidene," as used herein, refers to an aryl
group attached to the parent molecular moiety through an alkylidene
group
[0119] The term "arylalkylthio," as used herein, refers to an
arylalkyl group attached to the parent molecular moiety through a
sulfur atom.
[0120] The term "arylalkynyl," as used herein, refers to an aryl
group attached to the parent molecular moiety through an alkynyl
group.
[0121] The term "arylcarbonyl," as used herein, refers to an aryl
group attached to the parent molecular moiety through a carbonyl
group.
[0122] The term "aryloxy," as used herein, refers to an aryl group
attached to the parent molecular moiety through an oxygen atom.
[0123] The term "arylsulfonyl," as used herein, refers to an aryl
group attached to the parent molecular moiety through an sulfonyl
group.
[0124] The term "arylthio," as used herein, refers to an aryl group
attached to the parent molecular moiety through a sulfur atom.
[0125] The term "carbonyl," as used herein, refers to a --C(O)--
group.
[0126] The term "carboxy," as used herein, refers to --C(O)OH.
[0127] The term "cyano," as used herein, refers to --CN.
[0128] The term "cyanoalkenyl," as used herein, refers to a cyano
group attached to the parent molecular moiety through an alkenyl
group
[0129] The term "cycloalkyl," as used herein, refers to a saturated
monocyclic, bicyclic, or tricyclic hydrocarbon ring system having
three to twelve carbon atoms. Examples of cycloalkyl groups include
cyclopropyl, cyclopentyl, bicyclo[3.1.1]heptyl, adamantyl, and the
like.
[0130] The term "(cycloalkyl)alkylidene," as used herein, refers to
a cycloalkyl group attached to the parent molecular moiety through
an alkylidene group.
[0131] The term "halo," or "halogen," as used herein, refers to F,
Cl, Br, or I.
[0132] The term "haloalkoxy," as used herein, refers to a haloalkyl
group attached to the parent molecular moiety through an oxygen
atom.
[0133] The term "haloalkyl," as used herein, refers to an alkyl
group substituted by one, two, three, or four halogen atoms.
[0134] The term "haloalkylcarbonyl," as used herein, refers to an
haloalkyl group attached to the parent molecular moiety through a
carbonyl group.
[0135] The term "heteroaryl," as used herein, refers to an aromatic
five- or six-membered ring where at least one atom is selected from
the group consisting of N, O, and S, and the remaining atoms are
carbon. The five-membered rings have two double bonds, and the
six-membered rings have three double bonds. The heteroaryl groups
are connected to the parent molecular group through a substitutable
carbon or nitrogen atom in the ring. The term "heteroaryl" also
includes systems where a heteroaryl ring is fused to an aryl group,
as defined herein, a heterocycle group, as defined herein, or an
additional heteroaryl group. Heteroaryls are exemplified by
benzothienyl, benzoxadiazolyl, benzofuranyl, benzimidazolyl,
benzotriazolyl, cinnolinyl, furyl, imidazolyl, indazolyl, indolyl,
isoxazolyl, isoquinolinyl, isothiazolyl, naphthyridinyl,
oxadiazolyl, oxadiazolyl, oxazolyl, purinyl, thiazolyl,
thienopyridinyl, thienyl, triazolyl, thiadiazolyl, pyridinyl,
pyridazinyl, pyrimidinyl, pyrazinyl, pyrazolyl, pyrrolyl,
pyrido[2,3-d]pyrimidinyl, pyrrolo[2,3-b]pyridinyl, quinazolinyl,
quinolinyl, thieno[2,3-c]pyridinyl, tetrazolyl, triazinyl, and the
like. The heteroaryl groups of the present invention can be
optionally substituted with one, two, three, four, or five
substituents independently selected from the group consisting of
alkenyl, alkoxy, alkoxyalkyl, alkoxycarbonyl, alkyl, alkynyl,
alkylcarbonyl, amino, aminoalkyl, aryl, arylalkoxy, arylalkyl,
arylalkylthio, arylalkynyl, aryloxy, carboxy, cyano, cycloalkyl,
halo, haloalkoxy, haloalkyl, a second heteroaryl group,
heteroarylalkoxy, heteroarylalkyl, heterocycle,
(heterocycle)alkoxy, (heterocycle)alkyl, hydroxy, hydroxyalkyl,
nitro, and oxo, wherein the aryl, the aryl part of the arylalkoxy,
the arylalkyl, the arylalkylthio, the arylalkynyl, and the aryloxy,
the second heteroaryl group, the heteroaryl part of the
heteroarylalkoxy and the heteroarylalkyl, the heterocycle, and the
heterocycle part of the (heterocycle)alkoxy and the
(heterocycle)alkyl can be further optionally substituted with one,
two, three, four, or five substituents independently selected from
the group consisting of alkenyl, alkoxy, alkoxyalkyl, alkyl, cyano,
halo, haloalkoxy, haloalkyl, hydroxy, hydroxyalkyl, nitro, and
oxo.
[0136] The term "heteroarylalkenyl," as used herein, refers to a
heteroaryl group attached to the parent molecular moiety through an
alkenyl group.
[0137] The term "heteroarylalkoxy," as used herein, refers to a
heteroaryl group attached to the parent molecular moiety through an
alkoxy group.
[0138] The term "heteroarylalkyl," as used herein, refers to a
heteroaryl group attached to the parent molecular moiety through an
alkyl group.
[0139] The term "heteroarylalkylidene," as used herein, refers to a
heteroaryl group attached to the parent molecular moiety through an
alkylidene group.
[0140] The term "heteroaryloxy," as used herein, refers to a
heteroaryl group attached to the parent molecular moiety through an
oxygen atom.
[0141] The term "heteroarylsulfonyl," as used herein, refers to a
heteroaryl group attached to the parent molecular moiety through a
sulfonyl group.
[0142] The term "heterocycle," as used herein, refers to cyclic,
non-aromatic, three-, four-, five-, six-, or seven-membered rings
containing at least one atom selected from the group consisting of
oxygen, nitrogen, and sulfur. The five-membered rings have zero or
one double bonds and the six- and seven-membered rings have zero,
one, or two double bonds. The heterocycle groups of the invention
are connected to the parent molecular group through a substitutable
carbon or nitrogen atom in the ring. The term "heterocycle" also
includes systems where a heterocycle ring is fused to an aryl
group, as defined herein, or an additional heterocycle group.
Heterocycle groups of the invention are exemplified by aziridinyl,
azetidinyl, 1,3-benzodioxolyl, dihydroisoindolyl,
dihydroisoquinolinyl, dihydrocinnolinyl, dihydrobenzodioxinyl,
dihydro[1,3]oxazolo[4,5-b]pyridinyl, benzothiazolyl,
dihydroindolyl, dihydropyridinyl, 1,3-dioxanyl, 1,4-dioxanyl,
1,3-dioxolanyl, isoindolinyl, morpholinyl, piperazinyl,
pyrrolidinyl, tetrahydropyridinyl, piperidinyl, thiomorpholinyl,
and the like. The heterocycle groups of the present invention can
be optionally substituted with one, two, three, four, or five
substituents independently selected from the group consisting of
alkenyl, alkoxy, alkoxyalkyl, alkoxycarbonyl, alkyl, alkylcarbonyl,
alkylidene, amino, aminoalkyl, aryl, arylalkoxy, arylalkyl,
arylalkylidene, cyano, (cycloalkyl)alkylidene, halo, haloalkoxy,
haloalkyl, heteroaryl, heteroarylalkoxy, heteroarylalkyl,
heteroarylalkylidene, iminohydroxy, a second heterocycle,
(heterocycle)alkoxy, (heterocycle)alkyl, (heterocycle)alkylidene,
hydroxy, hydroxyalkyl, nitro, and oxo, wherein the aryl, the aryl
part of the arylalkoxy and the arylalkyl, the heteroaryl, the
heteroaryl part of the heteroarylalkoxy, the heteroarylalkyl, and
the heteroarylalkylidene, the second heterocycle, and the
heterocycle part of the (heterocycle)alkoxy, the
(heterocycle)alkyl, and the (heterocycle)alkylidene can be further
optionally substituted with one, two, three, four, or five
substituents independently selected from the group consisting of
alkenyl, alkoxy, alkoxyalkyl, alkyl, cyano, halo, haloalkoxy,
haloalkyl, hydroxy, hydroxyalkyl, nitro, and oxo.
[0143] The term "(heterocycle)alkenyl," as used herein, refers to a
heterocycle group attached to the parent molecular moiety through
an alkenyl group.
[0144] The term "(heterocycle)alkoxy," as used herein, refers to a
heterocycle group attached to the parent molecular group through an
oxygen atom.
[0145] The term "(heterocycle)alkyl," as used herein, refers to a
heterocycle group attached to the parent molecular moiety through
an alkyl group.
[0146] The term "(heterocycle)alkylidene," as used herein, refers
to a heterocycle group attached to the parent molecular moiety
through an alkylidene group.
[0147] The term "hydroxy," as used herein, refers to --OH.
[0148] The term "hydroxyalkyl," as used herein, refers to a hydroxy
group attached to the parent molecular moiety through an alkyl
group.
[0149] The term "iminohydroxy," as used herein, refers to
.dbd.N(OH).
[0150] The term "--NR.sup.cR.sup.d" as used herein, refers to two
groups, R.sup.c and R.sup.d, which are attached to the parent
molecular moiety through a nitrogen atom. R.sup.c and R.sup.d are
each independently selected from hydrogen and alkyl.
[0151] The term "(NR.sup.cR.sup.d)alkyl," as used herein, refers to
a --NR.sup.cR.sup.d group attached to the parent molecular moiety
through an alkyl group.
[0152] The term "(NR.sup.cR.sup.d)alkylcarbonyl," as used herein,
refers to a (NR.sup.cR.sup.d)alkyl group attached to the parent
molecular moiety through a carbonyl group.
[0153] The term "nitro," as used herein, refers to --NO.sub.2.
[0154] The term "oxo," as used herein, refers to .dbd.O.
[0155] The term "sulfonyl," as used herein, refers to
--S(O).sub.2--.
[0156] The compounds of the present invention can exist as
therapeutically acceptable salts.
[0157] The term "therapeutically acceptable salt," as used herein,
represents salts or zwitterionic forms of the compounds of the
present invention which are water or oil-soluble or dispersible,
which are suitable for treatment of diseases without undue
toxicity, irritation, and allergic response; which are commensurate
with a reasonable benefit/risk ratio, and which are effective for
their intended use. The salts can be prepared during the final
isolation and purification of the compounds or separately by
reacting an amino group with a suitable acid. Representative acid
addition salts include acetate, adipate, alginate, citrate,
aspartate, benzoate, benzenesulfonate, bisulfate, butyrate,
camphorate, camphorsulfonate, digluconate, glycerophosphate,
hemisulfate, heptanoate, hexanoate, formate, fumarate,
hydrochloride, hydrobromide, hydroiodide, 2-hydroxyethansulfonate
(isethionate), lactate, maleate, mesitylenesulfonate,
methanesulfonate, naphthylenesulfonate, nicotinate,
2-naphthalenesulfonate, oxalate, pamoate, pectinate, persulfate,
3-phenylproprionate, picrate, pivalate, propionate, succinate,
tartrate, trichloroacetate, trifluoroacetate, phosphate, glutamate,
bicarbonate, para-toluenesulfonate, and undecanoate. Also, amino
groups in the compounds of the present invention can be quaternized
with methyl, ethyl, propyl, and butyl chlorides, bromides, and
iodides; dimethyl, diethyl, dibutyl, and diamyl sulfates; decyl,
lauryl, myristyl, and steryl chlorides, bromides, and iodides; and
benzyl and phenethyl bromides. Examples of acids which can be
employed to form therapeutically acceptable addition salts include
inorganic acids such as hydrochloric, hydrobromic, sulfuric, and
phosphoric, and organic acids such as oxalic, maleic, succinic, and
citric.
[0158] Basic addition salts can be prepared during the final
isolation and purification of the compounds by reacting a carboxy
group with a suitable base such as the hydroxide, carbonate, or
bicarbonate of a metal cation or with ammonia or an organic
primary, secondary, or tertiary amine. The cations of
therapeutically acceptable salts include lithium, sodium,
potassium, calcium, magnesium, and aluminum, as well as nontoxic
quaternary amine cations such as ammonium, tetramethylammonium,
tetraethylammonium, methylamine, dimethylamine, trimethylamine,
triethylamine, diethylamine, ethylamine, tributylamine, pyridine,
N,N-dimethylaniline, N-methylpiperidine, N-methylmorpholine,
dicyclohexylamine, procaine, dibenzylamine,
N,N-dibenzylphenethylamine, 1-ephenamine, and
N,N'-dibenzylethylenediamine. Other representative organic amines
useful for the formation of base addition salts include
ethylenediamine, ethanolamine, diethanolamine, piperidine, and
piperazine.
[0159] The present compounds can also exist as therapeutically
acceptable prodrugs. The term "therapeutically acceptable prodrug,"
refers to those prodrugs or zwitterions which are suitable for use
in contact with the tissues of patients without undue toxicity,
irritation, and allergic response, are commensurate with a
reasonable benefit/risk ratio, and are effective for their intended
use. The term "prodrug," refers to compounds which are transformed
in vivo to parent compounds of formula (I) for example, by
hydrolysis in blood.
[0160] When any variable, substituent, or term (e.g. aryl,
heterocycle, R.sup.12, etc.) occurs more than one time in a formula
or generic structure, its definition at each occurrence is
independent of the definition at every other occurrence. Also,
combinations of substituents and/or variables are permissible only
if such combinations result in stable combinations.
[0161] Because carbon-carbon double bonds exist in the present
compounds, the invention contemplates various geometric isomers and
mixtures thereof resulting from the arrangement of substituents
around these carbon-carbon double bonds. It should be understood
that the invention encompasses both isomeric forms, or mixtures
thereof, which possess the ability to inhibit protein kinases.
These substituents are designated as being in the E or Z
configuration wherein the term "E" represents higher order
substituents on opposite sides of the carbon-carbon double bond,
and the term "Z" represents higher order substituents on the same
side of the carbon-carbon double bond.
[0162] Asymmetric centers exist in the compounds of the present
invention. These centers are designated by the symbols "R" or "S,"
depending on the configuration of substituents around the chiral
carbon atom. It should be understood that the invention encompasses
all stereochemical isomeric forms, or mixtures thereof, which
possess the ability to inhibit protein kinases. Individual
stereoisomers of compounds can be prepared synthetically from
commercially available starting materials which contain chiral
centers or by preparation of mixtures of enantiomeric products
followed by separation such as conversion to a mixture of
diastereomers followed by separation or recrystallization,
chromatographic techniques, or direct separation of enantiomers on
chiral chromatographic columns. Starting compounds of particular
stereochemistry are either commercially available or can be made
and resolved by techniques known in the art.
[0163] In accordance with methods of treatment and pharmaceutical
compositions of the invention, the compounds can be administered
alone or in combination with other anticancer agents. When using
the compounds, the specific therapeutically effective dose level
for any particular patient will depend upon factors such as the
disorder being treated and the severity of the disorder; the
activity of the particular compound used; the specific composition
employed; the age, body weight, general health, sex, and diet of
the patient; the time of administration; the route of
administration; the rate of excretion of the compound employed; the
duration of treatment; and drugs used in combination with or
coincidently with the compound used. The compounds can be
administered orally, parenterally, osmotically (nasal sprays),
rectally, vaginally, or topically in unit dosage formulations
containing carriers, adjuvants, diluents, vehicles, or combinations
thereof. The term "parenteral" includes infusion as well as
subcutaneous, intravenous, intramuscular, and intrasternal
injection.
[0164] Parenterally adminstered aqueous or oleaginous suspensions
of the compounds can be formulated with dispersing, wetting, or
suspending agents. The injectable preparation can also be an
injectable solution or suspension in a diluent or solvent. Among
the acceptable diluents or solvents employed are water, saline,
Ringer's solution, buffers, monoglycerides, diglycerides, fatty
acids such as oleic acid, and fixed oils such as monoglycerides or
diglycerides.
[0165] The anticancer effect of parenterally administered compounds
can be prolonged by slowing their absorption. One way to slow the
absorption of a particular compound is administering injectable
depot forms comprising suspensions of crystalline, amorphous, or
otherwise water-insoluble forms of the compound. The rate of
absorption of the compound is dependent on its rate of dissolution
which is, in turn, dependent on its physical state. Another way to
slow absorption of a particular compound is administering
injectable depot forms comprising the compound as an oleaginous
solution or suspension. Yet another way to slow absorption of a
particular compound is administering injectable depot forms
comprising microcapsule matrices of the compound trapped within
liposomes, microemulsions, or biodegradable polymers such as
polylactide-polyglycoli- de, polyorthoesters or polyanhydrides.
Depending on the ratio of drug to polymer and the composition of
the polymer, the rate of drug release can be controlled.
[0166] Transdermal patches can also provide controlled delivery of
the compounds. The rate of absorption can be slowed by using rate
controlling membranes or by trapping the compound within a polymer
matrix or gel. Conversely, absorption enhancers can be used to
increase absorption.
[0167] Solid dosage forms for oral administration include capsules,
tablets, pills, powders, and granules. In these solid dosage forms,
the active compound can optionally comprise diluents such as
sucrose, lactose, starch, talc, silicic acid, aluminum hydroxide,
calcium silicates, polyamide powder, tableting lubricants, and
tableting aids such as magnesium stearate or microcrystalline
cellulose. Capsules, tablets and pills can also comprise buffering
agents, and tablets and pills can be prepared with enteric coatings
or other release-controlling coatings. Powders and sprays can also
contain excipients such as talc, silicic acid, aluminum hydroxide,
calcium silicate, polyamide powder, or mixtures thereof. Sprays can
additionally contain customary propellants such as
chlorofluorohydrocarbons or substitutes therefore.
[0168] Liquid dosage forms for oral administration include
emulsions, microemulsions, solutions, suspensions, syrups, and
elixirs comprising inert diluents such as water. These compositions
can also comprise adjuvants such as wetting, emulsifying,
suspending, sweetening, flavoring, and perfuming agents.
[0169] Topical dosage forms include ointments, pastes, creams,
lotions, gels, powders, solutions, sprays, inhalants, and
transdermal patches. The compound is mixed under sterile conditions
with a carrier and any needed preservatives or buffers. These
dosage forms can also include excipients such as animal and
vegetable fats, oils, waxes, paraffins, starch, tragacanth,
cellulose derivatives, polyethylene glycols, silicones, bentonites,
silicic acid, talc and zinc oxide, or mixtures thereof.
Suppositories for rectal or vaginal administration can be prepared
by mixing the compounds with a suitable non-irritating excipient
such as cocoa butter or polyethylene glycol, each of which is solid
at ordinary temperature but fluid in the rectum or vagina.
Ophthalmic formulations comprising eye drops, eye ointments,
powders, and solutions are also contemplated as being within the
scope of this invention.
[0170] The total daily dose of the compounds administered to a host
in single or divided doses can be in amounts from about 0.1 to
about 200 mg/kg body weight or preferably from about 0.25 to about
100 mg/kg body weight. Single dose compositions can contain these
amounts or submultiples thereof to make up the daily dose.
[0171] Determination of Biological Activity
[0172] Enzymatic Assays:
[0173] The Akt1 assay uses His-Akt1-S36, a truncated Akt1
containing a His tag at the N-terminus, amino acid 139-460 of Akt1
and the following point mutations: S378A, S381A, T450D and S473D.
The His-Akt1-S36 assay is run in 96 well plates by incubating 1 nM
His-Akt1-S36, 5 .mu.M Biotin-BAD-peptide (Biotin) and 5 .mu.M
.sup.33P-ATP in 50 .mu.L of reaction buffer (20 mM HEPES, pH 7.5,
10 mM MgCl.sub.2, 0.009% Triton X-100) for 30 minutes at room
temperature. The reactions are stopped by adding 25 .mu.L of
stopping buffer (4M NaCl and 0.1M EDTA). The samples are
transferred to a Flash plate coated with streptavidin. The
phosphorylation of BAD-peptide in the reactions is measured by
counting the plate with the TopCount. Other kinase assays (Akt2,
Akt3, PKA, PKC, Erk2, Chk1, Cdc2, Src, CK2, MAPK AP kinase 2, and
SGK) are carried out similarly using their specific biotinylated
peptide substrates and buffer conditions. Compounds of the
invention inhibited Akt by 0-100% at a concentration of 1 .mu.M.
Preferred compounds had percent inhibitions of between 77 and 100
at 1 .mu.M and more preferred compounds had percent inhibitions of
between 92 and 100 at 1 .mu.M. Thus, the compounds of the invention
are useful in treating disorders which are caused or exacerbated by
increased protein kinase levels.
[0174] Synthetic Methods
[0175] Abbreviations which have been used in the descriptions of
the scheme and the examples that follow are: DEAD for diethyl
azodicarboxylate; THF for tetrahydrofuran; MTBE for methyl
tert-butyl ether, PPh.sub.3 for triphenylphosphine; OAc for
acetate; P(o-tol).sub.3 for tri-o-tolylphoshphine; dba for
dibenzylideneacetone; DME for 1,2-dimethoxyethane; BINAP for
2,2'-bis(diphenylphosphino)-1,1'-binaphthy- l; DMAP for
4-dimethylaminopyridine; dppf for diphenylphosphinoferrocene; dppe
for diphenylphosphinoethane; EDC for
1-ethyl-3-[3-(dimethylamino)pro- pyl]carbodiimide hydrochloride;
HOBt for 1-hydroxybenzotriazole; DCC for
1,3-dicyclohexylcarbodiimide; DMF for dimethylformamide; NMP for
N-methylpyrrolidinone; DMSO for dimethylsulfoxide; Boc for
tert-butoxycarbonyl; TFA for trifluoroacetic acid; DIBAL for
diisobutylaluminum hydride; n-BuLi for n-butyllithium; 9-BBN for
9-borabicyclo[3.3.1]nonane; OiPr for isopropoxide; DMA for
dimethylacetamide; AIBN for 2,2'-azobisisobutyronitrile; TEA for
triethylamine; and NBS for N-bromosuccinimide.
[0176] The compounds and processes of the present invention will be
better understood in connection with the following synthetic
schemes which illustrate the methods by which the compounds of the
invention may be prepared. The groups L.sup.1, L.sup.2, L.sup.3,
R.sup.1, R.sup.2, R.sup.3, R.sup.4, R.sup.6, and R.sup.7 are as
defined above unless otherwise noted below.
[0177] This invention is intended to encompass compounds having
formula (I) when prepared by synthetic processes or by metabolic
processes. Preparation of the compounds of the invention by
metabolic processes include those occurring in the human or animal
body (in vivo) or processes occurring in vitro. 5
[0178] As shown in Scheme 1, compounds of formula (2) (Z is Cl, Br,
I, or OTf) can be converted to compounds of formula (4) by
treatment with compounds of formula (3) in the presence of
triphenylphosphine and an activating agent such as DEAD. The
reaction can be carried out neat or in the presence of a solvent
such as THF, diethyl ether, and MTBE. The reaction temperature is
typically about -10.degree. C. to about 35.degree. C. and reaction
times are typically about 8 to about 24 hours.
[0179] Compounds of formula (4) can be converted to compounds of
formula (Ia) by treatment with compounds of formula (5) (M is
selected from B(OH).sub.2; Sn(R.sup.a).sub.3, where R.sup.a is an
alkyl or aryl group; and hydrogen) in the presence of a palladium
catalyst and an optional additive such as triethylamine. Examples
of palladium catalysts include Pd(PPh.sub.3).sub.4, and
Pd(OAc).sub.2 and P(o-tol).sub.3. Representative solvents include
toluene, acetonitrile, and DME. The reaction is typically conducted
at temperatures between about 60.degree. C. and about 110.degree.
C. and reaction times are typically about 4 to about 12 hours.
6
[0180] Scheme 2 shows that compounds of formula (6) (Z.sup.1 and
Z.sup.2 are independently Cl, Br, I, or OTf) can be converted to
compounds of formula (8) by treatment with compounds of formula (7)
according to the procedure described in Scheme 1. These compounds
can be converted to compounds of formula (9) by treatment with
benzophenone imine, a palladium catalyst, and a base. Examples of
palladium catalysts include Pd.sub.2 dba.sub.3 and a ligand such as
BINAP, dppf, or dppe. Representative bases include sodium
tert-butoxide and potassium tert-butoxide. Typically, the reaction
is conducted in a solvent such as toluene, acetonitrile, or DME; at
temperatures from about 60.degree. C. to about 90.degree. C.; and
at times from about 8 to about 24 hours.
[0181] Compounds of formula (9) can be treated with compounds of
formula (10) in the presence of an acid such as acetic acid and
then treated with sodium cyanoborohydride to provide compounds of
formula (Ib). Representative solvents include methanol and ethanol.
The reaction is typically conducted at about 20.degree. C. to about
70.degree. C. and reaction times are typically about 1 to about 4
hours. 7
[0182] Scheme 3 shows the preparation of compounds of formula (Ic).
Compounds of formula (11) (Z is Br) can be treated with a palladium
catalyst under CO atmosphere to provide compounds of formula (12).
Examples of palladium catalysts include PdCl.sub.2.dppf, PdCl.sub.2
and BINAP, and PdCl.sub.2.dppe. Representative solvents include
THF, water, DME, and mixtures thereof. The reaction is typically
conducted at about 80.degree. C. to about 100.degree. C. and
reaction times are typically between 12 and 24 hours.
[0183] Compounds of formula (12) can be converted to compounds of
formula (Ic) by treatment with a substituted amine in the presence
of a coupling agent. Representative coupling agents include EDC,
HOBt, DCC, DMAP, and mixtures thereof. Examples of solvents used
include dichloromethane, DMF, and DME. The reaction is typically
conducted at about 0.degree. C. to about 35.degree. C. and reaction
times are typically about 12 to about 24 hours. 8
[0184] As shown in Scheme 4, compounds of formula (13) can be
hydrolyzed to provide compounds of formula (14) using methods known
to those of ordinary skill in the art. Compounds of formula (14)
can be converted to compounds of formula (Id) using the conditions
described in Scheme 3. 9
[0185] Scheme 5 shows the synthesis of compounds of formula (Ie).
Compounds of formula (15) can be converted to compounds of formula
(16) by treatment with a reducing agent. Examples of reducing
agents include Pd/C and ammonium formate, Pd/C and hydrogen, and
PtO.sub.2 and hydrogen. Representative solvents include methanol
and ethanol. The reaction is typically conducted at about
50.degree. C. to about 70.degree. C. for about 15 minutes to about
2 hours.
[0186] Compounds of formula (16) can be converted to compounds of
formula (Ie) by treatment with an electrophile such as a
halo-substituted heteroaryl group. Examples of solvents used in
these reactions include ethanol and methanol. The reaction is
typically conducted at about 50.degree. C. to about 70.degree. C.
for about 6 to about 18 hours. 10
[0187] As shown in Scheme 6, compounds of formula (8) can be
converted to compounds of formula (If) (where L.sup.2 is a bond) by
treatment with compounds of formula (17) (M is B(OR.sup.z).sub.2,
wherein R.sup.z is hydrogen or alkyl) in the presence of a
palladium catalyst and a base such as cesium carbonate or sodium
carbonate. Representative palladium catalysts include
PdCl.sub.2.dppf, Pd(PPh.sub.3).sub.4, and
PdCl.sub.2(PPh.sub.3).sub.2. Examples of solvents used in these
reactions include DMF, DME, and NMP. The reaction is typically
conducted at about 30.degree. C. to about 100.degree. C. for about
4 to about 12 hours. 11
[0188] As shown in Scheme 7, compounds of formula (9) can be
reacted with compounds of formula (18) using the conditions
described in Scheme 3 to provide compounds of formula (Ig).
[0189] The present invention will now be described in connection
with certain preferred embodiments which are not intended to limit
its scope. On the contrary, the present invention covers all
alternatives, modifications, and equivalents as can be included
within the scope of the claims. Thus, the following examples, which
include preferred embodiments, will illustrate the preferred
practice of the present invention, it being understood that the
examples are for the purposes of illustration of certain preferred
embodiments and are presented to provide what is believed to be the
most useful and readily understood description of its procedures
and conceptual aspects.
EXAMPLE 1
N,N-dimethyl-N-[2-({5-[(E)-2-pyridin-4-ylvinyl]pyridin-3-yl}oxy)ethyl]amin-
e
Example 1A
N-{2-[(5-bromopyridin-3-yl)oxy]ethyl}-N,N-dimethylamine
[0190] A solution of N,N-dimethylethanolamine(0.5 mL) in DMF (10
mL) at room temperature was treated with sodium hydride (0.2 g, 8.4
mmol), stirred for 30 minutes, and treated with 3,5-dibromopyridine
(1.0 g, 4.2 mmol). The mixture was stirred at 90.degree. C. for 8
hours, and partitioned between ethyl acetate and water. The organic
layer was washed with brine, dried (Na.sub.2SO.sub.4), filtered,
and concentrated under vacuum. Purification by flash column
chromatography on silica gel with 50% ethyl acetate/hexane provided
the desired product (0.8 g, 78%). MS (DCI/NH.sub.3) m/e 246
(M+H).sup.+.
Example 1B
N,N-dimethyl-N-[2-({5-[(E)-2-pyridin-4-ylvinyl]pyridin-3-yl}oxy)ethyl]amin-
e
[0191] A mixture of Example 1A (0.8 g, 3.27 mmol), 4-vinylpyridine
(0.69 g, 5.53 mmol), tri-o-tolylphosphine (0.6 g, 1.96 mmol),
palladium acetate (0.16 g, 0.65 mmol) and triethylamine (0.66 g,
6.53 mmol) in acetonitrile (15 mL) was stirred for 8 hours at
80.degree. C. The reaction solution was partitioned between ethyl
acetate and water. The organic layer was washed with brine, dried
(Na.sub.2SO.sub.4), filtered, and concentrated under vacuum.
Purification by flash column chromatography on silica gel with 10%
methanol/dichloromethane provided the desired product (0.64 g,
73%). MS (DCI/NH.sub.3) m/e 270 (M+H).sup.+; .sup.1H NMR
(DMSO-d.sub.6) .delta. 8.58 (d, J=6.0 Hz, 2H), 8.39 (s, 1H), 8.24
(s, 1H), 7.73 (s, 1H), 7.56 (d, J=6.0 Hz, 1H), 7.56 (m, 2H), 7.45
(d, J=16.5 Hz, 2H), 4.19 (t, J=6.0 Hz, 2H), 2.67 (t, J=6.0 Hz, 2H),
2.23 (s, 6H).
EXAMPLE 2
(1S)-2-(1H-indol-3-yl)-1-[({5-[(E)-2-pyridin-4-ylvinyl]pyridin-3-yl}oxy)me-
thyl]ethylamine
Example 2A
tert-butyl
(1S)-2-[({5-hydroxypyridin-3-yl)oxy]-1-(1H-indol-3-ylmethyl)eth-
ylcarbamate
[0192] A solution of 3-bromo-5-hydroxypyridine (2.0 g, 11.5 mmol),
L-Boc-tryptophanol (3.67 g, 12.6 mmol), and triphenylphosphine
(4.53 g, 17.3 mmol) at 0.degree. C. was treated dropwise with DEAD
(3.01 g, 17.3 mmol), warmed to room temperature, stirred overnight,
and concentrated. The concentrate was purified by flash column
chromatography on silica gel with hexane/ethyl acetate (4:1) to
provide the desired product (4.55 g, 88.7%). MS (DCI/NH.sub.3):m/e
446, 448 (M+H).sup.+.
Example 2B
tert-butyl
(1S)-2-(1H-indol-3-yl)-1-[(5-[(E)-2-pyridin-4-ylvinyl]pyridin-3-
-yl}oxy)methyl]ethylcarbamate
[0193] The desired product was prepared by substituting Example 2A
for Example 1A in Example 1B. MS (DCI/NH.sub.3) m/e 471
(M+H).sup.+.
Example 2C
(1S)-2-(1H-indol-3-yl)-1-[({5-[(E)-2-pyridin-4-ylvinyl]pyridin-3-yl}oxy)me-
thyl]ethylamine
[0194] A solution of Example 2B (603 mg, 1.28 mmol) in
dichloromethane (20 mL) at room temperature was treated with 4N HCl
in dioxane (5 mL), stirred for 2 hours, and concentrated. The
residue was dissolved in water (1.5 mL) and freeze-dried to provide
the desired product as the hydrochloride salt (610 mg, 99%). MS
(DCI/NH.sub.3) m/e 371 (M+H).sup.+, .sup.1HNMR (CD.sub.3OD) .delta.
8.76 (d, J=6.8 Hz, 2H), 8.52 (d, J=1.4 Hz, 1H), 8.38 (d, J=2.4 Hz,
1H), 8.16 (d, J=7.1 Hz, 2H), 7.86 (d, J=16.6 Hz, 1H), 7.77 (m, 1H),
7.60 (d, J=8.1 Hz, 1H), 7.52 (d, J=8.1 Hz, 1H), 7.50 (d, J=16.6 Hz,
1H), 7.39 (d, J=8.1 Hz, 1H), 7.28 (s, 1H), 7.13 (m, 1H), 7.03 (m,
1H), 4.39 (dd, J=3.4, 10.5 Hz, 1H), 4.25 (dd, J=5.4, 10.5 Hz, 1H),
4.00 (m, 1H), 3.30 (m, 2H).
Example 2D
(1S)-2-(1H-indol-3-yl)-1-[({5-[(E)-2-pyridin-4-ylvinyl]pyridin-3-yl}oxy)me-
thyl]ethylamine
[0195] A solution of Example 2B (500 mg, 1.06 mmol) in
dichloromethane (5 mL) at room temperature was treated with
trifluoroacetic acid (5 mL), stirred for 2 hours, and concentrated.
The residue was dissolved in water (1.5 mL) and freeze-dried to
provide the desired product as the trifluoroacetate salt (643 mg,
85%). MS (DCI/NH.sub.3) m/c 371 (M+H).sup.+; .sup.1HNMR
(CD.sub.3OD) .delta. 8.83 (d, J=7 Hz, 2H), 8.77 (br s, 1H), 8.58
(br s, 1H), 8.39 (br s, 1H), 8.29 (d, J=7 Hz, 2H), 7.98 (d, J=17
Hz, 1H), 7.82 (d, J=17 Hz, 1H), 7.61 (d, J=7 Hz, 1H), 7.48 (d, J=7
Hz, 1H), 7.28 (s, 1H), 7.09-7.14 (m, 1H), 6.99-7.04 (m, 1H),
4.50-4.57 (m, 1H), 4.39-4.45 (m, 1H), 4.02-4.08 (m, 1H), 3.30-3.38
(m, 2H).
EXAMPLE 3
(1R)-2-(1H-indol-3-yl)-1-[({5-[(E)-2-pyridin-4-ylvinyl]pyridin-3-yl}oxy)me-
thyl]ethylamine
[0196] The desired product was prepared as the hydrochloride salt
by substituting D-Boc-tryptophanol for L-Boc-tryptophanol in
Example 2A then proceeding as described for to Examples 2B and 2C.
MS (DCI/NH.sub.3) m/e 371 (M+H).sup.+; .sup.1HNMR (CD.sub.3OD)
.delta. 8.76 (d, J=6.1 Hz, 2H), 8.52 (m, 1H), 8.37 (m, 1H), 8.17
(d, J=6.1 Hz, 2H), 7.86 (d, J=16.6 Hz, 1H), 7.79 (m, 1H), 7.59 (d,
J=7.8 Hz, 1H), 7.53 (d, J=16.6 Hz, 1H), 7.50 (d, J=16.6 Hz, 1H),
7.38 (d, J=8.1 Hz, 1H), 7.23 (s, 1H), 7.12 (m, 1H), 7.02 (m, 1H),
4.38 (dd, J=3.1, 10.5 Hz, 1H), 4.25 (dd, J=5.4, 10.5 Hz, 1H), 3.99,
(m, 1H), 3.26 (m, 2H).
EXAMPLE 4
1-(1H-indol-3-yl)-3-({5-[(E)-2-pyridin-4-ylvinyl]pyridin-3-yl}oxy)propan-2-
-ol
[0197] A solution of Example 2C (150 mg, 0.400 mmol) in acetic acid
(2.4 mL) at room temperature was treated portionwise with
NaNO.sub.2 (117 mg. 1.70 mmol), stirred for 18 hours, quenched with
water (40 .mu.L), stirred for an additional hour, poured into 2N
NaOH, and extracted with isopropanol/dichloromethane. The combined
extracts were concentrated. The residue was treated with
LiOH.H.sub.2O (25 mg) in THF/water (1 mL/0.5 mL), heated to
55.degree. C. overnight, diluted with dichloromethane, washed with
water, dried (MgSO.sub.4), filtered, and concentrated. The residue
was purified by HPLC on a C18 column with 0-100%
CH.sub.3CN/H.sub.2O/0.1% TFA to provide the desired product as the
trifluoroacetate salt (9.7 mg, 5%). MS (DCI/NH.sub.3) m/e 372
(M+H).sup.+; .sup.1H NMR (DMSO-d.sub.6) .delta. 10.82 (s, 1H), 8.85
(d, J=6.6 Hz, 2H), 8.49 (s, 1H), 8.37 (s, 1H), 8.08 (d, J=6.6 Hz,
2H), 7.90 (d, J=16.5 Hz, 1H), 7.79 (m, 1H), 7.65 (d, J=16.6 Hz,
1H), 7.56 (d, J=7.8 Hz, 1H), 7.32 (d, J=8.1 Hz, 1H), 7.18 (d, J=2.2
Hz, 1H), 7.04 (m, 1H), 6.95 (m, 1H), 4.06 (m, 2H), 3.83 (m, 1H),
3.03 (dd, J=6.2, 14.5 Hz, 1H), 2.91 (dd, J=6.2, 14.5 Hz, 1H).
EXAMPLE 5
(1S)-2-(1-benzothien-3-yl)-1-[({5-[(E)-2-pyridin-4-ylvinyl]pyridin-3-yl}ox-
y)methyl]ethylamine
[0198] The desired product was prepared as the trifluoroacetate
salt by substituting
2-tert-butoxycarbonylamino-3-benzo[b]thiophen-3-yl-propan-1-- ol
for L-Boc-tryptophanol in Example 2A then proceeding as described
for Examples 2B and 2D. MS (DCI/NH.sub.3) m/e 388 (M+H).sup.+;
.sup.1H NMR (DMSO-d.sub.6) .delta. 8.87 (d, J=6.3 Hz, 2H), 8.55 (s,
1H), 8.49 (br.s, 2H), 8.40 (d, J=7.2 Hz, 1H), 8.10 (d, J=6.3 Hz,
2H), 8.02 (d, J=7.2 Hz, 1H), 7.96 (d, J=7.2 Hz, 1H), 7.90 (d,
J=16.2 Hz, 1H), 7.80 (m, 1H), 7.68 (s, 1H), 7.63 (d, J=16.2 Hz,
1H), 7.42 (m, 2H), 4.36 (dd, J=3.1, 10.6 Hz, 1H), 4.20 (dd, J=5.3,
10.6 Hz, 1H), 3.99 (m, 1H), 3.36 (m, 2H).
EXAMPLE 6
(1S)-2,2-diphenyl-1-[({5-[(E)-2-pyridin-4-ylvinyl]pyridin-3-yl}oxy)methyl]-
ethylamine
[0199] The desired product was prepared as the hydrochloride salt
by substituting L-Boc-diphenylalaminol for L-Boc-tryptophanol in
Example 2A then proceeding as described for Examples 2B and 2C. MS
(DCI/NH.sub.3) m/e 408 (M+H).sup.+; .sup.1H NMR (DMSO-d.sub.6)
.delta. 8.89 (d, J=6.8 Hz, 2H), 8.57 (s, 1H), 8.45 (br s, 2H), 8.42
(d, J=2.4 Hz, 1H), 8.16 (d, J=6.8 Hz, 2H), 7.99 (d, J=16.6 Hz, 1H),
7.84 (s, 1H), 7.73 (d, J=16.6 Hz, 1H), 7.62 (m, 2H), 7.49 (m, 2H),
7.39 (m, 2H), 7.28 (m, 3H), 7.18 (m, 1H), 4.77 (m, 1H), 4.46 (m,
2H), 4.03 (m, 1H).
EXAMPLE 7
(1S)-1-{4-[(2,6-dichlorobenzyl)oxy]benzyl}-2-({5-[(E)-2-pyridin-4-ylvinyl]-
pyridin-3-yl}oxy)ethylamine
[0200] The desired product was prepared as the hydrochloride salt
by substituitng L-Boc-(4-(2,6-dichlorobenzyloxy)phenyl)alaninol for
L-Boc-tryptophanol in Example 2A then proceeding as described for
Examples 2B and 2C. MS (DCI/NH.sub.3) m/e 506, 508, 510
(M+H).sup.+; .sup.1H NMR (CD.sub.3OD) .delta. 8.81 (d, J=7.1 Hz,
2H), 8.71 (d, J=1.0 Hz, 1H), 8.55 (d, J=2.7 Hz, 1H), 8.28 (d, J=7.1
Hz, 2H), 8.25 (m, 1H), 7.99 (d, J=16.3 Hz, 1H), 7.79 (d, J=16.3 Hz,
1H), 7.46 (d, J=1.7 Hz, 1H), 7.43 (s, 1H), 7.36 (m, 1H), 7.30 (m,
2H), 7.05 (m, 2H), 5.28 (s, 2H), 4.45(dd, J=3.1, 10.5 Hz, 1H), 4.31
(dd, J=5.8, 10.5 Hz, 1H), 3.95 (m, 1H), 3.21 (m, 2H).
EXAMPLE 8
(1S)-2-(benzyloxy)-1-[({5-[(E)-2-pyridin-4-ylvinyl]pyridin-3-yl}oxy)methyl-
]ethylamine
[0201] The desired product was prepared as the hydrochloride salt
by substituting L-Boc-3-benzyloxyalaminol for L-Boc-tryptophanol in
Example 2A then proceeding as described for Examples 2B and 2C. MS
(DCI/NH.sub.3) m/e 362 (M+H).sup.+; .sup.1H NMR (CD.sub.3OD)
.delta. 8.80-8.89 (m, 4H), 8.53-8.62 (m, 3H), 8.28-8.34 (m, 3H),
8.00-8.06 (m, 1H), 7.98 (d, J=16.3 Hz, 1H), 7.87 (d, J=16.3 Hz,
1H), 7.28-7.43 (m, 3H), 4.66 (s, 2H), 4.56-4.64 (m, 2H), 3.94-3.99
(m, 1H), 3.83-3.87 (m, 2H).
EXAMPLE 9
N,N-dimethyl-N-[(1S,2S)-1-methyl-2-phenyl-2-({5-[(E)-2-pyridin-4-ylvinyl]p-
yridin-3-yl}oxy)ethyl]amine
Example 9A
5-bromopyridin-3-yl Acetate
[0202] A mixture of 3-bromo-5-hydroxypyridine (9.00 g, 51.7 mmol),
acetic anhydride (6.0 mL) and triethylamine (12.0 mL) in THF (50
mL) was heated to reflux overnight, cooled to room temperature,
diluted with diethyl ether, washed with water, 5% NaHCO.sub.3,
water, and brine, dried (MgSO.sub.4), filtered, and concentrated to
provide the desired product (9.37 g, 84%).
Example 9B
5-[(E)-2-pyridin-4-ylvinyl]pyridin-3-ol
[0203] A mixture of Example 9A (9.37 g, 43.3 mmol), 4-vinylpyridine
(14.0 mL, 130 mmol), tri-o-tolylphosphine (13.5 g, 44.4 mmol),
palladium acetate (2.65 g, 11.8 mmol) and triethylamine (120 mL,
0.861 mol) in acetonitrile (40 mL) was heated to reflux overnight
and partitioned between ethyl acetate and water. The organic layer
was washed with brine, dried (Na.sub.2SO.sub.4), filtered, and
concentrated under vacuum. Purification by flash column
chromatography on silica gel with 5% methanol/dichloromethane
containing 0.5% ammonia provided the acetate (8.53 g). This was
stirred with LiOH.H.sub.2O (6.00 g, 143 mmol) in THF/water (40
mL/20 mL) at room temperature for 4 hours, concentrated, adjusted
to pH 7 with 1N HCl (aq.), and filtered. The filter cake was washed
with water and dried under vacuum at 60.degree. C. to provide the
desired product (7.23 g, 84%). MS (DCI/NH.sub.3) m/e 199
(M+H).sup.+; .sup.1H NMR (CD.sub.3OD) .delta. 8.51 (m, 2H), 8.24
(d, J=1.4 Hz, 1H), 8.04 (d, J=2.4 Hz, 1H), 7.61 (m, 2H), 7.50 (m,
1H), 7.49 (d, J=16.6 Hz, 1H), 7.27 (d, J=16.6 Hz, 1H).
Example 9C
N,N-dimethyl-N-[(1S,2S)-1-methyl-2-phenyl-2-({5-[(E)-2-pyridin-4-ylvinyl]p-
yridin-3-yl}oxy)ethyl]amine
[0204] The desired product was prepared as the trifluoracetate salt
by substituting Example 9B and
(1S,2S)-2-(dimethylamino)-1-phenylpropan-1-ol for
3-bromo-5-hydroxypyridine and L-Boc-tryptophanol, respectively, in
Example 2A then proceeding as described for Examples 2B and 2D. MS
(DCI/NH.sub.3) m/e 360 (M+H).sup.+; .sup.1H NMR (DMSO-d.sub.6)
.delta. 8.78 (d, 2H), 8.44 (s, 1H), 8.33 (d, 1H), 7.94 (d, 1H),
7.80 (s, 1H), 7.75 (d, 1H), 7.59 (d, 2H), 7.46-7.34 (m, 5H), 5.84
(d, 1H), 3.55-3.45 (m, 1H), 2.95 (s, 3H), 2.84 (s, 3H), 1.02 (d,
3H).
EXAMPLE 10
(1S)-2-(2-naphthyl)-1-[({5-[(E)-2-pyridin-4-ylvinyl]pyridin-3-yl}oxy)methy-
l]ethylamine
[0205] The desired product was prepared as the trifluoracetate salt
by substituting L-Boc-(2-naphthyl)alaminol for L-Boc-tryptophanol
in Example 92A then proceeding as described for Examples 2B and 2D.
MS (DCI/NH.sub.3) m/e 382 (M+H).sup.+; .sup.1HNMR (DMSO-d.sub.6)
.delta. 8.88 (d, J=6.8 Hz, 2H), 8.57 (d, J=1.0 Hz, 1H), 8.43 (d,
J=2.4 Hz, 1H), 8.15 (d, J=6.8 Hz, 2H), 7.99 (d, J=16.6 Hz, 1H),
7.90 (m, 5H), 7.73 (d, J=16.6 Hz, 1H), 7.50 (m, 3H), 4.35 (dd,
J=3.4, 10.5 Hz, 1H), 4.21 (dd, J=5.4, 10.5 Hz, 1H), 3.97 (m, 1H),
3.32 (dd, J=5.8, 13.6 Hz, 1H), 3.21 (dd, J=9.2, 13.6 Hz, 1H).
EXAMPLE 11
N-[(2S)-2-amino-3-(1H-indol-3-yl)propyl]-N-{5-[(E)-2-pyridin-4-ylvinyl]pyr-
idin-3-yl}amine
Example 11A
3-bromo-5-[(E)-2-pyridin-4-ylvinyl]pyridine
[0206] A solution of 3,5-dibromopyridine (5.56 g, 23.4 mmol),
4-vinylpyridine (5.1 mL), palladium acetate (1.05 g),
tri-o-tolylphosphine (5.00 g) and triethylamine (33 mL) in
acetonitrile (100 mL) was heated overnight at 80.degree. C. and
concentrated. The residue was partitioned between 5% NaHCO.sub.3
and dichloromethane and filtered. The filtrate was separated and
the organic layer was washed with water, dried (MgSO.sub.4),
filtered, and concentrated. The concentrate was purified by flash
column chromatography on silica gel with 4%
methanol/dichloromethane to provide the desired product (2.18 g,
36%). (DCI/NH.sub.3) m/e 261, 263 (M+H).sup.+.
Example 11B
5-[(E)-2-pyridin-4-ylvinyl]pyridin-3-amine
[0207] A mixture of Example 11A (1.88 g, 7.2 mmol), benzophenone
imine (1.22 mL), Pd.sub.2(dba).sub.3 (66 mg), BINAP (125 mg),
sodium tert-butoxide (0.97 g), and toluene (19 mL) was heated to
80.degree. C. overnight and concentrated. The residue was purified
by flash column chromatography on silica gel with ethyl acetate to
provide a solid (2.44 g). This was stirred with 2N HCl (aq.) (5.0
mL) in THF (50 mL) at room temperature for 2 hours and
concentrated. The residue was dissolved in 0.5N HCl (aq.) (100 mL)
and washed three times with ethyl acteate. The aqueous layer was
adjusted to pH 11 with 1N NaOH and extracted with dichloromethane.
The combined extracts were washed with water, dried (MgSO.sub.4),
filtered, and concentrated to provide the desired product (1.23 g,
87%). MS (DCI/NH.sub.3) m/e 198 (M+H).sup.+; .sup.1H NMR
(DMSO-d.sub.6) .delta. 8.55 (m; 2H), 8.00 (d, J=1.7 Hz, 1H), 7.89
(d, J=2.4 Hz, 1H), 7.56 (m, 2H), 7.42 (d, J=16.6 Hz, 1H), 7.17 (d,
J=16.6 Hz, 1H), 7.15 (m, 1H).
Example 11C
tert-butyl
(1S)-2-(1H-indol-3-yl)-1-[({5-[(E)-2-pyridin-4-ylvinyl]pyridin--
3-yl}amino)methyl]ethylcarbamate
[0208] A mixture of Example 11B (52 mg, 0.264 mmol),
L-Boc-tryptophanal (J. Med. Chem., 1985, 28(12), 1874.) (80 mg,
0.277 mmol) and acetic acid (80 .mu.L) in methanol (4 mL) was
stirred at room temperature for 3 hours, refluxed for 2 hours,
cooled to room temperature, treated with sodium cyanoborohydride
(35 mg) stirred for 1 hour, and filtered. The filtrate was
concentrated and the residue was purified by HPLC on a C18 column
with 0-100% CH.sub.3CN/H.sub.2O/0.1% TFA to provide the designed
product (43 mg, 35%). MS (DCI/NH.sub.3) m/e 470 (M+H).sup.+.
Example 11D
N-[(2S)-2-amino-3-(1H-indol-3-yl)propyl]-N-{5-[(E)-2-pyridin-4-ylvinyl]pyr-
idin-3-yl}amine
[0209] A solution of Example 11C (40 mg, 0.085 mmol) in
dichloromethane (3.0 mL) at room temperature was treated with 4N
HCl in dioxane (0.5 mL), stirred for 1 hour, and concentrated to
provide the desired product as the hydrochloride salt (30 mg, 74%).
MS (DCI/NH.sub.3) m/e 370 (M+H).sup.+; .sup.1H NMR (DMSO-d.sub.6)
.delta. 11.09 (br s, 1H), 8.90 (d, J=5.8 Hz, 2H), 8.47 (br s, 2H),
8.33 (s, 1H), 8.22 (d, J=1.8 Hz, 1H), 8.14 (d, J=5.8 Hz, 2H), 7.98
(s, 1H), 7.94 (d, J=16.5 Hz, 1H), 7.86 (d, J=16.5 Hz, 1H), 7.62 (d,
J=7.9 Hz, 1H), 7.37 (d, J=4.5 Hz, 1H), 7.36 (s, 1H), 7.08 (m, 1H),
6.98 (m, 1H), 3.71 (m, 1H), 3.67 (m, 1H), 3.54 (m, 1H), 3.15 (m,
2H).
EXAMPLE 12
(1S)-2-({2-chloro-5-[(E)-2-pyridin-4-ylvinyl]pyridin-3-yl}oxy)-1-(1H-indol-
-3-ylmethyl)ethylamine
Example 12A
3-(benzyloxy)-5-bromo-2-chloropyridine
[0210] A solution of 3-(benzyloxy)-5-bromopyridine N-oxide (2.0 g,
7.1 mmol) in POCl.sub.3 (20 mL) was stirred at 100.degree. C. for 7
hours, cooled to room temperature, concentrated, treated with ethyl
acetate (50 mL), washed with brine, dried (MgSO.sub.4), filtered,
and concentrated. The concentrate was purified by flash column
chromatography on silica gel with 10% ethyl acetate/hexane to
provide the desired product (1.0 g, 40%). MS (DCI/NH.sub.3) m/e 299
(M+H).sup.+.
Example 12B
5-bromo-2-chloro-3-hydroxypyridine
[0211] A mixture of Example 12A in HBr/HOAc (30%, 50 mL) was
stirred at 100.degree. C. for 8 hours, cooled to room temperature
and concentrated. The concentrate was partitioned between ethyl
acetate and saturated Na.sub.2CO.sub.3 (aq.). The organic layer was
washed with brine, dried (Na.sub.2SO.sub.4), filtered, and
concentrated under vacuum. Purification by flash column
chromatography on silica gel with 30% ethyl acetate/hexane provided
the desired product (0.51 g, 72%). MS (DCI/NH.sub.3) m/e 209
(M+H).sup.+.
Example 12C
tert-butyl
(1S)-2-[(5-bromo-2-chloropyridin-3-yl)oxy]-1-(1H-indol-3-ylmeth-
yl)ethylcarbamate
[0212] The desired product was prepared by substituting Example 12B
for 3-bromo-5-hydroxypyridine in Example 2A (0.78 g, 66%). MS
(DCI/NH.sub.3) m/e 481 (M+H).sup.+.
Example 12D
(1S)-2-({2-chloro-5-[(E)-2-pyridin-4-ylvinyl]pyridin-3-yl}oxy)-1-(1H-indol-
-3-ylmethyl)ethylamine
[0213] The desired product was prepared as the trifluoroacetate
salt by substituting Example 12C for Example 2A in Examples 2B and
2D. MS (DCI/NH.sub.3) m/e 405, 407 (M+H).sup.+; .sup.1H NMR
(DMSO-d.sub.6) .delta. 11.04 (s, 1H), 8.72 (d, J=6.0 Hz, 2H), 8.30
(s, 1H), 8.23 (br s, 2H), 7.84 (s, 1H), 7.78 (d, J=6.0 Hz, 2H),
7.70 (d, J=16.8 Hz, 1H), 7.62 (d, J=8.1 Hz, 1H), 7.50 (d, J=16.8
Hz, 1H), 7.38 (d, J=8.1 Hz, 1H), 7.28 (s, 1H), 7.10 (t, J=7.2 Hz,
1H), 7.00 (t, J=7.2 Hz, 1H), 4.38 (m; 1H), 4.18 (m, 1H), 3.91 (m,
1H), 3.20 (m, 2H).
EXAMPLE 13
(1S)-2-({6-chloro-5-[(E)-2-pyridin-4-ylvinyl]pyridin-3-yl}oxy)-1-(1H-indol-
-3-ylmethyl)ethylamine
Example 13A
tert-butyl
(1S)-2-[(5-bromo-6-chloropyridin-3-yl)oxy]-1-(1H-indol-3-ylmeth-
yl)ethylcarbamate
[0214] A solution of 5-bromo-6-chloro-3-hydroxypyridine (2.50 g, 12
mmol) N-.alpha.-(tert-butoxycarbonyl)-L-tryptophanol (3.77 g, 18
mmol) and triphenylphosphine (4.72 g, 18 mmol) in THF (100 mL) was
stirred at 0.degree. C. for 20 minutes, treated with DEAD (2.83 mL,
18 mmol), stirred for 1 hour, warmed to room temperature, stirred
for 15 hours, treated with ethyl acetate (300 mL), washed with
brine, dried (MgSO.sub.4), filtered, and concentrated. The
concentrate was purified by flash column chromatography on silica
gel with 25% ethyl acetate/hexane to provide the desired product
(4.58 g, 80%). MS (APCI) m/e 480, 482 (M+H).sup.+.
Example 13B
tert-butyl
(1S)-2-({6-chloro-5-[(E)-2-pyridin-4-ylvinyl]pyridin-3-yl}oxy)--
1-(1H-indol-3-ylmethyl)ethylcarbamate
[0215] A solution Example 13A (1.50 g, 3.125 mmol),
Pd.sub.2(dba).sub.3 (71 mg, 0.078 mmol) and tri-o-tolylphosphine
(71 mg, 0.23 mmol) in DMF (30 mL) was treated with 4-vinylpyridine
(492 mg, 4.68 mmol) and triethylamine (1.30 mL, 9.4 mmol), purged
with nitrogen, and heated to 100.degree. C. for 4 hours. The
mixture was cooled to room temperature, treated with ethyl acetate
(200 mL), washed with brine, dried (MgSO.sub.4), filtered, and
concentrated. The concentrate was purified by flash column
chromatography on silica gel with 75% ethyl acetate/hexanes to
provide the desired product (1.37 g, 87%). MS (APCI) m/e 505, 507
(M+H).sup.+.
Example 13C
(1S)-2-({6-chloro-5-[(E)-2-pyridin-4-ylvinyl]pyridin-3-yl}oxy)-1-(1H-indol-
-3-ylmethyl)ethylamine
[0216] The desired product was prepared as the trifluoroacetate
salt by substituting Example 13B for Example 2B in Example 2D. MS
(APCI) m/e 405,407 (M+H).sup.+; .sup.1H NMR (300 MHz, CD.sub.3OD)
.delta. 8.76 (d, J=6.7 Hz, 2H), 8.18 (d, J=2.7 Hz, 1H), 8.15 (d,
J=6.5 Hz, 2H), 7.95 (d, J=16.2 Hz, 1H), 7.86 (d, J=3.0 Hz, 1H),
7.58 (d, J=7.8 Hz, 1H), 7.43 (d, J=16.3 Hz, 1H), 7.38 (d, J=8.1 Hz,
1H), 7.23 (s, 1H), 7.13 (t, J=7.1 Hz, 1H), 7.03 (t, J=7.8 Hz, 1H),
4.38 (dd, J=10.5, 3.0 Hz, 1H), 4.25 (dd, J=10.6, 5.8 Hz, 1H), 3.97
(m, 1H), 3.31 (m, 2H); Anal. Calcd for
C.sub.23H.sub.21ClN.sub.4O.2.3TFA: C, 49.69; H, 3.52; N, 8.40.
Found: C, 49.82; H, 3.48; N, 8.32.
EXAMPLE 14
(1S)-2-(1H-indol-3-yl)-1-({[5-(pyridin-4-ylethynyl)pyridin-3-yl]oxy}methyl-
)ethylamine
Example 14A
tert-butyl
(1S)-2-(1H-indol-3-yl)-1-[({5-[(trimethylsilyl)ethynyl]pyridin--
3-yl}oxy)methyl]ethylcarbamate
[0217] A mixture of Example 2A (500 mg, 1.12 mmol),
Pd.sub.2Cl.sub.2(PPh.sub.3).sub.2 (77 mg, 0.112 mmol), and CuI (52
mg, 0.27 mmol) was purged with nitrogen, treated with DMF (7 mL),
trimethylsilylacetylene (475 .mu.L, 3.36 mmol) and triethylamine
(468 .mu.L, 3.36 mmol) stirred at 50.degree. C. for 15 hours,
cooled to room temperature, treated with ethyl acetate (50 mL),
washed with brine, dried (MgSO.sub.4), filtered, and concentrated.
The residual oil was purified by flash column chromatography on
silica gel with 1:2 ethyl acetate/hexanes to provide the desired
product (417 mg, 80%). MS (APCI) m/e 464 (M+H).sup.+.
Example 14B
tert-butyl
(1S)-2-[(5-ethynylpyridin-3-yl)oxy]-1-(1H-indol-3-ylmethyl)ethy-
lcarbamate
[0218] A solution of Example 14A (400 mg, 0.86 mmol) in THF (6 mL)
at room temperature was treated with tetrabutylammonium fluoride
(1.0 M solution in THF, 1.12 mL, 1.12 mmol), stirred for 1 hour,
treated with ethyl acetate (50 mL), washed with brine, dried
(MgSO.sub.4), filtered, and concentrated. The residual oil was
purified by flash column chromatography on silica gel with 40%
ethyl acetate/hexanes to provide the desired product (290 mg, 86%).
MS (APCI) m/e 392 (M+H).sup.+.
Example 14C
tert-butyl
(1S)-2-(1H-indol-3-yl)-1-({[5-(pyridin-4-ylethynyl)pyridin-3-yl-
]oxy}methyl)ethylcarbamate
[0219] A mixture of Example 14B (150 mg, 0.384 mmol),
4-bromopyridine hydrochloride (75 mg, 0.34 mmol),
Pd.sub.2Cl.sub.2(PPh.sub.3).sub.2 (27 mg, 0.0384 mmol), and CuI (18
mg, 0.093 mmol), was purged with nitrogen, treated with DMF (4 mL)
and triethylamine (214 mL, 1.54 mmol), stirred at 50.degree. C. for
20 hours, cooled to room temperature, treated with ethyl acetate
(50 mL), washed with brine, dried (MgSO.sub.4), filtered, and
concentrated. The residual oil was purified by flash column
chromatography on silica gel with 2:1 ethyl acetate/hexanes to
provide the desired product (122 mg, 68%). MS (APCI) m/e 469
(M+H).sup.+.
Example 14D
(1S)-2-(1H-indol-3-yl)-1-({[5-(pyridin-4-ylethynyl)pyridin-3-yl]oxy}methyl-
)ethylamine
[0220] The desired product was prepared as the trifluoroacetate
salt by substituting Example 14C for Example 2B in Example 2D. MS
(APCI) m/e 369 (M+H).sup.+; .sup.1H NMR (300 MHz, CD.sub.3OD)
.delta. 8.76 (d, J=6.5 Hz, 2H), 8.47 (d, J=1.7 Hz, 1H), 8.42 (d,
J=2.7 Hz, 1H), 7.92 (d, J=6.5 Hz, 2H), 7.66 (dd, J=2.7, 1.7 Hz,
1H), 7.58 (d, J=7.8 Hz, 1H), 7.38 (d, J=8.2 Hz, 1H), 7.23 (s, 1H),
7.13 (td, J=7.1, 1.0 Hz, 1H), 7.03 (td, J=7.8, 1.1 Hz, 1H), 4.34
(dd, J=10.1, 3.0 Hz, 1H), 4.19 (dd, J=10.5, 5.8 Hz, 1H), 3.98 (m,
1H), 3.28 (m, 2H); Anal. Calcd for C.sub.23H.sub.20N.sub.4O.3.3
TFA: C, 47.74; H, 3.15; N, 7.52. Found: C, 47.53; H, 3.18; N,
7.48.
EXAMPLE 15
(1S)-2-(1H-indol-3-yl)-1-[({5-[(Z)-2-pyridin-4-ylvinyl]pyridin-3-yl}oxy)me-
thyl]ethylamine
[0221] A mixture of Example 14D (40 mg, 0.11 mmol), 5%
Pd/BaSO.sub.4 (8.1 mg) and quinoline (8.1 .mu.L) in methanol (3 mL)
was stirred under hydrogen (20 psi) at room temperature for 12
minutes and filtered. The filtrate was concentrated and the
residual oil was purified by HPLC on a C18 column with 0-100%
CH.sub.3CN/H.sub.2O/0.1% TFA to provide the desired product (30 mg,
75%). MS (APCI) m/e 369 (M-H).sup.-; .sup.1H NMR (300 MHz,
CD.sub.3OD) .delta. 8.57 (d, J=6.8 Hz, 2H), 8.29 (d, J=2.4 Hz, 1H),
8.04 (s, 1H), 7.69 (d, J=6.4 Hz, 2H), 7.57 (d, J=7.8 Hz, 1H), 7.53
(d, J=7.8 Hz, 1H), 7.40 (d, J=8.1 Hz, 1H), 7.33 (t, J=1.7 Hz, 1H),
7.21 (s, 1H), 7.14 (m, 2H), 7.02 (td, J=8.1, 1.0 Hz, 1H), 6.95 (d,
J=12.2 Hz, 1H), 4.24 (dd, J=10.5, 3.0 Hz, 1H), 4.08 (dd, J=10.5,
5.6 Hz, 1H), 3.92 (m, 1H), 3.26 (m, 2H); Anal. Calcd for
C.sub.23H.sub.22N.sub.4O.3.6 TFA: C, 46.45; H, 3.30; N, 7.17.
Found: C, 46.56; H, 3.35; N, 7.34.
EXAMPLE 16
(2S)-2-amino-4-phenyl-N-{5-[(E)-2-pyridin-4-ylvinyl]pyridin-3-yl}butanamid-
e
Example 16A
tert-butyl
(1S)-3-phenyl-1-[({5-[(E)-2-pyridin-4-ylvinyl]pyridin-3-yl}amin-
o)carbonyl]propylcarbamate
[0222] A mixture of Example 11B (200 mg, 1.0 mmol), HOBt (210 mg),
EDC (290 mg), DMAP (25 mg) and Boc-homophenylalanine was stirred at
room temperature overnight and concentrated. The residue was
dissolved in ethyl acetate, washed sequentially with water, 5%
NaHCO.sub.3, and water, dried (MgSO.sub.4), filtered, and
concentrated. The residue was purified by flash column
chromatography on silica gel with 3% methanol/dichloromethane to
provide the desired product (192 mg, 41%). MS (DCI/NH.sub.3) m/e
459 (M+H).sup.+.
Example 16B
(2S)-2-amino-4-phenyl-N-{5-[(E)-2-pyridin-4-ylvinyl]pyridin-3-yl}butanamid-
e
[0223] The desired product was prepared as the hydrochloride salt
by substituting Example 16A for Example 2B in Example 2C (173 mg,
89%). MS (DCI/NH.sub.3) m/e 359 (M+H).sup.+; .sup.1H NMR
(DMSO-d.sub.6) .delta. 12.03 (s, 1H), 8.97 (s, 1H), 8.91 (d, J=6.6
Hz, 2H), 8.85 (s, 1H), 8.70 (d, J=4.1 Hz, 2H), 8.60 (s, 1H), 8.28
(d, J=6.6 Hz, 2H), 8.09 (d, J=16.5 Hz, 1H), 7.68 (d, J=16.5 Hz,
1H), 7.24 (m, 5H), 4.33 (m, 1H), 2.78 (m, 2H), 2.25 (m, 2H).
EXAMPLE 17
5-{[(2S)-2-amino-3-(1H-indol-3-yl)propyl]oxy}-N-pyridin-4-ylnicotinamide
Example 17A
5-{[(2S)-2-[(tert-butoxycarbonyl)amino]-3-(1H-indol-3-yl)propyl]oxy}nicoti-
nic Acid
[0224] A solution of Example 2A (1.30 g, 3.02 mmol) and
PdCl.sub.2.dppf (123 mg) in THF/water (6.3 mL/6.3 mL) was heated to
100.degree. C. under CO (800 psi) for 19 hours, cooled to room
temperature, and diluted with water. The mixture was extracted with
dichloromethane and the combined extracts were washed with water,
dried (MgSO.sub.4), filtered, and concentrated to provide the
desired product (912 mg, 76%). MS (DCI/NH.sub.3) m/e 396
(M+H).sup.+.
Example 17B
tert-butyl
(1S)-2-(1H-indol-3-yl)-1-[({5-[(pyridin-4-ylamino)carbonyl]pyri-
din-3-yl}oxy)methyl]ethylcarbamate
[0225] A solution of Example 17A (410 mg, 1.0 mmol),
4-aminopyridine (100 mg, 1.0 mmol), EDC (960 mg), and HOBt (680 mg)
in DMF (10 mL) was stirred at room temperature overnight, diluted
with dichloromethane, washed with water, dried (MgSO.sub.4),
filtered, and concentrated. The residue was purified by flash
column chromatography on silica gel with ethyl acetate/methanol
(8:1) to provide the desired product (87 mg, 18%). MS
(DCI/NH.sub.3) m/e 488 (M+H).sup.+.
Example 17C
5-{[(2S)-2-amino-3-(1H-indol-3-yl)propyl]oxy}-N-pyridin-4-ylnicotinamide
[0226] The desired product was prepared as the hydrochloride salt
by substituting Example 17B for Example 2B in Example 2C (27 mg,
31%). MS (DCI/NH.sub.3) m/e 388 (M+H).sup.+; .sup.1H NMR
(DMSO-d.sub.6) .delta. 11.32 (br s, 1H), 11.04 (br s, 1H), 8.83 (d,
J=1.4 Hz, 1H), 8.69 (apparent d, J=6.8 Hz, 2H), 8.59 (d, J=2.7 Hz,
1H), 8.15 (br s, 2H), 8.08 (apparent d, J=6.8 Hz, 2H), 7.85 (dd,
J=1.4, 2.7 Hz, 1H), 7.61 (d, J=7.8 Hz, 1H), 7.38 (d, J=8.12 Hz,
1H), 7.29 (d, J=2.7 Hz, 1H), 7.10 (m, 1H), 7.01 (m, 1H), 4.33 (m,
1H), 4.16 (m, 1H), 3.87 (m, 1H), 3.16 (m, 2H).
EXAMPLE 18
N-(aminoethyl)-5-[(E)-2-pyridin-4-ylvinyl]nicotinamide Example
18A
Ethyl 5-[(E)-2-pyridin-4-ylvinyl]nicotinate
[0227] The desired product was prepared by substituting
3-bromo-5-ethoxycarbonylpyridine for Example 1A in Example 1B. MS
(DCI/NH.sub.3) m/e 355 (M+H).sup.+.
Example 18B
5-[(E)-2-pyridin-4-ylvinyl]nicotinic Acid
[0228] A mixture of Example 18A (1.60 g, 6.3 mmol) and
LiOH.H.sub.2O (2.64 g) in THF/water (50 mL/50 mL) was stirred at
room temperature for 2 hours. The THF was removed under vacuum and
the aqueous layer was acidified with 1N HCl (aq.). The solid was
collected by filtration and dried to provide the desired product.
MS (DCI/NH.sub.3) m/e 227 (M+H).sup.+.
Example 18C
N-(aminoethyl)-5-[(E)-2-pyridin-4-ylvinyl]nicotinamide
[0229] The desired product was prepared as the hydrochloride salt
by substituting Example 18B and
N-tert-butoxycarbonylaminoethylamine for Example 17A and
4-aminopyridine, respectively, in Examples 17B and 17C. MS
(DCI/NH.sub.3) m/e 384 (M+H).sup.+; .sup.1HNMR (DMSO-d.sub.6)
.delta. 9.19 (t, J=5.4 Hz, 1H), 9.09 (d, J=1.7 Hz, 1H), 9.01 (d,
J=2.0 Hz, 1H), 8.89 (d, J=6.5 Hz, 2H), 8.82 (dd, J=1.7, 2.0 Hz,
1H), 8.18 (d, J=6.5 Hz, 2H), 8.07 (d, J=16.6 Hz, 1H), 7.87 (d,
J=16.6 Hz, 1H), 3.72 (br s, 2H), 3.59 (m, 2H), 3.05 (m, 2H).
EXAMPLE 19
N-[(2E)-3-(4-bromophenyl)prop-2-enyl]-N-[2-({5-[(E)-2-pyridin-4-ylvinyl]py-
ridin-3-yl}oxy)ethyl]amine
Example 19A
(2E)-3-(4-bromophenyl)prop-2-en-1-ol
[0230] A solution of ethyl 4-bromocinnamide (5.430 g, 22.07 mmol)
in toluene (20 mL) at -78.degree. C. was treated over 10 minutes
with DIBAL (1.5 M in toluene, 37.0 mL, 55.5 mmol), stirred for 30
minutes at -78.degree. C., warmed to room temperature, stirred for
1 hour, quenched with 10% HCl (aq.), and extracted twice with
diethyl ether. The combined extracts were washed with water and
brine, dried (MgSO.sub.4), filtered, and concentrated to provide
the desired product (4.463 g, 95%). MS (DCI/NH.sub.3) m/e 212, 214
(M+H).sup.+, 228, 230 (M+18).sup.+.
Example 19B
1-bromo-4-[(1E)-3-chloroprop-1-enyl]benzene
[0231] A mixture of Example 19A (2.0 g, 9.387 mmol) and SOCl.sub.2
(3.5 mL, 47.9 mmol) in benzene (10 mL) was stirred at room
temperature for 24 hours and concentrated to provide the desired
product (2.167 g, 99%). (DCI/NH.sub.3) m/e 231, 233, 235
(M+H).sup.+.
Example 19C
2-({5-[(E)-2-pyridin-4-ylvinyl]pyridin-3-yl}oxy)ethanamine
[0232] The desired product was prepared as the hydrochloride salt
by substituting Example 9B and N-tert-butoxylcarbonylaminoethanol
(200 mg, 1.00 mmol) for 3-bromo-5-hydroxypyridine and
L-Boc-tryptophanol, respectively, in Examples 2A and 2C. MS
(DCI/NH.sub.3) m/e 242 (M+H).sup.+; .sup.1H NMR (CD.sub.3OD)
.delta. 8.88 (d, J=6.1 Hz, 2H), 8.59 (s, 1H), 8.43 (s, 1H), 8.19
(d, J=6.1 Hz, 2H), 8.03 (d, J=16.3 Hz, 1H), 8.01 (s, 1H), 7.82 (d,
J=16.3 Hz, 1H), 4.42 (t, J=4.9 Hz, 2H), 3.28 (m, 2H).
Example 19D
N-[(2E)-3-(4-bromophenyl)prop-2-enyl]-N-[2-({5-[(E)-2-pyridin-4-ylvinyl]py-
ridin-3-yl}oxy)ethyl]amine
[0233] A solution of Example 19C (100 mg, 0.285 mmol), Example 19B
(66.0 mg, 0.285 mmol), and triethylamine (250 .mu.L, 1.79 mmol) in
DMF (5 mL) at room temperature was stirred for 3 days, and poured
into water. The aqueous layer was extracted three times with
dichloromethane and the combined extracts were washed with water,
dried (MgSO.sub.4), filtered, and concentrated. The residue was
chromatographed on silica gel with
dichloromethane/methanol/NH.sub.4OH (100:5:0.5) to provide the free
base. The material was treated with 2M HCl/Et.sub.2O to provide the
hydrochloride salt (34.0 mg, 22%). MS (DCI/NH.sub.3) m/e 436,438
(M+H).sup.+; .sup.1HNMR (CDCl.sub.3) .delta. 8.61 (m, 2H), 8.37 (d,
J=1.7 Hz, 1H), 8.27 (d, J=2.7 Hz, 1H), 7.37 (m, 4H), 7.26 (m, 5H),
7.25 (d, J=16.3 Hz, 1H), 7.05 (d, J=16.3 Hz, 1H), 6.53 (d, J=15.9
Hz, 1H), 6.31 (dt, J=6.1, 15.9 Hz, 1H), 4.23 (t, J=5.1 Hz, 2H),
3.53 (dd, J=1.1, 6.1 Hz, 1H), 3.13 (t, J=5.1 Hz, 1H).
EXAMPLE 20
N.sup.4-(3-{[(2S)-2-amino-3-(1H-indol-3-yl)propyl]oxy}phenyl)pyrimidine-2,-
4-diamine
Example 20A
tert-butyl
(1S)-2-(1H-indol-3-yl)-1-[(3-nitrophenoxy)methyl]ethylcarbamate
[0234] The desired product was prepared by substituting
3-nitrophenol for 3-bromo-5-hydroxypyridine in Example 2A (257 mg,
61%). MS (DCI/NH.sub.3) m/e 412 (M+H).sup.+, 419 (M+18).sup.+.
Example 20B
tert-butyl
(1S)-2-(3-aminophenoxy)-1-(1H-indol-3-ylmethyl)ethylcarbamate
[0235] A solution of Example 20A (247 mg, 0.600 mmol), ammonium
formate (400 mg, 6.34 mmol) and 10% Pd/C (25 mg) in methanol (10
mL) was heated to reflux for 30 minutes, cooled to room
temperature, filtered through diatomaceous earth (Celite.RTM.), and
concentrated. The concentrate was purified by flash column
chromatography on silica gel with ethyl acetate/hexanes (1:1) to
provide the desired product (200 mg, 87%). MS (DCI/NH.sub.3) m/e
382 (M+H).sup.+.
Example 20C
tert-butyl
(1S)-2-{3-[(2-aminopyrimidin-4-yl)amino]phenoxy}-1-(1H-indol-3--
ylmethyl)ethylcarbamate
[0236] A solution of Example 20B (41.2 mg, 0.108 mmol) and
2-amino-4-chloropyrimidine (14.0 mg, 0.108 mmol) in ethanol (0.5
mL) was heated to 80.degree. C. for 13 hours and purified by flash
column chromatography on silica gel with
dichloromethane/methanol/NH.sub.4OH (100:5:0.5) to provide the
desired product (50 mg, 98%). MS (DCI/NH.sub.3) m/e
475(M+H).sup.+.
Example 20D
N.sup.4-(3-1[(2S)-2-amino-3-(1H-indol-3-yl)propyl]oxy
phenyl)pyrimidine-2,4-diamine
[0237] The desired product was prepared as the hydrochloride salt
by substituting Example 20C for Example 2B in Example 2C (33 mg,
81%). MS (DCI/NH.sub.3) m/e 375 (M+H).sup.+; .sup.1H NMR
(DMSO-d.sub.6) .delta. 12.3 (br s, 1H), 10.8 (br s, 1H), 8.35 (br
s, 4H), 7.85 (d, J=7.1 Hz, 1H), 7.61 (d, J=7.8 Hz, 1H), 7.45 (br s,
2H), 7.37 (d, J=7.8 Hz, 1H), 7.30 (m, 2H), 7.09 (m, 1H), 6.99 (m,
1H), 6.75 (m, 1H), 6.35 (m, 1H), 4.17 (dd, J=3.4, 10.5 Hz, 1H),
4.03 (dd, J=5.8, 10.5 Hz, 1H), 3.77 (m, 1H), 3.18 (d, J=7.5 Hz,
2H).
EXAMPLE 21
(1R)-3-{6-chloro-5-[(E)-2-pyridin-4-ylvinyl]pyridin-3-yl}-1-(1H-indol-3-yl-
methyl)propylamine
Example 21A
6-chloro-5-[(E)-2-pyridin-4-ylvinyl]pyridin-3-amine
[0238] A solution of 3-amino-5-bromo-6-chloropyridine (2.0 g, 9.64
mmol), Pd.sub.2(dba).sub.3 (440 mg, 0.48 mmol),
tri-o-tolylphosphine (438 mg, 1.44 mmol), 4-vinylpyridine (2.08 mL,
19.28 mmol), and triethylamine (4.03 mL, 29 mmol) in DMF (30 mL)
was stirred at 100.degree. C. for 15 hours, cooled to room
temperature, treated with ethyl acetate (200 mL), washed twice with
brine, dried (MgSO.sub.4), filtered and concentrated. The residual
solid recrystallized from hexanes/dichloromethane to provide
desired product (1.86 g, 84%). MS (APCI) m/e 232 (M+H).sup.+.
Example 21B
2-chloro-5-iodo-3-[(E)-2-pyridin-4-ylvinyl]pyridine
[0239] A solution of Example 21A (1.0 g, 4.3 mmol) in 30%
H.sub.2SO.sub.4 (10 mL) at 0.degree. C. was treated with NaNO.sub.2
(386 mg, 5.6 mmol), stirred for 5 hours, treated with a solution of
NaI (2.1 g, 14 mmol) in H.sub.2O (2 mL), stirred for 2 hours,
treated with additional NaI (2.1 g, 14 mmol), stirred for 2 hours,
poured into 30% NaOH (aq.) (200 mL) at 0.degree. C. and extracted
three times with 10% methanol/ethyl acetate. The combined organic
phases were dried (MgSO.sub.4), filtered, and concentrated. The
residual solid was purified by flash column chromatography on
silica gel with 70% ethyl acetate/hexanes to provide the desired
product (1.03 g, 70%). MS (DCI) m/e 343 (M+H).sup.+.
Example 21C
tert-butyl (1S)-1-(1H-indol-3-ylmethyl)prop-2-enylcarbamate
[0240] A suspension of methyltriphenylphosphonium bromide (5.65 g,
15.81 mmol) in THF (50 mL) at 0.degree. C. was treated with n-BuLi
(2.5 M solution in hexane, 6.33 mL, 15.81 mmol), stirred for 10
minutes, warmed to room temperature, stirred for 30 minutes, cooled
to 0.degree. C., treated with a solution of L-Boc-tryptophanal
(3.80 g, 13.2 mmol) in THF (10 mL), stirred for 2 hours, treated
with diethyl ether (200 mL), washed with brine, dried (MgSO.sub.4),
filtered, and concentrated. The residual oil was purified by flash
column chromatography on silica gel with 20% ethyl acetate/hexanes
to provide the desired product (700 mg, 18%). MS (DCI) m/e 287
(M+H).sup.+.
Example 21D
tert-butyl
(1R)-3-{6-chloro-5-[(E)-2-pyridin-4-ylvinyl]pyridin-3-yl}-1-(1H-
-indol-3-ylmethyl)propylcarbamate
[0241] A solution of Example 21C (100 mg, 0.35 mmol) in THF (3 mL)
at 0.degree. C. was treated with 9-BBN (0.5 M solution in THF, 0.70
mL, 0.35 mmol), stirred overnight while gradually warming to room
temperature, cannulated into a mixture of Example 21B (108 mg, 0.32
mmol), PdCl.sub.2(dppf) (26 mg, 0.032 mmol) and Cs.sub.2CO.sub.3
(228 mg, 0.7 mmol) in DMF, purged with nitrogen, and stirred at
50.degree. C. for 8 hours. The mixture was treated with ethyl
acetate (50 mL), washed with brine, dried (MgSO.sub.4), filtered,
and concentrated. The residual oil was purified by flash column
chromatography on silica gel with 80% ethyl acetate/hexanes to
provide the desired product (69 mg, 40%).
Example 21E
(1R)-3-{6-chloro-5-[(E)-2-pyridin-4-ylvinyl]pyridin-3-yl}-1-(1H-indol-3-yl-
methyl)propylamine
[0242] The desired product was prepared as the trifluoroacetate
salt by substituting Example 21D for Example 2B in Example 2D. MS
(APCI) m/e 403, 405 (M+H).sup.+; .sup.1H NMR (300 MHz, CD.sub.3OD)
.delta. 8.78 (d, J=6.8 Hz, 2H), 8.19 (d, J=1.7 Hz, 1H), 8.18 (d,
J=6.8 Hz, 2H), 7.97 (d, J=2.4 Hz, 1H), 7.93 (d, J=16.3 Hz, 1H),
7.48 (d, J=7.8 Hz, 1H), 7.34 (d, J=9.5 Hz, 1H), 7.33 (d, J=16.0 Hz,
1H), 7.20 (s, 1H), 7.11 (td, J=7.1, 1.0 Hz, 1H), 7.00 (td, J=6.8,
1.0 Hz, 1H), 3.55 (p, J=6.4 Hz, 1H), 3.16 (m, 2H), 2.82 (m, 2H),
2.06 (m, 2H); Anal. Calcd for C.sub.24H.sub.23ClN.sub.4.2.8 TFA: C,
49.23; H, 3.60; N, 7.76. Found: C, 49.11; H, 3.64; N, 7.66.
EXAMPLE 22
4-(5-{[(2S)-2-amino-3-(1H-indol-3-yl)propyl]oxy}pyridin-3-yl)benzonitrile
Example 22A
tert-butyl
(1S)-2-{[5-(4-cyanophenyl)pyridin-3-yl]oxy}-1-(1H-indol-3-ylmet-
hyl)ethylcarbamate
[0243] A solution of Example 2A (250 mg, 0.56 mmol) in ethylene
glycol dimethyl ether (20.0 mL) at room temperature was treated
with tetrakis(triphenylphosphine)palladium(0) (32 mg, 0.03 mmol),
stirred for 10 minutes, treated with a solution of
(4-cyanophenyl)boronic acid (123 mg, 0.84 mmol) in ethanol (5.0
mL), stirred for 15 minutes, treated with 2M Na.sub.2CO.sub.3 (aq.)
(1.4 mL), heated to reflux for 4 hours, cooled to room temperature,
and concentrated. The concentrate was purified by flash column
chromatography on silica gel with hexanes/ethyl acetate (1:1) to
provide the desired product (230 mg, 88%). MS (DCI/NH.sub.3) m/e
469 (M+H).sup.+.
Example 22B
4-(5-{[(2S)-2-amino-3-(1H-indol-3-yl)propyl]oxy}pyridin-3-yl)benzonitrile
[0244] A solution of Example 22A (20 mg, 0.043 mmol) in
dichloromethane (2.0 mL) at 0.degree. C. was treated dropwise with
trifluoroacetic acid (0.5 mL) and stirred for 2 hours while warming
to room temperature. The reaction mixture was concentrated to
provide the desired product as the trifluoroacetate salt (27 mg,
88%). MS (DCI/NH.sub.3) m/e 369 (M+H).sup.+; .sup.1H NMR
(DMSO-d.sub.6) .delta. 11.02 (s, 1H), 8.63 (d, J=1.9 Hz, 1H), 8.42
(d, J=2.8 Hz, 1H), 8.21 (br s, 2H), 7.99-7.92 (m, 4H), 7.73 (t,
J=1.9 Hz, 1H), 7.61 (d, J=8.1 Hz, 1H), 7.38 (d, J=8.1 Hz, 1H), 7.29
(d, J=2.5 Hz, 1H), 7.10 (m, 1H), 7.01 (m, 1H), 4.36 (dd, J=10.6,
3.1 Hz, 1H), 4.19 (dd, J=10.9, 5.9 Hz, 1H), 3.89-3.82 (m, 1H), 3.16
(d, J=7.2 Hz, 2H).
EXAMPLE 23
N-[(2S)-2-amino-3-(1H-indol-3-yl)propyl]-N'-isoquinolin-5-ylpyridine-3,5-d-
iamine
Example 23A
Isoquinolin-5-yl Trifluoromethanesulfonate
[0245] A mixture of 5-hydroxyisoquinoline (1.6 g; 11.0 mmol) and
triethylamine (1.38 g; 13.6 mmol) in dichloromethane (25 mL) at
0.degree. C. was treated slowly with triflic anhydride (3.35 g;
12.1 mmol), stirred overnight while warming to room temperature,
diluted with dichloromethane, washed twice with water and saturated
NH.sub.4Cl (aq.), once with water and brine, dried
(Na.sub.2SO.sub.4), filtered, and concentrated. The concentrate was
purified by flash column chromatography on silica gel with 7% ethyl
acetate/dichloromethane to provide the desired product (1.54 g;
50%).
Example 23B
3-amino-5-bromopyridine
[0246] A solution of 3M NaOH (250 mL) at room temperature was
treated with bromine (25.9 g, 162 mmol), stirred for 15 minutes,
treated with 5-bromonicotinamide (25 g, 124 mmol), stirred for 45
minutes, heated to 85-100.degree. C. for 3 hours, cooled to room
temperature, adjusted to pH 1 with 10% HCl (aq.) washed twice with
diethyl ether. The aqueous layer was adjusted to pH.about.10-11
with solid NaOH, and extracted four times with diethyl ether and
twice with dichloromethane. The combined extracts were dried
(MgSO.sub.4), filtered, and concentrated to provide the desired
product (13.3 g, 62%).
Example 23C
N-(5-bromopyridin-3-yl)isoquinolin-5-amine
[0247] A mixture Example 23A (500 mg, 1.8 mmol), Example 23B (600
mg, 3.5 mmol), Pd.sub.2(dba).sub.3 (42 mg; 0.045 mmol), BINAP (56
mg; 0.09 mmol), and sodium tert-butoxide (350 mg; 3.6 mmol) in 10
mL toluene was heated to reflux for 2 hours, diluted with water,
and extracted three times with ethyl acetate. The combined extracts
were washed successively with saturated NaHCO.sub.3, water, and
brine, dried (Na.sub.2SO.sub.4), and concentrated. The concentrate
was purified by flash column chromatography on silica gel with 3%
methanol/dichloromethane to provide the desired product (97 mg,
18%).
Example 23D
N-(diphenylmethylene)-N'-isoquinolin-5-ylpyridine-3,5-diamine
[0248] A mixture-of Example 23C (175 mg, 0.58 mmol), benzophenone
imine (150 mg, 0.83 mmol), Pd.sub.2(dba).sub.3 (54 mg, 0.06 mmol),
BINAP (55 mg, 0.09 mmol), and sodium tert-butoxide (80 mg, 0.82
mmol) in 3 mL toluene was heated to 75-80.degree. C. for 4 hours
and concentrated. The concentrate was purified by flash column
chromatography on silica gel with 3% methanol/dichloromethane to
provide the desired product (150 mg, 64%).
Example 23E
N-isoquinolin-5-ylpyridine-3,5-diamine
[0249] A mixture of Example 23D (145 mg; 0.36 mmol) in 3 mL THF at
room temperature was treated with 10 drops of water and 3 drops of
conc. HCl, stirred for 2 hours, and concentrated. The residue was
partitioned between ethyl acetate and concentrated NaHCO.sub.3
(aq). The aqueous layer was extracted three times with ethyl
acetate. The combined extracts were washed with brine, dried
(MgSO.sub.4), filtered, and concentrated. The concentrate was
purified by flash column chromatography on silica gel with 10%
methanol/dichloromethane to provide the desired product (59 mg,
68%).
Example 23F
tert-butyl
(1S)-2-(1H-indol-3-yl)-1-({[5-(isoquinolin-5-ylamino)pyridin-3--
yl]amino}methyl)ethylcarbamate
[0250] A mixture of Example 23E (55 mg, 0.23 mmol) and
L-Boc-tryptophanal (84 mg, 0.29 mmol) in 2 mL dichloromethane at
room temperature was treated with Ti(iPrO).sub.4 (1 mL), stirred
for 2 hours, and concentrated. The residue was dissolved in 2 mL
ethanol, treated with NaBH.sub.3CN (30 mg; 0.46 mmol), stirred for
2 hours, diluted with water, and filtered. The filter cake was
washed with methanol and the filtrate was concentrated. The residue
was suspended in methanol/dichloromethane and filtered. The
filtrate was concentrated and the concentrate was purified by flash
column chromatography on silica gel with 5%
methanol/dichloromethane to provide the desired product (28 mg,
24%).
Example 23G
N-[(2S)-2-amino-3-(1H-indol-3-yl)propyl]-N'-isoquinolin-5-ylpyridine-3,5-d-
iamine
[0251] A solution of Example 23F (26 mg, 0.05 mmol) in 2 mL
dichloromethane at room temperature was treated with 0.5 mL TFA,
stirred for 3 hours, and concentrated. The concentrate was purifed
by reverse phase HPLC on a C18 column with 0-100%
CH.sub.3CN/H.sub.2O/0.1% TFA and the residue was dissolved in water
and lyophilized to provide the desired product as the
trifluoroacetate salt (27 mg, 70%). MS (ESI(+)) m/e 409
(M+H).sup.+; .sup.1H NMR (DMSO-d.sub.6, 500 MHz) .delta. 11.02 (s,
1H), 9.44 (s, 1H), 9.07 (s, 1H), 8.57 (d, J=9 Hz, 1H), 7.95-8.01
(m, 2H), 7.88-7.93 (m, 2H), 7.68-7.73 (m, 3H), 7.57-7.59 (m, 1H),
7.53 (d, J=8 Hz, 1H), 7.38 (d, J=8 Hz, 1H), 7.24-7.27 (m, 1H),7.09
(t, J=9 Hz, 1H), 6.89 (t, J=9 Hz, 1H), 6.92 (s, 1H), 6.83 (br s,
1H), 3.33-3.40 (m, 1H), 3.00-3.14 (m, 4H); Anal. Calcd for
C.sub.25H.sub.24N.sub.6.3TFA.3H.sub.2O- : C, 46.28; H, 4.13; N,
10.44; F, 21.25. Found: C, 46.32; H, 3.54; N, 10.02; F, 21.58.
EXAMPLE 24
N-[(2S)-2-amino-3-(1H-indol-3-yl)propyl]-N-[5-(isoquinolin-5-yloxy)pyridin-
-3-yl]amine
Example 24A
5-[(5-bromopyridin-3-yl)oxy]isoquinoline
[0252] A sealed tube was charged with 5-hydroxyisoquinoline (0.15
g, 1.03 mmol), 3,5-dibromopyridine (0.24 g, 1.03 mmol), potassium
carbonate (0.27 g, 2.0 mmol) and DMF (4 mL). The reaction was
heated to 240.degree. C. for 10 minutes in a personal chemistry
microwave. The reaction was partitioned between water and ethyl
acetate. The aqueous layer was extracted twice with ethyl acetate.
The combined extracts were concentrated and the residue was
purified by flash column chromatography on silica gel with 2:1
ethyl acetate/hexanes to provide the desired product (0.071 g,
23%).
Example 24B
N-[(2S)-2-amino-3-(1H-indol-3-yl)propyl]-N-[5-(isoquinolin-5-yloxy)pyridin-
-3-yl]amine
[0253] The desired product was prepared by substituting Example 24A
for Example 23C in Examples 23D then proceeding as described for
Examples 23E, 23F, and 23G. MS (ESI) m/e 410 (M+H).sup.+; .sup.1H
NMR (DMSO-d.sub.6, 300 MHz) .delta. 11.00 (br s, 1H),9.47 (br s,
1H), 8.58 (d, J=8 Hz, 1H), 7.97-8.03 (m, 1H), 7.92-7.94 (m, 1H),
7.85-7.87 (m, 1H), 7.79-7.82 (m, 2H), 7.66-7.72 (m, 2H), 7.51-7.54
(m, 1H), 7.26-7.36 (m, 3H), 7.02-7.08 (m, 1H), 6.94-6.98 (m, 1H),
6.68-6.71 (m, 1H), 6.39 (br s, 1H), 3.73-3.80 (m, 1H), 3.43-3.52
(m, 2H), 3.16-3.19 (m, 2H);
[0254] Anal. Calcd for C.sub.25H.sub.23N.sub.5O.sub.3TFA: C, 49.53;
H, 3.46; N, 9.30; F, 22.76. Found: C, 49.44; H, 3.58; N, 9.14; F,
22.30.
EXAMPLE 25
(2S)-2-amino-3-(1H-indol-3-yl)-N-[5-(1,6-naphthyridin-2-yl)pyridin-3-yl]pr-
opanamide
Example 25A
2,2-dimethyl-N-pyridin-4-ylpropanamide
[0255] A mixture of 4-aminopyridine (10 g, 106 mmol) and pivaloyl
chloride (12.9 g, 107 mmol) in 200 mL dichloromethane was cooled to
0.degree. C. and treated slowly with triethylamine (10.9 g, 108
mmol), warmed to room temperature, stirred overnight, and diluted
with water. The aqueous layer was extracted three times with
dichloromethane and the combined extracts were washed with brine,
dried (Na.sub.2SO.sub.4), filtered, and concentrated. The product
was recrystallized from toluene to provide the desired product (14
g, 74%).
Example 25B
N-(3-formylpyridin-4-yl)-2,2-dimethylpropanamide
[0256] A mixture of Example 25A (11.4 g, 64 mmol) in 200 mL THF was
cooled to -78.degree. C., treated with 1.6 M nBuLi in hexanes (100
mL, 160 mmol), warmed to .sup.0.degree. C., stirred for 1 hour,
treated with a solution of DMF (22 g, 215 mmol) in 100 mL THF,
warmed to room temperature, stirred for 1 hour, diluted with brine,
and extracted three times with ethyl acetate. The combined extracts
were washed with water, washed twice with brine, dried
(MgSO.sub.4), filtered, and concentrated. The concentrate was
purified by flash column chromatography on silica gel with 3%
methanol/dichloromethane to provide the desired product (9.1 g,
69%).
Example 25C
4-aminonicotinaldehyde
[0257] A solution of Example 25B (870 mg, 4.2 mmol) in 3N HCl (aq.)
(10 mL) was heated to reflux overnight, and extracted three times
with diethyl ether. The aqueous layer was adjusted to pH>7 with
solid K.sub.2CO.sub.3 and extracted six times with 20%
isopropanol/chloroform. The combined extracts were dried
(Na.sub.2SO.sub.4), filtered, and concentrated to provide the
desired product (450 mg; 87%).
Example 25D
5-acetylnicotinamide
[0258] A mixture of 5-bromonicotinamide (2.5 g, 12.4 mmol),
tributyl(1-ethoxyvinyl)tin (5.0 g, 13.8 mmol) and
dichlorobis(triphenylph- osphine)palladium(II) (800 mg, 1.1 mmol)
in 25 mL toluene was heated to reflux for 3 hours. The mixture was
cooled to room temperature, treated with 25 mL 2N HCl (aq.), and
stirred for 1 hour. The aqueous layer was washed with ethyl
acetate, adjusted to pH>7 with solid K.sub.2CO.sub.3, and
extracted six times into 20% isopropanol/chloroform. The combined
extracts were dried (Na.sub.2SO.sub.4), filtered, and concentrated
to provide the desired product (1.6 g, 78%).
Example 25E
5-(1,6-naphthyridin-2-yl)nicotinamide
[0259] A mixture of Example 25C (450 mg, 3.68 mmol) and Example 25D
(605 mg, 3.68 mmol) in 20 mL ethanol and 1.2 mL of 10% NaOH (aq)
was heated to reflux for 3 hours and concentrated. The solid was
collected and rinsed with ethyl acetate to provide the desired
product (740 mg, 80%).
Example 25F
5-(1,6-naphthyridin-2-yl)pyridin-3-amine
[0260] The desired product was prepared by substituting Example 25E
for 5-bromonicotinamide in Example 23B.
Example 25G
tert-butyl
(1S)-1-(1H-indol-3-ylmethyl)-2-{[5-(1,6-naphthyridin-2-yl)pyrid-
in-3-yl]amino}-2-oxoethylcarbamate
[0261] The desired product was prepared by substituting Example 25F
(100 mg, 0.45 mmol) and L-Boc-tryptophan (150 mg, 0.49 mmol) for
Example 11B and Boc-homophenylalanine, respectively, in Example
16A.
Example 25H
(2S)-2-amino-3-(1H-indol-3-yl)-N-[5-(1,6-naphthyridin-2-yl)pyridin-3-yl]pr-
opanamide
[0262] The desired product was prepared as the trifluoroacetate
salt by substituting Example 25G for Example 2B in Example 2D. MS
(ESI) m/e 409 (M+H).sup.+; .sup.1H NMR (DMSO-d.sub.6, 500 MHz)
.delta. 11.04 (br s, 1H), 10.91 (s, 1H), 9.50 (s, 1H), 9.23 (d, J=3
Hz, 1H), 8.95 (d, J=3 Hz, 1H), 8.77-8.83 (m, 3H), 8.42 (d, J=8 Hz,
1H), 8.28-8.32 (m, 2H), 7.97-8.00 (m, 1H), 7.65-7.69 (m, 1H), 7.37
(d, J=8 Hz, 1H), 7.26-7.28 (m, 1H), 7.06-7.11 (m, 1H), 6.96-7.01
(m, 1H), 4.18-4.25 (m, 1H), 3.25-3.45 (m, 2H); Anal. Calcd for
C.sub.24H.sub.20N.sub.6O.3TFA.1H.sub.2O: C, 46.88; H, 3.28; N,
10.93; F, 22.25. Found: C, 47.19; H, 3.39; N, 11.14; F, 21.81.
EXAMPLE 26
N-[(2S)-2-amino-3-(1H-indol-3-yl)propyl]-N-[5-(1,6-naphthyridin-2-yl)pyrid-
in-3-yl]amine
[0263] The desired product was prepared as the trifluoroacetate
salt by substituting Example 25F for Example 23E in Examples 23F
and 23G. MS (ESI) m/e 395 (M+H).sup.+; .sup.1H NMR (DMSO-d.sub.6,
500 MHz) .delta. 11.07 (br s, 1H), 9.51 (s, 1H), 8.74-8.83 (m, 3H),
8.27 (d, J=9 Hz, 1H), 8.18 (d, J=4 Hz, 1H), 7.93-7.97 (m, 4H),
7.60-7.64 (m, 1H), 7.39 (d, J=9 Hz, 1H), 7.34 (d, J=4 Hz, 1H),
7.06-7.12 (m, 1H), 6.96-7.02 (m, 1H), 6.78 (br s, 1H), 3.40-3.67
(m, 3H), 3.11-3.16 (m, 2H); Anal. Calcd for
C.sub.24H.sub.22N.sub.6.3.25TFA: C, 47.88; H, 3.33; N, 10.98; F,
24.21. Found: C, 47.51; H, 3.29; N, 10.94; F, 24.16.
EXAMPLE 27
(1S)-2-(1H-indol-3-yl)-1-{[(5-isoquinolin-6-ylpyridin-3-yl)oxy]methyl}ethy-
lamine
Example 27A
6-(trimethylstannyl)isoquinoline
[0264] A solution of 6-bromoisoquinoline (0.35 g, 1.7 mmol) in DMA
(6 mL) was treated with hexamethylditin (0.55 mL, 1.9 mmol) and
Pd(PPh.sub.3).sub.4 (0.23 g, 0.2 mmol), stirred at 100.degree. C.
for 1 hour, diluted with water, and extracted three times with
ethyl acetate. The combined extracts were concentrated and the
residue was purified by flash column chromatography on silica gel
with 1:1 hexanes/ethyl acetate to provide the desired product
(0.247 g, 50%).
Example 27B
tert-butyl
(1S)-2-(1H-indol-3-yl)-1-{[(5-isoquinolin-6-ylpyridin-3-yl)oxy]-
methyl}ethylcarbamate
[0265] A solution of Example 27A (0.25 g, 0.86 mmol) and Example 2A
(0.444 g, 1.00 mmol) in 6 mL of DMF was treated with
Pd.sub.2(dba).sub.3 (0.08 g, 0.086 mmol), tri-o-tolylphosphine
(0.02 g, 0.04 mmol), and triethylamine (0.15 mL, 1.0 mmol), heated
to 75.degree. C. in a sealed tube for 8 hours, and concentrated.
The residue was purified by flash column chromatography on silica
gel with 2.5% methanol/dichloromethane to provide the desired
product (0.125 g, 30%).
Example 27C
(1S)-2-(1H-indol-3-yl)-1-{[(5-isoquinolin-6-ylpyridin-3-yl)oxy]methyl}ethy-
lamine
[0266] A solution of Example 27B (0.125 g, 0.25 mmol) in
dichloromethane (3 mL) at room temperature was treated with TFA
(400 .mu.L), stirred for 1 hour, and concentrated. The concentrate
was azeotropically distilled with diethyl ether two times and the
residue was purified by reverse phase HPLC on a C18 column with
0-100% CH.sub.3CN/H.sub.2O/0.1% TFA to provide the desired product
as the di-trifluoroacetate salt (0.110 g, 70%). MS (ESI) m/e 395
(M+H).sup.+; .sup.1H NMR (DMSO-d.sub.6, 300 MHz) .delta. 11.02 (br
s, 1H), 9.52 (s, 1H), 8.76 (d, J=3 Hz, 1H), 8.62 (d, J=8 Hz, 1H),
8.44-8.46 (m, 2H), 8.38 (d, J=9 Hz, 1H), 8.11-8.20 (m, 3H),
8.04-8.08 (m, 1H), 7.83-7.86 (m, 1H), 7.62 (d, J=9 Hz, 1H),
7.37-7.40 (m, 1H), 7.31 (d, J=3 Hz, 1H), 7.08-7.12 (m, 1H),
6.99-7.03 (m, 1H), 4.37-4.41 (m, 1H), 4.18-4.23 (m, 1H), 3.86-3.91
(m, 1H), 3.16-3.20 (m, 2H); Anal. Calcd for
C.sub.25H.sub.22N.sub.4O.2TFA.H.sub.2O: C, 49.35; H, 3.61; N, 7.43;
F, 22.67. Found: C, 49.04; H, 3.55; N, 7.42; F, 22.28.
EXAMPLE 28
(1R)-2-(1H-indol-3-yl)-1-{[(5-quinolin-6-ylpyridin-3-yl)oxy]methyl}ethylam-
ine
Example 28A
tert-butyl
(1R)-2-[(5-hydroxypyridin-3-yl)oxy]-1-(1H-indol-3-ylmethyl)ethy-
lcarbamate
[0267] The desired product was prepared by substituting
D-Boc-tryptophanol for L-Boc tryptophanol in Example 2A.
Example 28B
(1R)-2-(1H-indol-3-yl)-1-{[(5-quinolin-6-ylpyridin-3-yl)oxy]methyl}ethylam-
ine
[0268] The desired product was prepared as the trifluoroacetate
salt by substituting 28A for 2A in Example 27B then removing the
Boc group as in Example 27C. MS (ESI) m/e 395 (M+H).sup.+; .sup.1H
NMR (DMSO-d.sub.6, 500 MHz) .delta. 11.02 (s, 1H), 8.97-9.00 (m,
1H), 8.74 (d, J=3 Hz, 1H), 8.50-8.54 (m, 1H), 8.39-8.42 (m, 2H),
8.18-8.23 (m, 3H), 8.13-8.17 (m, 1H), 7.81-7.83 (m, 1H), 7.61-7.66
(m, 2H), 7.39 (d, J=8 Hz, 1H), 7.31 (d, J=3 Hz, 1H), 7.07-7.10 (m,
1H), 6.99-7.02 (m, 1H), 4.38-4.41 (m, 1H), 4.21-4.24 (m, 1H),
3.79-3.83 (m, 1H), 3.16-3.19 (m, 2H).
EXAMPLE 29
(1S)-2-[(6-chloro-5-isoquinolin-6-ylpyridin-3-yl)oxy]-1-(1H-indol-3-ylmeth-
yl)ethylamine
[0269] The desired product was prepared as the trifluoroacetate
salt by substituting Example 13A for Example 2A in Example 27. MS
(APCI) m/e 429, 431 (M+H).sup.+; .sup.1H NMR (300 MHz, CD.sub.3OD)
.delta. 9.77 (s, 1H), 8.63 (d, J=6.4 Hz, 1H), 8.54 (d, J=8.8 Hz,
1H), 8.43 (d, J=6.4 Hz, 1H), 8.30 (s, 1H), 8.27 (d, J=3.1 Hz, 1H),
8.06 (dd, J=8.4, 1.7 Hz, 1H), 7.58 (s, 1H), 7.56 (d, J=5.4 Hz, 1H),
7.35 (d, J=8.1 Hz, 1H), 7.22 (s, 1H), 7.10 (td, J=7.1, 1.4 Hz, 1H),
7.00 (td, J=7.8, 1.0 Hz, 1H), 4.37 (dd, J=10.5, 3.4 Hz, 1H), 4.24
(dd, J=10.5, 5.8 Hz, 1H), 3.98 (m, 1H), 3.27 (m, 2H); Anal. Calcd
for C.sub.25H.sub.21ClN.sub.4O.2.25TFA: C, 51.69; H, 3.42; N, 8.17.
Found: C, 51.75; H, 3.39; N, 8.13.
EXAMPLE 30
(1S)-2-[(2-chloro-5-isoquinolin-6-ylpyridin-3-yl)oxy]-1-(1H-indol-3-ylmeth-
yl)ethylamine
[0270] The desired product was prepared as the trifluoracetate salt
by substituting Example 12C for Example 2A in Example 27 (0.02 g,
80%). MS (DCI/NH.sub.3) m/e 429, 431 (M+H).sup.+; .sup.1H NMR
(DMSO-d.sub.6) .delta. 11.04 (s, 1H), 9.50 (s, 1H), 8.62 (d, J=6.0
Hz, 1H), 8.57 (s, 1H), 8.44 (s, 1H), 8.35 (d, J=9.0 Hz, 1H), 8.22
(s, 2H), 8.13 (d, J=9.0 Hz, 1H), 8.00 (d, J=6.0 Hz, 1H), 7.98 (s,
1H), 7.64 (d, J=7.5 Hz, 1H), 7.38 (d, J=7.5 Hz, 1H), 7.30 (s, 1H),
7.10 (t, J=7.2 Hz, 1H), 7.00 (t, J=7.2 Hz, 1H), 4.46 (m, 1H), 4.30
(m, 1H), 3.92 (m, 1H), 3.21 (m, 2H).
EXAMPLE 31
(1R)-1-(1H-indol-3-ylmethyl)-3-(5-isoquinolin-6-ylpyridin-3-yl)propylamine
Example 31A
6-(5-bromopyridin-3-yl)isoquinoline
[0271] A solution of 3,5-dibromopyridine (284 mg, 1.2 mmol),
Pd.sub.2(dba).sub.3 (110 mg, 0.12 mmol) and tri-o-tolylphosphine
(110 mg, 0.36 mmol) in DMF (15 mL) was treated with Example 27A
(500 mg, 1.2 mmol) and triethylamine (500 .mu.L, 3.6 mmol), purged
with nitrogen, heated to 70.degree. C. for 6 hours, cooled to room
temperature, treated with ethyl acetate (100 mL), washed with
brine, dried (MgSO.sub.4), filtered, and concentrated. The residual
oil was purified by flash column chromatography on silica gel with
ethyl acetate to provide the desired product (110 mg, 32%). MS
(APCI) m/e 285, 287 (M+H).sup.+.
Example 31B
(1R)-1-(1H-indol-3-ylmethyl)-3-(5-isoquinolin-6-ylpyridin-3-yl)propylamine
[0272] The desired product was prepared as the trifluoroacetate
salt by substituting Example 31A for Example 21B in Example 21D
then removing the Boc protecting group as described for Example
21E. MS (DCI/NH.sub.3) m/e 458 (M+H).sup.+; .sup.1H NMR
(CD.sub.3OD) .delta. 9.78 (s, 1H), 8.97 (d, J=1.1 Hz, 1H), 8.64 (d,
J=6.4 Hz, 1H), 8.61 (d, J=8.9 Hz, 1H), 8.55 (s, 1H), 8.53 (s, 1H),
8.47 (d, J=6.5 Hz, 1H), 8.25 (dd, J=8.4, 1.7 Hz, 1H), 8.23 (s, 1H),
7.49 (d, J=7.9 Hz, 1H), 7.30 (d, J=8.2 Hz, 1H), 7.22 (s, 1H), 7.06
(td, J=7.1, 1.0 Hz, 1H), 6.97 (td, J=7.1, 1.0 Hz, 1H), 3.59 (p,
J=6.5 Hz, 1H), 3.18 (dd, J=7.1, 3.4 Hz, 2H), 2.99 (m, 2H), 2.15 (m,
2H).
EXAMPLE 32
5-(5-{[(2S)-2-amino-3-(1H-indol-3-yl)propyl]oxy}pyridin-3-yl)-1H-isoindole-
-1,3(2H)-dione
Example 32A
tert-butyl
(1S)-2-(1H-indol-3-yl)-1-({[5-(trimethylstannyl)pyridin-3-yl]ox-
y{methyl)ethylcarbamate
[0273] A solution of Example 2A (1 g, 2.23 mmol) in DMA (15 mL) was
treated with hexamethylditin (1.8 mL, 5.6 mmol) and
Pd(PPh.sub.3).sub.4 (0.4 g, 0.2 mmol), heated to 75.degree. C. for
1.5 days, added to water, and extracted three times with ethyl
acetate. The combined extracts were concentrated and the residue
was purified by flash column chromatography on silica gel with 1:1
hexanes/ethyl acetate to provide the desired product (0.4 g,
34%).
Example 32B
tert-butyl
(1S)-2-{[5-(1,3-dioxo-2,3-dihydro-1H-isoindol-5-yl)pyridin-3-yl-
]oxy}-1-(1H-indol-3-ylmethyl)ethylcarbamate
[0274] A solution of Example 32A (0.2 g, 0.31 mmol) and
6-bromophthalimide (0.084 g, 0.4 mmol) in DMF (2 mL) was treated
with Pd.sub.2 dba.sub.3 (0.04 g, 0.02 mmol), tri-o-tolylphosphine
(0.02 g, 0.01 mmol), and triethylamine (0.06 mL, 0.4 mmol). The
reaction was heated to 75.degree. C. for 6 hours in a sealed tube
and concentrated. The residue was purified by flash column
chromatography on silica gel with 1:1 hexanes/ethyl acetate to
provide the desired product (0.116 g, 55%).
Example 32C
5-(5-{[(2S)-2-amino-3-(1H-indol-3-yl)propyl]oxy}pyridin-3-yl)-1H-isoindole-
-1,3(2H)-dione
[0275] The desired product was prepared as the trifluoracetate salt
by substituting Example 32B for Example 27B in Example 27C. MS
(ESI) m/e 413 (M+H).sup.+; .sup.1H NMR (DMSO-d.sub.6, 300 MHz)
.delta. 11.43 (s, 1H), 11.02 (br s, 1H), 8.67 (d, J=3 Hz, 1H), 8.42
(d, J=6 Hz, 1H), 8.14-8.18 (m, 4H), 7.92-7.96 (m, 1H), 7.79-7.81
(m, 1H), 7.61 (d, J=9 Hz, 1H), 7.38 (d, J=9 Hz, 1H), 7.30 (d, J=3
Hz, 1H), 7.08-7.12 (m, 1H), 6.98-7.03 (m, 1H), 4.35-4.40 (m, 1H),
4.17-4.22 (m, 1H), 3.83-3.88 (m, 1H), 3.13-3.17 (m, 2H). Anal.
Calcd for C.sub.24H.sub.20N.sub.4O.sub.3.2.1TFA: C, 51.96; H, 3.42;
N, 8.59; F, 18.30. Found: C, 51.45; H, 3.46; N, 8.56; F, 17.47.
EXAMPLE 33
5-(5-{[(2S)-2-amino-3-(1H-indol-3-yl)propyl]oxy}pyridin-3-yl)isoindolin-1--
one
Example 33A
Methyl 4-bromo-2-methylbenzoate
[0276] A solution of 4-bromo-2-methyl benzoic acid (1.0 g, 4.7
mmol) in methanol (24 mL) was treated with 20 drops of HCl, heated
at reflux for 6 hours, and concentrated to provide the desired
product (1.07 g, 100%).
Example 33B
Methyl 4-bromo-2-(bromomethyl)benzoate
[0277] A solution of Example 33A (1.02 g, 4.47 mmol) in CCl.sub.4
(22 mL) was treated with AIBN (0.065 g, 0.4 mmol) and NBS (0.955 g,
5.4 mmol), heated to reflux for 4 hours, washed with water, dried
(Na.sub.2SO.sub.4), filtered, and concentrated to provide the
desired product (1.1 g, 79%).
Example 33C
5-bromoisoindolin-1-one
[0278] A solution of Example 33B (1.1 g, 3.57 mmol) in THF (20 mL)
at room temperature was treated with 1N NH.sub.3 in methanol (7.14
mL, 7.14 mmol), stirred for 24 hours, and filtered. The filter cake
was washed with diethyl ether (100 mL) to provide the desired
product (0.4 g, 52%).
Example 33D
5-(5-{[(2S)-2-amino-3-(1H-indol-3-yl)propyl]oxy}pyridin-3-yl)isoindolin-1--
one
[0279] The desired product was prepared as the trifluoroacetate
salt by substituitng Example 33C for 6-bromophthalimide in Example
32. MS (ESI) m/e 399 (M+H).sup.+; .sup.1H NMR (DMSO-d.sub.6, 300
MHz) .delta. 11.03 (br s, 1H), 8.63 (s, 1H), 8.57 (s, 1H), 8.35 (br
s, 3H), 7.90 (s, 1H), 7.78 (s, 2H), 7.67 (s, 1H), 7.61 (d, J=8 Hz,
1H), 7.37 (d, J=8 Hz, 1H), 7.79 (d, J=2 Hz, 1H), 7.03-7.10 (m, 1H),
6.96-7.01 (m, 1H), 4.32-4.36 (m, 1H), 4.17-4.22 (m, 1H), 3.80-3.83
(m, 1H), 3.18 (d, J=8 Hz, 2H), 2.50 (s, 2H).
EXAMPLE 34
(1S)-2-[(5-cinnolin-6-ylpyridin-3-yl)oxy]-1-(1H-indol-3-ylmethyl)ethylamin-
e
Example 34A
N-(2-acetylphenyl)acetamide
[0280] A solution of 2'-aminoacetophenone (5.0 g, 37 mmol) in
dichloromethane (150 mL) at room temperature was treated with
triethylamine (5.3 mL, 40 mmol) and acetyl chloride (3.2 mL, 45
mmol), stirred for 3 hours, then washed with water. The aqueous
layer was extracted with ethyl acetate (2.times.20 mL) and the
combined extracts were concentrated to provide the desired product
(6.5 g, 100%).
Example 34B
N-(2-acetyl-4-bromophenyl)acetamide
[0281] A solution Example 34A (6.5 g, 37 mmol) in acetic acid (100
mL) at room temperature was treated with Br.sub.2 (4 mL, 84 mmol),
stirred for 1 hour and 15 minutes, poured into water (200 mL), and
filtered. The solid was washed with water (2.times.100 mL), and
hexanes (2.times.100 mL), dissolved in diethyl ether, washed with
brine (50 mL), and concentrated to provide the desired product (8.5
g, 89%).
Example 34C
6-bromocinnolin-4(1H)-one
[0282] A solution of Example 34B (6.28 g, 24.4 mmol) in THF (75 mL)
was treated with concentrated HCl (aq.) (15 mL) and water (15 mL),
heated to reflux for 1 hour, and concentrated to remove the THF.
The aqueous solution was treated with additional water (5 mL) and
concentrated HCl (5 mL), cooled to 0.degree. C., treated with a
solution of NaNO.sub.2 (1.85 g, 26.84 mmol) in water (10 mL) in 5
portions, warmed to room temperature gradually over a 2-hour
period, and stirred overnight at room temperature. The reaction was
heated to reflux for 6 hours, and filtered. The solid was washed
with water (50 mL) and diethyl ether (50 mL) and dried under vacuum
to provide the desired product (3.0 g, 54%).
Example 34D
6-bromo-4-chlorocinnoline
[0283] A solution of Example 34C (0.4 g, 1.8 mmol) in POCl.sub.3
(2.5 mL) was heated to 100.degree. C. for 2 hours, and poured
slowly onto ice. The aqueous layer was cooled to 0.degree. C. and
adjusted to pH 5-7 with 50% NaOH. The aqueous layer was extracted
with ethyl acetate (2.times.50 mL), and the combined organic layers
were concentrated. The residue was purified by flash column
chromatography on silica gel with 4:1 hexanes/ethyl acetate to
provide the desired product (0.190 g, 43%).
Example 34E
6-bromo-4-hydrazinocinnoline
[0284] A solution of Example 34D (2.6 g, 10.6 mmol) in ethanol (70
mL) was treated with hydrazine monohydrate (3 mL, 90% solution),
stirred at room temperature for 3 days, and filtered. The solid
washed with water (50 mL) and diethyl ether (50 mL) and dried under
vacuum to provide the desired product (2.5 g, 100%).
Example 34F
6-bromocinnoline
[0285] A solution of Example 34E (3.5 g, 14 mmol) in water (50 mL)
was heated to reflux, treated dropwise with a solution of
CuSO.sub.4 (2.8 g, 17.5 mmol) in water (20 mL), refluxed for 2
hours, cooled to room temperature, adjusted to pH 7 with saturated
NaHCO.sub.3 (aq), and extracted with ethyl acetate (2.times.25 mL).
The combined extracts were concentrated and the residue was
purified by flash column chromatography on silica gel with 1:1
hexanes/ethyl acetate to provide the desired product (0.7 g,
24%).
Example 34G
(1S)-2-[(5-cinnolin-6-ylpyridin-3-yl)oxy]-1-(1H-indol-3-ylmethyl)ethylamin-
e
[0286] The desired product was prepared as the trifluoroacetate
salt by substituting Example 34F for 6-bromophthalimide in Example
32. MS (ESI) m/e 396 (M+H).sup.+; .sup.1H NMR (DMSO-d.sub.6, 300
MHz) .delta. 11.04 (s, 1H), 9.43 (d, J=6 Hz, 1H), 8.78 (d, J=2 Hz,
1H), 8.60 (d, J=8 Hz, 1H), 8.45-8.49 (m, 2H), 8.30-8.34 (m, 1H),
8.26 (d, J=6 Hz, 1H), 8.21-8.25 (m, 2H), 7.89 (t, J=2 Hz, 1H), 7.63
(d, J=8 Hz, 1H), 7.39 (d, J=8 Hz, 1H), 7.31 (d, J=2 Hz, 1H),
7.08-7.12 (m, 1H), 7.01-7.04 (m, 1H), 4.38-4.42 (m, 1H), 4.22-4.26
(m, 1H), 3.83-3.88 (m, 1H), 3.17-3.20 (m, 2H).
EXAMPLE 35
(1S)-2-{[5-(1H-indazol-5-yl)pyridin-3-yl]oxy}-1-(1H-indol-3-ylmethyl)ethyl-
amine
Example 35A
5-bromo-1H-indazole
[0287] A mixture of 5-bromo-2-fluorobenzaldehyde (10 g, 49.2 mmol)
and 98% hydrazine (20 mL) was heated to reflux for 5 hours, poured
over ice, and filtered. The solid was recrystallized from
H.sub.2O/methanol to provide the desired product (3.7 g, 38%).
Example 35B
(1S)-2-{[5-(1H-indazol-5-yl)pyridin-3-yl]oxy}-1-(1H-indol-3-ylmethyl)ethyl-
amine
[0288] The desired product was prepared as the trifluoroacetate
salt by substituting Example 35A for 6-bromophthalimide in Example
32. MS (ESI) m/e 384 (M+H).sup.+; .sup.1H NMR (DMSO-d.sub.6, 300
MHz) .delta. 13.22 (br s, 1H), 11.04 (br s, 1H), 8.62 (d, J=2 Hz,
1H), 8.33 (d, J=3 Hz, 1H), 8.13-8.21 (m, 3H), 8.12 (s, 1H),
7.67-7.72 (m, 3H), 7.64 (d, J=8 Hz, 1H), 7.39 (d, J=8 Hz, 1H), 7.30
(d, J=2 Hz, 1H), 7.06-7.13 (m, 1H), 6.98-7.04 (m, 1H), 4.14-4.39
(m, 2H), 3.33-3.38 (m, 1H), 3.13-3.16 (m, 2H); Anal. Calcd for
C.sub.23H.sub.21N.sub.5O.2TFA.H.sub.2O: C, 51.52; H, 4.00; N,
11.13. Found: C, 51.80; H, 3.61; N, 11.03.
EXAMPLE 36
5-(5-{[(2S)-2-amino-3-(1H-indol-3-yl)propyl]oxy}pyridin-3-yl)-1,3-dihydro--
2H-indol-2-one
[0289] The desired product was prepared as the trifluoroacetate
salt by substituting 5-bromooxindole for 6-bromophthalimide in
Example 32. MS (APCI) m/e 399 (M+H).sup.+; .sup.1H NMR (300 MHz,
CD.sub.3OD) .delta. 8.59 (s, 1H), 8.35 (s, 1H), 7.92 (s, 1H), 7.60
(d, J=6.9 Hz, 1H), 7.58 (s, 1H), 7.55 (d, J=10.1 Hz, 1H), 7.38 (d,
J=8.1 Hz, 1H), 7.24 (s, 1H), 7.13 (t, J=7.6 Hz, 1H), 7.03 (d, J=8.0
Hz, 1H), 7.03 (t, J=7.5 Hz, 1H), 4.45 (dd, J=10.5, 3.2 Hz, 1H),
4.31 (dd, J=10.5, 5.8 Hz, 1H), 4.01 (m, 1H), 3.62 (s, 2H), 3.32 (m,
1H), 3.29 (m, 1H); Anal. Calcd for
C.sub.24H.sub.22N.sub.4O.sub.2.2.5 TFA: C, 50.96; H, 3.61; N, 8.20.
Found: C, 50.96; H, 3.62; N, 8.12.
EXAMPLE 37
(1S)-2-{[5-(2,1,3-benzoxadiazol-5-yl)pyridin-3-yl]oxy}-1-(1H-indol-3-ylmet-
hyl)ethylamine
[0290] The desired product was prepared as the trifluoroacetate
salt by substituting 5-chloro-2,1,3-benzoxadiazole for
6-bromophthalimide in Example 32. MS (APCI) m/e 386 (M+H).sup.+;
.sup.1H NMR (300 MHz, CD.sub.3OD) .delta. 8.64 (s, 1H), 8.44 (s,
1H), 8.18 (s, 1H), 8.05 (d, J=10.4 Hz, 1H), 7.81 (d, J=10.9 Hz,
1H), 7.78 (s, 1H), 7.59 (d, J=6.7 Hz, 1H), 7.37 (d, J=7.1 Hz, 1H),
7.24 (s, 1H), 7.12 (t, J=8.1 Hz, 1H), 7.03 (t, J=6.9 Hz, 1H), 4.44
(dd, J=10.5, 3.1 Hz, 1H), 4.29 (dd, J=10.6, 5.8 Hz, 1H), 3.99 (m,
1H), 3.32 (s, 1H), 3.30 (s, 1H); Anal. Calcd for
C.sub.22H.sub.19N.sub.5O.sub.2.2.45 TFA: C, 48.60; H, 3.25; N,
10.53. Found: C, 48.68; H, 3.48; N, 10.58.
EXAMPLE 38
(1S)-2-(1H-indol-3-yl)-1-{[(5-thieno[2,3-c]pyridin-2-ylpyridin-3-yl)oxy]me-
thyl}ethylamine
Example 38A
2-(trimethylstannyl)thieno[2,3-c]pyridine
[0291] A solution of thieno[2,3-c]pyridine (J. Wikel, et al., J.
Heterocycl. Chem., 1993, 30, 289) (2.0 g, 14.8 mmol) in THF (50 mL)
at -78.degree. C. was treated with n-butyllithium (2.5 M solution
in hexane, 7.1 mL, 17.8 mmol), warmed to 0.degree. C., stirred for
15 minutes, cooled to -78.degree. C., treated slowly with
trimethyltin chloride (3.54 g, 17.8 mmol) in THF (10 mL), warmed to
room temperature for 2 hours, and partitioned between ethyl acetate
and brine. The ethyl acetate solution was washed with water, and
concentrated. The residue was purified by flash chromatography
(10-35% ethyl acetate in hexane) to provide the desired product
(3.15 g, 71%). MS (APCI) m/e 298 (M+H).sup.+.
Example 38B
(1S)-2-(1H-indol-3-yl)-1-{[(5-thieno[2,3-c]pyridin-2-ylpyridin-3-yl)oxy]me-
thyl}ethylamine
[0292] The desired product was prepared as the trifluoroacetate by
substituting Example 38A for Example 27A in Examples 27B and 27C.
MS (APCI) m/e 402 (M+H).sup.+; .sup.1H NMR (300 MHz, CD.sub.3OD)
.delta. 9.58 (s, 1H), 8.78 (s, 1H), 8.63 (d, J=6.4 Hz, 1H), 8.49
(s, 1H), 8.36 (d, J=6.4 Hz, 1H), 8.20 (s, 1H), 7.86 (s, 1H), 7.60
(d, J=8.6 Hz, 1H), 7.38 (d, J=8.1 Hz, 1H), 7.25 (s, 1H), 7.12 (t,
J=8.1 Hz, 1H), 7.03 (t, J=7.5 Hz, 1H), 4.45 (dd, J=10.6, 3.2 Hz,
1H), 4.30 (dd, J=10.5, 5.7 Hz, 1H), 4.02 (m, 1H), 3.32 (s, 1H),
3.30 (s, 1H); Anal. Calcd for C.sub.23H.sub.20N.sub.4OS.3.6 TFA: C,
44.73; H, 2.93; N, 6.91. Found: C, 44.74; H, 2.91; N, 6.77.
EXAMPLE 39
(3Z)-5-(5-{[(2S)-2-amino-3-(1H-indol-3-yl)propyl]oxy}pyridin-3-yl)-3-(1H-p-
yrrol-2-ylmethylene)-1,3-dihydro-2H-indol-2-one
[0293] The desired product was prepared by as the trifluoroacetate
salt substituting
5-bromo-3-(1H-pyrrol-2-ylmethylene)-1,3-dihydro-indol-2-one for
6-bromophthalimide (L. Sun, et al., J. Med. Chem., 1998, 41, 2588.)
in Example 32. MS (APCI) m/e 476 (M+H).sup.+; .sup.1H NMR (400 MHz,
DMSO-d.sub.6) .delta. 13.33 (br s, 1H), 11.05 (s, 1H), 11.04 (d,
J=6.5 Hz, 1H), 8.64 (s, 1H), 8.34 (s, 1H), 8.22 (br s, 2H), 8.09
(s, 1H), 7.91 (s, 1H), 7.74 (br s, 1H), 7.62 (d, J=7.7 Hz, 1H),
7.51 (dd, J=8.3 Hz, 1H), 7.40 (s, 1H), 7.38 (d, J=8.3 Hz, 1H), 7.30
(d, J=2.2 Hz, 1H), 7.1 (dd, J=7.9 Hz, 1H), 7.01 (d, J=7.7 Hz, 1H),
7.00 (d, J=8.0 Hz, 1H), 6.85 (br s, 1H), 6.39 (s, 1H), 4.37 (dd,
J=12.00, 3.1 Hz, 1H), 4.20 (dd, J=8.00, 6.0 Hz, 1H), 3.15-3.21 (m,
1H); Anal. Calcd for C.sub.29H.sub.25N.sub.5O.sub.2.2.6TFA: C,
53.21; H, 3.60; N, 9.07. Found: C, 53.36; H, 3.67; N, 8.92.
EXAMPLE 40
6-(5-{[(2R)-2-amino-3-(1H-indol-3-yl)propyl]oxy}pyridin-3-yl)-1,3-benzothi-
azol-2(3H)-one
[0294] The desired product was prepared by substituting
6-bromo-2-benzothiazolinone for 6-bromophthalimide in Example 32.
MS (APCI) m/e 417 (M+H).sup.+; .sup.1H NMR (300 MHz, CD.sub.3OD)
.delta. 8.52 (s, 1H), 8.31 (d, J=2.4 Hz, 1H), 7.77 (d, J=1.7 Hz,
1H), 7.71 (t, J=1.7 Hz, 1H), 7.59 (d, J=7.8 Hz, 1H), 7.56 (dd,
J=6.0, 1.7 Hz, 1H), 7.39 (d, J=8.2 Hz, 1H), 7.25 (d, J=8.2 Hz, 1H),
7.23 (s, 1H), 7.14 (t, J=7.2 Hz, 1H), 7.03 (t, J=7.2 Hz, 1H), 4.41
(dd, J=12.0, 3.4 Hz, 1H), 4.26 (dd, J=9.0, 5.7 Hz, 1H), 3.97-4.02
(m, 1H); Anal. Calcd for C.sub.23H.sub.20N.sub.4O.sub.2.1.9 TFA: C,
50.84; H, 3.49; N, 8.85. Found: C, 51.22; H, 3.67; N, 8.49.
EXAMPLE 41
2-(1H-indol-3-yl)-2-(5-isoquinolin-6-ylpyridin-3-yl)ethanamine
Example 41A
tert-butyl 3-(cyanomethyl)-1H-indole-1-carboxylate
[0295] A solution of 3-cyanomethylindole (7.50 g, 48 mmol),
di-tert-butyl dicarbonate (11.5 g, 52.8 mmol), and DMAP (300 mg) in
dichloromethane (200 mL) was stirred at room temperature overnight.
The mixture was concentrated and the residue was purified by flash
column chromatography on silica gel with dichloromethane to provide
the desired product (11.44 g, 93%). MS (DCI/NH.sub.3) m/e 257
(M+H).sup.+.
EXAMPLE 41B
tert-butyl
3-[(5-bromopyridin-3-yl)(cyano)methyl]-1H-indole-1-carboxylate
[0296] A solution of Example 41A (5.46 g, 21.3 mmol) and
3,5-dibromopyridine (5.03 g, 21.3 mmol) in DMF (25 mL) at room
temperature was treated with NaH (60% in mineral oil, 1.08 g, 25.6
mmol) in several portions. The reaction was stirred at room
temperature for 20 minutes, heated to 60.degree. C. for 2 hours,
and poured into water. The aqueous layer was extracted with diethyl
ether and the combined extracts were washed with water, dried
(MgSO.sub.4), filtered, and concentrated. The residue was purified
by flash column chromatography on silica gel with ethyl
acetate/hexanes (1:7) to provide the desired product (336 mg, 4%).
MS (DCI/NH.sub.3) m/e 413 (M+H).sup.+.
EXAMPLE 41C
tert-butyl
3-[cyano(5-isoquinolin-6-ylpyridin-3-yl)methyl]-1H-indole-1-car-
boxylate
[0297] The desired product was prepared by substituting Example 41B
for Example 2A in Example 27B. MS (DCI/NH.sub.3) m/e 461
(M+H).sup.+.
Example 41D
2-(1H-indol-3-yl)-2-(5-isoquinolin-6-ylpyridin-3-yl)ethanamine
[0298] A mixture of Example 41C (159 mg, 0.345 mmol), RaNi 2800
(525 mg), ammonia (2 mL), and triethylamine (2 mL) in methanol (20
mL) was stirred under hydrogen (60 psi) at room temperature for 73
hours and concentrated. The residue was triturated with ethyl
acetate and methanol. The resulting solid was dissolved in
trifluoroacetic acid (1 mL), stirred for 5 minutes at room
temperature, and concentrated. The residue was purified by HPLC on
a C18 column with 0-100% CH.sub.3CN/H.sub.2O/0.1% TFA to provide
the desired product as the trifluoroacetate salt (64 mg, 26%). MS
(DCI/NH.sub.3) m/e 365 (M+H).sup.+; .sup.1H NMR (CD.sub.3OD)
.delta. 9.80 (s, 1H), 9.12 (br s, 1H), 8.87 (br s, 1H), 8.68 (s,
1H), 8.64 (m, 3H), 8.51 (d, J=6.6 Hz, 1H), 8.35 (dd, J=1.6, 8.4 Hz,
1H), 7.52 (d, J=8.1 Hz, 1H), 7.50 (s, 1H), 7.42 (d, J=8.4 Hz, 1H),
7.15 (m, 1H), 7.03 (m, 1H), 4.95 (t, J=7.8 Hz, 1H), 3.91 (m,
2H).
EXAMPLE 42
2-(1H-indol-3-yl)-3-(5-isoquinolin-6-ylpyridin-3-yl)propan-1-amine
Example 42A
(2Z)-3-(5-bromopyridin-3-yl)-2-(1H-indol-3-yl)acrylonitrile
[0299] A solution of 3-cyanomethylindole (156 mg, 1.0 mmol) in
anhydrous ethanol (1.5 mL) at room temperature was treated with 21%
sodium ethoxide in ethanol (450 .mu.L), stirred for 1 hour, treated
with 3-bromopyridine-5-carboxaldehyde (J. Heterocycl. Chem., 1995,
32, 1801.) (187 mg, 1.0 mmol), stirred overnight, and concentrated.
The residue was purified by flash column chromatography on silica
gel with 2% methanol/dichloromethane to provide the desired product
(52 mg, 16%). MS (DCI/NH.sub.3) m/e 325 (M+H).sup.+.
Example 42B
2-(1H-indol-3-yl)-3-(5-isoquinolin-6-ylpyridin-3-yl)propan-1-amine
[0300] The desired product was prepared as the trifluoroacetate
salt by substituting Example 42A for Example 41B in Examples 41C
and 41D. MS (DCI/NH.sub.3) m/e 379 (M+H).sup.+; .sup.1H NMR
(CD.sub.3OD) .delta. 9.70 (s, 1H), 8.88 (s, 1H), 8.61 (d, J=6.6 Hz,
1H), 8.47 (m, 2H), 8.86 (d, J=6.6 Hz, 1H), 8.03 (s, 1H), 7.86 (s,
1H), 7.83 (dd, J=1.6, 8.4 Hz, 1H), 7.54 (d, J=7.8 Hz, 1H), 7.45 (d,
J=8.1 Hz, 1H), 7.21 (s, 1H), 7.17 (m, 1H), 7.04 (m, 1H), 8.82 (m
1H), 3.61 (m, 2H), 3.36 (dd, J=4.1, 13.4 Hz, 1H), 3.30 (m, 1H).
EXAMPLE 43
(1S)-2-(1H-indol-3-yl)-1-[[(6-pyridin-4-ylquinolin-3-yl)oxy]methyl}ethylam-
ine
Example 43A
6-bromo-3-hydroxyquinoline-4-carboxylic Acid
[0301] A solution of 5-bromoisatin (2.26 g, 10 mmol) and potassium
hydroxide (4.48 g, 80 mmol) in water (10 mL) was warmed until the
materials were dissolved then cooled to room temperature, treated
with bromopyruvic acid (2.3 g, 14 mmol), stirred for 6 days,
adjusted to pH<7 with concentrated HCl, and filtered. The solid
was washed with water and ethanol and dried to provide the desired
product (1.5 g, 58%). MS (DCI/NH.sub.3) m/e 269 (M+H).sup.+.
Example 43B
6-bromo3-hydroxyquinoline
[0302] A solution of Example 43A (1.5 g, 5.6 mmol) in nitrobenzene
(10 mL) was refluxed for 5 minutes, filtered, cooled to room
temperature and filtered again. The solid was washed with hexanes
and dried to provide the desired product (0.68 g, 55%). MS
(DCI/NH.sub.3) m/e 225 (M+H).sup.+.
Example 43C
tert-butyl
(1S)-2-[(6-bromoquinolin-3-yl)oxy]-1-(1H-indol-3-ylmethyl)ethyl-
carbamate
[0303] The desired product was prepared by substituting Example 43B
for 3-bromo-5-hydroxypyridine in Example 2A. Purification by flash
column chromatography on silica gel with 100% ethyl acetate
provided the desired product (0.89 g, 72%). MS (DCI/NH.sub.3) m/e
497 (M+H).sup.+.
Example 43D
tert-butyl
(1S)-2-(1H-indol-3-yl)-1-{[(6-pyridin-4-ylquinolin-3-yl)oxy]met-
hyl}ethylcarbamate
[0304] A mixture of Example 43C (0.33 g, 0.67 mmol),
pyridine-4-boronic acid (0.13 g, 0.99 mmol), cesium floride (0.2 g,
1.34 mmol) and tetrakistriphenylphosphine palladium (0.038 g, 0.034
mmol) in DMF (10 mL) was stirred at 100.degree. C. for 8 hours,
treated with ethyl acetate (10 mL), washed with brine, dried
(MgSO.sub.4), filtered, and concentrated. The concentrate was
purified by flash column chromatography on silica gel with 10%
methanol/dichloromethane to provide the desired product (0.25 g,
76%). MS (DCI/NH.sub.3) m/e 495 (M+H).sup.+.
Example 43E
(1S)-2-(1H-indol-3-yl)-1-{[(6-pyridin-4-ylquinolin-3-yl)oxy]methyl}ethylam-
ine
[0305] The desired product was prepared as the trifluoroacetate
salt by substituting Example 43D for Example 27B in Example 27C. MS
(DCI/NH.sub.3) m/e 395 (M+H).sup.+; .sup.1H NMR (DMSO-d.sub.6)
.delta. 10.89 (s, 1H), 8.74 (d, J=3.0 Hz, 1H), 8.71 (d, J=5.0 Hz,
2H), 8.25 (s, 1H), 8.07 (d, J=9.0 Hz, 1H), 7.99 (d, J=9.0 Hz, 1H),
7.83 (d, J=5.0 Hz, 2H), 7.72 (d, J=3.0 Hz, 1H), 7.58 (d; J=7.5 Hz,
1H), 7.35 (d, J=8.4 Hz, 1H), 7.23 (s, 1H), 7.06 (t, J=7.5 Hz, 1H),
6.95 (t, J=8.4 Hz, 1H), 4.05 (m, 2H), 3.53 (m, 1H), 3.01 (dd,
J=6.3, 14.9 Hz, 1H), 2.87 (dd, J=6.9, 14.9 Hz, 1H).
EXAMPLE 44
(3Z)-3-[(2S)-2-amino-3-(1H-indol-3-yl)propylidene]-5-isoquinolin-6-yl-1,3--
dihydro-2H-pyrrolo[2,3-b]pyridin-2-one
Example 44A
tert-butyl
(1S,2Z)-2-(5-bromo-2-oxo-1,2-dihydro-3H-pyrrolo[2,3-b]pyridin-3-
-ylidene)-1-(1H-indol-3-ylmethyl)ethylcarbamate
[0306] A mixture of 5-bromo-7-aza-oxindole (D. Mazeas, et al.,
Heterocycles 1999, 50, 1065.) (213 mg, 1.0 mmol),
L-BOC-tryptophanal (290 mg, 1.0 mmol) and piperidine (40 .mu.L) in
ethanol was refluxed for 2.5 hours and concentrated. The residue
was triturated with dichloromethane (1 mL) and hexane (6 mL) and
dried to provide the desired product (512 mg). MS (DCI/NH.sub.3)
m/e 483, 485 (M+H).sup.+.
Example 44B
(3Z)-3-[(2S)-2-amino-3-(1H-indol-3-yl)propylidene]-5-isoquinolin-6-yl-1,3--
dihydro-2H-pyrrolo[2,3-b]pyridin-2-one
[0307] The desired product was prepared by substituting Example 44A
(260 mg) for Example 2A in Example 27. MS (DCI/NH.sub.3) m/e 432
(M+H).sup.+; .sup.1H NMR (CD.sub.3OD) .delta. 9.57 (s, 1H), 8.64
(d, J=2.5 Hz, 1H), 8.52 (d, J=7.6 Hz, 1H), 8.26 (s, 1H), 8.24 (s,
1H), 8.08 (d, J=6.4 Hz, 1H), 7.64 (s, 1H), 7.60 (dd, J=8.7, 1.7 Hz,
1H), 7.55 (d, J=6.6 Hz, 1H), 7.54 (d, J=7.1 Hz, 1H), 7.33 (dd,
J=7.0, 1.1 Hz, 1H), 7.29 (dd, J=3.3, 1.3 Hz, 1H), 7.26 (dd, J=7.1,
1.0 Hz, 1H), 6.26 (d, J=2.2 Hz, 1H), 4.20 (s, 1H), 3.94 (d, J=6.8
Hz, 1H), 3.61 (s, 1H), 2.78 (d, J=14.7 Hz, 1H), 2.68 (dd, J=16.3,
6.9 Hz, 1H). New Examples Following the procedures described in
Example 1, using the appropriate alcohols, the following compounds
were made.
EXAMPLE 45
3-Butoxyl-5-[2-(4-pyridinyl)vinyl]pyridine
[0308] MS (DCI/NH.sub.3) m/e 255 (M+1). .sup.1H NMR (DMSO-d.sub.6):
.delta. 8.58 (d; J=6.0 Hz, 1H), 8.39 (s; 1H), 8.22 (s; 1H), 7.70
(s; 1H), 7.56 (d; J=6.0 Hz, 1H), 7.56 (d, J=16.5 Hz, 1H), 7.45 (d;
J=16.5 Hz, 2H), 4.12 (t; J=8.6 Hz, 3H), 1.74 (m; 2H), 1.47 (m; 2H),
0.96 (t; J=8.6 Hz, 2H).
EXAMPLE 46
3-Methoxyl-5-[2-(4-pyridinyl)vinyl]pyridine
[0309] MS (DCI/NH.sub.3) m/e 213 (M+1). .sup.1H NMR (DMSO-d.sub.6):
.delta. ppm 8.58 (m, 2H), 8.41 (d, J=1.7 Hz, 1H), 8.24 (d, J=2.7
Hz, 1H), 7.71 (m, 1H) 7.57 (m, 3H), 7.47 (d, J=16.5 Hz, 1H), 3.89
(s, 3H).
EXAMPLE 47
S-3-[2-Amino-3-phenyl-propyloxyl]-5-[2-(4-pyridinyl)vinyl]pyridine
Hydrochloride
[0310] MS (DCI/NH.sub.3) m/e 332 (M+1). .sup.1H NMR (DMSO-d.sub.6):
.delta. 8.58 (d; J=6.0 Hz, 2H), 8.40 (s; 1H), 8.25 (s; 1H), 7.69
(s; 1H), 7.56 (d; J=6.0 Hz, 1H), 7.56 (d; J=16.5 Hz, 1H), 7.43 (d;
J=16.5 Hz, 1H), 7.26 (m; 5H), 3.94 (m; 2H), 3.28 (m; 1H), 2.87 (dd;
J=6.0 Hz and 13.5 Hz, 1H), 2.65 (dd; J=9 Hz, 13.5 Hz, 1H).
EXAMPLE 48
3-[2-(1H-3-Indolyl)-ethoxyl]-5-[2-(4-pyridinyl)vinyl]pyridine
Hydrochloride
[0311] MS (DCI/NH.sub.3): m/z 342 (M+1). .sup.1H NMR
(DMSO-d.sub.6): .delta. 10.39 (br s, 1H), 8.60 (d, J=6.6 Hz, 2H),
8.38 (d, J=2.5 Hz, 1H), 8.25 (d, J=3.3 Hz, 1H), 7.72 (dd, J=2.5,
3.3 Hz, 1H), 7.62 (d, J=8.5 Hz, 1H), 7.55 (d, J=17.4 Hz, 1H), 7.36
(d, J=8.1 Hz, 1H), 7.54 (d, J=6.6 Hz, 2H), 7.28 (d, J=3.3 Hz, 1H),
4.36 (t, J=7.5 Hz, 2H), 3.11 (t, J=3.11 Hz, 2H).
EXAMPLE 49
3-[2-(1H-3-Indolyl)-propyloxyl]-5-[2-(4-pyridinyl)vinyl]pyridine
[0312] MS (DCI/NH.sub.3): m/z 356 (M+1). .sup.1H NMR
(DMSO-d.sub.6): .delta. 10.79 (br s, 1H), 8.57 (m, 2H), 8.39 (d,
J=1.7 Hz, 1H), 8.25 (d, J=3.1 Hz, 1H), 7.69 (t, J=2.0 Hz, 1H), 7.56
(m, 2H), 7.55 (d, J=16.6 Hz, 1H), 7.52 (m, 1H), 7.43 (d, J=16.6 Hz,
1H), 7.33 (d, J=8.1 Hz, 1H), 7.15 (d, J=2.4 Hz, 1H), 7.06 (m, 1H),
6.96 (m, 1H), 4.16 (t, J=6.5 Hz, 2H), 2.89 (t, J=8.1 Hz, 2H), 2.14
(m, 2H).
EXAMPLE 50
S-3-[2-Amino-3-(4-benzyloxy]phenyl)-propyloxyl]-5-[2-(4-pyridinyl)vinyl]py-
ridine Hydrochloride
[0313] MS (DCI/NH.sub.3): m/z 438 (M+1). .sup.1H NMR
(DMSO-d.sub.6): .delta. 10.04 (br s, 3H), 8.86 (d, J=7.5 Hz, 2H),
8.54 (s, 1H), 8.39 (d, J=3.3 Hz, 1H), 8.13 (d, J=7.5 Hz, 2H), 7.98
(d, J=17.4 Hz, 1H), 7.88 (m, 1H), 7.73 (d, J=17.4 Hz, 1H), 7.39 (m,
5H), 7.24 (d, J=9.0 Hz, 2H), 6.99 (d, J=9.0 Hz, 2H), 4.28 (dd,
J=3.9, 11.5 Hz, 1H), 5.07 (s, 2H), 4.12 (dd, J=6.5, 11.5 Hz, 1H),
3.29 (m, 1H), 3.05 (m, 2H).
EXAMPLE 51
3-(Piperidin-4-yl)-5-[2-(4-pyridinyl)vinyl]pyridine
[0314] MS (DCI/NH.sub.3): m/z 282 (M+1). .sup.1H NMR
(DMSO-d.sub.6): .delta. 8.55 (m, 2H), 8.34 (d, J=1.7 Hz, 1H), 8.18
(d, J=2.7 Hz, 1H), 7.72 (m, 1H), 7.62 (m, 2H), 7.52 (d, J=16.3 Hz,
1H), 7.35 (d, J=16.3 Hz, 1H), 4.66 (m, 1H), 3.10 (m, 2H), 2.78 (m,
2H), 2.06 (m, 2H), 1.70 (m, 2H).
EXAMPLE 52
R-3-{2-Amino-3-benzyloxypropyloxyl}-5-[2-(4-pyridinyl)vinyl]pyridine
Hydrochloride
[0315] MS (DCI/NH.sub.3): m/z 362 (M+1). .sup.1H NMR (CD.sub.3CD):
.delta. 8.84 (m, 2H), 8.81 (m, 1H), 8.58 (m, 1H), 8.53 (m, 1H),
8.32 (m, 2H), 7.98 (d, J=16.3 Hz, 1H), 7.87 (d, J=16.3 Hz, 1H),
7.35 (m, 5H), 4.66 (s, 2H), 3.95 (m, 2H), 3.85 (m, 1H).
EXAMPLE 53
3-(1-Methyl-imidazole-4-methoxyl)-5-[2-(4-pyridinyl)vinyl]pyridine
[0316] MS (DCI/NH.sub.3): m/z 393 (M+1). .sup.1H NMR (CD.sub.3OD):
.delta. 8.52 (m, 2H), 8.39 (d, J=1.6 Hz, 1H), 8.27 (d, J=2.5 Hz,
1H), 7.84 (m, 1H), 7.69 (s, 1H), 7.62 (m, 2H), 7.53 (d, J=16.5 Hz,
1H), 7.88 (d, J=16.5 Hz, 1H), 7.15 (s, 1H), 5.29 (s, 2H), 3.78 (s,
3H).
EXAMPLE 54
S-3-{2-Amino-3-[3-hydroxylphenyl]-propyloxyl}-5-[2-(4-pyridinyl)vinyl]pyri-
dine Trifluoroacetic Acid Salt
[0317] MS (DCI/NH.sub.3): m/z 348 (M+1). .sup.1H NMR
(DMSO-d.sub.6): .delta. 8.84 (d, j=6.8 Hz, 2H), 8.54 (m, 1H), 8.37
(d, J=2.7 Hz, 1H), 8.06 (d, J=6.8 Hz, 2H), 7.91 (m, J=16.6 Hz, 1H),
7.62 (d, J=16.6 Hz, 1H), 7.09 (d, J=8.5 Hz, 2H), 6.73 (d, J=8.5 Hz,
2H), 4.22 (dd, J=3.1, 10.5 Hz, 1H), 4.06 (dd, J=5.4, 10.5 Hz, 1H),
3.77 (m, 1H), 2.93 (m, 2H).
EXAMPLE 55
S-3-{2-Amino-3-[3-cyanophenyl]-propyloxyl}-5-[2-(4-pyridinyl)vinyl]pyridin-
e Hydrochloride Salt
[0318] MS (DCI/NH.sub.3): m/z 357 (M+1). .sup.1H NMR
(DMSO-d.sub.6): .delta. 8.92 (d,j=6.4 Hz, 2H), 8.66 (s, 1H), 8.49
(d, J=1.8 Hz, 1H), 8.21 (d, J=6.4 Hz, 2H), 8.13 (s, 1H), 8.06 (d,
J=16.5 Hz, 1H), 7.90 (d, J=16.5 Hz, 1H), 7.83 (d, J=8.2 Hz, 2H),
7.59 (d, J=8.2 Hz, 2H), 4.40 (dd, J=3.4, 10.7 Hz, 1H), 4.24 (dd,
J=5.8, 10.7 Hz, 1H), 3.91 (m, 1H), 3.29 (dd, J=6.1, 13.7 Hz, 1H),
3.16 (dd, J=8.5, 13.7 Hz, 1H).
EXAMPLE 56
3-[1-(4-Cyanobenzyl)-imidazole-4-methoxyl]-5-[2-(4-pyridinyl)vinyl]pyridin-
e
[0319] MS (DCI/NH.sub.3): m/z 394 (M+1). .sup.1HNMR (CD.sub.3OD)
.delta. 8.51 (d; J=6.1 Hz, 2H), 8.33 (d, J=1.5 Hz, 1H), 7.94 (d,
J=2.5 Hz, 1H), 7.93 (s, 1H), 7.67 (d, J=8.2 Hz, 2H), 7.62 (d, J=6.1
Hz, 2H), 7.48 (m, 1H), 7.47 (d, J=16.5 Hz, 1H), 7.30 (d, J=16.5 Hz,
1H), 7.27 (s, 1H), 7.25 (d, J=8.2 Hz, 2H), 5.47 (s, 2H), 5.26 (s,
2H).
EXAMPLE 57
S-3-[2-Amino-3-(1-methyl-1H-3-indolyl)-propyloxyl]-5-[2-(4-pyridinyl)vinyl-
]pyridine Hydrochloride Salt
[0320] MS (DCI/NH.sub.3): m/z 385 (M+1). .sup.1HNMR (CD.sub.3OD)
.delta. 8.87 (d; J=6.8 Hz, 2H), 8.55 (s, 1H), 8.41 (d, J=2.7 Hz,
1H), 8.13 (d, J=6.8 Hz, 2H), 7.96 (d, J=6.8 Hz, 2H), 7.96 (d,
J=16.6 Hz, 1H), 7.86 (m, 1H), 7.71 (d, J=16.6 Hz, 1H), 7.65 (d,
J=8.1 Hz, 1H), 7.42 (d, J=8.1 Hz, 1H), 7.29 (s, 1H), 7.17 (m, 1H),
7.04 (m, 1H), 4.84 (dd, J=3.4, 10.5 Hz, 1H), 4.21 (dd, J=5.8, 10.5
Hz, 1H), 3.90 (m, 1H), 3.19 (m, 2H), 3.17 (s, 3H).
EXAMPLE 58
S-3-[2-Dimethylamino-3-(1H-3-indolyl)-propyloxyl]-5-[2-(4-pyridinyl)vinyl]-
pyridine Hydrochloride Salt
[0321] MS (DCI/NH.sub.3): m/z 399 (M+1). .sup.1HNMR (DMSO-d.sub.6)
.delta. 8.88 (d; J=6.6 Hz, 2H), 8.58 (s, 1H), 8.45 (s, 1H), 8.16
(d, J=6.6 Hz, 2H), 7.96 (d, J=16.5 Hz, 1H), 7.95 (s, 1H), 7.76 (d,
J=16.5 Hz, 1H), 7.74 (d, J=7.8 Hz, 1H), 7.35 (d, J=8.1 Hz, 1H),
7.29 (d, J=2.2 Hz, 1H), 7.07 (m, 1H), 6.97 (m, 1H), 4.54 (dd,
J=1.6, 11.9 HZ), 4.35 (dd, J=5.0, 11.9 Hz, 1H), 3.95 (m, 1H), 3.51
(dd, J=3.1, 13.7 Hz, 1H), 3.29 (dd, J=11.5, 13.7 Hz, 1H), 2.96 (s,
6H).
EXAMPLE 59
S-3-[2-Amino-3-(1-naphthyl)-propyloxyl]-5-[2-(4-pyridinyl)vinyl]pyridine
Hydrochloride Salt
[0322] MS (DCI/NH.sub.3): m/z 382 (M+1). .sup.1HNMR (DMSO-d.sub.6)
.delta. 8.66 (d; J=6.1 Hz, 2H), 8.48 (d, J=1.4 Hz, 1H), 8.32 (d,
J=2.7 Hz, 1H), 8.20 (m, 1H), 7.98 (m, 1H), 7.90 (m, 1H), 7.69 (m,
3H), 7.60 (m, 3H), 7.46 m, 3H), 4.25 (dd, J=2.7, 10.5 Hz, 1H), 4.09
(dd, J=5.1, 10.5 Hz, 1H), 3.92 (m, 1H), 3.53 (m, 2H).
EXAMPLE 60
3-(2-Aminoethoxyl)-5-[2-(4-pyridinyl)vinyl]pyridine Hydrochcloride
Salt
[0323] MS (DCI/NH.sub.3) m/e 242 (M+1). .sup.1H NMR (CD.sub.3OD):
.delta. 8.88 (d, J=6.1 Hz, 2H), 8.59 (s, 1H), 8.43 (s, 1H), 8.19
(d, J=6.1 Hz, 2H), 8.03 (d, J=16.3 Hz, 1H), 8.01 (s, 1H), 7.82 (d,
J=16.3 Hz, 1H), 4.42 (t, J=4.9 Hz, 2H), 3.28 (m, 2H).
EXAMPLE 61
3-(3-Aminopropyloxyl)-5-[2-(4-pyridinyl)vinyl]pyridine
Hydrochloride Salt
[0324] MS (DCI/NH.sub.3) m/e 256 (M+1). .sup.1H NMR (DMSO-d.sub.6):
.delta. 8.88 (d; J=6.4 Hz, 2H), 8.53 (d; J=1.4 Hz, 1H), 8.40 (d,
J=2.7 Hz, 1H), 8.15 (d, J=6.4 Hz, 2H), 8.00 (d, J=16.6 Hz, 1H),
7.93 (m, 1H), 7.78 (d, J=16.6 Hz, 1H), 4.27 (t, J=6.1 Hz, 2H), 2.99
(m, 2H), 2.10 m(m, 2H).
EXAMPLE 62
S-3-(2-Amino3-methylbutyloxyl)-5-[2-(4-pyridinyl)vinyl]pyridine
Hydrochloride Salt
[0325] MS (DCI/NH.sub.3) m/e 284 (M+1). .sup.1H NMR (DMSO-d.sub.6):
.delta. 8.85 (d; J=6.5 Hz, 2H), 8.54 (d; J=1.4 Hz, 1H), 8.40 (d,
J=3.1 Hz, 1H), 8.09 (d, J=6.5 Hz, 2H), 7.95 (d, J=16.3 Hz, 1H),
7.90 (m, 1H), 7.71 (d, J=16.3 Hz, 1H), 4.39 (m, 1H), 4.24 (m, 1H),
3.08 (m, 1H), 2.10 (m, 1H), 1.06 (d, J=8.1 Hz, 3H), 1.03 (d, J=7.8
Hz, 3H).
EXAMPLE 63
3-(1-Methyl-3-piperidinyloxyl)-5-[2-(4-pyridinyl)vinyl]pyridine
Trifluoroacetic Acid Salt
[0326] MS (DCI/NH.sub.3) m/z 296 (M+H). .sup.1H NMR (DMSO-d.sub.6):
.delta. 8.82 (d, 2H), 8.53 (s, 1H), 8.41 (d, 1H), 8.00 (t, 2H),
7.88 (dd, 2H), 7.59 (dd, 2H), 4.53 (dd, 1H), 4.37 (dd, 1H), 3.89
(bs, 1H), 3.64 (bs, 1H), 3.24-3.13 (m, 1H), 3.01 (s, 3H), 2.35-2.28
(m, 1H), 2.13-2.07 (m, 1H), 2.02-1.93 (m, 1H), 1.90-1.83 (m,
1H).
EXAMPLE 64
3-(2-Chlorobenzyl)-5-[2-(4-pyridinyl)vinyl]pyridine Trifluoroacetic
Acid Salt
[0327] MS (DCI/NH.sub.3) m/z 323 (M+H). .sup.1H NMR (DMSO-d.sub.6):
.delta. 8.84 (d, 2H), 8.53 (s, 1H), 8.44 (d, 1H), 8.07 (d, 2H),
7.96-7.92 (m, 2H), 7.70-7.67 (m, 2H), 7.57-7.55 (m, 1H), 7.46-7.43
(m, 2H), 5.33 (s, 2H). 6
Example 65
3-(N-Benzyl-N-methylaminoethoxyl)-5-[2-(4-pyridinyl)vinyl]pyridine
Trifluoroacetic Acid Salt
[0328] MS (DCI/NH.sub.3) m/z 346 (M+H). .sup.1H NMR (DMSO-d.sub.6):
.delta. 8.80 (d, 2H), 8.53 (s, 1H), 8.37 (d, 1H), 7.98 (d, 2H),
7.87 (d, 1H), 7.81 (s, 1H), 7.60 (d, 1H), 7.58-7.47 (m, 5H),
4.58-4.50 (m, 2H), 3.59-3.56 (m, 2H), 2.85 (s, 3H), 2.79 (t,
2H).
EXAMPLE 66
3-(6-(N,N-Dimathylamino)hexyloxyl)-5-[2-(4-pyridinyl)vinyl]pyridine
Trifluoroacetic Acid Salt
[0329] MS (DCI/NH.sub.3) m/z 326 (M+H). .sup.1H NMR (DMSO-d.sub.6):
.delta. 8.82 (d, 2H), 8.49 (d, 1H), 8.33 (d, 1H), 8.04 (d, 2H),
7.89 (d, 1H), 7.80 (t, 1H), 7.66 (d, 1H), 4.14 (t, 2H), 3.06-3.02
(m, 2H), 2.78 (s, 3H), 2.77 (s, 3H), 1.82-1.76 (m, 2H), 1.68-1.62
(m, 2H), 1.51-1.45 (m, 2H), 1.40-1.34 (m, 2H).
EXAMPLE 67
3-(2-Thiophenoxyl-ethoxyl)-5-[2-(4-pyridinyl)vinyl]pyridine
Trifluoroacetic Acid Salt
[0330] MS (DCI/NH.sub.3) m/z 335 (M+H). .sup.1H NMR (DMSO-d.sub.6):
.delta. 8.76 (d, 2H), 8.46 (s, 1H), 8.27 (d, 1H), 7.93 (d, 1H),
7.80 (d, 1H), 7.77-7.74 (m, 2H), 7.59 (d, 1H), 7.43-742 (m, 1H),
7.36-7.31 (m, 3H), 7.24-7.16 (m, 1H), 4.33 (t, 2H), 3.43 (t,
2H).
EXAMPLE 68
3-(1-Methyl-3-pyrrolidinyloxyl)-5-[2-(4-pyridinyl)vinyl]pyridine
Trifluoroacetic Acid Salt
[0331] MS (DCI/NH.sub.3) m/z 282 (M+H). .sup.1H NMR (DMSO-d.sub.6):
.delta. 8.75 (d, 2H), 8.52 (s, 1H), 8.31 (d, 1H), 7.88 (d, 2H),
7.80-7.77 (m, 2H), 7.57 (d, 1H), 5.36-5.30 (m, 1H), 3.46-3.39 (m,
1H), 3.23-3.15 (m, 1H), 2.97-2.95 (m, 1H), 2.91 (s, 3H), 2.73-2.63
(m, 1H), 2.36-2.25 (m, 1H), 2.17-2.09 (m, 1H).
EXAMPLE 69
3-[(1-Methyl-2-piperidinyl)methoxyl]-5-[2-(4-pyridinyl)vinyl]pyridine
Trifluoroacetic Acid Salt
[0332] MS (DCI/NH.sub.3) m/z 310 (M+H). .sup.1H NMR (DMSO-d.sub.6):
.delta. 8.81 (d, 2H), 8.54-8.53 (m, 1H), 8.40-8.38 (m, 1H),
8.01-7.99 (m, 2H), 7.91-7.85 (m, 2H), 7.64-7.59 (m, 1H), 4.55-4.52
(m, 1H), 4.38-4.31 (m, 1H), 3.71-3.62 (m, 1H), 3.55-3.45 (m, 1H),
3.35-3.23 (m, 1H), 2.91 (s, 3H), 2.88 (dt, 1H), 2.10-1.52 (m,
5H).
EXAMPLE 70
3-(1-Pyridinyl-ethoxyl)-5-[2-(4-pyridinyl)vinyl]pyridine
Trifluoroacetic Acid Salt
[0333] MS (DCI/NH.sub.3) m/z 304 (M+H). .sup.1H NMR (DMSO-d.sub.6)
.delta. 8.81 (d, 2H), 8.73 (d, 2H), 8.48 (s, 1H), 8.34 (d, 1H),
8.01 (d, 1H), 7.85-7.81 (m, 2H), 7.74 (d, 2H), 7.57 (d, 1H), 5.89
(q, 1H), 1.65 (d, 3H).
EXAMPLE 71
4-{5-[(2S)-2-Amino-3-(1H-indol-3-yl)-propoxy]-pyridin-3-yl}-N-hydroxyl-ben-
zamidine Trifluoroacetic Acid Salt
Example 71A
4-{5-[(2S)-2-BOCamino-3-(1H-indol-3-yl)-propoxy]-pyridin-3-yl}-N-hydroxyl--
benzamidine
[0334] To a solution of Example 22 (200 mg, 0.43 mmol) in toluene
(7.0 ml) and methanol (0.5 ml) were added hydroxylamine
hydrochloride (33 mg, 0.48 mmol) and potassium tert-butoxide (54
mg, 0.48 mmol) and the mixture was stirred for 8 h at room
temperature under a nitrogen atmosphere. Another portion of
hydroxylamine hydrochloride (33 mg, 0.48 mmol) and potassium
tert-butoxide (54 mg, 0.48 mmol) was added and the mixture was
heated to 80.degree. C. for 16 h. The mixture was concentrated and
purified by column chromatography on silica gel using
dichloromethane/methanol (15:1) as solvent system. Obtained were
130 mg (61%) of the product as a white powder.
[0335] MS (DCI/NH.sub.3) m/z 487 (M-OH+2H).
EXAMPLE 71B
[0336]
4-{5-[(2S)-2-Amino-3-(1H-indol-3-yl)-propoxy]-pyridin-3-yl}-N-hydro-
xyl-benzamidine Trifluoroacetic Acid Salt
[0337] The desired product was prepared by substituting Example 71A
for Example 22A in example 22B. MS (DCI/NH.sub.3) m/z 369 (M-NHOH).
.sup.1H NMR (DMSO-d.sub.6) .delta. 11.02 (s, 1H), 8.63 (d, 1H),
8.40 (d, 1H), 8.23 (bs, 2H), 8.01-7.91 (m, 2H), 7.85-7.79 (m, 2H),
7.71 (t, 1H), 7.62 (d, 1H), 7.38 (d, 1H), 7.29 (d, 1H), 7.10 (t,
1H), 7.01 (q, 1H), 4.35 (dd, 1H), 4.19 (dd, 1H), 3.85-3.82 (m, 1H),
3.16 (m, 2H).
EXAMPLE 72
4-{5-[(2S)-2-Amino-3-(1H-indol-3-yl)-propoxy]-pyridin-3-yl}-benzamidine
Trifluoroacetic Acid Salt
Example 72A
4-{5-[(2S)-2-BOC-amino-3-(1H-indol-3-yl)-propoxy]-pyridin-3-yl}-benzamidin-
e
[0338] To a solution of the product of Example 71 (110 mg, 0.22
mmol) in glacial acetic acid (5.0 ml) was added acetic anhydride
(0.15 ml, 1.6 mmol) and the mixture was stirred for 2 h at ambient
temperature. The acetic anhydride was hydrolyzed by addition of
water (0.1 ml), 10% palladium on charcoal (25 mg) was added and the
mixture was stirred vigorously under a hydrogen atmosphere (1 atm.)
for 4 h. The mixture was filtered through a pad of diatomaceous
earth (Celite.RTM.) and the filtercake was washed with acetic acid.
The combined filtrates were evaporated in high vacuum and the
residue was triturated with ethyl acetate to give 80 mg (39%) of
the product as a beige powder.
[0339] MS (DCI/NH.sub.3) m/z 486 (M+H). .sup.1H NMR (DMSO-d.sub.6):
.delta. 10.93 (s, 1H), 8.56 (s, 1H), 8.32 (d, 1H), 7.93-7.88 (m,
4H), 7.66 (s, 1H), 7.57 (d, 1H), 7.34 (d, 1H), 7.17 (s, 1H),
7.07-7.05 (m, 2H), 6.96 (t, 1H), 4.17-4.11 (m, 2H), 4.09-4.05 (m,
1H), 3.00 (dd, 1H), 2.92 (dd, 1H), 1.36 (s, 9H).
Example 72B
4-{5-[(2S)-2-Amino-3-(1H-indol-3-yl)-propoxy]-pyridin-3-yl}-benzamidine
Trifluoroacetic Acid Salt
[0340] The desired product was prepared by substituting Example 72A
for Example 22A in Example 22B. MS (DCI/NH.sub.3) m/z 386 (M+H).
.sup.1H NMR (DMSO-d.sub.6): .delta. 11.03 (s, 1H), 9.38 (s, 2H),
9.24 (s, 2H), 8.65 (d, 1H), 8.42 (d, 1H), 8.25 (bs, 2H), 8.00-7.94
(m, 4H), 7.74 (t, 1H), 7.62 (d, 1H), 7.38 (d, 1H), 7.29 (d, 1H),
7.10 (t, 1H), 7.01 (t, 1H), 4.36 (dd, 1H), 4.20 (dd, 1H), 3.90-3.82
(m, 1H), 3.17 (m, 2H).
EXAMPLE 73
3-[(2S)-2-Amino-3-(1H-3-indolyl)-propyloxyl]-6-(3-pyridinyl)-quinoline
[0341] The desired product was prepared by substituting
pyridine-3-boronic acid for pyridine-4-boronic acid in Example 43.
MS (DCI/NH.sub.3) m/e 395 (M+1). .sup.1H NMR (DMSO-d.sub.6):
.delta. 10.89 (s; 1H), 9.02 (s; 1H), 8.72 (d; J=3.0 Hz, 1H), 8.62
(d; J=5.0 Hz, 1H), 8.20 (d; J=7.5 Hz, 1H), 8.15 (s; 1H), 8.06 (d;
J=9.0 Hz, 1H), 7.95 (d; J=9.0 Hz, 1H), 7.70 (S; 1H), 7.59 (d; J=6.0
Hz, 1H), 7.57 (m; 1H), 7.35 (d; J=8.4 Hz, 1H), 7.22 (s; 1H), 7.06
(t; J=7.5 Hz, 1H), 6.95 (t; J=7.5 Hz, 1H), 4.05 (m; 2H), 3.53 (m;
1H), 3.01 (dd; J=6.3, 14.9 Hz, 1H), 2.87 (dd; J=6.9, 14.9 Hz,
1H)
EXAMPLE 74
3-[(2S)-2-Amino-3-(1H-3-indolyl)-propyloxyl]-6-(3-quinolinyl)-quinoline
[0342] The desired product was prepared by substituting
quinoline-3-boronic acid for pyridine-4-boronic acid in Example 43.
MS (DCI/NH.sub.3) m/e 445 (M+1). .sup.1H NMR (DMSO-d.sub.6):
.delta. 0.89 (s; 1H), 9.49 (s; 1H), 8.80 (s; 1H), 8.74 (s; 1H),
8.31 (s; 1H), 8.10 (m; 4H), 7.82 (t; J=6.6 Hz, 1H), 7.73 (s; 1H),
7.69 (t; J=6.6 Hz, 1H), 7.49 (d; J=8.4 Hz, 1H), 7.35 (d; J=8.4 Hz,
1H), 7.23 (s; 1H), 7.06 (t; J=7.5 Hz, 1H), 6.95 (t; J=7.5 Hz, 1H),
4.05 (m; 2H), 3.52 (m; 1H), 3.01 (dd; J=6.3, 14.9 Hz, 1H), 2.87
(dd; J=6.9, 14.9 Hz, 1H).
EXAMPLE 75
3-[(2S)-2-Amino-3-(1H-3-indolyl)-propyloxyl]-5-[2-(2-amino-4-pyridinyl)vin-
yl]pyridine Trifluoroacetic Acid Salt
Example 75A
2-Amino-4-iodopyridine
[0343] A mixture of 2-floro-4-iodopyridine (3.0 g, 13.5 mmol),
acetylamide (15.8 g, 269 mmol) and potassium carbonate (9.2 g, 67
mmol) was stirred at 180.degree. C. for 7 hours, poured into ice
(100 g), extracted with ethyl acetate, washed with brine, dried
(MgSO.sub.4), filtered, and concentrated. The concentrate was
purified by flash column chromatography on silica gel with 50%
ethyl acetate/hexane to provide the title compound (1.1 g, 37%). MS
(DCI/NH.sub.3) m/e 221 (M+H).
Example 75B
N,N-Bis(tert-butyloxylcarbonyl)amino-4-iodopyridine
[0344] A solution of the product from Example 75A above (1.0 g, 4.5
mmol) in THF (25 mL) was treated dropwise with 1.0M LiHMDS (9.0 mL,
9.0 mmol), stirred for 30 minutes, treated with di-t-butyl
dicarbonate(1.96 g, 9.0 mmol) and stirred for 1 hour. The mixture
was quenched with water (10 mL), warmed to room temperature and
extracted with ethyl acetate. The combined extracts were washed
with brine, dried (MgSO.sub.4), filtered, and concentrated. The
concentrate was triturated with 1:1 hexanes/ethyl acetate to
provide the desired product (1.0 g, 53%). MS (DCI/NH.sub.3) m/z 421
(M+H).
Example 75C
N,N-Bis(tert-butyloxylcarbonyl)amino-4-vinylyridine
[0345] A mixture of the product from Example 75B above (0.7 g, 1.67
mmol), vinyltributyltin (0.83 g, 2.6 mmol) and
tetrakis-(triphenylphosphine)-pal- ladium(0) (0.12 g, 0.11 mmol)
was heated at 100.degree. C. for 6 hours, cooled to room
temperature, treated with ethyl acetate (10 mL), washed with brine,
dried (MgSO.sub.4), filtered, and concentrated. The concentrate was
purified by flash column chromatography on silica gel with 20%
ethyl acetate/hexane to provide the title compound (0.4 g, 75%). MS
(DCI/NH.sub.3) m/e 321 (M+H).
Example 75D
3-[(2S)-2-(N-tert-Butoxylcarbonyl)amino-3-(1H-3-indolyl)-propyloxyl]-5-{2--
[2-(N,N-bis(tert-butoxylcarbonyl)amino]-4-pyridinyl)vinyl}pyridine
[0346] The desired product was prepared by substituting Example 75C
for 4-vinylpyridine in Example 2B. Purification on silica gel
eluting with 100% ethyl acetate provided the title compound (0.15
g, 49%). MS (DCI/NH.sub.3) m/e 685 (M+H).
Example 75E
4-(2-{5-[(2S)-2-Amino-3-(1H-indol-3-yl)-propoxy]-pyridin-3-yl}-vinyl)-pyri-
din-2-ylamine
[0347] The desired product was prepared by substituting Example 75D
for Example 2B in Example 2C. Purification on HPLC provided the
title compound (0.06 g, 70%). MS (DCI/NH.sub.3) m/e 386 (M+1).
.sup.1H NMR (DMSO-d.sub.6): .delta. 11.05 (s; 1H), 8.50 (s; 1H),
8.35 (s; 1H), 8.23 (bs; 2H), 8.13 (bs; 2H), 7.95 (d; J=6.3 Hz, 1H),
7.72 (s; 1H), 7.65 (d; J=15.9 Hz, 1H), 7.61 (d; J=6.3 Hz), 7.42 (d;
J=15.9 Hz, 1H), 7.38 (d; J=6.9 Hz, 1H), 7.28 (s; 1H), 7.18 (d;
J=6.9 Hz, 1H), 7.10 (t; J=6.9 Hz, 1H), 7.00 (t; J=6.9 Hz, 1H), 6.93
(s; 1H), 4.29 (m; 1H), 4.14 (m; 1H), 3.87 (m; 1H), 3.17 (m;
2H).
EXAMPLE 76
5-[(2S)-2-(Amino-3-(1H-3-indolyl)-propyloxyl]-3-[2-(2-amino-4-pyridinyl)vi-
nyl]-2-chloro-pyridine Trifluoroacetic Acid Salt
[0348] The desired product was prepared by substituting
3-bromo-2-chloro-5-hydroxylpyridine for 3-bromo-5-hydroxylpyridine
in Example 75. MS (DCI/NH.sub.3) m/e 420 (M+1). .sup.1H NMR
(DMSO-d.sub.6): .delta. 11.05 (s; 1H), 8.21 (s; 1H), 8.21 (bs; 2H),
8.04 (bs; 2H), 7.95 (d; J=6.3 Hz, 1H), 7.93 (s; 1H), 7.61 (d; J=6.3
Hz, 1H), 7.58 (d; J=15.9 Hz, 1H), 7.39 (d; J=15.9 Hz, 1H), 7.39 (d;
J=6.9 Hz, 1H), 7.28 (s; 1H), 7.18 (d; J=6.9 Hz, 1H), 7.10 (t; J=6.9
Hz, 1H), 7.00 (t; J=6.9 Hz, 1H), 6.99 (s; 1H), 4.32 (m; 1H), 4.16
(m; 1H), 3.87 (m; 1H), 3.17 (m; 2H).
EXAMPLE 77
(1S)-1-(1H-Indol-3-ylmethyl)-2-(5-naphthalen-2-yl-pyridin-3-yloxy)-ethylam-
ine
[0349] The desired product was prepared by substituting
2-bromonaphthalene for 6-bromoisoquinoline in Example 27. .sup.1H
NMR (d.sub.6-DMSO, 500 MHz) .delta.: 11.02 (s, 1H), 8.74 (s, 1H),
8.38 (s, 1H), 8.30 (s, 1H), 8.18-8.21 (m, 2H), 8.04 (d, J=8 Hz,
1H), 7.97-8.01 (m, 2H), 8.85 (d, J=8 Hz, 1H), 7.81 (s, 1H), 7.62
(d, J=8 Hz, 1H), 7.50-7.58 (m, 1H), 7.35-7.39 (m, 1H), 7.23-7.31
(m, 1H), 7.08-7.12 (m, 1H), 6.96-7.03 (m, 2H), 4.18-4.41 (m, 2H),
3.82-3.87 (m, 1H), 3.17-3.21 (m, 2H). MS: (ESI) (M+H).sup.+
m/z=394
EXAMPLE 78
(1S)-1-(1H-Indol-3-ylmethyl)-2-(5-isoquinolin-5-yl-pyridin-3-yloxy)-ethyla-
mine
Example 78A
5-Bromoisoquinoline
[0350] To a solution of 5-aminoisoquinoline (2.0 g, 13.8 mmol) and
48% HBr (6 mL) in 20 mL water cooled to 0.degree. C. was added a
solution of sodium nitrite (0.95 g, 13.8 mmol) in 6 mL water. The
solution was stirred at 0.degree. C. for 20 minutes. The solution,
while kept at 0.degree. C., was added to a solution of CuBr (2.11
g, 15.9 mmol) in 48% HBr (4.77 mL) and water (10 mL). The reaction
was stirred at room temperature for an additional 1 hr. The
reaction was neutralized with NaOH (50%) and extracted with ethyl
acetate (3.times.). The combined organic layer was concentrated in
vacuo and chromatographed using 1:1 hexanes/ethyl acetate to yield
1.4 g product (50%).
Example 78B
(1S)-1-(1H-Indol-3-ylmethyl)-2-(5-isoquinolin-5-yl-pyridin-3-yloxy)-ethyla-
mine
[0351] The desired product was prepared by substituting Example 78A
for 6-bromoisoquinoline in Example 27. MS (ESI) m/z 395
(M+H).sup.+; .sup.1H NMR (d.sub.6-DMSO, 300 MHz) .delta. 11.02 (bs,
1H), 9.53 (s, 1H), 8.52 (d, J=8 Hz, 1H), 8.49 (d, J=4 Hz, 1H), 8.37
(d, J=3 Hz, 1H), 8.30-8.34 (m, 1H), 8.15-8.19 (m, 2H), 7.84-7.88
(m, 2H), 7.68 (d, J=8 Hz, 1H), 7.56-7.60 (m, 2H), 7.47 (d, J=8 Hz,
1H), 7.28 (d, J=4 Hz, 1H), 7.60-7.12 (m, 1H), 6.94-6.99 (m, 1H),
4.12-4.32 (m, 2H), 3.82-3.87 (m, 1H), 3.13-3.17 (m, 2H).
EXAMPLE 79
6-{5-[(2S)-2-Amino-3-(1H-indol-3-yl)-propoxy]-pyridin-3-yl}-2H-isoquinolin-
-1-one
[0352] The desired product was prepared by substituting
2-hydroxylisoquinoline for 6-bromoisoquinoline in Example 27. MS
(ESI) m/z 411 (M+H).sup.+; .sup.1H NMR (DMSO-d.sub.6, 300 MHz)
.delta. 11.30 (bs, 1H), 11.04 (bs, 1H), 8.66-8.68 (m, 1H), 8.41 (d,
J=3 Hz, 1H), 8.27 (d, J=8 Hz, 1H), 8.17-8.20 (m, 2H), 8.02-8.03 (m,
1H), 7.76-7.81 (m, 2H), 7.62 (d, J=8 Hz, 1H), 7.38 (d, J=8 Hz, 1H),
7.29-7.31 (m, 1H), 7.20-7.26 (m, 1H), 7.07-7.12 (m, 1H), 6.98-7.04
(m, 1H), 6.60 (d, J=8 Hz, 1H), 4.14-4.39 (m, 2H), 3.33-3.38 (m,
1H), 3.13-3.16 (m, 2H).
[0353] Anal. Calcd for C.sub.25H.sub.22N.sub.4O.2TFA: C, 54.54; H,
3.78; N, 8.78; F, 17.86. Found: C, 54.54; H, 4.00; N, 8.56; F,
17.10.
EXAMPLE 80
(1S)-2-[5-(3-Chloro-isoquinolin-6-yl)-pyridin-3-yloxy]-1-(1H-indol-3-ylmet-
hyl)-ethylamine
Example 80A
6-Bromo-indan-1,2-dione 1-oxime
[0354] A solution of 5-bromo-1-indanone (1.8 g, 8.5 mmol) in
ethanol (150 ml) was cooled to 0.degree. C., treated with
t-butylnitrite (2.1 ml), stirred at room temperature for 2 hours,
filtrated and washed the desired product with ether. The yield is
76%. MS (DCI/NH.sub.3) m/e 242 (M+1).sup.+.
Example 80B
6-Bromo-1,3-dichloro-isoquinoline
[0355] A suspension solution of Example 80A (1.5 g, 6.2 mmol) in
POCl.sub.3 (40 ml) was treated with PCl.sub.5 (1.55 g, 7.4 mmol)
and introduced HCl gas until solution was saturated. The reaction
was stirred at 60.degree. C. for 6 hours and concentrated under
vacumm.
[0356] The residue was slowly hydrolysed by adding water, treated
with ethyl acetate (200 mL), washed with brine, dried (MgSO.sub.4),
filtered, and concentrated. The concentrate was purified by flash
column chromatography on silica gel with 10% ethyl acetate/hexane
to provide the title compound (1.7 g, 100%). MS (DCI/NH.sub.3) m/e
278 (M+H).sup.+.
Example 80C
6-Bromo-3-chloro-isoquinoline
[0357] A mixture of Example 80B (1.8 g, 6.5 mmol), P (0.48 g, 15.5
mmol) and HI (3 ml, 48%) in acetic acid (20 ml) was refluxed for 8
hours, filtrated under hot condition and concentrated under vacumm.
The residue was basified by adding sodium hydroxide solution,
treated with ethyl acetate (200 mL), washed with brine, dried
(MgSO.sub.4), filtered, and concentrated. The concentrate was
purified by flash column chromatography on silica gel with 30%
ethyl acetate/hexane to provide the title compound (0.81 g, 50%).
MS (DCI/NH.sub.3) m/e 244 (M+H).sup.+.
Example 80D
3-Chloro-6-trimethylstannanyl-isoquinoline
[0358] The desired product was prepared by substituting Example 80C
for 6-bromoisoquinoline in Example 27A. MS (DCI/NH.sub.3) m/e 327
(M+H).sup.+.
Example 80E
(1S)-[2-[5-(3-Chloro-isoquinolin
6-yl)-pyridin-3-yloxy]-1-(1H-indol-3-ylme- thyl)-ethyl]-carbamic
Acid Tert-Butyl Ester
[0359] The desired product was prepared by substituting Example 80D
for Example 27A in Example 27B. MS (DCI/NH.sub.3) m/e 530
(M+H).sup.+.
Example 80F
(1S)-2-[5-(3-Chloro-isoquinolin-6-yl)-pyridin-3-yloxy]-1-(1H-indol-3-ylmet-
hyl)-ethylamine
[0360] The desired product was prepared by substituting Example 80E
for Example 27B in Example 27C. MS (DCI/NH.sub.3) m/e 429
(M+1).sup.+; .sup.1H NMR (DMSO-d.sub.6, 300 MHz) .delta. 11.04 (s;
1H), 9.28 (s; 1H), 8.72 (s; 1H), 8.44 (s; 1H), 8.33 (s; 1H), 8.32
(d; 1H; J=8.4 Hz), 8.17 (s; 2H), 8.07 (s; 1H), 8.05 (d; 1H; J=8.4
Hz), 7.80 (s; 1H), 7.63 (d; 1H; J=7.5 Hz), 7.48 (d; 1H; J=7.5 Hz),
7.30 (s; 1H), 7.10 (t; 1H; J=7.2 Hz), 7!00 (t; 1H; J=7.2 Hz), 4.38
(m; 1H), 4.20 (m; 1H), 3.88 (m; 1H), 3.18 (m; 2H).
EXAMPLE 81
(1S)-2-([3,4']Bipyridinyl-5-yloxy)-1-(1H-indol-3-ylmethyl)-ethylamine
Trifluoroacetic Acid
[0361] The desired product was prepared by substituting
4-tributylstannylpyridine for Example 27A in Example 27. MS (APCI)
m/z 345 (M+1).sup.+; .sup.1H NMR (CD.sub.3OD, 300 MHz) .delta. 8.85
(d, J=6.8 Hz, 2H), 8.73 (d, J=1.7 Hz, 1H), 8.53 (d, J=2.7 Hz, 1H),
8.20 (d, J=6.8 Hz, 2H), 7.84 (t, J=1.7 Hz, 1H), 7.59 (d, J=7.8 Hz,
1H), 7.38 (d, J=8.2 Hz, 1H), 7.24 (s, 1H), 7.12 (t, J=6.8 Hz, 1H),
7.01 (t, J=8.1 Hz, 1H), 4.44 (dd, J=10.8, 3.4 Hz, 1H), 4.30 (dd,
J=10.5, 5.8 Hz, 1H), 4.01 (m, 1H), 3.33 (m, 2H); Anal. Calcd for
C.sub.21H.sub.20N.sub.4O.box-solid.2.7 TFA: C, 48.61; H, 3.51; N,
8.59. Found: C, 48.69; H, 3.50; N, 8.46.
EXAMPLE 82
(1S)-1-(1H-Indol-3-ylmethyl)-2-[5-(2-pyridin-2-yl-vinyl)-pyridin-3-yloxy]--
ethylamine
[0362] The desired product was prepared by substituting
2-vinylpyridine for 4-vinylpyridine in Example 2. MS (APCI) m/z 371
(M+1).sup.+; .sup.1H NMR (CD.sub.3OD, 300 MHz) .delta. 8.72 (d,
J=5.5 Hz, 1H), 8.55 (s, 1H), 8.39 (d, J=2.4 Hz, 1H), 8.34 (td,
J=7.8, 1.7 Hz, 1H), 8.12 (d, J=8.2 Hz, 1H), 7.88 (t, J=1.7 Hz, 1H),
7.82 (d, J=16.3 Hz, 1H), 7.74 (t, J=6.7 Hz, 1H), 7.59 (d, J=7.8 Hz,
1H), 7.53 (d, J=16.3 Hz, 1H), 7.38 (d, J=8.1 Hz, 1H), 7.24 (s, 1H),
7.12 (td, J=7.1, 1.0 Hz, 1H), 7.03 (td, J=7.1, 1.0 Hz, 1H), 4.41
(tt, J=10.5, 3.4 Hz, 1H), 4.27 (dd, J=10.5, 5.5 Hz, 1H), 4.00 (m,
1H), 3.33 (m, 2H); Anal. Calcd for
C.sub.23H.sub.22N.sub.4O.box-solid- .3.8 TFA: C, 45.73; H, 3.24; N,
6.97. Found: C, 45.60; H, 3.34; N, 6.86.
EXAMPLE 83
(1S)-1-(1H-Indol-3-ylmethyl)-2-(5-pyridin-3-ylethynyl-pyridin-3-yloxy)-eth-
ylamine Trifluoroacetic Acid Salt
[0363] The desired product was prepared by substituting
3-bromopyridine for 4-bromopyridine in Example 14. MS (APCI) m/z
367 (M-1).sup.-; .sup.1H NMR (CD.sub.3OD, 300 MHz) .delta. 8.80 (s,
1H), 8.62 (br d, J=4.7 Hz, 1H), 8.42 (s, 1H), 8.36 (d, J=2.7 Hz,
1H), 8.12 (dt, J=8.2, 1.7 Hz, 1H), 7.60 (m, 3H), 7.39 (d, J=8.1 Hz,
1H), 7.22 (s, 1H), 7.14 (td, J=7.1, 1.4 Hz, 1H), 7.04 (td, J=8.2,
1.1 Hz, 1H), 4.33 (dd, J=10.5, 3.0 Hz, 1H), 4.19 (dd, J=10.5, 5.4
Hz, 1H), 3.97 (m, 1H), 3.29 (m, 2H);
[0364] Anal. Calcd for C.sub.23H.sub.20N.sub.4O.box-solid.3.0 TFA:
C, 49.02; H, 3.26; N, 7.89. Found: C, 48.86; H, 3.14; N, 8.01.
EXAMPLE 84
(1S)-2-[5-(2-Fluoro-pyridin-4-ylethynyl)-pyridin-3-yloxy]-1-(1H-indol-3-yl-
methyl)-ethylamine Trifluoroacetic Acid Salt
[0365] The desired product was prepared by substituting
4-iodo-2-fluoropyridine for 4-bromopyridine in Example 14. MS
(APCI) m/z 385 (M-1).sup.-; .sup.1H NMR (CD.sub.3OD, 300 MHz)
.delta. 8.42 (d, J=1.4 Hz, 1H), 8.38 (d, J=2.7 Hz, 1H), 8.26 (d,
J=5.1 Hz, 1H), 7.61 (dd, J=2.7, 1.7 Hz, 1H), 7.58 (d, J=7.8 Hz,
1H), 7.43 (dt, J=5.1, 1.7 Hz, 1H), 7.38 (d, J=8.1 Hz, 1H), 7.23 (m,
2H), 7.13 (td, J=7.1, 1.3 Hz, 1H), 7.04 (td, J=7.8, 1.3 Hz, 1H),
4.33 (dd, J=10.5, 3.4 Hz, 1H), 4.18 (dd, J=10.5, 5.8 Hz, 1H), 3.97
(m, 1H), 3.30 (m, 2H); Anal. Calcd for
C.sub.23H.sub.19FN.sub.4O.box-solid.2.3 TFA: C, 51.10; H, 3.31; N,
8.64. Found: C, 51.06; H, 3.32; N, 8.69.
EXAMPLE 85
(1S)-4-{5-[2-Amino-3-(1H-indol-3-yl)-propoxy]-pyridin-3-ylethynyl}-pyridin-
-2-ol Trifluoroacetic Acid Salt
[0366] A solution of N-BOC protected Example 84 (45 mg, 0.093
mmol)) in acetic acid (5 mL) was heated at 80.degree. C. for 15 h
and at 100.degree. C. for 5 h. The solution was concentrated and
the residual oil was dissolved in CH.sub.2Cl.sub.2 (5 mL).
Trifluoroacetic acid (1.25 mL) was added at 0.degree. C. The
solution was stirred at 0.degree. C. for 10 min and at rt for 30
min, and was concentrated. The residual material was purified on
HPLC (Zorbax, C-18) to provide the title compound (15 mg, 33%). MS
(APCI) m/z 383 (M-1).sup.-; .sup.1H NMR (CD.sub.3OD, 300 MHz)
.delta. 8.40 (s, 1H), 8.36 (d, J=2.3 Hz, 1H), 7.58 (m, 2H), 7.46
(d, J=6.8 Hz, 1H), 7.39 (d, J=8.2 Hz, 1H), 7.22 (s, 1H), 7.14 (td,
J=7.1, 1.0 Hz, 1H), 7.03 (td, J=8.2, 1.1 Hz, 1H), 6.69 (brs, 1H),
6.46 (dd, J=6.8, 1.7 Hz, 1H), 4.32 (dd, J=10.5, 3.4 Hz, 1H), 4.18
(dd, J=10.5, 5.8 Hz, 1H), 3.98 (m, 1H), 3.34 (m, 2H).
EXAMPLE 86
(1S)-2-[6-Chloro-5-(1-chloro-isoquinolin-6-yl)-pyridin-3-yloxy]-1-(1H-indo-
l-3-ylmethyl)-ethylamine Trifluoroacetic Acid Salt
[0367] The title compound was prepared by substituting Example 13A
for Example 2A and Example 80D for Example 27A in Example 27. MS
(APCI) m/z 464 (M+1).sup.+; .sup.1H NMR (CD.sub.3OD, 300 MHz)
.delta. 8.44 (d, J=8.8 Hz, 1H), 8.31 (d, J=5.8 Hz, 1H), 8.22 (d,
J=3.1 Hz, 1H), 8.03 (d, J=1.7 Hz, 1H), 7.84 (m, 2H), 7.57 (dt,
J=7.8, 1.0 Hz, 1H), 7.53 (d, J=3.0 Hz, 1H), 7.34 (d, J=7.2 Hz, 1H),
7.22 (s, 1H), 7.10 (td, J=7.2, 1.4 Hz, 1H), 7.01 (td, J=7.7, 1.0
Hz, 1H), 4.36 (dd, J=10.5, 3.0 Hz, 1H), 4.22 (dd, J=10.5, 5.7 Hz,
1H), 3.97 (m, 1H), 3.27 (m, 2H); Anal. Calcd for
C.sub.25H.sub.20Cl.sub.2N.sub.4O.box-solid.2.05 TFA: C, 50.14; H,
3.19; N, 8.04. Found: C, 50.16; H, 3.03; N, 7.88.
EXAMPLE 87
Bis-[3-(4-Bromo-phenyl)-allyl]-{2-[5-(2-pyridin-4-yl-vinyl)-pyridin-3-ylox-
y]-ethyl}-amine Hydrochloride
[0368] The title compound was obtained from the less polar product
in Example 19D (5.3 mg, 3%). MS (DCI/NH.sub.3) m/z 630,632, 634
(M+H).sup.+; .sup.1H NMR (CDCl.sub.3, 300 MHz) .delta. 8.62 (m,
2H), 8.36 (s, 1H), 8.26 (d, J=2.7 Hz, 1HO, 7.0-7.5 (m, 13H0, 6.52
(m, 2H), 6.35 (m, 2H), 4.25 (m, 2H), 3.49 (m, 4H), 3.08 (m,
2H).
EXAMPLE 88
N.sup.4-[3-(2-Amino-ethoxy)-phenyl]-pyrimidine-2,4-diamine
Hydrochloride
[0369] The title compound was prepared by substituting
N-Boc-aminoethanol for BOC-tryptophanol in Example 20. MS
(DCI/NH.sub.3) m/z 246(M+1).sup.+; .sup.1H NMR (DMSO-d.sub.6, 300
mHz) .delta. 12.4 (br s, 1H), 11.0 (br s, 1H), 8.26 (br, 5H), 7.86
(d, J=7.1 Hz, 1H), 7.55 (m, 1H), 7.44 (m, 1H), 7.31 9t, J=8.1 Hz,
1h0, 6.79 (d, J=8.1 Hz, 1H), 6.46 (d, J=7.1 Ha, 1H), 4.22 (t, J=5.1
Hz, 2H), 3.22 (m, 2H).
EXAMPLE 89
trans-[4-(2-{5-[(2S)-2-Amino-3-(1H-indol-3-yl)-propylamino]-pyridin-3-yl}--
vinyl)-pyrimidin-2-yl]-carbamic Acid Ethyl Ester Trifluoroacetic
Acid Salt
Example 89A
trans-4-[(5-Bromo-pyridin-3-yl)-vinyl]-2-amino-pyrimidine
[0370] A solution of 5-bromo-pyridine-3-carbaldehyde (436 mg, 2.34
mmol) and 2-amino-4-methylpyrimidine (246 mg, 2.35 mmol) in formic
acid (96%, 3 mL) was heated for 18 h. After cooling to rt, it was
then diluted with water and basified to pH 13 with 1 N NaOH. The
mixture was then extracted with methylene chloride. The combined
extracts was washed with water (1.times.), dried over MgSO.sub.4
and concentrated. The residue was chromatographed on silica gel
eluting with CH.sub.2Cl.sub.2:MeOH:NH.sub.4- OH (100:5:0.5) to give
the title compound (463 mg, 71%). MS (DCI/NH.sub.3) m/z 277,
279(M+1).sup.+.
Example 89B
trans-4-[(5-Bromo-pyridin-3-yl)-vinyl]-2-[bis(tert-butoxycarbonyl)amino]-p-
yrimidine
[0371] A suspension of Example 89A (439 mg, 1.58 mmol),
(BOC).sub.2O (1.040 g, 4.77 mmol), DMAP (50 mg, 0.41 mmol), and
triethylamine (670 .mu.L, 4.81 mmol) in THF (10 mL) was stirred at
rt overnight. Reaction was concentrated and chromatographed on
silica gel eluting with AcOEt:hexane (1:1) to give the title
compound (511 mg, 68%). MS (DCI/NH.sub.3) m/z 477, 479(M+1).
Example 89C
trans-4-[(5-amino-pyridin-3-yl)-vinyl-2-(tert-butoxycarbonyl)amino-pyrimid-
ine
[0372] Example 89B was converted to the title compound according to
the procedures described for Example 51, Steps 4 and 5. MS
(DCI/NH.sub.3) m/z 314(M+1).sup.+.
Example 89D
trans-[4-(2-{5-[(2S)-2-Amino-3-(1H-indol-3-yl)-propylamino]-pyridin-3-yl}--
vinyl)-pyrimidin-2-yl]-carbamic Acid Ethyl Ester Trifluoroacetic
Acid Salt
[0373] The title compound was prepared by substituting Example 89C
for Example 11B in Example 11. (DCI/NH.sub.3) m/z 458(M+1).sup.+;
NMR (DMSO-d.sub.6): .delta. 8.58 (d, J=5.3 Hz, 1H), 8.17 (s, 1H),
7.91 (d, J=2.2 Hz, 1H), 7.75 (d, J=15.9 Hz, 1H), 7.58 (m, 1H), 7.35
(m, 2H), 7.32 (s, 1H), 7.22 (d, J=5.3 Hz, 1H), 7.15 (d, J=15.9 Hz,
1H), 7.11 (m, 1H), 7.04 (m, 1H), 4.28 (q, J=7.2 Hz, 2H), 3.80 (m,
1H), 3.62 (dd, J=4.4, 14.7 Hz, 1H), 3.50 (dd, J=8.1, 14.7 Hz, 1H),
3.20 (m, 2H), 1.35 (t, J=7.2 Hz, 3H).
EXAMPLE 90
1-Amino-6-{5-[(2S)-2-amino-3-(1H-indol-3-yl)-propoxy]-pyridin-3-yl}-isoqui-
noline Trifluoroacetic Acid Salt
Example 90A
6-Bromo-1-chloroisoquinoline
[0374] A solution of 6-bromo-1-hydroxy]isoquinoline (9.205 g, 41.0
mmol) in POCl.sub.3 (100 mL) was heated to 100.degree. C. for 4 h.
The reaction was concentrated to dryness. The residue was dissolved
in ethyl acetate and the organic layer was washed with 5%
NaHCO.sub.3, water, brine, dried over MgSO.sub.4 and concentrated.
The residue was was chromatographed on silica gel eluting with
CH.sub.2Cl.sub.2:hexane (3:7) to give the title compound (6.176 g,
62%). MS (DCI/NH.sub.3) m/z 241, 243 (M+1).sup.+.
Example 90B
1-Amino-6-bromoisoquinoline
[0375] A mixture of the chloride from Example 90A (264 mg, 1.09
mmol), acetamide (1.3 g) and K.sub.2CO.sub.3 (0.45 g) was heated to
180.degree. C. for 5 h. After cooling to rt, the mixture was
dissolved in ethyl acetate, which was washed with water, brine,
dried over MgSO.sub.4, and concentrated. The residue was
chromatographed on silica gel eluting with
CH.sub.2Cl.sub.2:MeOH:NH.sub.4OH (100:5:0.5) to give the title
compound (159 mg, 65%). MS (DCI/NH.sub.3) m/z 223, 225
(M+1).sup.+.
Example 90C
1-[(Bis(tert-butoxycarbonyl)]amino-6-bromoisoquinoline
[0376] A solution of Example 90B (616 mg, 2.76 mmol), BOC.sub.2O
(1.81 g), DMAP (67 mg), and triethylamine (1.15 mL) in acetonitrile
(15 mL) was stirred at rt for 2 h. The reaction was concentrated
and the residue was chromatographed on silica gel eluting with
AcOEt:hexane (3:7) to give the title compound (1.18 g, 71%). MS
(DCI/NH.sub.3) m/z 423 (M+1).sup.+.
Example 90D
1-Amino-6-{5-[(2S)-2-amino-3-(1H-indol-3-yl)-propoxy]-pyridin-3-yl}-isoqui-
noline Trifluoroacetic Acid Salt
[0377] The title compound was prepared by substituting Example 90C
for 6-bromophthalimide in Example 32. MS (DCI/NH.sub.3) m/z
410(M+1).sup.+; .sup.1H NMR (DMSO-d.sub.6, 300 MHz) .delta. 8.77
(s, 1H), 8.55 (d, J=8.6 Hz, 1H), 8.45 (d, J=2.5 Hz, 1H), 8.20 (d,
J=1.5 Hz, 1H), 8.05 (dd, J=1.8. 8.6 Hz, 1H), 7.83 (dd, J=1.8, 2.5
Hz, 1H), 7.61 (m, 2H), 7.38 (d, J=7.1 Hz, 1H), 7.24 (s, 1H), 7.12
(m, 1H), 7.02 (m, 1H), 4.44 (dd, J=3.1, 10.4 Hz, 1H), 4.30 (dd,
J=5.8, 10.4 Hz, 1H), 4.01 (m, 1H), 3.32 (m, 2H).
EXAMPLE 91
6-{5-[(2S)-2-amino-3-(1H-indol-3-yl)-propoxy]-pyridin-3-yl}-1-chloro-isoqu-
inoline Trifluoroacetic Acid Salt
[0378] The title compound was prepared by substituting Example 90A
for 6-bromophthalimide in Example 32. MS (ESI) m/z 429,
431(M+1).sup.+; .sup.1HNMR (DMSO-d.sub.6, 300 MHz) .delta. 11.03
(br s, 1H), 8.75 (d, J=1.6 Hz, 1H), 8.47 (d, J=1.6 Hz, 1H), 8.45
(d, J=5.6 Hz, 1H), 7.84 (m, 1H), 7.62 (d, J=8.1 Hz, 1H), 7.39 (d,
J=8.1 Hz, 1H), 7.31 (d, J=2.2 Hz, 1H), 7.10 (m, 1H), 7.01 (m, 1H),
4.38 (dd, J=3.1, 10.6 Hz, 1H), 4.22 (dd, J=6.2, 10.4 Hz, 1H), 3.88
(m, 1H), 3.18 (m, 2H).
EXAMPLE 92
(2S)-2-Amino-3-(1H-indol-3-yl)-N-[5-(2-pyridin-4-yl-vinyl)-pyridin-3-yl]-p-
ropionamide
[0379] The title compound was prepared by substituting
Boc-tryptophane for Boc-homnophenyalanine in Example 16. MS
(DCI/NH.sub.3) m/z 384 (M+1).sup.+; .sup.1H NMR (DMSO-d.sub.6, 300
MHz) .delta. 11.37 (s, 1H), 11.05 (s, 1H), 8.88 (d, J=6.44 Hz, 2H),
8.74 (m, 2H), 8.42 (m, 1H), 8.35 (s, 1H), 8.22 (d, J=6.10 Hz, 2H),
8.02 (d, J=16.61 Hz, 1H), 7.71 (d, J=7.80 Hz, 1H), 7.56 (d, J=16.27
Hz, 1H), 7.36 (d, J=7.80 Hz, 1H), 7.30 (m, 1H), 7.07 (m, 1H), 6.95
(m, 1H), 4.31 (m, 1H), 3.36 (m, 2H).
EXAMPLE 93
(2S)-2-Amino-3-(naphtha-1-yl)-N-[5-(2-pyridin-4-yl-vinyl)-pyridin-3-yl]-pr-
opionamide Hydrochloride
[0380] The title compound was prepared by substituting
Boc-3-(1-naphthyl)alanine for Boc-homnophenyalanine in Example 16.
MS (DCI/NH.sub.3) m/z 395 (M+1).sup.+. .sup.1H NMR (DMSO-d.sub.6,
500 MHz,) .delta. 11.86 (s, 1H), 8.90 (d, J=6.86 Hz, 2H), 8.78 (m,
1H), 8.85 (m, 1H), 8.58 (m, 1H), 8.45 (m, 1H), 8.26 (d, J=6.86 Hz,
2H), 8.04 (d, J=16.53 Hz, 1H), 7.89 (m, 2H) 7.84 (m, 1H), 7.60 (d,
J=16.53 Hz, 1H), 7.58 (m, 1H), 7.49 (m, 2H), 4.53 (m, 1H), 3.49 (m,
1H), 3.36 (m, 1H).
EXAMPLE 94
(2S)-2-Amino-3-phenyl-N-[5-(2-pyridin-4-yl-vinyl)-pyridin-3-yl]-propionami-
de Hydrochloride
[0381] The title compound was prepared by substituting
Boc-phenylalanine for Boc-homnophenyalanine in Example 16. MS
(DCI/NH.sub.3) m/z 345 (M+1).sup.+; .sup.1H NMR (,DMSO-d.sub.6, 500
MHz) .delta.) 11.85 (s, 1H), 8.93 (m, 2H) 8.53 (m, 2H), 8.49 (m,
1H), 8.29 (m, 2H), 8.07 (d, J=16.22 Hz, 1H), 7.63 (d, J=16.53 Hz,
1H,) 7.32 (m, 5H), 4.44 (m, 1H), 3.24 (m, 2H)
EXAMPLE 95
S-2-Amino-3-(imidazol-4-yl)-N-[5-(2-pyridin-4-yl-vinyl)-pyridin-3-yl]-prop-
ionamide Hydrochloride
[0382] The title compound was prepared by substituting
bis(Boc)-histidine for Boc-homnophenyalanine in Example 16. MS
(DCI/NH.sub.3) m/z 335 (M+1).sup.+, .sup.1H NMR (DMSO-d.sub.6, 300
MHz) .delta. 10.95 (s, 1H), 9.04 (s, 1H), 8.74 (m, 1H), 8.70 (m,
1H), 8.52 (m, 2H) 8.32 (m, 1H) 8.08 (m, 2H), 7.93 (d, J=16.61 Hz,
1H), 7.50 (m, 2H), 4.50 (m, 1H), 3.33 (m, 2H).
EXAMPLE 96
(1R)-2-(1H-indol-3-yl)-1-[[(5-isoquinolin-6-ylpyridin-3-yl)oxy]methyl]ethy-
lamine
[0383] The title compound was prepared as the trifluoroacetate salt
by substituting R-Boc-tryptophanol for L-Boc-tryptophanol in
Example 27. MS (ESI) m/e 395 (M+H).sup.+; .sup.1H NMR
(DMSO-d.sub.6, 300 MHz) .delta. 11.02 (br s, 1H), 9.52 (s, 1H),
8.76 (d, J=3 Hz, 1H), 8.62 (d, J=8 Hz, 1H), 8.44-8.46 (m, 2H), 8.38
(d, J=9 Hz, 1H), 8.11-8.20 (m, 3H), 8.04-8.08 (m, 1H), 7.83-7.86
(m, 1H), 7.62 (d, J=9 Hz, 1H), 7.37-7.40 (m, 1H), 7.31 (d, J=3 Hz,
1H), 7.08-7.12 (m, 1H), 6.99-7.03 (m, 1H), 4.37-4.41 (m, 1H),
4.18-4.23 (m, 1H), 3.86-3.91 (m, 1H), 3.16-3.20 (m, 2H); Anal.
Calcd for C.sub.25H.sub.22N.sub.4O.2.65 TFA: C, 52.24; H, 3.57; N,
8.04;. Found: C, 52.26; H, 3.70; N, 7.42.
EXAMPLE 97
(1S)-5-{5-[2-Amino-3-(1H-indol-3-yl)-propoxy]-pyridin-3-yl}-1H-indazol-3-y-
lamine
Example 97A
2-Fluoro-5-(trimethylstannyl)benzonitrile
[0384] The desired product was prepared by substituting
5-bromo-2-fluorobenzonitrile for 6-bromoisoquinoline in Example
27A.
Example 97B
(1S)-[2-[5-(3-Cyano-4-fluoro-phenyl)-pyridin-3-yloxy]-1-(1H-indol-3-ylmeth-
yl)-ethyl]-carbamic Acid Tert-Butyl Ester
[0385] The desired product was prepared by substituting Example 97A
for in Example 27A in Example 27B.
Example 97C
(1S)-[2-[5-(3-Amino-1H-indazol-5-yl)-pyridin-3-yloxy]-1-(1H-indol-3-ylmeth-
yl)-ethyl]-carbamic Acid Tert-Butyl Ester
[0386] A mixture of Example 97B (120 mg, 0.25 mmol) and 98%
hydrazine (5 mL) was heated to reflux for 5 hours, poured over ice,
diluted with brine, extracted with ethyl acetate, dried over
MgSO.sub.4, and concentrated. Purification by flash chromatography
(7% MeOH/CH.sub.2Cl.sub.2) provided the desired product (103 mg,
84%).
Example 97D
(1S)-5-{5-[2-Amino-3-(1H-indol-3-yl)-propoxy]-pyridin-3-yl}-1H-indazol-3-y-
lamine
[0387] The desired product was prepared as the trifluoroacetate
salt by substituting Example 97C for Example 27B in Example 27C. MS
(ESI) m/e 399 (M+H).sup.+; .sup.1H NMR (DMSO-d.sub.6, 300 MHz)
.delta. 3.17(d,J=7.12 Hz, 2H) 3.84 (m, 1H) 4.18 (dd,J=10.51, 5.76
Hz, 1H) 4.36 (m, 1H) 7.12 (m, 4H) 7.30 (d, J=2.37 Hz, 1H) 7.38 (m,
1H) 7.42 (s, 1H) 7.63 (d, J=7.46 Hz, 1H) 7.66 (s, 1H) 8.18 (m, 4H)
8.32 (d,J=2.71 Hz, 1H) 8.57 (d,J=1.70 Hz, 1H) 11.04(s, 1H) 11.92
(bs, 1H); Anal. Calcd for C.sub.23H.sub.22N.sub.6O- .2.9 TFA: C,
47.44; H, 3.44; N, 11.53;. Found: C, 47.87; H, 3.49; N, 11.19.
EXAMPLE 98
(1S)-6-{5-[2-Amino-3-(1H-indol-3-yl)-propoxy]-pyridin-3-yl}-1H-indazol-3-y-
lamine
[0388] The desired product was prepared as the trifluoroacetate
salt by substituting 4-bromo-2-fluorobenzonitrile for
5-bromo-2-fluorobenzonitril- e in Example 97. MS (ESI) m/e 399
(M+H).sup.+; .sup.1H NMR (DMSO-d.sub.6, 300 MHz) .delta. 3.16 (d,
J=5.42 Hz, 2H) 3.91 (d, J=30.85 Hz, 1H) 4.19 (s, 1H) 4.35 (m, 1H)
7.07 (m, 2H) 7.34 (m, 3H) 7.63 (m, 2H) 7.71 (s, 1H) 7.88 (d, J=8.14
Hz, 1H) 8.17 (s, 4H) 8.37 (d, J=2.37 Hz, 1H) 8.60 (d, J=1.36 Hz,
1H) 11.03 (s, 1H) 11.93 (bs, 1H); Anal. Calcd for
C.sub.23H.sub.22N.sub.6O.3.5 TFA: C, 45.18; H, 3.22; N, 10.54, F,
25.01; Found: C, 44.83; H, 3.19; N, 10.40, F, 25.01.
EXAMPLE 99
2-Amino-N-[(1S)-1-(1H-indol-3-ylmethyl)-2-(5-isoquinolin-6-yl-pyridin-3-yl-
oxy)-ethyl]-acetamide
Example 99A
{[(1S)-1-(1H-Indol-3-ylmethyl)-2-(5-isoquinolin-6-yl-pyridin-3-yloxy)-ethy-
lcarbamoyl]-methyl}-carbamic Acid Tert-Butyl Ester
[0389] A solution of Example 27C (175 mg, 0.35 mmol), N-Boc-glycine
(91 mg, 0.52 mmol), EDC (100 mg), iPr.sub.2EtN (0.30 mL) and DMAP
(10 mg) in CH.sub.2Cl.sub.2 (7 mL) was stirred at room temperature
overnight, diluted with EtOAc, washed with water and brine, dried
(MgSO.sub.4), filtered, and concentrated. The residue was purified
by flash column chromatography on silica gel with 3%
methanol/CH.sub.2Cl.sub.2 to provide the desired product (112 mg,
58%).
Example 99B
2-Amino-N-[(1S)-1-(1H-indol-3-ylmethyl)-2-(5-isoquinolin-6-yl-pyridin-3-yl-
oxy)-ethyl]-acetamide
[0390] The desired product was prepared as the trifluoroacetate
salt by substituting Example 99A for Example 27B in Example 27C. MS
(ESI) m/e 452 (M+H).sup.+; .sup.1H NMR (DMSO-d.sub.6, 300 MHz)
.delta. ppm 3.07 (m, 2H) 3.58 (m, 2H) 4.22 (m, 2H) 4.48 (m, 1H)
6.97 (t, J=6.95 Hz, 1H) 7.06 (t, J=6.95 Hz, 1H) 7.21 (d, J=2.37 Hz,
1H) 7.34 (d, J=8.14 Hz, 1H) 7.64 (d, J=7.46 Hz, 1H) 7.86 (m, 1H)
7.99 (bs, 2H) 8.13 (d, J=6.10 Hz, 1H) 8.19 (dd, J=8.82, 1.70 Hz,
1H) 8.42 (m, 2H) 8.51 (s, 1H) 8.64 (d, J=6.10 Hz, 1H) 8.67 (d,
J=7.80 Hz, 1H) 8.74 (d, J=1.70 Hz, 1H) 9.60 (s, 1H) 10.88 (s, 1H);
Anal. Calcd for C.sub.27H.sub.25N.sub.5O.sub.2.2.9 TFA: C, 50.37;
H, 3.60; N, 8.95;. Found: C, 50.59; H, 3.43; N, 8.83.
EXAMPLE 100
(2S)-2-Amino-N-[(1S)-1-(1H-indol-3-ylmethyl)-2-(5-isoquinolin-6-yl-pyridin-
-3-yloxy)-ethyl]-propionamide
[0391] The desired product was prepared by substituting
L-Boc-alanine for N-Boc-glycine in Example 99. MS (ESI) m/e 466
(M+H).sup.+; .sup.1H NMR (DMSO-d.sub.6, 500 MHz) .delta. 1.36 (d,
J=6.86 Hz, 3H) 3.09 (m, 2H) 3.88 (m, 1H) 4.35 (m, 2H) 4.46 (m, 1H)
6.97 (t, J=7.33 Hz, 1H) 7.05 (t, J=7.33 Hz, 1H) 7.29 (d, J=1.87 Hz,
1H) 7.35 (d, J=8.11 Hz, 1H) 7.66 (d, J=7.80 Hz, 1H) 8.30 (s, 1H)
8.34 (bs, 2H) 8.47 (dd, J=8.74, 1.56 Hz, 1H) 8.53 (d, J=6.55 Hz,
1H) 8.62 (d, J=1.87 Hz, 1H) 8.70 (d, J=6.74, 1H) 8.75 (d, J=6.24,
1H) 8.89 (s, 1H) 8.93 (s, 1H) 9.01 (d, J=8.11 Hz, 1H) 9.99 (s, 1H)
10.98 (s, 1H)
EXAMPLE 101
2-Dimethylamino-N-[(1S)-1-(1H-indol-3-ylmethyl)-2-(5-isoquinolin-6-yl-pyri-
din-3-yloxy)-ethyl]-acetamide
[0392] The desired product was prepared by substituting
N,N-dimethylglycine for N-Boc-glycine in Example 99A. MS (ESI) m/e
480 (M+H).sup.+; .sup.1H NMR (DMSO-d.sub.6, 500 MHz) .delta. 2.71
(s, 3H) 2.77 (s, 3H) 3.10 (m, 2H) 3.95 (m, 2H) 4.40 (m, 2H) 4.52
(m, 1H) 6.97 (t, J=7.33 Hz, 1H) 7.05 (t, J=7.49 Hz, 1H) 7.28 (s,
1H) 7.34 (d, J=8.11 Hz, 1H) 7.67 (d, J=7.80 Hz, 1H) 8.38 (s, 1H)
8.50 (d, J=8.73 Hz, 1H) 8.55 (d, J=6.24 Hz, 1H) 8.67 (d, J=1.87 Hz,
1H) 8.71 (d, J=8.73 Hz, 1H) 8.75 (d, J=6.55 Hz, 1H) 8.92 (s, 1H)
8.98 (s, 1H) 9.34 (d, J=8.42 Hz, 1H) 10.00 (s, 1H) 11.02 (s,
1H).
EXAMPLE 102
(1S)-1-(1H-Indol-3-ylmethyl)-2-[5-(3-methyl-1H-indazol-5-yl)-pyridin-3-ylo-
xy]-ethylamine
Example 102A
[0393] A solution of 5-bromo-2-fluorobenzaldehyde (24.75 g; 122
mmol) in Et.sub.2O (125 mL) at 0.degree. C. was treated with 3.0 M
MeMgBr in Et.sub.2O (43 mL, 129 mmol), stirred for 30 min.,
carefully diluted with water then acidified with 10% HCl (aq). The
aqueous was extracted with Et.sub.2O, rinsed successively with 10%
HCl (aq), water, and brine, dried (MgSO.sub.4), and evaporated to
give the desired product (26.6 g; 99%) of sufficient purity to
carry on to the next step.
Example 102B
1-(5-Bromo-2-fluoro-phenyl)-ethanone
[0394] A solution of Example 102A (26.6 g; 121 mmol) and
manganese(IV) oxide (53 g; 610 mmol) in p-dioxane (500 mL) was
heated at reflux for 4 hrs., cooled, filtered through Celite.RTM.,
evaporated, and purified by flash chromatography (5-10%
Et.sub.2O/hexane) to yield the desired product as a nearly
colorless oil that solidified upon standing (20.5 g; 78%).
Example 102C
5-Bromo-3-methyl-1H-indazole
[0395] A mixture of 102B (10 g, 46 mmol) and 98% hydrazine (25 mL)
was heated to reflux for 9 hours, and poured over ice. The
precipitate was collected and purified by flash chromatography (1:1
Et.sub.2O:hexane) to give the desired product as a white solid (5.8
g, 60%).
Example 102D
3-Methyl-5-trimethylstannanyl-1H-indazole
[0396] A mixture of Example 102C (10.08 g, 47.8 mmol),
hexamethyl-di-tin 2 (18 g, 55 mmol) and
tetrakis(triphenylphosphine)palladium (5.5 g, 4.8 mmol) in toluene
(100 ml) was stirred at 95.degree. C. for 6 h. The mixture was then
evaporated and the residue was taken into ethyl acetate (300 ml),
washed with saturated sodium bicarbonate (100 ml), water (100 ml)
and brine (100 ml). The ethyl acetate was evaporated off and the
residue was purified by flash column chromatography on silica gel,
eluting with 1:4 ethyl acetate/hexanes to give 11.2 g desired
product (80%). MS: (ESI) m/z 409 (M+H).sup.+.
Example 102E
(1S)-{1-(1H-Indol-3-ylmethyl)-2-[5-(3-methyl-1H-indazol-5-yl)-pyridin-3-yl-
oxy]-ethyl}-carbamic Acid Tert-Butyl Ester
[0397] The desired product was prepared by substituting Example
Example 102D for Example 27A in Example 27B.
Example 102F
(1S)-1-(1H-Indol-3-ylmethyl)-2-[5-(3-methyl-1H-indazol-5-yl)-pyridin-3-ylo-
xy]-ethylamine
[0398] The desired product was prepared as the trifluoroacetate
salt by substituting Example 102E for Example 27B in Example 27C.
MS (ESI) m/e 398 (M+H).sup.+; .sup.1H NMR (DMSO-d.sub.6, 300 MHz)
.delta. 2.55 (s, 3H) 2.79 (dd, J=14.07, 7.29 Hz, 1H) 2.99 (dd,
J=14.07, 7.29 1H) 3.32 (s, 2H) 3.40 (m, 1H) 4.03 (m, 2H) 6.95 (t,
J=7.46 Hz, 1H) 7.05 (t, J=6.95 Hz, 1H) 7.21 (d, J=2.37 Hz, 1H) 7.34
(d, J=7.80 Hz, 1H) 7.56 (m, 2H) 7.67 (m, 2H) 8.08 (s, 1H) 8.26 (d,
J=2.37 Hz, 1H) 8.54 (d, J=2.03 Hz, 1H) 10.85 (s, 1H) 12.73 (s, 1H);
Anal. Calcd for C.sub.24H.sub.23N.sub.5O.2.25 HCl: C, 59.62; H,
5.31; N, 14.60;. Found: C, 59.62; H, 5.31; N, 14.28.
EXAMPLE 103
(1S)-1-(1H-Indol-3-ylmethyl)-2-{5-[3-(1H-pyrrol-2-yl)-1H-indazol-5-yl]-pyr-
idin-3-yloxy}-ethylamine
Example 103A
5-Bromo-2-fluoro-benzoic Acid
[0399] A mixture of 5-bromo-2-fluorobenzaldehyde (810 mg; 4.0
mmol), 15% NaOH (aq.) (3 mL), MeOH (5 mL), and 30% H.sub.2O.sub.2
(5 mL) was stirred at r.t. for 2 hrs., then acidified with 10% HCl
(aq.). The resulting white solid was collected, rinsed with water,
and dried to give the desired product (670 mg; 77%).
Example 103B
5-Bromo-2-fluoro-benzoyl Chloride
[0400] Example 103A (665 mg; 3.0 mmol) in thionyl chloride (7 mL)
was heated at reflux for 2 hrs., concentrated, and azeotroped with
toluene to give a colorless oil that was carried on with no further
purification.
Example 103C
(5-Bromo-2-fluoro-phenyl)-(1H-pyrrol-2-yl)-methanone
[0401] A solution of 103B (720 mg; 3.0 mmol), and pyrrole (203 mg;
3.0 mmol) in 1,2-dichloroethane (10 mL) at 0.degree. C. was treated
portionwise with AlCl.sub.3, stirred overnight while gradually
warming to r.t., treated with ice and 1 N HCl, stirred for 1.5
hrs., and extracted with CH.sub.2Cl.sub.2. The extracts were rinsed
with water and saturated NaHCO.sub.3 (aq.), dried over
Na.sub.2SO.sub.4, concentrated, and isolated by flash
chromatography (10% EtOAc/hexane) to give the desired product as a
purple solid (252 mg; 31%).
Example 103D
5-Bromo-3-(1H-pyrrol-2-yl)-1H-indazole
[0402] The desired product was prepared by substituting Example
103C for Example 102B in Example 102C.
Example 103E
(1S)-1-(1H-Indol-3-ylmethyl)-2-{5-[3-(1H-pyrrol-2-yl)-1H-indazol-5-yl]-pyr-
idin-3-yloxy}-ethylamine
[0403] The desired product was prepared as the trifluoroacetate
salt by substituting Example 103D for 6-bromoisoquinoline in
Example 27. MS (ESI) m/e 449 (M+H).sup.+; .sup.1H NMR
(DMSO-d.sub.6, 300 MHz) .delta. 3.18 (m, 2H) 3.87 (m, 1H) 4.20
(dd,J=10.51, 5.76 Hz, 1H) 4.38 (m, 1H) 6.21 (m, 1H) 6.86 (m, 2H)
7.01 (t, J=7.46 Hz, 1H) 7.10 (t, J=7.46 Hz, 1H) 7.30 (d, J=2.03 Hz,
1H) 7.38 (d, J=8.14 Hz, 1H) 7.67 (m, 4H) 8.15 (bs, 2H) 8.26 (s, 1H)
8.35 (d, J=2.37 Hz, 1H) 8.68 (s, 1H) 11.03 (s, 1H) 11.38 (s, 1H)
13.10 (bs, 1H); Anal. Calcd for C.sub.21H.sub.24N.sub.6O.2.5 TFA:
C, 52.39; H, 3.64; N, 11.46;. Found: C, 52.26; H, 3.67; N,
11.39.
EXAMPLE 104
(S)-1-(1H-Indol-3-ylmethyl)-2-[5-(3-phenyl-1H-indazol-5-yl)-pyridin-3-ylox-
y]-ethylamine
[0404] The desired product was prepared as the trifluoroacetate
salt by substituting phenyl magnesium bromide for methyl magnesium
bromide in Example 102. MS (ESI) m/e 460 (M+H).sup.+; .sup.1H NMR
(300 MHz, DMSO-D6) .delta. ppm 3.17 (m, 2H) 3.87 (m, 1H) 4.19 (dd,
J=10.51, 5.76 Hz, 1H) 4.38 (m, 1H) 7.00 (t, J=7.46 Hz, 1H) 7.09 (t,
J=7.46 Hz, 1H) 7.30 (d, J=2.37 Hz, 1H) 7.39 (m, 1H) 7.44 (d, J=7.12
Hz, 1H) 7.54 (m, J=7.46, 7.46 Hz, 2H) 7.62 (d, J=7.46 Hz, 1H) 7.72
(s, 2H) 7.76 (m, 1H) 8.05 (s, 1H) 8.08 (s, 1H) 8.16 (m, 2H) 8.30
(s, 1H) 8.36 (d, J=2.71 Hz, 1H) 8.68 (d, J=1.70 Hz, 1H) 11.03 (s,
1H) 13.45 (bs, 1H); Anal. Calcd for C.sub.27H.sub.24N.sub.6O.3
TFA.2H.sub.2O: C, 53.24; H, 4.08; N, 8.87;. Found: C, 52.91; H,
3.68; N, 8.80.
EXAMPLE 105
(1S)-2-[5-(3-Cyclopropyl-1H-indazol-5-yl)-pyridin-3-yloxy]-1-(1H-indol-3-y-
lmethyl)-ethylamine
[0405] The desired product was prepared as the trifluoroacetate
salt by substituting cyclopropyl magnesium bromide for methyl
magnesium bromide in Example 102. MS (ESI) m/e 424 (M+H).sup.+;
.sup.1H NMR (300 MHz, DMSO-D6) .delta. ppm 1.02 (m, 4H) 2.36 (m,
1H) 3.15 (m, 2H) 3.86 (m, 1H) 4.19 (dd, J=10.68, 5.93 Hz, 1H) 4.37
(dd, J=10.68, 3.22 Hz, 1H) 7.01 (t, J=7.46 Hz, 1H) 7.10 (t, J=6.95
Hz, 1H) 7.30 (d, J=2.37 Hz, 1H) 7.38 (d, J=8.14 Hz, 1H) 7.56 (d,
J=8.48 Hz, 1H) 7.65 (m, 2H) 7.73 (m, 1H) 8.12 (s, 1H) 8.19 (m, 2H)
8.33 (d, J=2.37 Hz, 1H) 8.63 (d, J=1.36 Hz, 1H) 11.03 (d, J=2.03
Hz, 1H) 12.73 (m, 1H); Anal. Calcd for C.sub.26H.sub.21N.sub.5-
O.2.6 TFA: C, 52.05; H, 3.86; N, 9.73;. Found: C, 52.03; H, 3.89;
N, 9.69.
EXAMPLE 106
(1S)-2-[5-(3-Ethyl-1H-indazol-5-yl)-pyridin-3-yloxy]-1-(1H-indol-3-ylmethy-
l)-ethylamine
[0406] The desired product was prepared as the trifluoroacetate
salt by substituting ethyl magnesium bromide for methyl magnesium
bromide in Example 102. MS (ESI) m/e 412 (M+H).sup.+; .sup.1H NMR
(300 MHz, DMSO-D6) .delta. ppm 1.35 (t, J=7.63 Hz, 3H) 2.99 (q,
J=7.57 Hz, 2H) 3.17 (m, 2H) 3.86 (m, 1H) 4.19 (dd, J=10.85, 6.10
Hz, 1H) 4.37 (m, 1H) 7.01 (t, J=7.46 Hz, 1H) 7.11 (t, J=7.46 Hz,
1H) 7.30 (d, J=2.37 Hz, 1H) 7.38 (d, J=7.80 Hz, 1H) 7.63 (m, 3H)
7.72 (m, 1H) 8.08 (s, 1H) 8.16 (m, 2H) 8.33 (d, J=2.71 Hz, 1H) 8.63
(d, J=1.70 Hz, 1H) 11.04 (d, J=2.03 Hz, 1H) 12.80 (m, 1H); Anal.
Calcd for C.sub.25H.sub.25N.sub.5O.2.7 TFA: C, 50.76; H, 3.88; N,
9.74;. Found: C, 51.09; H, 3.88; N, 9.66.
EXAMPLE 107
(1S)-1-(1H-Indol-3-ylmethyl)-2-{5-[3-(1-methyl-1H-imidazol-2-yl)-1H-indazo-
l-5-yl]-pyridin-3-yloxy}-ethylamine
[0407] The desired product was prepared as the trifluoroacetate
salt by substituting N-methyl-2-imidazolyl lithium chloride for
methyl magnesium bromide in Example 102. MS (ESI) m/e 464
(M+H).sup.+; .sup.1H NMR (400 MHz, DMSO-D6) .delta. ppm 3.18 (m,
2H) 3.84 (s, 1H) 4.07 (s, 3H) 4.20 (dd, J=10.59, 5.98 Hz, 1H) 4.36
(m, 1H) 7.00 (t, J=7.36 Hz, 1H) 7.09 (t, J=7.36 Hz, 1H) 7.18 (s,
1H) 7.31 (d, J=2.15 Hz, 1H) 7.37 (m, 2H) 7.64 (m, 2H) 7.72 (s, 2H)
8.33 (m, 3H) 8.56 (d, J=1.53 Hz, 1H) 8.63 (s, 1H) 11.06 (s, 1H)
13.56 (s, 1H).
EXAMPLE 108
(1S)-1-(1H-Indol-3-ylmethyl)-2-[5-(3-thiazol-2-yl-1H-indazol-5-yl)-pyridin-
-3-yloxy]-ethylamine
[0408] The desired product was prepared as the trifluoroacetate
salt by substituting 2-thiozolyl lithium chloride for methyl
magnesium bromide in Example 102. MS (ESI) m/e 467 (M+H).sup.+;
.sup.1H NMR (500 MHz, DMSO-D6) .delta. ppm 3.19 (d, J=7.18 Hz, 2H)
3.86 (m, 1H) 4.22 (dd, J=10.29, 5.93 Hz, 1H) 4.38 (dd, J=10.45,
2.65 Hz, 1H) 7.01 (t, J=7.49 Hz, 1H) 7.09 (t, J=7.49 Hz, 1H) 7.31
(d,J=1.56 Hz, 1H) 7.38 (d,J=8.11 Hz, 1H) 7.64 (d,J=7.80 Hz, 1H)
7.73 (s, 1H) 7.78 (s, 2H) 7.79 (d, J=3.12 Hz, 1H) 8.04 (d, J=3.43
Hz, 1H) 8.28 (s, 2H) 8.38 (d, J=2.18 Hz, 1H) 8.60 (s, 2H) 11.04(s,
1H) 13.74(s, 1H)
EXAMPLE 109
(1S)-2-15-[3-(1H-Imidazol-2-yl)-1H-indazol-5-yl]-pyridin-3-yloxy}-1-(1H-in-
dol-3-ylmethyl)-ethylamine
Example 109A
(1S)-[1-(1H-Indol-3-ylmethyl)-2-(5-{3-[1-(2-trimethylsilanyl-ethoxymethyl)-
-1H-imidazol-2-yl]-1H-indazol-5-yl}-pyridin-3-yloxy)-ethyl]-carbamic
Acid Tert-Butyl Ester
[0409] The desired product was prepared as the trifluoroacetate
salt by substituting
N-[2-trimethylsilanyl)ethoxy{methyl)-2-imidazolyl lithium chloride
for methyl magnesium bromide in Example 102 without doing the last
step.
Example 109B
(1S)-2-{5-[3-(1H-Imidazol-2-yl)-1H-indazol-5-yl]-pyridin-3-yloxy}-1-(1H-in-
dol-3-ylmethyl)-ethylamine
[0410] A solution of Example 109A (40 mg; 0.06 mmol) in MeOH (4 mL)
was treated with conc. HCl (1 mL) and heated at reflux for 6 hrs.,
concentrated and purified by reverse phase HPLC on a C18 column
with 0-100% CH.sub.3CN/H.sub.2O/0.1% TFA to provide the desired
product as the trifluoroacetate salt. MS (ESI) m/e 450 (M+H).sup.+;
.sup.1H NMR (500 MHz, DMSO-D6) .delta. ppm 3.19 (d, J=7.17 Hz, 2H)
3.86 (s, 1H) 4.22 (dd, J=10.45, 5.77 Hz, 1H) 4.37 (dd, J=10.45,
2.96 Hz, 1H) 7.00 (t, J=7.49 Hz, 1H) 7.09 (t, J=7.49 Hz, 1H) 7.30
(d, J=2.18 Hz, 1H) 7.38 (d, J=8.11 Hz, 1H) 7.63 (d, J=8.11 Hz, 1H)
7.76 (s, 1H) 7.83 (s, 1H) 7.86 (s, 2H) 8.26 (bs, 3H) 8.39 (d,
J=2.50 Hz, 1H) 8.61 (s, 1H) 8.72 (s, 1H) 11.04 (s, 1H) 14.36 (s,
1H)
EXAMPLE 110
(1S)-1-(1H-Indol-3-ylmethyl)-2-[5-(3-thiophen-2-yl-1H-indazol-5-yl)-pyridi-
n-3-yloxy]-ethylamine
[0411] The desired product was prepared by substituting
2-thiophenyl lithium chloride for methylmagnesium bromide in
Example 102. MS (ESI) m/e 466 (M+H).sup.+; .sup.1H NMR (400 MHz,
DMSO-D6) .delta. ppm 3.21 (d, J=7.06 Hz, 2H) 3.86 (bs, 1H) 4.23
(dd, J=10.43, 5.83 Hz, 1H) 4.38 (m, 1H) 7.00 (t, J=7.52 Hz, 1H)
7.10 (t, J=7.06 Hz, 1H) 7.23 (dd, J=5.22, 3.68 Hz, 1H) 7.31 (d,
J=2.15 Hz, 1H) 7.39 (d, J=7.98 Hz, 1H) 7.59 (d, J=6.14 Hz, 1H) 7.64
(d, J=7.98 Hz, 1H) 7.73 (m, 3H) 7.91 (d, J=2.76 Hz, 1H) 8.34 (m,
4H) 8.67 (s, 1H) 11.06 (s, 1H) 13.39 (s, 1H)
EXAMPLE 111
(1S)-1-(1H-Indol-3-ylmethyl)-2-[5-(3-morpholin-4-yl-1H-indazol-5-yl)-pyrid-
in-3-yloxy]-ethylamine
Example 111A
5-Bromo-3-morpholin-4-yl-1H-indazole
[0412] The reaction between Example 35A and morpholine was carried
out according to the procedure described by U. Wrzeciono, K.
Majewska, J. Dudzinska-Usarewicz, M. Bemas, Pharmzie, 1986, 41,
472-474.
Example 111B
(1S)-1-(1H-Indol-3-ylmethyl)-2-[5-(3-morpholin-4-yl-1H-indazol-5-yl)-pyrid-
in-3-yloxy]-ethylamine
[0413] The desired product was prepared by substituting Example
111A for 6-bromoisoquinoline in Example 27. MS (ESI) m/e 469
(M+H).sup.+; .sup.1H NMR (300 MHz, DMSO-D6) .delta. ppm 3.16 (d,
J=7.12 Hz, 2H) 3.35 (m, 4H) 3.81 (m, 4H) 3.88 (m, 1H) 4.19 (dd,
J=10.68, 5.93 Hz, 1H) 4.35 (m, 1H) 7.01 (t, J=7.46 Hz, 1H) 7.10 (t,
J=7.46 Hz, 1H) 7.30 (d, J=2.37 Hz, 1H) 7.38 (d, J=7.80 Hz, 1H) 7.48
(d, J=8.82 Hz, 1H) 7.62 (m, 2H) 7.72 (m, 1H) 8.09 (s, 1H) 8.17 (m,
2H) 8.33 (d, J=2.71 Hz, 1H) 8.65 (d, J=1.70 Hz, 1H) 11.03 (s, 1H)
12.21 (s, 1H);
[0414] Anal. Calcd for C.sub.27H.sub.28N.sub.6O.sub.2.3.4 TFA: C,
47.41; H, 3.70; N, 9.82;. Found: C, 47.10; H, 3.86; N, 9.95.
EXAMPLE 112
(1S)-2-[5-(1,3-Dimethyl-1H-indazol-5-yl)-pyridin-3-yloxy]-1-(1H-indol-3-yl-
methyl)-ethylamine
Example 112A
5-Bromo-1,3-dimethyl-1H-indazole
[0415] Example 102C (500 mg; 2.37 mmol) was added to a mixture of
60% NaH (115 mg; 2.84 mmol) in DMF (10 mL). After 15 min. at r.t.
iodomethane (456 mg; 3.21 mmol) was added, the reaction was stirred
for 2 hrs then diluted with water and extracted with EtOAc. The
extracts were rinsed with water and brine, dried (MgSO.sub.4),
evaporated, and isolated by flash chromatography (1:1
Et.sub.2O:hexane) to give the desired product (360 mg; 67%).
Example 112B
[0416] The desired product was prepared as the trifluoroacetate
salt by substituting Example 112A for Example 6-bromoisoquinoline
in Example 27. MS (ESI) m/e 412 (M+H).sup.+; .sup.1H NMR (300 MHz,
DMSO-D6) .delta. ppm 2.54 (s, 3H) 3.18 (m, 2H) 3.86 (s, 1H) 4.00
(s, 3H) 4.20 (dd, J=10.51, 6.10 Hz, 1H) 4.37 (m, 1H) 7.01 (t,
J=7.46 Hz, 1H) 7.10 (t, J=7.12 Hz, 1H) 7.30 (d, J=2.37 Hz, 1H) 7.39
(d, J=7.80 Hz, 1H) 7.63 (d, J=7.80 Hz, 1H) 7.73 (m, 2H) 8.08 (s,
1H) 8.18 (m, 3H) 8.34 (d, J=2.71 Hz, 1H) 8.66 (d, J=1.70 Hz, 1H)
11.04 (s, 1H); Anal. Calcd for C.sub.25H.sub.25N.sub.5O.2.- 8 TFA:
C, 50.29; H, 3.83; N, 9.58;. Found: C, 50.36; H, 3.84, N, 9.60.
EXAMPLE 113
(1S)-1-(1H-Indol-3-ylmethyl)-2-[3-(3-methyl-1H-indazol-5-yl)-phenoxy]-ethy-
lamine
[0417] The desired product was prepared as the trifluoroacetate
salt by substituting 3-bromophenol for 3-bromo-5-hydroxypyridine in
Example 102. MS (ESI) m/e 397 (M+H).sup.+; .sup.1H NMR (300 MHz,
DMSO-D6) .delta. ppm 2.54 (s, 3H) 3.17 (m, 2H) 3.81 (m, 1H) 4.09
(dd, J=10.51, 5.76 Hz, 1H) 4.25 (dd, J=10.51, 3.05 Hz, 1H) 6.93 (m,
1H) 7.01 (t, J=7.46 Hz, 1H) 7.10 (t, J=7.46 Hz, 1H) 7.28 (m, 2H)
7.37 (m, 3H) 7.52 (d, J=8.48 Hz, 1H) 7.61 (m, 2H) 7.93 (s, 1H) 8.15
(bs, 2H) 11.03 (s, 1H) 12.62 (bs, 1H)
EXAMPLE 114
(1S)-1-(1H-Indol-3-ylmethyl)-2-{5-[3-(4-methyl-piperazin-1-yl)-1H-indazol--
5-yl]-pyridin-3-yloxy}-ethylamine
Example 114A
5-Bromo-3-(4-methyl-piperazin-1-yl)-1H-indazole
[0418] The reaction between Example 35A and N-methyl piperazine was
carried out according to the procedure described by U. Wrzeciono,
K. Majewska, J. Dudzinska-Usarewicz, M. Bemas, Pharmzie, 1986, 41,
472-474.
Example 114B
(1S)-1-(1H-Indol-3-ylmethyl)-2-{5-[3-(4-methyl-piperazin-1-yl)-1H-indazol--
5-yl]-pyridin-3-yloxy}-ethyl Amine
[0419] The desired product was prepared by substituting Example
114A for 6-bromoisoquinoline in Example 27. MS (ESI) m/e 482
(M+H).sup.+; .sup.1H NMR (300 MHz, DMSO-D6) .delta. ppm 2.54 (s,
3H) 2.90 (m, 2H) 3.21 (m, 4H) 3.54 (m, 2H) 3.83 (m, 1H) 4.06 (m,
2H) 4.19 (dd, J=10.68, 5.93 Hz, 1H) 4.35 (dd, J=10.51, 2.71 Hz, 1H)
7.01 (t, J=6.95 Hz, 1H) 7.10(t, J=7.12 Hz, 1H) 7.30 (d, J=2.03 Hz,
1H) 7.38 (d, J=8.14 Hz, 1H) 7.51 (d, J=8.82 Hz, 1H) 7.65 (m, 3H)
8.15 (s, 1H) 8.21 (m, 2H) 8.33 (d, J=2.71 Hz, 1H) 8.66 (d, J=1.70
Hz, 1H) 11.04 (s, 1H) 12.36 (s, 1H); Anal. Calcd for
C.sub.21H.sub.31N.sub.7O.4.45 TFA: C, 44.81; H, 3.61; N, 9.91;.
Found: C, 44.83; H, 3.53, N, 9.97.
EXAMPLE 115
(1S)-(5-{5-[2-Amino-3-(1H-indol-3-yl)-propoxy]-pyridin-3-yl}-1H-indazol-3--
yl)-dimethyl-amine
Example 115A
(5-Bromo-1H-indazol-3-yl)-dimethyl-amine
[0420] The reaction between Example 35A and dimethylamine was
carried out according to the procedure described by U. Wrzeciono,
K. Majewska, J. Dudzinska-Usarewicz, M. Bemas, Pharmzie, 1986, 41,
472-474.
Example 115B
(1S)-(5-{5-[2-Amino-3-(1H-indol-3-yl)-propoxy]-pyridin-3-yl}-1H-indazol-3--
yl)-dimethyl-amine
[0421] The desired product was prepared by substituting Example
115A for 6-bromoisoquinoline in Example 27. MS (ESI) m/e 427
(M+H).sup.+; .sup.1H NMR (300 MHz, DMSO-D6) .delta. ppm 3.04 (s,
6H) 3.16 (m, 2H) 3.86 (s, 1H) 4.19 (m, 1H) 4.36 (m, 1H) 7.01 (t,
J=6.95 Hz, 1H) 7.10 (t, J=7.12 Hz, 1H) 7.30 (d, J=2.37 Hz, 1H) 7.38
(d, J=8.14 Hz, 1H) 7.45 (d, J=8.82 Hz, 1H) 7.61 (m, 2H) 7.73 (s,
1H) 8.07 (s, 1H) 8.17 (m, 2H) 8.33 (d, J=2.37 Hz, 1H) 8.62 (d,
J=1.36 Hz, 1H) 11.03 (s, 1H) 12.04 (s, 1H); Anal. Calcd for
C.sub.25H.sub.26N.sub.6O.3.5 TFA: C, 46.55; H, 3.60; N, 10.18;.
Found: C, 46.71; H, 3.65, N, 10.02.
EXAMPLE 116
(1S)-(4-(5-(2-Amino-3-(1H-indol-3-yl)-propoxy)-pyridin-3-yl)-benzyl)-pheny-
l-amine
Example 116A
(1S)-[2-[5-(4-Formyl-phenyl)-pyridin-3-yloxy]-1-(1H-indol-3-ylmethyl)-ethy-
l]-carbamic Acid Tert-Butyl Ester
[0422] The desired product was prepared by substituting
4-formylphenylboronic acid for 4-cyanophenylboronice acid in
Example 22. MS: (ESI) m/z 472 (M+H).sup.+.
Example 116B
(1S)-1-(1H-Indol-3-ylmethyl)-2-[5-(4-phenylaminomethyl-phenyl)-pyridin-3-y-
loxy]-ethyl}-carbamic Acid Tert-Butyl Ester
[0423] A solution of Example 116A (0.03 g, 0.06 mmol) in 2 mL of
MeOH was cooled to 0.degree. C. then treated with aniline (0.018 g
0.2 mmol), NaBH.sub.3CN (0.004 g, 0.06 mmol) and AcOH (1 ml). The
mixture was allowed to warm to room temperature overnight. The
mixture was diluted with ethyl acetate (20 ml), washed with water
(10 ml) and brine (10 ml). The ethyl acetate was evaporated off and
the residue was used without further purification.
Example 116C
(1S)-(4-(5-(2-Amino-3-(1H-indol-3-yl)-propoxy)-pyridin-3-yl)-benzyl)-pheny-
l-amine
[0424] The desired product was prepared by substituting Example
116B for Example 27B in Example 27C. MS: (ESI) (M+H).sup.+ m/z=449.
.sup.1H NMR (500 MHz, DMSO-D6) .delta. ppm 3.82 (m, 7H) 4.18 (m,
1H) 4.32 (d, J=4.06 Hz, 2H) 6.55 (d, J=32.76 Hz, 1H) 6.59 (d,
J=7.49 Hz, 1H) 6.89 (d, J=7.49 Hz, 1H) 7.04 (m, 3H) 7.18 (m, 1H)
7.29 (d, J=2.50 Hz, 1H) 7.37 (d, J=7.80 Hz, 1H) 7.48 (d, J=8.11 Hz,
1H) 7.62 (m, 3H) 8.31 (bs, 3H) 8.52 (d, J=1.56 Hz, 1H) 11.04 (d,
J=1.87 Hz, 1H)
EXAMPLE 117
(1S)-(4-(5-(2-Amino-3-(1H-indol-3-yl)-propoxy)-pyridin-3-yl)-phenyl)-metha-
nol
Example 117A
(1S)-{2-[5-(4-Hydroxymethyl-phenyl)-pyridin-3-yloxy]-1-phenyl-ethyl}-carba-
mic Acid Tert-Butyl Ester
[0425] Example 116A (0.03 g, 0.06 mmol) was dissolved in 2 mL of
MeOH and cooled to 0.degree. C., then treated with NaBH.sub.4
(0.003 g, 0.08 mmol). The mixture was allowed to warm to room
temperature over 2 h. The mixture was diluted with ethyl acetate
(20 ml), washed with water (10 ml) and brine (10 ml). The ethyl
acetate was evaporated off and the residue was used without further
purification.
Example 117B
(1S)-(4-(5-(2-Amino-3-(1H-indol-3-yl)-propoxy)-pyridin-3-yl)-phenyl)-metha-
nol
[0426] The desired product was prepared by substituting Example
117A for Example 27B in Example 27C. MS: (ESI) m/z 374 (M+H).sup.+;
.sup.1H NMR (500 MHz, DMSO-D6) .delta. ppm 3.15 (m, 4H) 3.72 (m,
1H) 4.16 (dd, J=10.29, 5.93 Hz, 1H) 4.29 (m, 1H) 4.55 (s, 2H) 5.29
(s, 1H) 6.99 (t, J=7.02 Hz, 1H) 7.09 (t, J=7.02 Hz, 1H) 7.28 (d,
J=2.18 Hz, 1H) 7.37 (d, J=8.11 Hz, 1H) 7.43 (d, J=8.42 Hz, 2H) 7.59
(m, 1H) 7.64 (dd, J=10.61, 8.42 Hz, 3H) 8.30 (d, J=2.81 Hz, 1H)
8.51 (d, J=1.56 Hz, 1H) 11.03 (s, 1H)
EXAMPLE 118
(1S)-2-(5-(4-Fluoro-phenyl)-pyridin-3-yloxy)-1-(1H-indol-3-ylmethyl)-ethyl-
amine
[0427] The desired product was prepared by substituting
4-fluorophenylboronic acid for 4-cyanophenylboronice acid in
Example 22. MS: (ESI) m/z 362 (M+H).sup.+; .sup.1H NMR (500 MHz,
DMSO-D6) .delta. ppm 3.09 (m, 2H) 3.17 (d, J=4.68 Hz, 1H) 3.71 (s,
1H) 4.12 (dd, J=10.29, 6.24 Hz, 1H) 4.26 (dd, J=10.29, 3.43 Hz, 1H)
6.99 (t, J=7.49 Hz, 1H) 7.09 (m, 1H) 7.26 (d, J=2.18 Hz, 1H) 7.34
(m, 3H) 7.59 (m, 2H) 7.74 (m, 2H) 8.32 (d, J=2.50 Hz, 1H) 8.50 (d,
J=1.87 Hz, 1H) 10.97 (s, 1H).
EXAMPLE 119
(1S)-4-(5-(2-Amino-3-(1H-indol-3-yl)-propoxy)-pyridin-3-yl)-benzoic
Acid
[0428] The desired product was prepared by substituting
4-hydroxycarbonylphenylboronic acid for 4-cyanophenylboronice acid
in Example 22. MS (ESI) m/z 388 (M+H).sup.+; .sup.1H NMR (500 MHz,
DMSO-D6) .delta. ppm 3.17 (m, 1H) 3.84 (m, 1H) 4.20 (m, 1H) 4.35
(m, 1H) 7.00 (t, J=6.86 Hz, 1H) 7.10 (t, J=7.02 Hz, 1H) 7.30 (d,
J=2.18 Hz, 1H) 7.38 (d, J=8.11 Hz, 1H) 7.63 (d, J=7.49 Hz, 1H) 7.68
(m, 1H) 7.83 (d, J=8.42 Hz, 1H) 8.04 (m, 2H) 8.26 (s, 3H) 8.38 (d,
J=2.50 Hz, 1H) 8.59 (d, J=1.87 Hz, 1H) 11.02 (d, J=1.87 Hz, 1H)
EXAMPLE 120
(1S)-2-(3-Bromo-5-isoquinolin-6-yl-phenoxyoxy)-1-(1H-indol-3-ylmethyl)-eth-
ylamine
[0429] Step 1.
Example 120A
(2S)-[1-(3,5-Dibromo-phenoxymethyl)-2-(1H-indol-3-yl)-ethyl]-carbamic
Acid Tert-Butyl Ester
[0430] A solution of 3,5-dibromo-phenol (1 g, 4.1 mmol),
(2-hydroxy-1-phenyl-ethyl)-carbamic acid tert-butyl ester (1.2 g,
4.1 mmol), and triphenylphosphine (1.6 g, 2 mmol) in THF (30 mL)
was stirred at 0.degree. C. for 30 min. To the mixture was added a
solution of di-t-butyl azidodicarboxylate (1.45 g, 9.2 mmol) in 5
ml of THF. The mixture was allowed to warm to room temperature then
stirred at room temperature for 20 h. The THF was evaporated off
and the residue was taken into ethyl acetate (75 ml), washed with
saturated sodium bicarbonate (50 ml) water (50 ml) and brine (50
ml). The ethyl acetate was evaporated of and the residue was
purified by flash column chromatography on silica gel, eluting with
a solvent gradient of 1:4 to 1:1 ethyl acetate/hexane. Recovered
1.33 g of product (64%).
Example 120B
(2S)-[1-(3-Bromo-5-isoquinolin-6-yl-phenoxymethyl)-2-(1H-indol-3-yl)-ethyl-
]-carbamic Acid Tert-Butyl Ester
[0431] A solution of Example 120A above (0.6 g, 01.1 mmol) and
6-trimethylstannanyl-isoquinoline (0.26 g, 1 mmol) in 5 mL of DMF
was treated with Pd.sub.2(dba).sub.3 (0.1 g, 0.1 mmol),
P(o-tol).sub.3 (0.07 g, 0.2 mmol), and TEA (0.3 mL, 2.3 mmol). The
reaction was heated to 95.degree. C. for 6.5 h, then cooled and
diluted with ethyl acetate (75 ml), washed with saturated sodium
bicarbonate (50 ml) water (50 ml) and brine (50 ml). The ethyl
acetate was evaporated off and the residue was purified by flash
column chromatography on silica gel, eluting with a solvent
gradient of 1:4 to 1:1 ethyl acetate/hexane.
[0432] 0.2 g of product (30%). MS (ESI) m/z 572 (M+H).sup.+.
Example 120C
(1S)-2-(3-Bromo-5-isoquinolin-6-yl-phenoxyoxy)-1-(1H-indol-3-ylmethyl)-eth-
ylamine
[0433] The desired product was prepared by substituting Example
120B for Example 27B in Example 27C. MS (ESI) m/z 472 (M+H).sup.+;
.sup.1H NMR (500 MHz, DMSO-D6) .delta. ppm 2.87 (d, J=6.55 Hz, 1H)
3.00 (d, J=6.55 Hz, 1H) 3.47 (m, 2H) 3.99 (dd, J=9.67, 6.24 Hz, 1H)
4.07 (d, J=4.37 Hz, 1H) 6.96 (t, J=7.02 Hz, 1H) 7.06 (t, J=7.02 Hz,
1H) 7.22 (d, J=2.18 Hz, 1H) 7.24 (m, 1H) 7.35 (d, J=8.11 Hz, 1H)
7.41 (m, 1H) 7.58 (d, J=7.80 Hz, 1H) 7.62 (s, 1H) 7.89 (d, J=5.93
Hz, 1H) 8.00 (dd, J=8.42, 1.87 Hz, 1H) 8.21 (d, J=8.73 Hz, 1H) 8.32
(s, 1H) 8.54 (d, J=5.62 Hz, 1H) 9.35 (s, 1H) 10.87 (s, 1H)
EXAMPLE 121
N4-(3-(5-(2-Amino-3-(1H-indol-3-yl)-propoxy)-pyridin-3-yl)-phenyl)-pyrimid-
ine-2,4-diamine
Example 121A
(1S)-{2-[5-(3-Amino-phenyl)-pyridin-3-yloxy]-1-(1H-indol-3-ylmethyl)-ethyl-
}-carbamic Acid Tert-Butyl Ester
[0434] The desired product was prepared by substituting
3-aminophenylboronic acid for 4-cyanophenylboronice acid in Example
22.
Example 121B
(S)-[2-{5-[3-(2-Amino-pyrimidin-4-ylamino)-phenyl]-pyridin-3-yloxy}-1-(1H--
indol-3-ylmethyl)-ethyl]-carbamic Acid Tert-Butyl Ester
[0435] A mixture of Example 121A (0.07 g, 0.153 mmol) and
4-chloro-2-pyrimidinylamine (0.021 g, 0.163 mmol) was dissolved in
EtOH (1 mL). The mixture was heated to 80.degree. C. overnight then
cooled and evaporated. The product was used without further
purification.
EXAMPLE 121C
(1S)-[2-[5-(3-Amino-phenyl)-pyridin-3-yloxy]-1-(1H-indol-3-ylmethyl)-ethyl-
]-carbamic Acid Tert-Butyl Ester
[0436] The desired product was prepared by substituting Example
121B for Example 27B in Example 27C. MS (ESI) m/z 452 (M+H).sup.+.
.sup.1H NMR (500 MHz, DMSO-D6) .delta. ppm 3.17 (m, 2H) 3.85 (m,
1H) 3.97 (s, 1H) 4.19 (m, 1H) 4.35 (m, 1H) 6.35 (d, J=6.86 Hz, 1H)
7.00 (t, J=7.49 Hz, 1H) 7.10 (m, 1H) 7.29 (d, J=2.18 Hz, 1H) 7.38
(d, J=8.11 Hz, 1H) 7.52 (m, J=7.80 Hz, 2H) 7.62 (d, J=7.80 Hz, 1H)
7.66 (m, 1H) 7.88 (d, J=7.18 Hz, 1H) 8.25 (d, J=4.37 Hz, 2H) 8.38
(d, J=2.50 Hz, 1H) 8.58 (d, J=1.56 Hz, 1H) 10.73 (s, 1H) 11.02 (d,
J=1.87 Hz, 1H).
EXAMPLE 122
(1S)-3-(2-Amino-3-(1H-indol-3-yl)-propoxy)-5-isoquinolin-6-yl-phenylamine
Example 122A
(1S)-[2-[3-(Benzhydrylidene-amino)-5-isoquinolin-6-yl-phenoxy]-1-(1H-indol-
-3-ylmethyl)-ethyl]-carbamic Acid Tert-Butyl Ester
[0437] A solution of Example 120B (0.165 g, 0.29 mmol) and
benzophenone imine (0.1 mL, 0.6 mmol) in 5 mL of toluene was
treated with Pd.sub.2 dba.sub.3 (0.026 g, 0.028 mmol), BINAP (0.036
g, 0.058 mmol) and sodium tbutoxide (0.042 g, 0.44 mmol). The
reaction was heated to 80.degree. C. overnight then to 95.degree.
C. for 24 h. The mixture was cooled and filtered through celite.
The residue was purified by flash column chromatography on silica
gel, eluting with 1:1 ethyl acetate/hexane. Recovered 0.175 g of
product (90%). MS (ESI) m/z 673 (M+H).sup.+.
Example 122B
(1S)-3-(2-Amino-3-(1H-indol-3-yl)-propoxy)-5-isoquinolin-6-yl-phenylamine
[0438] A solution of Example 122A (0.175 g, 0.26 mmol) in 2 mL of
THF was cooled to 0.degree. C. then treated with 1 mL of 3N HCl.
The mixture was stirred at 0.degree. C. for 15 minutes then at room
temperature for 4 h. The mixture was evaporated and the residue was
purified by flash column chromatography on silica gel, eluting with
10% methanol in methylene chloride. Recovered 0.029 g of product
(23%). MS (ESI) m/z 408 (M+H).sup.+; .sup.1H NMR (500 MHz, DMSO-D6)
.delta. ppm 3.20 (m, 2H) 3.77 (m, 1H) 4.12 (d, J=5.62 Hz, 1H) 4.21
(d, J=3.43 Hz, 1H) 6.58 (s, 1H) 6.86 (m, 1H) 6.95 (s, 1H) 7.01 (m,
1H) 7.08 (d, J=7.18 Hz, 1H) 7.29 (d, J=2.18 Hz, 1H) 7.37 (d, J=8.11
Hz, 1H) 7.66 (d, J=7.80 Hz, 1H) 8.13 (d, J=8.73 Hz, 1H) 8.38 (d,
J=6.24 Hz, 1H) 8.43 (s, 1H) 8.52 (m, 3H) 8.65 (d, J=6.24 Hz, 1H)
9.78 (s, 1H) 11.06 (d, J=1.87 Hz, 1H)
EXAMPLE 123
4-(5-Isoquinolin-6-yl-pyridin-3-yl)-piperazine-1-carboxylic Acid
Tert-Butyl Ester
Example 123A
4-(5-Bromo-pyridin-3-yl)-piperazine-1-carboxylic Acid Tert-Butyl
Ester
[0439] A solution of the 3,5-dibromo-pyridine (12.8 g, 68.8 mmol)
and piperazine-1-carboxylic acid tert butyl ester (10 g, 42.4 mmol)
in 200 mL of dioxane was treated with Pd.sub.2(dba).sub.3 (5 g, 5.5
mmol), 2-(di-tbutyl-phosphino)biphenyl (4 g, 13.4 mmol), and sodium
t-butoxide (7.2 g, 75 mmol). The reaction was heated to 95.degree.
C. for 8 h then cooled and filtered through celite. The mixture was
evaporated and the residue was purified by flash column
chromatography on silica gel, eluting with a solvent gradient of
1:4 ethyl acetate/hexane to 100% ethyl acetate. Recovered 2.9 g of
product (20%). MS (ESI) m/z 344 (M+H).sup.+.
Example 123B
4-(5-Isoquinolin-6-yl-pyridin-3-yl)-piperazine-1-carboxylic Acid
Tert-Butyl Ester
[0440] The desired product was prepared by substituting Example
123A for Example 27A in Example 123B. MS (ESI) m/z 408 (M+H).sup.+;
.sup.1H NMR (500 MHz, CHLOROFORM-D) .delta. ppm 1.50 (m, 9H) 3.29
(m, 4H) 3.65 (m, 4H) 7.46 (m, 1H) 7.72 (d, J=5.62 Hz, 1H) 7.83 (d,
J=1.87 Hz, 1H) 7.99 (s, 1H) 8.09 (d, J=8.74 Hz, 1H) 8.37 (d, J=2.81
Hz, 1H) 8.46 (d, J=1.87 Hz, 1H) 8.59 (d, J=5.93 Hz, 1H) 9.31 (s,
1H).
EXAMPLE 124
6-(5-Piperazin-1-yl-pyridin-3-yl)-isoquinoline
[0441] The desired product was prepared by substituting Example 123
for Example 27B in Example 27C. MS (ESI) m/z 291 (M+H).sup.+;
.sup.1H NMR (500 MHz, Solvent) .delta. ppm 3.47 (m, 4H) 3.79 (m,
4H) 8.30 (m, 1H) 8.39 (dd, J=8.58, 1.72 Hz, 1H) 8.49 (d, J=6.55 Hz,
1H) 8.57 (d, J=2.50 Hz, 1H) 8.63 (m, 2H) 8.70 (m, 2H) 9.78 (s,
1H).
EXAMPLE 125
((2S)-2-Amino-5-(5-(2-amino-3-(1H-indol-3-yl)-propoxy)-pyridin-3-yl)-pheny-
l-(3-chloro-phenyl-methanone
[0442] The title compound was prepared by substituting
2-amino-5-iodo-3'-chloro benzophenone for Example 32A in Example
32. MS (ESI) m/z 291 (M+H).sup.+; .sup.1H NMR (500 MHz, DMSO-D6)
.delta. ppm 3.15 (m, 2H) 3.81 (m, 1H) 4.11 (m, 1H) 4.26 (m, 1H)
7.00 (m, 2H) 7.09 (m, 1H) 7.27 (m, 1H) 7.39 (m, 2H) 7.60 (m, 4H)
8.21 (m, 1H) 8.32 (m, 3H) 11.07 (m, 1H).
EXAMPLE 126
(1S)-N-6-(3-(5-(2-Amino-3-(1H-indol-3-yl)-propoxy)-pyridin-3-yl)-phenyl)-9-
H-purine-2,6-diamine
[0443] The title compound was prepared by substituting
6-Chloro-9H-purin-2-ylamine for 4-chloro-2-pyrimidinylamine in
Example 121. MS (ESI) m/z 492 (M+H).sup.+; .sup.1H NMR (400 MHz,
DMSO-D6) .delta. ppm 3.18 (d, J=8.29 Hz, 2H) 3.83 (m, 1H) 4.01 (m,
1H) 4.19 (m, 1H) 4.36 (m, 1H) 7.01 (m, 2H) 7.09 (t, J=7.06 Hz, 1H)
7.16 (s, 1H) 7.30 (m, 2H) 7.38 (d, J=8.29 Hz, 1H) 7.63 (m, 2H) 8.18
(s, 2H) 8.30 (m, 2H) 8.35 (d, J=2.45 Hz, 1H) 8.56 (d, J=1.84 Hz,
1H) 11.02 (s, 1H).
EXAMPLE 127
(3-(5-((2S)-2-Amino-3-(1H-indol-3-yl)-propoxy)-pyridin-3-yl)-phenyl)-pyrim-
idin-2yl-amine
[0444] The title compound was prepared by substituting
2-chloropyrimidine for 4-chloro-2-pyrimidinylamine in Example 121.
MS (ESI) m/z 437 (M+H).sup.+; .sup.1H NMR (500 MHz, DMSO-D6)
.delta. ppm 3.17 (d, J=5.30 Hz, 1H) 4.06 (q, J=5.30 Hz, 5H) 6.86
(t, J=4.84 Hz, 2H) 6.96 (d, J=7.18 Hz, 1H) 7.05 (s, 1H) 7.26 (m,
1H) 7.34 (d, J=8.11 Hz, 1H) 7.40 (t, J=7.96 Hz, 1H) 7.54 (m, 1H)
7.55 (s, 1H) 7.85 (m, 2H) 8.07 (t, J=1.72 Hz, 1H) 8.30 (d, J=2.50
Hz, 1H) 8.44 (d, J=1.87 Hz, 1H) 8.50 (d, J=4.68 Hz, 2H) 9.68 (s,
1H) 10.85 (s, 1H).
EXAMPLE 128
(3-(5-((2S)-2-Amino-3-(1H-indol-3-yl)-propoxy)-pyridin-3-yl)-phenyl)-thiaz-
ol-2yl-amine
[0445] The title compound was prepared by substituting
2-chlorothiazole for 4-chloro-2-pyrimidinylamine in Example 121. MS
(ESI) m/z 442 (M+H).sup.+; .sup.1H NMR (500 MHz, DMSO-D6) .delta.
ppm 3.16 (m, 3H) 4.16 (m, 1H) 4.34 (m, 1H) 6.94 (d, J=3.74 Hz, 1H)
7.01 (m, 1H) 7.10 (m, 1H) 7.22 (m, 1H) 7.28 (dd, J=7.96, 2.96 Hz,
2H) 7.38 (d, J=8.42 Hz, 1H) 7.42 (d, J=7.80 Hz, 1H) 7.57 (m, 1H)
7.62 (d, J=8.11 Hz, 1H) 8.02 (s, 1H) 8.14 (s, 2H) 8.35(d, J=2.50
Hz, 1H) 8.48 (d, J=1.87 Hz, 1H) 10.31 (s, 1H) 11.01 (s, 1H).
EXAMPLE 129
N-(3-(5-((2S)-2-Amino-3-(1H-indol-3-yl)-propoxy)-pyridin-3-yl)-phenyl)-ace-
tamide
Example 129A
(1S)-[2-[5-(3-Acetylamino-phenyl)-pyridin-3-yloxy]-1-(1H-indol-3-ylmethyl)-
-ethyl]-carbamic Acid Tert-Butyl Ester
[0446] Example 121A (0.05 g, 0.11 mmol) was taken in methylene
chloride (1.5 mL) and treated with acetic anhydride (0.2 mL, 2.1
mmol) and triethylamine (0.1 mL, 0.77 mmol). The mixture was
stirred overnight at room temperature then diluted with methylene
chloride (25 mL) and washed with water (15 mL) and brine (15 mL).
The mixture was evaporated and used without further
purification.
Example 129B
N-(3-(5-((2S)-2-Amino-3-(1H-indol-3-yl)-propoxy)-pyridin-3-yl)-phenyl)-ace-
tamide
[0447] The desired product was prepared by substituting Example
129A for Example 27B in Example 27C. MS (ESI) m/z 401 (M+H).sup.+;
.sup.1H NMR (400 MHz, DMSO-D6) .delta. ppm 2.07 (m, 3H) 3.16 (m,
3H) 4.16 (m, 1H) 4.33 (m, 1H) 7.01 (m, 1H) 7.10 (m, 1H) 7.29 (m,
1H) 7.38 (m, 3H) 7.55 (m, 2H) 7.62 (m, 1H) 7.99 (m, 1H) 8.14 (m,
2H) 8.35 (m, 1H) 8.48 (m, 1H) 10.06 (m, 1H) 11.01 (m, 1H).
EXAMPLE 130
6-(5-(4-(1H-Indol-3-ylmethyl)-piperazin-1-yl)-pyridin-3-yl)-isoquinoline
[0448] The title compound was prepared by substituting Example 124
for aniline, and 3-formylindole for Example 116A in example 116B.
MS (ESI) (m/z 420M+H).sup.+; .sup.1H NMR (400 MHz, DMSO-D6) .delta.
ppm 1.89 (s, 2H) 2.50 (m, 4H) 2.60 (m, 4H) 7.02 (m, 2H) 7.27 (d,
J=2.46 Hz, 1H) 7.36 (d, J=7.98 Hz, 1H) 7.68 (m, 2H) 7.87 (d, J=5.83
Hz, 1H) 8.05 (dd, J=8.59, 1.53 Hz, 1H) 8.22 (d, J=8.90 Hz, 1H) 8.34
(m, 2H) 8.44 (d, J=1.84 Hz, 1H) 8.54 (d, J=5.83 Hz, 1H) 9.35 (s,
1H) 10.93 (s, 1H).
EXAMPLE 131
3-((2S)-2-Amino-3-(1H-indol-3-yl)-propoxy)-5-isoquinolin-6-yl-benzoic
Acid
Example 131A
3-[(2S)-2-tert-Butoxycarbonylamino-3-(1H-indol-3-yl)-propoxy]-5-isoquinoli-
n-6-yl-benzoic Acid
[0449] A solution of Example 120 (0.2 g, 0.3 mmol) 6 mL of DMF was
treated with Pd(dppf).sub.2Cl.sub.2 (0.039 g, 0.07 mmol),
Pd(OAc).sub.2 (0.016 g, 0.07 mmol), ammonium hydroxide (0.15 mL),
and triethylamine (0.5 mL, 3.9 mmol). The reaction was heated to
80.degree. C. after which CO was bubbled through for 30 minutes.
The mixture was heated-to 80.degree. C. overnight then cooled,
neutralized with HCl and washed with ethyl acetate. The water was
evaporated off to yield the product. MS (ESI) m/z 538
(M+H).sup.+.
EXAMPLE 131B
3-((2S)-2-Amino-3-(1H-indol-3-yl)-propoxy)-5-isoquinolin-6-yl-benzoic
Acid
[0450] The desired product was prepared by substituting Example
131A for Example 27B in Example 27C. MS (ESI) m/z 438 (M+H).sup.+;
.sup.1H NMR (500 MHz, DMSO-D6) .delta. ppm 3.14 (m, 3H) 4.20 (m,
1H) 4.35 (d, J=2.81 Hz, 1H) 7.02 (m, 1H) 7.09 (d, J=8.11 Hz, 1H)
7.30 (d, J=2.50 Hz, 1H) 7.38 (d, J=8.11 Hz, 1H) 7.63 (m, 2H) 7.68
(s, 1H) 8.04 (s, 1H) 8.11 (m, 2H) 8.18 (s, 3H) 8.36 (d, J=8.73 Hz,
1H) 8.42 (s, 1H) 8.61 (d, J=5.93 Hz, 1H) 9.53 (s, 1H) 11.02 (d,
J=1.56 Hz, 1H). 12
EXAMPLE 132
4-(5-((2S)-2-Amino-3-(1H-indol-3-yl)-propoxy)-pyridin-3-yl)-phenylamine
[0451] The desired product was prepared by substituting
4-aminophenylboronic acid for 4-cyanophenylboronice acid in Example
22. MS (ESI) m/z 359 (M+H).sup.+; .sup.1H NMR (500 MHz, DMSO-D6)
.delta. ppm 3.16 (m, 2H) 3.90 (d, J=63.33 Hz, 3H) 4.16 (dd,
J=10.61, 6.24 Hz, 1H) 4.33 (m, 1H) 6.77 (d, J=8.42 Hz, 1H) 7.01 (m,
1H) 7.11 (s, 1H) 7.29 (d, J=2.18 Hz, 1H) 7.38 (d, J=8.11 Hz, 1H)
7.47 (d, J=8.42 Hz, 1H) 7.61 (m, 2H) 8.17 (s, 2H) 8.24 (d, J=2.50
Hz, 1H) 8.50 (d, J=1.56 Hz, 1H) 11.02 (s, 1H).
EXAMPLE 133
N-(4-(5-((2S)-2-Amino-3-(1H-indol-3-yl)-propoxy)-pyridin-3-yl)-phenyl)-ace-
tamide
[0452] The desired product was prepared by substituting Example 132
for Example 121A in Example 129. MS (ESI) m/z 401 (M+H).sup.+;
.sup.1H NMR (500 MHz, DMSO-D6) .delta. ppm 3.17 (d, J=6.86 Hz, 5H)
4.18 (d, J=5.93 Hz, 1H) 4.32 (d, J=3.12 Hz, 1H) 7.01 (m, 1H) 7.09
(d, J=7.18 Hz, 1H) 7.29 (d, J=2.18 Hz, 1H) 7.38 (d, J=8.11 Hz, 1H)
7.58 (d, J=2.18 Hz, 1H) 7.65 (m, 4H) 8.28 (m, 4H) 8.51 (d, J=1.25
Hz, 1H) 10.10 (s, 1H) 11.03 (d, J=1.25 Hz, 1H).
EXAMPLE 134
N6-(4-(5-((2S)-2-Amino-3-(1H-indol-3-yl)-propoxy)-pyridin-3-yl)-phenyl)-9H-
-purine-2,6-diamine
[0453] The title compound was prepared by substituting Example 132
for Example 121A in Example 126. MS (ESI) m/z 492 (M+H).sup.+;
.sup.1H NMR (500 MHz, DMSO-D6) .delta. ppm 2.51 (m, 3H) 3.16 (t,
J=7.49 Hz, 1H) 3.91 (d, J=53.97 Hz, 2H) 4.19 (dd, J=10.76, 6.08 Hz,
1H) 4.35 (dd, J=10.76, 2.96 Hz, 1H) 7.01 (t, J=7.18 Hz, 1H) 7.11
(t, J=7.02 Hz, 1H) 7.30 (d, J=2.18 Hz, 1H) 7.39 (d, J=8.11 Hz, 1H)
7.64 (m, 2H) 7.74 (d, J=8.73 Hz, 1H) 8.02 (d, J=8.42 Hz, 1H) 8.20
(d, J=3.74 Hz, 2H) 8.26 (s, 1H) 8.34 (d, J=2.50 Hz, 1H) 8.58 (d,
J=1.56 Hz, 1H) 10.52 (s, 1H) 11.03 (d, J=1.87 Hz, 1H).
EXAMPLE 135
N4-(4-(5-((2S)-2-Amino-3-(1H-indol-3-yl)-propoxy)-pyridin-3-yl)-phenyl)-py-
rimidine-2,4-diamine
[0454] The title compound was prepared by substituting Example 132
for Example 121A in Example 121. MS (ESI) m/z 452 (M+H).sup.+;
.sup.1H NMR (500 MHz, DMSO-D6) .delta. ppm 3.16 (d, J=7.18 Hz, 2H)
3.86 (m, 2H) 4.18 (m, 1H) 4.33 (d, J=3.12 Hz, 1H) 6.35 (d, J=7.18
Hz, 1H) 7.01 (t, J=7.33 Hz, 1H) 7.10 (t, J=7.02 Hz, 1H) 7.29 (d,
J=2.18 Hz, 1H) 7.39 (d, J=8.11 Hz, 1H) 7.62 (dd, J=4.52, 2.03 Hz,
2H) 7.73 (d, J=8.73 Hz, 2H) 7.88 (d, J=7.49 Hz, 2H) 8.20 (s, 3H)
8.34 (d, J=2.81 Hz, 1H) 8.56 (d, J=1.87 Hz, 1H) 10.69 (s, 1H) 11.02
(d, J=1.87 Hz, 1H).
EXAMPLE 136
(4-(5-((2S)-2-Amino-3-(1H-indol-3-yl)-propoxy)-pyridin-3-yl)-phenyl)-pyrim-
idin-2-yl-amine
[0455] The title compound was prepared by substituting Example 132
for Example 121A in Example 127. MS (ESI) m/z 437 (M+H).sup.+;
.sup.1H NMR (500 MHz, DMSO-D6) .delta. ppm 2.94 (d, J=6.55 Hz, 1H)
3.04 (m, 1H) 3.17 (d, J=3.74 Hz, 1H) 3.55 (m, 1H) 4.04 (dd, J=9.83,
6.40 Hz, 1H) 4.16 (dd, J=9.98, 4.06 Hz, 1H) 6.88 (t, J=4.84 Hz, 1H)
6.98 (t, J=7.49 Hz, 1H) 7.08 (t, J=7.64 Hz, 1H) 7.24 (d, J=2.18 Hz,
1H) 7.36 (d, J=8.11 Hz, 1H) 7.55 (m, 1H) 7.59 (d, J=7.80 Hz, 1H)
7.64 (d, J=8.73 Hz, 2H) 7.90 (d, J=9.05 Hz, 2H) 8.25 (d, J=2.81 Hz,
1H) 8.49 (d, J=1.56 Hz, 1H) 8.52 (d, J=4.99 Hz, 2H) 9.78 (s,
1H).
EXAMPLE 137
3-((2S)-2-Amino-3-(1H-indol-3-yl)-propoxy)-5-isoquinolin-6-yl-benzonitrile
[0456] 13
Example 137A
(1S)-[2-(3-Cyano-5-isoquinolin-6-yl-phenoxy)-1-(1H-indol-3-ylmethyl)-ethyl-
]-carbamic Acid Tert-Butyl Ester
[0457] A solution of Example 120 (0.15 g, 0.3 mmol) 3 mL of dioxane
and 1 mL of DMF was treated with Pd(PPh.sub.3).sub.4 (0.030 g,
0.026 mmol), and zinc cyanide (0.037 g, 0.3 mmol). The reaction was
heated to 95.degree. C. for 3 days. The mixture was diluted with
ethyl acetate (25 mL) and washed with water (15 mL) and brine (15
mL). The mixture was evaporated and the residue was purified by
flash column chromatography on silica gel, eluting 1:1 ethyl
acetate/hexane. Recovered 0.108 g of product (79%). MS (ESI) m/z
519 (M+H).sup.+.
Example 137B
3-((2S)-2-Amino-3-(1H-indol-3-yl)-propoxy)-5-isoquinolin-6-yl-benzonitrile
[0458] The desired product was prepared by substituting Example
137A for Example 27B in Example 27C. MS (ESI) m/z 419 (M+H).sup.+;
.sup.1H NMR (500 MHz, DMSO-D6) .delta. ppm 2.95 (d, J=6.55 Hz, 1H)
3.05 (dd, J=14.35, 7.18 Hz, 1H) 3.57 (m, 1H) 4.07 (m, 1H) 4.16 (d,
J=4.06 Hz, 1H) 6.96 (t, J=7.18 Hz, 1H) 7.06 (t, J=7.18 Hz, 1H) 7.23
(d, J=2.18 Hz, 1H) 7.34 (d, J=8.11 Hz, 1H) 7.50 (s, 1H) 7.58 (d,
J=7.80 Hz, 1H) 7.73 (s, 1H) 7.87 (d, J=5.93 Hz, 1H) 7.93 (s, 1H)
8.04 (dd, J=8.58, 1.72 Hz, 1H) 8.23 (d, J=8.42 Hz, 1H) 8.36 (s, 1H)
8.55 (d, J=5.62 Hz, 1H) 9.36 (s, 1H) 10.91 (s, 1H).
EXAMPLE 138
5'-Benzyloxy-5-isoquinolin-6-yl-(3,3')bipyridinyl
Example 138A
6-(5-Bromo-pyridin-3-yl)-isoquinoline
[0459] The title compound was prepared by substituting
3,5-dibromopyridine for Example 2A in Example 27B.
Example 138B
3-Benzyloxy-5-trimethylstannanyl-pyridine
[0460] The title compound was prepared by substituting
3-benzyloxy-5-bromopyridine for 6-bromoisoquinoline in Example
27A.
Example 138C
5'-Benzyloxy-5-isoquinolin-6-yl-(3,3')bipyridinyl
[0461] The title compound was prepared by substituting Example 138A
for Example 2A, Example 138B for Example 27A in Example 27B. MS
(ESI) m/z 390 (M+H).sup.+; .sup.1H NMR (400 MHz, DMSO-D6) .delta.
ppm 5.35 (s, 2H) 7.38 (d, J=7.36 Hz, 1H) 7.44 (t, J=7.21 Hz, 2H)
7.53 (d, J=6.75 Hz, 2H) 8.11 (m, 1H) 8.32 (d, J=6.14 Hz, 1H) 8.50
(m, 2H) 8.57 (m, 1H) 8.70 (d, J=6.14 Hz, 1H) 8.74 (t, J=2.15 Hz,
1H) 8.79 (m, 2H) 9.14 (d, J=2.15 Hz, 1H) 9.22 (d, J=1.84 Hz, 1H)
9.76 (s, 1H).
EXAMPLE 140
(7-(5-((2S)-2-Amino-3-(1H-indol-3-yl)-propoxy)-pyridin-3-yl)-pyrido(2,3-d)-
pyrimidin-4-yl)-phenyl-amine
Example 140A
2-Amino-6-chloro-nicotinic Acid
[0462] A mixture of 2,6-dichloro-nicotonic acid (17.77 g, 92.6
mmol) in concenterated aqueous ammonia (173 mL) at 200 psi, was
heated to 130.degree. C. for 24 h. The mixture evaporated and the
residue was taken into water (200 mL) and neuteralized with conc
HCl then extracted into ether (200 ml). The ether was evaporated
off to yield 12 g of product (75%). MS (DCI/NH.sub.3) m/z 173
(M+1).sup.+.
Example 140B
2-Amino-6-chloro-nicotinamide
[0463] To a mixture of Example 140A (11.9 g, 69.2 mmol) in
1,2-dichloroethane (100 mL) was added thionyl chloride (30 mL, 411
mmol) and DMF (catalytic). The mixture was refluxed for 4 h then
evaporated. The residue was taken in ether (200 mL) and ammonia was
bubbled through for 15 min. The mixture was stirred overnight at rt
then washed with water (100 mL) and brine (100 ml). The ether was
evaporated off to yield 9.2 g of product (78%). MS (DCI/NH3) m/z
172 (M+1).sup.+. 14
Example 140C
7-Chloro-pyrido[2,3-d]pyrimidin-4-ol
[0464] A mixture of Example 140B (1 g, 5.8 mmol) in
triethylorthoformate (30 mL) was refluxed for 6 h then cooled.
Hexane (150 mL) was added and the solid formed was filtered and
washed with water and hexane to yield 0.27 g of product (26%). MS:
(DCI/NH.sub.3) m/z=182 (M+1) 15
Example 140D
4,7-Dichloro-pyrido[2,3-d]pyrimidine
[0465] A mixture of Example 140C (1 g, 5.5 mmol) in phosphorus
oxychloride (40 mL) was refluxed for 2 h then cooled and
evaporated. The residue was taken into ethyl acetate (75 ml),
washed with saturated sodium bicarbonate (50 ml) water (50 ml) and
brine (50 ml). The ethyl acetate was evaporated to yield 0.8 g of
product (73%). 16
Example 140E
(7-Chloro-pyrido[2,3-d]pyrimidin-4-yl)-phenyl-amine
[0466] A solution of Example 140D (0.5 g, 2.5 mmol), and aniline
(0.23 mL, 2.5 mmol) in THF (25 mL) and 2-propanol (2.5 mL) was
stirred at 0.degree. C. for 1 h then at room temperature for 2
days. The THF was evaporated off and the residue was taken into
ethyl acetate (75 ml), washed with water (50 ml) and brine (50 ml).
The ethyl acetate was evaporated off and the residue was purified
by flash column chromatography on silica gel, eluting with 1:1
ethyl acetate/hexane. Recovered 0.15 g of product (23%). MS (ESI)
m/z 390 (M+H).sup.+. 17
Example 140F
(7-(5-((2S)-2-Amino-3-(1H-indol-3-yl)-propoxy)-pyridin-3-yl)-pyrido(2,3-d)-
pyrimidin-4-yl)-phenyl-amine
[0467] The title compound was prepared by substituting Example 140E
for 6-bromoisoquinoline in Example 27. MS (ESI) m/z 257
(M+H).sup.+; .sup.1H NMR (500 MHz, DMSO-D6) .delta. ppm 3.15 (m,
3H) 3.38 (s, 4H) 4.06 (dd, J=10.29, 5.93 Hz, 4H) 4.21 (dd, J=10.45,
2.96 Hz, 1H) 6.99 (t, J=7.18 Hz, 1H) 7.09 (t, J=7.18 Hz, 1H) 7.26
(d, J=2.18 Hz, 1H) 7.35 (m, 4H) 8.21 (d, J=4.37 Hz, 3H) 11.02 (s,
1H) 18
EXAMPLE 141
(7-(5-((2S)-2-Amino-3-(1H-indol-3-yl)-propoxy)-pyridin-3-yl)-pyrido(2,3-d)-
pyrimidin-4-yl)-ethyl-amine
[0468] The title compound was prepared by substituting ethylamine
for aniline in Example 140. MS (ESI) m/z 440 (M+H).sup.+; .sup.1H
NMR (500 MHz, DMSO-D6) .delta. ppm 1.30 (m, 3H) 3.19 (m, 2H) 3.78
(m, 2H) 4.05 (s, 2H) 4.21 (dd, J=10.45, 5.77 Hz, 1H) 4.38 (dd,
J=10.45, 2.96 Hz, 1H) 7.00 (t, J=7.49 Hz, 1H) 7.09 (t, J=7.49 Hz,
1H) 7.30 (d, J=2.18 Hz, 1H) 7.38 (d, J=7.80 Hz, 1H) 7.61 (d, J=7.80
Hz, 1H) 8.15 (s, 1H) 8.24 (d, J=4.06 Hz, 2H) 8.51 (d, J=8.42 Hz,
1H) 8.56 (d, J=1.56 Hz, 1H) 8.96 (s, 1H) 9.01 (d, J=8.74 Hz, 1H)
9.12 (s, 1H) 11.03, (d, J=1.56 Hz, 1H). 19
EXAMPLE 142
(7-(5-((2S)-2-Amino-3-(1H-indol-3-yl)-propoxy)-pyridin-3-yl)-pyrido(2,3-d)-
pyrimidin-4-yl)-benzyl-amine
[0469] The title compound was prepared by substituting benzylamine
for aniline in Example 140. MS (ESI) m/z 502 (M+H).sup.+; .sup.1H
NMR (400 MHz, DMSO-D6) .delta. ppm 3.19 (m, J=6.60, 6.60 Hz, 2H)
3.89 (m, 1H) 4.22 (dd, J=10.43, 5.52 Hz, 1H) 4.38 (m, 1H) 5.00 (d,
J=5.52 Hz, 2H) 7.00 (m, 1H) 7.09 (m, 1H) 7.34 (m, 5H) 7.45 (m, 1H)
7.62 (d, J=7.98 Hz, 1H) 8.17 (m, 1H) 8.31 (d, J=3.68 Hz, 2H) 8.54
(m, 2H) 8.97 (s, 1H) 9.07 (d, J=8.90 Hz, 1H) 9.12 (d, J=1.84 Hz,
1H) 10.81 (s, 1H) 11.05 (d, J=2.15 Hz, 1H). 20
EXAMPLE 143
(1S)-1-(1H-Indol-3-ylmethyl)-2-(6-isoquinolin-6-yl-pyrazin-2-yloxy)-ethyla-
mine
[0470] The title compound was prepared by substituting
6-chloro-pyrazin-2-ol for 3-bromo-5-hydroxypyridine in Example 27.
MS (ESI) m/z 396 (M+H).sup.+; .sup.1H NMR (400 MHz, DMSO-D6)
.delta. ppm 3.20 (m, 1H) 3.95 (m, 1H) 4.52 (m, J=7.36 Hz, 1H) 4.76
(m, 1H) 7.02 (m, J=7.06 Hz, 1H) 7.11 (m, J=7.98 Hz, 1H) 7.34 (d,
J=2.15 Hz, 1H) 7.41 (d, J=8.29 Hz, 1H) 7.65 (d, J=7.98 Hz, 1H) 7.99
(d, J=5.83 Hz, 1H) 8.17 (s, 3H) 8.28 (m, 2H) 8.41 (s, 1H) 8.62 (m,
1H) 8.72 (s, 1H) 9.10 (s, 1H) 11.05 (s, 1H). 21
(1S)-[2-(5-Bromo-pyridin-3-yloxy)-1-phenyl-ethyl]-carbamic Acid
Tert-Butyl Ester
[0471] A solution of 5-bromo-pyridin-3-ol (0.3 g, 1.7 mmol),
(2-hydroxy-1-phenyl-ethyl)-carbamic acid tert-butyl ester (0.41 g
1.7 mmol), and triphenylphosphine (0.52 g, 2 mmol) in THF (15 mL)
was stirred at 0.degree. C. for 30 min. To the mixture was added a
solution of di-t-butyl azidodicarboxylate (0.46 g, 2 mmol) in 5 ml
of THF. The mixture was allowed to warm to room temperature then
stirred at room temperature for 20 h. The THF was evaporated off
and the residue was taken into ethyl acetate (75 ml), washed with
saturated sodium bicarbonate (50 ml) water (50 ml) and brine (50
ml). The ethyl acetate was evaporated off and the residue was
purified by flash column chromatography on silica gel, eluting with
a solvent gradient of 1:4 to 1:2 ethyl acetate/hexane. Recovered
0.82 g of a mixture of product and di-tert-butyl
azidodicarboxylate. MS (ESI) m/z 395 (M+H).sup.+. 22
Example 144B
5
(1S)-2-(5-isoquinolin-6-yl-pyridin-3-yloxy)-1-phenyl-ethylamine
[0472] The title compound was prepared by substituting Example 144A
for Example 2A in Example 27. MS (ESI) m/z 342 (M+H).sup.+; .sup.1H
NMR (500 MHz, DMSO-D6) .delta. ppm 4.51 (m, J=18.74 Hz, 1H) 4.57
(m, 1H) 4.87 (m, 1H) 7.49 (m, 3H) 7.63 (d, J=7.18 Hz, 2H) 7.90 (d,
J=5.62 Hz, 1H) 7.93 (m, 1H) 8.10 (dd, J=8.73, 1.56 Hz, 1H) 8.26 (d,
J=8.73 Hz, 1H) 8.39 (s, 1H) 8.45 (d, J=2.50 Hz, 1H) 8.56 (d, J=5.62
Hz, 1H) 8.69 (m, 2H) 8.74 (d, J=1.56 Hz, 1H) 9.39 (s, 1H). 23
EXAMPLE 145
(1S)-1-(1H-Indol-3-ylmethyl)-2-(6-(3-methyl-1H-indazol-5-yl)-pyrazin-2-ylo-
xy)-ethylamine
[0473] The title compound was prepared by substituting 102C for
6-bromoisoquinoline in Example 143. MS (ESI) m/z 399 (M+H).sup.+;
.sup.1H NMR (400 MHz, DMSO-D6) .delta. ppm 2.54 (s, 3H) 3.18 (m,
2H) 3.92 (m, 1H) 4.47 (d, J=7.06 Hz, 1H) 4.70 (m, 1H) 7.02 (d,
J=7.06 Hz, 1H) 7.10 (m, 1H) 7.32 (d, J=2.15 Hz, 1H) 7.39 (d, J=8.29
Hz, 1H) 7.49 (d, J=8.59 Hz, 1H) 7.64 (d, J=8.29 Hz, 1H) 7.92 (dd,
J=8.75, 1.69 Hz, 1H) 8.15 (m, 2H) 8.24 (s, 1H) 8.46 (s, 1H) 8.95
(s, 1H) 11.04 (d, J=1.53 Hz, 1H).
[0474] The following compounds were made according the procedures
used in Example 27 or 102, using the appropriate Boc protected
N-Boc-aminoethanols. 24
EXAMPLE 146
(1S)-1-Cyclohexylmethyl-2-(5-isoquinolin-6-yl-pyridin-3-yloxy)-ethylamine
[0475] MS (ESI) m/z 362 (M+H).sup.+; .sup.1H NMR (500 MHz, DMSO-D6)
.delta. ppm 0.92 (s, 2H) 1.24 (m, 3H) 1.64 (m, 6H) 3.52 (s, 2H)
4.23 (dd, J=10.61, 6.55 Hz, 1H) 4.40 (dd, J=10.61, 3.12 Hz, 1H)
7.91 (m, 1H) 7.96 (d, J=5.93 Hz, 1H) 8.13 (dd, J=8.58, 1.72 Hz, 4H)
8.32 (d, J=8.73 Hz, 1H) 8.43 (m, 2H) 8.59 (m, J=5.62 Hz, 1H) 8.74
(d, J=1.56 Hz, 1H) 9.44 (s, 1H). 25
EXAMPLE 147
(1S)-1-Benzyl-2-(5-(3-methyl-1H-indazol-5-yl)-pyridin-3-yloxy)-ethylamine
[0476] MS (ESI) m/z 359 (M+H).sup.+; .sup.1H NMR (500 MHz, DMSO-D6)
.delta. ppm 2.55 (m, 3H) 3.05 (m, 1H) 3.38 (m, 1H) 3.87 (m, 1H)
4.12 (dd, J=10.76, 5.77 Hz, 1H) 4.28 (dd, J=10.76, 2.96 Hz, 1H)
7.33 (m, 4H) 7.57 (d, J=8.73 Hz, 1H) 7.67 (m, 2H) 8.06 (s, 1H) 8.21
(s, 2H) 8.31 (d, J=1.56 Hz, 1H) 8.61 (s, 1H) 12.74 (s, 1H). 26
EXAMPLE 148
(1S)-2-(5-(3-Methyl-1H-indazol-5-yl)-pyridin-3-yloxy)-1-phenyl-ethylamine
[0477] MS (ESI) m/z 345 (M+H).sup.+; .sup.1H NMR (400 MHz, DMSO-D6)
.delta. ppm 2.55 (m, 3H) 4.01 (s, 1H) 4.31 (m, 1H) 4.39 (m, 1H)
4.57 (m, 1H) 7.36 (m, 1H) 7.43 (t, J=7.36 Hz, 2H) 7.55 (t, J=7.67
Hz, 4H) 7.70 (m, 1H) 8.08 (s, 1H) 8.29 (d, J=2.76 Hz, 1H) 8.57 (d,
J=1.84 Hz, 1H) 12.72 (s, 1H). 27
EXAMPLE 149
(1S)-2-(5-(3-Methyl-1H-indazol-5-yl)-pyridin-3-yloxy)-1-phenyl-ethylamine
[0478] MS (ESI) m/z 365 (M+H).sup.+; .sup.1H NMR (400 MHz, DMSO-D6)
.delta. ppm 0.90 (d, J=14.12 Hz, 2H) 1.16 (m, 3H) 1.44 (m, 3H) 1.69
(m, 3H) 2.55 (d, J=5.22 Hz, 3H) 3.37 (m, 3H) 4.03 (m, 1H) 4.17 (dd,
J=9.97, 4.14 Hz, 1H) 7.56 (d, J=8.59 Hz, 1H) 7.71 (m, 2H) 8.08 (s,
1H) 8.28 (d, J=2.76 Hz, 1H) 8.57 (d, J=1.53 Hz, 1H) 12.73 (s, 1H).
28
EXAMPLE 150
4-((2S)-2-Amino-3-(5-(3-methyl-1H-indazol-5-yl)-pyridin-3-yloxy)propyl)-be-
nzonitrile
[0479] MS (ESI) m/z 384 (M+H).sup.+; .sup.1H NMR (400 MHz, DMSO-D6)
.delta. ppm 2.55 (s, 3H) 3.14 (d, J=7.06 Hz, 2H) 3.94 (m, 1H) 4.15
(dd, J=10.74, 5.52 Hz, 1H) 4.32 (dd, J=10.74, 3.07 Hz, 1H) 7.57 (t,
J=8.13 Hz, 2H) 7.69 (m, 1H) 7.73 (t, J=1.99 Hz, 1H) 7.85 (d, J=7.98
Hz, 2H) 8.07 (s, 1H) 8.24 (m, 2H) 8.32 (d, J=2.45 Hz, 1H) 8.64 (d,
J=1.53 Hz, 1H). 29
EXAMPLE 151
(1S)-2-(5-(3-Methyl-1H-indazol-5-yl)-pyridin-3-yloxy)-1-napthalen-2-ylmeth-
yl-ethylamine
[0480] MS: (ESI) m/z 409 (M+H).sup.+; .sup.1H NMR (400 MHz,
DMSO-D6) .delta. ppm 2.54 (s, 3H) 3.23 (d, J=7.06 Hz, 2H) 4.00 (s,
1H) 4.21 (dd, J=10.74, 5.52 Hz, 1H) 4.37 (dd, J=10.74, 3.07 Hz, 1H)
7.51 (m, 3H) 7.56 (d, J=8.29 Hz, 1H) 7.67 (dd, J=8.59, 1.84 Hz, 1H)
7.78 (m, 1H) 7.86 (m, 2H) 7.91 (m, 2H) 8.07 (s, 1H) 8.26 (m, 2H)
8.36 (d, J=2.76 Hz, H) 8.65 (d, J=1.84 Hz, 1H). 30
EXAMPLE 152
4-((2S)-2-Amino-3-(5-isoquinolin-6-yl-pyridin-3-yloxy-propyl)-benzonitrile
[0481] MS (ESI) m/z 381 (M+H).sup.+; .sup.1H NMR (400 MHz, DMSO-D6)
.delta. ppm 3.16 (m, 2H) 3.97 (s, 1H) 4.26 (m, 2H) 7.56 (d, J=8.29
Hz, 2H) 7.84 (d, J=8.29 Hz, 2H) 7.90 (m, 1H) 8.24 (m, 2H) 8.33 (m,
2H) 8.48 (m, 2H) 8.55 (s, 1H) 8.67 (d, J=6.14 Hz, 1H) 8.79 (d,
J=1.84 Hz, 1H) 9.67 (s, 1H). 31
EXAMPLE 153
(1S)-2-(5-Isoquinolin-6-yl-pyridin-3-yloxy)-1-nanpthalen-2-ylmethyl)-ethyl-
amine
[0482] MS: (ESI) m/z 406 (M+H).sup.+; .sup.1H NMR (400 MHz,
DMSO-D6) .delta. ppm 3.24 (m, 2H) 4.03 (s, 1H) 4.31 (m, 2H) 7.50
(m, 3H) 7.89 (m, 5H) 8.22 (m, 2H) 8.33 (s, 3H) 8.48 (m, 2H) 8.54
(s, 1H) 8.66 (m, J=6.14 Hz, 1H) 8.78 (d, J=1.84 Hz, 1H). 32
EXAMPLE 154
(1S)-1-Benzyl-2-(5-isoquinolin-6-yl-pyridin-3-yloxy)-ethylamine
[0483] MS (ESI) m/z 356 (M+H).sup.+; .sup.1H NMR (500 MHz, DMSO-D6)
.delta. ppm 3.05 (m, 2H) 3.88 (s, 1H) 4.16 (dd, J=10.61, 5.62 Hz,
1H) 4.32 (dd, J=10.76, 2.96 Hz, 1H) 7.29 (m, 1H) 7.35 (m, 3H) 7.85
(m, 1H) 7.99 (d, J=5.62 Hz, 1H) 8.12 (dd, J=8.58, 1.72 Hz, 1H) 8.27
(m, 3H) 8.33 (d, J=8.74 Hz, 1H) 8.43 (m, 2H) 8.60 (d, J=5.93 Hz,
1H) 8.75 (d, J=1.87 Hz, 1H) 9.47 (s, 1H). 33
EXAMPLE 155
(1S)-1-(4-Fluoro-benzyl)-2-(5-(3-methyl-1H-indazol-5-yl)-pyridin-3-yloxy)--
ethylamine
[0484] MS (ESI) m/z 377 (M+H).sup.+; .sup.1H NMR (500 MHz, DMSO-D6)
.delta. ppm 2.55 (s, 3H) 3.04 (d, J=7.18 Hz, 2H) 3.85 (m, 1H) 4.14
(dd, J=10.76, 5.77 Hz, 1H) 4.30 (m, 1H) 7.19 (m, J=8.89, 8.89 Hz,
2H) 7.37 (dd, J=8.58, 5.46 Hz, 2H) 7.58 (d, J=8.73 Hz, 1H) 7.69
(dd, J=8.74, 1.56 Hz, 1H) 7.75 (s, 1H) 8.08 (s, 1H) 8.23 (s, 3H)
8.34 (s, 1H) 8.65 (s, 1H) 34
EXAMPLE 156
(1S)-1-(4-Fluoro-benzyl)-2-(5-isoquinolin-6-yl-pyridin-3-yloxy)-ethylamine
[0485] MS (ESI) m/z 374 (M+H).sup.+; .sup.1H NMR (500 MHz, DMSO-D6)
.delta. ppm 3.05 (m, 2H) 3.88 (s, 1H) 4.17 (dd, J=10.92, 5.62 Hz,
1H) 4.34 (dd, J=10.76, 2.96 Hz, 1H) 7.18 (m, 2H) 7.38 (dd, J=8.58,
5.46 Hz, 2H) 7.90 (m, 1H) 8.24 (m, 5H) 8.47 (d, J=8.73 Hz, 2H) 8.53
(d, J=9.98 Hz, 1H) 8.79 (s, 1H) 9.67 (s, 1H). 35
EXAMPLE 157
2-((2S)-2-Amino-3-(5-(3-methyl-1H-indazol-5-yl)-pyridin-3-yloxy)-propyl)-b-
enzonitrile
[0486] MS (ESI) m/z 384 (M+H).sup.+; .sup.1H NMR (500 MHz, DMSO-D6)
.delta. ppm 2.54 (d, J=4.06 Hz, 3H) 3.34 (m, 2H) 4.03 (m, 1H) 4.11
(dd, J=10.61, 4.99 Hz, 1H) 4.33 (dd, J=10.92, 3.12 Hz, 1H) 7.50 (t,
J=7.64 Hz, 1H) 7.65 (m, 7H) 7.85 (d, J=7.80 Hz, 1H) 8.06 (s, 1H)
8.37 (s, 2H) 8.65 (s, 1H). 36
EXAMPLE 158
2-((2S)-2-Amino-3-(5-isoquinolin-6-yl)-pyridin-3-yloxy)-propyl)-benzonitri-
le
[0487] MS (ESI) m/z 381 (M+H).sup.+; .sup.1H NMR (500 MHz, DMSO-D6)
.delta. ppm 3.32 (m, 2H) 4.04 (m, 1H) 4.16 (m, 1H) 4.37 (dd,
J=10.76, 3.28 Hz, 1H) 7.50 (t, J=7.64 Hz, 1H) 7.64 (d, J=7.49 Hz,
1H) 7.71 (d, J=7.49 Hz, 1H) 7.84 (m, 2H) 8.00 (d, J=5.62 Hz, 1H)
8.12 (dd, J=8.73, 1.87 Hz, 1H) 8.34 (d, J=8.73 Hz, 1H) 8.40 (m, 2H)
8.54 (s, 2H) 8.60 (d, J=5.61 Hz, 1H) 8.74 (d, J=1.56 Hz, 1H) 9.48
(s, 1H). 37
EXAMPLE 159
(1S)-2-5-(3-methyl-1H-indazol-5-yl)-pyridin-3-yloxy)-1-pyridin-4-ylmethyl--
ethylamine
[0488] MS (ESI) m/z 360 (M+H).sup.+; .sup.1H NMR (500 MH1H N z,
DMSO-D6) .delta. ppm 2.50 (s, 3H) 3.24 (d, J=6.86 Hz, 2H) 4.05 (m,
1H) 4.12 (m, 1H) 4.25 (m, J=3.43 Hz, 1H) 7.49 (m, J=4.68 Hz, 2H)
7.53 (d, J=1.87 Hz, 1H) 7.59 (m, 1H) 7.71 (m, 1H) 7.80 (m, 3H) 8.09
(s, 1H) 8.30 (d, J=4.06 Hz, 1H) 8.40 (s, 2H) 8.78 (m, J=4.99 Hz,
1H). 38
EXAMPLE 160
(1S)-2-(5-Isoquinolin-6-yl-pyridin-3-yloxy)-1-pyridin-4-ylmethyl-ethylamin-
e
[0489] MS (ESI) m/z 357 (M+H).sup.+; .sup.1H NMR (500 MHz, DMSO-D6)
.delta. ppm 3.24 (d, J=7.17 Hz, 1H) 3.28 (d, J=7.18 Hz, 1H) 4.04
(m, 1H) 4.26 (m, 1H) 4.40 (d, J=3.43 Hz, 1H) 7.83 (dd, J=14.66,
6.24 Hz, 3H) 7.93 (m, 1H) 8.26 (m, 2H) 8.38 (m, 1H) 8.47 (d, J=2.81
Hz, 2H) 8.51 (d, J=8.42 Hz, 1H) 8.58 (s, 1H) 8.68 (d, J=6.24 Hz,
1H) 8.80 (m, 2H) 9.71 (s, 1H). 39
EXAMPLE 161
(1S)-1-(4-Methyl-benzyl)-2-(5-(3-methyl-1H-indazol-5-yl)-pyridin-3-yloxy)--
ethylamine
[0490] MS (ESI) m/z 373 (M+H).sup.+; .sup.1H NMR (500 MHz, DMSO-D6)
.delta. ppm 2.28 (m, 3H) 2.55 (s, 3H) 2.98 (m, 2H) 3.81 (s, 1H)
4.11 (dd, J=10.45, 6.08 Hz, 1H) 4.27 (dd, J=10.76, 2.96 Hz, 1H)
7.16 (m, 3H) 7.21 (m, 1H) 7.57 (d, J=8.73 Hz, 1H) 7.69 (m, 2H) 8.07
(s, 1H) 8.21 (m, 3H) 8.31 (d, J=2.18 Hz, 1H) 8.62 (s, 1H). 40
EXAMPLE 162
(1S)-2-(5-Isoquinolin-6-yl-pyridin-3-yloxy)-1-(4-methyl-benzyl)-ethylamine
[0491] MS (ESI) m/z 370 (M+H).sup.+; .sup.1H NMR (500 MHz, DMSO-D6)
.delta. ppm 2.28 (m, 3H) 3.01 (m, 2H) 3.83 (s, 1H) 4.14 (dd,
J=10.76, 5.77 Hz, 1H) 4.30 (m, 1H) 7.18 (m, 6H) 7.84 (m, 1H) 7.97
(d, J=5.93 Hz, 1H) 8.10 (dd, J=8.58, 1.72 Hz, 1H) 8.24 (m, 2H) 8.31
(d, J=8.74 Hz, 1H) 8.59 (d, J=5.93 Hz, 1H) 8.74 (d, J=1.87 Hz, 1H)
9.45 (s, 1H) 41
EXAMPLE 163
(1S)-2-(5-(3-methyl-1H-indazol-5-yl)-pyridin-3-yloxy)-1-quinolin-3-ylmethy-
l-ethylamine
[0492] MS (ESI) m/z 410 (M+H).sup.+; .sup.1H NMR (500 MHz, DMSO-D6)
.delta. ppm 2.56 (m, 3H) 3.29 (m, 2H) 4.12 (m, 1H) 4.29 (m, 1H)
4.42 (dd, J=10.76, 3.28 Hz, 1H) 7.56 (d, J=8.73 Hz, 1H) 7.66 (m,
2H) 7.78 (m, 2H) 7.97 (t, J=7.18 Hz, 2H) 8.05 (m, 2H) 8.36 (m, 4H)
8.91 (m, 2H) 42
EXAMPLE 164
(1S)-2-(5-Isoquinolin-6-yl-pyridin-3-yloxy)-1-quinolin-3-ylmethyl-ethylami-
ne
[0493] MS (ESI) m/z 407 (M+H).sup.+; .sup.1H NMR (500 MHz, DMSO-D6)
.delta. ppm 3.27 (m, 2H) 4.09 (d, J=5.62 Hz, 1H) 4.27 (dd, J=10.92,
5.62 Hz, 1H) 4.43 (dd, J=10.61, 3.43 Hz, 1H) 5.75 (s, 1H) 7.62 (m,
1H) 7.76 (m, 1H) 7.86 (m, 1H) 7.94 (m, 2H) 8.06 (m, 1H) 8.30 (m,
5H) 8.46 (d, J=2.81 Hz, 1H) 8.59 (d, J=5.93 Hz, 1H) 8.74 (m, J=1.87
Hz, 1H) 8.89 (dd, J=20.28, 2.18 Hz, 1H) 9.43 (s, 1H). 43
EXAMPLE 165
(1R)-1-Benzyl-2-(5-(3-methyl-1H-indazol-5-yl)-pyridin-3-yloxy)-ethylamine
[0494] MS (ESI) m/z 358 (M+H).sup.+; .sup.1H NMR (500 MHz, DMSO-D6)
.delta. ppm 2.49 (s, 3H) 2.99 (m, 2H) 3.79 (s, 1H) 4.07 (dd,
J=10.61, 5.93 Hz, 1H) 4.23 (dd, J=10.76, 2.96 Hz, 1H) 7.22 (m, 2 H)
7.29 (m, 3H) 7.51 (d, J=8.73 Hz, 1H) 7.62 (dd, J=8.73, 1.56 Hz, 1H)
7.64 (m, 1H) 8.00 (s, 1H) 8.19 (s, 3H) 8.26 (m, 1H) 8.56 (s, 1H).
44
EXAMPLE 166
(1R)-1-Benzyl-2-(5-isoquinolin-6-yl-pyridin-3-yloxy)-ethylamine
[0495] MS (ESI m/z 356) (M+H).sup.+; .sup.1H NMR (500 MHz, DMSO-D6)
.delta. ppm 2.86 (m, 1H) 2.95 (m, 1H) 3.58 (m, 1H) 4.08 (m, 1H)
4.18 (m, 1H) 7.28 (m, 5H) 7.81 (m, 1H) 7.88 (m, 1H) 8.06 (m, 1H)
8.25 (m, 1H) 8.36 (m, 1H) 8.39 (m, 1H) 8.55 (m, 1H) 8.69 (m, 1H)
9.37 (m, 1H) 45
EXAMPLE 167
4-((2S)-2-Amino-3-(5-(3-methyl-1H-indazol-5-yl)-pyridin-3-yloxy)-propyl)-p-
henol
[0496] MS (ESI) m/z 374 (M+H).sup.+; .sup.1H NMR (400 MHz, DMSO-D6)
.delta. ppm 2.55 (s, 3H) 3.50 (m, 8H) 6.73 (dd, J=8.44, 2.92 Hz,
1H) 7.09 (m, 1H) 7.59 (m, 2H) 7.69 (m, 2H) 7.87 (s, 1H) 8.14 (m,
2H) 8.23 (d, J=1.84 Hz, 1H) 8.62 (s, 1H). 46
EXAMPLE 168
(1S)-1-(4-Benzyloxy-benzyl)-2-(5-(3-methyl-1H-indazol-5-yl)-pyridin-3-ylox-
y)-ethylamine
[0497] MS m/z 465 (ESI) (M+H).sup.+; .sup.1H NMR (400 MHz, DMSO-D6)
.delta. ppm 2.55 (s, 3H) 2.97 (m, 2H) 3.82 (m, 1H) 4.13 (m, 1H)
4.28 (m, 1H) 5.07 (s, 2H) 6.99 (d, J=8.59 Hz, 3H) 7.24 (d, J=8.59
Hz, 2H) 7.32 (m, J=7.06 Hz, 1H) 7.40 (m, 4H) 7.69 (dd, J=8.75, 1.69
Hz, 1H) 7.73 (m, 1H) 8.08 (s, 1H) 8.19 (m, 3H) 8.33 (m, J=2.46 Hz,
1H) 8.64 (d, J=1.53 Hz, 1H). 47
EXAMPLE 169
(1S)-1-(3-Methyl-benzyl)-2-(5-(3-methyl-1H-indazol-5-yl)-pyridin-3-yloxy)--
ethylamine
[0498] MS (ESI) m/z 373 (M+H).sup.+; .sup.1H NMR (500 MHz, DMSO-D6)
.delta. ppm 2.28 (s, 3H) 2.56 (s, 3H) 3.01 (m, 2H) 4.15 (dd,
J=10.92, 5.62 Hz, 1H) 4.30 (m, J=2.81 Hz, 1H) 7.11 (m, J=17.00,
7.64 Hz, 3H) 7.23 (m, J=7.49 Hz, 1H) 7.58 (d, J=8.73 Hz, 1H) 7.70
(dd, J=8.73, 1.56 Hz, 1H) 7.80 (m, 1H) 8.10 (s, 1H) 8.26 (s, 3H)
8.35 (d, J=2.81 Hz, 1H) 8.67 (d, J=1.56 Hz, 1H). 48
EXAMPLE 170
(1S)-1-(2-Methyl-benzyl)-2-(5-(3-methyl-1H-indazol-5-yl)-pyridin-3-yloxy)--
ethylamine
[0499] MS (ESI) m/z 373 (M+H).sup.+; .sup.1H NMR (500 MHz, DMSO-D6)
.delta. ppm 2.30 (d, J=7.80 Hz, 1H) 2.33 (s, 3H) 2.56 (m, 3H) 3.07
(d, J=7.80 Hz, 1H) 3.80 (s, 1H) 4.12 (dd, J=10.76, 4.84 Hz, 1H)
4.26 (dd, J=10.61, 2.81 Hz, 1H) 7.19 (m, 4H) 7.57 (d, J=8.73 Hz,
1H) 7.68 (dd, J=11.07, 2.03 Hz, 2H) 8.06 (s, 1H) 8.31 (s, 3H) 8.62
(s, 1H). 49
EXAMPLE 171
(1S)-2-(5-(3-methyl-1H-indazol-5-yl)-pyridin-3-yloxy)-1-(4-nitro-benzyl)-e-
thylamine
[0500] MS (ESI) m/z 404 (M+H).sup.+; .sup.1H NMR (500 MHz, DMSO-D6)
.delta. ppm 2.55 (s, 3H) 3.19 (m, 2H) 3.97 (s, 1H) 4.18 (dd,
J=10.92, 5.62 Hz, 1H) 4.34 (dd, J=10.76, 3.28 Hz, 1H) 7.57 (d,
J=8.74 Hz, 1H) 7.64 (m, J=8.73 Hz, 2H) 7.69 (dd, J=8.58, 1.72 Hz,
1H) 7.77 (m, 1H) 8.08 (s, 1H) 8.23 (d, J=8.73 Hz, 2H) 8.29 (m, 2H)
8.34 (d, J=2.50 Hz, 1H) 8.66 (d, J=1.25 Hz, 1H). 50
EXAMPLE 172
(1S)-1-(4-Methoxy-benzyl)-2-(5-(3-methyl-1H-indazol-5-yl)-pyridin-3-yloxy)-
-ethylamine
[0501] MS (ESI) m/z 389 (M+H).sup.+; .sup.1H NMR (500 MHz, DMSO-D6)
.delta. ppm 2.56 (s, 3H) 2.98 (dd, J=15.13, 6.08 Hz, 2H) 3.73 (m,
3H) 3.80 (m, 1H) 4.16 (dd, J=10.76, 5.77 Hz, 1H) 4.32 (dd, J=10.61,
3.12 Hz, 1H) 6.91 (m, 2H) 7.21 (dd, J=8.58, 2.65 Hz, 1H) 7.25 (d,
J=8.73 Hz, 2H) 7.59 (d, J=8.73 Hz, 1H) 7.71 (dd, J=8.73, 1.87 Hz,
1H) 7.84 (m, 1H) 8.11 (s, 1H) 8.28 (m, 2H) 8.37 (d, J=2.81 Hz, 1H)
8.69 (d, J=1.56 Hz, 1H). 51
EXAMPLE 173
(1S)-1-Biphenyl-4-ylmethyl-2-(5-(3-methyl-1H-indazol-5-yl)-pyridin-3-yloxy-
)-ethylamine
[0502] MS (ESI) m/z 435 (M+H).sup.+; .sup.1H NMR (500 MHz, DMSO-D6)
.delta. ppm 2.55 (s, 3H) 3.10 (m, 2H) 3.92 (s, 1H) 4.21 (dd,
J=10.92, 5.62 Hz, 1H) 4.36 (dd, J=10.76, 2.96 Hz, 1H) 7.36 (t,
J=7.49 Hz, 1H) 7.44 (m, 4H) 7.57 (d, J=8.73 Hz, 1H) 7.65 (dd,
J=10.29, 7.80 Hz, 4H) 7.70 (dd, J=8.73, 1.56 Hz, 1H) 7.82 (s, 1H)
8.10 (s, 1H) 8.30 (d, J=2.81 Hz, 3H) 8.37 (d, J=2.50 Hz, 1H) 8.67
(d, J=1.25 Hz, 1H). 52
EXAMPLE 174
(1S)-2-(5-(3-Methyl-1H-indazol-5-yl)-pyridin-3-yloxy)-1-napthalen-1-ylmeth-
yl-ethylamine
[0503] MS (ESI) m/z 409 (M+H).sup.+; .sup.1H NMR (500 MHz, DMSO-D6)
.delta. ppm 2.55 (s, 3H) 3.44 (dd, J=14.04, 6.86 Hz, 2H) 3.93 (s,
1H) 4.17 (dd, J=10.61, 4.99 Hz, 1H) 4.32 (m, 1H) 7.48 (m, 2H) 7.59
(m, 3H) 7.66 (dd, J=8.58, 1.72 Hz, 1H) 7.69 (m, 1H) 7.89 (dd,
J=6.24, 3.12 Hz, 1H) 7.98 (d, J=8.11 Hz, 1-H) 8.05 (s, 1H) 8.21 (d,
J=8.42 Hz, 1H) 8.29 (m, 2H) 8.32 (d, J=2.81 Hz, 1H) 8.63 (d, J=1.56
Hz, 1H). 53
EXAMPLE 175
(1S)-1-(3-Chloro-benzyl)-2-(5-(3-methyl-1H-indazol-5-yl)-pyridin-3-yloxy)--
ethylamine
[0504] MS (ESI) m/z 393 (M+H).sup.+, .sup.1H NMR (500 MHz, DMSO-D6)
.delta. ppm 2.55 (s, 3H) 3.06 (d, J=7.49 Hz, 2H) 3.92 (m, 1H) 4.16
(m, 1H) 4.33 (dd, J=10.92, 3.12 Hz, 1H) 7.31 (d, J=7.49 Hz, 1H)
7.37 (m, J=14.51, 7.02 Hz, 2H) 7.45 (s, 1H) 7.58 (d, J=8.73 Hz, 1H)
7.70 (dd, J=8.73, 1.56 Hz, 1H) 7.77 (s, 1H) 8.08 (s, 1H) 8.23 (s,
3H) 8.34 (d, J=2.50 Hz, 1H) 8.65 (s, 1H). 54
EXAMPLE 176
3-((2S)-2-Amino-3-(5-(3-methyl-1H-indazol-5-yl)-pyridin-3-yloxy)-propyl)-b-
enzonitrile
[0505] MS (ESI) m/z 384 (M+H).sup.+; .sup.1H NMR (500 MHz, DMSO-D6)
.delta. ppm 2.55 (s, 3H) 3.12 (d, J=7.49 Hz, 2H) 3.96 (s, 1H) 4.17
(dd, J=110.76, 5.77 Hz, 1H) 4.33 (m, 1H) 7.57 (dd, J=8.11, 6.55 Hz,
2H) 7.69 (dd, J=8.42, 1.56 Hz, 2H) 7.76 (m, 2H) 7.84 (s, 1H) 8.08
(s, 1H) 8.23 (s, 3H) 8.33 (d, J=2.81 Hz, 1H) 8.64 (d, J=1.56 Hz,
1H). 55
EXAMPLE 177
(1S)-1-(3,4-Difluoro-benzyl)-2-(5-(3-methyl-1H-indazol-5-yl)-pyridin-3-ylo-
xy)-ethylamine
[0506] MS (ESI) m/z 395 (M+H).sup.+; .sup.1H NMR (500 MHz, DMSO-D6)
.delta. ppm 2.56 (s, 3H) 3.05 (d, J=7.18 Hz, 2H) 3.90 (m, 1H) 4.17
(dd, J=10.92, 5.93 Hz, 1H) 4.34 (dd, J=110.61, 3.12 Hz, 1H) 7.19
(m, J=2.18 Hz, 1H) 7.44 (m, 2H) 7.58 (d, J=8.73 Hz, 1H) 7.70 (dd,
J=8.73, 1.56 Hz, 1H) 7.77 (d, J=2.50 Hz, 1H) 8.08 (s, 1H) 8.23 (s,
3H) 8.34 (d, J=2.50 Hz, 1H) 8.65 (d, J=1.56 Hz, 1H). 56
EXAMPLE 178
(1S)-1-(3,4-Dimethoxy-benzyl)-2-(5-(3-methyl-1H-indazol-5-yl)-pyridin-3-yl-
oxy)-ethylamine
[0507] MS (ESI) m/z 419 (M+H).sup.+; .sup.1H NMR (500 MHz, DMSO-D6)
.delta. ppm 2.55 (s, 3H) 2.98 (m, 2H) 3.70 (s, 3H) 3.71 (s, 3H)
3.82 (s, 1H) 4.14 (dd, J=10.61, 5.62 Hz, 1H) 4.31 (dd, J=10.76,
2.96 Hz, 1H) 6.82 (d, J=8.11 Hz, 1H) 6.91 (m, 2H) 7.57 (d, J=8.42
Hz, 1H) 7.68 (m, 1H) 7.71 (s, 1H) 8.07 (s, 1H) 8.28 (s, 3H) 8.32
(s, 1H) 8.62 (s, 1H). 57
EXAMPLE 179
(1S)-1-(3-Fluoro-benzyl)-2-(5-(3-methyl-1H-indazol-5-yl)-pyridin-3-yloxy)--
ethylamine
[0508] MS (ESI) m/z 377 (M+H).sup.+; .sup.1H NMR (500 MHz, DMSO-D6)
.delta. ppm 2.55 (s, 3H) 3.08 (m, 2H) 3.91 (s, 1H) 4.15 (dd,
J=10.61, 5.93 Hz, 1H) 4.32 (dd, J=10.61, 3.12 Hz, 1H) 7.12 (m, 1H)
7.20 (m, 2H) 7.40 (m, 1H) 7.57 (d, J=8.73 Hz, 1H) 7.69 (dd, J=8.42,
1.56 Hz, 1H) 7.71 (d, J=1.87 Hz, 1H) 8.07 (s, 1H) 8.29 (s, 3H) 8.31
(d, J=2.81 Hz, 1H) 8.62 (s, 1H). 58
EXAMPLE 180
(1S)-2-(5-(3-methyl-1H-indazol-5-yl)-pyridin-3-yloxy)-1-(3-trifluoromethyl-
-benzyl)-ethylamine
[0509] MS (ESI) m/z 427. (M+H).sup.+; .sup.1H NMR (500 MHz,
DMSO-D6) .delta. ppm 2.55 (s, 3H) 3.16 (dd, J=7.33, 2.34 Hz, 2H)
3.97 (s, 1H) 4.16 (dd, J=10.61, 5.62 Hz, 1H) 4.34 (dd, J=10.76,
3.28 Hz, 1H) 7.58 (d, J=8.42 Hz, 1H) 7.61 (d, J=7.49 Hz, 1H) 7.65
(s, 1H) 7.66 (s, 1H) 7.69 (dd, J=8.74, 1.56 Hz, 1H) 7.73 (s, 1H)
7.75 (m, 1H) 8.07 (s, 1H) 8.22 (s, 3H) 8.33 (d, J=2.50 Hz, 1H) 8.64
(d, J=1.56 Hz, 1H). 59
EXAMPLE 181
(1S)-1-(4-Ethoxy-benzyl)-2-[5-(3-methyl-1H-indazol-5-yl)-pyridin-3-yloxy]--
ethylamine
[0510] MS (ESI) m/z 403 (M+H).sup.+; .sup.1H NMR (500 MHz, DMSO-D6)
.delta. ppm 1.30 (t, J=7.02 Hz, 3H) 2.55 (s, 3H) 2.97 (m, 2H) 3.79
(s, 1H) 3.98 (q, J=6.86 Hz, 2H) 4.13 (dd, J=10.76, 5.77 Hz, 1H)
4.29 (dd, J=10.76, 2.96 Hz, 1H) 6.89 (d, J=8.42 Hz, 1H) 7.22 (d,
J=8.42 Hz, 1H) 7.57 (d, J=8.42 Hz, 2H) 7.61 (m, J=11.85 Hz, 1H)
7.69 (dd, J=8.73, 1.56 Hz, 1H) 7.75 (s, 1H) 8.08 (s, 1H) 8.18 (s,
3H) 8.33 (d, J=2.50 Hz, 1H) 8.65 (d, J=1.56 Hz, 1H). 60
EXAMPLE 182
(1S)-1-(4-tert-Butyl-benzyl)-2-(5-(3-methyl-1H-indazol-5-yl)-pyridin-3-ylo-
xy)-ethylamine
[0511] MS (ESI) m/z 415 (M+H).sup.+; .sup.1H NMR (500 MHz, DMSO-D6)
.delta. ppm 1.26 (m, 9H) 2.55 (s, 3H) 2.80 (dd, J=13.73, 6.86 Hz,
1H) 2.92 (m, 1H) 3.55 (m, 1H) 4.06 (dd, J=9.98, 5.93 Hz, 1H) 4.15
(m, 1H) 7.21 (d, J=8.11 Hz, 2H) 7.34 (d, J=8.42 Hz, 2H) 7.56 (d,
J=8.42 Hz, 1H) 7.69 (m, 2H) 8.08 (s, 1H) 8.28 (d, J=2.50 Hz, 1H)
8.57 (d, J=1.56 Hz, 1H) 12.73 (s, 1H). 61
EXAMPLE 183
(1S)-1-(4-Methoxy-3-methyl-benzyl)-2-(5-(3-methyl-1H-indazol-5-yl)-pyridin-
-3-yloxy)-ethylamine
[0512] MS (ESI) m/z 403 (M+H).sup.+; .sup.1H NMR (500 MHz, DMSO-D6)
.delta. ppm 2.11 (s, 3H) 2.55 (s, 3H) 2.71 (m, 1H) 2.83 (dd,
J=13.73, 6.86 Hz, 1H) 3.17 (d, J=3.74 Hz, 2H) 3.47 (m, 1H) 3.74 (m,
3H) 4.07 (m, 2H) 6.86 (d, J=8.11 Hz, 1H) 7.05 (m, 2H) 7.56 (m,
J=8.73 Hz, 1H) 7.67 (m, 2H) 8.07 (s, 1H) 8.27 (d, J=2.81 Hz, 1H)
8.57 (d, J=1.56 Hz, 1H) 12.72 (s, 1H). 62
EXAMPLE 184
2-((2S)-2-Amino-3-(5-(3-methyl-1H-indazol-5-yl)-pyridin-3-yloxy)-propyl)-4-
-methyl-phenol
[0513] MS (ESI) m/z 403 (M+H).sup.+; .sup.1H NMR (500 MHz, DMSO-D6)
.delta. ppm 2.18 (s, 3H) 2.55 (s, 3H) 2.98 (d, J=7.49 Hz, 2H) 3.73
(d, J=3.74 Hz, 3H) 3.79 (m, 1H) 4.12 (dd, J=10.61, 5.62 Hz, 1H)
4.27 (dd, J=10.61, 3.12 Hz, 1H) 6.90 (d, J=8.11 Hz, 1H) 7.02 (s,
1H) 7.07 (d, J=8.42 Hz, 1H) 7.57 (d, J=8.73 Hz, 1H) 7.68 (dd,
J=8.73, 1.56 Hz, 1H) 7.71 (s, 1H) 8.07 (s, 1H) 8.17 (s, 3H) 8.31
(d, J=2.50 Hz, 1H) 8.64 (d, J=1.56 Hz, 1H). 63
EXAMPLE 185
(1S)-1-Methyl-2-[5-(3-methyl-1H-indazol-5-yl)-pyridin-3-yloxy]-ethylamine
[0514] MS (ESI) m/e 283 (M+H).sup.+; .sup.1H NMR (300 MHz, DMSO-D6)
.delta. ppm 1.32 (d, J=6.78 Hz 3H) 2.56 (s, 3H) 3.66 (m, 1H) 4.16
(dd, J=10.51, 7.12 Hz, 1H) 4.35 (dd, J=10.51, 3.73 Hz, 1H) 7.57 (d,
J=8.81 Hz, 1H) 7.72 (m, 1H) 7.78 (m, 1H) 8.01 (m, 2H) 8.10 (m, 1H)
8.33 (d, J=2.71 Hz, 1H) 8.63 (d, J=1.70 Hz, 1H) 12.70 (bs, 1H);
Anal. Calcd for C.sub.16H.sub.18N.sub.4O.2.2 TFA: C, 45.95; H,
3.82; N, 10.51; Found: C, 46.11; H, 3.76; N, 10.55. 64
EXAMPLE 186
(1)-1-(1H-Benzoimidazol-2-ylmethyl)-2-(5-isoquinolin-6-yl-pyridin-3-yloxy)-
-ethylamine
[0515] MS (ESI) m/e 396 (M+H).sup.+; .sup.1H NMR (500 MHz, DMSO-D6)
.delta. ppm 3.51 (m, 2H) 4.32 (m, 1H) 4.44 (m, 1H) 4.55 (m, 1H)
7.36 (dd, J=6.24, 3.12 Hz, 2H) 7.68 (dd, J=5.93, 3.12 Hz, 2H) 7.88
(d, J=2.18 Hz, 1H) 8.12 (d, J=6.24 Hz, 1H) 8.19 (dd, J=8.58, 1.40
Hz, 1H) 8.42 (m, 2H) 8.49 (s, 1H) 8.64 (d, J=5.93 Hz, 1H) 8.77 (d,
J=1.56 Hz, 1H) 9.60 (s, 1H). 65
EXAMPLE 187
(.+-.)-1-(1H-Indazol-3-ylmethyl)-2-(5-isoquinolin-6-yl-pyridin-3-yloxy)-et-
hylamine
[0516] MS (ESI) m/e 396 (M+H).sup.+; .sup.1H NMR (400 MHz, DMSO-D6)
.delta. ppm 3.21 (m, 2H) 3.84 (m, 1H) 4.21 (dd, J=9.97, 5.98 Hz,
1H) 4.31 (dd, J=9.97, 5.98 Hz, 1H) 7.08 (t, J=7.21 Hz, 1H) 7.33 (t,
J=7.21 Hz, 1H) 7.49 (d, J=8.59 Hz, 1H) 7.80 (m, 2H) 7.89 (d, J=5.83
Hz, 1H) 8.06 (dd, J=8.59, 1.84 Hz, 1H) 8.25 (d, J=8.59 Hz, 1H) 8.36
(s, 1H) 8.39 (d, J=2.76 Hz, 1H) 8.56 (d, J=5.83 Hz, 1H) 8.69 (d,
J=1.84 Hz, 1H) 9.37 (s, 1H) 12.87 (s, 1H). 66
EXAMPLE 188
(1S)-1-(2-Fluoro-benzyl)-2-[5-(3-methyl-1H-indazol-5-yl)-pyridin-3-yloxy]--
ethylamine
[0517] MS (ESI) m/e 377 (M+H).sup.+; .sup.1H NMR (300 MHz, DMSO-D6)
.delta. ppm 2.55 (s, 3H) 3.11 (d, J=7.12 Hz, 2H) 3.86 (m, 1H) 4.15
(m, 1H) 4.31 (dd, J=10.85, 3.39 Hz, 1H) 7.20 (m, 2H) 7.37 (m, 2H)
7.57 (d, J=9.49 Hz, 1H) 7.71 (m, 2H) 8.08 (s, 1H) 8.29 (s, 2H) 8.31
(d, J=2.71 Hz, 1H) 8.64 (d, J=1.69 Hz, 1H) 12.74 (bs, 1H). 67
EXAMPLE 189
(1S)-1-(2-Chloro-benzyl)-2-[5-(3-methyl-1H-indazol-5-yl)-pyridin-3-yloxy]--
ethylamine
[0518] MS (ESI) m/e 393 (M+H).sup.+; .sup.1H NMR (300 MHz, DMSO-D6)
.delta. ppm 2.55 (s, 3H) 3.22 (m, 2H) 3.89 (m, 1H) 4.15 (m, 1H)
4.31 (m, 1H) 7.35 (m, 2H) 7.48 (m, 3H) 7.58 (d, J=8.82 Hz, 1H) 7.70
(m, 2H) 8.08 (s, 1H) 8.31 (d, J=2.71 Hz, 2H) 8.64 (d, J=1.70 Hz,
1H) 12.84 (bs, 1H). 68
EXAMPLE 190
(1S)-2-[5-(3-Methyl-1H-indazol-5-yl)-pyridin-3-yloxy]-1-thiophen-2-ylmethy-
l-ethylamine
[0519] MS (ESI) m/e 365 (M+H).sup.+; .sup.1H NMR (300 MHz, DMSO-D6)
.delta. ppm 2.55 (s, 3H) 3.28 (m, 2H) 3.90 (m, 1H) 4.20 (m, 1H)
4.35 (m, 1H) 7.03 (m, 2H) 7.46 (m, 1H) 7.58 (d, J=8.82 Hz, 1H) 7.70
(m, 1H) 7.75 (m, 1H) 8.09 (s, 1H) 8.26 (m, 2H) 8.33 (d, J=2.71 Hz,
1H) 8.64 (d, J=1.70 Hz, 1H) 12.53 (bs, 1H). 69
EXAMPLE 191
(1R)-1-(1H-Indol-3-ylmethyl)-2-[5-(3-methyl-1H-indazol-5-yl)-pyridin-3-ylo-
xy]-ethylamine
[0520] MS (ESI) m/e 398 (M+H).sup.+; .sup.1H NMR (300 MHz, DMSO-D6)
.delta. ppm 2.55 (s, 3H) 3.16 (m, 2H) 3.86 (d, J=1.70 Hz, 1H) 4.19
(dd, J=10.51, 6.10 Hz, 1H) 4.36 (dd, J=10.85, 3.39 Hz, 1H) 7.01 (t,
J=7.46 Hz, 1H) 7.10 (t, J=6.95 Hz, 1H) 7.30 (d, J=2.37 Hz, 1H) 7.38
(d, J=8.14 Hz, 1H) 7.65 (m, 5H) 8.07 (s, 1H) 8.16 (s, 2H) 8.33 (d,
J=2.71 Hz, 1H) 8.63 (d, J=1.70 Hz, 1H) 11.04 (bs, 1H); Anal. Calcd
for C.sub.24H.sub.23N.sub.5O.2.9 TFA: C, 49.16; H, 3.59; N, 9.62;.
Found: C, 49.36; H, 3.66; N, 9.78. 70
EXAMPLE 192
1-(4-Chloro-benzyl)-2-[5-(3-methyl-1H-indazol-5-yl)-pyridin-3-yloxy]-ethyl-
amine
[0521] MS (ESI) m/e 393 (M+1).sup.+; .sup.1H NMR (300 MHz, Solvent)
.delta. ppm 2.63 (s, 3H) 3.16 (m, 2H) 3.98 (m, 1H) 4.29 (m, 1H)
4.44 (m, 1H) 7.34 (m, 2H) 7.39 (m, 2H) 7.63 (d, J=8.82 Hz, 1H) 7.74
(dd, J=8.82, 1.70 Hz, 1H) 8.09 (m, 1H) 8.11 (m, 1H) 8.42 (br. s.,
1H) 8.73 (br. s., 1H). 71
Example 193
(1S)-2-[5-(3-Methyl-1H-indazol-5-yl)-pyridin-3-yloxy]-1-(4-pyrrol-1-yl-ben-
zyl)-ethylamine
[0522] MS (ESI) m/e 424 (M+1).sup.+; .sup.1H NMR (300 MHz, Solvent)
.delta. ppm 2.61 (m, 3H) 3.19 (m, 2H) 4.10 (m, 1H) 4.30 (m, 1H)
4.44 (m, 1H) 6.27 (t, J=2.03 Hz, 2H) 7.16 (t, J=2.03 Hz, 2H) 7.41
(d, J=8.48 Hz, 1H) 7.49 (d, J=8.48 Hz, 2H) 7.59 (d, J=8.48 Hz, 1H)
7.70 (m, 1H) 7.94 (m, 1H) 8.07 (m, 1H) 8.38 (br. s., 1H) 8.66 (br.
s., 1H). 72
EXAMPLE 194
(1S)-1-(4-Methyl-benzylsulfanylmethyl)-2-[5-(3-methyl-1H-indazol-5-yl)-pyr-
idin-3-yloxy]-ethylamine
[0523] MS (ESI) m/e 419 (M+1).sup.+; .sup.1H NMR (300 MHz, MeOH)
.delta. ppm 2.26 (s, 3H) 2.62 (s, 3H) 2.88 (m, 2H) 3.67 (m, 1H)
3.82 (s, 2H) 4.38 (m, 2H) 7.18 (m, 6H) 7.62 (d, J=8.81 Hz, 1H) 7.72
(dd, J=8.81, 1.70 Hz, 1H) 7.85 (dd, J=2.71, 1.70 Hz, 1H) 8.06 (m,
1H) 8.30 (d, J=2.71 Hz, 1H) 8.62 (d, J=1.70 Hz, 1H). 73
EXAMPLE 195
(1S)-2-[5-(3-Methyl-1H-indazol-5-yl)-pyridin-3-yloxy]-1-(2-trifluoromethyl-
-benzyl)-ethylamine
[0524] MS m/z 427 (M+H).sup.+; .sup.1H NMR (300 MHz, DMSO-D6)
.delta. ppm 2.57 (s, 3H) 3.30 (m, 2H) 3.93 (s, 1H) 4.32 (dd,
J=10.85, 5.42 Hz, 1H) 4.45 (m, 1H) 7.53 (td, J=8.22, 3.90 Hz, 1H)
7.61 (dd, J=8.82, 0.68 Hz, 1H) 7.68 (m, 2H) 7.77 (m, 2H) 8.14 (s,
1H) 8.23 (d, J=0.68 Hz, 1H) 8.46 (d, J=2.03 Hz, 1H) 8.65 (s, 3H)
8.83 (s, 1H). 74
EXAMPLE 196
(1R)-1-Benzyl-3-[5-(3-methyl-1H-indazol-5-yl)-pyridin-3-yloxy]-propylamine
[0525] MS m/z 373 (M+H).sup.+; .sup.1H NMR (300 MHz, DMSO-D6)
.delta. ppm 2.05 (m, 2H) 2.57 (s, 3H) 2.91 (dd, J=13.73, 8.65 Hz,
1H) 3.11 (m, 1H) 3.63 (m, 1H) 4.41 (m, 2H) 7.25 (m, 1H) 7.33 (m,
4H) 7.61 (dd, J=8.81, 0.68 Hz, 1H) 7.81 (dd, J=8.81, 1.70 Hz, 1H)
8.21 (s, 1H) 8.28 (s, 2H) 8.47 (d, J=2.37 Hz, 1H) 8.82 (s, 1H).
75
EXAMPLE 197
(1R)-1-Benzyl-4-[5-(3-methyl-1H-indazol-5-yl)-pyridin-3-yloxy]-butylamine
[0526] MS m/z 387 (M+H).sup.+; .sup.1H NMR (300 MHz, DMSO-D6)
.delta. ppm 1.70 (q, J=7.23 Hz, 2H) 1.91 (m, 2H) 2.57 (s, 3H) 2.82
(dd, J=13.56, 8.48 Hz, 1H) 3.06 (dd, J=13.73, 5.26 Hz, 1H) 3.47 (s,
1H) 4.27 (m, 2H) 7.27 (m, 5H) 7.61 (d, J=8.48 Hz, 1H) 7.84 (dd,
J=8.81, 1.70 Hz, 1H) 8.29 (s, 2H) 8.33 (s, 1H) 8.49 (d, J=2.37 Hz,
1H) 8.87 (s, 1H). 76
EXAMPLE 198
(1S)-1-[5-(3-Methyl-1H-indazol-5-yl)-pyridin-3-yloxymethyl]-3-phenyl-propy-
lamine
[0527] MS m/z 373 (M+H).sup.+; .sup.1H NMR (300 MHz, DMSO-D6)
.delta. ppm 2.04 (m, 2H) 2.57 (s, 3H) 2.80 (m, 2H) 3.57 (m, 1H)
4.44 (dd, J=10.68, 6.61 Hz, 1H) 4.59 (m, 1H) 7.24 (m, 5H) 7.62 (d,
J=8.82 Hz, 1H) 7.82 (dd, J=8.65, 1.53 Hz, 1H) 8.27 (s, 2H) 8.50 (s,
2H) 8.54 (d, J=2.71 Hz, 1H) 8.86 (s, 1H). 77
EXAMPLE 199
(1S)-2-(5-Isoquinolin-6-yl-pyridin-3-yloxy)-1-(1-methyl-1H-indol-3-ylmethy-
l)-ethylamine Trifloroacetic Acid Salt
[0528] MS (DCI/NH.sub.3) m/z 409(M+1).sup.+; .sup.1HNMR (500 MHz,
MeOD) .delta. ppm 3.28 (m, 1H) 3.33 (m, 1H) 3.77 (s, 3H) 4.00 (m,
1H) 4.33 (dd, J=10.61, 5.93 Hz, 1H) 4.46 (dd, J=10.61, 3.12 Hz, 1H)
7.04 (m, 1H) 7.17 (m, 1H) 7.17 (s, 1H) 7.36 (d, J=8.42 Hz, 1H) 7.59
(d, J=7.80 Hz, 1H) 7.93 (m, 1H) 8.28 (dd, J=8.73, 1.87 Hz, 1H) 8.49
(m, 2H) 8.59 (m, 3H) 8.76 (s, 1H) 9.77 (s, 1H). 78
EXAMPLE 199
(1S)-[1-(1H-Indol-3-ylmethyl)-2-(5-isoquinolin-6-yl-pyridin-3-yloxy)-ethyl-
]-dimethyl-amine
[0529] .sup.1HNMR (400 MHz, MeOD) .delta. ppm 3.16 (s, 6H) 3.44 (m,
2H) 4.11 (m, 1H) 4.46 (m, 1H) 4.55 (m, 1H) 7.00 (m, 1H) 7.09 (m,
1H) 7.26 (m, 1H) 7.35 (d, J=8.29 Hz, 1H) 7.60 (d, J=7.98 Hz, 1H)
7.81 (m, 1H) 8.22 (dd, J=8.59, 1.53 Hz, 1H) 8.42 (m, 2H) 8.50 (m,
1H) 8.55 (d, J=8.90 Hz, 1H) 8.61 (m, 1H) 8.72 (m, 1H) 9.73 (s, 1H)
79
EXAMPLE 200
(1S)-1-Benzo[b]thiophen-3-ylmethyl-2-[5-(3-methyl-1H-indazol-5-yl)-pyridin-
-3-yloxy]-ethylamine
[0530] MS (DCI/NH.sub.3) m/z 415 (M+1); .sup.1HNMR (400 MHz, MeOD)
.delta. ppm 2.62 (s, 3H) 3.41 (dd, J=14.73, 6.75 Hz, 1H) 3.50 (dd,
J=14.42, 8.59 Hz, 1H) 4.12 (m, 1H) 4.32 (dd, J=10.43, 5.22 Hz, 1H)
4.45 (dd, J=10.74, 3.07 Hz, 1H) 7.40 (m, 2H) 7.55 (m, 1H) 7.61 (d,
J=8.90 Hz, 1H) 7.68 (dd, J=8.59, 1.53 Hz, 1H) 7.91 (m, 3H) 8.03 (s,
1H) 8.35 (s, 1H) 8.64,(s, 1H). 80
EXAMPLE 201
(1S)-2-[5-(3-Methyl-1H-indazol-5-yl)-pyridin-3-yloxy]-1-thiophen-3-ylmethy-
l-ethylamine
[0531] MS (DCI/NH.sub.3) m/z 365 (M+1).sup.+; .sup.1HNMR (500 MHz,
MeOD) .delta. ppm 2.63 (s, 3H) 3.43 (m, 2H) 3.98 (m, 1H) 4.40 (dd,
J=10.61, 5.62 Hz, 3H) 4.52 (dd, J=10.61, 3.12 Hz, 1H) 7.03 (dd,
J=8.42, 3.43 Hz, 1H) 7.06 (m, 1H) 7.36 (dd, J=4.99, 1.25 Hz, 1H)
7.64 (d, J=8.73 Hz, 1H) 7.75 (dd, J=8.73, 1.87 Hz, 1H) 8.14 (s, 1H)
8.21 (m, 1H) 8.47 (brs, 1H) 8.77 (s, 1H). 81
EXAMPLE 202
(1S)-1-Benzyloxymethyl-2-(5-isoquinolin-6-yl-pyridin-3-yloxy)-ethylamine
[0532] 82
Example 202A
(1S)-[1-Benzyloxymethyl-2-(5-bromo-pyridin-3-yloxy)-ethyl]-carbamic
Acid Tert-Butyl Ester
[0533] The product was prepared by substituting Boc-serinol(Bn) for
Boc-tryptophanol in Example 2A. MS m/z 437, 439 (M+H).sup.+;
.sup.1H NMR (300 MHz, DMSO-D6) .delta. ppm 1.37 (s, 9H) 3.50 (d,
J=6.10 Hz, 2H) 3.97 (m, 1H) 4.11 (m, 2H) 4.50 (s, 2H) 6.99 (d,
J=7.80 Hz, 1H) 7.29 (m, 5H) 7.70 (m, 1H) 8.28 (dd, J=4.75, 2.37 Hz,
2H). 83
Example 202B
(1S)-[1-Benzyloxymethyl-2-(5-isoquinolin-6-yl-pyridin-3-yloxy)-ethyl]-carb-
amic Acid Tert-Butyl Ester
[0534] The desired product was prepared by substituting 202A for
Example 2A in Example 27B. .sup.1H NMR (300 MHz, DMSO-D6) .delta.
ppm 1.38 (s, 9H) 3.56 (d, J=6.10 Hz, 2H) 4.04 (m, 1H) 4.22 (d,
J=5.43 Hz, 2H) 4.52 (s, 2H) 7.05 (d, J=8.14 Hz, 1H) 7.28 (m, 5H)
7.87 (m, 2H) 8.10 (dd, J=8.65, 1.53 Hz, 1H) 8.25 (d, J=8.82 Hz, 1H)
8.35 (d, J=2.71 Hz, 1H) 8.40 (s, 1H) 8.56 (d, J=5.76 Hz, 1H) 8.68
(d, J=1.70 Hz, 1H) 9.37 (s, 1H). 84
Example 202C
(1S)-1-Benzyloxymethyl-2-(5-isoquinolin-6-yl-pyridin-3-yloxy)-ethylamine
[0535] The desired product was prepared by substituting Example
202B for Example 27A in Example 202. in Example 27C. MS m/z 386
(M+1).sup.+; .sup.1H NMR (300 MHz, DMSO-D6) .delta. ppm 3.76 (m,
3H) 3.97 (s, 2H) 4.44 (m, 2H) 4.60 (s, 2H) 7.35 (m, 5H) 8.00 (m,
1H) 8.33 (m, 2H) 8.48 (d, J=2.71 Hz, 1H) 8.54 (d, J=8.81 Hz, 1H)
8.66 (s, 1H) 8.68 (d, J=6.10 Hz, 1H) 8.81 (d, J=1.70 Hz, 1H) 9.75
(s, 1H). 85
EXAMPLE 203
(1S)-1-Benzyloxymethyl-2-[5-(3-methyl-1H-indazol-5-yl)-pyridin-3-yloxy]-et-
hylamine
[0536] 86
Example 203A
5-Bromo-3-methyl-indazole-1-carboxylic Acid Tert-Butyl Ester
[0537] A solution of Example 102C (1.0 g; 4.7 mmol), TEA (526 mg;
5.2 mmol), DMAP (200 mg; 1.6 mmol) and di-tert-butyldicarbonate
(1.1 g; 5.0 mmol) in CH.sub.3CN (15 mL) was stirred at r.t. for 3
hrs, evaporated, and isolated by flash chromatography (30%
Et.sub.2O/hexane) to give the desired product as a white solid (1.4
g; 95%). 87
Example 203B
3-Methyl-5-trimethylstannanyl-indazole-1-carboxylic Acid Tert-Butyl
Ester
[0538] A solution of Example 203A (1.35 g; 4.3 mmol),
hexamethylditin (1.56 g; 4.8 mmol), and Pd(PPh.sub.3).sub.4 (250
mg, 0.22 mmol) in toluene (15 mL) was stirred overnight at
85.degree. C., evaporated and purified by flash chromatography (20%
Et.sub.2O/hexane) to provide the desired product (1.32 g; 77%).
88
Example 203C
(2S)-5-[5-(3-Benzyloxy-2-tert-butoxycarbonylamino-propoxy)-pyridin-3-yl]-3-
-methylindazole-1-carboxylic Acid Tert-Butyl Ester
[0539] The desired product was prepared by substituting 203B for
Example 27A in Example 202B. MS m/z 589 (M+H).sup.+; .sup.1H NMR
(300 MHz, DMSO-D6) .delta. ppm 1.38 (s, 9H) 1.66 (s, 9H) 2.59 (s,
3H) 3.32 (m, 1H) 3.56 (d, J=6.10 Hz, 2H) 4.20 (d, J=5.76 Hz, 2H)
4.52 (s, 2H) 7.03 (d, J=8.14 Hz, 1H) 7.27 (m, 1H) 7.32 (m, 4H) 7.78
(s, 1H) 8.00 (dd, J=8.82, 1.70 Hz, 1H) 8.12 (m, 1H) 8.26 (d, J=1.02
Hz, 1H) 8.29 (d, J=2.71 Hz, 1H) 8.61 (d, J=1.70 Hz, 1H). 89
Example 203D
(1S)-1-Benzyloxymethyl-2-[5-(3-methyl-1H-indazol-5-yl)-pyridin-3-yloxy]-et-
hylamine
[0540] The desired product was prepared by substituting 203C for
Example 27B in Example 27C. MS m/z 389 (M+H).sup.+; .sup.1H NMR
(300 MHz, DMSO-D6) .delta. ppm 2.57 (s, 3H) 3.79 (m, 3H) 4.51 (m,
2H) 4.60 (s, 2H) 4.90 (br s, 2H) 7.34 (m, 5H) 7.61 (d, J=8.81 Hz,
1H) 7.80 (dd, J=8.81, 1.70 Hz, 1H) 8.23 (s, 1H) 8.27 (s, 1H) 8.52
(m, 2H) 8.85 (d, J=1.70 Hz, 1H). 90
EXAMPLE 204
(1S)-2-(5-Isoquinolin-6-yl-pyridin-3-yloxy)-1-(naphthalen-2-yloxymethyl)-e-
thylamine
[0541] 91
Example 204A
(1S)-l
1-Hydroxymethyl-2-(5-isoquinolin-6-yl-pyridin-3-yloxy)-ethyl]-carba-
mic Acid Tert-Butyl Ester
[0542] To Example 202B (290 mg, 0.60 mmol) was added sequentially:
ammonium formate (377 mg, 5.97 mmol), MeOH (wet) (15 mL), and 10%
Pd/C (320 mg). The resulting black reaction mixture was warmed to
70.degree. C. for 6 d and then cooled to room temperature and
filtered through Celite. K.sub.2CO.sub.3 (50 mg) and silica gel
were added and the volatiles removed on a rotary evaporator. Flash
chromatography (2-3-5-7% MeOH/CH.sub.2Cl.sub.2) gave 40 mg (14%)
recovered starting material and 89 mg (38%) of as a colorless waxy
solid. R.sub.f=0.32 (10% MeOH/CH.sub.2Cl.sub.2); .sup.1H NMR (300
MHz, DMSO-D6) .delta. ppm 1.38 (s, 9H) 3.51 (td, J=5.76, 2.71 Hz,
2H) 3.84 (m, 1H) 4.19 (m, 2H) 4.84 (t, J=5.76 Hz, 1H) 6.82 (d,
J=8.14 Hz, 1H) 7.89 (m, 2H) 8.11 (dd, J=8.65, 1.53 Hz, 1H) 8.25 (d,
J=8.82 Hz, 1H) 8.36 (d, J=2.71 Hz, 1H) 8.41 (s, 1H) 8.56 (d, J=5.76
Hz, 1H) 8.68 (d, J=1.70 Hz, 1H) 9.37 (s, 1H). 92
Example 204B
(1S)-[2-(5-Isoquinolin-6-yl-pyridin-3-yloxy)-1-(naphthalen-2-yloxymethyl)--
ethyl]-carbamic Acid Tert-Butyl Ester
[0543] 2-Napthol (15 mg, 101 .mu.mol), Example 204A (20 mg, 51
.mu.mol), DBAD (17 mg, 76 .mu.mol), and PPh.sub.3-polymer (3
mmol/g) (34 mg, 101 .mu.mol) were combined in a 10 mL round bottom
flask. THF (2 mL) was added and the reaction mixture stirred 2 d at
23.degree. C. and then rotavapped with silica gel. Flash
chromatography (2-3-5-10% MeOH/CH.sub.2Cl.sub.2) gave 19 mg (73%)
of as a colorless waxy solid. R.sub.f=0.47 (10%
MeOH/CH.sub.2Cl.sub.2); .sup.1H NMR (300 MHz, DMSO-D6) .delta. ppm
1.41 (s, 9H) 4.24 (m, 3H) 4.37 (m, 2H) 7.19 (dd, J=8.82, 2.71 Hz,
1H) 7.34 (m, 3H) 7.45 (td, J=7.54, 1.19 Hz, 1H) 7.78 (s, 1H) 7.81
(s, 1H) 7.84 (s, 1H) 7.88 (d, J=5.76 Hz, 1H) 7.92 (s, 1H) 8.10 (dd,
J=8.48, 1.70 Hz, 1H) 8.24 (d, J=8.48 Hz, 1H) 8.40 (m, 2H) 8.56 (d,
J=5.76 Hz, 1H) 8.69 (d, J=1.70 Hz, 1H) 9.37 (s, 1H). 93
Example 204C
(1S)-2-(5-Isoquinolin-6-yl-pyridin-3-yloxy)-1-(naphthalen-2-yloxymethyl)-e-
thylamine
[0544] The desired product was prepared by substituting Example
204B for Example 27B in Example 27C. LCMS m/z 422 (M+1).sup.+;
.sup.1H NMR (300 MHz, DMSO-D6) .delta. ppm 3.54 (dt, J=11.44, 5.64
Hz, 1H) 4.23 (m, 4H) 7.20 (dd, J=8.98, 2.54 Hz, 1H) 7.34 (m, 2H)
7.45 (ddd, J=8.05, 6.87, 1.36 Hz, 1H) 7.81 (m, 3H) 7.88 (m, 2H)
8.09 (m, 1H) 8.24 (d, J=8.48 Hz, 1H) 8.38 (s, 1H) 8.42 (d, J=2.71
Hz, 1H) 8.55 (d, J=5.76 Hz, 1H) 8.67 (d, J=1.70 Hz, 1H) 9.37 (s,
1H).
EXAMPLE 205
(1S)-2-(5-Isoquinolin-6-yl-pyridin-3-yloxy)-1-(pyridin-3-yloxymethyl)-ethy-
lamine
[0545] The desired product was prepared as tri-TFA salt by
substituting 3-hydroxypyridine for 2-naphthol in Example 204. MS
m/z 373 (M+1).sup.+; .sup.1H NMR (300 MHz, DMSO-D6) .delta. ppm
4.10 (m, 1H) 4.48 (m, 4H) 7.44 (dd, J=8.65, 4.92 Hz, 1H) 7.54 (m,
1H) 7.96 (t, J=2.03 Hz, 1H) 8.09 (d, J=6.78 Hz, 1H) 8.21 (dd,
J=8.65, 1.53 Hz, 1H) 8.27 (d, J=4.75 Hz, 1H) 8.41 (m, 2H) 8.49 (m,
4H) 8.63 (d, J=5.76 Hz, 1H) 8.79 (d, J=1.70 Hz, 1H) 9.56 (s,
1H).
EXAMPLE 206
(1S)-2-(5-Isoquinolin-6-yl-pyridin-3-yloxy)-1-(quinolin-7-yloxymethyl)-eth-
ylamine
[0546] The desired product was prepared as trifluoroacedic acid
salt by substituting 7-hydroxyquinoline for 2-naphthol in Example
204. .sup.1H NMR (300 MHz, DMSO-D6) .delta. ppm 4.24 (m, 4H) 7.45
(m, 3H) 7.90 (m, 3H) 8.09 (dd, J=8.48, 1.70 Hz, 1H) 8.23 (s, 1H)
8.25 (s, 1H) 8.39 (s, 1H) 8.42 (d, J=2.71 Hz, 1H) 8.56 (d, J=5.43
Hz, 1H) 8.67 (d, J=1.70 Hz, 1H) 8.73 (dd, J=4.41, 1.70 Hz, 1H) 9.37
(s, 1H).
EXAMPLE 207
(2S)-4-[2-Amino-3-(5-isoquinolin-6-yl-pyridin-3-yloxy)-propoxy]-benzonitri-
le
[0547] The desired product was prepared as trifluoroacedic acid
salt by substituting 4-cyanophenol for 2-naphthol in Example 204.
.sup.1H NMR (300 MHz, DMSO-D6) .delta. ppm 2.27 (br s, 2H) 3.49 (m,
1H) 4.18 (m, 4H) 7.16 (m, 2H) 7.76 (m, 2H) 7.86 (dd, J=2.71, 2.03
Hz, 1.H) 7.89 (d, J=5.76 Hz, 1H) 8.09 (dd, J=8.65, 1.86 Hz, 1H)
8.25 (d, J=8.82 Hz, 1H) 8.39 (m, 2H) 8.56 (d, J=5.76 Hz, 1H) 8.68
(d, J=1.69 Hz, 1H) 9.37 (s, 1H).
EXAMPLE 208
(2S)-N'-(5-(3-methyl-1H-indazol-5-yl)-pyridin-3-yl)-3-phenyl-propane-1,2-d-
iamine
Example 208A
(2S)-{1-[(5-Bromo-pyridin-3-ylamino)-methyl]-2-phenyl-ethyl}-carbamic
Acid Tert-Butyl Ester
[0548] A solution of Example 23B (0.4 g, 2.3 mmol),
(1-formyl-2-phenyl-ethy)-carbamic acid tert-butyl ester (0.7 g, 2.8
mmol), and Ti(iPrO).sub.4 (10 ml) in CH.sub.2Cl.sub.2 (15 mL) was
stirred at room temperature for 2 h. The solvent was evaporated off
and the residue was dissolved in 15 ml of EtOH. The solution was
treated with NaBH.sub.3CN (0.5 g, 4.9 mmol) then stirred overnight
at room temperature. The mixture was diluted with ethyl acetate (50
ml), washed with water (25 ml) and brine (25 ml). The ethyl acetate
was evaporated off and the residue was purified by flash column
chromatography on silica gel, eluting with a solvent gradient of
1:4 to 1:1 ethyl acetate/hexane to give 0.28 g of product (30%).
MS: (ESI) m/z 408 (M+H).sup.+.
Example 208B
(2S)-5-[5-(2-tert-Butoxycarbonylamino-3-phenyl-propylamino)-pyridin-3-yl]--
3-methylindazole-1-carboxylic Acid Tert-Butyl Ester
[0549] The desired product was prepared by substituting Example
208A for Example 202A in Example 203C.
Example 208C
(2S)-N'-(5-(3-methyl-1H-indazol-5-yl)-pyridin-3-yl)-3-phenyl-propane-1,2-d-
iamine
[0550] The desired product was prepared by substituting Example
208B for Example 27B in Example 27C. MS: (ESI) m/z 358 (M+H).sup.+;
.sup.1H NMR (500 MHz, DMSO-D6) .delta. ppm 2.56 (d, J=3.74 Hz, 3H)
3.00 (m, 2H) 3.42 (d, J=5.30 Hz, 3H) 6.89 (m, 1H) 7.27 (m, 2H) 7.35
(m, 3H) 7.57 (s, 1H) 7.62 (d, J=4.06 Hz, 2H) 8.01 (s, 1H) 8.07 (m,
1H) 8.13 (s, 2H) 8.38 (s, 1H).
EXAMPLE 209
(2S)-N-(2-Amino-3-phenyl-propyl)-N-[5-(3-methyl-1H-indazol-5-yl)-pyridin-3-
-yl-methanesulfonamide
[0551] Example 208B (500 mg, 0.90 mmol) in pyridine (8 ml) was
added dropwise with methyl sulfonyl chloride (308 mg, 2.7 mmol) in
an ice-bath. The reaction mixture was allowed to warm up to rt and
stirred for 12 hrs. The solvent was removed by bubbling nitrogen to
the reaction flask. The residue was chromatographed on silica gel
eluting with EtOAc to give the Boc protected product, which was
deprotected according to the procedure described in Example 27C to
give the title compound as trifluoroacetic acid salt (21.2 mg, 4%).
MS (DCI/NH.sub.3) m/z 436 (M+1).sup.+; .sup.1HNMR (500 MHz, MeOD)
.delta. ppm 2.62 (s, 3H) 2.89 (dd, J=14.35, 9.36 Hz, 1H) 3.03 (s,
3H) 3.05 (dd, J=14.35, 5.62 Hz, 1H) 3.59 (m, 1H) 4.06 (d, J=5.93
Hz, 2H) 7.07 (s, 1H) 7.09 (s, 1H) 7.18 (d, J=7.18 Hz, 1H) 7.24 (m,
2H) 7.60 (s, 1H) 7.60 (s, 1H) 7.95 (s, 1H) 8.10 (t, J=1.87 Hz, 1H)
8.59 (s, 1H) 8.87 (s, 1H).
EXAMPLE 210
(2S)-N-(2-Amino-3-phenyl-propyl)-N-[5-(3-methyl-1H-indazol-5-yl)-pyridin-3-
-yl]-benzenesulfonamide
[0552] The desired product was prepared as trifluoroacetic acid
salt by substituting benzenesulfonyl chloride for methanesulfonyl
chloride in Example 209. MS (DCI/NH.sub.3) m/z 498 (M+1).sup.+;
.sup.1H NMR (500 MHz, DMSO-D6) .delta. ppm 2.55 (s, 3H) 2.84 (dd,
J=14.04, 8.42 Hz, 1H) 2.97 (dd, J=14.04, 5.62 Hz, 1H) 3.45 (m, 1H)
3.78 (m, 2H) 7.17 (s, 1H) 7.19 (s, 1H) 7.24 (d, J=7.18 Hz, 1H) 7.30
(m, 2H) 7.43 (s, 1H) 7.44 (d, J=0.62 Hz, 1H) 7.50 (dd, J=8.73, 1.56
Hz, 1H) 7.57 (d, J=8.42 Hz, 1H) 7.62 (m, 3H) 7.78 (t, J=7.49 Hz,
1H) 7.82 (s, 1H) 8.11 (s, 3H) 8.25 (d, J=2.18 Hz, 1H) 8.92 (d,
J=1.87 Hz, 1H).
EXAMPLE 211
(2S)-N-(2-Amino-3-phenyl-propyl)-N-[5-(3-methyl-1H-indazol-5-yl)-pyridin-3-
-yl]-benzamide
[0553] The desired product was prepared as trifluoroacetic acid
salt by substituting benzoyl chloride for methanesulfonyl chloride
in Example 209. MS (DCI/NH.sub.3) m/z 462 (M+1).sup.+; .sup.1H NMR
(500 MHz, DMSO-D6) .delta. ppm 2.54 (s, 3H) 2.90 (dd, J=14.04, 9.05
Hz, 1H) 3.03 (dd, J=14.04, 5.30 Hz, 1H) 3.65 (m, 1H) 4.09 (dd,
J=14.97, 4.06 Hz, 1H) 4.28 (dd, J=14.97, 8.42 Hz, 1H) 7.19 (m, 3H)
7.27 (m, 4H) 7.33 (m, 2H) 7.44 (dd, J=8.73, 1.56 Hz, 1H) 7.54 (d,
J=8.73 Hz, 1H) 7.75 (s, 1H) 7.86 (m, 1H) 8.09 (s, 3H) 8.22 (d,
J=2.18 Hz, 1H) 8.69 (d, J=1.87 Hz, 1H).
EXAMPLE 212
(2S)-N-(2-Amino-3-phenyl-propyl)-N-[5-(3-methyl-1H-indazol-5-yl)-pyridin-3-
-yl]-acetamide
[0554] The desired product was prepared as trifluoroacetic acid
salt by substituting acetyl chloride for methanesulfonyl chloride
in Example 209. MS (DCI/NH.sub.3) m/z 400 (M+1).sup.+; .sup.1H NMR
(400 MHz, MeOD) .delta. ppm 1.98 (s, 3H) 2.63 (s, 3H) 2.90 (dd,
J=14.12, 8.90 Hz, 1H) 3.02 (dd, J=13.81, 5.83 Hz, 1H) 3.68 (m, 1H)
3.76 (dd, J=15.04, 2.46 Hz, 1H) 4.31 (dd, J=15.04, 7.98 Hz, 1H)
7.25-7.11 (m, 6H) 7.64 (m, 2H) 8.00 (s, 1H) 8.03 (s, 1H) 8.46 (s,
1H) 8.93 s, 1H)
EXAMPLE 213
(2S)-3-[2-Amino-3-(1H-indol-3-yl)-propylidene]-5-isoquinolin-6-yl-1,3-dihy-
dro-indol-2-one
[0555] The desired product was prepared as trifluoroacetic acid
salt by substituting 5-bromooxindole for 5-bromo-7 aza-oxindole in
Example 44. MS (DCI/NH.sub.3) m/z 431 (M+1).sup.+; .sup.1HNMR (500
MHz, MeOD) .delta. ppm 3.26 (dd, J=14.35, 9.67 Hz, 1H) 3.57 (dd,
J=14.66, 4.06 Hz, 1H) 5.05 (dt, J=19.34, 4.06 Hz, 1H) 6.71 (m, 1H)
6.83 (d, J=9.98 Hz, 1H) 6.85 (m, 1H) 6.98 (d, J=8.42 Hz, 1H) 7.03
(m, 1H) 7.06 (d, J=8.11 Hz, 1H) 7.14 (d, J=1.56 Hz, 1H) 7.55 (dd,
J=8.73, 1.87 Hz, 1H) 7.64 (dd, J=8.11, 1.56 Hz, 1H) 7.69 (d, J=8.11
Hz, 1H) 7.94 (s, 1H) 8.18 (d, J=6.24 Hz, 1H) 8.31 (d, J=8.73 Hz,
1H) 8.52 (s, 1H) 9.55 (s, 1H).
EXAMPLE 214
(1S)-2-(5-Isoquinolin-6-yl-pyridin-3-yloxy)-1-(1-methyl-1H-indol-3-ylmethy-
l)-ethylamine
[0556] The title compound was prepared as trifluoroacetic acid salt
by substituting 5-bromo-7-azaindole (D. Mazeas, et al.,
Heterocycles 1990, 50, 1065) for 6-bromophthalimide in Example 32.
MS (DCI/NH.sub.3) m/z 384 (M+1).sup.+; .sup.1HNMR (500 MHz, MeOD)
.delta. ppm 3.29 (m, 1H) 3.33 (dd, J=8.11, 2.81 Hz, 1H) 4.03 (m,
1H) 4.36 (dd, J=10.61, 5.62 Hz, 1H) 4.49 (dd, J=10.61, 3.12 Hz, 1H)
6.69 (d, J=3.12 Hz, 1H) 7.02 (m, 1H) 7.10 (t, J=7.49 Hz, 1H) 7.25
(s, 1H) 7.36 (d, J=8.11 Hz, 1H) 7.57 (m, 2H) 8.08 (s, 1H) 8.45 (s,
2H) 8.58 (s, 1H) 8.80 (s, 1H).
EXAMPLE 215
(1S)-1-(1H-Indol-3-ylmethyl)-2-[5-(1H-pyrrolo[2,3-b]pyridin-5-yl)-pyridin--
3-yloxy]-ethylamine
Example 215A
(1S)-N-[1-(1H-Indol-3-ylmethyl)-2-(5-isoquinolin-6-yl-pyridin-3-yloxy)-eth-
yl]-2-nitro-benzenesulfonamide
[0557] To a solution of Example 27 (400 mg, 1.01 mmol) and DIEA
(1.06 mL, 6.06 mmol) in THF (30 mL) in ice-bath cooling was added
2-nitrobenzylsulfonyl chloride (896 mg, 4.04 mmol). The reaction
was allowed to warm up to rt for 12 hrs. The reaction mixture was
concentrated and the resulting crude oil was purified by flash
column chromatography eluting with EtOAc/Hex (1:1), EtOAc, and
EtOAc/MeOH (20:1) to give the title compound (267 mg, 46%). MS
(DCI/NH.sub.3) m/z 580(M+1).sup.+.
Example 215B
(1S)-N-[11-(1H-Indol-3-ylmethyl)-2-(5-isoquinolin-6-yl-pyridin-3-yloxy)-et-
hyl]-N-methyl-2-nitro-benzenesulfonamide
[0558] To a solution of Example 215A (260 mg, 0.45 mmol), MeOH (16
uL, 4.5 mmol), and Ph.sub.3P (591 mg, 2.25 mmol) in THF (10 mL) in
an ice-bath was added dropwise DEAD (392 mg, 2.25 mmol). The
reaction was allowed to ward up to rt for 12 hrs. The reaction
mixture was concentrated and the resulting crude oil was purified
by flash column chromatography eluting with EtOAc, and EtOAc/MeOH
(40:3) to give the title compound (47 mg, 18%). MS (DCI/NH.sub.3)
m/z 594(M+1).sup.+.
Example 215C
(1S)-1-(1H-Indol-3-ylmethyl)-2-[5-(1H-pyrrolo[2,3-b]pyridin-5-yl)-pyridin--
3-yloxy]-ethylamine
[0559] A mixture of Example 215B (47 mg, 0.08 mmol), PhSH (9.7 uL,
0.095 mmol), and K.sub.2CO.sub.3 (33 mg, 0.237 mmol) in DMF (5 mL)
was stirred at rt for 2 hrs. The reaction was Concentrated to
dryness. The resulting residue was purified on C18 HPLC to afford
the title compound (34.2 mg, 58%). MS (DCI/NH.sub.3) m/z
409(M+1).sup.+; .sup.1H NMR (500 MHz, MeOD) .delta. ppm 2.91 (s,
3H) 2.99 (brs, 1H) 3.37 (dd, J=14.66, 9.36 Hz, 1H) 3.43 (dd,
J=14.66, 5.93 Hz, 1H) 3.96 (m, 1H) 4.38 (dd, J=10.92, 4.37 Hz, 1H)
4.52 (dd, J=10.92, 2.81 Hz, 1H) 6.99 (dt, J=8.11, 0.94 Hz, 1H)
7.10(dt, J=8.11, 0.94 Hz, 1H) 7.25 (s, 1H) 7.36(d, J=8.11 Hz, 1H)
7.58 (d, J=8.11 Hz, 1H) 7.92 (m, 1H) 8.29 (dd, J=8.73, 1.87 Hz, 1H)
8.49 (d, J=6.55 Hz, 1H) 8.50 (s, 1H) 8.56 (s, 1H) 8.60 (d, J=8.73
Hz, 1H) 8.63 (d, J=6.55 Hz, 1H) 8.77 (s, 1H) 9.78 (s, 1H).
EXAMPLE 216
(1S)-2-{5-[2-(2-Fluoro-pyridin-4-yl)-vinyl]-pyridin-3-yloxy}-1-(1H-indol-3-
-ylmethyl)-ethylamine
Example 216A
2-Fluoro-4-vinylpyridine
[0560] A mixture of 2-fluoro-4-iodopyridine (2.23 g, 10.0 mmol),
tributyl vinyl tin (3.8 g, 12 mmol), and
Pd.sub.2Cl.sub.2(PPh.sub.3).sub.2 (703 mg, 1.0 mmol) in dioxane (20
mL) was heated under nitrogen at 80.degree. C. overnight. After
cooled, ethyl acetate (40 ml) and saturated KF aqueous solution
were added to the reaction mixture. The mixture was stirred for 30
min. The organic layer was separated and washed with water, dried
(MgSO.sub.4), and concentrated. The resulting residue was purified
by flash column chromatography eluting with hexane/ethyl acetate
(20:1) to provide the title compound (463 mg, 38%). .sup.1HNMR (500
MHz, CDCl.sub.3) .delta. ppm 5.55 (d, J=10.92 Hz, 1H) 5.99 (d,
J=17.47 Hz, 1H) 6.67 (dd, J=17.47, 10.61 Hz, 1H) 6.88 (m, 1H) 7.17
(dt, J=5.30, 1.56 Hz, 1H) 8.16 (d, J=5.30 Hz, 1H). 94
Example 216B
(1S)-[2-{5-[2-(2-Fluoro-pyridin-4-yl)-vinyl]-pyridin-3-yloxy}-1-(1H-indol--
3-ylmethyl)-ethyl]-carbamic Acid Tert-Butyl Ester
[0561] The desired product was prepared as a trifluoroacetic acid
salt by substituting Example 216A for 4-vinylpyridine in Example 2
(1.067 g, 84%). MS (DCI/NH.sub.3) m/z 489 (M+1).sup.+; .sup.1HNMR
(400 MHz, MeOD) .delta. ppm 1.42 (m, 9H) 2.98 (m, 1H) 3.04 (m, 1H)
3.14 (m, 1H) 4.09 (m, 2H) 4.25 (m, 1H) 6.96 (t, J=7.36 Hz, 1H) 7.07
(t, J=7.07 Hz, 1H) 7.09 (m, 1H) 7.20 (m, 1H) 7.29 (m, 2H) 7.45 (m,
2H) 7.59 (m, 2H) 8.16 (d, J=5.52 Hz, 1H) 8.19 (s, 1H) 8.32 (s,
1H).
EXAMPLE 217
(1S)-1-(1H-Indol-3-ylmethyl)-2-{5-[2-(2-methoxy-pyridin-4-yl)-vinyl]-pyrid-
in-3-yloxy}-ethylamine
Example 217A
(1S)-(1-(1H-Indol-3-ylmethyl)-2-{5-[2-(2-methoxy-pyridin-4-yl)-vinyl]-pyri-
din-3-yloxy}-ethyl)-carbamic Acid Tert-Butyl Ester
[0562] A mixture of Example 216B (100 mg, 0.2 mmol), NaOMe (25% in
MeOH) (1 mL) in MeOH (10 mL) was refluxed for 8 hrs. The mixture
was concentrated to give the crude product.
Example 217B
(1S)-1-(1H-Indol-3-ylmethyl)-2-{5-[2-(2-methoxy-pyridin-4-yl)-vinyl]-pyrid-
in-3-yloxy}-ethylamine
[0563] Example 217A was treated with TFA (1 mL) at rt for 10 min.
Upon Removal of the TFA, the crude product was purified on C18 HPLC
to give the title compound (101.8 mg, 69%). MS (DCI/NH.sub.3) m/z
401 (M+1).sup.+; .sup.1HNMR (400 MHz, MeOD) .delta. ppm 3.31 (m,
2H) 3.99 (s, 3H) 4.00 (m, 1H) 4.29 (dd, J=10.43, 5.52 Hz, 1H) 4.41
(dd, J=10.43, 3.07 Hz, 1H) 7.03 (m, 1H) 7.06 (s, 1H) 7.13 (m, 1H)
7.24 (s, 1H) 7.27 (dd, J=5.52, 1.23 Hz, 1H) 7.34 (d, J=16.26 Hz,
1H) 7.39 (d, J=8.29 Hz, 1H) 7.48 (d, J=16.57 Hz, 1H) 7.59 (d,
J=7.98 Hz, 1H) 7.87 (s, 1H) 8.16 (d, J=5.22 Hz, 1H) 8.40 (brs, 1H)
8.57 (brs, 1H).
EXAMPLE 218
(1S)-1-(1H-Indol-3-ylmethyl)-2-{5-[2-(2-phenoxy-pyridin-4-yl)-vinyl]-pyrid-
in-3-yloxy}-ethylamine
[0564] A mixture of Example 216B (50 mg, 0.1 mmol), phenol (94 mg,
1.0 mmol) and KOH (11.2 mg, 0.2 mmol) was heated at 140 C in a
sealed bottle for 2 hrs. The mixture was concentrated to dryness.
The residue was then treated with TFA (1 mL) at rt for 10 min. Upon
Removal of TFA, the crude product was purified on C18 HPLC to give
rhe title compound (4.3 mg, 5.3%). MS (DCI/NH.sub.3) m/z 463
(M+1).sup.+; .sup.1HNMR (400 MHz, MeOD) .delta. ppm 3.30 (m, 1H)
3.48 (dd, J=13.81, 7.06 Hz, 1H) 4.00 (m, 1H) 4.27 (dd, J=10.43,
5.83 Hz, 1H) 4.40 (dd, J=10.43, 3.07 Hz, 1H) 7.15-7.01 (m, 5H)
7.26-7.23 (m, 2H) 7.48-7.32 (m, 6H) 7.59 (d, J=7.98 Hz, 1H) 7.87
(m, 1H) 8.16 (d, J=5.52 Hz, 1H) 8.35 (s, 1H) 8.53 (s, 1H).
EXAMPLE 219
(1S)-2-{5-[2-(2-Benzylsulfanyl-pyridin-4-yl)-vinyl]-pyridin-3-yloxy}-1-(1H-
-indol-3-ylmethyl)-ethylamine
[0565] The title compound was prepared as trifloroacetic acid salt
by substituting benzylthiol for phenol in Example 218. MS
(DCI/NH.sub.3) m/z 493(M+1).sup.+; .sup.1HNMR (500 MHz, MeOD)
.delta. ppm 3.31 (m, 1H) 3.35 (m, 1H) 4.00 (m, 1H) 4.26 (dd,
J=10.61, 5.62 Hz, 1H) 4.39 (dd, J=10.61, 3.43 Hz, 1H) 4.48 (m, 2H)
7.03 (m, 1H) 7.13 (m, 1H) 7.27 (m, 6H) 7.40 (m, 4H) 7.47 (d,
J=16.53 Hz, 1H) 7.52 (m, 1H) 7.59 (d, J=7.80 Hz, 1H) 7.78 (s, 1H)
8.43 (d, J=5.30 Hz, 1H) 8.56 (s, 1H).
EXAMPLE 220
[4-(2-{5-[(2S)-2-Amino-3-(1H-indol-3-yl)-propoxy]-pyridin-3-yl}-vinyl)-pyr-
idin-2-yl]-cyclopropyl-amine
[0566] A mixture of Example 216 (100 mg, 0.2 mmol) and cyclopropyl
amine (1.5 mL) was heated at 125.degree. C. for 36 hrs. The mixture
was concentrated to dryness. The residue was then treated with TFA
(1 mL) at rt for 10 min. Upon removal of TFA, the crude product was
purified on C18 HPLC to give the title compound (4.1 mg, 3%). MS
(DCI/NH.sub.3) m/z 426(M+1).sup.+;
[0567] .sup.1HNMR (500 MHz, MeOD) .delta. ppm 0.74 (m, 2H) 1.03 (m,
2H) 2.71 (m, 1H) 3.29 (m, 1H) 3.34 (m, 1H) 4.00 (m, 1H) 4.27 (dd,
J=10.61, 5.62 Hz, 1H) 4.39 (dd, J=10.61, 3.43 Hz, 1H) 7.03 (m,
J=15.91 Hz, 1H) 7.10 (s, 1H) 7.13 (m, 1H) 7.23 (s, 1H) 7.26 (dd,
J=6.86, 1.56 Hz, 1H) 7.39-7.34 (m, 2H) 7.58 (d, J=5.30 Hz, 1H) 7.60
(d, J=3.12 Hz, 1H) 7.83 (m, 1H) 7.87 (d, J=6.86 Hz, 1H) 8.37 (s,
1H) 8.52 (s, 1H).
EXAMPLE 221
[4-(2-{5-[(2S)-2-Amino-3-(1H-indol-3-yl)-propoxy]-pyridin-3-yl}-vinyl)-pyr-
idin-2-yl]-benzyl-amine
[0568] The title compound was prepared as trifloroacetic acid salt
by substituting benzylamine for cyclopropylamine in Example 220
(38.2 mg, 23%). MS (DCI/NH.sub.3) m/z 476 (M+1).sup.+; .sup.1HNMR
.sup.1H NMR (500 MHz, MeOD) .delta. ppm 3.30 (m, 1H) 3.34 (m, 1H)
3.99 (m, 1H) 4.24 (dd, J=10.61, 5.62 Hz, 1H) 4.37 (dd, J=10.61,
3.12 Hz, 1H) 4.63 (s, 2H) 7.02 (m, 1H) 7.10 (m, 1H) 7.12 (m, 1H)
7.22 (m, 2H) 7.41 (m, 3H) 7.39-7.29(m, 4H) 7.57 (d, J=9.05 Hz, 1H)
7.59 (m, 1H) 7.73 (s, 1H) 7.82 (d, J=6.86 Hz, 1H) 8.37 (s, 1H) 8.52
(s, 1H).
EXAMPLE 222
[4-(2-{5-[(2S)-2-Amino-3-(1H-indol-3-yl)-propoxy]-pyridin-3-yl}-vinyl)-pyr-
idin-2-yl]-ethyl-amine
[0569] The title compound was prepared as trifloroacetic acid salt
by substituting ethylamine for cyclopropylamine in Example 220 (16
mg, 15%). MS (DCI/NH.sub.3) m/z 414(M+1).sup.+; .sup.1HNMR (400
MHz, MeOD) .delta. ppm 1.36 (t, J=7.06 Hz, 3H) 3.98 (m, 4H) 4.24
(dd, J=10.43, 5.52 Hz, 1H) 4.37 (dd, J=10.74, 3.38 Hz, 1H) 7.02 (m,
2H) 7.12 (d, J=8.29 Hz, 1H) 7.18 (d, J=8.29 Hz, 1H) 7.23 (s, 1H)
7.30 (d, J=16.26 Hz, 1H) 7.38 (d, J=8.90 Hz, 1H) 7.56 (d, J=11.97
Hz, 1H) 7.59 (d, J=3.68 Hz, 1H) 7.72 (s, 1H) 7.77 (d, J=7.06 Hz,
1H) 7.87 (m, 2H) 8.33 (s, 1H) 8.48 (s, 1H).
EXAMPLE 223
[4-(2-{5-[(2S)-2-Amino-3-(1H-indol-3-yl)-propoxy]-pyridin-3-yl}-vinyl)-pyr-
idin-2-yl]-methyl-amine
[0570] The title compound was prepared as trifloroacetic acid salt
by substituting methylamine for cyclopropylamine in Example 220
(11.9 mg, 8%). MS (DCI/NH.sub.3): m/z 400 (M+1).sup.+; .sup.1HNMR
(400 MHz, MeOD) .delta. ppm ppm 3.05 (s, 3H) 3.32 (m, 2H) 3.99 (m,
1H) 4.24 (dd, J=10.43, 5.52 Hz, 1H) 4.37 (dd, J=10.74, 3.38 Hz, 1H)
7.03 (m, 1H) 7.05 (m, 1H) 7.13 (m, 1H) 7.19 (d, J=7.06 Hz, 1H) 7.23
(m, 1H) 7.31 (d, J=16.57 Hz, 1H) 7.39 (d, J=7.36 Hz, 1H) 7.57 (d,
J=7.06 Hz, 1H) 7.60 (m, 1H) 7.74 (s, 1H) 7.80 (d, J=7.06 Hz, 1H)
8.41 (brs, 1H) 8.57 (brs, 1H).
EXAMPLE 224
(1S)-1-(1H-Indol-3-ylmethyl)-2-{5-[2-(2-indol-1-yl-pyridin-4-yl)-vinyl]-py-
ridin-3-yloxy}-ethylamine
[0571] A mixture of Example 216 (100 mg, 0.2 mmol), indole (48 mg,
0.4 mmol), and NaH (60%) (29 mg, 0.72 mmol) in DMF (5 mL) was
heated at 125.degree. C. for 1.5 hrs. The mixture was concentrated
to dryness. The residue was then treated with TFA (1 mL) at rt for
10 min. Upon removal of TFA, the crude product was purified on C18
HPLC to give the title compound (8.1 mg, 5%). MS (DCI/NH.sub.3) m/z
486(M+1).sup.+; .sup.1HNMR (500 MHz, MeOD) .delta. ppm 3.29 (m, 1H)
3.35 (m, 1H) 4.00 (m, 1H) 4.26 (dd, J=10.61, 5.93 Hz, 1H) 4.39 (dd,
J=10.29, 3.12 Hz, 1H) 6.73 (d, J=3.43 Hz, 1H) 7.05 (m, 1H)
7.11-7.18 (m, 2H) 7.24 (s, 1H) 7.26 (m, 1H) 7.63-7.38 (m, 6H) 7.75
(m, 1H) 7.80 (m, 1H) 7.84 (d, J=3.43 Hz, 1H) 8.22 (dd, J=8.42, 0.62
Hz, 1H) 8.32 (s, 1H) 8.52 (s, 1H) 8.53 (s, 1H).
EXAMPLE 225
(.+-.)-2-[5-(3-Methyl-1H-indazol-5-yl)-pyridin-3-yloxy]-1-(2-methyl-1H-ind-
ol-3-ylmethyl)-ethylamine
Example 225A
3-Bromo-2-hydroxyimino-propionic Acid Ethyl Ester
[0572] Ethyl bromopyruvate (5.0 mL, 39.8 mmol) was added to
hydroxylamine hydrochloride (2.52 g, 36.2 mmol) in H.sub.2O (10 mL)
and CHCl.sub.3 (10 mL). The reaction mixture was capped and stirred
overnight at 23.degree. C. at which time CH.sub.2Cl.sub.2 and
H.sub.2O were added, the layers separated, the organics dried over
Na.sub.2SO.sub.4, and the volatiles removed on a rotary evaporator
to yield 7.58 g (100%) of as a white solid. .sup.1H NMR (300 MHz,
DMSO-D6) .delta. ppm 1.26 (t, J=7.12 Hz, 3H) 4.20 (s, 2H) 4.24 (m,
2H) 13.19 (s, 1H).
Example 225B
2-Hydroxyimino-3-(2-methyl-1H-indol-3-yl)-propionic Acid Ethyl
Ester
[0573] The desired compound was prepared by a reference method (J.
Chem. Soc. Chem. Comm. 1979, 1089). To 2-methylindole (1.28 g, 9.76
mmol) and Na.sub.2CO.sub.3 (1.24 g, 11.7 mmol) in CH.sub.2Cl.sub.2
was added Example 225A (2.05 g, 9.76 mmol). The resulting reaction
mixture was stirred overnight at 23.degree. C. at which time
H.sub.2O was added, the layers separated, and the organics dried
over Na.sub.2SO.sub.4. Flash chromatography (20-30-50-70%
EtOAc/hexanes) gave 1.41 g (56%) of as a green solid. R.sub.f=0.30
(50% EtOAc/hexanes); MS m/z 261 (M+H).sup.+; .sup.1H NMR (300 MHz,
DMSO-D6) .delta. ppm 1.13 (t, J=7.12 Hz, 3H) 2.35 (s, 3H) 3.84 (s,
2H) 4.08 (q, J=7.12 Hz, 2H) 6.92 (m, 2H) 7.19 (d, J=7.80 Hz, 1H)
7.44 (d, J=7.46 Hz, 1H) 10.74 (s, 1H) 12.34 (s, 1H).
Example 225C
(.+-.)-2-tert-Butoxycarbonylamino-3-(2-methyl-1H-indol-3-yl)-propionic
Acid Ethyl Ester
[0574] The desired compound was prepared by a reference method
(Angew. Chem. Int. Ed. Engl. 1979, 78, and Tet. Lett. 1988, p447).
Aluminum foil (1.18 g, 43.8 mmol) was cut into long thin (1 cm)
strips then dipped into a 2% aqueous HgCl.sub.2 solution (30 sec
each strip). Each strip was immediately washed successively with
H.sub.2O, MeOH, then Et.sub.2O. Each strip was then immediately cut
into small pieces (.about.1.times.0.5 cm) into a solution of
Example 225B (1.14 g, 4.38 mmol) in THF (60 mL) and H.sub.2O (6 mL)
which was kept at room temperature with a water bath. The mixture
was stirred vigorously at 23.degree. C. After a short time fine
black solids began to form and much bubbling was observed. The
reaction mixture was stirred 3 h then filtered through Celite, and
the filter cake washed with Et.sub.2O. All volatiles were removed
on a rotary evaporator. MeOH (50 mL) was added followed by
Na.sub.2CO.sub.3 (0.51 g, 4.82 mmol) and Boc.sub.2O (1.00 g, 4.60
mmol). The resulting reaction mixture was stirred 30 min at
23.degree. C. and then silica gel was added and the volatiles
removed on a rotary evaporator. Flash chromatography (10-30-40-50%
EtOAc/hexanes) gave 1.33 g (88%) of as an off-white solid.
R.sub.f=0.68 (70% EtOAc/hexanes); MS m/z 345 (M-H).sup.+; .sup.1H
NMR (300 MHz, DMSO-D6) .delta. ppm 1.02 (t, J=7.12 Hz, 3H) 1.33 (s,
9H) 2.28 (s, 3H) 3.00 (m, 2H) 3.97 (q, J=7.12 Hz, 2 H) 4.10 (m, 1H)
6.94 (m, 2H) 7.14 (d, J=8.14 Hz, 1H) 7.21 (d, J=7.12 Hz, 1H) 7.38
(d, J=7.12 Hz, 1H) 10.73 (s, 1H).
Example 225D
(.+-.)-[2-Hydroxy-1-(2-methyl-1H-indol-3-ylmethyl)-ethyl]-carbamic
Acid Tert-Butyl Ester
[0575] To Example 225C (1.30 g, 3.75 mmol) and CaCl.sub.2
(anhydrous) (0.83 g, 7.51 mmol) in a 500 mL round bottom flask
equipped with a stirbar was added sequentially: EtOH (wet) (30 mL),
THF (20 mL) and NaBH.sub.4 (0.57 g, 15.0 mmol). The resulting
cloudy reaction mixture was stirred 1 h at 23.degree. C. and then
poured onto 1 M citric acid and extracted with EtOAc. The organic
extracts were washed with brine and dried over MgSO.sub.4. Silica
gel and NaHCO.sub.3 (100 mg) were added and the volatiles removed
on a rotary evaporator. Flash chromatography (35-50-60%
EtOAc/hexanes) gave 1.08 g (95%) of as a white solid. R.sub.f=0.51
(70% EtOAc/hexanes); MS m/z 303 (M-H).sup.+; .sup.1H NMR (300 MHz,
DMSO-D6) .delta. ppm 1.35 (s, 9H) 2.31 (s, 3H) 2.71 (m, 2H) 3.29
(t, J=5.42 Hz, 2H) 3.57 (m, 1H) 4.54 (t, J=5.42 Hz, 1H) 6.45 (d,
J=8.48 Hz, 1H) 6.92 (m, 2H) 7.19 (dd, J=6.78, 1.02 Hz, 1H) 7.48 (d,
J=7.12 Hz, 1H) 10.64 (s, 1H).
Example 225E
(.+-.)-[2-(5-Bromo-pyridin-3-yloxy)-1-(2-methyl-1H-indol-3-ylmethyl)-ethyl-
]-carbamic Acid Tert-Butyl Ester
[0576] The desried product was prepared by substituting Example
225D for Boc-tryptophanol in Example 2A. R.sub.f=0.41 (50%
EtOAc/hexanes); MS m/z 460, 462 (M+H).sup.+; .sup.1H NMR (300 MHz,
DMSO-D6) .delta. ppm 1.35 (s, 9H) 2.30 (s, 3H) 2.86 (m, 2H) 3.97
(s, 2H) 6.93 (m, 3H) 7.21 (d, J=7.80 Hz, 1H) 7.46 (d, J=7.46 Hz,
1H) 7.59 (s, 1H) 8.13 (dd, J=3.56, 2.20 Hz, 1H) 8.25 (dd, J=5.09,
2.03 Hz, 2H) 10.72 (s, 1H).
Example 225F
(.+-.)-[1-(2-Methyl-1H-indol-3-ylmethyl)-2-(5-trimethylstannanyl-pyridin-3-
-yloxy)-ethyl]-carbamic Acid Tert-Butyl Ester
[0577] Example 225D (350 mg, 0.76 mmol), Pd(PPh.sub.3).sub.4 (88
mg, 0.08 mmol) and hexamethylditin (300 mg, 0.92 mmol) were
combined in a 25 mL round bottom flask with a stirbar. The
atmosphere of the flask was evacuated and replaced with argon.
Toluene (4 mL) was added and the resulting reaction mixture warmed
to 100.degree. C. for 2 h and then cooled to room temperature.
EtOAc and silica gel were added and the volatiles removed on a
rotary evaporator. Flash chromatography (30-40-50-60% EtOAc/hexanes
gave 294 mg (71%) of as a yellow solid. R.sub.f=0.43 (70%
EtOAc/hexanes); MS m/z 546 (M+H).sup.+; .sup.1H NMR (300 MHz,
DMSO-D6) .delta. ppm 0.28 (s, 9H) 1.36 (s, 9H) 2.30 (s, 3H) 2.86
(m, 2H) 3.95 (s, 3H) 6.93 (m, 3H) 7.21 (d, J=7.80 Hz, 1H) 7.33 (d,
J=2.03 Hz, 1H) 7.44 (d, J=7.46 Hz, 1H) 8.14 (s, 2H) 10.72 (s,
1H).
Example 225G
(.+-.)-[2-[5-(3-Methyl-1H-indazol-5-yl)-pyridin-3-yloxy]-1-(2-methyl-]H-in-
dol-3-ylmethyl)-ethyl]-carbamic Acid Tert-Butyl Ester
[0578] Bromo-methylindazole (71 mg, 0.33 mmol), Example 225F (200
mg, 367 mmol), Pd.sub.2 dba.sub.3 (61 mg, 0.7 mmol), and
P(o-tol).sub.3 (41 mg, 0.14 mmol) were combined in a 10 mL round
bottom flask with a stirbar. DMF (2 mL) was added and the
atmosphere of the flask evacuated and replaced with argon twice.
Et.sub.3N (0.09 mL, 0.67 mmol) was added and the reaction mixture
warmed to 80.degree. C. for 5 h and then cooled to room
temperature. EtOAc was added and the resulting mixture filtered
through Celite. The filtrate was washed twice with H.sub.2O and
once with brine. Silica gel was added and the volatiles removed on
a rotary evaporator. Flash chromatography (70-85-100%
EtOAc/hexanes) gave 48 mg (28%) of as a yellow solid. R.sub.f=0.30
(EtOAc); MS m/z 512 (M+H).sup.+; .sup.1H NMR (300 MHz, DMSO-D6)
.delta. ppm 1.36 (s, 9H) 2.31 (s, 3H) 2.54 (s, 3H) 2.90 (m, 2H)
4.05 (m, 3H) 6.93 (m, 3H) 7.20 (m, 2H) 7.58 (m, 3H) 8.06 (s, 1H)
8.20 (d, J=2.71 Hz, 1H) 8.53 (d, J=1.70 Hz, 1H) 10.72 (s, 1H) 12.72
(s, 1H).
Example 225H
(.+-.)-2-[5-(3-Methyl-1H-indazol-5-yl)-pyridin-3-yloxy]-1-(2-methyl-1H-ind-
ol-3-ylmethyl)-ethylamine
[0579] The title compound was prepared as trifluoroacetic acid salt
by substituting Example 225G for Example 27B in Example 27C (31.9
mg, 84%). MS m/z 412 (M+H).sup.+; .sup.1H NMR (300 MHz, DMSO-D6)
.delta. ppm 2.33 (s, 3H) 2.55 (s, 3H) 2.75 (dd, J=14.41, 6.61 Hz,
1H) 2.92 (m, 1H) 3.18 (s, 2H) 3.99 (m, 2H) 4.09 (q, J=5.43 Hz, 1H)
6.89 (m, 1H) 6.96 (td, J=7.46, 1.02 Hz, 1H) 7.22 (d, J=7.80 Hz, 1H)
7.46 (d, J=7.46 Hz, 1H) 7.54 (d, J=8.82 Hz, 1H) 7.63 (m, 1H) 7.67
(m, 1H) 8.08 (s, 1H) 8.25 (d, J=2.37 Hz, 1H) 8.54 (d, J=1.70 Hz,
1H) 10.75 (s, 1H) 12.73 (s, 1H).
EXAMPLE 226
7-{5-[(2S)-2-Amino-3-(1H-indol-3-yl)-propoxy]-pyridin-3-yl}-quinazolin-2-y-
lamine
Example 226A
7-Bromo-quinazolin-2-ylamine
[0580] The 4-Bromo-2-fluoro-benzaldehyde (0.61 g, 3 mmol),
guanidine (1.05 g, 5.83 mmol) and DMF were heated at 140.degree. C.
for 2.5 hours. 50 ml water was added to the mixture. The orange
precipitate was filtered and washed with water. The solid was
dissolved in 2N HCl. and filtered. The HCl solution was neutralized
by ammonia hydroxyl. The off white solid was filtered and dried
under vacuum to afforded the desired product (91 mg, 14%). MS (ESI)
m/c 224 (M+1).sup.+; .sup.1H NMR (300 MHz, DMSO-D6) .delta. ppm
7.00 (br. s., 2H) 7.36 (d, J=8.82 Hz, 1H) 7.77 (dd, J=9.16, 2.37
Hz, 1H) 8.05 (d, J=2.37 Hz, 1H) 9.09 (br. s., 1H).
Example 226B
7-{5-[(2S)-2-Amino-3-(1H-indol-3-yl)-propoxy]-pyridin-3-yl}-quinazolin-2-y-
lamine
[0581] The desired product was prepared by substituting Example
226A for 6-bromophthalimide in Example 32 as the tri-TFA salt. MS
m/z 11 (M+H).sup.+, (M-H).sup.+; .sup.1H NMR (300 MHz, DMSO-D6)
.delta. ppm 2.85 (m, 1H) 3.01 (m, 1H) 3.32 (m, 1H) 4.06 (m, 2H)
6.96 (m, 3H) 7.05 (m, 1H) 7.22 (d, J=2.03 Hz, 1H) 7.34 (d, J=8.14
Hz, 1H) 7.54 (m, 1H) 7.68 (m, 1H) 8.05 (dd, J=8.99, 2.20 Hz, 1H)
8.19 (d, J=2.03 Hz, 1H) 8.30 (d, J=2.71 Hz, 1H) 8.57 (d, J=2.03 Hz,
1H) 9.16 (s, 1H) 10.88 (s, 1H).
EXAMPLE 227
2-Phenyl-2-(3-pyridin-4-yl-1H-pyrazolo[3,4-b]pyridin-6-yl)-ethylamine
Example 227A
(2,6-Difluoro-pyridin-3-yl)-pyridin-4-yl-methanol
[0582] To diisopropylamine (9.3 mL, 66.1 mmol) in THF (100 mL) at
-78.degree. C. was added n-BuLi (23.1 mL of a 2.5 M solution in
hexanes, 57.8 mmol) dropwise via syringe. 2,6-difluoropyridine (5.0
mL, 55.1 mmol) in THF (100 mL) at -78.degree. C. was added to the
above prepared LDA solution dropwise via canula to give a clear
yellow-green solution. isonicotinaldehyde (6.3 mL, 66.1 mmol) was
added causing a white precipitate to form. The reaction mixture was
warmed to room temperature and then glacial acetic acid (3.3 mL,
57.8 mmol) was added. Silica gel was added and the volatiles
removed on a rotary evaporator. Flash chromatography (80-100%
EtOAc/hexanes-3-5-7% MeOH/EtOAc) gave 8.48 g (69%) of as an off
white solid. R.sub.f=0.38 (5% MeOH/EtOAc); MS m/z 223 (M+H).sup.+;
.sup.1H NMR (300 MHz, DMSO-D6) .delta. ppm 5.91 (d, J=4.41 Hz, 1H)
6.49 (d, J=4.41 Hz, 1H) 7.20 (dd, J=8.31, 2.54 Hz, 1H) 7.36 (m, 2H)
8.19 (m, 1H) 8.53 (m, 2H); Found: 223, 221; Anal calcd for
C.sub.11H.sub.8F.sub.2N.sub.2O: C, 59.46; H, 3.63; N, 12.61. Found:
C: 59.45, H: 3.66, N: 12.62.
Example 227B
(2,6-Difluoro-pyridin-3-yl)-pyridin-4-yl-methanone
[0583] Example 227A (7.36 g, 33.1 mmol) and MnO.sub.2 (8.64 g, 99.4
mmol) were combined in a 500 mL round bottom flask with a stirbar.
1,4-dioxane (120 mL) was added and the resulting black mixture
warmed to 110.degree. C. MnO.sub.2 (.about.22 g) was added in 2 g
amounts every couple of hours over the next 2 days. The reaction
mixture was cooled to room temperature and filtered through Celite.
The filter cake was washed with EtOAc and then all volatiles were
removed on a rotary evaporator. Flash chromatography (50-70-80%
EtOAc/hexanes) gave 4.61 g (63%) of as a green solid. R.sub.f=0.58
(5% MeOH/EtOAc); MS m/z 221. (M+H).sup.+; .sup.1H NMR (300 MHz,
DMSO-D6) .delta. ppm 7.41 (ddd, J=8.14, 2.37, 0.68 Hz, 1H) 7.72 (m,
2H) 8.47 (dt, J=9.41, 8.01 Hz, 1H) 8.85 (m, 2H); Anal calcd for
C.sub.11H.sub.6F.sub.2N.sub.2O: C, 60.01; H, 2.75; N, 12.72. Found:
C: 60.05, H: 2.87, N: 12.97.
Example 227C
6-Fluoro-3-pyridin-4-yl-1H-pyrazolo[3,4-b]pyridine
[0584] To Example 227B (4.20 g, 19.1 mmol) in 1,4-dioxane (100 mL)
was added hydrazine hydrate (0.93 mL, 19.1 mmol). The resulting
yellow reaction mixture was stirred 20 min at 23.degree. C. and
then silica gel was added and the volatiles removed on a rotary
evaporator. Flash chromatography (60-80-100% EtOAc/hexanes-1-5%
MeOH/EtOAc) gave 2.49 g (61%) of as a white solid. R.sub.f=0.40 (5%
MeOH/EtOAc); MS m/z 215 (M+H).sup.+; .sup.1H NMR (300 MHz, DMSO-D6)
.delta. ppm 7.14 (dd, J=8.65, 0.85 Hz, 1H) 8.02 (m, 2H) 8.71 (m,
2H) 8.87 (dd, J=8.48, 7.80 Hz, 1H) 14.25 (s, 1H); Anal calcd for
C.sub.11H.sub.7FN.sub.4: C, 61.68; H, 3.29; N, 26.16. Found: C:
61.35, H: 3.35, N: 25.81.
Example 227D
Phenyl-(3-pyridin-4-yl-1H-pyrazolo[3,4-b]pyridin-6-yl)-acetonitrile
[0585] To a stirred mixture of Example 227C (0.96 g, 4.48 mmol) in
DMF (20 mL) at -35.degree. C. was added benzyl cyanide (1.55 mL,
13.4 mmol) and then NaH (0.57 g of 95% NaH, 22.4 mmol). The
resulting dark red mixture was stirred 15 min while being slowly
warmed to .about.-20.degree. C. At this time most of the bubbling
had stopped and the reaction mixture was then quickly warmed to
room temperature and then to 100.degree. C. overnight. The reaction
mixture was cooled to room temperature and saturated aqueous
NH.sub.4Cl was added. The mixture was extracted with EtOAc and the
organic extracts washed twice with H.sub.2O and once with brine.
Silica gel was added and the volatiles removed on a rotary
evaporator. Flash chromatography (60-80-100% EtOAc-3% MeOH/EtOAc)
gave 1.14 g (82%) of as an orange solid. R.sub.f=0.40 (5%
MeOH/EtOAc); MS m/z 312 (M+H).sup.+; .sup.1H NMR (300 MHz, DMSO-D6)
.delta. ppm 6.17 (s, 1H) 7.40 (m, 4H) 7.52 (m, 2H) 8.00 (m, 2H)
8.70 (m, 2H) 8.74 (d, J=8.48 Hz, 1H) 14.36 (s, 1 H); Anal Calcd for
C.sub.19H.sub.13N.sub.5: C, 73.30; H, 4.21; N, 22.49. Found: C:
73.09, H: 4.10, N: 22.58.
Example 227E
2-Phenyl-2-(3-pyridin-4-yl-1H-pyrazolo[3,4-b]pyridin-6-yl)-ethylamine
[0586] The desire product was prepared by substituting Example 227D
for Example 41C in Example 41D (84 mg, 27%). R.sub.f=0.33 (20%
MeOH/CH.sub.2Cl.sub.2); MS m/z 316 (M+H).sup.+; .sup.1H NMR (300
MHz, DMSO-D6) .delta. ppm 3.23 (m, 1H) 3.34 (br s, 3H) 3.52 (m, 1H)
4.34 (m, 1H) 7.27 (m, 6H) 7.99 (d, J=6.10 Hz, 2H) 8.57 (d, J=8.48
Hz, 1H) 8.68 (d, J=6.10 Hz, 2H).
EXAMPLE 228
Naphthalen-2-yl-(3-pyridin-4-yl-1H-pyrazolo[3,4-b]pyridin-6-yl)-acetonitri-
le
[0587] The desired product was obtained by substituting 2-napthyl
acetonitrile for benzyl nitrile in Example 227D (244 mg, 42%).
R.sub.f=0.46 (EtOAc); MS m/z 362 (M+H).sup.+; .sup.1H NMR (300 MHz,
DMSO-D6) .delta. ppm 6.36 (s, 1H) 7.44 (d, J=8.48 Hz, 1H) 7.57 (m,
3H) 7.98 (m, 6H) 8.09 (d, J=1.36 Hz, 1H) 8.69 (m, 2H) 8.75 (d,
J=8.48 Hz, 1H).
EXAMPLE 229
2-Naphthalen-2-yl-2-(3-pyridin-4-yl-1H-pyrazolo[3,4-b]pyridin-6-yl)-ethyla-
mine
[0588] The desire product was prepared by substituting Example 228
for Example 41C in Example 41D. MS m/z 366 (M+H).sup.+; .sup.1H NMR
(300 MHz, DMSO-D6) .delta. ppm 3.96 (m, 2H) 4.82 (t, J=7.46 Hz, 1H)
7.39 (d, J=8.48 Hz, 1H) 7.52 (m, 3H) 7.89 (m, 4H) 8.20 (d, J=6.10
Hz, 2H) 8.68 (d, J=8.48 Hz, 1H) 8.80 (m, 3H).
EXAMPLE 230
(3-Isoquinolin-6-yl-1H-pyrazolo[3,4-b]pyridin-6-yl)-phenyl-acetonitrile
Example 230A
Isoquinoline-6-carbaldehyde
[0589] A solution of 6-bromoisoquinoline (19.9 g, 95.6 mmol),
PdCl.sub.2(dppf).CH.sub.2Cl.sub.2 (1.8 g), and triethylamine (30
mL) in toluene (50 mL) was heated to 130.degree. C. under 850 psi
of H.sub.2/CO (1:1) for 4 h. After cooling to rt, the reaction
mixture was filtered. The filtrate was concentrated and the residue
was purified by flash chromatography eluting with 70-80-90-100%
EtOAc/hexanes to give 6.11 g (41%) of the aldehyde as a yellow
solid. R.sub.f=0.55 (EtOAc); .sup.1H NMR (300 MHz, DMSO-D6) .delta.
ppm 8.07 (m, 2H) 8.30 (dd, J=8.48, 0.68 Hz, 1H) 8.64 (s, 1H) 8.67
(d, J=5.76 Hz, 1H) 9.47 (s, 1H) 10.23 (s, 1H).
Example 230B
(3-Isoquinolin-6-yl-1H-pyrazolo[3,4-b]pyridin-6-yl)-phenyl-acetonitrile
[0590] The desired product (244 mg, 42%) was obtained by
substituting Example 230A for isonicotinaldehyde in Example 227.
R.sub.f=0.46 (EtOAc); MS m/z 362 (M+H).sup.+; .sup.1H NMR (300 MHz,
DMSO-D6) .delta. ppm 6.18 (s, 1H) 7.40 (m, 4H) 7.54 (m, 2H) 7.99
(d, J=5.76 Hz, 1H) 8.25 (d, J=8.48 Hz, 1H) 8.36 (m, 1H) 8.56 (d,
J=5.42 Hz, 1H) 8.63 (s, 1H) 8.87 (d, J=8.48 Hz, 1H) 9.35 (s, 1H)
14.27 (s, 1H).
EXAMPLE 231
2-(3-Isoquinolin-6-yl-1H-pyrazolo[3,4-b]pyridin-6-yl)-2-phenyl-ethylamine
[0591] The desire product was prepared by substituting Example 230
for Example 41C in Example 41D. MS m/z 366 (M+H).sup.+; .sup.1H NMR
(300 MHz, DMSO-D6) .delta. ppm 3.11 (m, 1H) 3.90 (m, 1H) 4.66 (dd,
J=9.16, 6.10 Hz, 1H) 7.31 (m, 8H) 8.28 (d, J=6.10 Hz, 1H) 8.42 (d,
J=8.82 Hz, 1H) 8.54 (d, J=8.48 Hz, 1H) 8.63 (d, J=6.44 Hz, 1H) 8.78
(s, 1H) 8.82 (d, J=8.48 Hz, 1H) 9.59 (s, 1H) 14.26 (s, 1H).
EXAMPLE 232
(1S)-1-Benzyl-2-(3-pyridin-4-yl-1H-pyrazolo[3,4-b]pyridin-5-yloxy)-ethylam-
ine
Example 232B
5-(tert-Butyl-dimethyl-silanyloxy)-2-fluoro-pyridine
[0592] A mixture of 2-fluoro-5-hydroxypyridine (1.00 g, 8.84 mmol)
and BDCS reagent (0.5M TBSCl, 1.0M imidazole in DMF) (35.4 mL, 17.7
mmol) was stirred at rt for 1 h. The reaction was poured into satd.
aqueous NaHCO.sub.3 solution. The aqueous layer was extracted with
ether. The combined extracts were washed with water, brine, dried
over MgSO.sub.4, and concentrated. The residue was purified by
flash column chromatography on silica gel eluting with 10% ethyl
acetate/hexanes to give the title compound (1.96 g, 98%).
Example 232B
5-(tert-Butyl-dimethyl-silanyloxy)-3-pyridin-4-yl-1H-pyrazolo[3,4-b]pyridi-
ne
[0593] The desired product was prepared according to the procedures
used for Example 227C by substituting Example 232A for
2,6-difluoropyridine in Example 227A.
Example 232C
5-(tert-Butyl-dimethyl-silanyloxy)-3-pyridin-4-yl-pyrazolo[3,4-b]pyridine--
1-carboxylic Acid Tert-Butyl Ester
[0594] The desired product was prepared by substituting Example
232B for Example 102C in Example 203A (75%).
Example 232D
5-Hydroxy-3-pyridin-4-yl-pyrazolo[3,4-b]pyridine-1-carboxylic Acid
Tert-Butyl Ester
[0595] A mixture of Example 232C (91 mg, 0.213 mmol) and TBAF (IM
in THF, 213 .mu.L, 0.213 mmol) in THF (10 mL) was stirred at rt for
5 min. Reaction was concentrated. Flash column chromatography
eluting with 5% methanol/CH.sub.2Cl.sub.2 to give the dedired
product purified the residue (75%).
Example 232E
5-((2S)-2-tert-Butoxycarbonylamino-3-phenyl-propoxy)-3-pyridin-4-yl-pyrazo-
lo[3,4-bipyridine-1-carboxylic Acid Tert-Butyl Ester
[0596] The title compound was prepared by substituting Example 232D
for Example 238A and Boc-phenylalaminol for
Boc-4'-bromophenylalaminol in Example 238B.
Example 232F
(1S)-1-Benzyl-2-(3-pyridin-4-yl-1H-pyrazolo[3,4-b]pyridin-5-yloxy)-ethylam-
ine
[0597] To Example 232E (39 mg, 71 .mu.mol) in CH.sub.2Cl.sub.2 (4
mL) was added 4-methoxybenzyl mercaptan (30 .mu.L, 214 .mu.mol) and
then TFA (1 mL). The resulting yellow reaction mixture was stirred
50 min at 23.degree. C. at which time all volatiles were removed on
a rotary evaporator. K.sub.2CO.sub.3 (excess) and MeOH (5 mL) were
added and the resulting mixture stirred 1 h at 23.degree. C. at
which time silica gel was added and the volatiles removed on a
rotary evaporator. Flash chromatography (EtOAc-5-10-12%
MeOH/CH.sub.2Cl.sub.2) gave a light yellow waxy product which was
dissolved in 20% MeOH/CH.sub.2Cl.sub.2 and stirred for 1 h with 1 N
HCl (1 mL of a 1 N solution in Et.sub.2O, 1 mmol). The volatiles
were removed to give 111 mg (17%, two steps) of a yellow solid
which was the bis-HCl salt. MS m/z 346 (M+H).sup.+; .sup.1H NMR
(300 MHz, DMSO-D6) .delta. ppm 2.92 (dd, J=13.73, 8.98 Hz, 1H) 3.12
(dd, J=14.24, 5.09 Hz, 1H) 4.14 (dd, J=5.59, 1.86 Hz, 1H) 4.74 (t,
J=5.93 Hz, 2H) 7.20 (m, 5H) 7.97 (d, J=2.37 Hz, 1H) 8.38 (m, 5H)
8.90 (d, J=6.78 Hz, 2H) 10.31 (s, 1H).
EXAMPLE 233
2-Benzyl-3-[5-(3-methyl-1H-indazol-5-yl)-pyridin-3-yloxy]-propylamine
[0598] The desired product was prepared as trifluoroacetic acid by
substituting (2-Benzyl-3-hydroxy-propyl)-carbamic acid tert-butyl
ester (Khumtaveepom, K.; Ullmann, A.; Matsumoto, K.; Davis, B. G.;
Jones, J. B. Tetrahedron: Asymmetry 2001, 12, 249) for Example
Boc-tryptophanol in Example 102. MS m/z 373 (M+H).sup.+,
(M-H).sup.+; .sup.1H NMR (300 MHz, DMSO-D6) .delta. ppm 2.55 (s,
3H) 2.81 (dd, J=7.29, 3.56 Hz, 2H) 2.92 (m, 1H) 3.05 (m, 1H) 4.09
(dd, J=10.17, 5.76 Hz, 2H) 4.16 (m, 2H) 7.28 (m, 5H) 7.57 (dd,
J=8.48, 0.68 Hz, 1H) 7.69 (m, 1H) 7.74 (m, 1H) 7.82 (s, 2H) 8.09
(m, 1H) 8.30 (d, J=2.71 Hz, 1H) 8.62 (d, J=1.70 Hz, 1H).
EXAMPLE 234
(1S)-1-(1H-Indol-3-ylmethyl)-2-(2-pyridin-4-yl-[1,7]naphthyridin-5-yloxy)--
ethylamine
Example 234A
3-Bromo-5-(4-methoxy-benzyloxy)-pyridine
[0599] 3-Bromo-5-hydroxypyridine (14.7 g, 84.3 mmol),
tetrabutylammonium iodide (0.3 g, 0.8 mmol), and K.sub.2CO.sub.3
(14.0 g, 101 mmol) were combined in a dry 500 mL round bottom flask
with a stirbar. DMF (170 mL) was added followed by PMBCl (12.0 mL,
88.5 mmol). The resulting brown colored mixture was stirred 3.5
days at 23.degree. C. and then silica gel was added and the
volatiles removed on a rotary evaporator. Flash chromatography
(10-20-40% EtOAc/hexanes) gave 14.1 g (57%) of as an orange solid.
R.sub.f=0.52 (50% EtOAc/hexanes) .sup.1H NMR (300 MHz, DMSO-D6)
.delta. ppm 3.32 (s, 3H) 5.12 (s, 2H) 6.96 (m, 2H) 7.39 (m, 2H)
7.79 (m, 1H) 8.28 (d, J=2.03 Hz, 1H) 8.34 (d, J=2.71 Hz, 1H).
.sup.13C NMR (100 MHz, DMSO-D6) .delta. ppm 55.0, 69.8, 113.8,
119.9, 124.0, 127.8, 129.8, 137.1, 142.1, 155.1, 159.2; Anal Calcd
for C.sub.12H.sub.10BrNO: C, 53.08; H, 4.11; N, 4.76. Found: C:
53.00, H: 3.98, N: 4.66.
Example 234B
3-Amino-5-(4-methoxy-benzyloxy)-pyridine
[0600] Example 234A (16.15 g, 54.9 mmol), Pd.sub.2 dba.sub.3 (0.50
g, 0.55 mmol), rac-BINAP (1.03 g, 1.65 mmol), and sodium
tert-butoxide (7.39 g, 76.9 mmol) were combined in a 500 mL round
bottom flask with a stirbar. Benzophenone imine (11.1 mL, 65.9
mmol) was added followed by toluene (180 mL). The resulting
reaction mixture was warmed to 80.degree. C. for 3 h and then
allowed to cool to room temperature, diluted with Et.sub.2O, and
filtered through Celite. The volatiles were removed on a rotary
evaporator. Flash chromatography (30-40-50% EtOAc/hexanes) yielded
an impure orange oil which was dissolved in THF (180 mL) and 1 N
HCl (60 mL). The resulting orange mixture was stirred 15 min and
then partitioned between 30% EtOAc/hexanes and 0.5 M HCl. The
layers were separated and the organic layer washed once with 0.5 M
HCl. The combined HCl layers were washed once with 30%
EtOAc/hexanes and then cooled to 0.degree. C. 50% aqueous NaOH was
added until the mixture was basic on litmus paper and then the
mixture was extracted twice with CH.sub.2Cl.sub.2. The combined
organic extracts were dried over Na.sub.2SO.sub.4 and the volatiles
removed on a rotary evaporator to yield 8.92 g (71%, two steps) of
as a yellow solid. .sup.1H NMR (300 MHz, DMSO-D6) .delta. ppm 3.75
(s, 3H) 4.97 (s, 2H) 4.97 (s, 2H) 5.29 (s, 2H) 6.54 (t, J=2.37 Hz,
1H) 7.35 (m, 2H) 7.50 (d, J=2.37 Hz, 1H) 7.54 (d, J=2.37 Hz, 1H),
.sup.13C NMR (100 MHz, DMSO-D6) .delta. ppm 55.0, 68.9, 105.6,
113.8, 125.3, 128.7, 129.3, 129.4, 145.7, 155.1, 159.0.
Example 234C
[5-(4-Methoxy-benzyloxy)-pyridin-3-yl]-carbamic Acid Tert-Butyl
Ester
[0601] To a stirred solution of Example 234B (8.92 g, 38.7 mmol) in
THF (240 mL) at 23.degree. C. was added NaHMDS (129 mL of a 0.6 M
solution in toluene, 77.5 mmol) dropwise via syringe. The resulting
cloudy yellow-brown mixture was stirred 5 min and then Boc.sub.2O
(8.45 g, 38.7 mmol) was added all at once. The cloudiness of the
mixture disappeared leaving a clear yellow-brown solution. 0.1 M
HCl was added and the resulting aqueous and organic layers
separated. The pH of the aqueous layer was 8. The organic layer was
washed with brine and then combined with silica gel before the
volatiles were removed on a rotary evaporator. Flash chromatography
(30-40-50-70% EtOAc/hexanes-5-10% MeOH/CH.sub.2Cl.sub.2) gave 1.69
(10%) of bis-Boc protected as an orange solid, 7.04 g (55%) of the
desired mono-Boc protected as a yellow solid, and 1.51 g (17%) of
starting amine as an orange solid. Data for bis-Boc: R.sub.f=0.38
(50% EtOAc/hexanes) .sup.1H NMR (300 MHz, DMSO-D6) .delta. ppm 1.35
(s, 18H) 3.75 (s, 3H) 5.11 (s, 2H) 6.94 (m, 2H) 7.39 (m, 2H) 7.43
(dd, J=2.71, 2.03 Hz, 1H) 8.02 (d, J=2.03 Hz, 1H) 8.28 (d, J=2.37
Hz, 1H). Data for mono-Boc: R.sub.f=0.30 (50% EtOAc/hexanes)
.sup.1H NMR (300 MHz, DMSO-D6) .delta. ppm 1.48 (s, 9H) 3.76 (s,
3H) 5.04 (s, 2H) 6.95 (m, 2H) 7.39 (m, 2H) 7.60 (t, J=2.20 Hz, 1H)
7.96 (d, J=2.71 Hz, 1H) 8.22 (d, J=2.03 Hz, 1H) 9.57 (s, 1H).
.sup.13C NMR (100 MHz, DMSO-D6) .delta. ppm 28.0, 55.0, 69.3, 79.6,
110.8, 113.8, 128.3, 129.6, 131.1, 132.3, 136.9, 152.7, 154.4,
159.1, Anal Calcd for C.sub.18H.sub.22N.sub.2- O.sub.4: C, 65.44;
H, 6.71; N, 8.48. Found: C: 65.40, H: 6.66, N: 8.40.
Example 234D
[4-Formyl-5-(4-methoxy-benzyloxy)-pyridin-3-yl]-carbamic Acid
Tert-Butyl Ester
[0602] To Example 234C (2.50 g, 7.54 mmol) in THF (125 mL) at
-78.degree. C. was added dropwise via syringe n-BuLi (6.64 mL of a
2.5 M solution in hexanes, 16.6 mmol). The resulting dark orange
reaction mixture was slowly warmed to -10.degree. C. over 45 min
and then recooled to -78.degree. C. Methyl formate (1.40 mL, 22.6
mmol) was added dropwise via syringe and the reaction was stirred
an additional 10 min at -78.degree. C. Saturated aqueous NH.sub.4Cl
was added and the quenched reaction mixture warmed to room
temperature. H.sub.2O and Et.sub.2O were added and the layers
separated. The organics were washed with brine and dried over
MgSO.sub.4. Flash chromatography (20-40-60-80% EtOAc/hexanes gave
0.3 g (12%) of recovered starting material, and 1.7 g (63%) of as a
yellow solid. (.sup.1H NMR (400 MHz, DMSO-D6) .delta. ppm 1.47 (s,
9H) 3.75 (s, 3H) 5.28 (s, 2H) 6.95 (d, J=8.59 Hz, 2H) 7.43 (d,
J=8.59 Hz, 2H) 8.38 (s, 1H) 9.07 (s, 1H) 10.17 (s, 1H) 10.35 (s,
1H), .sup.13C NMR (100 MHz, DMSO-D6) .delta. ppm 27.7, 55.0, 70.8,
81.1, 113.9, 114.6, 127.7, 129.6, 130.0, 133.3, 134.6, 151.7,
154.7, 159.2, 192.8, Anal Calcd for C.sub.19H.sub.22N.sub.2O.sub.5:
C, 63.67; H, 6.19; N, 7.82. Found: C: 63.59, H: 6.21, N: 7.64.
Example 234E
5-(4-Methoxy-benzyloxy)-[1,7naphthyridin-2-ol
[0603] To
Bis(2,2,2-trifluoroethyl)(methoxycarbonylmethyl)phosphonate (1.27
mL, 5.99 mmol) in THF (45 mL) at -78.degree. C. was added KHMDS
(11.I mL of a 0.5 M solution in toluene, 5.53 mmol) dropwise via
syringe. The resulting clear, light yellow solution was added
dropwise via canula to Example 234D (1.65 g, 4.60 mmol) in THF (60
mL) at -78.degree. C. The resulting cloudy yellow reaction mixture
was stirred 20 min at -78.degree. C. at which time saturated
aqueous NH.sub.4Cl was added and the quenched reaction mixture
warmed to room temperature. H.sub.2O and Et.sub.2O were added and
the layers separated. The organics were washed with brine and dried
over MgSO.sub.4. Flash chromatography (40-50-60-70% EtOAc/hexanes)
gave 1.98 g of impure product which was a 5:1 mixture of Z:E olefin
isomers. To the crude product in THF (150 mL) was added NaHMDS
(11.6 mL of a 0.6 M solution in toluene, 6.95 mmol). The resulting
reaction mixture was stirred 30 min at 23.degree. C. at which time
silica gel was added and the volatiles removed on a rotary
evaporator. Flash chromatography (60-100% EtOAc/hexanes-5-10%
MeOH/CH.sub.2Cl.sub.2) gave 0.23 g (12%) of E-olefin as a yellow
solid and the desired product 0.98 g (75%, two steps) of as a white
solid. R.sub.f=0.32 (10% MeOH/CH.sub.2Cl.sub.2), .sup.1H NMR (400
MHz, DMSO-D6) .delta. ppm 3.77 (s, 3H) 5.27 (s, 2H) 6.68 (d, J=9.51
Hz, 1H) 6.98 (m, 2H) 7.46 (m, 2H) 8.00 (d, J=9.82 Hz, 1H) 8.18 (s,
1H) 8.31 (s, 1H) 11.98 (s, 1H), .sup.13C NMR (100 MHz, DMSO-D6)
.delta. ppm 55.0, 70.2, 113.7, 113.9, 125.7, 125.8, 128.1, 129.5,
131.0, 132.7, 134.9, 149.3, 159.2, 161.2, Anal Calcd for
C.sub.16H.sub.14N.sub.2O.sub.3: C, 68.07; H, 5.00; N, 9.92. Found:
C: 67.75, H: 4.89, N: 9.88.
Example 234F
2-Chloro-5-(4-methoxy-benzyloxy)-[1,7]naphthyridine
[0604] To a suspension of Example 234D (2.21 g, 7.83 mmol) in DMF
(50 mL) at 23.degree. C. was added POCl.sub.3 (2.2 mL, 23.5 mmol).
All the solid starting material dissolved and the resulting yellow
reaction mixture was warmed to 45.degree. C. for 6 h. The color of
the reaction changed from yellow to dark red-brown. The reaction
was poured onto NaHCO.sub.3 (13.2 g 157 mmol) in ice water (250 mL)
in a 1 L Ehrlenmeyer flask with vigorous stirring. The product was
extracted with EtOAc and Et.sub.2O and the organic extracts washed
twice with H.sub.2O and once with brine. Silica gel was added and
the volatiles removed on a rotary evaporator. Flash chromatography
(20-30-45-50% EtOAc/hexanes) gave 1.86 g (79%) of as an off-white
solid. R.sub.f=0.65 (10% MeOH/CH.sub.2Cl.sub.2), .sup.1H NMR (400
MHz, DMSO-D6) .delta. ppm 3.79 (s, 3H) 5.35 (s, 2H) 6.99 (d, J=8.59
Hz, 2H) 7.51 (d, J=8.90 Hz, 2H) 7.77 (d, J=8.90 Hz, 1H) 8.47 (s,
1H) 8.52 (dd, J=8.90, 0.61 Hz, 1H) 8.96 (s, 1H), .sup.13C NMR (100
MHz, DMSO-D6) .delta. ppm 55.0, 70.4, 113.9, 121.8, 125.9, 126.5,
127.9, 129.6, 133.7, 142.4, 144.0, 148.5, 151.7, 159.2; Anal Calcd
for C.sub.16H.sub.13ClN.sub- .2O.sub.2: C, 63.90; H, 4.36; N, 9.31.
Found: C: 63.54, H: 4.17, N: 9.14.
Example 234G
5-(4-Methoxy-benzyloxy)-2-pyridin-4-yl-[1,7]naphthyridine
[0605] Example 234F (164 mg, 0.55 mmol), 4-tributylstannylpyridine
(401 mg, 1.09 mmol), Pd.sub.2 dba.sub.3 (50 mg, 0.06 mmol), and
2-dicyclohexylphosphino-2'-(N,N-dimethylamino)biphenyl (43 mg, 0.11
mmol) were combined in a 10 mL round bottom flask with a stirbar.
The atmosphere of the flask was evacuated and replaced with argon
twice. DMF (2 mL) and Et.sub.3N (0.5 mL, 3.27 mmol) were added and
the reaction mixture warmed to 100.degree. C. for 5 h. The reaction
mixture was cooled to room temperature, diluted with EtOAc and
Et.sub.2O, and filtered through Celite. The filtrate was washed
twice with H.sub.2O and once with brine. Silica gel was added and
the volatiles removed by rotary evaporation. Flash chromatography
(70-100% EtOAc/hexanes-2-5% MeOH/CH.sub.2Cl.sub.2 gave 92 mg (49%)
of as a yellow solid. R.sub.f=0.39 (10% MeOH/CH.sub.2Cl.sub.2),
.sup.1H NMR (400 MHz, DMSO-D6) .delta. ppm 3.79 (s, 3H) 5.37 (s,
2H) 7.01 (m, 2H) 7.53 (m, 2H) 8.21 (d, J=5.83 Hz, 2H) 8.43 (m, 2H)
8.64 (d, J=8.59 Hz, 1H) 8.80 (d, J=4.30 Hz, 2H) 9.13 (s, 1H),
.sup.13C NMR (100 MHz, DMSO-D6) .delta. ppm 55.1, 70.3, 113.9,
121.3, 122.1, 122.6, 126.0, 128.1, 129.6, 131.3, 142.7, 144.6,
145.8, 148.4, 150.5, 155.5, 159.2; Anal Calcd for
C.sub.21H.sub.17N.sub.3O.sub.2- : C, 73.45; H, 4.99; N, 12.24.
Found: C: 73.32, H: 5.10, N: 12.17.
Example 234I
2-Pyridin-4-yl-[1,7]naphthyridin-5-ol
[0606] To Example 234H (108 mg, 0.32 mmol) in a 50 mL round bottom
flask with a stirbar was added a mixture of 1 N HCl (1.6 mL, 1.57
mmol) in EtOH (8 mL). The resulting reaction mixture was warmed to
90.degree. C. for 2 h, cooled to room temperature, and then poured
onto K.sub.2CO.sub.3 (120 mg, 0.87 mmol) in a 100 mL round bottom
flask. MeOH (10 mL) was added and the mixture was stirred
vigorously for 1 h at which time silica gel was added and the
volatiles removed on a rotary evaporator. Flash chromatography
(3-5-7-12% MeOH/CH.sub.2Cl.sub.2) gave 52 mg (74%) of as an
off-white solid. R.sub.f=0.24 (10% MeOH/CH.sub.2Cl.sub.2); MS m/z
224 (M+H).sup.+; .sup.1H NMR (300 MHz, DMSO-D6) .delta. ppm 8.20
(s, 1H) 8.24 (m, 2H) 8.44 (d, J=8.82 Hz, 1H) 8.69 (d, J=8.82 Hz,
1H) 8.80 (m, 2H) 9.01 (s, 1H) 10.91 (Br S, 1H).
Example 234J 5
(1S)-[1-(1H-Indol-3-ylmethyl)-2-(2-pyridin-4-yl-[1,7]naphth-
yridin-5-yloxy)-ethyl]-carbamic Acid Tert-Butyl Ester
[0607] The desired product was prepared by substituting Example
2321 for 3-bromo-5-hydroxypyridine in Example 27A. R.sub.f=0.41
(10% MeOH/CH.sub.2Cl.sub.2); .sup.1H NMR (300 MHz, DMSO-D6) .delta.
ppm 1.37 (s, 9H) 3.07 (m, 1H) 3.38 (m, 1H) 4.25 (m, 3H) 6.93 (m,
1H) 7.05 (td, J=7.54, 1.19 Hz, 1H) 7.15 (d, J=2.03 Hz, 1H) 7.21 (d,
J=7.80 Hz, 1H) 7.33 (d, J=7.80 Hz, H) 7.56 (d, J=7.80 Hz, 1H) 8.27
(m, 3H) 8.51 (d, J=8.82 Hz, 1H) 8.82 (m, 3H) 9.13 (s, 1H) 10.82 (s,
1H).
Example 234K
(1S)-1-(1H-Indol-3-ylmethyl)-2-(2-pyridin-4-yl-[1,7]naphthyridin-5-yloxy)--
ethylamine
[0608] The desire product was prepared as trifluoroacetic acid salt
by substituting Example 234K for Example 232D in Example 232E. MS
m/z 396 (M+H).sup.+; .sup.1H NMR (300 MHz, DMSO-D6) (of the free
base) .delta. ppm 2.96 (m, 1H) 3.11 (m, 1H) 3.24 (m, 1H) 3.61 (s,
1H) 4.09 (q, J=5.09 Hz, 1H) 4.16 (dd, J=9.49, 6.10 Hz, 1H) 4.26 (m,
1H) 6.93 (m, 1H) 7.06 (td, J=7.46, 1.02 Hz, 1H) 7.22 (d, J=2.37 Hz,
1H) 7.34 (d, J=8.14 Hz, 1H) 7.58 (d, J=8.14 Hz, 1H) 8.27 (m, 3H)
8.51 (d, J=8.82 Hz, 1H) 8.82 (m, 2H) 8.89 (d, J=8.82 Hz, 1H) 9.14
(s, 1H) 10.88 (s, 1H).
EXAMPLE 235
(1R)-1-(1H-Indol-3-ylmethyl)-2-(2-pyridin-4-yl-[1,7]naphthyridin-5-yloxy)--
ethylamine
[0609] The desired product was prepared by substituting
Boc-R-Tryptophanol for Boc-L-tryptophanol in Example 234. MS m/z
396 (M+H).sup.+; .sup.1H NMR (300 MHz, DMSO-D6) .delta. ppm 3.31
(m, 2H) 4.34 (dd, J=10.51, 5.42 Hz, 1H) 4.50 (dd, J=10.68, 2.54 Hz,
1H) 6.95 (m, 1H) 7.08 (m, 1H) 7.29 (d, J=2.03 Hz, 1H) 7.37 (d,
J=8.14 Hz, 1H) 7.63 (d, J=7.80 Hz, 1H) 8.30 (s, 1H) 8.65 (m, 6H)
8.99 (d, J=5.76 Hz, 2H) 9.23 (s, 1H) 9.29 (m, 1H) 11.04 (d, J=1.70
Hz, 1H).
EXAMPLE 236
(1S)-1-(1H-Indol-3-ylmethyl)-2-(5-isoquinolin-6-yl-pyridin-3-ylsulfanyl)-e-
thylamine
Example 236A
3-Bromo-5-(4-methoxy-benzylsulfanyl)-pyridine
[0610] To a suspension of sodium hydride (370 mg, 60% in mineral
oil, 9.25 mmol) in DMF (30 ml) (4-Methoxy-phenyl)-methanethiol
(1.25 ml, 9 mmol) was added. The resulting solution was stirred at
room temperature for 1 hour and added to 3.5-dibromopyridine (2.13
g, 8.99 mmol) in DMF (30 ml). The mixture was stirred at room
temperature for 48 hours. The reaction solution was partitioned
between ether and water. The organic layer was washed (brine),
dried (Na.sub.2SO.sub.4), filtered and concentrated under vacuum.
Purification on silica gel eluting with 5% ethyl acetate/hexane
provides the title compound (1.75 g, 63%). MS (DCI/NH.sub.3) m/e
310 (M+1).sup.+; .sup.1H NMR (300 MHz, DMSO-D6) .delta. ppm 3.72
(s, 3H) 4.30 (s, 2H) 6.85 (d, J=2.03 Hz, 1H) 6.89 (d, J=2.37 Hz,
1H) 7.26 (d, J=2.37 Hz, 1H) 7.29 (d, J=2.03 Hz, 1H) 8.04 (dd,
J=2.03 Hz, 1H) 8.45 (d, J=2.03 Hz, 1H) 8.48 (d, J=2.03 Hz, 1H).
Example 236B
5-Bromo-pyridine-3-thiol
[0611] A mixture of Example 236A (1.43 g, 4.6 mmol), m-cresol (4.9
ml, 47 mmol) and TFA (4 ml) was refluxed for 24hours. After cooled
to room temperature, the solution was dried by vacuum. Purification
on silica gel eluted with 5% ethyl acetate in hexanes to provide
the crude title compound (contaminated with disulfide).
Example 236C
(1S)-[2-(5-Bromo-pyridin-3-ylsulfanyl)-1-(1H-indol-3-ylmethyl)-ethyl]-carb-
amic Acid Tert-Butyl Ester
[0612] A 100 ml RBF was charged with Example 236B (0.620 mg, 3.26
mmol), 2-Hydroxy-1-(1H-indol-3-ylmethyl)-ethyl]-carbamic acid
tert-butyl ester (1.077 g, 3.71 mmol), Ph.sub.3P (1.23 g, 4.69
mmol) and DBAD (1.0968 g, 4.763 mmol). THF (10 ml) was added at
0.degree. C. The reaction mixture was stirred at 0.degree. C. for 1
h and at room temperature for 22 hours. The reaction mixture was
concentrated and the residue was separated by flash chromatography
(30% EtOAc in hexane) to provide 0.614 g product with DBAD.
Example 236D
(1S)-1-(1H-Indol-3-ylmethyl)-2-(5-isoquinolin-6-yl-pyridin-3-ylsulfanyl)-e-
thylamine
[0613] The desired compound was prepared by substituting Example
236C for Example 2A in Example 27. MS (ESI) m/e 411 (M+1).sup.+;
.sup.1H NMR (300 MHz, DMSO-D6) .delta. ppm 3.13 (m, 2H) 3.37 (m,
2H) 3.57 (m, 1H) 6.90 (t, J=8.14 Hz, 1H) 7.02 (t, J=8.14 Hz, 1H)
7.25 (d, J=2.37 Hz, 1H) 7.31 (d, J=8.14 Hz, 1H) 7.47 (m, 1H) 8.06
(br. s., 2H) 8.18 (m, 2H) 8.28 (t, J=2.03 Hz, 1H) 8.46 (m, 1H) 8.52
(br. s., 1H) 8.67 (d, J=6.10 Hz, 1H) 8.69 (d, J=2.03 Hz, 1H) 8.97
(d, J=2.03 Hz, 1H) 9.66 (br. s., 1H) 11.03 (br. s., 1H).
EXAMPLE 237
(1S)-1-(1H-Indol-3-ylmethyl)-2-[5-(3-methyl-1H-indazol-5-yl)-pyridin-3-yls-
ulfanyl]-ethylamine
[0614] The title compound was prepared by substituting Example 102C
for 6-bromoisoquinoline in Example 236. MS (ESI) m/e 414
(M+1).sup.+; .sup.1H NMR (300 MHz, MeOH) .delta. ppm 3.20 (d,
J=6.78 Hz, 2H) 3.25 (m, 1H) 3.50 (m, 1H) 3.69 (m, 1H) 6.91 (td,
J=8.14, 6.10, 1.02 Hz, 1H) 7.02 (td, J=8.14, 6.10, 1.02 Hz, 1H)
7.15 (br. s., 1H) 7.26 (d, J=8.14 Hz, 1H) 7.40 (d, J=8.14 Hz, 1H)
7.53 (t, J=8.82 Hz, 1H) 7.60 (d, J=8.82 Hz, 1H) 7.93 (m, 1H) 8.12
(t, J=2.03 Hz, 1H) 8.51 (br. s., 1H) 8.74 (br. s., 1H).
EXAMPLE 238
(1S)-1-(4-Bromo-benzyl)-2-[5-(3-methyl-1
H-indazol-5-yl)-pyridin-3-yloxy]-- ethylamine
Example 238A
5-(5-Hydroxy-pyridin-3-yl)-3-methyl-indazole-1-carboxylic Acid
Tert-Butyl Ester
[0615] The desired product was prepared by substituting
3-bromo-5-hydroxypyridine for Example 203B in Example 203C.
Example 238B
(1S)-{1-(4-Bromo-benzyl)-2-[5-(3-methyl-1H-indazol-5-yl)-pyridin-3-yloxy]--
ethyl}-carbamic Acid Tert-Butyl Ester
[0616] The desired product was prepared according to the procedures
described for Example 2A, substituting Example 238A for
3-bromo-5-hydroxypyridine, and 3'-bromo-Boc-phenylalaminol for
Boc-tryptophanol in Example 2A.
Example 238C
(1S)-1-(4-Bromo-benzyl)-2-[5-(3-methyl-1H-indazol-5-yl)-pyridin-3-yloxy]-e-
thylamine
[0617] The desired product was prepared as trifluoroacetic acid
salt by substituting Example 238B for Example 27B in Example 27. MS
(ESI) m/e 437 (M+1); .sup.1H NMR (300 MHz, TRIFLUOROACETIC ACID-D)
.delta. ppm 3.16 (s, 3H) 3.46 (m, 2H) 4.48 (m, 1H) 4.86 (m, 2H)
7.34 (m, 2H) 7.70 (m, 2H) 8.24 (m, 2H) 8.57 (m, 2H) 8.86 (m, 1H)
9.07 (m, 1H).
EXAMPLE 239
(1S)-1-(1H-Indol-3-ylmethyl)-2-[5-(2-methyl-quinazolin-7-yl)-pyridin-3-ylo-
xy]-ethylamine
Example 239A
7-Bromo-2-methyl-quinazoline
[0618] The 4-Bromo-2-fluoro-benzaldehyde (1 g, 4.9 mmol),
acetamidine and DMA were mixed and heated to 140.degree. C. for 5
hours. The mixture was cooled to room temperature and dried under
vacuum. The mixture was purified by flash column afforded 47 mg
product in 4% yield. MS (ESI) m/e 223 (M+1).sup.+.
Example 239B
(1S)-1-(1H-Indol-3-ylmethyl)-2-[5-(2-methyl-quinazolin-7-yl)-pyridin-3-ylo-
xy]-ethylamine
[0619] The desired product was prepared by substituting Example
239A for 6-bromophthalimide in Example 32. MS (ESI) m/e 410
(M+1).sup.+; .sup.1H NMR (300 MHz, DMSO-D6) .delta. ppm 2.57 (s,
3H) 3.10 (m, 2H) 3.85 (m, 1H) 4.29 (m, 1H) 4.46 (m, 1H) 7.39 (m,
5H) 7.62 (dd, J=8.81, 0.68 Hz, 1H) 7.80 (dd, J=8.81, 1.70 Hz, 1H)
8.28 (d, J=0.68 Hz, 2H) 8.56 (m, 5H) 8.89 (d, J=1.70 Hz, 1H).
EXAMPLE 240
(1S)-1-(1H-Indol-3-ylmethyl)-2-[5-(1H-indol-5-yl)-pyridin-3-yloxy]-ethylam-
ine
[0620] The desired product was prepared by substituting
5-bromoindole for 6-bromophthalimide in Example 32. MS (ESI) m/e
383 (M+1).sup.+; .sup.1H NMR (300 MHz, DMSO-D6) .delta. ppm 3.58
(m, 1H) 4.09 (m, 3H) 4.18 (m, 1H) 6.67 (br. s., 2H) 6.98 (m, 1H)
7.08 (m, 1H) 7.27 (m, 3H) 7.38 (m, 4H) 7.50 (m, 1H) 7.60 (m, 2H)
7.88 (br. s., 1H) 8.23 (br. s., 1H) 8.51 (br. s., 1H).
EXAMPLE 241
(1S)-1-(1H-Indol-3-ylmethyl)-2-{5-[4-(1H-tetrazol-5-yl)-phenyl]-pyridin-3--
yloxy}-ethylamine
[0621] The desired product was prepared by substituting
5-(4-bromo-phenyl)-1H-tetrazole for 6-bromophthalimide in Example
32. MS (ESI) m/e 412 (M+1).sup.+; .sup.1H NMR (300 MHz, Solvent)
.delta. ppm 3.24 (m, 2H) 3.99 (m, 1H) 4.29 (m, 1H) 4.44 (m, 1H)
7.04 (m, 1H) 7.14 (m, 1H) 7.24 (m, 1H) 7.39 (m, 1H) 7.61 (m, 1H)
7.79 (m, 1H) 7.86 (m, 2H) 8.17 (br. s., 1H) 8.20 (br. s., 1H) 8.39
(br. s., 1H) 8.61 (br. s., 1H).
EXAMPLE 242
(1S)-1-(1H-Indol-3-ylmethyl)-2-(5-isoquinolin-6-yl-pyrimidin-4-yloxy)-ethy-
lamine
Example 242A
5-Bromo-pyrimidin-4-ol
[0622] The Pyrimidin-4-ol (366 mg, 3.8 mmol) and AcOH were cooled
to 0.degree. C. Br.sub.2 (0.27 ml) was added slowly via syringe.
The mixture was stirred at room temperature for 3 hours. The AcOH
was removed under pressure. The residue was dissolved in
CH.sub.2Cl.sub.2, washed with saturated NaHCO.sub.3, brine, and
dried over MgSO.sub.4. The solvent was removed and the product was
purified by flash column chromatography to afforded the desired
product (605 mg, 91%). MS (ESI) m/e 175 (M+1).sup.+; .sup.1H NMR
(300 MHz, DMSO-D6) .delta. ppm 8.23 (br. s., 1H) 8.33 (br. s., 1H)
13.08 (br. s., 1H).
Example 242B
(1S)-1-(1H-Indol-3-ylmethyl)-2-(5-isoquinolin-6-yl-pyrimidin-4-yloxy)-ethy-
lamine
[0623] The title compound was prepared by substituting Example 242A
for 3-bromo-5-hydroxypyridine in Example 27. MS (ESI) m/e 396
(M+1).sup.+; .sup.1H NMR (300 MHz, DMSO-D6) .delta. ppm 3.10 (m,
2H) 4.35 (m, 1H) 4.48 (m, 1H) 4.72 (m, 1H) 6.96 (m, 2H) 7.31 (m,
3H) 8.26 (m, 3H) 8.50 (m, 3H) 8.68 (m, 1H) 8.88 (s, 2H) 9.74 (br.
s., 1H) 10.99 (br. s., 1H)
EXAMPLE 243
(1S)-1-Benzyl-2-[3-(3-methyl-1H-indazol-5-yl)-phenoxy]-ethylamine
Example 243A
[1-Benzyl-2-(3-bromo-phenoxy)-ethyl]-carbamic Acid Tert-Butyl
Ester
[0624] The desired product was prepared by substituting
3-bromophenol for 3-bromo-5-hydroxypyridine and
L-Boc-phenylalaminol for L-Boc-tryptophanol in Example 2A.
Example 243B
5-[3-((2S)-2-tert-Butoxycarbonylamino-3-phenyl-propoxy)-phenyl]-3-methyl-i-
ndazole-1-carboxylic Acid Tert-Butyl Ester
[0625] The desired product was prepared by substituting Example
243A for Example 2A in Example 102E.
Example 243C
(1S)-1-Benzyl-2-[3-(3-methyl-1H-indazol-5-yl)-phenoxy]-ethylamine
[0626] The desired product was prepared as the trifluoroacetate
salt by substituting Example 243B for Example 27B in Example 27C.
MS (ESI) m/e 358 (M+H).sup.+; .sup.1H NMR (500 MHz, DMSO-D6)
.delta. ppm 2.54 (s, 3H) 3.06 (m, 2H) 3.82 (m, 1H) 4.02 (dd,
J=10.61, 5.62 Hz, 1H) 4.18 (dd, J=0.61, 3.12 Hz, 1H) 6.93 (dd,
J=7.80, 1.56 Hz, 1H) 7.28 (d, J=2.18 Hz, 1H) 7.36 (m, 7H) 7.53 (d,
J=8.42 Hz, 1H) 7.62 (m, 1H) 7.94 (s, 1H) 8.27 (s, 2H) 12.68 (bs,
1H); Anal. Calcd for C.sub.23H.sub.23N.sub.3O.1.45 TFA: C, 59.50;
H, 4.71; N, 8.04;. Found: C, 59.46; H, 4.69, N, 8.25.
EXAMPLE 244
(1S)-1-Benzyl-2-[6-(3-methyl-1H-indazol-5-yl)-pyridin-2-yloxy]-ethylamine
[0627] The desired product was prepared as the trifluoroacetate
salt by substituting Example 3-bromo-6-hydroypyridine for
3-bromophenol in Example 243. MS (ESI) m/e 359 (M+H).sup.+; .sup.1H
NMR (300 MHz, DMSO-D6) .delta. ppm 2.54 (s, 3H) 3.05 (m, 2H) 3.90
(m, 1H) 4.33 (dd, J=11.70, 6.27 Hz, 1H) 4.60 (dd, J=11.87, 3.39 Hz,
1H) 6.80 (d, J=8.14 Hz, 1H) 7.33 (m, 5H) 7.49 (d, J=7.80 Hz, 1H)
7.68 (d, J=7.12 Hz, 1H) 7.83 (m, 1H) 7.96 (dd, J=8.81, 1.70 Hz, 1H)
8.20 (s, 2H) 8.35 (s, 1H) 12.69 (bs, 1H); Anal. Calcd for
C.sub.22H.sub.22N.sub.4O.1.4 TFA.1H.sub.2O: C, 55.56; H, 4.78; N,
10.45;. Found: C, 55.45; H, 4.51, N, 10.50.
EXAMPLE 245
(1S)-2-[5-(3-Methyl-1H-indazol-5-yl)-pyridin-3-yloxy]-1-(4-thiophen-3-yl-b-
enzyl)-ethylamine
Example 245A
(1S)-[2-Hydroxy-1-(4-iodo-benzyl)-ethyl]-carbamic Acid Tert-Butyl
Ester
[0628] The material was prepared from L-Boc-(4-iodophenyl)alanine
according to the procedure described by M. Rodriguez, M. Llinares,
S. Doulut, A. Heitz, J. Martinez Tetrahedron Letters 1991, 32 (7),
923-926.
Example 245B
(1S)-[2-(5-Bromo-pyridin-3-yloxy)-1-(4-iodo-benzyl)-ethyl]-carbamic
Acid Tert-Butyl Ester
[0629] The desired product was prepared by substituting Example
245A for L-Boc-tryptophanol in Example 2A.
Example 245C
(1S)-[2-(5-Bromo-pyridin-3-yloxy)-1-(4-thiophen-3-yl-benzyl)-ethyl]-carbam-
ic Acid Tert-Butyl Ester
[0630] A solution of Example 245B (200 mg; 0.37 mmol),
3-thiopheneboronic acid (50 mg; 0.39 mmol), Pd(PPh.sub.3).sub.4 (25
mg; 0.02 mmol) and CsF (115 mg; 0.76 mmol) in 1:2 MeOH:DME (5 mL)
was heated at reflux for 4 hrs, cooled, diluted with water, and
extracted with EtOAc. The extracts were rinsed with brine, dried
(MgSO.sub.4), evaporated, and purified by flash chromatography (30%
Et.sub.2O/hexane) to provide the desired product (145 mg, 79%).
Example 245D
(1S)-[2-[5-(3-Methyl-1H-indazol-5-yl)-pyridin-3-yloxy]-1-(4-thiophen-3-yl--
benzyl)-ethyl]-carbamic Acid Tert-Butyl Ester
[0631] The desired product was prepared by substituting Example
245C for Example 2A in Example 102E.
Example 245E
(1S)-2-[5-(3-Methyl-1H-indazol-5-yl)-pyridin-3-yloxy]-1-(4-thiophen-3-yl-b-
enzyl)-ethylamine
[0632] The desired product was prepared as the trifluoroacetate
salt by substituting Example 245D for Example 27B in Example 27C.
MS (ESI) m/e 441 (M+H).sup.+; .sup.1H NMR (300 MHz, DMSO-D6)
.delta. ppm 2.54 (s, 3H) 3.06 (d, J=7.12 Hz, 2H) 3.89 (m, 1H) 4.16
(dd, J=10.68, 5.59 Hz, 1H) 4.33 (dd, J=10.68, 2.88 Hz, 1H) 7.37 (d,
J=8.48 Hz, 2H) 7.55 (m, 2H) 7.63 (m, 1H) 7.70 (m, 3H) 7.76 (m, 1H)
7.85 (dd, J=3.05, 1.36 Hz, 1H) 8.08 (s, 1H) 8.22 (m, 2H) 8.35 (d,
J=2.71 Hz, 1H) 8.64 (d, J=1.70 Hz, 1H) 12.47 (bs, 1H).
EXAMPLE 246
(1S)-1-(4-Iodo-benzyl)-2-[5-(3-methyl-1H-indazol-5-yl)-pyridin-3-yloxy]-et-
hylamine
[0633] The desired product was prepared as the trifluoroacetate
salt by substituting Boc-3'-bromophenylalaminol for Example 245A in
Example 238. MS (ESI) m/e 485 (M+H).sup.+; .sup.1H NMR (300 MHz,
DMSO-D6) .delta. ppm 2.55 (s, 3H) 3.00 (d, J=7.12 Hz, 2H) 3.85 (m,
1H) 4.13 (m, 1H) 4.30 (m, 1H) 7.16 (d, J=8.14 Hz, 2H) 7.58 (d,
J=8.82 Hz, 1H) 7.70 (m, 3H) 8.08 (s, 1H) 8.19 (d, J=3.05 Hz, 2H)
8.32 (d, J=2.71 Hz, 1H) 8.63 (d, J=1.70 Hz, 1H) 8.97 (s, 1H) 12.72
(bs, 1H).
EXAMPLE 247
[4-((2S)-2-Amino-3-phenyl-propoxy)-2-(3-methyl-1H-indazol-5-yl)-phenyl]-me-
thanol
Example 247A
(1S)-[1-Benzyl-2-(3-chloro-4-formyl-phenoxy)-ethyl]-carbamic Acid
Tert-Butyl Ester
[0634] The desired product was prepared by substituting
2-chloro-4-hydroxybenzaldehyde for 3-bromo-5-hydroxypyridine and
L-Boc-phenylalaminol for L-Boc-tryptophanol in Example 2A.
Example 247B
(1S)-{1-Benzyl-2-[4-formyl-3-(3-methyl-1H-indazol-5-yl)-phenoxy]-ethyl}-ca-
rbamic Acid Tert-Butyl Ester
[0635] A solution of Example 102D (230 mg; 0.78 mmol) and Example
247A (300 mg; 0.77 mmol) in DMF (4 mL) was treated with
Pd2(dba).sub.3 (73 mg; 0.0.08
mmol),2-dicyclohexylphosphino-2'-(N,N-dimethylamino)biphenyl (61
mg; 0.15 mmol), and triethylamine (97 mg; 0.96 mmol), heated at
110.degree. C. for 4 hrs., partitioned between brine and EtOAc,
filtered through Celite.RTM., and extracted with EtOAc. The
extracts were rinsed with brine, dried (MgSO4), concentrated, and
purified by flash chromatography (40% EtOAc/hexane) to provide the
desired product (235 mg; 63%).
Example 247C
(1S)-{1-Benzyl-2-[4-hydroxymethyl-3-(3-methyl-1H-indazol-5-yl)-phenoxy]-et-
hyl}-carbamic Acid Tert-Butyl Ester
[0636] A solution of Example 247B (225 mg; 0.46 mmol) in EtOH (4
mL) was treated portionwise with NaBH.sub.4 (26 mg; 0.70 mmol) and
stirred for 30 min., diluted with water, and extracted into EtOAc.
The extracts were rinsed with brine, dried (MgSO.sub.4),
concentrated, and purified by flash chromatography (60%
EtOAc/hexane) to provide the desired product (150 mg; 66%).
Example 247D
[4-((2S)-2-Amino-3-phenyl-propoxy)-2-(3-methyl-1H-indazol-5-yl)-phenyl]-me-
thanol
[0637] Example 247C (115 mg; 0.23 mmol) was heated neat at
190.degree. C. for 45 min. then purified by flash chromatography on
silica gel eluting with 10% MeOH/CH.sub.2Cl.sub.2 to provide the
desired product (17 mg; 19%). MS (ESI) m/e 388 (M+H).sup.+; .sup.1H
NMR (300 MHz, DMSO-D6) .delta. ppm 2.50 (s, 3H) 2.60 (dd, J=13.22,
7.80 Hz, 1H) 2.83 (dd, J=13.22, 5.76 Hz, 1H) 3.25 (m, 1H) 3.82 (t,
J=5.59 Hz, 2H) 4.33 (d, J=5.09 Hz, 2H) 4.99 (t, J=5.26 Hz, 1H) 6.81
(d, J=2.37 Hz, 1H) 6.93 (dd, J=8.48, 2.37 Hz, 1H) 7.23 (m, 5H) 7.36
(d, J=8.48 Hz, 1H) 7.46 (m, 3H) 7.69 (s, 2H) 12.66 (s, 1H).
EXAMPLE 248
(1S)-2-[5-(1H-Benzotriazol-5-yl)-pyridin-3-yloxy]-1-(1H-indol-3-ylmethyl)--
ethylamine
Example 248A
4-Bromo-benzene-1,2-diamine
[0638] A mixture of 4-bromo-2-nitroaniline (1 g; 4.6 mmol) and
SnCl.sub.2.2H.sub.2O (6.2 g; 27.6 mmol) in MeOH (30 mL) with 5-6
drops of conc. HCl was heated at reflux for 5 hrs., concentrated,
suspended in sat'd NaHCO.sub.3 (aq.) and extracted with EtOAc. The
extracts were rinsed with brine, dried (MgSO.sub.4), and
concentrated to provide the product of sufficient purity to carry
on.
Example 248B
5-Bromo-1H-benzotriazole
[0639] A mixture of Example 248A (262 mg; 1.4 mmol) in 10%
H.sub.2SO.sub.4 (4 mL) was treated with NaNO.sub.2 (120 mg; 1.7
mmol) in water (1 mL), stirred for 30 min., diluted with water, and
extracted with EtOAc. The extracts were rinsed with brine, dried
(Na.sub.2SO.sub.4), concentrated and purified by flash
chromatography (5% MeOH/CH.sub.2Cl.sub.2) to provide the desired
product.
Example 248C
5-Bromo-benzotriazole-1-carboxylic Acid Tert-Butyl Ester
[0640] A solution of Example 248B (770 mg; 5 mmol) in THF (5 mL)
was added to a solution of 20% phosgene in toluene (10 mL) at
-20.degree. C., stirred for 1 hr. at -20.degree. C. then 2 hrs. at
r.t., evaporated and dissolved in THF (4 mL). This solution was
added to a solution of tBuOH (1 mL), and pyridine (426 mg; 5.4
mmol) in THF (3 mL) at -20.degree. C. then stirred overnight at
r.t. The solids were removed by filtration and rinsed with EtOAc.
The filtrate was rinsed with water and brine, dried (MgSO.sub.4),
concentrated, and isolated by flash chromatography (1:1
Et.sub.2O:hexane) to provide the desired product (970 mg; 76%).
Example 248D
(1S)-2-[5-(1H-Benzotriazol-5-yl)-pyridin-3-yloxy]-1-(1H-indol-3-ylmethyl)--
ethylamine
[0641] The desired product was prepared as the trifluoroacetate
salt by substituting Example 248C for 6-bromophthalimide in Example
32. MS (ESI) m/e 385 (M+H).sup.+; .sup.1H NMR (300 MHz, DMSO-D6)
.delta. ppm 3.17 (d, J=7.12 Hz, 2H) 3.86 (m, 1H) 4.21 (dd,
J=110.68, 6.27 Hz, 1H) 4.38 (dd, J=10.68, 2.88 Hz, 1H) 7.01 (t,
J=6.95 Hz, 1H) 7.10 (t, J=7.12 Hz, 1H) 7.30 (d, J=2.37 Hz, 1H) 7.38
(d, J=8.14 Hz, 1H) 7.63 (d, J=7.80 Hz, 1H) 7.78 (m, 1H) 8.01 (m,
1H) 8.18 (m, 3H) 8.27 (m, 1H) 8.38 (d, J=2.71 Hz, 1H) 8.66 (d,
J=1.36 Hz, 1H) 11.03 (s, 1H).
EXAMPLE 249
(1S)-2-[5-(1H-Benzotriazol-5-yl)-pyridin-3-yloxy]-1-benzyl-ethylamine
Example 249A
(1S)-[1-Benzyl-2-(5-bromo-pyridin-3-yloxy)-ethyl]-carbamic Acid
Tert-Butyl Ester
[0642] The desired product was prepared by substituting
L-Boc-phenylalaminol for L-Boc-tryptophanol in Example 2A.
Example 249B
(1S)-[1-Benzyl-2-(5-trimethylstannanyl-pyridin-3-yloxy)-ethyl]-carbamic
Acid Tert-Butyl Ester
[0643] The desired product was prepared by substituting Example
249A for Example 2A in Example 32A.
Example 249C
5-[5-((2S)-2-tert-Butoxycarbonylamino-3-phenyl-propoxy)-pyridin-3-yl]-benz-
otriazole-1-carboxylic Acid Tert-Butyl Ester
[0644] A solution of Example 249B (400 mg; 0.81 mmol) and Example
73C (255 mg; 0.85 mmol) in DMF (6 mL) was treated with
Pd.sub.2(dba).sub.3 (111 mg; 0.12 mmol),tri-o-tolylphosphine (74
mg; 0.24 mmol), and triethylamine (102 mg; 1.0 mmol), heated at
110.degree. C. for 4 hrs., partitioned between brine and EtOAc,
filtered through Celite.RTM., and extracted with EtOAc. The
extracts were rinsed with brine, dried (MgSO4), concentrated, and
purified by flash chromatography (80% EtOAc/CH.sub.2Cl.sub.2) to
provide the desired product (110 mg; 25%).
Example 249D
(1S)-2-[5-(1H-Benzotriazol-5-yl)-pyridin-3-yloxy-1-benzyl-ethylamine
[0645] The desired product was prepared as the trifluoroacetate
salt by substituting Example 249C for Example 27B in Example 27C.
MS (ESI) m/e 346 (M+H).sup.+; .sup.1H NMR (300 MHz, DMSO-D6)
.delta. ppm 3.04(m, 2H) 3.86 (m, 1H) 4.14 (m, 1H) 4.30 (m, 1H) 7.32
(m, 5H) 7.78 (m, 2H) 8.02 (m, 1H) 8.22 (m, 3H) 8.38 (d, J=2.37 Hz,
1H) 8.66 (d, J=2.03 Hz, 1H); Anal. Calcd for
C.sub.21H.sub.19N.sub.5O.2.6 TFA: C, 47.16; H, 3.39; N, 10.91;.
Found: C, 46.90; H, 3.26; N, 11.01.
EXAMPLE 250
(1S)-1-Benzyl-2-[5-(3-morpholin-4-yl-1H-indazol-5-yl)-pyridin-3-yloxy]-eth-
ylamine
[0646] The desired product was prepared as the trifluoroacetate
salt by substituting Example 111A for Example 249A in Example 249.
MS (ESI) m/e 430 (M+H).sup.+; .sup.1H NMR (400 MHz, DMSO-D6)
.delta. ppm 3.04 (m, 2H) 3.36 (m, 4H) 3.81 (m, 4H) 3.87 (m, 1H)
4.13 (dd, J=10.74, 5.83 Hz, 1H) 4.29 (dd, J=10.74, 2.76 Hz, 1H)
7.30 (m, 5H) 7.49 (d, J=8.90 Hz, 1H) 7.64 (d, J=8.59 Hz, 1H) 7.71
(s, 1H) 8.09 (s, 1H) 8.26 (bs, 2H) 8.32 (d, J=2.15 Hz, 1H) 8.64 (s,
1H) 12.20 (bs, 1H).
EXAMPLE 251
(1S)-1-Benzyl-2-{5-[3-(4-methyl-piperazin-1-yl)-1H-indazol-5-yl]-pyridin-3-
-yloxy}-ethylamine
[0647] The desired product was prepared as the trifluoroacetate
salt by substituting Example 114A for Example 249A in Example 249.
MS (ESI) m/e 443 (M+H).sup.+; .sup.1H NMR (300 MHz, DMSO-D6)
.delta. ppm 2.53 (s, 3H) 2.90 (m, 4H) 3.04 (m, 2H) 3.17 (m, 2H)
3.53 (m, 2H) 3.84 (m, 1H) 4.10 (m, 1H) 4.27 (dd, J=11.02, 3.22 Hz,
1H) 7.32 (m, 5H) 7.52 (d, J=8.82 Hz, 1H) 7.66 (m, 2H) 8.15 (s, 1H)
8.24 (m, 2H) 8.32 (d, J=2.71 Hz, 1H) 8.66 (d, J=1.70 Hz, 1H) 12.36
(s, 1H); Anal. Calcd for C.sub.26H.sub.30N.sub.6O.3 TFA: C, 48.98;
H, 4.21; N, 10.71;. Found: C, 48.60; H, 4.39; N, 11.05.
EXAMPLE 252
(1S)-{5-[5-(2-Amino-3-phenyl-propoxy)-pyridin-3-yl]-1H-indazol-3-yl}-dimet-
hyl-amine
[0648] The desired product was prepared as the trifluoroacetate
salt by substituting Example 115A for Example 249A in Example 249.
MS (ESI) m/e 388 (M+H).sup.+; .sup.1H NMR (300 MHz, DMSO-D6)
.delta. ppm 3.03 (m, 8H) 3.83 (m, 1H) 4.13 (m, 1H) 4.29 (m, 1H)
7.34 (m, 5H) 7.46 (d, J=8.81 Hz, 1H) 7.63 (dd, J=8.65, 1.53 Hz, 1H)
7.75 (m, 1H) 8.08 (s, 1H) 8.21 (m, 2H) 8.33 (d, J=2.71 Hz, 1H) 8.64
(d, J=1.70 Hz, 1H) 12.01 (bs, 1H); Anal. Calcd for
C.sub.23H.sub.25N.sub.5O.3 TFA: C, 47.74; H, 3.87; N, 9.60;. Found:
C, 47.76; H, 3.76; N, 9.52.
EXAMPLE 253
(1S)-{5-[5-(2-Amino-3-phenyl-propoxy)-pyridin-3-yl]-1H-indazol-3-yl}-(2-me-
thoxy-ethyl)-amine
Example 253A
(5-Bromo-1H-indazol-3-yl)-(2-methoxy-ethyl)-amine
[0649] The reaction between Example 35A and O-methyl ethanolamine
was carried out according to the procedure described by U.
Wrzeciono, K. Majewska, J. Dudzinska-Usarewicz, M. Bemas, Pharmzie,
1986, 41, 472-474.
Example 253A
(1S)-{5-[5-(2-Amino-3-phenyl-propoxy)-pyridin-3-yl]-1H-indazol-3-yl}-(2-me-
thoxy-ethyl)-amine
[0650] The desired product was prepared as the trifluoroacetate
salt by substituting Example 253A for Example 249A in Example 249.
MS (ESI) m/e 418 (M+H).sup.+; .sup.1H NMR (300 MHz, DMSO-D6)
.delta. ppm 3.04 (m, 2H) 3.30 (s, 3H) 3.46 (m, 2H) 3.57 (m, 2H)
3.83 (m, 1H) 4.11 (dd, J=10.68, 5.60 Hz, 1H) 4.28 (m, 1H) 7.34 (m,
5H) 7.64 (dd, J=10.68, 1.87 Hz, 3H) 8.21 (s, 3H) 8.30 (d, J=2.37
Hz, 1H) 8.58 (d, J=1.70 Hz, 1H) 11.67 bs, 1H); Anal. Calcd for
C.sub.24H.sub.27N.sub.5,.sub.2-3 TFA: C, 46.34; H, 4.15; N, 9.01.
Found: C, 46.54; H, 4.34; N, 8.79.
EXAMPLE 254
{5-[5-((2S)-2-Amino-3-phenyl-propoxy)-pyridin-3-yl]-1H-indazol-3-yl}-(2-mo-
rpholin-4-yl-ethyl)-amine
Example 254A
(5-Bromo-1H-indazol-3-yl)-(2-morpholin-4-yl-ethyl)-amine
[0651] The reaction between Example 35A and
4-(2-aminoethyl)morpholine was carried out according to the
procedure described by U. Wrzeciono, K. Majewska, J.
Dudzinska-Usarewicz, M. Bernas, Pharmzie, 1986, 41, 472-474.
Example 254B
{5-[5-((2S)-2-Amino-3-phenyl-propoxy)-pyridin-3-yl]-1H-indazol-3-yl}-(2-mo-
rpholin-4-yl-ethyl)-amine
[0652] The desired product was prepared as the trifluoroacetate
salt by substituting Example 254A for Example 249A in Example 249.
MS (ESI) m/e 473 (M+H).sup.+; .sup.1H NMR (300 MHz, DMSO-D6)
.delta. ppm 2.50 (m, 8H) 3.04 (m, 2H) 3.43 (m, 2H) 3.68 (m, 2H)
3.87 (m, 1H) 4.10 (m, 1H) 4.28 (m, 1H) 7.36 (m, 7H) 7.65 (m, 2H)
8.07 (s, 1H) 8.21 (m, 2H) 8.31 (d, J=2.71 Hz, 1H) 8.55 (d, J=1.70
Hz, 1H) 11.83 (bs, 1H)
EXAMPLE 255
5-[5-((2S)-2-Amino-3-phenyl-propoxy)-pyridin-3-yl]-1H-indazol-3-ylamine
[0653] The desired product was prepared as the trifluoroacetate
salt by substituting Example 249A for Example 2A in Example 97. MS
(ESI) m/e 360 (M+H).sup.+; .sup.1H NMR (300 MHz, DMSO-D6) .delta.
ppm 3.04 (m, 2H) 3.85 (m, 1H) 4.11 (dd, J=10.68, 5.59 Hz, 1H) 4.28
(dd, J=110.68, 2.88 Hz, 1H) 7.35 (m, 6H) 7.65 (m, 2H) 8.14 (s, 1H)
8.21 (m, 4H) 8.31 (d, J=2.71 Hz, 1H) 8.56 (d, J=2.03 Hz, 1H) 11.87
(bs, 1H); Anal. Calcd for C.sub.21H.sub.21N.sub.5O.3.1 TFA: C,
45.83; H, 3.41; N, 9.82;. Found: C, 45.58; H, 3.34; N, 9.57.
EXAMPLE 256
N-{5-[5-((2S)-2-Amino-3-phenyl-propoxy)-pyridin-3-yl]-1H-indazol-3-yl}-2,2-
,2-trifluoro-acetamide
Example 256A
5-Bromo-1H-indazol-3-ylamine
[0654] The desired product was prepared by substituting
5-bromo-2-fluorobenzonitrile for 5-bromo-2-fluorobenzaldehyde in
Example 35A.
Example 256B
N-(5-Bromo-1H-indazol-3-yl)-2,2,2-trifluoro-acetamide
[0655] A solution of 256A (2.5 g; 12 mmol) and trifluoroacetic
anhydride (3.4 mL; 24 mmol) in pyridine (50 mL) was stirred at r.t.
for 2 days, acidified with 10% HCl (aq), and extracted with EtOAc.
The extracts were rinsed with water and brine, dried (MgSO.sub.4),
concentrated and purified by flash chromatography (1:1
EtOAc:hexane) to provide the desired product (3.0 g; 84%).
Example 256C
N-{5-[5-((2S)-2-Amino-3-phenyl-propoxy)-pyridin-3-yl]-1H-indazol-3-yl}-2,2-
,2-trifluoro-acetamide
[0656] The desired product was prepared as the trifluoroacetate
salt by substituting Example 256B for Example 249A in Example 249.
MS (ESI) m/e 454 (M-H).sup.+; .sup.1H NMR (300 MHz, DMSO-D6)
.delta. ppm 3.04 (m, 2H) 3.84 (m, 1H) 4.11 (dd, J=10.85, 5.76 Hz,
1H) 4.28 (dd, J=10.68, 2.88 Hz, 1H) 7.35 (m, 6H) 7.68 (m, 2H) 8.16
(s, 1H) 8.22 (m, 3H) 8.32 (d, J=2.71 Hz, 1H) 8.57 (d, J=1.70 Hz,
1H) 11.87 (bs, 1H).
EXAMPLE 257
(2S)-2-Amino-N-[5-(3-methyl-1H-indazol-5-yl)-pyridin-3-yl]-3-phenyl-propio-
namide
Example 257A
5-(5-Amino-pyridin-3-yl)-3-methyl-indazole-1-carboxylic Acid
Tert-Butyl Ester
[0657] The desired product was prepared by substituting Example
203B for Example 27A and Example 23B for Example 2A in Example
27B.
Example 257B
5-15-((2S)-2-tert-Butoxycarbonylamino-3-phenyl-propionylamino)-pyridin-3-y-
l]-3-methylindazole-1-carboxylic acid tert-butyl Ester
[0658] The desired product was prepared by substituting Example
257A for Example 25E and L-Boc-phenylalanine for Boc-tryptophane in
Example 25G.
Example 257C
(2S)-2-Amino-N-[5-(3-methyl-1H-indazol-5-yl)-pyridin-3-yl]-3-phenyl-propio-
namide
[0659] The desired product was prepared as the trifluoroacetate
salt by substituting Example 257B for Example 27B in Example 27C.
MS (ESI) m/e 372 (M+H).sup.+; .sup.1H NMR (300 MHz, DMSO-D6)
.delta. ppm 2.55 (s, 3H) 3.19 (m, 2H) 4.23 (m, 1H) 7.32 (m, 6H)
7.62 (s, 1H) 8.01 (s, 1H) 8.19 m, 1H) 8.36 (s, 2H) 8.68 (d, J=2.03
Hz, 1H) 8.74 (d, J=2.03 Hz, 1H) 10.70 (s, 1H) 12.85 (bs, 1H); Anal.
Calcd for C.sub.22H.sub.21N.sub.5O.2.6 TFA: C, 48.91; H, 3.56; N,
10.49;. Found: C, 48.96; H, 3.71; N, 10.64.
EXAMPLE 258
(1S)-2-[5-(3-Benzyl-1H-indazol-5-yl)-pyridin-3-yloxy]-1-(1H-indol-3-ylmeth-
yl)-ethylamine
[0660] The desired product was prepared as the trifluoroacetate
salt by substituting benzyl magnesium chloride for methyl magnesium
bromide in Example 102. MS (ESI) m/e 474 (M+H).sup.+; .sup.1H NMR
(300 MHz, DMSO-D6) .delta. ppm 3.17 (m, 2H) 3.86 (m, 1H) 4.17 (dd,
J=10.68, 5.93 Hz, 1H) 4.35 (s, 2H) 4.42 (dd, J=110.68, 5.93 Hz, 1H)
7.02 (t, J=7.12 Hz, 1H) 7.08 (m, 1H) 7.29 (m, 7H) 7.61 (m, 4H) 7.98
(s, 1H) 8.15 (m, 3H) 8.32 (d, J=2.71 Hz, 1H) 8.55 (d, J=1.70 Hz,
1H) 11.03 (s, 1H); Anal. Calcd for C.sub.30H.sub.27N.sub.5O.3.9
TFA: C, 49.44; H, 3.39; N, 7.63;. Found: C, 49.07; H, 3.75; N,
7.42.
EXAMPLE 259
(1S)-1-Benzyl-2-[5-(3-benzyl-1H-indazol-5-yl)-pyridin-3-yloxy]-ethylamine
[0661] The desired product was prepared as the trifluoroacetate
salt by substituting 249B for Example 2A in Example 258. MS (ESI)
m/e 435 (M+H).sup.+; .sup.1H NMR (300 MHz, DMSO-D6) .delta. ppm
3.03 (m, 2H) 3.86 (m, 1H) 4.11 (dd, J=10.85, 5.76 Hz, 1H) 4.28 (dd,
J=10.68, 2.88 Hz, 1H) 5.72 (s, 2H) 7.30 (m, 8H) 7.72 (m, 3H) 7.84
(m, 1H) 8.13 (s, 1H) 8.21 (m, 3H) 8.33 (d, J=2.71 Hz, 1H) 8.60 (d,
J=1.70 Hz, 1H)
EXAMPLE 260
(1S)-2-[5-(3-Benzyl-1H-indazol-5-yl)-pyridin-3-yloxy]-1-methyl-ethylamine
Example 260A
(1S)-[2-(5-Bromo-pyridin-3-yloxy)-1-methyl-ethyl]-carbamic Acid
Tert-Butyl Ester
[0662] The desired product was prepared by substituting
Boc-alaminol for Boc-tryprophanol in Example 2A.
Example 260B
(1S)-[1-Methyl-2-(5-trimethylstannanyl-pyridin-3-yloxy)-ethyl]-carbamic
Acid Tert-Butyl Ester
[0663] The desire product was prepared by substituting Example 260A
for Example 249A in Example 249B.
Example 260C
(1S)-2-[5-(3-Benzyl-1H-indazol-5-yl)-pyridin-3-yloxy]-1-methyl-ethylamine
[0664] The desired product was prepared as the trifluoroacetate
salt by substituting 260B for Example 32A in Example 258. MS (ESI)
m/e 359 (M+H).sup.+; .sup.1H NMR (300 MHz, DMSO-D6) .delta. ppm
1.31 (m, 3H) 4.10 (m, 1H) 4.30 (m, 1H) 4.35 (s, 2H) 4.41 (m, 1H)
7.17 (m, 1H) 7.29 (m, 2H) 7.36 (m, 2H) 7.61 (s, 2H) 7.69 (s, 2H)
8.02 (bs, 2H) 8.33 (d, J=2.37 Hz, 1H) 8.56 (s, 1H) 12.71 (bs, 1H);
Anal. Calcd for C.sub.22H.sub.22N.sub.4O- .3.2 TFA: C, 47.16; H,
3.51; N, 7.75;. Found: C, 47.27; H, 3.60; N, 7.60.
EXAMPLE 261
(6-{5-[(2S)-2-Amino-3-(1H-indol-3-yl)-propoxy]-pyridin-3-yl}-cinnolin-4-yl-
)-phenyl-amine
Example 261A
(6-Bromo-cinnolin-4-yl)-phenyl-amine
[0665] A solution of Example 34D (500 mg; 2.5 mmol) and aniline
(1.5 mL) in MeOH (11 mL) was stirred at r.t. for 2.5 hrs, the
resulting precipitate was collected, rinsed with water and dried
under vacuum to provide the desired product (400 mg; 62%).
Example 261B
(6-{5-[(2S)-2-Amino-3-(1H-indol-3-yl)-propoxy]-pyridin-3-yl}-cinnolin-4-yl-
)-phenyl-amine
[0666] The desired product was prepared as the trifluoroacetate
salt by substituting Example 261A for Example 27A in Example 27. MS
(ESI) m/e 487 (M+H).sup.+; .sup.1H NMR (500 MHz, DMSO-D6) .delta.
ppm 3.18 (m, 2H) 3.86 (m, 1H) 4.25 (dd, J=10.61, 5.93 Hz, 1H) 4.39
(m, 1H) 6.99 (t, J=7.49 Hz, 1H) 7.09 (t, J=7.02 Hz, 1H) 7.31 (d,
J=2.50 Hz, 1H) 7.38 (d, J=8.11 Hz, 1H) 7.45 (t, J=7.33 Hz, 1H) 7.60
(m, 6H) 7.90 (m, 1H) 8.19 (d, J=9.05 Hz, 1H) 8.35 (bs, 2H) 8.44 (m,
2H) 8.64 (s, 1H) 8.81 (d, J=1.56 Hz, 1H) 9.08 (s, 1H) 11.04 (d,
J=1.87 Hz, 1H).
EXAMPLE 262
(1S)-2-[5-(1H-Indazol-6-yl)-pyridin-3-yloxy]-1-(1H-indol-3-ylmethyl)-ethyl-
amine
[0667] The desired product was prepared as the trifluoroacetate
salt by substituting 4-bromo-2-fluorobenzaldehyde for
5-bromo-2-fluorobenzaldehyd- e in Example 35. MS (ESI) m/e 384
(M+H).sup.+; .sup.1H NMR (500 MHz, DMSO-D6) .delta. ppm 2.97 (m,
2H) 3.60 (m, 1H) 4.13 (m, 2H) 6.99 (m, 2H) 7.24 (m, 1H) 7.38 (m,
2H) 7.61 (m, 3H) 7.84 (m, 3H) 8.11 (m, 1H) 8.31 (m, 1H) 8.55 (m,
1H) 11.03 (m, 1H) 12.98 (m, 1H)
EXAMPLE 263
5-{5-[(2S)-2-Amino-3-(1H-indol-3-yl)-propoxy]-pyridin-3-yl}-2,3-dihydro-is-
oindol-1-one
Example 263A
4-Bromo-2-methyl-benzoic Acid Methyl Ester
[0668] A solution of 4-bromo-2-methyl benzoic acid (1.0 g; 4.7
mmol) in MeOH (24 mL) with 20 drops conc. HCl was heated at reflux
for 6 hrs. the concentrated to provide the desired product (1.1 g;
100%).
Example 263B
4-Bromo-2-bromomethyl-benzoic acid methyl Ester
[0669] A solution of Example 263A (1.02 g; 4.5 mmol) in CCl.sub.4
(22 mL) was treated with AIBN (65 mg; 0.4 mmol), heated at reflux
for 4 hrs., washed with water, dried (Na.sub.2SO.sub.4) and
concentrated to provide the desired product (1.1 g; 79%).
Example 263C
5-Bromo-2,3-dihydro-isoindol-1-one
Example 263D
5-{5-[(2S)-2-Amino-3-(1H-indol-3-yl)-propoxy]-pyridin-3-yl}-2,3-dihydro-is-
oindol-1-one
[0670] The desired product was prepared as the trifluoroacetate
salt by substituting Example 263C for 5-bromooxindole in Example
36. MS (ESI) m/e 399 (M+H).sup.+; .sup.1H NMR (d.sub.6-DMSO, 300
MHz) .delta.: 11.03 (bs, 1H), 8.63 (s, 1H), 8.57 (s, 1H), 8.35 (bs,
3H), 7.90 (s, 1H), 7.78 (s, 2H), 7.67 (s, 1H), 7.61 (d, J=8 Hz,
1H), 7.37 (d, J=8 Hz, 1H), 7.79 (d, J=2 Hz, 1H), 7.03-7.10 (m, 1H),
6.96-7.01 (m, 1H), 4.32-4.36 (m, 1H), 4.17-4.22 (m, 1H), 3.80-3.83
(m, 1H), 3.18 (d, J=8 Hz, 2H), 2.50 (s, 2H).
EXAMPLE 264
6-{5-[(2S)-2-Amino-3-(1H-indol-3-yl)-propoxy]-pyridin-3-yl}-1H-cinnolin-4--
one
[0671] The desired product was prepared as the trifluoroacetate
salt by substituting Example 34A for 6-bromophthalimide in Example
32. MS (ESI) m/e 412 (M+H).sup.+; .sup.1H NMR (500 MHz, DMSO-D6)
.delta. ppm 3.19 (d, J=7.18 Hz, 2H) 3.84 (m, 1H) 4.24 (dd, J=10.61,
5.93 Hz, 1H) 4.39 (dd, J=10.61, 3.12 Hz, 1H) 7.01 (t, J=7.02 Hz,
1H) 7.10 (t, J=7.18 Hz, 1H) 7.31 (d, J=2.50 Hz, 1H) 7.38 (d, J=8.11
Hz, 1H) 7.64 (d, J=7.80 Hz, 1H) 7.76 (d, J=8.73 Hz, 1H) 7.80 (m,
2H) 7.96 (s, 1H) 8.17 (dd, J=8.73, 2.18 Hz, 1H) 8.32 (d, J=2.18 Hz,
2H) 8.40 (d, J=2.81 Hz, 1H) 8.65 (d, J=1.87 Hz, 1H) 11.05 (d,
J=1.56 Hz, 1H) 13.72 (bs, 1H); Anal. Calcd for
C.sub.24H.sub.21N.sub.5O.sub.2.3 TFA: C, 47.82; H, 3.21; N, 9.29.
Found: C, 47.88; H, 3.41; N, 9.35.
EXAMPLE 265
(1S)-1-(1H-Indol-3-ylmethyl)-2-[5-(4-phenyl-cinnolin-6-yl)-pyridin-3-yloxy-
]-ethylamine
Example 265A
1-(1H-Indol-3-ylmethyl)-2-[5-(4-phenyl-cinnolin-6-yl)-pyridin-3-yloxy]-eth-
ylamine
[0672] A solution of Example 34C (200 mg; 0.8 mmol) in THF (10 mL)
was treated with 3.0 M phenylmagnesium bromide in Et.sub.2O (1.6
mL; 4.8 mmol), stirred at r.t. for 4 hrs., sat;d NH.sub.4Cl (aq)
was added, and extracted with EtOAc. The extracts were rinsed with
brine, dried (MgSO.sub.4), concentrated and purified by flash
chromatography (30% EtOAc/hexane) to provide the desired product
(67 mg; 29%).
Example 265B
(1S)-1-(1H-Indol-3-ylmethyl)-2-[5-(4-phenyl-cinnolin-6-yl)-pyridin-3-yloxy-
]-ethylamine
[0673] The desired product was prepared as the trifluoroacetate
salt by substituting Example 265A for 6-bromophthalimide in Example
32. MS (ESI) m/e 472 (M+H).sup.+; .sup.1H NMR (500 MHz, DMSO-D6)
.delta. ppm 3.15 (d, J=7.18 Hz, 2H) 3.84 (m, 1H) 4.17 (dd, J=10.61,
5.93 Hz, 1H) 4.33 (dd, J=10.61, 3.12 Hz, 1H) 6.98 (t, J=7.49 Hz,
1H) 7.08 (t, J=7.49 Hz, 1H) 7.28 (d, J=2.18 Hz, 1H) 7.37 (d, J=8.11
Hz, 1H) 7.64 (m, 5H) 7.70 (d, J=1.87 Hz, 1H) 7.78 (d, J=6.55 Hz,
2H) 8.16 (bs, 2H) 8.30 (dd, J=8.89, 1.72 Hz, 1H) 8.42 (d, J=2.50
Hz, 1H) 8.61 (d, J=1.56 Hz, 1H) 8.69 (d, J=9.05 Hz, 1H) 9.41 (s,
1H) 11.01 (s, 1H); Anal. Calcd for C.sub.30H.sub.25N.sub.5O.1.9
TFA: C, 58.99; H, 3.94; N, 10.18; Found: C, 58.87; H, 3.85; N,
10.08.
EXAMPLE 266
(6-{5-[(2S)-2-Amino-3-(1H-indol-3-yl)-propoxy]-pyridin-3-yl}-cinnolin-4-yl-
)-benzyl-amine
Example 266A
Benzyl-(6-bromo-cinnolin-4-yl)-amine
[0674] A solution of 34D (100 mg; 0.41 mmol) and benzylamine (0.5
mL) in MeOH (3 mL) was stirred at r.t. for 24 hrs., concentrated,
suspended in Et.sub.2O, and the precipitate was collected to
provide the desired product (100 mg; 78%).
Example 266B
(6-{5-[(2S)-2-Amino-3-(1H-indol-3-yl)-propoxy]-pyridin-3-yl-cinnolin-4-yl)-
-benzyl-amine
[0675] The desired product was prepared as the trifluoroacetate
salt by substituting Example 266A for 6-bromophthalimide in Example
32. MS (ESI) m/e 501 (M+H).sup.+; .sup.1H NMR (500 MHz, DMSO-D6)
.delta. ppm 3.18 (d, J=7.18 Hz, 2H) 3.87 (m, 1H)-4.23 (dd, J=10.61,
5.62 Hz, 1H) 4.38 (dd, J=10.45, 2.96 Hz, 1H) 5.00 (d, J=5.62 Hz,
2H) 7.00 (t, J=7.49 Hz, 1H) 7.09 (t, J=7.18 Hz, 1H) 7.30 (d, J=2.50
Hz, 1H) 7.37 (m, 4H) 7.50 (d, J=7.49 Hz, 2H) 7.62 (d, J=8.11 Hz,
1H) 7.83 (d, J=2.18 Hz, 1H) 8.10 (d, J=9.05 Hz, 1H) 8.29 (bs, 2H)
8.40 (dd, J=8.89, 1.40 Hz, 1H) 8.45 (d, J=2.50 Hz, 1H) 8.78 (d,
J=1.56 Hz, 1H) 8.80 (s, 1H) 8.98 (s, 1H) 10.35 (bs, 1H) 11.03 (s,
1H); Anal. Calcd for C.sub.31H.sub.28N.sub.6O.3.1 TFA: C, 52.31; H,
3.67; 30 N, 9.84;. Found: C, 52.36; H, 3.47; N, 9.67.
EXAMPLE 267
(6-{5-[(2S)-2-Amino-3-(1H-indol-3-yl)-propoxy]-pyridin-3-yl}-cinnolin-4-yl-
)-methyl-amine
[0676] The desired product was prepared as the trifluoroacetate
salt by substituting methylamine for benzylamine in Example 266. MS
(ESI) m/e 425 (M+H).sup.+; .sup.1H NMR (500 MHz, DMSO-D6) .delta.
ppm 2.50 (d, J=1.87 Hz, 3H) 3.19 (m, 2H) 3.85 (m, 1H) 4.26 (dd,
J=10.92, 5.93 Hz, 1H) 4.40 (dd, J=10.61, 3.12 Hz, 1H) 6.99 (t,
J=7.49 Hz, 1H) 7.09 (t, J=7.33 Hz, 1H) 7.32 (d, J=1.87 Hz, 1H) 7.37
(d, J=8.11 Hz, 1H) 7.63 (d, J=8.11 Hz, 1H) 7.87 (s, 1H) 8.10 (d,
J=9.05 Hz, 1H) 8.37 (m, 3H) 8.43 (d, J=2.81 Hz, 1H) 8.72 (s, 1H)
8.76 (d, J=1.56 Hz, 1H) 8.93 (s, 1H) 10.00 (bs, 1H) 11.04 (d,
J=1.25 Hz, 1H)
EXAMPLE 268
6-{5-[(2S)-2-Amino-3-(1H-indol-3-yl)-propoxy]-pyridin-3-yl}-cinnolin-4-yla-
mine
[0677] The desired product was prepared as the trifluoroacetate
salt by substituting ammonia for benzylamine in Example 266. MS
(ESI) m/e 411 (M+H).sup.+; .sup.1H NMR (500 MHz, DMSO-D6) .delta.
ppm 3.18 m, 2H) 3.86 (m, 1H) 4.27 (m, 1H) 4.41 (m, 1H) 6.99 (m, 1H)
7.08 (m, 1H) 7.36 (m, 2H) 7.64 (d, J=6.55 Hz, 1H) 7.89 (s, 1H) 8.10
(d, J=8.42 Hz, 1H) 8.46 (m, 4H) 8.59 (s, 1H) 8.76 (s, 1H) 9.00 (s,
1H) 10.06 (s, 2H) 11.08 (s, 1H)
EXAMPLE 269
[(3S)-3-(5-Isoquinolin-6-yl-pyridin-3-yloxymethyl)-1,2,3,4-tetrahydro-b-ca-
rbolin-9-yl]-methanol
[0678] A solution of Example 27 (100 mg; 0.19 mmol) and 37%
formaldehyde (aq) (18 .mu.L) in water (1 mL) with 2 drops conc.
H.sub.2SO.sub.4 was heated at reflux for 3 hrs., evaporated and
purified by reverse phase HPLC on a C18 column with 0-100%
CH.sub.3CN/H.sub.2O/0.1% TFA to provide the desired product as the
trifluoroacetate salt. MS (ESI) m/e 412 (M+H).sup.+; .sup.1H NMR
(400 MHz, DMSO-D6) .delta. ppm 3.04 (m, 1H) 3.20 (m, 3H) 4.19 (bs,
1H) 4.53 (m, 6.75 Hz, 1H) 4.64 (m, 1H) 4.70 (m, 1H) 5.52 (m, 2H)
7.12 ((t, J=7.67 Hz, 1H) 7.22 (t, J=7.67 Hz, 1H) 7.52 (d, J=7.98
Hz, 1H) 7.58 (d, J=8.29 Hz, 1H) 8.05 (s, 1H) 8.26 (d, J=6.44 Hz,
1H) 8.33 (d, J=8.59 Hz, 1H) 8.53 (m, 2H) 8.63 (s, 1H) 8.68 (d,
J=5.83 Hz, 1H) 8.83 (s, 1H) 9.71 (s, 1H) 9.94 (bs, 1H)
EXAMPLE 270
3-(5-Isoquinolin-6-yl-pyridin-3-yloxymethyl)-2,3,4,9-tetrahydro-1H-.beta.--
carboline
[0679] A solution of Example 27 (100 mg; 0.19 mmol) and 37%
formaldehyde (aq) (17 .mu.L) in water (1 mL) with conc.
H.sub.2SO.sub.4 (6 .mu.L) was stirred overnight at r.t.,
neutralized with NH.sub.3/MeOH, concentrated and purified by flash
chromatography (10% MeOH/CH.sub.2Cl.sub.2) to provide the desired
product. MS (ESI) m/e 407 (M+H).sup.+; .sup.1H NMR (500 MHz,
DMSO-D6) .delta. ppm 2.58 (dd, J=14.66, 9.98 Hz, 1H) 2.85 (dd,
J=14.97, 3.74 Hz, 1H) 3.38 (m, 2H) 4.02 (d, J=4.99 Hz, 1H) 4.33 (m,
2H) 6.95 (t, J=7.02 Hz, 1H) 7.02 (t, J=7.49 Hz, 1H) 7.29 (d, J=8.11
Hz, 1 H) 7.39 (d, J=8.11 Hz, 1H) 7.91 (m, 2H) 8.12 (dd, J=8.42,
1.56 Hz, 1H) 8.25 (d, J=8.42 Hz, 1H) 8.41 (s, 1H) 8.45 (t, J=2.65
Hz, 1H) 8.56 (d, J=5.62 Hz, 1H) 8.69 (d, J=1.56 Hz, 1H) 9.37 (s,
1H) 10.72 (s, 1H).
EXAMPLE 271
5-{5-[(2S)-2-Amino-3-(1H-indol-3-yl)-propoxy]-pyridin-3-yl}-1H-indazole-3--
carboxylic Acid
Example 271A
1H-Indazole-3-carboxylic Acid Methyl Ester
[0680] A solution of 3-carboxyindazole (2.0 g; 12.3 mmol) and
conc.HCl (2 mL) in MeOH (50 mL) was heated at reflux overnight,
concentrated, diluted with 2N NaOH (aq), and extracted with EtOAc.
The extracts were rinsed with brine, dried (MgSO.sub.4), and
concentrated to provide the desired product.
Example 271B
5-Iodo-1H-indazole-3-carboxylic Acid Methyl Ester
[0681] A solution of Example 271A (300 mg; 1.7 mmol),
bis(trifluoroacetoxy)iodobenzene (800 mg; 1.9 mmol), and iodine
(253 mg; 1.0 mmol) in CH.sub.2Cl.sub.2 (10 mL) was stirred
overnight at r.t., and treated with sodium bisulfite (aq). The
precipitate was collected, rinsed with water and hexane, and dried
under vacuum to provide the desired product (180 mg; 36%).
Example 271C
5-{5-[(2S)-2-tert-Butoxycarbonylamino-3-(1H-indol-3-yl)-propoxy]-pyridin-3-
-yl}-1H-indazole-3-carboxylic Acid Methyl Ester
[0682] The desired product was prepared by substituting Example
271B for 6-bromophthalimide in Example 32B.
Example 271D
5-5-[(2S)-2-Amino-3-(1H-indol-3-yl)-propoxy]-pyridin-3-yl}-1H-indazole-3-c-
arboxylic Acid Methyl Ester
[0683] The desired product was prepared by substituting Example
271C for Example 27B in Example 27C.
Example 271E
5-{5-[(2S)-2-Amino-3-(1H-indol-3-yl)-propoxy]-pyridin-3-yl}-1H-indazole-3--
carboxylic Acid
[0684] A solution of Example 271D (150 mg; 0.34 mmol) and 1N NaOH
(5 mL) in MeOH (1 mL) was heated at reflux for 6 hrs.,
concentrated, and purified by reverse phase HPLC on a C18 column
with 0-100% CH.sub.3CN/H.sub.2O/0.1% TFA to provide the desired
product as the trifluoroacetate salt. MS (ESI) m/e 428 (M+H).sup.+;
.sup.1H NMR (500 MHz, DMSO-D6) .delta. ppm 3.18 (d, J=7.49 Hz, 2H)
3.86 (m, 1H) 4.21 (dd, J=10.29, 5.93 Hz, 1H) 4.37 (dd, J=10.29,
2.50 Hz, 1H) 7.01 (t, J=7.33 Hz, 1H) 7.10 (t, J=7.33 Hz, 1H) 7.30
(d, J=1.87 Hz, 1H) 7.38 (d, J=8.11 Hz, 1H) 7.63 (d, J=7.80 Hz, 1H)
7.71 (s, 1H) 7.77 (m, 2H) 8.26 (s, 3H) 8.32 (s, 1H) 8.37 (s, 1H)
8.59 (s, 1H) 11.03 (s, 1H) 13.64 (m, 1H).
EXAMPLE 272
5-[5-((2S)-2-tert-Butoxycarbonylamino-3-hydroxy-propoxy)-pyridin-3-yl]-3-m-
ethylindazole-1-carboxylic Acid Tert-Butyl Ester
[0685] Example 203 (719 mg, 1.22 mmol) was dissolved in 30 mL EtOAc
in a 100 mL round bottom flask with a stirbar. A combination
vacuum/Ar/H.sub.2 manifold was attached and the flask evacuated and
filled with Ar twice. Pd/C (800 mg, 10 wt. % (dry basis)) was added
and the flask evacuated and filled with H.sub.2 twice. The
resultant black mixture was stirred vigorously and warmed to
50.degree. C. for 20 h at which time TLC indicated .about.70%
consumption of starting material. Another 480 mg of the Pd/C was
added and a fresh H.sub.2 balloon attached. The reaction was
stirred another 26 h at 50.degree. C. at which time it was cooled
to room temperature and the flask evacuated and filled with Ar. The
cooled reaction mixture was filtered through Celite and the filter
cake washed with EtOAc. The filtrate was subjected to rotary
evaporation and then dried with house vacuum to yield the desired
product (540 mg, 89%) as a colorless foam/solid. R.sub.f=0.26
(EtOAc); MS m/z 499 (M+H).sup.+; .sup.1H NMR (300 MHz, DMSO-D6)
.delta. ppm 1.39 (s, 9H) 1.66 (s, 9H) 2.60 (s, 3H) 3.50 (m, 2H)
3.82 (m, 1H) 4.17 (m, 2H) 4.83 (t, J=5.59 Hz, 1H) 6.82 (d, J=8.14
Hz, 1H) 7.79 (s, 1H) 8.02 (dd, J=8.65, 1.53 Hz, 1H) 8.12 (m, 1H)
8.27 (d, J=1.02 Hz, 1H) 8.29 (d, J=2.71 Hz, 1H) 8.61 (d, J=2.03 Hz,
1H).
EXAMPLE 273
5-[5-((2S)-Aziridin-2-ylmethoxy)-pyridin-3-yl]-3-methyl-1H-indazole
Example 273A
(1R)-[2-(5-Bromo-pyridin-3-yloxy)-1-(tert-butyl-dimethyl-silanyloxymethyl)-
-ethyl]-carbamic Acid Tert-Butyl Ester
[0686] A 100 mL RBF was charged with 3-bromo-5-hydroxypyridine
(1.20 g, 6.87 mmol),
(R)-[1-(tert-butyl-dimethyl-silanyloxymethyl)-2-hydroxy-ethyl-
]-carbamic acid tert-butyl ester (2.1 g, 6.87 mmol) and Ph.sub.3P
(2.34 g, 8.93 mmol), and was purged with nitrogen. THF (30 mL) was
added at 0.degree. C. After stirring at 0.degree. C. for 10 min,
DEAD (1.41 mL, 8.93 mmol) was added via syringe. The reaction
mixture was stirred at 0.degree. C. for 0.5 h and at rt for 2 h.
The reaction mixture was concentrated and the residue was separated
by flash chromatography (5-25% EtOAc in hexane) to provide the
desired product (3.14 g, 99%). MS (DCI) m/z 461, 463
(M+1).sup.+.
Example 273B
(1S)-12-(5-Bromo-pyridin-3-yloxy)-1-hydroxymethyl-ethyl]-carbamic
Acid Tert-Butyl Ester
[0687] To a solution of Example 273A (3.14 g, 6.8 mmol) in THF (40
mL) was added TBAF (7.14 mL, 7.14 mmol) at rt. The solution was
stirred at rt for 1 h and was concentrated. The residual oil was
purified by flash chromatography (40-80% EtOAc in hexane) to give
the desired product (2.19 g, 93%). MS (DCI) m/z 347, 349
(M+1).sup.+.
Example 273C
(2S)-2-(5-Bromo-pyridin-3-yloxymethyl)-aziridine-1-carboxylic Acid
Tert-Butyl Ester
[0688] Ph.sub.3P (1.13 g, 4.32 mmol) was dissolved in 9:1
THF/CH.sub.3CN (30 mL) and cooled to 4.degree. C. with an ice/water
bath. DIAD (850 .mu.L, 4.32 mmol) was added slowly. After stirring
15 min, a solution of Example 273B (1.0 g, 2.88 mmol) in THF (4 mL)
was added slowly. The solution was allowed to warm to rt and
stirred for over night. The solution was concentrated and the
residual oil was purified by flash chromatography (20-40% EtOAc in
hexane) to give the desired product (1.0 g, 75%). MS (DCI) m/z 329,
331 (M+1).sup.+.
Example 273D
5-[5-((2S)-1-tert-Butoxycarbonyl-aziridin-2-ylmethoxy)-pyridin-3-yl]-3-met-
hyl-indazole-1-carboxylic Acid Tert-Butyl Ester
[0689] Method 1. A 100 mL RBF was charged with Example 273C (950
mg, 2.88 mmol), Example 203B (1.14 g, 2.88 mmol),
Pd.sub.2(dba).sub.3 (263 mg, 0.288 mmol), and tri-o-tolylphosphine
(263 mg), and was purged with N.sub.2. Anhydrous DMF (35 mL) and
Et.sub.3N (1.2 mL) were added via syringe. The solution was purged
with N.sub.2 again and was heated at 72.degree. C. for 4 h. After
cooled, ethyl acetate (150 mL) was added. The mixture was washed
with brine (200 mL) and water (200 mL). The ethyl acetate solution
was concentrated and the residual oil was separated by flash
chromatography (50-80% EtOAc in hexane) to give the desired product
(634 mg, 65%). MS (APCI) m/z 481 (M+1).sup.+.
[0690] Method 2. To a stirred solution of PPh.sub.3 (2.16 g, 8.24
mmol) in THF (130 mL) and CH.sub.3CN (20 mL) at 0.degree. C. was
added DIAD (1.62 mL, 8.24 mmol) slowly via syringe. After 20 min
the resulting light yellow solution was canulated onto Example 272
(2.74 g, 5.50 mmol) in THF (150 mL). The reaction mixture was
stirred 6 h at 23.degree. C. and then silica gel was added and the
volatiles removed on a rotary evaporator. Flash chromatography
(50-60-70-80% EtOAc/hexanes) gave 3.72 g of a white solid which was
a 1.33:1 mixture of triphenylphosphine oxide:aziridine.
R.sub.f=0.50 (EtOAc). This was used without further
purification.
Example 273E
5-[5-((2S)-Aziridin-2-ylmethoxy)-pyridin-3-yl]-3-methyl-1H-indazole
[0691] The desired product was prepared as the trifluoroacetate by
substituting Example 273D for Example 27B in Examples 27C. MS
(APCI) m/z 281 (M+1).sup.+; .sup.1H NMR (300 MHz, CD.sub.3OD)
.delta. 2.63 (s, 3H), 3.31 (dd, J=3.30, 1.83 Hz, 2H), 3.62 (dd,
J=6.23, 1.83 Hz, 2H), 3.89 (m, 1H), 4.60 (m, 2H), 7.64 (d, J=8.79
Hz, 1H), 7.77 (d, J=8.79 Hz, 1H), 8.15 (s, 1H), 8.22 (s, 1H).
EXAMPLE 274
(1S)-2-[5-(3-Methyl-1H-indazol-5-yl)-pyridin-3-yloxy]-1-(3-trifluoromethox-
y-benzyl)-ethylamine
Example 274A
5-{5-[(2S)-2-tert-Butoxycarbonylamino-3-(3-trifluoromethoxy-phenyl)-propox-
y]-pyridin-3-yl}-3-methyl-indazole-1-carboxylic acid tert-butyl
Ester
[0692] To a suspension of CuBr--SMe.sub.2(25 mg, 0.12 mmol) and
Example 273D (100 mg, 0.21 mmol) in THF (6 mL) was added
3-trifluoromethoxyphenyl- magnesium bromide (0.5 M solution in THF,
1.6 mL, 0.8 mmol) at approximately -35.degree. C. The formed clear
solution was allowed to warm up to -20.degree. C. within 40 min and
was partitioned between ether and water. The organic layer was
concentrated and the residue was separated by flash chromatography
(40-65% EtOAc in hexane) to give the desired product (88 mg, 66%).
MS (APCI) m/z 643 (M+1).sup.+.
Example 274B
(1S)-2-[5-(3-Methyl-1H-indazol-5-yl)-pyridin-3-yloxy]-1-(3-trifluoromethox-
y-benzyl)-ethylamine
[0693] The desired product was prepared as the trifluoroacetate by
substituting Example 274A for Example 27B in Examples 27C. MS
(APCI) m/z 444 (M+1).sup.+; .sup.1H NMR (300 MHz, CD.sub.3OD)
.delta. 2.62 (s, 3H), 3.22 (dd, J=7.29, 5.26 Hz, 2H), 4.00 (m, 1H),
4.26 (dd, J=10.51, 5.09 Hz, 1H), 4.43 (dd, J=10.85, 3.05 Hz, 1H),
7.25 (d, J=8.48 Hz, 1H), 7.30 (s, 1H), 7.36 (d, J=7.46 Hz, 1H),
7.49 (t, J=7.97 Hz, 1H), 7.62 (d, J=8.48 Hz, 1H), 7.72 (dd, J=8.82,
1.70 Hz, 1H), 8.00 (s, 1H), 8.08 (s, 1H), 8.40 (d, J=2.03 Hz, 1H),
8.68 (s, 1H). Anal. Calcd for C.sub.23H.sub.21F.sub.3-
N.sub.4O.sub.2.box-solid.2.6 TFA: C, 45.84; H, 3.22; N, 7.58.
Found: C, 45.87; H, 3.17; N, 7.28.
[0694] The following compounds were prepared by substituting the
appropriate Grignard reagents for 3-trifluoromethoxyphenylmagnesium
bromide in Example 274.
EXAMPLE 275
(1S)-1-(3,5-Dichloro-benzyl)-2-[5-(3-methyl-1H-indazol-5-yl)-pyridin-3-ylo-
xy]-ethylamine
[0695] MS (APCI) m/z 427 (M+1).sup.+; .sup.1H NMR (300 MHz,
CD.sub.3OD) .delta. 2.63 (s, 3H), 3.18 (dd, J=7.32, 3.30 Hz, 2H),
4.02 (m, 1H), 4.32 (dd, J=10.44, 5.31 Hz, 1H), 4.47 (dd, J=10.62,
2.93 Hz, 1H), 7.37 (s, 1H), 7.39 (d, J=8.06 Hz, 1H), 7.63 (d,
J=8.79 Hz, 1H), 7.74 (d, J=8.06 Hz, 1H), 8.10 (s, 3H), 8.44 (s,
1H), 8.73 (s, 1H); Anal. Calcd for
C.sub.22H.sub.20Cl.sub.2N.sub.4O.box-solid.3.2 TFA: C, 43.38; H,
2.98; N, 7.18. Found: C, 43.49; H, 3.18; N, 6.92.
EXAMPLE 276
(1S)-1-(2,3-Dichloro-benzyl)-2-[5-(3-methyl-1H-indazol-5-yl)-pyridin-3-ylo-
xy]-ethylamine
[0696] MS (APCI) m/z 427 (M+1).sup.+; .sup.1H NMR (300 MHz,
CD.sub.3OD) .delta. 2.63 (s, 3H), 3.40 (dd, J=7.32, 5.13 Hz, 2H),
4.10 (m, 1H), 4.33 (dd, J=10.62, 4.76 Hz, 1H), 4.47 (dd, J=10.99,
2.93 Hz, 1H), 7.30 (t, J=7.69 Hz, 1H), 7.39 (d, J=7.32 Hz, 1H),
7.52 (d, J=7.69 Hz, 1H), 7.63 (d, J=8.79 Hz, 1H), 7.74 (d, J=8.79
Hz, 1H), 8.11 (s, 2H), 8.45 (s, 1H), 8.75 (s, 1H); Anal. Calcd for
C.sub.22H.sub.20Cl.sub.2N.sub.4O.box-solid.- 3.5TFA: C, 42.15; H,
2.87; N, 6.78. Found: C, 41.86; H, 3.05; N, 6.60.
EXAMPLE 277
(1S)-1-Biphenyl-3-ylmethyl-2-[5-(3-methyl-1H-indazol-5-yl)-pyridin-3-yloxy-
]-ethylamine
[0697] MS (APCI) m/z 435 (M+1).sup.+; .sup.1H NMR (300 MHz,
CD.sub.3OD) .delta. 2.61 (s, 3H), 3.25 (d, J=7.69 Hz, 2H), 4.05 (m,
1H), 4.33 (dd, J=10.62, 5.13 Hz, 1H), 4.46 (d, J=10.25 Hz, 1H),
7.36 (m, 4H), 7.46 (t, J=7.14 Hz, 1H), 7.57 (m, 6H), 8.06 (s, 2H),
8.42 (s, 1H), 8.69 (s, 1H); Anal. Calcd for
C.sub.28H.sub.26N.sub.4O.box-solid.3.2 TFA: C, 51.68; H, 3.68; N,
7.01. Found: C, 51.94; H, 3.66; N, 6.85.
EXAMPLE 278
(1S)-1-(3-Chloro-4-fluoro-benzyl)-2-[5-(3-methyl-1H-indazol-5-yl)-pyridin--
3-yloxy]-ethylamine
[0698] MS (APCI) m/z 411 (M+1).sup.+; .sup.1H NMR (300 MHz,
CD.sub.3OD) .delta. 2.62 (s, 3H) 3.15 (t, J=7.12 Hz, 2H) 3.98 (m,
1H) 4.28 (dd, J=10.51, 5.42 Hz, 1H) 4.44 (dd, J=10.51, 3.05 Hz, 1H)
7.23 (d, J=8.48 Hz, 1H) 7.30 (m, 1H) 7.51 (dd, J=7.12, 2.03 Hz, 1H)
7.62 (d, J=8.81 Hz, 1H) 7.72 (dd, J=8.48, 1.36 Hz, 1H) 7.99 (s, 1H)
8.08 (s, 1H) 8.39 (s, 1H) 8.68 (s, 1H); Anal. Calcd for
C.sub.22H.sub.20ClFN.sub.4O.box-solid.2.7 TFA: C, 45.79; H, 3.18;
N, 7.80. Found: C, 45.86; H, 3.44; N, 7.66.
EXAMPLE 279
(1S)-1-(4-Chloro-3-fluoro-benzyl)-2-[5-(3-methyl-1H-indazol-5-yl)-pyridin--
3-yloxy]-ethylamine
[0699] MS (APCI) m/z 411 (M+1).sup.+; .sup.1H NMR (300 MHz,
CD.sub.3OD) .delta. 2.63 (s, 3H), 3.17 (t, J=6.95 Hz, 2H), 4.00 (m,
1H), 4.28 (dd, J=10.51, 5.43 Hz, 1H), 4.44 (dd, J=10.51, 3.05 Hz,
1H), 7.17 (dd, J=8.14, 1.70 Hz, 1H), 7.29 (dd, J=10.00, 1.87 Hz,
1H), 7.49 (t, J=7.97 Hz, 1H), 7.62 (d, J=8.82 Hz, 1H), 7.73 (d,
J=7.12 Hz, 1H), 8.01 (m, 1H), 8.09 (s, 1H), 8.40 (d, J=2.37 Hz,
1H), 8.68 (d, J=1.70 Hz, 1H); Anal. Calcd for
C.sub.22H.sub.20ClFN.sub.4O.box-solid.2.7 TFA: C, 45.79; H, 3.18;
N, 7.80. Found: C, 45.86; H, 3.44; N, 7.66.
EXAMPLE 280
(1S)-2-[5-(3-Methyl-1H-indazol-5-yl)-pyridin-3-yloxy]-1-(4-trifluoromethox-
y-benzyl)-ethylamine
[0700] MS (APCI) m/z 443 (M+1).sup.+; .sup.1H NMR (300 MHz,
CD.sub.3OD) .delta. 2.62 (s, 3H) 3.20 (t, J=6.95 Hz, 2H) 3.98 (m,
1H) 4.28 (dd, J=10.51, 5.42 Hz, 1H) 4.43 (dd, J=10.51, 2.71 Hz, 1H)
7.30 (d, J=7.80 Hz, 2H) 7.45 (d, J=8.48 Hz, 2H) 7.62 (d, J=8.48 Hz,
1H) 7.73 (d, J=8.81 Hz, 1H) 8.00 (s, 1H) 8.08 (s, 1H) 8.40 (s, 1H)
8.68 (s, 1H). Anal. Calcd for
C.sub.23H.sub.21F.sub.3N.sub.4O.sub.2.box-solid.2.4 TFA: C, 46.63;
H, 3.29; N, 7.82. Found: C, 46.57; H, 3.30; N, 7.80.
EXAMPLE 281
(1S)-1-(2-Fluoro-4-trifluoromethyl-benzyl)-2-[5-(3-methyl-1H-indazol-5-yl)-
-pyridin-3-yloxy]-ethylamine
[0701] MS (APCI) m/z 445 (M+1).sup.+; .sup.1H NMR (300 MHz,
CD.sub.3OD) .delta. 2.62 (s, 3H), 3.31 (m, 2H), 4.04 (m, 1H), 4.29
(dd, J=10.85, 5.09 Hz, 1H), 4.45 (dd, J=10.85, 3.39 Hz, 1H), 7.54
(d, J=8.81 Hz, 1H), 7.55 (s, 1H), 7.60 (dd, J=4.07, 3.39 Hz, 1H),
7.63 (s, 1H), 7.72 (dd, J=8.81, 1.70 Hz, 1H), 7.96 (s, 1H), 8.07
(s, 1H), 8.39 (s, 1H), 8.67 (s, 1H).
EXAMPLE 282
(1S)-1-(3-Fluoro-5-trifluoromethyl-benzyl)-2-[5-(3-methyl-1H-indazol-5-yl)-
-pyridin-3-yloxy]-ethylamine
[0702] MS (APCI) m/z 445 (M+1).sup.+; .sup.1H NMR (300 MHz,
CD.sub.3OD) .delta. 2.62 (s, 3H), 3.30 (m, 2H), 4.06 (m, 1H), 4.29
(dd, J=10.51, 5.09 Hz, 1H), 4.45 (dd, J=10.85, 3.05 Hz, 1H), 7.45
(dd, J=7.80, 5.76 Hz, 2H), 7.55 (s, 1H), 7.62 (d, J=8.81 Hz, 1H),
7.73 (d, J=8.48 Hz, 1H), 7.98 (s, 1H), 8.07 (s, 1H), 8.42 (br s,
1H), 8.73 (br s, 1H).
EXAMPLE 283
(1S)-1-(2-Methoxy-benzyl)-2-[5-(3-methyl-1H-indazol-5-yl)-pyridin-,3-yloxy-
]-ethylamine
[0703] MS (APCI) m/z 389 (M+1).sup.+; .sup.1H NMR (300 MHz,
CD.sub.3OD) .delta. 2.62 (s, 3H), 3.16 (d, J=7.46 Hz, 2H), 3.85 (s,
3H), 3.99 (m, 1H), 4.23 (dd, J=10.51, 5.76 Hz, 1H), 4.39 (dd,
J=10.85, 3.39 Hz, 1H), 6.94 (t, J=7.46 Hz, 1H), 7.03 (d, J=8.14 Hz,
1H), 7.23 (d, J=7.46 Hz, 1H), 7.32 (dd, J=8.14, 7.46 Hz, 1H), 7.62
(d, J=8.48 Hz, 1H), 7.71 (d, J=8.82 Hz, 1H), 7.91 (d, J=2.03 Hz,
1H), 8.06 (s, 1H), 8.34 (d, J=2.71 Hz, 1H), 8.65 (s, 1H).
EXAMPLE 284
(3-{(2S)-2-Amino-3-[5-(3-methyl-1H-indazol-5-yl)-pyridin-3-yloxy]-propyl}--
phenyl)-dimethyl-amine
[0704] MS (DCI/NH.sub.3) m/e 402 (M+1).sup.+; .sup.1H NMR (300 MHz,
CD.sub.3OD) .delta.=8.73 (s; 1H), 8.43 (s; 1H), 8.10 (m; 2H), 7.74
(d; 1H; J=7.5 Hz), 7.63 (d; 1H; J=7.5 Hz), 7.38(t; 1H; J=7.5 Hz),
7.09 (s; 1H), 7.08 (d; 1H; J=7.5 Hz), 7.04 (d; 1H; J=7.5 Hz), 4.45
(dd; 1H; J=10.8 Hz; J=3.0 Hz), 4.31 (dd; 1H; J=10.8 Hz; J=6.0 Hz),
4.00 (m; 1H), 3.17 (m; 2H), 3.05 (s; 6H), 2.64 (s; 3H).
EXAMPLE 285
(1S)-1-(4-Chloro-2-methyl-benzyl)-2-[5-(3-methyl-1H-indazol-5-yl)-pyridin--
3-yloxy]-ethylamine
[0705] MS (DCI/NH.sub.3) m/e 407 (M+1).sup.+; .sup.1H NMR (300 MHz,
CD.sub.3OD) .delta.=8.71 (s; 1H), 8.41 (s; 1H), 8.10 (s; 1H), 8.04
(s; 1H), 7.73 (d; 1H; J=8.1 Hz), 7.62 (d; 1H; J=8.1 Hz), 7.28 (s;
1H), 7.22 (m; 2H), 4.40 (dd; 1H; J=10.8 Hz; J=3.0 Hz), 4.26 (dd;
1H; J=10.8 Hz; J=4.5 Hz), 3.94 (m; 1H), 3.17 (m; 2H), 2.62 (s; 3H),
2.39 (s; 3H).
EXAMPLE 286
(1S)-1-(3-Iodo-benzyl)-2-[5-(3-methyl-1H-indazol-5-yl)-pyridin-3-yloxy]-et-
hylamine
[0706] MS (DCI/NH.sub.3) m/e 485 (M+1).sup.+; .sup.1H NMR (300 MHz,
CD.sub.3OD) .delta.=8.65 (s; 1H), 8.36 (s; 1H), 8.07 (s; 1H), 7.92
(s; 1H), 7.75 (s; 1H), 7.72 (d; 1H; J=8.1 Hz), 7.68 (d; 1H; J=7.8
Hz), 7.62 (d; 1H; J=8.1 Hz), 7.35 (d; 1H; J=7.8 Hz), 7.16 (d; 1H;
J=7.8 Hz), 4.40 (dd; 1H; J=10.8 Hz; J=3.0 Hz), 4.24 (dd; 1H; J=10.8
Hz; J=4.5 Hz), 3.96 (m; 1H), 3.12 (m; 2H), 2.62 (s; 3H).
EXAMPLE 287
(1S)-(1S)-1-(3-Fluoro-4-methyl-benzyl)-2-[5-(3-methyl-1H-indazol-5-yl)-pyr-
idin-3-yloxy]-ethylamine
[0707] MS (DCI/NH.sub.3) m/e 391 (M+1).sup.4; .sup.1H NMR (300 MHz,
CD.sub.3OD) .delta.=8.73 (s; 1H), 8.42 (s; 1H), 8.12 (s; 1H), 8.10
(s; 1H), 7.74 (d; 1H; J=8.1 Hz), 7.63 (d; 1H; J=8.14 Hz), 7.24 (t;
1H; J=8.4 Hz), 7.05 (m; 2H), 4.44 (dd; 1H; J=10.8 Hz; J=3.0 Hz),
4.28 (dd; 1H; J=10.8 Hz; J=4.5 Hz), 3.97 (m; 1H), 3.13 (m; 2H),
2.62 (s; 3H), 2.23 (s; 3H).
EXAMPLE 288
(1S)-1-(3-Fluoro-4-methoxy-benzyl)-2-[5-(3-methyl-1H-indazol-5-yl)-pyridin-
-3-yloxy]-ethylamine
[0708] MS (DCI/NH.sub.3) m/e 407 (M+1).sup.+; .sup.1H NMR (300 MHz,
CD.sub.3OD) .delta.=8.73 (s; 1H), 8.42 (s; 1H), 8.12 (s; 1H), 8.10
(s; 1H), 7.74 (d; 1H; J=8.1 Hz), 7.63 (d; 1H; J=8.1 Hz), 7.24 (t;
1H; J=8.4 Hz), 7.05 (m; 2H), 4.44 (dd; 1H; J=10.8 Hz; J=3.0 Hz),
4.28 (dd; 1H; J=10.8 Hz; J=4.5 Hz), 3.97 (m; 1H), 3.13 (m; 2H),
2.62 (s; 3H), 2.23 (s; 3H).
EXAMPLE 289
(1S)-2-[6-Chloro-5-(3-methyl-1H-indazol-5-yl)-pyridin-3-yloxy]-1-(3,4-dich-
loro-benzyl)-ethylamine
[0709] MS (DCI/NH.sub.3) m/e 462 (M+1).sup.+; .sup.1H NMR (300 MHz,
CD.sub.3OD) .delta.=8.16 (s; 1H), 7.78 (s; 1H), 7.54 (m; 4H), 7.48
(d; 1H; J=8.1 Hz), 7.25 (d; 1H; J=8.1 Hz), 4.32 (dd; 1H; J=10.8 Hz;
J=3.0 Hz), 4.15 (dd; 1H; J=10.8 Hz; J=4.5 Hz), 3.93 (m; 1H), 3.12
(m; 2H), 2.58 (s; 3H).
EXAMPLE 290
(1S)-1-(2-Fluoro-6-trifluoromethyl-benzyl)-2-[5-(3-methyl-1H-indazol-5-yl)-
-pyridin-3-yloxy]-ethylamine
[0710] MS (DCI/NH.sub.3) m/e 445 (M+1).sup.+; .sup.1H NMR (300 MHz,
CD.sub.3OD) .delta. 8.69 (s; 1H), 8.36 (s; 1H), 8.08 (s; 1H), 7.96
(s; 1H), 7.73 (d; 1H; J=8.1 Hz), 7.63 (m; 3H), 7.50 (t; 1H; J=9.0
Hz), 4.44 (dd; 1H; J=10.8 Hz; J=3.0 Hz), 4.32 (dd; 1H; J=10.8 Hz;
J=4.5 Hz), 4.08 (m; 1H), 3.48 (m; 1H), 3.35 (m; 1H), 2.62 (s;
3H).
EXAMPLE 291
(1S)-1-(4-Fluoro-3-trifluoromethyl-benzyl)-2-[5-(3-methyl-1H-indazol-5-yl)-
-pyridin-3-yloxy]-ethylamine
[0711] MS (DCI/NH.sub.3) m/e 445 (M+1).sup.+; .sup.1H NMR (300 MHz,
CD.sub.3OD) .delta.=8.70 (s; 1H), 8.41 (s; 1H), 8.09 (s; 1H), 8.04
(s; 1H), 7.74 (d; 1H; J=8.1 Hz), 7.68 (m; 1H), 7.62 (d; 1H; J=8.1
Hz), 7.36 (t; 1H; J=9.0 Hz), 4.44 (dd; 1H; J=10.8 Hz; J=3.0 Hz),
4.28 (dd; 1H; J=10.8 Hz; J=4.5 Hz), 4.02 (m; 1H), 3.23 (m; 2H),
2.62 (s; 3H).
EXAMPLE 292
(1S)-1-Furan-2-ylmethyl-2-[5-(3-methyl-1H-indazol-5-yl)-pyridin-3-yloxy]-e-
thylamine
[0712] MS (DCI/NH.sub.3) m/e 349 (M+1).sup.+; .sup.1H NMR (300 MHz,
CD.sub.3OD) .delta.=8.68 (s; 1H), 8.39 (s; 1H), 8.09 (m; 1H), 8.00
(s; 1H), 7.73 (d; 1H; J=9.0 Hz), 7.62 (d; 1H; J=9.0 Hz), 7.50 (s;
1H), 6.42 (m; 1H), 6.33 (m; 1H), 4.49 (dd; 1H; J=10.8 Hz; J=3.0
Hz), 4.31 (dd; 1H; J=10.8 Hz; J=4.5 Hz), 4.02 (m; 1H), 3.24 (m;
2H), 2.62 (s; 3H).
EXAMPLE 293
(1S)-1-Benzofuran-2-ylmethyl-2-[5-(3-methyl-1H-indazol-5-yl)-pyridin-3-ylo-
xy]-ethylamine
[0713] MS (DCI/NH.sub.3) m/e 398 (M+1).sup.+; .sup.1H NMR (300 MHz,
CD.sub.3OD) .delta.=8.72 (s; 1H), 8.42 (s; 1H), 8.09 (m; 2H), 7.72
(d; 1H; J=9.0 Hz), 7.62 (d; 1H; J=9.0 Hz), 7.55 (d; 1H; J=8.4 Hz),
7.45 (d; 1H; J=8.4 Hz), 7.44 (m; 2H), 6.78 (s; 1H), 4.58 (dd; 1H;
J=10.8 Hz; J=3.0 Hz), 4.44 (dd; 1H; J=10.8 Hz; J=4.5 Hz), 4.18 (m;
1H), 3.41 (m; 2H), 2.62 (s; 3H).
EXAMPLE 294
(1S)-1-(3-Fluoro-4-trifluoromethyl-benzyl)-2-[5-(3-methyl-1H-indazol-5-yl)-
-pyridin-3-yloxy]-ethyl Amine
[0714] MS (DCI/NH.sub.3) m/e 445 (M+1).sup.+; .sup.1H NMR (300 MHz,
CD.sub.3OD) .delta.=8.74 (s; 1H), 8.44 (s; 1H), 8.13 (m; 2H), 7.75
(d; 1H; J=8.1 Hz), 7.70 (t; 1H; J=8.4 Hz), 7.43 (d; 1H; J=8.4 Hz),
7.40 (d; 1H; J=12.0 Hz), 7.38 (d; 1H; J=8.1 Hz), 4.48 (dd; 1H;
J=10.8 Hz; J=3.0 Hz), 4.32 (dd; 1H; J=10.8 Hz; J=4.5 Hz), 4.08 (m;
1H), 3.28 (m; 2H), 2.62 (s; 3H).
EXAMPLE 295
(1S)-1-(4-Chloro-3-methyl-benzyl)-2-[5-(3-methyl-1H-indazol-5-yl)-pyridin--
3-yloxy]-ethylamine
[0715] MS (DCI/NH.sub.3) m/e 407 (M+1).sup.+; .sup.1H NMR (300 MHz,
CD.sub.3OD) .delta.=8.71 (s; 1H), 8.41 (s; 1H), 8.10 (s; 1H), 8.05
(s; 1H), 7.73 (d; 1H; J=8.4 Hz), 7.63 (d; 1H; J=8.4 Hz), 7.36 (d;
1H; J=8.4 Hz), 7.27 (s; 1H), 7.15 (d; 1H; J=8.4 Hz), 4.44 (dd; 1H;
J=10.8 Hz, J=3.0 Hz), 4.28 (dd; 1H; J=10.8 Hz; J=4.5 Hz), 3.96 (m;
1H), 3.11 (m; 2H), 2.62 (s; 3H), 2.34 (s; 3H).
EXAMPLE 296
(1S)-1-Furan-3-ylmethyl-2-[5-(3-methyl-1H-indazol-5-yl)-pyridin-3-yloxy]-e-
thylamine
[0716] MS (DCI/NH.sub.3) m/e 349 (M+1).sup.+; .sup.1H NMR (300 MHz,
CD.sub.3OD) .delta.=8.73 (s; 1H), 8.43 (s; 1H), 8.12 (m; 2H), 7.74
(d; 1H; J=8.4 Hz), 7.63 (d; 1H; J=8.4 Hz), 7.53 (m; 2H), 6.47 (m;
1H), 4.49 (dd; 1H; J=10.8 Hz; J=3.0 Hz), 4.33 (dd; 1H; J=10.8 Hz;
J=4.5 Hz), 3.91 (m; 1H), 3.00 (m; 2H), 2.62 (s; 3H).
EXAMPLE 297
(1S)-1-(2-Fluoro-5-methyl-benzyl)-2-[5-(3-methyl-1H-indazol-5-yl)-pyridin--
3-yloxy]-ethylamine
[0717] MS (DCI/NH.sub.3) m/e 391 (M+1).sup.+; .sup.1H NMR (300 MHz,
CD.sub.3OD) .delta.=8.65 (s; 1H), 8.36 (s; 1H), 8.05 (s; 1H), 7.90
(s; 1H), 7.70 (d; 1H; J=8.4 Hz), 7.62 (d; 1H; J=8.4 Hz), 7.09 (s;
1H), 7.27 (d; 1H; J=8.1 Hz) 7.18 (t; 1H; J=8.1 Hz), 4.39 (dd; 1H;
J=10.8 Hz; J=3.0 Hz), 4.25 (dd; 1H; J=10.8 Hz; J=4.5 Hz), 4.04 (m;
1H), 3.28 (m; 2H), 2.62 (s; 3H), 2.30 (s; 3H).
EXAMPLE 298
(1S)-1-(3-Chloro-5-fluoro-benzyl)-2-[5-(3-methyl-1H-indazol-5-yl)-pyridin--
3-yloxy]-ethylamine
[0718] MS (DCI/NH.sub.3) m/e 411 (M+1).sup.+; .sup.1H NMR (300 MHz,
CD.sub.3OD) .delta.=8.71 (s; 1H), 8.41 (s; 1H), 8.10 (s; 1H), 8.06
(s; 1H), 7.73 (d; 1H; J=8.4 Hz), 7.63 (d; 1H; J=8.4 Hz), 7.26 (s;
1H), 7.18 (d; 1H; J=8.4 Hz), 7.12 (d; 1H; J=8.4 Hz), 4.46 (dd; 1H;
J=10.8 Hz; J=3.0 Hz), 4.30 (dd; 1H; J=10.8 Hz; J=4.5 Hz), 4.02 (m;
1H), 3.18 (m; 2H), 2.62 (s; 3H).
EXAMPLE 299
(1S)-2-[5-(3-Methyl-1H-indazol-5-yl)-pyridin-3-yloxy]-1-(3,4,5-trifluoro-b-
enzyl)-ethylamine
[0719] MS (DCI/NH.sub.3) m/e 413 (M+1).sup.+; .sup.1H NMR (300 MHz,
CD.sub.3OD) .delta.=8.73 (s; 1H), 8.44 (s; 1H), 8.10 (m; 2H), 7.74
(d; 1H; J=8.4 Hz), 7.63 (d; 1H; J=8.4 Hz), 7.17 (t; 2H; J=9.0 Hz),
4.47 (dd; 1H; J=10.8 Hz; J=3.0 Hz), 4.32 (dd; 1H; J=10.8 Hz; J=4.5
Hz), 4.00 (m; 1H), 3.15 (m; 2H), 2.62 (s; 3H).
EXAMPLE 300
(1S)-1-(4-Fluoro-3-methyl-benzyl)-2-[5-(3-methyl-1H-indazol-5-yl)-pyridin--
3-yloxy]-ethylamine
[0720] MS (DCI/NH.sub.3) m/e 391 (M+1).sup.+; .sup.1H NMR (300 MHz,
CD.sub.3OD) .delta.=8.73 (s; 1H), 8.42 (s; 1H), 8.12 (s; 1H), 8.08
(s; 1H), 7.73 (d; 1H; J=8.4 Hz), 7.62 (d; 1H; J=8.4 Hz), 7.18 (m;
2H), 7.03 (t; 1H; J=9.0 Hz), 4.44 (dd; 1H; J=10.8 Hz; J=3.0 Hz),
4.28 (dd; 1H; J=10.8 Hz; J=4.5 Hz), 3.94 (m; 1H), 3.10 (m; 2H),
2.62 (s; 3H), 2.24 (s; 3H).
EXAMPLE 301
(1S)-1-(2,4-Dichloro-benzyl)-2-[5-(3-methyl-1H-indazol-5-yl)-pyridin-3-ylo-
xy]-ethylamine
[0721] MS (DCI/NH.sub.3) m/e 428 (M+1).sup.+; .sup.1H NMR (300 MHz,
CD.sub.3OD) .delta.=8.69 (s; 1H), 8.40 (s; 1H), 8.10 (s; 1H), 8.00
(s; 1H), 7.73 (d; 1H; J=8.4 Hz), 7.62 (d; 1H; J=8.4 Hz), 7.56 (s;
1H), 7.41 (d; 1H; J=8.1 Hz), 7.36 (d; 1H; J=8.1), 4.43 (dd; 1H;
J=10.8 Hz; J=3.0 Hz), 4.28 (dd; 1H; J=10.8 Hz; J=4.5 Hz), 4.05 (m;
1H), 3.31 (m; 2H), 2.62 (s; 3H).
EXAMPLE 302
(1S)-1-(4-Chloro-3-trifluoromethyl-benzyl)-2-[5-(3-methyl-1H-indazol-5-yl)-
-pyridin-3-yloxy]-ethylamine
[0722] MS (DCI/NH.sub.3) m/e 461 (M+1).sup.+; .sup.1H NMR (300 MHz,
CD.sub.3OD) .delta.=8.69 (s; 1H), 8.39 (s; 1H), 8.08 (s; 1H), 8.00
(s; 1H), 7.79 (s; 1H), 7.72 (d; 1H; J=8.4 Hz), 7.62 (m; 3H), 4.44
(dd; 1H; J=10.8 Hz; J=3.0 Hz), 4.28 (dd; 1H; J=10.8 Hz; J=4.5 Hz),
4.02 (m; 1H), 3.26 (m; 2H), 2.62 (s; 3H). 95
EXAMPLE 303
(1S)-2-[5-(3-Methyl-1H-indazol-5-yl)-pyridin-3-yloxy]-1-(2-trifluoromethox-
y-benzyl)-ethylamine
[0723] MS (DCI/NH.sub.3) m/e 443 (M+1).sup.+; .sup.1H NMR (300 MHz,
CD.sub.3OD) .delta. 8.70 (s; 1H), 8.39 (s; 1H), 8.09 (s; 1H), 8.01
(s; 1H), 7.73 (d; 1H; J=8.4 Hz), 7.63 (d; 1H; J=8.4 Hz), 7.42 (m;
4H), 4.40 (dd; 1H; J=10.8 Hz; J=3.0 Hz), 4.24 (dd; 1H; J=10.8 Hz;
J=4.5 Hz), 4.00 (m; 1H), 3.28 (m; 2H), 2.62 (s; 3H).
EXAMPLE 304
(1S)-1-(2,5-Dimethoxy-benzyl)-2-[5-(3-methyl-1H-indazol-5-yl)-pyridin-3-yl-
oxy]-ethylamine
[0724] MS (DCI/NH.sub.3) m/e 419 (M+1).sup.+; .sup.1H NMR (300 MHz,
CD.sub.3OD) .delta.=8.71 (s; 1H), 8.40 (s; 1H), 8.10 (s; 1H), 8.04
(s; 1H), 7.73 (d; 1H; J=8.4 Hz), 7.63 (d; 1H; J=8.4 Hz), 6.95 (d;
1H; J=9.0 Hz), 6.85 (m; 2H), 4.43 (dd; 1H; J=10.8 Hz; J=3.0 Hz),
4.27 (dd; 1H; J=10.8 Hz; J=4.5 Hz), 4.00 (m; 1H), 3.80 (s; 3H),
3.69 (s; 3H), 3.13 (m; 2H), 2.62 (s; 3H).
EXAMPLE 305
(1S)-2-[5-(3-Methyl-1H-indazol-5-yl)-pyridin-3-yloxy]-1-(4-methylsulfanyl--
benzyl)-ethylamine
[0725] MS (DCI/NH.sub.3) m/e 405 (M+1).sup.+; .sup.1H NMR (300 MHz,
CD.sub.3OD) .delta.=8.73 (s; 1H), 8.62 (s; 1H), 8.12 (s; 1H), 8.08
(s; 1H), 7.73 (d; 1H; J=8.4 Hz), 7.63 (d; 1H; J=8.4 Hz), 7.28 (s;
4H), 4.44 (dd; 1H; J=10.8 Hz; J=3.0 Hz), 4.29 (dd; 1H; J=10.8 Hz;
J=4.5 Hz), 3.95 (m; 1H), 3.12 (m; 2H), 2.62 (s; 3H), 2.44 (s;
3H).
EXAMPLE 306
(1S)-1-(2-Cyclohexyl-benzyl)-2-[5-(3-methyl-1H-indazol-5-yl)-pyridin-3-ylo-
xy]-ethylamine
[0726] MS (DCI/NH.sub.3) m/e 441 (M+1).sup.+; .sup.1H NMR (300 MHz,
CD.sub.3OD) .delta.=8.70 (s; 1H), 8.40 (s; 1H), 8.07 (s; 1H), 8.01
(s; 1H), 7.71 (d; 1H; J=8.4 Hz), 7.62 (d; 1H; J=8.4 Hz), 7.34 (d;
1H; J=7.8 Hz), 7.25 (m; 2H), 7.16 (t; 1H; J=7.8 Hz), 4.37 (dd; 1H;
J=10.8 Hz; J=3.0 Hz), 4.23 (dd; 1H; J=10.8 Hz; J=4.5 Hz), 3.38 (m;
1H), 3.27 (m; 2H), 2.77 (m; 1H), 2.62 (s; 3H), 1.85 (m; 1H), 1.74
(m; 4H), 1.48 (m; 3H), 1.29 (m, 2H).
EXAMPLE 307
(1S)-1-(2,5-Dichloro-benzyl)-2-[5-(3-methyl-1H-indazol-5-yl)-pyridin-3-ylo-
xy]-ethylamine
[0727] MS (DCI/NH.sub.3) m/e 428 (M+).sup.+; .sup.1H NMR (300 MHz,
CD.sub.3OD) .delta.=8.71 (s; 1H), 8.41 (s; 1H), 8.10 (s; 1H), 8.04
(s; 1H), 7.73 (d; 1H; J=8.4 Hz), 7.63 (d; 1H; J=8.4 Hz), 7.48 (m;
2H), 7.36 (d; 1H; J=8.4 Hz), 4.44 (dd; 1H; J=10.8 Hz; J=3.0 Hz),
4.28 (dd; 1H; J=10.8 Hz; J=4.5 Hz), 4.07 (m; 1H), 3.36 (m; 2H),
2.62 (s; 3H).
EXAMPLE 308
(1S)-1-(2,5-Dimethyl-benzyl)-2-[5-(3-methyl-1H-indazol-5-yl)-pyridin-3-ylo-
xy]-ethylamine
[0728] MS (DCI/NH.sub.3) m/e 387 (M+1).sup.+; .sup.1H NMR (300 MHz,
CD.sub.3OD) .delta.=8.74 (s; 1H), 8.2 (s; 1H), 8.11 (s; 1H), 8.08
(s; 1H), 7.73 (d; 1H; J=8.4 Hz), 7.63 (d; 1H; J=8.4 Hz), 7.11 (d;
1H; J=8.1 Hz), 7.03 (m; 2H), 4.41 (dd; 1H; J=10.8 Hz; J=3.0 Hz),
4.28 (dd; 1H; J=10.8 Hz; J=4.5 Hz), 3.94 (m; 1H), 3.14 (m; 2H),
2.62 (s; 3H), 2.34 (s; 3H), 2.23 (s; 3H).
EXAMPLE 309
(1S)-1-(2,3-Dimethyl-benzyl)-2-[5-(3-methyl-1H-indazol-5-yl)-pyridin-3-ylo-
xy]-ethylamine
[0729] MS (DCI/NH.sub.3) m/e 387 (M+1).sup.+; .sup.1H NMR (300 MHz,
CD.sub.3OD) .delta.=8.65 (s; 1H), 8.35 (s; 1H), 8.05 (s; 1H), 7.90
(s; 1H), 7.70 (d; 1H; J=8.4 Hz), 7.60 (d; 1H; J=8.4 Hz), 7.07 (m;
3H), 4.35 (dd; 1H; J=10.8 Hz; J=3.0 Hz), 4.22 (dd; 1H; J=10.8 Hz;
J=4.5 Hz), 3.88 (m; 1H), 3.21 (m; 2H), 2.62 (s; 3H), 2.31 (s; 3H),
2.28 (s; 3H).
EXAMPLE 310
(1S)-1-(3,4-Dichloro-benzyl)-2-[5-(3-methyl-1H-indazol-5-yl)-pyridin-3-ylo-
xy]-ethylamine
[0730] MS (DCI/NH.sub.3) m/e 428 (M+1).sup.+; .sup.1H NMR (300 MHz,
CD.sub.3OD) .delta.=8.68 (s; 1H), 8.39 (s; 1H), 8.08 (s; 1H), 7.98
(s; 1H), 7.72 (d; 1H; J=8.4 Hz), 7.62 (d; 1H; J=8.4 Hz), 7.56 (s;
1H), 7.54 (d; 1H; J=8.4 Hz), 7.28 (d; 1H; J=8.4 Hz), 4.43 (dd; 1H;
J=10.8 Hz; J=3.0 Hz), 4.27 (dd; 1H; J=10.8 Hz; J=4.5 Hz), 3.99 (m;
1H), 3.16 (m; 2H), 2.62 (s; 3H).
EXAMPLE 311
(1S)-1-(2,4-Dimethyl-benzyl)-2-[5-(3-methyl-1H-indazol-5-yl)-pyridin-3-ylo-
xy]-ethylamine
[0731] MS (DCI/NH.sub.3) m/e 387 (M+1).sup.+; .sup.1H NMR (300 MHz,
CD.sub.3OD) .delta. 8.68 (s; 1H), 8.37 (s; 1H), 8.08 (s; 1H), 7.96
(s; 1H), 7.71 (d; 1H; J=8.4 Hz), 7.61 (d; 1H; J=8.4 Hz), 7.10 (d;
1H; J=7.5 Hz), 7.06 (s; 1H), 6.98 (d; 1H; J=7.5 Hz), 4.37 (dd; 1H;
J=10.8 Hz; J=3.0 Hz), 4.24 (dd; 1H; J=10.8 Hz; J=4.5 Hz), 3.90 (m;
1H), 3.14 (m; 2H), 2.62 (s; 3H), 2.35 (s; 3H), 2.26 (s; 3H).
EXAMPLE 312
(1S)-1-(3-Fluoro-4-trifluoromethyl-benzyl)-2-[5-(3-methyl-1H-indazol-5-yl)-
-pyridin-3-yloxy]-ethylamine
[0732] MS (DCI/NH.sub.3) m/e 445 (M+1).sup.+; .sup.1H NMR (300 MHz,
CD.sub.3OD) .delta.=8.68 (s; 1H), 8.39 (s; 1H), 8.08 (s; 1H), 7.98
(s; 1H), 7.72 (d; 1H; J=8.4 Hz), 7.70 (d; 1H; J=8.4 Hz), 7.62 (d;
1H; J=8.4 Hz), 7.39 (d; 1H; J=12.0 Hz), 7.35 (d; 1H; J=8.4 Hz),
4.44 (dd; 1H; J=10.8 Hz; J=3.0 Hz), 4.28 (dd; 1H; J=10.8 Hz; J=4.5
Hz), 4.05 (m; 1H), 3.28 (m; 2H), 2.62 (s; 3H).
EXAMPLE 313
(1S)-1-(3,5-Dimethyl-benzyl)-2-[5-(3-methyl-1H-indazol-5-yl)-pyridin-3-ylo-
xy]-ethylamine
[0733] MS (DCI/NH.sub.3) m/e 387 (M+1).sup.+; .sup.1H NMR (300 MHz,
CD.sub.3OD) .delta.=8.68 (s; 1H), 8.38 (s; 1H), 8.08 (s; 1H), 7.97
(s; 1H), 7.71 (d; 1H; J=8.4 Hz), 6.94 (m; 3H), 4.41 (dd; 1H; J=10.8
Hz; J=3.0 Hz), 4.25 (dd; 1H; J=10.8 Hz; J=4.5 Hz), 3.92 (m; 1H),
3.07 (m; 2H), 2.62 (s; 3H), 2.26 (s; 6H).
EXAMPLE 314
(1S)-1-Biphenyl-2-ylmethyl-2-[5-(3-methyl-1H-indazol-5-yl)-pyridin-3-yloxy-
]-ethylamine
[0734] MS (DCI/NH.sub.3) m/e 435 (M+1).sup.+; .sup.1H NMR (300 MHz,
CD.sub.3OD) .delta.=8.64 (s; 1H), 8.11 (s; 1H), 8.05 (s; 1H), 7.70
(d; 1H; J=8.4 Hz), 7.68 (s; 1H), 7.63 (d; 1H; J=8.4 Hz), 7.34 (m;
9H), 4.12 (dd; 1H; J=10.8 Hz; J=3.0 Hz), 3.89 (dd; 1H; J=10.8 Hz;
J=4.5 Hz), 3.64 (m; 1H), 3.39 (dd; 1H; J=14.4 Hz; J=9.3 Hz), 3.16
(dd; 1H; J=14.4 Hz, J=4.5 Hz), 2.62 (s; 3H).
EXAMPLE 315
(1S)-1-(3,4-Dimethyl-benzyl)-2-[5-(3-methyl-1H-indazol-5-yl)-pyridin-3-ylo-
xy]-ethylamine
[0735] MS (DCI/NH.sub.3) m/e 387 (M+1).sup.+; .sup.1H NMR (300 MHz,
CD.sub.3OD) .delta.=8.69 (s; 1H), 8.38 (s; 1H), 8.08 (s; 1H), 7.99
(s; 1H), 7.72 (d; 1H; J=8.4 Hz), 7.62 (d; 1H; J=8.4 Hz), 7.08 (m;
3H), 4.41 (dd; 1H; J=10.8 Hz; J=3.0 Hz), 4.26 (dd; 1H; J=10.8 Hz;
J=4.5 Hz), 3.91 (m; 1H), 3.08 (m; 2H), 2.62 (s; 3H), 2.29 (s; 3H),
2.23 (s; 3H).
EXAMPLE 316
(1S)-1-(2,3-Difluoro-benzyl)-2-[5-(3-methyl-1H-indazol-5-yl)-pyridin-3-ylo-
xy]-ethylamine
[0736] MS (DCI/NH.sub.3) m/e 395 (M+1).sup.+; .sup.1H NMR (300 MHz,
CD.sub.3OD) .delta.=8.74(s; 1H), 8.44 (s; 1H), 8.12 (s; 2H), 7.74
(d; 1H; J=8.4 Hz), 7.62 (d; 1H; J=8.4 Hz), 7.19 (m; 3H), 4.48 (dd;
1H; J=10.8 Hz; J=3.0 Hz), 4.32 (dd; 1H; J=10.8 Hz; J=4.5 Hz), 4.03
(m; 1H), 3.30 (m; 2H), 2.62 (s; 3H).
EXAMPLE 317
(1S)-1-(2,5-Difluoro-benzyl)-2-[5-(3-methyl-1H-indazol-5-yl)-pyridin-3-ylo-
xy]-ethylamine
[0737] MS (DCI/NH.sub.3) m/e 395 (M+1).sup.+; .sup.1H NMR (300 MHz,
CD.sub.3OD) .delta.=8.77 (s; 1H), 8.46 (s; 1H), 8.18 (s; 1H), 8.13
(s; 1H), 7.75 (d; 1H; J=8.4 Hz), 7.63 (d; 1H; J=8.4 Hz), 7.17 (m;
3H), 4.49 (dd; 1H; J=10.8 Hz; J=3.0 Hz), 4.33 (dd; 1H; J=10.8 Hz;
J=4.5 Hz), 4.02 (m; 1H), 3.12 (m; 2H), 2.62 (s; 3H).
EXAMPLE 318
(1S)-1-(2,6-Dichloro-benzyl)-2-[5-(3-methyl-1H-indazol-5-yl)-pyridin-3-ylo-
xy]-ethylamine
[0738] MS (DCI/NH.sub.3) m/e 428 (M+1).sup.+; .sup.1H NMR (300 MHz,
CD.sub.3OD) .delta.=8.64 (s; 1H), 8.33 (s; 1H), 8.05 (s; 1H), 7.88
(s; 1H), 7.70 (d; 1H; J=8.4 Hz), 7.61 (d; 1H; J=8.4 Hz), 7.48 (d;
2H; J=7.2 Hz), 7.33 (t; 1H; J=7.2 Hz), 4.40 (dd; 1H; J=10.8 Hz;
J=3.0 Hz), 4.29 (dd; 1H; J=10.8 Hz; J=4.5 Hz), 4.10 (m; 1H), 3.67
(dd; 1H; J=15.0 Hz; J=9.6 Hz), 3.43 (dd; 1H; J=15.0 Hz; J=5.4 Hz),
2.62 (s; 3H).
EXAMPLE 319
(1S)-1-(2,4-Difluoro-benzyl)-2-[5-(3-methyl-1H-indazol-5-yl)-pyridin-3-ylo-
xy]-ethylamine
[0739] MS (DCI/NH.sub.3) m/e 395 (M+1).sup.+; .sup.1H NMR (300 MHz,
CD.sub.3OD) .delta.=8.67 (s; 1H), 8.37 (s; 1H), 8.08 (s; 1H), 7.94
(s; 1H), 7.71 (d; 1H; J=8.4 Hz), 7.61 (d; 1H; J=8.4 Hz), 7.40(m;
1H), 7.01 (m; 2H), 4.43 (dd; 1H; J=10.8 Hz; J=3.0 Hz), 4.27 (dd;
1H; J=10.8 Hz; J=4.5 Hz), 3.96 (m; 1H), 3.10 (m; 2H), 2.62 (s;
3H).
EXAMPLE 320
(1S)-1-(2,6-Dimethyl-benzyl)-2-[5-(3-methyl-1H-indazol-5-yl)-pyridin-3-ylo-
xy]-ethylamine
[0740] MS (DCI/NH.sub.3) m/e 387 (M+1).sup.+; .sup.1H NMR (300 MHz,
CD.sub.3OD) .delta.=8.62 (s; 1H), 8.32 (s; 1H), 8.03 (s; 1H), 7.83
(s; 1H), 7.69 (d; 1H; J=8.4 Hz), 7.60 (d; 1H; J=8.4 Hz), 7.70 (m;
3H), 4.29 (dd; 1H; J=10.8 Hz; J=3.0 Hz), 4.16 (dd; 1H; J=10.8 Hz;
J=4.5 Hz), 3.92 (m; 1H), 3.37 (dd; 1H; J=15.0 Hz; J=10.5 Hz), 3.15
(dd; 1H; J=15.0 Hz; J=5.4 Hz), 2.62 (s; 3H), 2.38 (s; 6H).
EXAMPLE 321
(1S)-1-(2,3-Dihydro-benzo[1,4]dioxin-6-ylmethyl)-2-[5-(3-methyl-1H-indazol-
-5-yl)-pyridin-3-yloxy]-ethylamine
[0741] MS (DCI/NH.sub.3) m/e 417 (M+1).sup.+; .sup.1H NMR (300 MHz,
CD.sub.3OD) .delta.=8.64 (s; 1H), 8.36 (s; 1H), 8.07 (s; 1H), 7.91
(s; 1H), 7.71 (d; 1H; J=8.4 Hz), 7.61 (d; 1H; J=8.4 Hz), 6.80(m;
3H), 4.40 (dd; 1H; J=10.8 Hz; J=3.0 Hz), 4.23 (dd; 1H; J=10.8 Hz;
J=4.5 Hz), 4.20 (s; 4H), 3.88 (m; 1H), 3.03 (m; 2H), 2.62 (s;
3H).
EXAMPLE 322
(1S)-1-(3,5-Difluoro-benzyl)-2-[5-(3-methyl-1H-indazol-5-yl)-pyridin-3-ylo-
xy]-ethylamine
[0742] MS (DCI/NH.sub.3) m/e 395 (M+1).sup.+; .sup.1H NMR (300 MHz,
CD.sub.3OD) .delta.=8.67 (s; 1H), 8.39 (s; 1H), 8.08 (s; 1H), 7.98
(s; 1H), 7.73 (d; 1H; J=8.4 Hz), 7.61 (d; 1H; J=8.4 Hz), 6.97(m;
3H), 4.44 (dd; 1H; J=10.8 Hz; J=3.0 Hz), 4.29 (dd; 1H; J=10.8 Hz;
J=4.5 Hz), 4.01 (m; 1H), 3.19 (m; 2H), 2.62 (s; 3H).
EXAMPLE 323
(1S)-1-(2,6-Difluoro-benzyl)-2-[5-(3-methyl-1H-indazol-5-yl)-pyridin-3-ylo-
xy]-ethylamine
[0743] MS (DCI/NH.sub.3) m/e 395 (M+1).sup.+; .sup.1H NMR (300 MHz,
CD.sub.3OD) .delta.=8.41 (s; 1H), 8.31 (s; 1H), 8.04 (s; 1H), 7.84
(s; 1H), 7.70 (d; 1H; J=8.4 Hz), 7.60 (d; 1H; J=8.4 Hz), 7.40(m;
1H), 7.06 (m; 2H), 4.42 (dd; 1H; J=10.8 Hz; J=3.0 Hz), 4.24 (dd;
1H; J=10.8 Hz; J=4.5 Hz), 3.97 (m; 1H), 3.31 (m; 2H), 2.62 (s; 3H).
96
EXAMPLE 324
(1S)-1-Benzo[1,3]dioxol-5-ylmethyl-2-[5-(3-methyl-1H-indazol-5-yl)-pyridin-
-3-yloxy]-ethylamine
[0744] MS (APCI) m/z 404 (M+1).sup.+; .sup.1H NMR (500 MHz,
CD.sub.3OD) .delta. ppm 2.63 (s, 3H), 3.08 (dd, J=7.64, 2.65 Hz,
2H), 3.92 (m, 1H), 4.32 (dd, J=10.45, 5.77 Hz, 1H), 4.46 (dd,
J=10.61, 2.81 Hz, 1H), 5.92 (d, J=1.87 Hz, 2H), 6.80 (d, J=1.87 Hz,
2H), 6.85 (s, 1H), 7.64 (d, J=8.73 Hz, 1H), 7.74 (dd, J=8.73, 1.56
Hz, 1H), 8.12 (s, 1H), 8.14 (d, J=1.87 Hz, 1H), 8.45 (d, J=1.87 Hz,
1H), 8.74 (s, 1H); Anal. Calcd for C.sub.23H.sub.22N.sub.4O.sub.3:
C, 48.46; H, 3.55; N, 8.02. Found: C, 48.59; H, 3.65; N, 8.13.
EXAMPLE 325
(S)-1-(4-Fluoro-3-methyl-benzyl)-2-[5-(3-methyl-1H-indazol-5-yl)-pyridin-3-
-yloxy]-ethylamine
[0745] MS (APCI) m/z 392 (M+1).sup.+; .sup.1H NMR (500 MHz,
CD.sub.3OD) .delta. ppm 2.24 (s, 3H), 2.63 (s, 3H), 3.11 (dd,
J=7.64, 3.90 Hz, 2H), 3.94 (m, 1H), 4.29 (dd, J=10.61, 5.62 Hz,
1H), 4.44 (dd, J=10.61, 2.81 Hz, 1H), 7.03 (m, 1H), 7.16 (m, 1H),
7.21 (d, J=7.18 Hz, 1H), 7.63 (d, J=8.73 Hz, 1H), 7.74 (d, J=1.87
Hz, 1H), 8.06 (s, 1H), 8.10 (s, 1H), 8.42 (s, 1H), 8.71 (s, 1H);
Anal. Calcd for C.sub.23H.sub.23FN.sub.4O: C, 50.79; H, 3.91; N,
8.58. Found: C, 51.10; H, 4.02; N, 8.43.
EXAMPLE 326
(S)-2-[5-(3-Methyl-1H-indazol-5-yl)-pyridin-3-yloxy]-1-(2,4,6-trimethyl-be-
nzyl)-ethylamine
[0746] MS (APCI) m/z 402 (M+1).sup.+; .sup.1H NMR (500 MHz,
CD.sub.3OD) .delta. ppm 2.21 (s, 3H), 2.34 (s, 6H), 2.62 (s, 3H),
3.14 (dd, J=14.19, 5.46 Hz, 2H), 3.92 (m, J=8.73, 4.99 Hz, 1H),
4.26 (dd, J=10.45, 4.84 Hz, 1H), 4.36 (m, 1H), 6.89 (s, 2H), 7.63
(d, J=8.74 Hz, 1H), 7.72 (dd, J=8.73, 1.56 Hz, 1H), 8.11 (s, 2H),
8.42 (s, 1H), 8.75 (s, 1H); Anal. Calcd for
C.sub.25H.sub.21N.sub.4O: C, 52.56; H, 4.48; N, 8.17. Found: C,
52.49; H, 4.41; N, 8.06.
EXAMPLE 327
(1S)-1-(2,4-Dimethoxy-benzyl)-2-[5-(3-methyl-1H-indazol-5-yl)-pyridin-3-yl-
oxy]-ethylamine
[0747] MS (APCI) m/z 419 (M+1).sup.+; .sup.1H NMR (500 MHz,
CD.sub.3OD) .delta. ppm 2.63 (s, 3H), 3.08 (dd, J=7.33, 2.96 Hz,
2H), 3.77 (s, 3H), 3.83 (s, 3H), 3.94 (m, 1H), 4.26 (dd, J=10.45,
5.77 Hz, 1H), 4.41 (dd, J=10.61, 3.12 Hz, 1H), 6.50 (dd, J=8.27,
2.34 Hz, 1H), 6.59 (d, J=2.50 Hz, 1H), 7.12 (d, J=8.42 Hz, 1H),
7.63 (d, J=8.73 Hz, 1H), 7.72 (m, 1H), 8.00 (s, 1H), 8.09 (s, 1H),
8.40 (s, 1H), 8.71 (s, 1H).
EXAMPLE 328
(1S)-2-[5-(3-Methyl-1H-indazol-5-yl)-pyridin-3-yloxy]-1-(4-trifluoromethyl-
-benzyl)-ethylamine
[0748] MS (APCI) m/z 428 (M+1).sup.+; .sup.1H NMR (500 MHz,
CD.sub.3OD) .delta. ppm 2.63 (s, 3H), 3.28 (m, 2H), 4.05 (m, 1H),
4.32 (dd, J=10.61, 5.30 Hz, 1H), 4.47 (dd, J=10.61, 2.81 Hz, 1H),
7.56 (d, J=7.80 Hz, 2H), 7.63 (d, J=8.74 Hz, 1H), 7.69 (d, J=8.11
Hz, 2H), 7.74 (dd, J=8.74, 1.56 Hz, 1H), 8.12 (d, J=6.55 Hz, 2H),
8.45 (br s, 1H), 8.74 (br s, 1H); Anal. Calcd for
C.sub.23H.sub.21F.sub.3N.sub.4O: C, 46.45; H, 3.25; N, 7.63. Found:
C, 46.55; H, 3.30; N, 7.64.
EXAMPLE 329
(1S)-1-(5-Fluoro-2-methyl-benzyl)-2-[5-(3-methyl-1H-indazol-5-yl)-pyridin--
3-yloxy]-ethylamine
[0749] MS (APCI) m/z 391 (M+1).sup.+; .sup.1H NMR (500 MHz,
CD.sub.3OD) .delta. ppm 2.36 (s, 3H), 2.62 (s, 3H), 3.16 (dd,
J=14.19, 6.71 Hz, 1H), 3.23 (m, 1H), 3.97 (m, 1H), 4.29 (dd,
J=10.45, 4.84 Hz, 1H), 4.42 (dd, J=10.61, 3.12 Hz, 1H), 6.95 (td,
J=8.42, 2.81 Hz, 1H), 7.04 (dd, J=9.67, 2.81 Hz, 1H), 7.25 (dd,
J=8.42, 5.93 Hz, 1H), 7.63 (d, J=8.74 Hz, 1H), 7.73 (dd, J=8.73,
1.56 Hz, 1H), 8.05 (s, 1H), 8.09 (s, 1H), 8.42 (s, 1H), 8.71 (s,
1H); Anal. Calcd for C.sub.23H.sub.23FN.sub.4O: C, 49.31; H, 3.76;
N, 8.16. Found: C, 49.28; H, 3.61; N, 8.10.
EXAMPLE 330
(1S)-1-(3,5-Bis-trifluoromethyl-benzyl)-2-[5-(3-methyl-1H-indazol-5-yl)-py-
ridin-3-yloxy]-ethylamine
[0750] MS (APCI) m/z 495 (M+1).sup.+; .sup.1H NMR (500 MHz,
CD.sub.3OD) .delta. ppm 2.62 (s, 3H), 3.35 (m, 1H), 3.42 (m, 1H),
4.12 (m, 1H), 4.31 (dd, J=10.61, 5.30 Hz, 1H), 4.49 (dd, J=10.61,
3.12 Hz, 1H), 7.63 (d, J=8.73 Hz, 1H), 7.73 (dd, J=8.74, 1.87 Hz,
1H), 7.94 (s, 1H), 8.01 (s, 2H), 8.05 (s, 1H), 8.08 (s, 1H), 8.43
(s, 1H), 8.72 (s, 1H); Anal. Calcd for
C.sub.24H.sub.20F.sub.6N.sub.4O: C, 43.69; H, 2.82; N, 6.89. Found:
C, 43.70; H, 2.65; N, 6.82.
EXAMPLE 331
(1S)-1-(4-Fluoro-2-methyl-benzyl)-2-[5-(3-methyl-1H-indazol-5-yl)-pyridin--
3-yloxy]-ethylamine
[0751] MS (APCI) m/z 392 (M+1).sup.+; .sup.1H NMR (500 MHz,
CD.sub.3OD) .delta. ppm 2.40 (s, 3H), 2.62 (s, 3H), 3.15 (dd,
J=14.19, 6.40 Hz, 1H), 3.22 (m, 1H), 3.94 (m, 1H), 4.29 (dd,
J=10.61, 4.99 Hz, 1H), 4.42 (dd, J=10.61, 2.81 Hz, 1H), 6.91 (td,
J=8.42, 2.50 Hz, 1H), 7.00 (dd, J=9.83, 2.34 Hz, 1H), 7.26 (dd,
J=8.42, 5.93 Hz, 1H), 7.63 (d, J=8.74 Hz, 1H), 7.73 (dd, J=8.74,
1.25 Hz, 1H), 8.08 (s, 1H), 8.10 (s, 1H), 8.43 (s, 1H), 8.72 (s,
1H); Anal. Calcd for C.sub.23H.sub.23FN.sub.4O: C, 48.40; H, 3.66;
N, 7.89. Found: C, 48.59; H, 3.85; N, 7.90.
EXAMPLE 332
(1S)-1-(5-Fluoro-2-methoxy-benzyl)-2-[5-(3-methyl-1H-indazol-5-yl)-pyridin-
-3-yloxy]-ethylamine
[0752] MS (APCI) m/z 408 (M+1).sup.+; .sup.1H NMR (500 MHz,
CD.sub.3OD) .delta. ppm 2.63 (s, 3H), 3.16 (d, J=7.18 Hz, 2H), 3.84
(s, 3H), 4.02 (m, 1H), 4.30 (dd, J=10.61, 5.93 Hz, 1H), 4.45 (dd,
J=10.45, 2.96 Hz, 1H), 7.04 (m, 3H), 7.64 (d, J=8.73 Hz, 1H), 7.74
(d, J=8.74 Hz, 1H), 8.12 (s, 2H), 8.43 (s, 1H), 8.74 (s, 1H); Anal.
Calcd for C.sub.23H.sub.23FN.sub.4- O.sub.2: C, 44.73; H, 3.32; N,
6.96. Found: C, 44.77; H, 3.46; N, 6.83.
EXAMPLE 333
(1S)-2-[5-(3-Methyl-1H-indazol-5-yl)-pyridin-3-yloxy]-1-(2-methyl-naphthal-
en-1-ylmethyl)-ethylamine
[0753] MS (APCI) m/z 424 (M+1).sup.+; .sup.1H NMR (500 MHz,
CD.sub.3OD) .delta. ppm 2.58 (s, 3H), 2.61 (s, 3H), 3.61 (dd,
J=14.19, 4.84 Hz, 1H), 3.84 (dd, J=14.19, 10.76 Hz, 1H), 4.06 (m,
J=9.20, 4.21 Hz, 1H), 4.14 (dd, J=10.29, 3.74 Hz, 1H), 4.28 (dd,
J=10.45, 2.65 Hz, 1H), 7.41 (m, 3H), 7.60 (d, J=8.42 Hz, 1H), 7.65
(m, 1H), 7.75 (d, J=8.42 Hz, 1H), 7.84 (m, 2H), 8.01 (s, 1H), 8.12
(d, J=8.11 Hz, 1H), 8.33 (s, 1H), 8.66 (s, 1H); Anal. Calcd for
C.sub.27H.sub.26N.sub.4O: C, 52.30; H, 3.87; N, 7.44. Found: C,
52.56; H, 4.00; N, 7.38.
EXAMPLE 334
(1S)-1-(2,2-Difluoro-benzo[1,3]dioxol-4-ylmethyl)-2-[5-(3-methyl-1H-indazo-
l-5-yl)-pyridin-3-yloxy]-ethylamine
[0754] MS (APCI) m/z 437 (M-1).sup.+; .sup.1H NMR (500 MHz,
CD.sub.3OD) .delta. ppm 2.63 (s, 3H), 3.28 (m, 2H), 4.07 (m, 1H),
4.34 (dd, J=10.61, 4.99 Hz, 1H), 4.51 (dd, J=10.61, 2.81 Hz, 1H),
7.17 (m, 3H), 7.64 (d, J=8.73 Hz, 1H), 7.75 (d, J=8.73 Hz, 1H),
8.12 (s, 1H), 8.16 (s, 1H), 8.46 (s, 1H), 8.76 (s, 1H); Anal. Calcd
for C.sub.23H.sub.20F.sub.2N.sub.4O.su- b.3: C, 44.63; H, 2.97; N,
7.18. Found: C, 44.74; H, 3.08; N, 7.23.
EXAMPLE 335
(1S)-1-(4-Fluoro-naphthalen-1-ylmethyl)-2-[5-(3-methyl-1H-indazol-5-yl)-py-
ridin-3-yloxy]-ethylamine
[0755] MS (APCI) m/z 428 (M+1).sup.+; .sup.1H NMR (500 MHz,
CD.sub.3OD) .delta. ppm 2.62 (s, 3H), 3.60 (dd, J=14.04, 6.55 Hz,
1H), 3.66 (m, 1H), 4.09 (m, 1H), 4.29 (dd, J=10.61, 4.99 Hz, 1H),
4.42 (dd, J=10.61, 3.12 Hz, 1H), 7.19 (dd, J=10.29, 7.80 Hz, 1H),
7.47 (dd, J=7.80, 5.30 Hz, 1H), 7.61 (d, J=8.73 Hz, 2H), 7.64 (d,
J=7.18 Hz, 1H), 7.68 (t, J=8.11 Hz, 1H), 7.96 (s, 1H), 8.05 (s,
1H), 8.15 (d, J=8.11 Hz, 1H), 8.18 (d, J=8.42 Hz, 1H), 8.38 (s,
1H), 8.68 (s, 1H).
EXAMPLE 336
(1S)-2-[5-(3-Methyl-1H-indazol-5-yl)-pyridin-3-yloxy]-1-(2,2,3,3-tetrafluo-
ro-2,3-dihydro-benzo[1,4]dioxin-6-ylmethyl)-ethylamine
[0756] MS (APCI) m/z 487 (M-1).sup.+; .sup.1H NMR (500 MHz,
CD.sub.3OD) .delta. ppm 2.63 (s, 3H), 3.18 (dd, J=14.19, 7.02 Hz,
1H), 3.24 (m, 1H), 4.02 (m, J=5.15, 2.65 Hz, 1H), 4.33 (dd,
J=10.45, 5.46 Hz, 1H), 4.47 (dd, J=10.61, 3.12 Hz, 1H), 7.29 (m,
2H), 7.34 (s, 1H), 7.63 (d, J=8.73 Hz, 1H), 7.74 (dd, J=8.74, 1.25
Hz, 1H), 8.11 (s, 2H), 8.44 (s, 1H), 8.72 (s, 1H); Anal. Calcd for
C.sub.23H.sub.20F.sub.2N.sub.4O.sub.3: C, 43.08; H, 2.77; N, 6.65.
Found: C, 42.94; H, 2.79; N, 6.64.
EXAMPLE 337
(1S)-2-[5-(3-Methyl-1H-indazol-5-yl)-pyridin-3-yloxy]-1-(4-methyl-naphthal-
en-1-ylmethyl)-ethylamine
[0757] MS (APCI) m/z 421 (M-1).sup.+; .sup.1H NMR (500 MHz,
CD.sub.3OD) .delta. ppm 2.61 (d, J=8.11 Hz, 3H), 2.67 (s, 3H), 3.62
(m, 2H), 4.09 (m, 1H), 4.28 (dd, J=10.61, 4.99 Hz, 1H), 4.40 (dd,
J=10.61, 3.12 Hz, 1H), 7.32 (d, J=7.49 Hz, 1H), 7.38 (m, 1H), 7.58
(m, 2H), 7.62 (d, J=8.73 Hz, 1H), 7.68 (m, 1H), 7.97 (s, 1H), 8.06
(s, 1H), 8.10 (m, 1H), 8.15 (m, 1H), 8.37 (d, J=2.50 Hz, 1H), 8.68
(s, 1H); Anal. Calcd for C.sub.27H.sub.26N.sub.4O: C, 52.79; H,
3.91; N, 7.55. Found: C, 52.64; H, 3.85; N, 7.53.
EXAMPLE 338
(1S)-2-[5-(3-Methyl-1H-indazol-5-yl)-pyridin-3-yloxy]-1-(2,4,6-trifluoro-b-
enzyl)-ethylamine
[0758] MS (APCI) m/z 411 (M-1).sup.+; .sup.1H NMR (500 MHz,
CD.sub.3OD) .delta. ppm 2.63 (s, 3H), 3.19 (m, 2H), 3.97 (m, 1H),
4.32 (dd, J=10.61, 4.99 Hz, 1H), 4.49 (dd, J=10.61, 3.12 Hz, 1H),
6.95 (t, J=8.27 Hz, 2H), 7.63 (d, J=8.73 Hz, 1H), 7.74 (dd, J=8.74,
1.56 Hz, 1H), 8.08 (d, J=2.18 Hz, 1H), 8.10 (s, 1H), 8.41 (s, 1H),
8.72 (s, 1H);Anal. Calcd for C.sub.22H.sub.19F.sub.3N.sub.4O: C,
44.57; H, 2.94; N, 7.43. Found: C, 44.47; H, 2.78; N, 7.46.
EXAMPLE 339
(1S)-2-[5-(3-Methyl-1H-indazol-5-yl)-pyridin-3-yloxy]-1-(2,3,4-trifluoro-b-
enzyl)-ethylamine
[0759] .sup.1H NMR (500 MHz, CD.sub.3OD) .delta. ppm 2.62 (s, 3H),
3.23 (m, 2H), 4.00 (m, 1H), 4.31 (dd, J=10.61, 5.30 Hz, 1H), 4.46
(dd, J=10.61, 3.12 Hz, 1H), 7.17 (m, 2H), 7.62 (d, J=8.73 Hz, 1H),
7.73 (dd, J=8.74, 1.56 Hz, 1H), 8.02 (s, 1H), 8.08 (s, 1H), 8.40
(s, 1H), 8.69 (s, 1H); Anal. Calcd for
C.sub.22H.sub.19F.sub.3N.sub.4O: C, 45.31; H, 3.00; N, 7.66. Found:
C, 45.59; H, 2.73; N, 7.84.
EXAMPLE 340
(1S)-1-(4-Bromo-2-fluoro-benzyl)-2-[5-(3-methyl-1H-indazol-5-yl)-pyridin-3-
-yloxy]-ethylamine
[0760] .sup.1H NMR (500 MHz, CD.sub.3OD) .delta. ppm 2.63 (s, 3H),
3.22 (m, 2H), 4.00 (m, 1H), 4.34 (dd, J=10.61, 5.30 Hz, 1H), 4.49
(dd, J=10.61, 3.12 Hz, 1H), 7.33 (t, J=8.11 Hz, 1H), 7.37 (d,
J=1.56 Hz, 1H), 7.41 (m, 1H), 7.64 (d, J=8.73 Hz, 1H), 7.75 (dd,
J=8.74, 1.56 Hz, 1H), 8.13 (s, 1H), 8.19 (s, 10H), 8.46 (s, 1H),
8.77 (s, 1H); Anal. Calcd for C.sub.22H.sub.20BrFN.sub.4O: C,
42.80; H, 2.97; N, 7.23. Found: C, 42.73; H, 3.17; N, 7.02.
EXAMPLE 341
(1S)-1-(4-Bromo-3-fluoro-benzyl)-2-[5-(3-methyl-1H-indazol-5-yl)-pyridin-3-
-yloxy]-ethylamine
[0761] MS (ESI) m/z 456 (M+1).sup.+; .sup.1H NMR (500 MHz,
CD.sub.3OD) .delta. ppm 2.63 (s, 3H), 3.18 (m, 2H), 4.01 (m, 1H),
4.32 (dd, J=10.61, 5.62 Hz, 1H), 4.46 (dd, J=10.61, 2.81 Hz, 1H),
7.11 (dd, J=8.11, 1.56 Hz, 1H), 7.26 (dd, J=9.36, 1.87 Hz, 1H),
7.62 (d, J=7.18 Hz, 1H), 7.63 (d, J=8.42 Hz, 1H), 7.74 (dd, J=8.73,
1.56 Hz, 1H), 8.10 (d, J=4.06 Hz, 2H), 8.43 (s, 1H), 8.72 (s,
1H);Anal. Calcd for C.sub.22H.sub.20BrFN.sub.4O: C, 43.46; H, 3.03;
N, 7.45. Found: C, 43.52; H, 3.07; N, 7.43.
EXAMPLE 342
(1S)-1-(2-Bromo-4,6-difluoro-benzyl)-2-[5-(3-methyl-1H-indazol-5-yl)-pyrid-
in-3-yloxy]-ethylamine
[0762] .sup.1H NMR (500 MHz, CD.sub.3OD) .delta. ppm 2.63 (s, 3H),
3.32 (m, 1H), 3.48 (m, 1H), 4.03 (m, 1H), 4.34 (dd, J=10.45, 4.84
Hz, 1H), 4.48 (dd, J=10.61, 3.43 Hz, 1H), 7.13 (t, J=8.11 Hz, 1H),
7.40 (d, J=8.11 Hz, 1H), 7.63 (d, J=8.73 Hz, 1H), 7.74 (dd, J=8.73,
1.56 Hz, 1H), 8.09 (s, 1H), 8.11 (s, 1H), 8.42 (s, 1H), 8.73 (s,
1H); Anal. Calcd for C.sub.22H.sub.19BrF.sub.2N.sub.4O: C, 41.24;
H, 2.72; N, 6.87. Found: C, 41.35; H, 2.68; N, 6.76.
EXAMPLE 343
(1S)-1-(4-Bromo-3-methyl-benzyl)-2-[5-(3-methyl-1H-indazol-5-yl)-pyridin-3-
-yloxy]-ethylamine
[0763] MS (ESI) m/z 452 (M+1).sup.+; .sup.1H NMR (500 MHz,
CD.sub.3OD) .delta. ppm 2.37 (s, 3H), 2.63 (s, 3H), 3.11 (m, 2H),
3.97 (m, 1H), 4.29 (dd, J=10.61, 5.62 Hz, 1H), 4.44 (dd, J=10.61,
3.12 Hz, 1H), 7.07 (dd, J=8.11, 1.87 Hz, 1H), 7.27 (s, 1H), 7.54
(d, J=8.11 Hz, 1H), 7.63 (d, J=8.73 Hz, 1H), 7.73 (d, J=8.73 Hz,
1H), 8.06 (s, 1H), 8.10 (s, 1H), 8.41 (s, 1H), 8.71 (s, 1H);Anal.
Calcd for C.sub.23H.sub.23BrN.sub.4O: C, 44.93; H, 3.41; N, 7.38.
Found: C, 45.11; H, 3.36; N, 7.28.
EXAMPLE 344
(1S)-Bromo-benzyl)-2-[5-(3-methyl-1H-indazol-5-yl)-pyridin-3-yloxy]-ethyla-
mine
[0764] .sup.1H NMR (500 MHz, CD.sub.3OD) .delta. ppm 2.62 (s, 3H),
3.37 (m, 2H), 4.10 (m, 1H), 4.30 (dd, J=10.61, 4.99 Hz, 1H), 4.43
(dd, J=10.61, 3.12 Hz, 1H), 7.25 (t, J=6.71 Hz, 1H), 7.37 (t,
J=6.86 Hz, 1H), 7.42 (m, 1H), 7.63 (d, J=8.74 Hz, 1H), 7.66 (d,
J=8.11 Hz, 1H), 7.73 (dd, J=8.73, 1.56 Hz, 1H), 8.03 (d, J=1.87 Hz,
1H), 8.09 (s, 1H), 8.40 (s, 1H), 8.70 (s, 1H); Anal. Calcd for
C.sub.22H.sub.21BrN.sub.4O: C, 43.48; H, 3.14; N, 7.30. Found: C,
43.67; H, 3.06; N, 7.10.
EXAMPLE 345
(1S)-1-(3-Methoxy-benzyl)-2-[5-(3-methyl-1H-indazol-5-yl)-pyridin-3-yloxy]-
-ethylamine
[0765] MS m/z 389 (M+H).sup.+; .sup.1H NMR (300 MHz, DMSO-D6)
.delta. ppm 2.57 (s, 3H) 3.00 (dd, J=13.56, 9.16 Hz, 1H) 3.12 (m,
1H) 3.73 (s, 3H) 4.28 (dd, J=10.85, 5.43 Hz, 1H) 4.44 (m, 2H) 6.85
(dd, J=8.48, 2.37 Hz, 1H) 6.91 (m, 2H) 7.27 (t, J=7.80 Hz, 1H) 7.61
(d, J=8.82 Hz, 1H) 7.79 (dd, J=8.82, 1.70 Hz, 1H) 8.23 (s, 1H) 8.26
(s, 1H) 8.53 (d, J=2.37 Hz, 4H) 8.86 (s, 1H).
EXAMPLE 346
(1S)-1-(3-Bromo-benzyl)-2-[5-(3-methyl-1H-indazol-5-yl)-pyridin-3-yloxy]-e-
thylamine
[0766] MS m/z 437, 439 (M+H).sup.+; .sup.1H NMR (300 MHz, DMSO-D6)
.delta. ppm 2.57 (s, 3H) 3.08 (m, 2H) 4.27 (dd, J=10.85, 5.43 Hz,
1H) 4.43 (m, 1H) 7.34 (m, 2H) 7.49 (dt, J=7.54, 1.65 Hz, 1H) 7.61
(m, 2H) 7.77 (dd, J=8.65, 1.53 Hz, 1H) 8.14 (s, 1H) 8.22 (s, 1H)
8.49 (s, 2H) 8.82 (s, 1H).
EXAMPLE 347
(1S)-1-(2-Methoxy-naphthalen-1-ylmethyl)-2-[5-(3-methyl-1H-indazol-5-yl)-p-
yridin-3-yloxy]-ethylamine
[0767] MS (ESI) m/e 439 (M+1).sup.+; .sup.1H NMR (300 MHz, Solvent)
.delta. ppm 2.62 (s, 3H) 3.55 (m, 1H) 3.74 (m, 1H) 3.97 (s, 3H)
4.03 (m, 1H) 4.23 (m, 1H) 4.39 (m, 1H) 7.33 (m, 1H) 7.46 (m, 2H)
7.64 (m, 2H) 7.84 (m, 1H) 7.92 (m, 2H) 8.03 (m, 2H) 8.34 (br. s.,
1H) 8.67 (br. s., 1H).
EXAMPLE 348
(1R)-1-(4-Chloro-benzyl)-2-[5-(3-methyl-1H-indazol-5-yl)-pyridin-3-yloxy]--
ethylamine
Example 348A
5-[5-((2R)-1-tert-Butoxycarbonyl-aziridin-2-ylmethoxy)-pyridin-3-yl]-3-met-
hyl-indazole-1-carboxylic Acid Tert-Butyl Ester
[0768] The desired product was prepared by substituting
(S)-[1-(tert-Butyl-dimethyl-silanyloxymethyl)-2-hydroxy-ethyl]-carbamic
acid tert-butyl ester for
(R)-[1-(tert-Butyl-dimethyl-silanyloxymethyl)-2-
-hydroxy-ethyl]-carbamic acid tert-butyl ester in Example 273D. MS
(APCI) m/z 481 (M+1).sup.+.
Example 348B
(1R)-1-(4-Chloro-benzyl)-2-[5-(3-methyl-1H-indazol-5-yl)-pyridin-3-yloxy]--
ethylamine
[0769] The desired product was prepared as the trifluoroacetate by
substituting Example 348A for Example 273D and
4-chlorophenylmagnesium bromide for
3-trifluoromethoxyphenyl-mangnesium bromide in Example 274. MS
(APCI) m/z 393 (M+1).sup.+; .sup.1H NMR (300 MHz, CD.sub.3OD)
.delta. 2.63 (s, 3H), 3.16 (dd, J=7.63, 2.54 Hz, 2H), 3.98 (m, 1H),
4.30 (dd, J=10.51, 5.42 Hz, 1H), 4.45 (dd, J=10.51, 3.05 Hz, 1H),
7.34 (d, J=8.81 Hz, 2H), 7.39 (d, J=8.81 Hz, 2H), 7.63 (d, J=8.81
Hz, 1H), 7.74 (dd, J=8.81, 1.70 Hz, 1H), 8.11 (m, 2H), 8.43 (d,
J=2.03 Hz, 1H), 8.73 (s, 1H); Anal. Calcd for
C.sub.22H.sub.21ClN.sub.4O.box-solid.3 TFA: C, 45.76; H, 3.29; N,
7.62. Found: C, 45.86; H, 3.28; N, 7.72.
[0770] The following compounds were prepared by substituting
appropriate Girgnard reagents for
3-trifluoromethoxyphenyl-mangnesium bromide in Example 348.
EXAMPLE 349
(1R)-1-Benzo[1,3]dioxol-5-ylmethyl-2-[5-(3-methyl-1H-indazol-5-yl)-pyridin-
-3-yloxy]-ethylamine
[0771] MS (APCI) m/z 403 (M+1).sup.+; .sup.1H NMR (300 MHz,
CD.sub.3OD) .delta. 2.63 (s, 3H), 3.08 (dd, J=8.14, 2.03 Hz, 2H),
3.92 (m, 1H), 4.31 (dd, J=10.51, 5.76 Hz, 1H), 4.46 (dd, J=10.51,
3.05 Hz, 1H), 5.92 (s, 2H), 6.79 (d, J=8.14 Hz, 1H), 6.81 (d,
J=8.14 Hz, 1H), 6.85 (s, 1H), 7.64 (d, J=8.81 Hz, 1H), 7.75 (d,
J=8.81 Hz, 1H), 8.14 (m, 2H), 8.44 (d, J=2.37 Hz, 1H), 8.75 (d,
J=1.70 Hz, 1H); Anal. Calcd for
C.sub.23H.sub.22N.sub.4O.sub.3.box-solid.3.3 TFA: C, 45.65; H,
3.27; N, 7.19. Found: C, 45.71; H, 3.15; N, 7.21.
EXAMPLE 350
(1R)-1-(3-Fluoro-4-methyl-benzyl)-2-[5-(3-methyl-1H-indazol-5-yl)-pyridin--
3-yloxy]-ethylamine
[0772] MS (APCI) m/z 391 (M+1).sup.+; .sup.1H NMR (300 MHz,
CD.sub.3OD) .delta. 2.24 (d, J=1.70 Hz, 3H), 2.63 (s, 3H), 3.11 (d,
J=8.14 Hz, 2H), 3.96 (m, 1H), 4.31 (dd, J=10.51, 5.76 Hz, 1H), 4.46
(dd, J=10.85, 3.05 Hz, 1H), 7.03 (t, J=8.48 Hz, 1H), 7.15 (m, 1H),
7.21 (d, J=7.46 Hz, 1H), 7.64 (d, J=8.48 Hz, 1H), 7.74 (dd, J=8.81,
1.70 Hz, 1H), 8.14 (m, 2H), 8.45 (d, J=2.37 Hz, 1H), 8.75 (d,
J=1.36 Hz, 1H); Anal. Calcd for
C.sub.23H.sub.23FN.sub.4O.box-solid.2.9 TFA: C, 47.97; H, 3.62; N,
7.77. Found: C, 48.09; H, 3.75; N, 7.87.
EXAMPLE 351
(1S)-1-Benzyl-2-[6-chloro-5-(3-methyl-1H-indazol-5-yl)-pyridin-3-yloxy]-et-
hylamine
Example 351A
5-(2-Chloro-5-hydroxy-pyridin-3-yl)-3-methyl-indazole-1-carboxylic
Acid Tert-Butyl Ester
[0773] A 250 mL RBF was charged with Example 12B (1.58 g, 7.59
mmol), Example 203B (3.0 g, 7.59 mmol), Pd.sub.2(dba).sub.3 (696
mg, 0.76 mmol), and tri-o-tolylphosphine (696 mg), and was purged
with N.sub.2. Anhydrous DMF (60 mL) and Et.sub.3N (3.17 mL) were
added via syringe. The solution was purged with N.sub.2 again and
was heated at 70.degree. C. for 15 h. After cooled, ethyl acetate
(300 mL) was added. The mixture was washed with brine (500 mL) and
water (500 mL). The ethyl acetate solution was concentrated and the
residual oil was separated by flash chromatography (40-65% EtOAc in
hexane) to give the desired produc. (1.86 g, 68%). MS (APCI) m/z
360 (M+1).sup.+.
Example 351B
5-[5-((2S)-2-tert-Butoxycarbonylamino-3-phenyl-propoxy)-2-chloro-pyridin-3-
-yl]-3-methylindazole-1-carboxylic Acid Tert-Butyl Ester
[0774] A 25 mL RBF was charged with Example 351A (150 mg, 0.417
mmol), Boc-phenylalaminol (157 mg, 0.625 mmol), DBAD (144 mg, 0.625
mmol) and Ph.sub.3P (163 mg, 0.625 mmol), and was purged with
nitrogen. THF (8 mL) was added at 0.degree. C. After stirring at
0.degree. C. for 30 min the ice-H.sub.2O bath was removed and the
reaction mixture was stirred at rt overnight. The reaction mixture
was concentrated and the residue was separated by flash
chromatography (20-40% EtOAc in hexane) to provide the desired
product (215.0 mg, 87%). MS (APCI) m/z 593 (M+1).sup.+.
Example 351C
(1S)-1-Benzyl-2-[6-chloro-5-(3-methyl-1H-indazol-5-yl)-pyridin-3-yloxy]-et-
hylamine
[0775] The desired product was prepared as the trifluoroacetate by
substituting Example 351B for Example 27B in Examples 27C. MS
(APCI) m/z 393 (M+1).sup.+; .sup.1H NMR (300 MHz, CD.sub.3OD)
.delta. 2.58 (s, 3H), 3.12 (d, J=7.46 Hz, 2H), 3.91 (m, 1H), 4.14
(dd, J=10.51, 5.43 Hz, 1H), 4.30 (dd, J=10.51, 3.05 Hz, 1H), 7.34
(m, 5H), 7.47 (dd, J=8.65, 1.53 Hz, 1H), 7.52 (d, J=3.05 Hz, 1H),
7.56 (d, J=8.82 Hz, 1H), 7.78 (s, 1H), 8.14 (d, J=2.71 Hz, 1H);
Anal. Calcd for C.sub.22H.sub.21ClN.sub.4O.box-solid.- 1.6 TFA: C,
52.61; H, 3.96; N, 9.74. Found: C, 52.87; H, 3.90; N, 9.81.
[0776] The following compounds were prepared by substituting the
appropriate Boc-aminoalcohol for Boc-phenylalaminol in Example
351.
EXAMPLE 352
(1S)-1-(4-Bromo-benzyl)-2-[6-chloro-5-(3-methyl-1H-indazol-5-yl)-pyridin-3-
-yloxy]-ethylamine
[0777] MS (APCI) m/z 471, 473 (M+1).sup.+; .sup.1H NMR (300 MHz,
CD.sub.3OD) .delta. 2.59 (s, 3H), 3.10 (dd, J=7.63, 2.88 Hz, 2H),
3.90 (m, 1H), 4.15 (dd, J=10.85, 5.43 Hz, 1H), 4.30 (dd, J=10.51,
3.05 Hz, 1H), 7.24 (d, J=8.48 Hz, 2H), 7.47 (dd, J=8.65, 1.53 Hz,
1H), 7.51 (s, 1H), 7.54 (s, 1H), 7.56 (d, J=8.48 Hz, 2H), 7.79 (s,
1H), 8.15 (d, J=3.05 Hz, 1H); Anal. Calcd for
C.sub.22H.sub.20BrClN.sub.4O.box-solid.1.5 TFA: C, 46.71; H, 3.37;
N, 8.72. Found: C, 46.62; H, 3.29; N, 8.64.
EXAMPLE 353
(1S)-1-(4-Chloro-benzyl)-2-[6-chloro-5-(3-methyl-1H-indazol-5-yl)-pyridin--
3-yloxy]-ethylamine
[0778] MS (APCI) m/z 427 (M+1).sup.+; .sup.1H NMR (300 MHz,
CD.sub.3OD) .delta. 2.59 (s, 3H), 3.12 (dd, J=7.63, 2.54 Hz, 2H),
3.91 (m, 1H), 4.15 (dd, J=10.51, 5.43 Hz, 1H), 4.30 (dd, J=10.51,
3.05 Hz, 1H), 7.30 (d, J=8.48 Hz, 2H), 7.37 (d, J=8.82 Hz, 2H),
7.47 (dd, J=8.65, 1.53 Hz, 1H), 7.53 (d, J=3.05 Hz, 1H), 7.56 (d,
J=8.48 Hz, 1H), 7.79 (s, 1H), 8.15 (d, J=3.05 Hz, 1H); Anal. Calcd
for C.sub.22H.sub.20Cl.sub.2N.sub.4O.box-soli- d.1.6 TFA: C, 49.64;
H, 3.57; N, 9.19. Found: C, 49.99; H, 3.56; N, 9.22.
EXAMPLE 354
(1S)-2-[6-Chloro-5-(3-methyl-1H-indazol-5-yl)-pyridin-3-yloxy]-1-cyclohexy-
lmethyl-ethylamine
[0779] MS (APCI) m/z 399 (M+1).sup.+; .sup.1H NMR (300 MHz,
CD.sub.3OD) .delta. 1.01 (m, 2H), 1.31 (m, 4H), 1.49 (m, 1H), 1.65
(q, J=6.89 Hz, 2H), 1.78 (m, 4H), 2.59 (s, 3H), 3.74 (m, 1H), 4.18
(dd, J=10.51, 6.44 Hz, 1H), 4.37 (dd, J=10.51, 3.39 Hz, 1H), 7.49
(dd, J=8.82, 1.70 Hz, 1H), 7.56 (dd, J=8.48, 0.68 Hz, 1H), 7.59 (d,
J=3.05 Hz, 1H), 7.80 (s, 1H), 8.17 (d, J=3.05 Hz, 1H); Anal. Calcd
for C.sub.22H.sub.27ClN.sub.4O.box-s- olid.1.75 TFA: C, 51.18; H,
4.84; N, 9.36. Found: C, 51.13; H, 4.75; N, 9.20.
EXAMPLE 355
(1S)-2-[6-Chloro-5-(3-methyl-1H-indazol-5-yl)-pyridin-3-yloxy]-1-(2,6-dime-
thyl-benzyl)-ethylamine
[0780] MS (DCI/NH.sub.3) m/e 421 (M+1).sup.+; .sup.1H NMR (300 MHz,
CD.sub.3OD) .delta.=8.10 (d; 1H; J=8.4 Hz), 7.75 (d; 1H; J=8.4 Hz),
7.55 (s; 1H), 7.53 (s; 1H), 7.44 (m; 3H), 7.04 (s; 1H), 4.30 (dd;
1H; J=10.8 Hz; J=3.0 Hz), 4.09 (dd; 1H; J=10.8 Hz; J=4.5 Hz), 4.87
(m; 1H), 3.30 (m; 2H), 2.62 (s; 3H), 2.36 (s; 6H).
EXAMPLE 356
(1S)-1-[6-Chloro-5-(3-methyl-1H-indazol-5-yl)-pyridin-3-yloxymethyl]-2-phe-
nyl-propylamine
[0781] The desired product was prepared by substituting Example 12B
for 3-bromo-5-hydroxypyridine and Boc-3-methyl-phenylalaminol for
Boc-tryptophanol in Example 102. MS (DCI/NH.sub.3) m/e 407
(M+1).sup.+; .sup.1H NMR (300 MHz, CD.sub.3OD) .delta.=8.20 (d; 1H;
J=3.0 Hz), 7.81 (s; 1H), 7.61 (d; 1H; J=3.0 Hz), 7.57 (d; 1H; J=8.4
Hz), 7.40 (m; 6H), 4.44 (d; 2H; J=4.5 Hz), 3.88 (m; 1H), 3.28 (m;
1H), 2.59 (s; 3H), 1.42 (d; 3H; J=7.5 Hz).
EXAMPLE 357
(1S)-1-[6-Chloro-5-(3-methyl-1H-indazol-5-yl)-pyridin-3-yloxymethyl]-2,2-d-
iphenyl-ethylamine
[0782] The desired product was prepared by substituting Example 12B
for 3-bromo-5-hydroxypyridine and Boc-3,3-diphenylalaminol for
Boc-tryptophanol in Example 102. MS (DCI/NH.sub.3) m/e 469
(M+1).sup.+; .sup.1H NMR (300 MHz, CD.sub.3OD) .delta.=8.08 (d; 1H;
J=3.0 Hz), 7.74 (s; 1H), 7.55 (m; 3H), 7.43 (m; 5H), 7.31 (m; 3H),
7.21 (m; 2H), 4.65 (d; 1H; J=11.1 Hz), 4.44 (d; 1H; J=11.1 Hz),
4.31 (d; 1H; J=11.1 Hz), 4.09 (d; 1H; J=11.1 Hz), 2.59 (s; 3H).
EXAMPLE 358
(1S)-1-[5-(3-Methyl-1H-indazol-5-yl)-pyridin-3-yloxymethyl]-2-phenyl-propy-
lamine
[0783] The desired product was prepared by substituting
Boc-3-methyl-phenylalaminol for Boc-tryptophanol in Example 102. MS
(DCI/NH.sub.3) m/e 373 (M+1).sup.+; .sup.1H NMR (300 MHz,
CD.sub.3OD) .delta.=8.11 (s; 2H), 8.05 (s; 2H), 7.74 (d; 1H; J=8.4
Hz), 7.62 (d; 1H; J=8.4 Hz), 7.40(m; 1H), 7.39 (m; 5H), 4.56 (m;
2H), 3.92 (m; 2H), 2.62 (s; 3H), 1.6 (d; 3H; J=7.5 Hz).
EXAMPLE 359
(1S)-1-[5-(3-Methyl-1H-indazol-5-yl)-pyridin-3-yloxymethyl]-2,2-diphenyl-e-
thylamine
[0784] The desired product was prepared by substituting
Boc-3,3-diphenylalaminol for Boc-tryptophanol in Example 102. MS
(DCI/NH.sub.3) m/e 435 (M+1).sup.+; .sup.1H NMR (300 MHz,
CD.sub.3OD) .delta.=8.62 (s; 1H), 8.31 (s; 1H), 8.02 (s; 1H), 7.82
(s; 1H), 7.67 (d; 1H; J=8.4 Hz), 7.60 (d; 1H; J=8.4 Hz), 7.58 (d;
1H; J=6.9 Hz), 7.43(m; 4H), 7.30 (m; 5H), 4.61 (d; 1H; J=12.0 Hz),
4.48 (d; 1H; J=12 Hz), 4.40 (dd; 1H; J=11.4 Hz; J=3.0 Hz), 4.00
(dd; 1H; J=11.4 Hz), 2.62 (s; 3H).
EXAMPLE 360
(1S)-3-Methyl-1-[5-(3-methyl-1H-indazol-5-yl)-pyridin-3-yloxymethyl]-butyl-
amine
[0785] The desired product was prepared by substituting Example 12B
for 3-bromo-5-hydroxypyridine and Boc-leucinol for Boc-tryptophanol
in Example 102. MS (APCI) m/z 357 (M-1).sup.+; .sup.1H NMR (500
MHz, CD.sub.3OD) .delta. ppm 1.02 (m, J=6.40, 3.90 Hz, 6H), 1.67
(m, 2H), 1.80 (dd, J=13.57, 6.71 Hz, 1H), 2.59 (s, 3H), 3.71 (m,
J=6.86, 3.12 Hz, 1H), 4.20 (dd, J=10.61, 6.55 Hz, 1H), 4.38 (dd,
J=10.45, 3.28 Hz, 1H), 7.49 (dd, J=8.58, 1.72 Hz, 1H), 7.56 (d,
J=8.11 Hz, 1H), 7.59 (d, J=3.12 Hz, 1H), 7.80 (s, 1H), 8.17 (d,
J=3.12 Hz, 1H); Anal. Calcd for C.sub.19H.sub.23ClN.sub.4O: C,
49.56; H, 5.21; N, 10.88. Found: C, 49.86; H, 4.83; N, 10.49.
EXAMPLE 361
(1S)-2-[6-Chloro-5-(3-methyl-1H-indazol-5-yl)-pyridin-3-yloxy]-1-(1H-indol-
-3-ylmethyl)-ethylamine
[0786] The desired product was prepared by substituting Example 12B
for 3-bromo-5-hydroxypyridine in Example 102. MS (APCI) m/z 533
(M+1).sup.+; .sup.1H NMR (500 MHz, CD.sub.3OD) .delta. ppm 2.58 (s,
3H), 3.28 (m, 2H), 3.96 (m, 1H), 4.20 (dd, J=10.45, 5.77 Hz, 1H),
4.34 (dd, J=10.61, 3.12 Hz, 1H), 7.02 (t, J=7.49 Hz, 1H), 7.12 (t,
J=7.64 Hz, 1H), 7.22 (s, 1H), 7.37 (d, J=8.42 Hz, 1H), 7.44 (dd,
J=8.42, 1.56 Hz, 1H), 7.47 (d, J=3.12 Hz, 1H), 7.54 (d, J=8.42 Hz,
1H), 7.57 (d, J=8.11 Hz, 1H), 7.74 (s, 1H), 8.12 (d, J=2.81 Hz,
1H); Anal. Calcd for C.sub.24H.sub.22ClN.sub.5O: C, 52.08; H, 4.12;
N, 11.61. Found: C, 52.45; H, 4.08; N, 11.24.
EXAMPLE 362
(1S)-2-(6-Chloro-5-thieno[2,3-c]pyridin-2-yl-pyridin-3-yloxy)-1-(1H-indol--
3-ylmethyl)-ethylamine
Example 362A
(1S)-[2-(6-Chloro-5-thieno[2,3-c]pyridin-2-yl-pyridin-3-yloxy)-1-(1H-indol-
-3-ylmethyl)-ethyl]-carbamic Acid Tert-Butyl Ester
[0787] The title compound was prepared by substituting Example 13A
for Example 2A and Example 38A for Example 27A in Example 27B.
Example 362B
(1S)-2-(6-Chloro-5-thieno[2,3-c]pyridin-2-yl-pyridin-3-yloxy)-1-(1H-indol--
3-ylmethyl)-ethylamine
[0788] The title compound was prepared by substituting Example 362A
for Example 27B in Example 27C. MS (APCI) m/z 436 (M+1).sup.+;
.sup.1H NMR (300 MHz, CD.sub.3OD) .delta. 3.29 (m, 2H), 4.00 (m,
1H), 4.26 (dd, J=10.51, 5.76 Hz, 1H), 4.40 (dd, J=10.51, 3.05 Hz,
1H), 7.02 (t, J=7.63 Hz, 1H), 7.10 (t, J=6.95 Hz, 1H), 7.23 (s,
1H), 7.36 (d, J=8.14 Hz, 1H), 7.58 (d, J=7.80 Hz, 1H), 7.74 (d,
J=3.05 Hz, 1H), 8.05 (s, 1H), 8.29 (d, J=3.05 Hz, 1H), 8.35 (d,
J=6.10 Hz, 1H), 8.64 (d, J=6.10 Hz, 1H), 9.57 (s, 1H); Anal. Calcd
for C.sub.23H.sub.19ClN.sub.4OS.box-solid.2.6 TFA: C, 46.31; H,
2.98; N, 7.66. Found: C, 46.22; H, 2.94; N, 7.52.
EXAMPLE 363
5-[(2S)-2-Amino-3-(1H-indol-3-yl)-propoxy]-3-isoquinolin-6-yl-pyridine-2-c-
arbonitrile
Example 363A
(1S)-[2-(6-Chloro-5-isoquinolin-6-yl-pyridin-3-yloxy)-1-(1H-indol-3-ylmeth-
yl)-ethyl]-carbamic Acid Tert-Butyl Ester
[0789] The title compound was prepared by substituting Example 13A
for Example 2A in Example 27B. MS (APCI) m/z 529 (M+1).sup.+.
Example 363B
(1S)-[2-(6-Cyano-5-isoquinolin-6-yl-pyridin-3-yloxy)-1-(1H-indol-3-ylmethy-
l)-ethyl]-carbamic Acid Tert-Butyl Ester
[0790] A 10 mL RBF was charged with Example 363A (100 mg, 0.189
mmol), zinc cyanide (56 mg, 0.47 mmol) and Pd(PPh.sub.3).sub.4 (44
mg, 0.0378 mmol), and was purged with nitrogen. Anhydrous DMF (3
mL) was added and the solution was purged with nitrogen again. The
reaction mixture was stirred at 90.degree. C. for 70 h. After
cooled, the mixture was partitioned between ethyl acetate and
brine, and the organic phase was washed with water. The Organic
layer was concentrated and the residue was separated by flash
chromatography (40-100% EtOAc in hexane) to give the desired
product (87.4 mg, 89%). MS (APCI) m/z 520 (M+1).sup.+.
Example 363C
5-[(2S)-2-Amino-3-(1H-indol-3-yl)-propoxy]-3-isoquinolin-6-yl-pyridine-2-c-
arbonitrile
[0791] The desired product was prepared as the trifluoroacetate by
substituting Example 363B for Example 27B in Examples 27C. MS
(APCI) m/z 421 (M+1).sup.+; .sup.1H NMR (300 MHz, CD.sub.3OD)
.delta. 3.31 (m, 2H), 4.03 (m, 1H), 4.34 (dd, J=10.85, 5.76 Hz,
1H), 4.48 (dd, J=10.85, 3.39 Hz, 1H), 7.00 (t, J=7.46 Hz, 1H), 7.10
(t, J=6.95 Hz, 1H), 7.23 (s, 1H), 7.35 (d, J=8.14 Hz, 1H), 7.57 (d,
J=7.80 Hz, 1H), 7.64 (d, J=2.71 Hz, 1H), 8.08 (dd, J=8.48, 1.69 Hz,
1H), 8.39 (d, J=7.46 Hz, 1H), 8.37 (d, J=6.44 Hz, 1H), 8.55 (d,
J=7.12 Hz, 1H), 8.56 (m, 1H), 8.65 (d, J=6.10 Hz, 1H), 9.72 (s,
1H); Anal. Calcd for C.sub.26H.sub.21N.sub.5O.box-solid- .2.9 TFA:
C, 50.92; H, 3.21; N, 9.34. Found: C, 50.98; H, 3.23; N, 9.48.
EXAMPLE 364
(1S)-1-(1H-Indol-3-ylmethyl)-2-[5-(3-phenyl-isoquinolin-6-yl)-pyridin-3-yl-
oxy]-ethylamine
Example 364A
(1S)-{1-(1H-Indol-3-ylmethyl)-2-[5-(3-phenyl-isoquinolin-6-yl)-pyridin-3-y-
loxy]-ethyl}-carbamic Acid Tert-Butyl Ester
[0792] To a solution of Example 80E (150 mg, 0.28 mmol),
(1,1,1-tributylstannyl)benzene (137 mg, 0.57 mmol),
tris(dibenzylideneacetone)-dipalladium (27 mg, 0.028 mmol) and
2-dicyclohexylphosphino-2'-dimethylamino-1,1'-biphenyl (22 mg,
0.057 mmol) in dry DMF (10 ml) triethyl amine was added under
N.sub.2. The resulting solution was stirred 3 hours at 100.degree.
C. The reaction solution was partitioned between ethylacetate and
water. The organic layer was washed (brine), dried
(Na.sub.2SO.sub.4), filtered and concentrated under vacumm.
Purification on silica gel with 60% ethyl acetate/hexane to provide
the title compound (70 mg, 47%). MS (DCI/NH.sub.3) m/e 571
(M+1).sup.+.
Example 364B
(1S)-1-(1H-Indol-3-ylmethyl)-2-[5-(3-phenyl-isoquinolin-6-yl)-pyridin-3-yl-
oxy]-ethylamine
[0793] The title compound was prepared as trifluoroacetic acid salt
by substituting Example 354A for Example 27B in Example 27C. MS
(DCI/NH.sub.3) m/e 471 (M+1).sup.+;. .sup.1H NMR (300 MHz, D6-DMSO)
.delta. 11.04 (s; 1H), 9.49 (s; 1H), 8.74 (s; 1H), 8.45 (s; 1H),
8.44 (s; 1H), 8.39 (s; 1H), 8.28 (d; 1H; J=8.4 Hz), 8.23 (d; 1H;
J=7.5 Hz), 8.08 (s; 2H), 8.02 (d; 1H; J=8.4 Hz), 7.83 (s; 1H), 7.63
(d; 1H; J=8.4 Hz), 7.55 (t; 3H; J=7.5 Hz), 7.47 (d; 1H; J=7.5 Hz),
7.37 (d; 1H; J=8.4 Hz), 7.31 (s; 1H), 7.10 (t; 1H; J=7.2 Hz), 7.00
(t; 1H; J=7.2 Hz), 4.40 (m; 1H), 4.23 (m; 1H), 3.88 (m; 1H), 3.18
(m; 2H) The following compounds were prepared by substituting the
appropriate tributylsannyl reagents for
(1,1,1-tributylstannyl)benzene in Example 364.
EXAMPLE 365
(1S)-2-[5-(3-Ethyl-isoquinolin-6-yl)-pyridin-3-yloxy]-1-(1H-indol-3-ylmeth-
yl)-ethylamine
[0794] MS (DCI/NH.sub.3) m/e 423 (M+1).sup.+;. .sup.1H NMR (300
MHz, D6-DMSO) .delta.=11.04 (s; 1H), 9.61 (s; 1H), 8.77 (s; 1H),
8.47 (s; 1H), 8.45 (s; 1H), 8.42 (d; 1H; J=9.0 Hz), 8.20 (s; 2H),
8.14 (d; 2H; J=9.0 Hz), 8.03 (s; 2H), 7.85 (s; 1H), 7.63 (d; 1H;
J=7.5 Hz), 7.38 (d; 1H; J=7.5 Hz), 7.30 (s; 1H), 7.10 (t; 1H; J=7.5
Hz), 7.00 (t; 1H; J=7.5 Hz), 4.40 (m; 1H), 4.22 (m; 1H), 3.88 (m;
1H), 3.18 (m; 2H), 3.04 (q; 2H; J=7.5 Hz), 1.37 (t; 3H; J=7.5
Hz).
EXAMPLE 366
(1S)-1-(1H-Indol-3-ylmethyl)-2-[5-(3-pyridin-4-yl-isoquinolin-6-yl)-pyridi-
n-3-yloxy]-ethylamine
[0795] MS (DCI/NH.sub.3) m/e 472 (M+1).sup.+;. .sup.1H NMR (300
MHz, D6-DMSO) .delta.=11.04 (s; 1H), 9.54 (s; 1H), 8.93 (d; 2H;
J=7.5 Hz), 8.87 (d; 2H; J=7.5 Hz), 8.83 (s; 1H), 8.70 (s; 1H), 8.43
(s; 2H), 8.35 (d; 1H; J=8.4 Hz), 8.09 (d; 2H; J=8.4 Hz), 7.84 (s;
1H), 7.61 (d; 1H; J=8.4 Hz), 7.38 (d; 1H; J=8.4 Hz), 7.25 (s; 1H),
7.12 (t; 1H; J=8.4 Hz), 7.03 (t; 1H; J=8.4 Hz), 4.45 (m; 1H), 4.30
(m; 1H), 4.00 (m; 1H), 3.30 (m; 2H)
EXAMPLE 367
(1S)-2-[5-(3-Furan-2-yl-isoquinolin-6-yl)-pyridin-3-yloxy]-1-(1H-indol-3-y-
lmethyl)-ethylamine
[0796] MS (DCI/NH.sub.3) m/e 461 (M+1).sup.+;. .sup.1H NMR (300
MHz, D6-DMSO) .delta.=11.04 (s; 1H), 9.39 (s; 1H), 8.74 (s; 1H),
8.44 (s; 1H), 8.41 (s; 1H), 8.25 (d; 1H; J=8.4 Hz), 8.18 (m; 3H),
8.00 (d; 2H; J=8.4 Hz), 7.89 (s; 1H), 7.83 (s; 1H), 7.63 (d; 1H;
J=8.4 Hz), 7.39 (d; 1H; J=8.4 Hz), 7.31 (s; 1H), 7.18 (s; 1H), 7.11
(t; 1H; J=8.4 Hz), 7.01 (t; 1H; J=8.4 Hz), 6.71 (s; 1H), 4.40 (m;
1H), 4.21 (m; 1H), 3.88 (m; 1H), 3.18 (m; 2H)
EXAMPLE 368
(1S)-1-(1H-Indol-3-ylmethyl)-2-[5-(3-phenylethynyl-isoquinolin-6-yl)-pyrid-
in-3-yloxy]-ethylamine
[0797] MS (DCI/NH.sub.3) m/e 495 (M+1).sup.+;. .sup.1H NMR (300
MHz, D6-DMSO) .delta.=11.04 (s; 1H), 9.41 (s; 1H), 8.73 (s; 1H),
8.45 (s; 1H), 8.35 (s; 1H), 8.31 (d; 1H; J=5.4 Hz), 8.24 (s; 2H),
8.21 (s; 1H), 8.07 (d; 1H; J=5.4 Hz), 7.82 (s; 1H), 7.65 m; 4H),
7.48 (m; 2H), 7.39 (d; 1H; J=5.4 Hz), 7.30 (s; 1H), 7.10 (t; 1H;
J=5.4 Hz), 7.00 (t; 1H; J=5.4 Hz), 4.40 (m; 1H), 4.22 (m; 1H), 4.13
(m; 1H), 3.18 (m; 2H).
EXAMPLE 369
(1S)-1-(1H-Indol-3-ylmethyl)-2-[5-(3-prop-1-ynyl-isoquinolin-6-yl)-pyridin-
-3-yloxy]-ethylamine
[0798] MS (DCI/NH.sub.3) m/e 433 (M+1).sup.+; .sup.1H NMR (300 MHz,
D6-DMSO) .delta.=11.04 (s; 1H), 9.32 (s; 1H), 8.71 (s; 1H), 8.43
(s; 1H), 8.28 (s; 1H), 8.25 (d; 1H; J=8.4 Hz), 8.18 (s; 2H), 8.02
(d; 1H; J=8.4 Hz), 7.99 (s; 1H), 7.80 (s; 1H), 7.62 (d; 1H; J=8.4
Hz), 7.38 (d; 1H; J=8.4 Hz), 7.30 (s; 1H), 7.10 (t; 1H; J=8.4 Hz),
7.00 (t; 1H; J=8.4 Hz), 4.40 (m; 1H), 4.21 (m; 1H), 3.88 (m; 1H),
3.18 (m; 2H), 2.13 (s; 3H).
EXAMPLE 370
(1S)-1-(1H-Indol-3-ylmethyl)-2-[5-(3-vinyl-isoquinolin-6-yl)-pyridin-3-ylo-
xy]-ethylamine
[0799] MS (DCI/NH.sub.3) m/e 421 (M+1).sup.+; .sup.1H NMR (300 MHz,
D6-DMSO) .delta.=11.04 (s; 1H), 9.36 (s; 1H), 8.71 (s; 1H), 8.42
(s; 1H), 8.28 (s; 1H), 8.25 (d; 1H; J=9.0 Hz), 8.18 (s; 2H), 8.00
(d; 1H; J=9.0 Hz), 7.85 (s; 1H), 7.81 (s; 1H), 7.63 (d; 1H; J=8.4
Hz), 7.38 (d; 1H; J=8.4 Hz), 7.29 (s; 1H), 7.10 (t; 1H; J=8.4 Hz),
7.01 (t; 1H; J=8.4 Hz), 6.98 (dd; 1H; J=17.4 Hz; J=12.0 Hz), 6.40
(d; 1H; J=17.4 Hz), 5.50 (d; 1H; J=12.0 Hz), 4.40 (m; 1H), 4.21 (m;
In), 3.88 (m; 1H), 3.18 (m; 2H).
EXAMPLE 371
(1S)-6-{5-[2-Amino-3-(1H-indol-3-yl)-propoxy]-pyridin-3-yl}-isoquinoline-3-
-carbonitrile
Example 371A
(1S)-[2-[5-(3-Cyano-isoquinolin-6-yl)-pyridin-3-yloxy]-1-(1H-indol-3-ylmet-
hyl)-ethyl]-carbamic Acid Tert-Butyl Ester
[0800] The desired product was obtained by substituting Example 80E
for example 363A in Example 363B.
Example 371B
(1S)-6-{5-[2-Amino-3-(1H-indol-3-yl)-propoxy]-pyridin-3-yl}-isoquinoline-3-
-carbonitrile
[0801] The desired product was obtained as trifluoroacetic acid
salt by substituting Example 371A for Example 27B in Example 27C.
MS (DCI/NH.sub.3) m/e 420 (M+1).sup.+;. .sup.1H NMR (300 MHz,
D6-DMSO) .delta.=11.04 (s; 1H), 9.52 (s; 1H), 8.75 (s; 1H), 8.64
(s; 1H), 8.47 (s; 2H), 8.42 (d; 1H; J=6.0 Hz), 8.26 (m; 3H), 7.84
(s; 1H), 7.62 (d; 1H; J=6.0 Hz), 7.38 (d; 1H; J=6.0 Hz), 7.31 (s;
1H), 7.10 (t; 1H; J=6.0 Hz), 7.00 (t; 1H; J=6.0 Hz), 4.40 (m; 1H),
4.22 (m; 1H), 3.88 (m; 1H), 3.18 (m; 2H).
EXAMPLE 372
(1S)-1-(1H-Indol-3-ylmethyl)-2-(5-isoquinolin-6-yl-6-vinyl-pyridin-3-yloxy-
)-ethylamine
[0802] The desired product was prepared as the trifluoroacetate by
substituting tributylvinyltin for tributylphenyltin and Example
363A for Example 80E in Example 364. MS (APCI) m/z 420 (M+1).sup.+;
.sup.1H NMR (300 MHz, CD.sub.3OD) .delta. 3.30 (m, 2H), 3.98 (m,
1H), 4.24 (dd, J=10.51, 5.76 Hz, 1H), 4.38 (dd, J=10.51, 3.05 Hz,
1H), 5.39 (dd, J=10.85, 1.70 Hz, 1H), 6.24 (dd, J=16.95, 1.70 Hz,
1H), 6.66 (dd, J=17.12, 10.68 Hz, 1H), 7.00 (dd, J=6.78, 6.10 Hz,
1H), 7.09 (t, J=7.63 Hz, 1H), 7.22 (s, 1H), 7.35 (d, J=8.14 Hz,
1H), 7.40 (d, J=2.71 Hz, 1H), 7.57 (d, J=7.80 Hz, 1H), 7.95 (dd,
J=8.48, 1.70 Hz, 1H), 8.22 (s, 1H), 8.45 (d, J=7.46 Hz, 1H), 8.45
(s, 1H), 8.56 (d, J=8.81 Hz, 1H), 8.64 (d, J=6.44 Hz, 1H), 9.79 (s,
1H); Anal. Calcd for C.sub.27H.sub.24N.sub.4O.bo- x-solid.4 TFA: C,
47.96, 3.22; N, 6.39. Found: C, 48.02; H, 3.00; N, 6.07.
EXAMPLE 373
(1S)-2-(6-Ethynyl-5-isoquinolin-6-yl-pyridin-3-yloxy)-1-(1H-indol-3-ylmeth-
yl)-ethylamine
[0803] The desired product was prepared as the trifluoroacetate by
substituting tributylethynyltin for tributylphenyltin and Example
363A for Example 80E in Example 364. MS (APCI) m/z 419 (M+1).sup.+;
.sup.1H NMR (300 MHz, CD.sub.3OD) .delta. 3.31 (m, 2H), 3.67 (s,
1H), 3.99 (m, 1H), 4.28 (dd, (J=10.74, 5.83 Hz, 1H), 4.42 (dd,
J=10.74, 3.07 Hz, 1H), 7.00 (t, J=7.06 Hz, 1H), 7.09 t, J=7.21 Hz,
1H), 7.23 (s, 1H), 7.35 (d, J=8.29 Hz, 1H), 7.55 (m, 1H), 7.56 (d,
J=7.98 Hz, 1H), 8.19 (dd, J=8.59, 1.53 Hz, 1H), 8.42 (s, 2H), 8.47
(d, J=6.44 Hz, 1H), 8.56 (d, J=8.59 Hz, 1H), 8.63 (d, J=6.44 Hz,
1H), 9.79 (s, 1H); Anal. Calcd for
C.sub.27H.sub.22N.sub.4O.box-solid.2.9 TFA: C, 52.59; H, 3.35; N,
7.48. Found: C, 52.52; H, 3.44; N, 7.01.
EXAMPLE 374
(1S)-2-(6-Furan-2-yl-5-isoquinolin-6-yl-pyridin-3-yloxy)-(1H-indol-3-ylmet-
hyl)-ethylamine
[0804] The desired product was prepared as the trifluoroacetate by
substituting tributylethynyltin for tributylstannylfuran and
Example 363A for Example 80E in Example 364. MS (APCI) m/z 461
(M+1).sup.+; .sup.1H NMR (300 MHz, CD.sub.3OD) .delta. 3.30 (m,
2H), 3.98 (m, 1H), 4.25 (dd, J=10.51, 5.76 Hz, 1H), 4.40 (dd,
J=10.51, 3.05 Hz, 1H), 6.39 (dd, J=3.39, 1.70 Hz, 1H), 6.44 (d,
J=4.41 Hz, 1H), 7.00 (dd, J=7.80, 7.12 Hz, 1H), 7.09 (t, J=6.78 Hz,
1H), 7.21 (s, 1H), 7.28 (d, J=1.70 Hz, 1H), 7.37 (d, J=8.14 Hz,
1H), 7.47 (d, J=2.71 Hz, 1H), 7.57 (d, J=7.80 Hz, 1H), 7.80 (dd,
J=8.65, 1.53 Hz, 1H), 8.21 (s, 1H), 8.42 (d, J=6.78 Hz, 1H), 8.46
(d, J=7.12 Hz, 1H), 8.48 (s, 1H), 8.62 (d, J=6.44 Hz, 1H), 9.77 (s,
1H); Anal. Calcd for C.sub.29H.sub.24N.sub.4O.sub.2.3.9 TFA: C,
48.83; H, 3.11; N, 6.19. Found: C, 48.86; H, 3.31; N, 6.18.
EXAMPLE 375
(1S)-1-(1H-Indol-3-ylmethyl)-2-(5-isoquinolin-6-yl-6-phenylethynyl-pyridin-
-3-yloxy)-ethylamine
[0805] The desired product was prepared as the trifluoroacetate by
substituting tributyl(phenylethynyl)tin tributylphenyltin and
Example 363A for Example 80E in Example 364. MS (APCI) m/z 495
(M+1).sup.+; .sup.1H NMR (300 MHz, CD.sub.3OD) .delta. 3.30 (m,
2H), 4.02 (m, 1 H), 4.30 (dd, J=10.51, 5.76 Hz, 1H), 4.44 (dd,
J=10.51, 3.05 Hz, 1H), 7.01 (t, J=7.46 Hz, 1H), 7.11 (t, J=7.46 Hz,
1H), 7.24 (s, 1H), 7.29 (m, 5H), 7.36 (d, J=8.14 Hz, 1H), 7.61 (d,
J=2.71 Hz, 1H), 7.59 (d, J=7.80 Hz, 1H), 8.24 (dd, J=8.65, 1.53 Hz,
1H), 8.38 (d, J=6.44 Hz, 1H), 8.46 (d, J=2.71 Hz, 1H), 8.46 (s,
1H), 8.55 (d, J=8.81 Hz, 1H), 8.62 (d, J=6.44 Hz, 1H), 9.72 (s,
1H); Anal. Calcd for C.sub.33H.sub.26N.sub.4O.box-solid- .2.3 TFA:
C, 59.67; H, 3.77; N, 7.40. Found: C, 59.61; H, 4.04; N, 7.36.
EXAMPLE 376
6-{5-[(2S)-2-Amino-3-(1H-indol-3-yl)-propoxy]-pyridin-3-yl}-isoquinolin-5--
ylamine
[0806] The desired product was prepared as the trifluoroacetate by
substituting 5-amino-6-bromoisoquinoline for 6-bromophthalimide in
Example 32. MS (APCI) m/z 410 (M+1).sup.+; .sup.1H NMR (300 MHz,
CD.sub.3OD) .delta. 3.32 (m, 2H), 4.00 (m, 1H), 4.27 (dd, J=10.51,
5.76 Hz, 1H), 4.44 (dd, J=10.51, 3.39 Hz, 1H), 7.01 (t, J=7.46 Hz,
1H), 7.10 (t, J=7.46 Hz, 1H), 7.24 (s, 1H), 7.36 (d, J=7.80 Hz,
1H), 7.59 (d, J=7.80 Hz, 1H), 7.67 (d, J=8.14 Hz, 1H), 7.73 (s,
1H), 7.80 (d, J=8.48 Hz, 1H) 8.45 (s, 2H), 8.50 (d, J=6.78 Hz, 1H),
8.66 (d, J=6.78 Hz, 1H), 9.60 (s, 1H); Anal. Calcd for
C.sub.25H.sub.23N.sub.5O.box-solid.3.3 TFA: C, 48.30; H, 3.37; N,
8.91. Found: C, 48.35; H, 3.44; N, 8.91.
EXAMPLE 377
(1S)-1-(1H-Indol-3-ylmethyl)-2-[5-(8-methyl-isoquinolin-6-yl)-pyridin-3-yl-
oxy]-ethylamine
[0807] The desired product was prepared as the trifluoroacetate by
substituting 6-bromo-8-methyl-isoquinoline for 6-bromophthalimide
in Example 32. MS (APCI) m/z 409 (M+1).sup.+; .sup.1H NMR (300 MHz,
CD.sub.3OD) .delta. 2.91 (s, 3H), 3.32 (m, 2H), 4.02 (m, 1H), 4.32
(dd, J=10.51, 5.76 Hz, 1H), 4.47 (dd, J=10.51, 3.39 Hz, 1H), 7.02
(t, J=7.46 Hz, 1H), 7.11 (t, J=7.63 Hz, 1H), 7.25 (s, 1H), 7.37 (d,
J=8.14 Hz, 1H), 7.60 (d, J=8.14 Hz, 1H), 7.91 (dd, J=8.31, 4.92 Hz,
1H), 7.96 (d, J=1.70 Hz, 1H), 8.15 (s, 1H), 8.31 (d, J=2.03 Hz,
1H), 8.46 (s, 1H), 8.74 (s, 1H), 8.87 (dd, J=8.48, 1.70 Hz, 1H),
9.08 (dd, J=4.92, 1.53 Hz, 1H); Anal. Calcd for
C.sub.26H.sub.24N.sub.4O.box-solid.3.5 TFA: C, 49.08; H, 3.43; N,
6.94. Found: C, 49.23; H, 3.24; N, 6.87.
EXAMPLE 378
(1S)-2-[5-(4-Chloro-thieno[2,3-c]pyridin-2-yl)-pyridin-3-yloxy]-1-(1H-indo-
l-3-ylmethyl)-ethylamine
[0808] The title compound was prepared by substituting
4-chlorothieno[2,3-c]pyridine for thieno[2,3-c]pyridine in Example
38. MS (APCI) m/z 435 (M+1).sup.+; .sup.1H NMR (300 MHz,
CD.sub.3OD) .delta. 3.31 (m, 2H), 4.01 (m, 1H), 4.29 (dd, J=10.51,
5.76 Hz, 1H), 4.44 (dd, J=10.51, 3.05 Hz, 1H), 7.04 (t, J=8.14 Hz,
1H), 7.12 (t, J=6.95 Hz, 1H), 7.25 (s, 1H), 7.39 (d, J=8.14 Hz,
1H), 7.61 (d, J=7.80 Hz, 1H), 7.84 (t, J=2.71 Hz, 1H), 8.04 (s,
1H), 8.42 (d, J=2.03 Hz, 1H), 8.51 (s, 1H), 8.72 (s, 1H), 9.13 (s,
1H); Anal. Calcd for C.sub.23H.sub.19ClN.sub.4OS.box-so- lid.2.8
TFA: C, 45.55; H, 2.91; N, 7.43. Found: C, 45.42; H, 2.70; N,
7.28.
EXAMPLE 379
(1S)-1-(1H-Indol-3-ylmethyl)-2-[5-(4-phenyl-thieno[2,3-c]pyridin-2-yl)-pyr-
idin-3-yloxy]-ethylamine
[0809] The title compound was prepared by substituting
4-phenylthieno[2,3-c]pyridine for thieno[2,3-c]pyridine in Example
38. MS (APCI) m/z 477 (M+1).sup.+; .sup.1H NMR (300 MHz,
CD.sub.3OD) .delta. 3.31 (m, 2H), 4.00 (m, 1H), 4.26 (dd, J=10.51,
5.76 Hz, 1H), 4.41 (dd, J=10.51, 3.39 Hz, 1H), 6.99 (t, J=6.95 Hz,
1H), 7.10,(t, J=7.12 Hz, 1H), 7.22 (s, 1H), 7.36 (d, J=7.80 Hz,
1H), 7.57 (d, J=7.80 Hz, 1H), 7.65 (m, 3H), 7.73 (t, J=2.03 Hz,
1H), 7.76 (d, J=1.70 Hz, 1H), 7.84 (m, 1H), 8.11 (s, 1H), 8.46 (s,
1H), 8.62 (s, 1H), 8.74 (s, 1H), 9.52 (s, 1H);. Anal. Calcd for
C.sub.29H.sub.24N.sub.4OS.box-solid.2.8 TFA: C, 52.22; H, 3.39; N,
7.04. Found: C, 52.11; H, 3.13; N, 6.91.
EXAMPLE 380
(1S)-1-(1H-Indol-3-ylmethyl)-2-[5-(4-phenoxy-thieno[2,3-c]pyridin-2-yl)-py-
ridin-3-yloxy]-ethylamine
[0810] The title compound was prepared by substituting
4-phenoxythieno[2,3-c]pyridine for thieno[2,3-c]pyridine in Example
38. MS (APCI) m/z 493 (M+1).sup.+; .sup.1H NMR (300 MHz,
CD.sub.3OD) .delta. 3.30 (m, 2H), 4.01 (m, 1H), 4.27 (dd, J=10.51,
5.76 Hz, 1H), 4.42 (dd, J=10.51, 3.05 Hz, 1H), 7.03 (t, J=7.46 Hz,
1H), 7.11 (t, J=7.46 Hz, 1H), 7.24 (s, 1H), 7.25 (d, J=8.82 Hz,
1H), 7.33 (t, J=7.46 Hz, 2H), 7.38 (d, J=7.80 Hz, 1H), 7.52 (t,
J=7.97 Hz, 2H), 7.60 (d, J=7.80 Hz, 1H), 7.85 (s, 1H), 8.00 (s,
1H), 8.16 (s, 1H), 8.44 (d, J=2.03 Hz, 1H), 8.72 (s, 1H), 9.17 (s,
1H).
EXAMPLE 381
(1S)-1-(1H-Indol-3-ylmethyl)-2-[5-(4-vinyl-thieno[2,3-c]pyridin-2-yl)-pyri-
din-3-yloxy]-ethylamine
Example 381A
(1S)-[2-[5-(4-Chloro-thieno[2,3-c]pyridin-2-yl)-pyridin-3-yloxy]-1-(1H-ind-
ol-3-ylmethyl)-ethyl]-carbamic Acid Tert-Butyl Ester
[0811] The title compound was prepared by substituting
4-chlorothieno[2,3-c]pyridine for thieno[2,3-c]pyridine in Example
38. MS (APCI) m/z 535 (M+1).sup.+.
Example 381B
(S)-{1-(1H-Indol-3-ylmethyl)-2-[5-(4-vinyl-thieno[2,3-c]pyridin-2-yl)-pyri-
din-3-yloxy]-ethyl}-carbamic Acid Tert-Butyl Ester
[0812] A 25 mL RBF was charged with Example 381A (102 mg, 0.19
mmol), Pd.sub.2(dba).sub.3 (18 mg, 0.019 mmol), and
2-dicyclohexylphosphino-2'-(- N,N-dimethylamino)biphenyl (15 mg,
0.038 mmol), and was purged with N.sub.2. Anhydrous DMF (5 mL),
tributylvinyltin (111 .mu.L, 0.38 mmol) and Et.sub.3N (80 .mu.L)
were added via syringe. The solution was purged with N.sub.2 again
and was heated at 70.degree. C. for 20 h. After cooled, ethyl
acetate (50 mL) was added. The mixture was washed with brine (50
mL) and water (50 mL). The ethyl acetate solution was concentrated,
and the residual oil was separated by flash chromatography (A: 2:1
EtOAc/hexane, 0-15% CH.sub.3OH in A) to give the desired product
(72 mg, 72%). MS (APCI) m/z 527 (M+1).sup.+.
Example 381C
(1S)-1-(1H-Indol-3-ylmethyl)-2-[5-(4-vinyl-thieno[2,3-c]pyridin-2-yl)-pyri-
din-3-yloxy]-ethylamine
[0813] The desired product was prepared as the trifluoroacetate by
substituting Example 381B for Example 27B in Examples 27C. MS
(APCI) m/z 427 (M+1).sup.+; .sup.1H NMR (300 MHz, CD.sub.3OD)
.delta. 3.32 (m, 2H), 4.03 (m, 1H), 4.30 (dd, J=10.51, 5.76 Hz,
1H), 4.46 (dd, J=10.51, 3.39 Hz, 1H), 5.84 (d, J=11.19 Hz, 1H),
6.26 (d, J=17.29 Hz, 1H), 7.03 (t, J=7.46 Hz, 1H), 7.12 (t, J=7.63
Hz, 1H), 7.25 (s, 1H), 7.35 (d, J=10.85 Hz, 1H), 7.41 (d, J=10.85
Hz, 1H), 7.60 (d, J=7.80 Hz, 1H), 7.90 (m, 1H), 8.44 (s, 1H), 8.49
(d, J=2.37 Hz, 1H), 8.79 (s, 2H), 9.42 (s, 1H); Anal. Calcd for
C.sub.25H.sub.22N.sub.4OS.box-solid.3.2 TFA: C, 47.65; H, 3.21; N,
7.08. Found: C, 47.74; H, 3.13; N, 6.96.
EXAMPLE 382
(1S)-2-[5-(4-Ethyl-thieno[2,3-c]pyridin-2-yl)-pyridin-3-yloxy]-1-(1H-indol-
-3-ylmethyl)-ethylamine
[0814] To a solution of Example 381A (50 mg, 0.063 mmol) in
methanol (4 mL) was added triethylamine (56 .mu.L) and 10% Pd/C (20
mg) under nitrogen. The suspension was purged with H.sub.2
(balloon) and was stirred at rt for 6 h. The solid material was
filtered off. The filtrate was concentrated and the residue was
purified by HPLC (Zorbax, C-18, 250.times.2.54 column, Mobile phase
A: 0.1% TFA in HO; B: 0.1% TFA in CH.sub.3CN; 0-100% gradient) to
provide the title compound (37.2 mg, 74%). MS (APCI) m/z 429
(M+1).sup.+; .sup.1H NMR (300 MHz, CD.sub.3OD) .delta. 1.46 (t,
J=7.46 Hz, 3H), 3.23 (q, J=7.46 Hz, 2H), 3.36 (m, 2H), 4.03 (m,
1H), 4.31 (dd, J=10.51, 5.76 Hz, 1H), 4.47 (dd, J=10.51, 3.39 Hz,
1H), 7.02 (t, J=7.46 Hz, 1H), 7.12 (t, J=7.46 Hz, 1H), 7.25 (s,
1H), 7.38 (d, J=8.14 Hz, 1H), 7.60 (d, J=7.80 Hz, 1H), 7.92 (t,
J=2.03 Hz, 1H), 8.39 (s, 1H), 8.49 (s, 1H), 8.49 (d, J=3.05 Hz,
1H), 8.81 (d, J=1.70 Hz, 1H), 9.45 (s, 1H); Anal. Calcd for
C.sub.25H.sub.24N.sub.4OS.box-soli- d.3.3 TFA: C, 47.16; H, 3.42;
N, 6.96. Found: C, 47.03; H, 3.34; N, 6.96.
EXAMPLE 383
(1S)-(2-{5-[2-Amino-3-(1H-indol-3-yl)-propoxy]-pyridin-3-yl}-thieno[2,3-c]-
pyridin-4-yl)-phenyl-amine
Example 383A
(1S)-{1-(1H-Indol-3-ylmethyl)-2-[5-(4-phenylamino-thieno[2,3-c]pyridin-2-y-
l)-pyridin-3-yloxy]-ethyl}-carbamic Acid Tert-Butyl Ester
[0815] A 25 mL RBF was charged with Example 381A (100 mg, 0.186
mmol), Pd.sub.2(dba).sub.3 (17 mg, 0.0186 mmol), and
1,3-bis(2,6-di-1-propylphen- yl)imidazolium chloride (Nolan ligand)
(16 mg, 0.0372 mmol), and was purged with N.sub.2. Anhydrous
dioxane (3 mL), aniline (21 mg, 0.224 mmol) and potassium
tert-butoxide (1.0 M solution in THF, 0.279 mL) were added via
syringe. The solution was purged with N.sub.2 again, and was heated
at 100.degree. C. for 20 h. After cooled, ethyl acetate (50 mL) was
added, and the mixture was washed with brine (50 mL) and water. The
EtOAc solution was concentrated, and the residue was separated by
flash chromatography (30-80% EtOAc in hexane) to provide the desire
product (34 mg, 31%). MS (APCI) m/z 592 (M+1).sup.+.
Example 383B
(1S)-(2-{5-[2-Amino-3-(1H-indol-3-yl)-propoxy]-pyridin-3-yl}-thieno[2,3-c]-
pyridin-phenyl-amine
[0816] The desired product was prepared as the trifluoroacetate by
substituting Example 383A for Example 27B in Examples 27C. MS
(APCI) m/z 492 (M+1).sup.+; .sup.1H NMR (300 MHz, DMSO-d.sub.6)
.delta. 3.19 (d, J=7.12 Hz, 2H), 3.88 (m, 1H), 4.20 (dd, J=10.51,
5.42 Hz, 1H), 4.38 (d, J=10.51 Hz, 1H), 7.01 (t, J=7.46 Hz, 1H),
7.11 (m, 3H), 7.38 (m, 6H), 7.62 (d, J=8.14 Hz, 1H), 7.78 (s, 1H),
8.22 (s, 2H), 8.29 (s, 1H), 8.47 (s, 1H), 8.74 (s, 1H), 8.98 (s,
1H), 9.06 (s, 1H), 11.04 (s, 1H); Anal. Calcd for
C.sub.29H.sub.25N.sub.5OS.box-solid.3 TFA: C, 50.42;,H, 3.39; N,
8.40. Found: C, 50.40; H, 3.58; N, 8.23.
EXAMPLE 384
5-{5-[(2S)-2-Amino-3-(1H-indol-3-yl)-propoxy]-pyridin-3-yl}-3,3-difluoro-1-
,3-dihydro-indol-2-one
[0817] The desired product was prepared as the trifluoroacetate by
substituting 5-Bromo-3,3-difluoro-1,3-dihydro-indol-2-one for
6-bromophthalimide in Example 32. MS (APCI) m/z 435 (M+1).sup.+;
.sup.1H NMR (300 MHz, CD.sub.3OD) .delta. 3.36 (m, 2H), 4.01 (m,
1H), 4.26 (dd, J=10.51, 5.76 Hz, 1H), 4.43 (dd, J=10.51, 3.05 Hz,
1H), 7.03 (t, J=7.46 Hz, 1H), 7.13 (t, J=7.46 Hz, 2H), 7.24 (s,
1H), 7.39 (d, J=8.14 Hz, 1H), 7.60 (d, J=8.14 Hz, 1H), 7.79 (m,
2H), 7.90 (d, J=1.70 Hz, 1H), 8.36 (d, J=2.03 Hz, 1H), 8.56 (s,
1H); Anal. Calcd for C.sub.24H.sub.20F.sub.2N.su-
b.4O.sub.2.box-solid.2.5 TFA: C, 48.41; H, 3.15; N, 7.79. Found: C,
48.66; H, 3.20; N, 7.82.
EXAMPLE 385
6-{5-[(2S)-2-Amino-3-(1H-indol-3-yl)-propoxy]-pyridin-3-yl}-3H-oxazolo[4,5-
-b]pyridin-2-one
[0818] The desired product was prepared as the trifluoroacetate by
substituting 6-Bromo-3H-oxazolo[4,5-b]pyridin-2-one for
6-bromophthalimide in Example 32. MS (APCI) m/z 402 (M+1).sup.+;
.sup.1H NMR (300 MHz, CD.sub.3OD) .delta. 3.34 (m, 2H), 4.00 (m,
1H), 4.28 (dd, J=110.51, 5.76 Hz, 1H), 4.42 (dd, J=10.51, 3.05 Hz,
1H), 7.02 (t, J=7.46 Hz, 1H), 7.12 (t, J=7.63 Hz, 1H), 7.23 (s,
1H), 7.38 (d, J=8.14 Hz, 1H), 7.59 (d, J=7.80 Hz, 1H), 7.74 (d,
J=1.70 Hz, 1H), 7.83 (d, J=1.70 Hz, 1H), 8.33 (d, J=2.03 Hz, 1H),
8.38 (d, J=2.37 Hz, 1H), 8.55 (s, 1H); Anal. Calcd for
C.sub.22H.sub.19N.sub.5O.sub.3.box-solid.2.6 TFA: C, 46.81; H,
3.12; N, 10.04. Found: C, 46.67; H, 2.98; N, 9.89.
EXAMPLE 386
N1-(5-Isoquinolin-6-yl-pyridin-3-yl)-ethane-1,2-diamine
Example 386A
[2-(5-Bromo-pyridin-3-ylamino)-ethyl]-carbamic Acid Tert-Butyl
Ester
[0819] A 50 mL RBF was charged with 3,5-dibromopyridine (3.70 g,
15.6 mmol), t-butyl N-(2-aminoethyl)carbamate (2.50 g, 15.6 mmol),
Pd.sub.2(dba).sub.3 (714 mg, 0.78 mmol), (R)-BINAP (1.46 g, 2.34
mol) and Cs.sub.2CO.sub.3 (7.62 g, 23.4 mmol), and was purged with
N.sub.2. Anhydrous toluene (120 mL) was added via syringe. The
solution was purged with N.sub.2 again, and was heated at
100.degree. C. overnight. After cooled, ethyl acetate (500 mL) was
added and the mixture was washed with water. The EtOAc solution was
concentrated and the residue was separated by flash chromatography
(20-80% EtOAc in hexane) to provide the desried product (2.1 g,
43%). MS (DCI) m/z 316, 318 (M+1).sup.+.
Example 386B
[2-(5-Isoquinolin-6-yl-pyridin-3-ylamino)-ethyl]-carbamic Acid
Tert-Butyl Ester
[0820] The desired product was prepared by substituting Example
386A for Example 2A in Example 27B. MS (APCI) m/z 365
(M+1).sup.+.
Example 386C
N1-(5-Isoquinolin-6-yl-pyridin-3-yl)-ethane-1,2-diamine
[0821] The desired product was prepared as the trifluoroacetate by
substituting Example 386B for Example 27B in Examples 27C. MS
(APCI) m/z 265 (M+1).sup.+; .sup.1H NMR (300 MHz, CD.sub.3OD)
.delta. 3.26 (t, J=5.76 Hz, 2H), 3.70 (t, J=5.76 Hz, 2H), 8.10 (s,
1H), 8.25 (s, 1H), 8.33 (d, J=8.82 Hz, 1H), 8.45 (d, J=6.44 Hz,
1H), 8.56 (s, 1H), 8.63 (m, 3H), 9.76 (s, 1H).
EXAMPLE 387
Naphthalene-2-sulfonic Acid
(2-amino-ethyl)-(5-isoquinolin-6-yl-pyridin-3-- yl)-amide
Example 387A
{2-[(5-Isoquinolin-6-yl-pyridin-3-yl)-(naphthalene-2-sulfonyl)-amino]-ethy-
l}-carbamic Acid Tert-Butyl Ester
[0822] To a solution of Example 386B (70 mg, 0.192 mmol) in
pyridine (3 mL) was added 2-naphthalenesulfonyl chloride (87 mg,
0.384 mmol) at rt. The formed yellow solution was stirred at rt for
15 h. Pyridine was removed under reduced pressure and the residual
oil was purified by flash chromatography (0-15% CH.sub.3OH in 2:1
EtOAc/hexane) to provide the desire product (69 mg, 65%). MS (APCI)
m/z 555 (M+1).sup.+.
Example 387B
Naphthalene-2-sulfonic Acid
(2-amino-ethyl)-(5-isoquinolin-6-yl-pyridin-3-- yl)-amide
[0823] The desired product was prepared as the trifluoroacetate by
substituting Example 387B for Example 27B in Examples 27C. MS
(APCI) m/z 455 (M+1).sup.+; .sup.1H NMR (300 MHz, CD.sub.3OD)
.delta. 3.17 (t, J=5.76 Hz, 2H), 4.09 (t, J=5.43 Hz, 2H), 7.66 (t,
J=6.78 Hz, 1H), 7.75 (t, J=7.46 Hz, 1H), 7.99 (m, 2H), 8.06 (m,
3H), 8.13 (d, J=8.82 Hz, 1H), 8.26 (m, 2H), 8.31 (s, 1H), 8.47 (d,
J=8.48 Hz, 1H), 8.59 (m, 2H), 9.08 (d, J=2.03 Hz, 1H), 9.69 (s,
1H).
EXAMPLE 388
Naphthalene-1-sulfonic Acid
(2-amino-ethyl)-(5-isoquinolin-6-yl-pyridin-3-- yl)-amide
[0824] The desired product was prepared as the trifluoroacetate by
substituting 1-naphthalenesulfonyl chloride for
2-naphthalenesulfonyl chloride in Examples 387. MS (APCI) m/z 455
(M+1).sup.+; .sup.1H NMR (300 MHz, CD.sub.3OD) .delta. 3.14 (t,
J=5.76 Hz, 2H), 4.04 (t, J=5.76 Hz, 2H), 7.33 (t, J=7.46 Hz, 1H),
7.51 (t, J=7.12 Hz, 1H), 7.70 (t, J=8.14 Hz, 1H), 7.85 (t, J=2.20
Hz, 1H), 7.92 (dd, J=8.48, 1.70 Hz, 1H), 8.04 (dd, J=8.31, 3.56 Hz,
2H), 8.15 (s, 1H), 8.29 (d, J=4.75 Hz, 1H), 8.31 (d, J=5.42 Hz,
2H), 8.47 (d, J=8.48 Hz, 1H), 8.60 (d, J=6.44 Hz, 1H), 8.63 (d,
J=2.37 Hz, 1H), 9.03 (d, J=2.03 Hz, 1H), 9.67 (s, 1H).
EXAMPLE 389
5-Dimethylamino-naphthalene-1-sulfonic Acid
(2-amino-ethyl)-(5-isoquinolin- -6-yl-pyridin-3-yl)-amide
[0825] The desired product was prepared as the trifluoroacetate by
substituting dansyl chloride for 2-naphthalenesulfonyl chloride in
Example 387. MS (APCI) m/z 498 (M+1).sup.+; .sup.1H NMR (300 MHz,
CD.sub.3OD) .delta. 2.81 (s, 6H), 3.16 (d, J=5.76 Hz, 2H), 4.06 (d,
J=5.76 Hz, 2H), 7.16 (d, J=7.12 Hz, 1H), 7.25 (t, J=7.80 Hz, 1H),
7.67 (dd, J=8.48, 7.80 Hz, 1H), 7.75 (d, J=8.48 Hz, 1H), 7.85 (t,
J=2.20 Hz, 1H), 7.98 (dd, J=8.48, 1.70 Hz, 1H), 8.29 (d, J=7.12 Hz,
1H), 8.30 (s, 1H), 8.43 (d, J=6.44 Hz, 1H), 8.53 (d, J=8.82 Hz,
1H), 8.64 (m, 3H), 9.03 (d, J=2.03 Hz, 1H), 9.76 (s, 1H); Anal.
Calcd for C.sub.21H.sub.27N.sub.5- O.sub.2S.box-solid.4 TFA: C,
45.34; H, 3.28; N, 7.34. Found: C, 45.28; H, 3.11; N, 7.23.
EXAMPLE 390
Quinoline-5-sulfonic Acid
(2-amino-ethyl)-(5-isoquinolin-6-yl-pyridin-3-yl- )-amide
[0826] The desired product was prepared as the trifluoroacetate by
substituting 8-quinolinesulfonyl chloride for 2-naphthalenesulfonyl
chloride in Example 387. MS (APCI) m/z 456 (M+1).sup.+; .sup.1H NMR
(300 MHz, CD.sub.3OD) .delta. 3.29 (t, J=5.43 Hz, 2H), 4.57 (t,
J=5.43 Hz, 2H), 7.65 (t, J=7.46 Hz, 1H), 7.76 (dd, J=8.48, 4.41 Hz,
1H), 8.12 (dd, J=8.48, 1.70 Hz, 1H), 8.18 (t, J=2.03 Hz, 1H), 8.29
(s, 1H), 8.31 (d, J=7.12 Hz, 1H), 8.33 (dd, J=7.46, 1.36 Hz, 1H),
8.41 (s, 1H), 8.42 (d, J=7.80 Hz, 1H), 8.55 (d, J=8.82 Hz, 1H),
8.56 (dd, J=8.31, 1.87 Hz, 1H), 8.62 (d, J=6.44 Hz, 1H), 8.95 (d,
J=1.70 Hz, 1H), 9.08 (dd, J=4.41, 1.70 Hz, 1H), 9.74 (s, 1H); Anal.
Calcd for C.sub.25H.sub.21N.sub.5O.sub.2S.bo- x-solid.3.3 TFA: C,
45.63; H, 2.94; N, 8.42. Found: C, 45.70; H, 2.64; N, 8.18.
EXAMPLE 391
Biphenyl-4-sulfonic Acid
(2-amino-ethyl)-(5-isoquinolin-6-yl-pyridin-3-yl)- -amide
[0827] The desired product was prepared as the trifluoroacetate by
substituting biphenyl-4-sulfonyl chloride for 2-naphthalenesulfonyl
chloride in Example 387. MS (APCI) m/z 481 (M+1).sup.+; .sup.1H NMR
(300 MHz, CD.sub.3OD) .delta. 3.16 (t, J=5.76 Hz, 2H), 4.10 (t,
J=5.76 Hz, 2H), 7.49 (m, 3H), 7.68 (d, J=8.14 Hz, 2H), 7.72 (d,
J=8.82 Hz, 2H), 7.89 (d, J=8.48 Hz, 2H), 8.07 (t, J=2.03 Hz, 1H),
8.22 (dd, J=8.48, 1.70 Hz, 1H), 8.29 (d, J=6.44 Hz, 1H), 8.45 (s,
1H), 8.53 (d, J=8.82 Hz, 1H), 8.57 (d, J=6.44 Hz, 1H), 8.63 (d,
J=2.03 Hz, 1H), 9.10 (d, J=1.70 Hz, 1H), 9.72 (s, 1H); Anal. Calcd
for C.sub.21H.sub.24N.sub.4O.sub.2S.box-solid.3- .1 TFA: C, 49.25;
H, 3.27; N, 6.72. Found: C, 49.20; H, 3.24; N, 6.62.
EXAMPLE 392
1-Methyl-1H-imidazole-4-sulfonic Acid
(2-amino-ethyl)-(5-isoquinolin-6-yl-- pyridin-3-yl)-amide
[0828] The desired product was prepared as the trifluoroacetate by
substituting 1-methylimidazole-4-sulfonyl chloride for
2-naphthalenesulfonyl chloride in Example 387. MS (APCI) m/z 409
(M+1).sup.+; .sup.1H NMR (300 MHz, CD.sub.3OD) .delta. 3.19 (t,
J=5.59 Hz, 2H), 3.77 (s, 3H), 4.18 (t, J=5.59 Hz, 2H), 7.71 (s,
1H), 7.89 (s, 1H), 8.31 (m, 2H), 8.50 (d, J=6.44 Hz, 1H), 8.57 (d,
J=8.14,Hz, 1H), 8.59 (s, 1H), 8.62 (d, J=8.48 Hz, 1H), 8.64 (d,
J=6.44 Hz, 1H), 9.07 (d, J=2.03 Hz, 1H), 9.78 (s, 1H); Anal. Calcd
for C.sub.20H.sub.20N.sub.6O.su- b.2S.box-solid.3.8 TFA: C, 39.38;
H, 2.85; N, 9.98. Found: C, 39.35; H, 2.73; N, 9.79.
EXAMPLE 393
3-Amino-2-[5-(3-methyl-1H-indazol-5-yl)-pyridin-3-yloxy]-propan-1-ol
Example 393A
[3-(tert-Butyl-dimethyl-silanyloxy)-2-hydroxy-propyl]-carbamic Acid
Tert-Butyl Ester
[0829] To a solution of t-butyl N-(2,3-dihydroxypropyl)carbamate
(9.0 g, 47 mmol) in CH.sub.2Cl.sub.2 (75 mL) was added
t-butyldimethylsilyl chloride (7.80 g, 51.7 mmol), triethylamine
(7.86 mL, 56.4 mmol) and DMAP (230 mg). The solution was stirred at
rt overnight. After diluting with CH.sub.2Cl.sub.2 (50 mL), the
solution was washed with water (2.times.100 mL), dried over
MgSO.sub.4 and concentrated. The residual oil was distilled by
Kugelrohr under vacuum to give the desired product (13.6 g, 95%).
MS (DCI) m/z 306 (M+1).sup.+.
Example 393B
[2-(5-Bromo-pyridin-3-yloxy)-3-(tert-butyl-dimethyl-silanyloxy)-propyl]-ca-
rbamic Acid Tert-Butyl Ester
[0830] A 100 mL RBF was charged with 3-bromo-5-hydroxypyridine (949
mg, 5.45 mmol), Example 393A (2.0 g, 6.45 mmol) and Ph.sub.3P (1.72
g, 6.54 mmol), and was purged with nitrogen. THF (22 mL) was added
at 0.degree. C. After stirring at 0.degree. C. for 10 min, DEAD
(1.03 mL, 6.54 mmol) was added via syringe. The reaction mixture
was stirred at 0.degree. C. for 1 h and at rt overnight. The
reaction mixture was concentrated and the residue was separated by
flash chromatography (5-30% EtOAc in hexane) to provide the desired
product (1.76 g, 70%). MS (DCI) m/z 461, 463 (M+1).sup.+.
Example 393C
5-{5-[2-tert-Butoxycarbonylamino-1-(tert-butyl-dimethyl-silanyloxymethyl)--
ethoxy]-pyridin-3-yl}-3-methyl-indazole-1-carboxylic Acid
Tert-Butyl Ester
[0831] A 100 mL RBF was charged with Example 393B (1.60 g, 3.47
mmol), Example 203B (1.37 g, 3.47 mmol), Pd.sub.2(dba).sub.3 (318
mg, 0.347 mmol), and tri-o-tolylphosphine (318 mg), and was purged
with N.sub.2. Anhydrous DMF (50 mL) and Et.sub.3N (1.45 mL) were
added via syringe. The solution was purged with N.sub.2 again and
was heated at 75.degree. C. for 5 h. After cooled, ethyl acetate
(200 mL) was added. The mixture was washed with brine (250 mL) and
water (250 mL). The ethyl acetate solution was concentrated and the
residual oil was separated by flash chromatography (20-60% EtOAc in
hexane) to give the desired product (1.51 g, 71%). MS (DCI) m/z 613
(M+1).sup.+.
Example 393D
5-[5-(2-tert-Butoxycarbonylamino-1-hydroxymethyl-ethoxy)-pyridin-3-yl]-3-m-
ethyl-indazole-1-carboxylic Acid Tert-Butyl Ester
[0832] To a solution of Example 393C (1.122 g, 1.83 mmol) in THF
(20 mL) was added TBAF (1.92 mL) at rt. The solution was stirred at
rt for 1 h and was concentrated. The residual oil was separated by
flash chromatography (0-15% CH.sub.3OH in 2:1 EtOAc/hexane) to give
the title compound (0.82 g, 90%). MS (DCI) m/z 499 (M+1).sup.+.
Example 393E
3-Amino-2-[5-(3-methyl-1H-indazol-5-yl)-pyridin-3-yloxy]-propan-1-ol
[0833] The desired product was prepared as HCl salt by substituting
Example 393D for Example 27B in Examples 27C. MS (APCI) m/z 299
(M+1).sup.+; .sup.1H NMR (300 MHz, DMSO-d.sub.6) .delta. 2.58 (s,
3H), 3.26 (m, 2H), 3.68 (dd, J=12.21, 5.09 Hz, 1H), 3.75 (dd,
J=12.54, 4.75 Hz, 1H), 5.05 (m, J=4.07 Hz, 1H), 7.62 (d, J=8.81 Hz,
1H), 7.85 (dd, J=8.81, 1.70 Hz, 1H), 8.35 (s, 4H), 8.52 (s, 1H),
8.64 (d, J=2.37 Hz, 1H), 8.90 (s, 1H); Anal. Calcd for
C.sub.16H.sub.18N.sub.4O.sub.2.box-sol- id.3.2 HCl: C, 46.31; H,
5.15; N, 13.50. Found: C, 46.46; H, 5.12; N, 13.42.
EXAMPLE 394
2-[5-(3-Methyl-1H-indazol-5-yl)-pyridin-3-yloxy]-3-phenoxy-propylamine
Example 394A
5-[5-(2-tert-Butoxycarbonylamino-1-phenoxymethyl-ethoxy)-pyridin-3-yl]-3-m-
ethyl-indazole-1-carboxylic Acid Tert-Butyl Ester
[0834] A 25 mL RBF was charged with phenol (42 mg, 0.45 mmol),
Example 393D (150 mg, 0.3 mmol) and Ph.sub.3P (142 mg, 0.54 mmol),
and was purged with nitrogen. THF (4 mL) was added at 0.degree. C.
After stirring at 0.degree. C. for 10 min, DEAD (85 .mu.L, 0.54
mmol) was added via syringe. The reaction mixture was stirred at
0.degree. C. for 1 h and at rt overnight. The reaction mixture was
concentrated and the residue was separated by flash chromatography
(20-60% EtOAc in hexane) to provide the desire product (163 mg,
95%). MS (DCI) m/z 575 (M+1).sup.+.
Example 394B
2-[5-(3-Methyl-1H-indazol-5-yl)-pyridin-3-yloxy]-3-phenoxy-propylamine
[0835] The desired product was prepared as the trifluoroacetate by
substituting Example 394A for Example 27B in Examples 27C. MS
(APCI) m/z 375 (M+1).sup.+; .sup.1H NMR (300 MHz, CD.sub.3OD)
.delta. 2.62 (s, 3H), 3.58 (d, J=5.76 Hz, 2H), 4.34 (dd, J=11.19,
5.09 Hz, 1H), 4.42 (dd, J=11.19, 3.73 Hz, 1H), 5.33 (m, 1H), 6.94
(m, 3H), 7.26 (dd, J=8.81, 7.46 Hz, 2H), 7.62 (d, J=7.80 Hz, 1H),
7.72 (dd, J=8.81, 1.70 Hz, 1H), 8.09 (s, 1H), 8.27 (s, 1H), 8.52
(d, J=2.37 Hz, 1H), 8.75 (d, J=1.36 Hz, 1H); Anal. Calcd for
C.sub.22H.sub.22N.sub.4O.sub.2.box-solid.2 TFA: C, 51.83; H, 4.02;
N, 9.30. Found: C, 51.97; H, 3.97; N, 9.41.
EXAMPLE 395
2-[5-(3-Methyl-1H-indazol-5-yl)-pyridin-3-yloxy]-3-(naphthalen-2-yloxy)-pr-
opylamine
[0836] The desired product was prepared as the trifluoroacetate by
substituting 2-naphthol for phenol in Examples 394. MS (APCI) m/z
425 (M+1).sup.+; .sup.1H NMR (300 MHz, CD.sub.3OD) .delta. 2.56 (s,
3H), 3.62 (d, J=5.76 Hz, 2H), 4.47 (dd, J=11.19, 5.09 Hz, 1H), 4.56
(dd, J=11.19, 3.73 Hz, 1H), 5.36 (m, 1H), 7.08 (dd, J=8.98, 2.54
Hz, 1H), 7.28 (m, 1H), 7.33 (d, J=8.14 Hz, 1H), 7.40 (t, J=8.14 Hz,
1H), 7.54 (d, J=8.48 Hz, 1H), 7.62 (dd, J=10.17, 1.70 Hz, 1H), 7.71
(d, J=8.14 Hz, 1H), 7.72 (d, J=2.03 Hz, 1H), 7.74 (s, 1H), 8.00 (s,
1H), 8.11 (m, 1H), 8.50 (d, J=2.37 Hz, 1H), 8.68 (d, J=1.36 Hz,
1H); Anal. Calcd for C.sub.26H.sub.24N.sub.4- O.sub.2.box-solid.2.8
TFA: C, 51.03; H, 3.63; N, 7.53. Found: C, 51.18; H, 3.47; N,
7.55.
EXAMPLE 396
3-(Biphenyl-4-yloxy)-2-[5-(3-methyl-1H-indazol-5-yl)-pyridin-3-yloxy]-prop-
ylamine
[0837] The desired product was prepared as the trifluoroacetate by
substituting 4-phenylphenol for phenol in Examples 394. MS (APCI)
m/z 452 (M+1).sup.+; .sup.1H NMR (300 MHz, CD.sub.3OD) .delta. 2.57
(s, 3H), 3.58 (d, J=6.10 Hz, 2H), 4.39 (dd, J=11.19, 5.09 Hz, 1H),
4.47 (dd, J=1.53, 3.73 Hz, 1H), 5.30 (m, 1H), 6.99 (d, J=8.81 Hz,
2H), 7.27 (d, J=7.12 Hz, 1H), 7.36 (t, J=7.46 Hz, 2H), 7.51 (m,
4H), 7.57 (d, J=8.48 Hz, 1H), 7.67 (dd, J=8.81, 1.70 Hz, 1H), 8.03
(s, 1H), 8.09 (dd, J=4.41, 2.37 Hz, 1H), 8.49 (d, J=2.37 Hz, 1H),
8.69 (s, 1H); Anal. Calcd for
C.sub.28H.sub.26N.sub.4O.sub.2.box-solid.3.2 TFA: C, 50.67; H,
3.61; N, 6.87. Found: C, 50.77; H, 3.51; N, 6.64.
EXAMPLE 397
2-[5-(3-Methyl-1H-indazol-5-yl)-pyridin-3-yloxy]-3-(quinolin-7-yloxy)-prop-
ylamine
[0838] The desired product was prepared as the trifluoroacetate by
substituting 7-hydroxyquinoline for phenol in Examples 394. MS
(APCI) m/z 426 (M+1).sup.+; .sup.1H NMR (300 MHz, CD.sub.3OD)
.delta. 2.59 (s, 3H), 3.64 (d, J=5.76 Hz, 2H), 4.62 (dd, J=10.85,
5.09 Hz, 1H), 4.70 (d, J=11.19 Hz, 1H), 5.42 (m, 1H), 7.50 (dd,
J=9.32, 2.20 Hz, 1H), 7.58 (dd, J=5.26, 3.22 Hz, 2H), 7.69 (d,
J=8.48 Hz, 1H), 7.78 (dd, J=8.14, 5.43 Hz, 1H), 8.03 (s, 1H), 8.07
(s, 1H), 8.16 (d, J=9.16 Hz, 1H), 8.47 (s, 1H), 8.67 (s, 1H), 8.88
(d, J=8.14 Hz, 1H), 8.98 (d, J=4.41 Hz, 1H); Anal. Calcd for
C.sub.25H.sub.23N.sub.5O.sub.2.box-solid.3.9 TFA: C, 45.27; H,
3.12; N, 8.05. Found: C, 45.26; H, 3.05; N, 7.92.
EXAMPLE 398
2-[5-(3-Methyl-1H-indazol-5-yl)-pyridin-3-yloxy]-3-(pyridin-4-yloxy)-propy-
lamine
[0839] The desired product was prepared as HCl salt by substituting
4-hydroxypyridine for phenol in Examples 394. MS (APCI) m/z 376
(M+1).sup.+; .sup.1H NMR (300 MHz, DMSO-d.sub.6) .delta. 2.58 (s,
3H), 3.40 (br s, 2H), 4.75 (d, J=11.87 Hz, 1H), 4.85 (d, J=11.49
Hz, 1H), 5.61 (m, 1H), 7.59 (m, 2H), 7.86 (d, J=8.82 Hz, 1H), 8.37
(s, 1H), 8.56 (s, 1H), 8.66 (s, 1H), 8.73 (s, 2H), 8.79 (s, 1H),
8.81 (s, 1H), 8.92 (s, 1H); Anal. Calcd for
C.sub.21H.sub.21N.sub.5O.sub.2.box-solid.4.5 HCl: C, 46.75; H,
4.76; N, 12.98. Found: C, 46.77; H, 4.41; N, 12.83.
EXAMPLE 399
2-[5-(3-Methyl-1H-indazol-5-yl)-pyridin-3-yloxy]-3-(naphthalen-1-yloxy)-pr-
opylamine
[0840] The desired product was prepared as the trifluoroacetate by
substituting 1-naphthol for phenol in Examples 394. MS (APCI) m/z
426 (M+1).sup.+; .sup.1H NMR (300 MHz, CD.sub.3OD) .delta. 3.34 (s,
3H), 3.65 (d, J=5.76 Hz, 2H), 4.57 (m, 2H), 5.49 (m, 1H), 6.97 (d,
J=7.46 Hz, 1H), 7.23 (t, J=7.63 Hz, 1H), 7.37 (d, J=7.46 Hz, 1H),
7.41 (d, J=8.82 Hz, 1H), 7.44 (d, J=8.48 Hz, 1H), 7.56 (s, 2H),
7.74 (d, J=8.48 Hz, 1H), 7.84 (d, J=7.80 Hz, 1H), 7.92 (s, 1H),
8.15 (s, 1H), 8.50 (d, J=2.03 Hz, 1H), 8.65 (s, 1H); Anal. Calcd
for C.sub.26H.sub.24N.sub.4O.sub.2.box-solid.3.- 1 TFA: C, 49.71;
H, 3.51; N, 7.20. Found: C, 49.70; H, 3.47; N, 7.07.
EXAMPLE 400
3-{(2S)-2-Amino-3-[5-(3-methyl-1H-indazol-5-yl)-pyridin-3-yloxy]-propyl}-1-
H-indol-5-ol
Example 400A
(2S)-2-tert-Butoxycarbonylamino-3-(5-hydroxy-1H-indol-3-yl)-propionic
Acid Methyl Ester
[0841] To a solution of BOC-5-hydroxy-tryptophan (5.9 g, 18.4 mmol)
and iodomethane (3.43 mL) in DMF (80 mL) was added powered
KHCO.sub.3 (3.68 g). The reaction mixture was stirred at rt for 4
hours. EtOAc (500 mL) was added and the mixture was washed with
brine (500 mL) and water (500 mL). The organic phase was
concentrated and the residual oil was triturated with
CH.sub.2Cl.sub.2 (20 mL). The formed white solid was collected by
filtration, washed with CH.sub.2Cl.sub.2 (20 mL) and dried to give
the desired product (4.48 g, 73%). MS (DCI) m/z 335
(M+1).sup.+.
Example 400B
(2S)-2-tert-Butoxycarbonylamino-3-[5-(tert-butyl-dimethyl-silanyloxy)-1H-i-
ndol-3-yl]-propionic Acid Methyl Ester
[0842] To a solution of Example 400A (1.20 g, 3.59 mmol) in DMF (20
mL) was added t-butyldimethylsilyl chloride (649 mg, 4.3 mmol),
imidazole (293 mg, 4.3 mmol) and DMAP (50 mg) at rt. The reaction
mixture was stirred at rt for 16 hours. EtOAc (100 mL) was added
and the mixture was washed with brine (100 mL) and water (100 mL).
The organic phase was concentrated and the residual oil was
purified by flash chromatography (10-40% EtOAc in hexane) to give
the desire product (1.6 g, 100%). MS (DCI) m/z 466
(M+18).sup.+.
Example 400C
(1S)-{2-[5-(tert-Butyl-dimethyl-silanyloxy)-1H-indol-3-yl]-1-hydroxymethyl-
-ethyl}-carbamic Acid Tert-Butyl Ester
[0843] To a solution of Example 400B (1.50 g, 3.3 mmol) in THF (15
mL) was slowly added LiAlH.sub.4 powder (127 mg, 3.3 mmol) in
several portion at rt. After the addition, the reaction mixture was
becoming sticky and the stirring stopped. The temperature of the
mixture arises to .about.50.degree. C. Ether (30 mL) was added and
the mixture was stirred for 20 min. Methanol (2 mL) and diluted HCl
was added slowly and the mixture was extracted with ether. The
organic phase was washed with water and concentrated. The residue
was separated by flash chromatography (20-60% EtOAc in hexane) to
give the desired product (982 mg, 70%). MS (DCI) m/z 421
(M+1).sup.+.
Example 400D
(1S)-{2-(5-Bromo-pyridin-3-yloxy)-1-[5-(tert-butyl-dimethyl-silanyloxy)-1H-
-indol-3-ylmethyl]-ethyl}-carbamic Acid Tert-Butyl Ester
[0844] A 100 mL RBF was charged with 3-bromo-5-hydroxypyridine (432
mg, 2.48 mmol), Example 400C (950 mg, 2.26 mmol) and Ph.sub.3P (711
mg, 2.71 mmol), and was purged with nitrogen. THF (15 mL) was added
at 0.degree. C. After stirring at 0.degree. C. for 10 min, DEAD
(427 .mu.L, 2.71 mmol) was added via syringe. The reaction mixture
was stirred at 0.degree. C. for 1 h and at rt overnight. The
reaction mixture was concentrated and the residue was separated by
flash chromatography (10-50% EtOAc in hexane) to provide the
desired product (1.05 g, 80%). MS (APCI) m/z 576, 578
(M+1).sup.+.
Example 400E
5-(5-{(2S)-2-tert-Butoxycarbonylamino-3-[5-(tert-butyl-dimethyl-silanyloxy-
)-1H-indol-3-yl]-propoxy}-pyridin-3-yl)-3-methyl-indazole-1-carboxylic
Acid Tert-Butyl Ester
[0845] The desire product was prepared by substituting Example 400D
for Example 202A in Example 203C. MS (DCI) m/z 728 (M+1).sup.+.
Example 400F
5-{5-[(2S)-2-tert-Butoxycarbonylamino-3-(5-hydroxy-1H-indol-3-yl)-propoxy]-
-pyridin-3-yl}-3-methyl-indazole-1-carboxylic Acid Tert-Butyl
Ester
[0846] To a solution of Example 400E (850 mg, 1.17 mmol) in THF (10
mL) was added TBAF (1.28 mL, 1.28 mmol) at rt. The solution was
stirred at rt for 2 h and was concentrated. The residual oil was
purified by flash chromatography (0-15% CH.sub.3OH in 2:1
EtOAc/hexane) to give the desired product (530 mg, 74%). MS (DCI)
m/z 614 (M+1).sup.+.
Example 400G
3-{(2S)-2-Amino-3-[5-(3-methyl-1H-indazol-5-yl)-pyridin-3-yloxy]-propyl}-1-
H-indol-5-ol
[0847] The desired product was prepared as the trifluoroacetate by
substituting Example 400F for Example 27B in Examples 27C. MS
(APCI) m/z 414 (M+1).sup.+; .sup.1H NMR (300 MHz, CD.sub.3OD)
.delta. 2.63 (s, 3H), 3.25 (dd, J=7.12, 2.37 Hz, 2H), 3.98 (m, 1H),
4.35 (dd, J=10.51, 5.76 Hz, 1H), 4.48 (dd, J=10.51, 3.39 Hz, 1H),
6.70 (dd, J=8.48, 2.37 Hz, 1H), 6.93 (d, J=2.03 Hz, 1H), 7.18 (s,
1H), 7.20 (d, J=8.48 Hz, H), 7.63 (d, J=8.81 Hz, 1H), 7.71 (dd,
J=8.81, 2.03 Hz, 1H), 8.11 (m, 2H), 8.41 (d, J=2.37 Hz, 1H), 8.74
(d, J=1.70 Hz, 1H); Anal. Calcd for
C.sub.24H.sub.23N.sub.5O.sub.2.box-solid.3.7 TFA: C, 45.15; H,
3.22; N, 8.38. Found: C, 45.15; H, 3.45; N, 8.43.
EXAMPLE 401
(1S)-1-(5-Methoxy-1H-indol-3-ylmethyl)-2-[5-(3-methyl-1H-indazol-5-yl)-pyr-
idin-3-yloxy]-ethylamine
Example 401A
5-{5-[(2S)-2-tert-Butoxycarbonylamino-3-(5-methoxy-1H-indol-3-yl)-propoxy]-
-pyridin-3-yl}-3-methyl-indazole-1-carboxylic Acid Tert-Butyl
Ester
[0848] A 25 mL RBF was charged with Example 400F (100 mg, 0.163
mmol) and Ph.sub.3P (85 mg, 0.325 mmol), and was purged with
nitrogen. THF (4 mL) and methanol (14 .mu.L) were added at
0.degree. C. After stirring at 0.degree. C. for 10 min, DEAD (51
.mu.L, 0.325 mmol) was added via syringe. The reaction mixture was
stirred at 0.degree. C. for 1 h and at rt over weekend. The
reaction mixture was concentrated and the residue was separated by
flash chromatography (50-80% EtOAc in hexane) to provide the
desired product (33 mg, 32%). MS (APCI) m/z 628 (M+1).sup.+.
Example 401B
(1S)-1-(5-Methoxy-1H-indol-3-ylmethyl)-2-[5-(3-methyl-1H-indazol-5-yl)-pyr-
idin-3-yloxy]-ethylamine
[0849] The desired product was prepared as the trifluoroacetate by
substituting Example 401A for Example 27B in Examples 27C. MS
(APCI) m/z 428 (M+1).sup.+; .sup.1H NMR (300 MHz, CD.sub.3OD)
.delta. 2.62 (s, 3H), 3.33 (m, 2H), 3.70 (s, 3H), 3.98 (m, 1H),
4.32 (dd, J=10.51, 5.42 Hz, 1H), 4.45 (dd, J=10.51, 3.05 Hz, 1H),
6.78 (dd, J=8.81, 2.37 Hz, 1H), 7.05 (d, J=2.03 Hz, 1H), 7.21 (s,
1H), 7.27 (d, J=8.81 Hz, 1H), 7.60 (d, J=7.80 Hz, 1H), 7.67 (dd,
J=8.81, 1.70 Hz, 1H), 7.91 (m, 1H), 8.03 (s, 1H), 8.35 (d, J=2.03
Hz, 1H), 8.65 (s, 1H).
EXAMPLE 402
(1S)-1-(5-Ethoxy-1H-indol-3-ylmethyl)-2-[5-(3-methyl-1H-indazol-5-yl)-pyri-
din-3-yloxy]-ethylamine
[0850] The desired product was prepared as the trifluoroacetate by
substituting ethanol for methanol in Example 401. MS (APCI) m/z 442
(M+1); .sup.1H NMR (300 MHz, CD.sub.3OD) .delta. 1.26 (t, J=6.95
Hz, 3H), 2.62 (s, 3H), 3.35 (m, 2H), 3.86 (q, J=7.12 Hz, 2H), 3.95
(m, 1H), 4.32 (dd, J=10.51, 5.42 Hz, 1H), 4.45 (dd, J=10.51, 3.39
Hz, 1H), 6.78 (dd, J=8.82, 2.37 Hz, 1H), 7.02 (d, J=2.37 Hz, 1H),
7.21 (s, 1H), 7.26 (d, J=8.81 Hz, 1H), 7.61 (d, J=9.49 Hz, 1H),
7.68 (d, J=8.81 Hz, 1H), 7.97 (s, 1H), 8.05 (s, 1H), 8.37 (d,
J=2.37 Hz, 1H), 8.68 (d, J=1.36 Hz, 1H); Anal. Calcd for
C.sub.26H.sub.27N.sub.5O.sub.2.box-solid.3.2 TFA: C, 48.26; H,
3.77; N, 8.68. Found: C, 48.14; H, 3.60; N, 8.45.
EXAMPLE 403
(1S)-1-(5-Butoxy-1H-indol-3-ylmethyl)-2-[5-(3-methyl-1H-indazol-5-yl)-pyri-
din-3-yloxy]-ethylamine
[0851] The desired product was prepared as the trifluoroacetate by
substituting n-butanol for methanol in Example 401. MS (APCI) m/z
470 (M+1).sup.+; .sup.1H NMR (300 MHz, CD.sub.3OD) .delta. 0.87 (t,
J=7.36 Hz, 3H), 1.37 (m, 2H), 1.59 (m, 2H), 2.61 (s, 3H), 3.29 (m,
2H), 3.81 (m, 2H), 3.97 (s, 1H), 4.35 (dd, J=10.13, 4.91 Hz, 1H),
4.46 (d, J=7.98 Hz, 1H), 6.76 (d, J=8.59 Hz, 1H), 7.01 (s, 1H),
7.21 (s, 1H), 7.25 (d, J=8.59 Hz, 1H), 7.61 (d, J=8.59 Hz, 1H),
7.68 (d, J=8.59 Hz, 1H), 8.06 (s, 2H), 8.38 (s, 1H), 8.71 (s, 1H);
Anal. Calcd for C.sub.21H.sub.31N.sub.5O.sub.- 2.box-solid.2.8 TFA:
C, 51.16; H, 4.32; N, 8.88. Found: C, 51.36; H, 4.51; N, 8.99.
EXAMPLE 404
(1S)-1-(5-Isopropoxy-1H-indol-3-ylmethyl)-2-[5-(3-methyl-1H-indazol-5-yl)--
pyridin-3-yloxy]-ethylamine
[0852] The desired product was prepared as the trifluoroacetate by
substituting isopropanol for methanol in Example 401. MS (APCI) m/z
456 (M+1).sup.+; .sup.1H NMR (400 MHz, CD.sub.3OD) .delta. 1.18 (m,
6H), 2.61 (s, 3H), 3.30 (m, 2H), 3.97 (s, 1H), 4.38 (m, 2H), 4.48
(d, J=8.29 Hz, 1H), 6.77 (d, J=7.98 Hz, 1H), 7.07 (s, 1H), 7.23 (s,
1H), 7.26 (d, J=8.90 Hz, 1H), 7.61 (d, J=8.90 Hz, 1H), 7.69 (d,
J=8.59 Hz, 1H), 8.08 (s, 1H), 8.12 (s, 1H), 8.42 (s, 1H), 8.74 (s,
1H); Anal. Calcd for C.sub.27H.sub.29N.sub.5O.sub.2.3.2 TFA: C,
48.90; H, 3.96; N, 8.54. Found: C, 48.93; H, 3.88; N, 8.55.
EXAMPLE 405
3-(1H-Indol-3-yl)-2-[5-(3-methyl-1H-indazol-5-yl)-pyridin-3-yloxy]-propan--
1-ol
Example 405A
2-(5-Bromo-pyridin-3-yloxy)-3-(1H-indol-3-yl)-propionic Acid Methyl
Ester
[0853] A 100 mL RBF was charged with 3-bromo-5-hydroxypyridine
(1.67 g, 9.58 mmol), 2-hydroxy-3-(1H-indol-3-yl)-propionic acid
methyl ester (2.1 g, 9.58 mmol) which was synthesized according to
literature method (M. E. Jung et al J. Org. Chem. 1999, 64, 2976)
and Ph.sub.3P (3.01 g, 11.5 mmol), and was purged with nitrogen.
THF (40 mL) was added at 0.degree. C. After stirring at 0.degree.
C. for 10 min, DEAD (1.81 mL, 11.5 mmol) was added via syringe. The
reaction mixture was stirred at 0.degree. C. for 1 h and at rt
overnight. The reaction mixture was concentrated and the residue
was separated by flash chromatography (20-60% EtOAc in hexane) to
provide the desired product (3.4 g, 94%). MS (DCI) m/z 375, 377
(M+1).sup.+.
Example 405B
2-(5-Bromo-pyridin-3-yloxy)-3-(1H-indol-3-yl)-propan-1-ol
[0854] To a solution of Example 405A (3.2 g, 8.5 mmol) in THF (20
mL) and ether (30 mL) was slowly added LiAlH.sub.4 powder (323 mg,
8.5 mmol) in several portion at rt. While LAH was added a lot of
solid material precipitated from the solution and the temperature
arises to about 40.degree. C. Water (2 mL) and diluted HCl was
added slowly and the mixture was neutralized with NaHCO.sub.3 and
extracted with ethyl acetate. The organic phase was washed with
water and concentrated. The residue was separated by flash
chromatography (20-80% EtOAc in hexane) to give the desired product
(1.24 g, 42%). MS (DCI) m/z 347, 349 (M+1).sup.+.
Example 405C
5-{5-[1-Hydroxymethyl-2-(1H-indol-3-yl)-ethoxy]-pyridin-3-yl}-3-methyl-ind-
azole-1-carboxylic Acid Tert-Butyl Ester
[0855] A 50 mL RBF was charged with Example 405B (580 mg, 1.67
mmol), Example 203B (660 mg, 1.67 mmol), Pd.sub.2(dba).sub.3 (153
mg, 0.167 mmol), and tri-o-tolylphosphine (153 mg), and was purged
with N.sub.2. Anhydrous DMF (22 mL) and Et.sub.3N (0.698 mL) were
added via syringe. The solution was purged with N.sub.2 again and
was heated at 70.degree. C. for 15 h. After cooled, ethyl acetate
(100 mL) was added. The mixture was washed with brine (100 mL) and
water (100 mL). The ethyl acetate solution was concentrated and the
residual oil was separated by flash chromatography (0-15%
CH.sub.3OH in 2:1 EtOAc/hexane) to give the desired product (656
mg, 79%). MS (APCI) m/z 499 (M+1).sup.+.
Example 405D
3-(1H-Indol-3-yl)-2-[5-(3-methyl-1H-indazol-5-yl)-pyridin-3-yloxy]-propan--
1-ol
[0856] The desired product was prepared as the trifluoroacetate by
substituting Example 405C for Example 27B in Examples 27C. MS
(APCI) m/z 399 (M+1).sup.+; .sup.1H NMR (400 MHz, CD.sub.3OD)
.delta. 2.56 (s, 3H), 3.09 (dd, J=14.73, 8.90 Hz, 1H), 3.19 (dd,
J=15.04, 3.99 Hz, 1H), 3.85 (dd, J=12.12, 6.60 Hz, 1H), 3.92 (m,
1H), 4.99 (m, 1H), 6.97 (dd, J=6.14, 3.07 Hz, 2H), 7.07 (s, 1H),
7.16 (m, 1H), 7.25 (dd, J=8.75, 1.38 Hz, 1H), 7.49 (d, J=8.90 Hz,
1H), 7.57 (dd, J=6.14, 2.76 Hz, 1H), 7.84 (d, J=10.43 Hz, 2H), 8.14
(s, 1H), 8.38 (s, 1H); Anal. Calcd for
C.sub.24H.sub.22N.sub.4O.sub.2.box-solid.1.7 TFA: C, 55.56; H,
4.03; N, 9.46. Found: C, 55.69; H, 4.02; N, 9.58.
EXAMPLE 406
3-(1H-Indol-3-yl)-2-[5-(3-methyl-1H-indazol-5-yl)-pyridin-3-yloxy]-propyla-
mine
Example 406A
5-{5-[1-Azidomethyl-2-(1H-indol-3-yl)-ethoxy]-pyridin-3-yl}-3-methyl-indaz-
ole-1-carboxylic Acid Tert-Butyl Ester
[0857] A 50 mL RBF was charged with Example 405C (580 mg, 1.16
mmol) and Ph.sub.3P (456 mg, 1.74 mmol), and was purged with
nitrogen. THF (14 mL) was added at 0.degree. C., followed by
addition of DPPA (375 .mu.L, 1.74 mmol). After stirring at
0.degree. C. for 1 min, DEAD (274 .mu.L, 1.74 mmol) was added via
syringe. The reaction mixture was stirred at 0.degree. C. for 0.5 h
and at rt overnight. The reaction mixture was concentrated and the
residue was separated by flash chromatography (20-80% EtOAc in
hexane) to provide the desired product (534 mg, 87%). MS (APCI) m/z
524 (M+1).sup.+.
Example 406B
5-{5-[1-Aminomethyl-2-(1H-indol-3-yl)-ethoxy]-pyridin-3-yl}-3-methyl-indaz-
ole-1-carboxylic Acid Tert-Butyl Ester
[0858] To a solution of Example 406A (480 mg) in ethanol was added
10% Pd/C (160 mg) under nitrogen. This suspension was purged with
hydrogen (3 circles) and was stirred under hydrogen (balloon) for 4
h. The solid material was filtered off and the filtrate was
concentrated to give the desired product (443 mg, 97%). MS (APCI)
m/z 498 (M+1).sup.+.
Example 406C
3-(1H-Indol-3-yl)-2-[5-(3-methyl-1H-indazol-5-yl)-pyridin-3-yloxy]-propyla-
mine
[0859] The desired product was prepared as the trifluoroacetate by
substituting Example 406B for Example 27B in Examples 27C. MS
(APCI) m/z 398 (M+1).sup.+; .sup.1H NMR (300 MHz, CD.sub.3OD)
.delta. 2.62 (s, 3H), 3.29 (m, 2H),3.40 (dd, J=13.56, 9.15 Hz, 1H),
3.53 (dd, J=13.90, 2.71 Hz, 1H), 5.32 (m, 1H), 7.03 (m, 2H), 7.14
(s, 1H), 7.20 (dd, J=6.27, 2.54 Hz, 1H), 7.28 (dd, J=8.81, 1.70 Hz,
1H), 7.55 (d, J=8.48 Hz, 1H), 7.59 (dd, J=6.10, 2.37 Hz, 1H), 7.80
(s, 1H), 7.85 (s, 1H), 8.22 (d, J=2.37 Hz, 1H), 8.47 (s, 1H); Anal.
Calcd for C.sub.24H.sub.23N.sub.5O.box-solid.3.3 TFA: C, 47.50; H,
3.43; N, 9.05. Found: C, 47.41; H, 3.71; N, 9.11.
EXAMPLE 407
Naphthalene-2-sulfonic Acid
(2-amino-ethyl)-[5-(3-methyl-1H-indazol-5-yl)--
pyridin-3-yl]-amide
Example 407A
{2-[(5-Bromo-pyridin-3-yl)-(naphthalene-2-sulfonyl)-amino]-ethyl}-carbamic
Acid Tert-Butyl Ester
[0860] To a solution of Example 386A (50 mg, 0.158 mmol) in
pyridine (2 mL) was added 2-naphthalenesulfonyl chloride (72 mg,
0.316 mmol) at rt. The formed yellow solution was stirred at rt for
15 h. Pyridine was removed by blowing with nitrogen and the
residual yellow solid was purified by flash chromatography (30-60%
EtOAc in hexane) to the desired product (81 mg, 100%). MS (DCI) m/z
506, 508 (M+1).sup.+.
Example 407B
{2-[[5-(3-Methyl-1H-indazol-5-yl)-pyridin-3-yl]-(naphthalene-2-sulfonyl)-a-
mino]-ethyl}-carbamic Acid Tert-Butyl Ester
[0861] A 25 mL RBF was charged with Example 407A (78 mg, 0.154
mmol), Example 203B (45 mg, 0.154 mmol), Pd.sub.2(dba).sub.3 (14
mg, 0.0154 mmol), and tri-o-tolylphosphine (14 mg), and was purged
with N.sub.2. Anhydrous DMF (4 mL) and Et.sub.3N (64 .mu.L) were
added via syringe. The solution was purged with N.sub.2 again and
was heated at 70.degree. C. for 15 h. After cooled, ethyl acetate
(50 mL) was added. The mixture was washed with brine (50 mL) and
water (50 mL). The ethyl acetate solution was concentrated and the
residual oil was separated by flash chromatography (A: 2:1
EtOAc/hexane, 0-15% CH.sub.3OH/A) to give the desired product (54
mg, 63%). MS (APCI) m/z 558 (M+1).sup.+.
Example 407C
Naphthalene-2-sulfonic Acid
(2-amino-ethyl)-[5-(3-methyl-1H-indazol-5-yl)--
pyridin-3-yl]-amide
[0862] The desired product was prepared as the trifluoroacetate by
substituting Example 407B for Example 27B in Examples 27C. MS
(APCI) m/z 458 (M+1).sup.+; .sup.1H NMR (300 MHz, CD.sub.3OD)
.delta. 2.50 (s, 3H), 3.14 (t, J=5.59 Hz, 2H), 4.06 (t, J=5.59 Hz,
2H), 7.48 (m, 2H), 7.66 (m, 2H), 7.74 (d, J=8.14 Hz, 1H), 7.77 (d,
J=8.14 Hz, 1H), 7.80 (t, J=2.03 Hz, 1H), 8.02 (d, J=8.14 Hz, 1H),
8.06 (d, J=8.48 Hz, 1H), 8.14 (d, J=8.48 Hz, 1H), 8.28 (s, 1H),
8.47 (d, J=2.37 Hz, 1H), 8.92 (d, J=1.70 Hz, 1H); Anal. Calcd for
C.sub.25H.sub.23N.sub.5O.sub.2S.box-solid.3.3 TFA: C, 45.52; H,
3.18; N, 8.40. Found: C, 45.42; H, 3.13; N, 8.43.
EXAMPLE 408 Biphenyl-4-sulfonic Acid
(2-amino-ethyl)-[5-(3-methyl-1H-indaz-
ol-5-yl)-pyridin-3-yl]-amide
[0863] The desired product was prepared as the trifluoroacetate by
substituting 4-biphenylsulfonyl chloride for 2-naphthalenesulfonyl
chloride in Examples 407. MS (APCI) m/z 484 (M+1).sup.+; .sup.1H
NMR (300 MHz, DMSO-d.sub.6) .delta. 2.42 (s, 3H), 2.96 (m, 2H),
3.95 (m, 2H), 7.54 (m, 4H), 7.69 (d, J=8.48 Hz, 2H), 7.77 (d,
J=7.12 Hz, 2H), 7.95 (m, 5H), 8.45 (s, 1H), 8.98 (s, 1H); Anal.
Calcd for C.sub.27H.sub.25N.sub.5O.sub.- 2S.box-solid.1.3 TFA: C,
56.27; H, 4.20; N, 11.08. Found: C, 56.00; H, 4.21; N, 10.87.
EXAMPLE 409
5-{5-[(2S)-2-Amino-3-(1H-indol-3-yl)-propoxy]-pyridin-3-yl}-3-isopropylide-
ne-1,3-dihydro-indol-2-one
[0864] The desired compound was prepared by as the trifluoroacetate
salt substituting 5-Bromo-3-isopropylidene-1,3-dihydro-indol-2-one
(L. Sun, et al., J. Med. Chem., 1998, 41, 2588.) for
6-bromophthalimide in Example 32. .sup.1H NMR (400 MHz, CD.sub.3OD)
.delta. ppm 2.47 (s, 3H), 2.60 (s, 3H), 3.31 (m, 2H), 4.01 (m, 1H),
4.34 (dd, J=10.43, 5.83 Hz, 1H), 4.47 (dd, J=10.43, 3.38 Hz, 1H),
7.01 (t, J=7.06 Hz, 1H), 7.04 (d, J=7.98 Hz, 1H), 7.12 (t, J=7.06
Hz, 1H), 7.24 (s, 1H), 7.38 (d, J=8.29 Hz, 1H), 7.50 (dd, J=7.98,
1.84 Hz, 1H), 7.58 (d, J=7.98 Hz, 1H), 7.79 (d, J=1.53 Hz, 1H),
7.97 (d, J=1.84 Hz, 1H), 8.37 (s, 1H), 8.63 (s, 1H); Anal. Calcd
for C.sub.27H.sub.26N.sub.4O.sub.2: C, 52.14; H, 3.88; N, 7.51.
Found: C, 52.19; H, 3.67; N, 7.42.
EXAMPLE 410
5-{5-[(2S)-2-Amino-3-(1H-indol-3-yl)-propoxy]-pyridin-3-yl}-3-(1H-imidazol-
-2-ylmethylene)-1,3-dihydro-indol-2-one
[0865] The desired compound was prepared by as the trifluoroacetate
salt substituting
5-Bromo-3-(1H-imidazol-2-ylmethylene)-1,3-dihydro-indol-2-on- e (L.
Sun, et al., J. Med. Chem., 1998, 41, 2588.) for 6-bromophthalimide
in Example 32. MS (DCI/NH.sub.3) m/z 477 (M+1).sup.+; .sup.1H NMR
(500 MHz, CD.sub.3OD) .delta. ppm 3.31 (m, 2H), 4.04 (m, 1H), 4.37
(dd, J=10.45, 5.77 Hz, 1H), 4.50 (dd, J=10.29, 3.12 Hz, 1H), 7.02
(t, J=7.49 Hz, 1H), 7.11 (d, J=7.49 Hz, 1H), 7.13 (m, 1H), 7.25 (s,
1H), 7.38 (d, J=8.11 Hz, 1H), 7.60 (d, J=7.80 Hz, 1H), 7.72 (d,
J=8.11 Hz, 1H), 7.77 (s, 2H), 7.85 (s, 1H), 8.02 (s, 1H), 8.13 (s,
1H), 8.42 (s, 1H), 8.67 (s, 1H).
EXAMPLE 411
5-{5-[2-Amino-3-(1H-indol-3-yl)-propoxy]-pyridin-3-yl}-3-pyridin-2-ylmethy-
lene-1,3-dihydro-indol-2-one
[0866] The desired compound was prepared by as the trifluoroacetate
salt substituting
5-Bromo-3-pyridin-2-ylmethylene-1,3-dihydro-indol-2-one (L. Sun, et
al., J. Med. Chem., 1998, 41, 2588.) for 6-bromophthalimide in
Example 32. MS (DCI/NH.sub.3) m/z 488 (M+1).sup.+; .sup.1H NMR (500
MHz, CD.sub.3OD) .delta. ppm 3.32 (m, 2H), 4.02 (m, 1H), 4.34 (dd,
J=10.61, 5.62 Hz, 1H), 4.47 (dd, J=10.45, 3.28 Hz, 1H), 7.03 (t,
J=7.02 Hz, 1H), 7.13 (m, 1H), 7.19 (d, J=8.11 Hz, 1H), 7.25 (s,
1H), 7.38 (d, J=8.42 Hz, 1H), 7.60 (d, J=7.80 Hz, 1H), 7.76 (dd,
J=8.11, 1.87 Hz, 1H), 7.94 (dd, J=2.50, 1.87 Hz, 1H), 8.14 (m, 1H),
8.17 (s, 1H), 8.26 (d, J=1.56 Hz, 1H), 8.38 (d, J=7.80 Hz, 1H),
8.41 (s, 1H), 8.66 (s, 1H), 8.72 (m, 1H), 9.08 (dd, J=5.62, 1.56
Hz, 1H); Anal. Calcd for C.sub.30H.sub.25N.sub.5O.- sub.2: C,
47.41; H, 3.02; N, 7.16. Found: C, 47.40; H, 2.93; N, 6.98.
EXAMPLE 412
5-{5-[(2S)-2-Amino-3-(1H-indol-3-yl)-propoxy]-pyridin-3-yl}-3-furan-2-ylme-
thylene-1,3-dihydro-indol-2-one
[0867] The desired compound was prepared by as the trifluoroacetate
salt substituting
5-Bromo-3-furan-2-ylmethylene-1,3-dihydro-indol-2-one (L. Sun, et
al., J. Med. Chem., 1998, 41, 2588.) for 6-bromophthalimide in
Example 32. MS (DCI/NH.sub.3) m/z 477 (M+1).sup.+; .sup.1H NMR (500
MHz, CD.sub.3OD) .delta. ppm 3.34 (m, 4H), 4.06 (m, 2H), 4.37 (dd,
J=10.45, 5.77 Hz, 2H), 4.51 (dd, J=10.45, 3.28 Hz, 2H), 6.68 (dd,
J=3.28, 1.40 Hz, 1H), 6.72 (dd, J=3.59, 1.72 Hz, 1H), 7.02 (t,
J=7.64 Hz, 2H), 7.05 (d, J=8.11 Hz, 2H), 7.12 (m, 3H), 7.26 (s,
1H), 7.27 (s, 1H), 7.38 (d, J=8.11 Hz, 2H), 7.43 (s, 1H), 7.55 (d,
J=1.87 Hz, 1H), 7.58 (dd, J=8.11, 1.87 Hz, 1H), 7.61 (d, J=7.80 Hz,
2H), 7.73 (s, 1H), 7.77 (d, J=1.56 Hz, 1H), 7.85 (d, J=1.87 Hz,
1H), 7.97 (d, J=1.56 Hz, 1H), 8.06 (d, J=4.37 Hz, 1H), 8.15 (d,
J=1.87 Hz, 1H), 8.30 (d, J=3.43 Hz, 1H), 8.44 (m, 2H), 8.69 (s,
1H), 8.73 (d, J=1.87 Hz, 2H); Anal. Calcd for
C.sub.29H.sub.24N.sub.4- O.sub.3: C, 50.33; H, 3.24; N, 6.61.
Found: C, 50.30; H, 3.12; N, 6.65.
EXAMPLE 413
5-{5-[(2S)-2-Amino-3-(1H-indol-3-yl)-propoxy]-pyridin-3-yl}-3-(5-methyl-fu-
ran-2-ylmethylene)-1,3-dihydro-indol-2-one
[0868] The desired compound was prepared by as the trifluoroacetate
salt substituting
5-Bromo-3-(5-methyl-furan-2-ylmethylene)-1,3-dihydro-indol-2- -one
(L. Sun, et al., J. Med. Chem., 1998, 41, 2588.) 6-bromophthalimide
in Example 32. MS (DCI/NH.sub.3) m/z 477 (M+1).sup.+; .sup.1H NMR
(500 MHz, CD.sub.3OD) .delta. ppm 2.41 (s, 3H), 3.32 (m, 2H), (4.02
(m, 1H), 4.31 (dd, J=10.45, 5.77 Hz, 1H), 4.45 (dd, J=10.45, 3.28
Hz, 1H), 6.38 (dd, J=3.43, 0.94 Hz, 1H), 7.03 (m, 3H), 7.12 (t,
J=7.18 Hz, 1H), 7.24 (s, 1H), 7.37 (s, 1H), 7.38 (d, J=8.11 Hz,
1H), 7.54 (dd, J=8.11, 1.87 Hz, 1H), 7.60 (d, J=8.11 Hz, 1H), 7.90
(dd, J=2.50, 1.87 Hz, 1H), 8.38 (s, 1H), 8.64 (s, 1H), 8.73 (s,
1H); Anal. Calcd for C.sub.30H.sub.26N.sub.4O.sub.3: C, 49.59; H,
3.31; N, 6.22. Found: C, 49.90; H, 3.18; N, 6.10.
EXAMPLE 414
5-{5-[(2S)-2-Amino-3-(1H-indol-3-yl)-propoxy]-pyridin-3-yl}-3-(4,5-dimethy-
l-furan-2-ylmethylene)-1,3-dihydro-indol-2-one
[0869] The desired compound was prepared by as the trifluoroacetate
salt substituting
5-Bromo-3-(4,5-dimethyl-furan-2-ylmethylene)-1,3-dihydro-ind-
ol-2-one (L. Sun, et al., J. Med. Chem., 1998, 41, 2588.) for
6-bromophthalimide in Example 32. MS (DCI/NH.sub.3) m/z 505
(M+1).sup.+; .sup.1H NMR (500 MHz, CD.sub.3OD) .delta. ppm 1.99 (s,
3H), 2.27 (s, 3H), 3.34 (m, 2H), 4.06 (m, 1H), 4.37 (dd, J=10.45,
5.77 Hz, 1H), 4.51 (dd, J=10.45, 3.28 Hz, 1H), 6.82 (s, 1H), 6.99
(d, J=8.42 Hz, 1H), 7.03 (t, J=7.02 Hz, 1H), 7.13 (t, J=7.02 Hz,
1H), 7.21 (s, 1H), 7.27 (s, 1H), 7.39 (d, J=8.11 Hz, 1H), 7.52 (dd,
J=8.11, 1.87 Hz, 1H), 7.61 (d, J=8.11 Hz, 1H), 8.05 (s, 1H), 8.45
(s, 1H), 8.62 (d, J=1.56 Hz, 1H), 8.66 (s, 1H); Anal. Calcd for
C.sub.31H.sub.28N.sub.4O.sub.3: C, 52.92; H, 3.73; N, 6.71. Found:
C, 52.90; H, 3.45; N, 6.97.
EXAMPLE 415
5-{5-[(2S)-2-Amino-3-(1H-indol-3-yl)-propoxy]-pyridin-3-yl}-3-thiophen-2-y-
lmethylene-1,3-dihydro-indol-2-one
[0870] The desired compound was prepared by as the trifluoroacetate
salt substituting
5-Bromo-3-thiophen-2-ylmethylene-1,3-dihydro-indol-2-one (L. Sun,
et al., J. Med. Chem., 1998, 41, 2588.) for 6-bromophthalimide in
Example 32. MS (APCI) m/z 493 (M+1).sup.+; .sup.1H NMR (500 MHz,
CD.sub.3OD) .delta. ppm 3.32 (m, 4H), 4.03 (m, 2H), 4.30 (dd,
J=10.45, 5.77 Hz, 1H), 4.35 (dd, J=10.61, 5.93 Hz, 1H), 4.44 (dd,
J=10.29, 3.12 Hz, 1H), 4.48 (dd, J=10.61, 3.12 Hz, 1H), 7.02 (m,
2H), 7.04 (s, 1H), 7.06 (d, J=0.94 Hz, 1H), 7.08 (d, J=8.11 Hz,
1H), 7.14 (t, J=7.49 Hz, 2H), 7.20 (dd, J=4.99, 3.74 Hz, 1H), 7.23
(d, J=1.25 Hz, 1H), 7.24 (s, 1H), 7.26 (m, 1H), 7.37 (s, 1H), 7.39
(d, J=8.11 Hz, 1H), 7.53 (dd, J=8.11, 1.87 Hz, 1H), 7.56 (dd,
J=8.11, 1.56 Hz, 1H), 7.59 (s, 1H), 7.61 (d, J=7.80 Hz, 1H), 7.71
(d, J=2.50 Hz, 1H), 7.74 (d, J=5.30 Hz, 1H), 7.79 (d, J=4.99 Hz,
1H), 7.92 (s, 1H), 7.93 (s, 1H), 7.96 (s, 1H), 7.98 (d, J=1.56 Hz,
1H), 8.09 (s, 1H), 8.37 (s, 2H), 8.48 (d, J=1.56 Hz, 1H), 8.56 (s,
1H), 8.65 (s, 1H); Anal. Calcd for C.sub.29H.sub.24N.sub.4O.sub.-
2S: C, 50.37; H, 3.26; N, 6.71. Found: C, 50.52; H, 3.45; N,
6.84.
(A-441246) EXAMPLE 416
5-{5-[(2S)-2-Amino-3-(1H-indol-3-yl)-propoxy]-pyridin-3-yl}-3-(1-methyl-1H-
-pyrrol-2-ylmethylene)-1,3-dihydro-indol-2-one
[0871] The desired compound was prepared by as the trifluoroacetate
salt substituting 5-Bromo-3-(1-methyl-1
H-pyrrol-2-ylmethylene)-1,3-dihydro-in- dol-2-one (L. Sun, et al.,
J. Med. Chem., 1998, 41, 2588.) for 6-bromophthalimide in Example
32. MS (APCI) m/z 490 (M+1).sup.+; .sup.1H NMR (500 MHz,
CD.sub.3OD) .delta. ppm 3.32 (m, 4H), 3.81 (s, 3H), 3.89 (s, 3H),
4.03 (m, 2H), 4.30 (dd, J=10.61, 5.93 Hz, 1H), 4.37 (dd, J=10.61,
5.93 Hz, 1H), 4.44 (dd, J=10.45, 3.28 Hz, 1H), 4.50 (dd, J=10.29,
3.12 Hz, 1H), 6.28 (m, 2H), 7.02 (m, 3H), 7.07 (m, 3H), 7.12 (m,
2H), 7.19 (d, J=3.74 Hz, 1H), 7.24 (s, 1H), 7.26 (s, 1H), 7.38 (d,
J=8.11 Hz, 1H), 7.39 (d, J=8.11 Hz, 1H), 7.46 (dd, J=8.11, 1.87 Hz,
1H), 7.50 (dd, J=8.27, 1.72 Hz, 1H), 7.59 (d, J=7.80 Hz, 1H), 7.61
(d, J=8.11 Hz, 1H), 7.70 (s, 1H), 7.74 (s, 1H), 7.86 (s, 1H), 7.98
(d, J=1.87 Hz, 1H), 8.08 (s, 1H), 8.30 (dd, J=4.37, 1.56 Hz, 1H),
8.34 (d, J=1.56 Hz, 1H), 8.38 (s, 2H), 8.57 (s, 1H), 8.73 (s, 1H);
Anal. Calcd for C.sub.30H.sub.27N.sub.5O.sub.2: C, 55.28; H, 3.93;
N, 9.32. Found: C, 55.32; H, 3.57; N, 9.08
EXAMPLE 417
5-{5-[(2S)-2-Amino-3-(1H-indol-3-yl)-propoxy]-pyridin-3-yl}-3-(1H-indol-3--
ylmethylene)-1,3-dihydro-indol-2-one
[0872] The desired compound was prepared by as the trifluoroacetate
salt substituting
5-Bromo-3-(1H-indol-3-ylmethylene)-1,3-dihydro-indol-2-one (L. Sun,
et al., J. Med. Chem., 1998, 41, 2588.) 6-bromophthalimide in
Example 32. MS (APCI) m/z 526 (M+1).sup.+; .sup.1H NMR (500 MHz,
CD.sub.3OD) .delta. ppm 3.32 (m, 4H), 4.05 (m, 2H), 4.15 (m, 1H),
4.25 (m, 1H), 4.38 (d, J=5.93 Hz, 1H), 4.49 (dd, J=10.29, 3.12 Hz,
1H), 7.02 (m, 2H), 7.06 (m, 1H), 7.09 (m, 2H), 7.14 (t, J=7.64 Hz,
2H), 7.23 (m, 4H), 7.28 (s, 1H), 7.39 (m, 2H), 7.43 (d, J=4.99 Hz,
1H), 7.47 (m, 4H), 7.56 (d, J=8.11 Hz, 1H), 7.59 (s, 1H), 7.63 (d,
J=8.11 Hz, 2H), 8.01 (m, 2H), 8.06 (d, J=1.56 Hz, 1H), 8.12 (s,
2H), 8.24 (s, 1H), 8.28 (s, 1H), 8.35 (s, 2H), 8.72 (s, 1H), 9.40
(s, 1H); Anal. Calcd for C.sub.33H.sub.27N.sub.5O.sub.2: C, 53.99;
H, 3.48; N, 8.07. Found: C, 54.27; H, 3.64; N, 7.84
EXAMPLE 418
5-{5-[(2S)-2-Amino-3-(1H-indol-3-yl)-propoxy]-pyridin-3-yl}-3-(1-phenyl-1H-
-pyrrol-3-ylmethylene)-1,3-dihydro-indol-2-one
[0873] The desired compound was prepared by as the trifluoroacetate
salt substituting
5-Bromo-3-(2,5-dimethyl-1-phenyl-1H-pyrrol-3-ylmethylene)-1,-
3-dihydro-indol-2-one (L. Sun, et al., J. Med. Chem., 1998, 41,
2588.) 6-bromophthalimide in Example 32. MS (APCI) m/z 580
(M+1).sup.+; .sup.1H NMR (500 MHz, CD.sub.3OD) .delta. ppm 1.98 (s,
3H) 2.01 (s, 3H) 2.18 (s, 3H) 2.28 (s, 3H) 3.32 (m, 4H), 4.02 (m,
2H) 4.32 (dd, J=10.45, 5.46 Hz, 1H) 4.37 (dd, J=10.61, 5.93 Hz, 1H)
4.49 (m, 2H) 6.68 (m, 1H) 7.01 (m, 3H) 7.10 (m, 3H) 7.25 (m, 6H)
7.36 (t, J=8.73 Hz, 2H) 7.47 (m, 3H) 7.57 (m, 8H) 7.84 (d, J=2.18
Hz, 2H) 7.93 (s, 2H) 8.13 (s, 1H) 8.32 (s, 1H) 8.38 (s, 2H) 8.60
(s, 1H) 8.73 (s, 1H); Anal. Calcd for
C.sub.37H.sub.33N.sub.5O.sub.2: C, 54.38; H, 3.79; N, 7.24. Found:
C, 54.45; H, 3.92; N, 6.97.
EXAMPLE 419
5-{5-[(2S)-2-Amino-3-(1H-indol-3-yl)-propoxy]-pyridin-3-yl}-3-pyridin-3-yl-
methylene-1,3-dihydro-indol-2-one
[0874] The desired compound was prepared by as the trifluoroacetate
salt substituting
5-Bromo-3-pyridin-3-ylmethylene-1,3-dihydro-indol-2-one (L. Sun, et
al., J. Med. Chem., 1998, 41, 2588.) 6-bromophthalimide in Example
32. MS (APCI) m/z 488 (M+1).sup.+; .sup.1H NMR (500 MHz,
CD.sub.3OD) .delta. ppm 3.32 (m, 4H), 4.03 (m, 2H), 4.26 (dd,
J=10.45, 5.46 Hz, 1H), 4.36 (dd, J=10.45, 5.77 Hz, 1H), 4.40 (dd,
J=10.29, 3.12 Hz, 1H), 4.49 (dd, J=10.29, 3.12 Hz, 1H), 7.01 (m,
1H), 7.05 (m, 3H), 7.08 (d, J=8.11 Hz, 1H), 7.12 (t, J=7.64 Hz,
2H), 7.23 (s, 1H), 7.25 (s, 1H), 7.38 (d, J=8.11 Hz, 1H), 7.57 (m,
1H), 7.59 (m, 1H), 7.61 (s, 1H), 7.64 (dd, J=8.11, 1.87 Hz, 1H),
7.66 (m, 1H), 7.71 (m, 1H), 7.78 (s, 1H), 7.93 (s, 1H), 7.99 (m,
J=8.27, 5.77 Hz, 3H), 8.09 (d, J=1.56 Hz, 1H), 8.34 (d, J=8.11 Hz,
2H), 8.41 (m, 2H), 8.56 (d, J=4.68 Hz, 1H), 8.67 (s, 1H), 8.77 (d,
J=5.30 Hz, 1H), 9.01 (s, 1H), 9.11 (d, J=8.11 Hz, 1H), 9.69 (s,
1H); Anal. Calcd for C.sub.30H.sub.25N.sub.5O.sub.2: C, 49.22; H,
3.17; N, 7.65. Found: C, 49.23; H, 3.15; N, 7.38.
EXAMPLE 420
5-{5-[(2S)-2-Amino-3-(1H-indol-3-yl)-propoxy]-pyridin-3-yl}-3-(1H-pyrrol-3-
-ylmethylene)-1,3-dihydro-indol-2-one
[0875] The desired compound was prepared by as the trifluoroacetate
salt substituting
5-Bromo-3-(1H-pyrrol-3-ylmethylene)-1,3-dihydro-indol-2-one (L.
Sun, et al., J. Med. Chem., 1998, 41, 2588.) for 6-bromophthalimde
in Example 32. MS (APCI) m/z 476 (M+1).sup.+; .sup.1H NMR (500 MHz,
CD.sub.3OD) .delta. ppm 3.32 (m, 4H), 4.04 (m, 2H), 4.32 (dd,
J=10.45, 5.77 Hz, 1H), 4.38 (dd, J=10.61, 5.93 Hz, 1H), 4.46 (dd,
J=10.45, 3.28 Hz, 1H), 4.50 (dd, J=10.29, 3.12 Hz, 1H), 6.77 (dd,
J=2.81, 1.56 Hz, 1H), 6.85 (dd, J=2.65, 2.03 Hz, 1H), 6.91 (m, 1H),
7.04 (m, 5H), 7.13 (m, 2H), 7.24 (s, 1H), 7.26 (s, 1H), 7.39 (t,
J=7.49 Hz, 2H), 7.43 (s, 1H), 7.48 (m, 2H), 7.60 (m, J=8.73, 8.73
Hz, 2H), 7.80 (s, 1H), 7.84 (s, 1H), 7.90 (m, 2H), 8.09 (s, 1H),
8.16 (s, 1H), 8.28 (d, J=1.56 Hz, 1H), 8.39 (s, 2H), 8.59 (s, 1H),
8.70 (s, 1H); Anal. Calcd for C.sub.29H.sub.25N.sub.5O- .sub.2: C,
51.42; H, 3.45; N, 8.57. Found: C, 51.73; H, 3.41; N, 8.58.
EXAMPLE 421
5-{5-[(2S)-2-Amino-3-(1H-indol-3-yl)-propoxy]-pyridin-3-yl}-3-(tetrahydro--
pyran-4-ylidene)-1,3-dihydro-indol-2-one
[0876] The desired compound was prepared by as the trifluoroacetate
salt substituting
5-Bromo-3-(tetrahydro-pyran-4-ylidene)-1,3-dihydro-indol-2-o- ne
(L. Sun, et al., J. Med. Chem., 1998, 41, 2588.) 6-bromophthalimide
in Example 32. MS (APCI) m/z 481 (M+1).sup.+; .sup.1H NMR (400 MHz,
DMSO-d.sub.6) .delta. ppm 3.02 (t, J=5.52 Hz, 2H), 3.19 (m, 2H)
3.44 (t, J=5.52 Hz, 2H), 3.80 (m, 5H), 4.18 (dd, J=10.74, 5.83 Hz,
1H), 4.34 (m, 1H), 7.00 (m, 1H), 7.10 (t, J=7.06 Hz, 1H), 7.29 (d,
J=2.15 Hz, 1H), 7.38 (d, J=7.98 Hz, 1H), 7.49 (dd, J=8.13, 1.69 Hz,
1H), 7.62 (m, 2H), 7.85 (s, 1H), 8.23 (s, 2H), 8.24 (s, 1H), 8.32
(d, J=2.76 Hz, 1H), 8.55 (d, J=1.53 Hz, 1H), 10.67 (s, 1H), 11.03
(d, J=1.84 Hz, 1H); Anal. Calcd for C.sub.29H.sub.29N.sub.4O.sub.3:
C, 55.38; H, 4.21; N, 7.78. Found: C, 55.29; H, 4.12; N, 7.70.
EXAMPLE 422
5-{5-[(2S)-2-Amino-3-(1H-indol-3-yl)-propoxy]-pyridin-3-yl}-3-(4-ethyl-3,5-
-dimethyl-1H-pyrrol-2-ylmethylene)-1,3-dihydro-indol-2-one
[0877] The desired compound was prepared by as the trifluoroacetate
salt substituting
5-Bromo-3-(4-ethyl-3,5-dimethyl-1H-pyrrol-2-ylmethylene)-1,3-
-dihydro-indol-2-one (L. Sun, et al., J. Med. Chem., 1998, 41,
2588.) 6-bromophthalimide in Example 32. MS (APCI) m/z 530
(M-1).sup.+; .sup.1H NMR (500 MHz, CD.sub.3OD) .delta. ppm 1.10 (t,
J=7.52 Hz, 3H), 2.31 (s, 3H), 2.34 (s, 3H), 2.49 (q, J=7.57 Hz,
2H), 3.32 (m, 2H), 4.03 (m, 1H), 4.36 (dd, J=10.59, 5.68 Hz, 1H),
4.49 (m, 1H), 7.05 (m, 2H), 7.13 (t, J=7.06 Hz, 1H), 7.25 (s, 1H),
7.41 (m, 2H), 7.61 (d, J=7.67 Hz, 1H), 7.66 (s, 1H), 7.93 (d,
J=1.53 Hz, 1H), 8.07 (m, 1H), 8.37 (s, 1H), 8.72 (s, 1H); Anal.
Calcd for C.sub.33H.sub.33N.sub.5O.sub.2: C, 54.94; H, 4.29; N,
8.34. Found: C, 55.03; H, 4.09; N, 8.20. 97
(A-485149) EXAMPLE 423
5-{5-[(2S)-2-Amino-3-(1H-indol-3-yl)-propoxy]-pyridin-3-yl}-3-cyclopropylm-
ethylene-1,3-dihydro-indol-2-one
[0878] The desired compound was prepared by as the trifluoroacetate
salt substituting
5-Bromo-3-cyclopropylmethylene-1,3-dihydro-indol-2-one (L. Sun, et
al., J. Med. Chem., 1998, 41, 2588.) 6-bromophthalimide in Example
32. MS (APCI) m/z 451 (M+1).sup.+; .sup.1H NMR (400 MHz,
DMSO-d.sub.6) .delta. ppm 0.79 (m, J=4.30, 2.45 Hz, 2H), 0.93 (m,
3H), 1.19 (m, 5H), 2.52 (m, 4H), 3.84 (s, 2H), 4.19 (m, 2H), 4.35
(m, 2H), 6.33 (d, J=11.66 Hz, 1H), 6.59 (d, J=11.05 Hz, 1H), 6.92
(d, J=7.98 Hz, 1H), 7.00 (m, 1H), 7.10 (t, J=7.06 Hz, 2H), 7.29 (d,
J=2.15 Hz, 2H), 7.38 (d, J=8.29 Hz, 2H), 7.51 (m, 2H), 7.62 (d,
J=7.67 Hz, 2H), 7.69 (m, J=5.06, 3.22 Hz, 2H), 7.86 (d, J=1.84 Hz,
1H), 8.03 (d, J=1.53 Hz, 1H), 8.23 (br s, 3H), 8.24 (br s, 3H),
8.32 (d, J=2.76 Hz, 1H), 8.33 (d, J=2.76 Hz, 1H), 8.57 (d, J=1.53
Hz, 1H), 8.60 (d, J=1.84 Hz, 1H), 10.54 (s, 1H), 10.58 (s, 1H),
11.03 (d, J=1.84 Hz, 2H); Anal. Calcd for
C.sub.29H.sub.26N.sub.4O.sub.2: C, 55.48; H, 4.05; N, 7.99. Found:
C, 55.63; H, 3.98; N, 7.90.
EXAMPLE 424
5-{5-[(2S)-2-Amino-3-(1H-indol-3-yl)-propoxy]-pyridin-3-yl}-3-pyrrolidin-2-
-ylmethylene-1,3-dihydro-indol-2-one
[0879] The desired compound was prepared by as the trifluoroacetate
salt substituting
5-Bromo-3-pyrrolidin-2-ylmethylene-1,3-dihydro-indol-2-one (L. Sun,
et al., J. Med. Chem., 1998, 41, 2588.) 6-bromophthalimide in
Example 32. MS (APCI) m/z 480 (M+1).sup.+; .sup.1H NMR (400 MHz,
CD.sub.3OD) .delta. ppm 1.53 (m, 1H), 1.60 (m, 1H), 1.70 (m, 1H),
2.01 (m, 1H), 2.20 (m, 2H), 2.49 (m, 1H), 3.44 (m, 2H), 4.01 (m,
1H), 4.32 (dd, J=10.43, 5.83 Hz, 1H), 4.46 (m, 1H), 7.05 (m, 3H),
7.13 (t, J=7.67 Hz, 1H), 7.24 (s, 1H), 7.38 (d, J=8.29 Hz, 1H),
7.61 (m, 2H), 7.92 (m, 2H), 8.36 (s, 1H), 8.59 (s, 1H); Anal. Calcd
for C.sub.29H.sub.29N.sub.5O- .sub.2: C, 52.24; H, 4.03; N, 8.83.
Found: C, 52.32; H, 4.24; N, 8.63.
EXAMPLE 425
5-(5-{5-[(2S)-2-Amino-3-(1H-indol-3-yl)-propoxy]-pyridin-3-yl}-2-oxo-1,2-d-
ihydro-indol-3-ylidenemethyl)-furan-2-carboxylic Acid
[0880] The desired compound was prepared by as the trifluoroacetate
salt substituting
5-(5-Bromo-2-oxo-1,2-dihydro-indol-3-ylidenemethyl)-furan-2--
carboxylic acid (L. Sun, et al., J. Med. Chem., 1998, 41, 2588.)
for 6-bromophthalimide in Example 32. MS (APCI) m/z 521
(M+1).sup.+; .sup.1H NMR (400 MHz, DMSO-d.sub.6) .delta. ppm 3.16
(d, J=6.75 Hz, 2H), 3.86 (m, 1H), 4.21 (dd, J=10.74, 6.44 Hz, 1H),
4.41 (m, 1H), 6.97 (t, J=6.90 Hz, 1H), 7.03 (d, J=7.98 Hz, 1H),
7.08 (t, J=7.06 Hz, 1H), 7.29 (d, J=2.46 Hz, 1H), 7.37 (d, J=8.29
Hz, 1H), 7.40 (d, J=3.99 Hz, 1H), 7.44 (m, 1H), 7.47 (s, 1H), 7.62
(m, 2H), 7.71 (m, 1H), 8.17 (br s, 2H), 8.33 (d, J=2.45 Hz, 1H),
8.71 (d, J=1.84 Hz, 1H), 8.98 (d, J=1.84 Hz, 1H), 10.84 (s, 1H),
11.01 (d, J=2.15 Hz, 1H); Anal. Calcd for
C.sub.30H.sub.24N.sub.4O.sub.5: C, 51.75; H, 3.28; N, 6.86. Found:
C, 51.69; H, 3.16; N, 6.71.
EXAMPLE 426
5-{5-[(2S)-2-Amino-3-(1H-indol-3-yl)-propoxy]-pyridin-3-yl}-3-benzylidene--
1,3-dihydro-indol-2-one
[0881] The desired compound was prepared by as the trifluoroacetate
salt substituting 3-Benzylidene-5-bromo-1,3-dihydro-indol-2-one (L.
Sun, et al., J. Med. Chem., 1998, 41, 2588.) for 6-bromophthalimide
in Example 32. MS (APCI) m/z 485 (M-1).sup.+; .sup.1H NMR (500 MHz,
CD.sub.3OD) .delta. ppm 3.32 (m, 2H), 4.01 (m, 1H), 4.23 (dd,
J=10.61, 5.62 Hz, 1H), 4.37 (m, 1H), 7.03 (m, 2H), 7.13 (t, J=7.64
Hz, 1H), 7.22 (s, 1H), 7.34 (t, J=7.49 Hz, 1H), 7.39 (d, J=8.42 Hz,
1H), 7.44 (m, 2H), 7.53 (dd, J=8.27, 1.72 Hz, 1H), 7.58 (d, J=8.11
Hz, 1H), 7.62 (s, 1H), 7.69 (d, J=7.80 Hz, 1H), 7.78 (d, J=1.87 Hz,
1H), 7.83 (s, 1H), 8.00 (d, J=1.56 Hz, 1H), 8.31 (m, J=6.40, 2.96
Hz, 1H), 8.37 (s, 1H); Anal. Calcd for
C.sub.31H.sub.26N.sub.4O.sub.2: C, 55.53; H, 3.68; N, 7.16. Found:
C, 55.74; H, 3.50; N, 7.05.
EXAMPLE 427
5-{5-[(2S)-2-Amino-3-(1H-indol-3-yl)-propoxy]-pyridin-3-yl}-1H-indole-2,3--
dione 3-oxime
[0882] The desired compound was prepared by as the trifluoroacetate
salt substituting 5-Bromo-1H-indole-2,3-dione 3-oxime (L. Sun, et
al., J. Med. Chem., 1998, 41, 2588.) 6-bromophthalimide in Example
32. MS (ESI) m/z 428 (M+1).sup.+; .sup.1H NMR (500 MHz, CD.sub.3OD)
.delta. ppm 3.32 (m, 2H), 4.00 (m, 1H), 4.29 (dd, J=10.45, 5.77 Hz,
1H), 4.44 (dd, J=10.61, 3.12 Hz, 1H), 7.05 (m, 2H), 7.13 (t, J=7.17
Hz, 1H), 7.24 (s, 1H), 7.38 (d, J=8.11 Hz, 1H), 7.60 (d, J=8.11 Hz,
1H), 7.65 (dd, J=8.27, 2.03 Hz, 1H), 7.78 (m, 1H), 8.32 (d, J=1.87
Hz, 1H), 8.34 (s, 1H), 8.52 (s, 1H); Anal. Calcd for
C.sub.24H.sub.21N.sub.5O.sub.3: C, 51.30; H, 3.54; N, 10.68. Found:
C, 50.99; H, 3.33; N, 10.47.
[0883] The following compounds were prepared by substituting the
appropriate tributylsannyl reagents for
(1,1,1-tributylstannyl)benzene and Example 362A for 80E in Example
364.
EXAMPLE 428
(1S)-2-(5-Benzo[b]thiophen-2-yl-6-furan-2-yl-pyridin-3-yloxy)-1-(1H-indol--
3-ylmethyl)-ethylamine
[0884] MS (APCI) m/z 465 (M-1).sup.+; .sup.1H NMR (500 MHz,
CD.sub.3OD) .delta. ppm 3.32 (m, 2H), 3.99 (m, 1H), 4.27 (dd,
J=10.61, 5.62 Hz, 1H), 4.41 (m, 1H), 6.47 (dd, J=3.43, 1.87 Hz,
1H), 6.66 (d, J=3.43 Hz, 1H), 7.01 (t, J=7.02 Hz, 1H), 7.10 (t,
J=8.11 Hz, 1H), 7.23 (s, 1H), 7.35 (d, J=8.11 Hz, 1H), 7.39 (d,
J=1.25 Hz, 1H), 7.56 (d, J=2.81 Hz, 1H), 7.58 (d, J=7.80 Hz, 1H),
7.72 (s, 1H), 8.31 (d, J=6.24 Hz, 1H), 8.50 (d, J=2.81 Hz, 1H),
8.61 (d, J=6.24 Hz, 1H), 9.51 (s, 1H); Anal. Calcd for
C.sub.27H.sub.22N.sub.4O.sub.2S: C, 52.57; H, 3.40; N, 7.81. Found:
C, 52.35; H, 3.20; N, 7.73.
EXAMPLE 429
(1S)-2-(5-Benzo[b]thiophen-2-yl-6-vinyl-pyridin-3-yloxy)-1(1H-indol-3-ylme-
thyl)-ethylamine
[0885] MS (APCI) m/z 427 (M+1).sup.+; .sup.1H NMR (400 MHz,
DMSO-d.sub.6) .delta. ppm 3.15 (m, 2H), 3.85 (m, 1H), 4.17 (dd,
J=10.76, 6.08 Hz, 1H), 4.33 (dd, J=10.76, 2.96 Hz, 1H), 5.44 (m,
1H), 6.30 (dd, J=16.85, 2.18 Hz, 1H), 6.93 (dd, J=16.69, 10.76 Hz,
1H), 7.00 (t, J=7.33 Hz, 1H), 7.08 (t, J=7.49 Hz, 1H), 7.29 (d,
J=2.18 Hz, 1H), 7.36 (d, J=8.11 Hz, 1H), 7.51 (d, J=2.81 Hz, 1H),
7.60 (d, J=8.11 Hz, 1H), 7.77 (s, 1H), 8.18 (d, J=5.93 Hz, 1H),
8.25 (m, 2H), 8.51 (d, J=2.81 Hz, 1H), 8.67 (d, J=5.93 Hz, 1H),
9.56 (s, 1H), 11.02 (s, 1H); Anal. Calcd for
C.sub.25H.sub.22N.sub.4OS: C, 48.44; H, 3.28; N, 7.29. Found: C,
48.38; H, 3.32; N, 7.02.
EXAMPLE 430
(1S)-2-(5-Benzo[b]thiophen-2-yl-6-thiophen-2-yl-pyridin-3-yloxy)-1-(1H-ind-
ol-3-ylmethyl)-ethylamine
[0886] MS (APCI) m/z 481 (M-1).sup.+; .sup.1H NMR (500 MHz,
DMSO-d.sub.6) .delta. ppm 3.15 (m, 2H), 3.85 (m, 1H), 4.18 (dd,
J=10.76, 6.08 Hz, 1H), 4.34 (dd, J=10.61, 3.12 Hz, 1H), 6.71 (dd,
J=3.59, 1.09 Hz, 1H), 6.90 (dd, J=4.99, 3.74 Hz, 1H), 7.00 (t,
J=7.02 Hz, 1H), 7.08 (t, J=7.18 Hz, 1H), 7.29 (d, J=2.18 Hz, 1H),
7.36 (d, J=7.80 Hz, 1H), 7.55 (dd, J=5.15, 1.09 Hz, 1H), 7.57 (d,
J=2.81 Hz, 1H), 7.60 (d, J=7.80 Hz, 1H), 7.78 (s, 1H), 8.13 (d,
J=5.93 Hz, 1H), 8.23 (br s, 2H), 8.50 (d, J=2.81 Hz, 1H), 8.64 (d,
J=5.93 Hz, 1H), 9.50 (s, 1H), 11.02 (d, J=1.56 Hz, 1H); Anal. Calcd
for C.sub.21H.sub.22N.sub.4OS.sub.2: C, 48.83; H, 3.12; N, 6.99.
Found: C, 48.74; H, 3.07; N, 6.88.
EXAMPLE 431
(1S)-2-(5-Benzo[b]thiophen-2-yl-6-thiazol-2-yl-pyridin-3-yloxy)-1-(1H-indo-
l-3-ylmethyl)-ethylamine
[0887] MS (APCI) m/z 484 (M+1).sup.+; .sup.1H NMR (500 MHz,
DMSO-d.sub.6) .delta. ppm 3.15 (m, 2H), 3.84 (m, J=14.12 Hz, 1H),
4.22 (dd, J=10.89, 5.98 Hz, 1H), 4.38 (dd, J=10.74, 3.07 Hz, 1H),
6.98 (t, J=7.06 Hz, 1H), 7.07 (t, J=7.52 Hz, 1H), 7.29 (d, J=2.15
Hz, 1H), 7.35 (d, J=7.98 Hz, 1H), 7.60 (d, J=7.98 Hz, 1H), 7.63 (d,
J=2.76 Hz, 2H), 7.73 (s, 1H), 7.77 (d, J=3.38 Hz, 1H), 8.16 (d,
J=5.83 Hz, 1H), 8.29 (br s, 2H), 8.56 (d, J=2.76 Hz, 1H), 8.63 (d,
J=5.83 Hz, 1H), 9.52 (s, 1H), 11.02 (d, J=1.84 Hz, 1H); Anal. Calcd
for C.sub.26H.sub.21N.sub.5OS: C, 46.55; H, 2.93; N, 8.48. Found:
C, 46.87; H, 2.97; N, 8.46.
EXAMPLE 432
(1S)-2-(5-Benzo[b]thiophen-2-yl-6-pyrazin-2-yl-pyridin-3-yloxy)-1-(1H-indo-
l-3-ylmethyl)-ethylamine
[0888] MS (APCI) m/z 479 (M-1).sup.+; .sup.1H NMR (500 MHz,
CD.sub.3OD) .delta. ppm 3.32 (m, 2H), 4.02 (m, 1H), 4.33 (dd,
J=10.61, 5.62 Hz, 1H), 4.47 (dd, J=10.61, 3.12 Hz, 1H), 7.02 (t,
J=7.02 Hz, 1H), 7.10 (t, J=7.18 Hz, 1H), 7.25 (s, 1H), 7.36 (d,
J=8.11 Hz, 1H), 7.60 (d, J=7.80 Hz, 1H), 7.63 (s, 1H), 7.67 (d,
J=2.50 Hz, 1H), 8.25 (d, J=5.93 Hz, 1H), 8.32 (s, 1H), 8.52 (d,
J=1.87 Hz, 1H), 8.58 (d, J=6.24 Hz, 1H), 8.63 (d, J=2.18 Hz, 1H),
9.09 (s, 1H), 9.46 (s, 1H).
EXAMPLE 433
{5-[(2S)-2-Amino-3-(1H-indol-3-yl)-propoxy]-3-benzo[b]thiophen-2-yl-pyridi-
n-2-yl}-phenyl-amine
[0889] The title compound was prepared by substituting Example 362A
for Example 381A in Example 318. MS (APCI) m/z 492 (M+1).sup.+;
.sup.1H NMR (500 MHz, DMSO-d.sub.6) .delta. ppm 3.16 (m, 2H), 3.83
(m, J=2.50 Hz, 1H), 4.13 (dd, J=10.61, 5.93 Hz, 1H), 4.29 (dd,
J=10.45, 2.96 Hz, 1H), 6.86 (t, J=7.18 Hz, 1H), 7.01 (t, J=7.49 Hz,
1H), 7.09 (t, J=7.33 Hz, 1H), 7.20 (t, J=7.80 Hz, 2H), 7.25 (m,
2H), 7.30 (d, J=2.18 Hz, 1H), 7.38 (d, J=8.11 Hz, 1H), 7.62 (d,
J=7.80 Hz, 1H), 7.72 (d, J=3.12 Hz, 1H), 8.11 (s, 1H), 8.16 (d,
J=3.12 Hz, 1H), 8.20 (d, J=6.24 Hz, 1H), 8.25 (br s, 2H), 8.38 (s,
1H), 8.64 (d, J=6.24 Hz, 1H), 9.55 (s, 1H), 11.03 (d, J=1.56 Hz,
1H); Anal. Calcd for C.sub.29H.sub.25N5OS: C, 48.90; H, 3.26; N,
7.96. Found: C, 48.88; H, 3.13; N, 7.90.
EXAMPLE 434
{5-[(2S)-2-Amino-3-(1H-indol-3-yl)-propoxy]-3-benzo[b]thiophen-2-yl-pyridi-
n-2-yl}-pyridin-3-yl-amine
[0890] The title compound was prepared by substituting
3-aminopyridine for aniline in Example 433. MS (APCI) m/z 491
(M-1).sup.+; .sup.1H NMR (500 MHz, CD.sub.3OD) .delta. ppm 3.32 (m,
2H), 3.97 (m, 1H), 4.24 (dd, J=10.29, 5.93 Hz, 1H), 4.37 (dd,
J=10.45, 3.28 Hz, 1H), 7.03 (t, J=7.18 Hz, 1H), 7.11 (t, J=7.18 Hz,
1H), 7.24 (s, 1H), 7.37 (d, J=8.42 Hz, 1H), 7.59 (d, J=8.11 Hz,
1H), 7.68 (d, J=3.12 Hz, 1H), 7.87 (dd, J=8.74, 5.62 Hz, 1H), 8.05
(s, 1H), 8.24 (d, J=3.12 Hz, 1H), 8.30 (d, J=5.30 Hz, 1H), 8.32 (d,
J=6.24 Hz, 1H), 8.42 (dd, J=8.73, 1.56 Hz, 1H), 8.63 (d, J=6.24 Hz,
1H), 9.15 (d, J=2.18 Hz, 1H), 9.53 (s, 1H); Anal. Calcd for
C.sub.28H.sub.24N.sub.6OS: C, 48.93; H, 3.26; N, 10.07. Found: C,
48.82; H, 3.35; N, 9.92.
EXAMPLE 435
6-{5-[(2S)-2-Amino-3-(1H-indol-3-yl)-propoxy]-pyridin-3-yl}-3H-benzooxazol-
-2-one
[0891] The desired compound was prepared by substituting
6-Bromo-3H-benzooxazol-2-one (C. Flouzat, et al, J. Med. Chem.,
1993, 36, 497) for 6-bromophthalimide in Example 32. MS (APCI) m/z
401 (M+1).sup.+; .sup.1H NMR (500 MHz, DMSO-d.sub.6) .delta. ppm
3.16 (d, J=9.67 Hz, 2H), 3.85 (m, 1H), 4.18 (dd, J=10.61, 5.93 Hz,
1H), 4.34 (dd, J=10.76, 2.96 Hz, 1H), 7.01 (t, J=7.49 Hz, 1H), 7.10
(t, J=7.49 Hz, 1H), 7.20 (d, J=8.11 Hz, 1H), 7.29 (d, J=2.18 Hz,
1H), 7.38 (d, J=8.11 Hz, 1H), 7.50 (dd, J=8.11, 1.56 Hz, 1H), 7.62
(d, J=7.80 Hz, 1H), 7.65 (s, 1H), 7.70 (s, 1H), 8.18 (s, 2H), 8.33
(d, J=2.81 Hz, 1H), 8.55 (d, J=1.56 Hz, 1H), 11.02 (s, 1H), 11.81
(s, 1H); Anal. Calcd for C.sub.23H.sub.20N.sub.4O.su- b.3: C,
50.53; H, 3.44; N, 8.60. Found: C, 50.71; H, 3.46; N, 8.42.
EXAMPLE 436
1-Benzoimidazol-1-ylmethyl-2-[5-(3-methyl-1H-indazol-5-yl)-pyridin-3-yloxy-
]-ethylamine
Example 436A
3-Bromo-5-oxiranylmethoxy-pyridine
[0892] To a solution of 5-Bromo-pyridin-3-ol (0.50 g, 2.87 mmol),
oxiranyl-methanol (0.38 mL, 5.74 mmol) and triphenylphosphine (1.50
g, 5.74 mmol) in anhydrous THF (20 mL) was added di-tert-butyl
azodicarboxylate (DBAD) (1.32 g, 5.74 mmol) and the reaction
mixture stirred at room temperature for 18 hrs and concentrated.
The residue was purified by flash column chromatography on silica
gel eluting with 10%-35% ethyl acetate/hexanes to provide the
desire product (0.48 g, 73%).
Example 436B
1-Benzoimidazol-1-yl-3-(5-bromo-pyridin-3-yloxy)-propan-2-ol
[0893] A solution of Example 436A (500 mg, 2.17 mmol) and
1H-Benzoimidazole (28 mg, 2.39 mmol) in 2-propanol (10 mL) was
refluxed under N.sub.2 for 2 hrs. The reaction mixture was cooled,
diluted with ethyl acetate(50 mL) and washed with brine (2.times.25
mL). The residue was concentrated and purified by flash column
chromatography on silica gel eluting with 100% ethyl acetate to 5%
methanol/ethyl acetate to provide the desire product (1.08 mmol,
50%).
Example 436C
5-[5-(3-Benzoimidazol-1-yl-2-hydroxy-propoxy)-pyridin-3-yl]-3-methyl-indaz-
ole-1-carboxylic Acid Tert-Butyl Ester
[0894] The product was prepared by substituting Example 436B for
Example 202A in Example 203B.
Example 436D
1-Benzoimidazol-1-ylmethyl-2-[5-(3-methyl-1H-indazol-5-yl)-pyridin-3-yloxy-
]-ethylamine
[0895] The desired compound was prepared by as trifluoroacetic acid
salt by substituting Example 436C for Example 27B in Example 27C.
MS (APCI) m/z 400 (M+1).sup.+; .sup.1H NMR (400 MHz, CD.sub.3OD)
.delta. ppm 2.53 (m, 3H), 4.31 (dd, J=13.81, 4.91 Hz, 2H), 4.42 (m,
J=7.98, 3.38 Hz, 1H), 4.54 (m, 2H), 7.56 (m, 3H), 7.67 (dd, J=8.75,
1.07 Hz, 1H), 7.78 (dd, J=5.83, 3.38 Hz, 1H), 7.94 (dd, J=6.14,
3.07 Hz, 1H), 8.05 (s, 1H), 8.12 (s, 1H), 8.35 (s, 1H), 8.64 (s,
1H), 9.36 (s, 1H).
EXAMPLE 437
2-[5-(3-Methyl-1H-indazol-5-yl)-pyridin-3-yloxy]-1-morpholin-4-ylmethyl-et-
hylamine
Example 437A
1-(5-Bromo-pyridin-3-yloxy)-3-morpholin-4-yl-propan-2-ol
[0896] The desired compound was prepared by substituting morpholine
for 1H-Benzoimidazole in Example 437B
Example 437B
[2-(5-Bromo-pyridin-3-yloxy)-1-morpholin-4-ylmethyl-ethyl]-carbamic
Acid Tert-Butyl Ester
[0897] To a solution of the Example 437A (250 mg, 0.79 mmol),
isoindole-1,3-dione (121 mg, 0.82 mmol) and triphenylphosphine (240
mg, 0.92 mmol) in anhydrous THF (10 mL) was added DIAD (0.16 mL,
0.83 mmol) and stirred at room temperature for 45 mins. The
concentrated residue was then purified by flash column
chromatography eluting with 60% ethyl acetate/hexanes to give the
desired intermediate which was dissolved in absolute ethanol (10
mL). Hydrazine monohydrate (40 .mu.L) was added and the reaction
mixture refluxed for 3 hrs. The cloudy solution was cooled,
concentrated and dissolved in DMF (10 mL).
Di-tert-butyl-dicarbonate (271 mg, 1.25 mmol) and triethyl amine
(0.18 mL, 1.25 mmol) were added and the clear solution stirred at
room temperature for 15 hrs. The clear solution was diluted with
ethyl acetate (25 mL) and washed with brine (25 mL) and water (25
mL). The concentrated residue was further purified by flash column
chromatography eluting with 15% ethyl acetate/hexanes to give the
desired product.
Example 437C
5-[5-(2-tert-Butoxycarbonylamino-3-morpholin-4-yl-propoxy)-pyridin-3-yl]-3-
-methylindazole-1-carboxylic Acid Tert-Butyl Ester
[0898] The product was prepared by substituting Example 437B for
Example 202A in Example 203B.
Example 437D
2-[5-(3-Methyl-1H-indazol-5-yl)-pyridin-3-yloxy]-1-morpholin-4-ylmethyl-et-
hylamine
[0899] The desired compound was prepared as trifluoroacetic acid
salt by substituting Example 437C for Example 27B in Example 27C.
MS (APCI) m/z 369 (M+1).sup.+; .sup.1H NMR (400 MHz, CD.sub.3OD)
.delta. ppm 2.62 (s, 3H), 2.73 (dd, J=11.51, 4.76 Hz, 2H), 2.86 (m,
2H), 2.98 (m, 2H), 3.79 (t, J=4.45 Hz, 4H), 4.04 (m, J=8.59, 3.38
Hz, 1H), 4.47 (dd, J=10.43, 5.52 Hz, 1H), 4.59 (m, 1H), 7.64 (d,
J=8.59 Hz, 1H), 7.76 (dd, J=8.90, 1.23 Hz, 1H), 8.15 (s, 1H), 8.24
(s, 1H), 8.48 (s, 1H), 8.78 (s, 1H); Anal. Calcd for
C.sub.20H.sub.21N.sub.5O.sub.2: C, 44.01; H, 3.98; N, 9.87. Found:
C, 43.92; H, 3.92; N, 9.73.
EXAMPLE 438
5-[5-((2S)-2-Amino-3-phenyl-propoxy)-pyridin-3-yl]-1,3-dihydro-indol-2-one
[0900] The desired product was prepared by substituting
Boc-phenylalaminol for Boc-tryptophanol in Example 36. MS (APCI)
m/z 360 (M+1).sup.+; .sup.1H NMR (500 MHz, CD.sub.3OD) .delta. ppm
3.15 (d, J=7.49 Hz, 2H), 3.61 (s, 2H), 3.95 (m, 1H), 4.26 (dd,
J=10.61, 5.62 Hz, 1H), 4.40 (dd, J=10.61, 3.12 Hz, 1H), 7.04 (d,
J=8.11 Hz, 1H), 7.33 (m, 5H), 7.58 (d, J=8.11 Hz, 1H), 7.62 (s,
1H), 7.96 (s, 1H), 8.38 (d, J=2.50 Hz, 1H), 8.60 (s, 1H); Anal.
Calcd for C.sub.22H.sub.21N.sub.3O.sub.2: C, 51.39; H, 3.78; N,
6.76. Found: C, 51.48; H, 3.63; N, 6.75.
EXAMPLE 439
5-[5-((2S)-2-Amino-3-phenyl-propoxy)-pyridin-3-yl]-3-(1H-pyrrol-2-ylmethyl-
ene)-1,3-dihydro-indol-2-one
[0901] The desired product was prepared by substituting
Boc-phenylalaminol for Boc-tryptophanol in Example 39. MS (APCI)
m/z 437 (M+1).sup.+; .sup.1H NMR (500 MHz, CD.sub.3OD) .delta. ppm
3.17 (d, J=7.80 Hz, 2H), 3.97 (m, 1H), 4.28 (dd, J=10.61, 5.62 Hz,
1H), 4.43 (dd, J=110.45, 2.96 Hz, 1H), 6.38 (m, 1H), 6.85 (d,
J=3.74 Hz, 1H), 7.06 (d, J=8.11 Hz, 1H), 7.25 (s, 1H), 7.34 (m,
5H), 7.51 (dd, J=8.11, 1.87 Hz, 1H), 7.73 (s, 1H), 7.94 (s, 1H),
8.03 (s, 1H), 8.38 (d, J=1.87 Hz, 1H), 8.67 (s, 1H), 13.32 (s, 1H);
Anal. Calcd for C.sub.27H.sub.24N.sub.4O.sub.2: C, 53.27; H, 3.70;
N, 7.76. Found: C, 53.46; H, 3.69; N, 7.77.
EXAMPLE 440
5-[5-((2S)-2-Amino-3-phenyl-propoxy)-pyridin-3-yl]-3-furan-2-ylmethylene-1-
,3-dihydro-indol-2-one
[0902] The desired product was prepared by substituting
Boc-phenylalaminol for Boc-tryptophanol in Example 412. MS (APCI)
m/z 438 (M+1).sup.+; .sup.1H NMR (500 MHz, CD.sub.3OD) .delta. ppm
3.85 (m, 4H), 4.75 (m, 2H), 4.93 (m, 2H), 5.10 (dd, J=10.61, 3.12
Hz, 2H), 7.64 (dd, J=3.43, 1.56 Hz, 1H), 7.77 (d, J=8.11 Hz, 1H),
7.82 (d, J=8.11 Hz, 1H), 8.08 (m, 2H), 8.14 (m, 8H), 8.22 (s, 1H),
8.39 (d, J=1.87 Hz, 1H), 8.42 (dd, J=8.11, 1.87 Hz, 1H), 8.45 (s,
1H), 8.53 (s, 1H), 8.68 (s, 1H), 8.80 (d, J=1.56 Hz, 1H), 8.90 (d,
J=1.87 Hz, 1H), 9.00 (d, J=1.56 Hz, 1H), 9.07 (s, 2H), 9.11 (d,
J=3.43 Hz, 1H), 9.16 (br s, 2H), 9.44 (d, J=1.56 Hz, 1H), 11.54 (s,
1H), 11.57 (s, 1H); Anal. Calcd for C.sub.27H.sub.23N.sub.3O.sub.3:
C, 55.36; H, 3.74; N, 6.21. Found: C, 55.09; H, 3.74; N, 6.07.
EXAMPLE 441
(1S)-1-Benzoimidazol-1-ylmethyl-2-[5-(3-methyl-1H-indazol-5-yl)-pyridin-3--
yloxy]-ethylamine
Example 441A
(2R)-1-Benzoimidazol-1-yl-3-benzyloxy-propan-2-ol
[0903] A solution of 2-(3-phenyl-propyl)-oxirane (3.0 g, 18.27
mmol) and benzimidazole (2.37 g, 20.1 mmol) in anhydrous 2-propanol
(50 mL) was purged with nitrogen and refluxed for 2.5 hrs. The
reaction mixture was cooled, concentrated and purified by flash
column chromatography on silica gel [0(1 min)-15% (16 min) methanol
in 2:1 ethyl acetate/hexanes to provide the desired product (4.72
g, 91%).
Example 441B
(2S)-1-(2-Azido-3-benzyloxy-propyl)-1H-benzoimidazole
[0904] To a solution of Example 441A (1.0 g, 3.54 mmol) and
triphenylphosphine (1.39 g, 5.31 mmol) in anhydrous THF (30 mL) was
added diphenylphosphoryl azide (1.14 mL, 5.31 mmol) at 0.degree. C.
followed by the addition of DEAD (836 .mu.L). The reaction mixture
was stirred at 0.degree. C. for 30 mins and at room temperature for
15 hrs. The concentrated residue was then purified by flash column
chromatography on silica gel eluting with 60%-80% ethyl
acetate/hexanes to provide the desired product.
EXAMPLE 441C
(2-Benzoimidazol-1-yl-1-benzyloxymethyl-ethyl)-carbamic Acid
Tert-Butyl Ester
[0905] To a solution of the Example 441B (.about.1 g, .about.3.54
mmol) in ethanol (25 mL) was added 10% Pd/C (230 mg) under
nitrogen. This suspension was purged with hydrogen and was stirred
under hydrogen (balloon) for 1 h. The solid material was filtered
off and the filtrate was concentrated. The residual foam was
dissolved in anhydrous DMF (20 mL). Triethylamine (1.08 mL, 7.78
mmol) and di-tert-butyl dicarbonate (0.85 g, 3.89 mmol) were then
added at room temperature and the solution stirred under nitrogen
for 2 h. EtOAc (200 mL) was added and the mixture was washed with
brine (200 mL), and water (100 mL). The organic phase was
concentrated and the residue was purified by flash chromatography
[60-80%(5 min) EtOAc in hexane] to give desired product.
EXAMPLE 441D
(1S)-(2-Benzoimidazol-1-yl-1-hydroxymethyl-ethyl)-carbamic Acid
Tert-Butyl Ester
[0906] To a solution of the Example (0.78 g) in methanol (20 mL)
was added 10% Pd-C (450 mg) under nitrogen. This reaction mixture
was purged with hydrogen and was stirred under hydrogen at
86.degree. C. for 3.5 days (balloon). The filtrate was concentrated
and the residual oil was separated by flash chromatography (0-15%
CH.sub.3OH in 2:1 EtOAc/hexane) to give the desired product (199.7
mg, 33%). 98
Example 441E
(1S)-[1-Benzoimidazol-1-ylmethyl-2-(5-bromo-pyridin-3-yloxy)-ethyl]-carbam-
ic Acid Tert-Butyl Ester
[0907] To a solution of 5-bromo-pyridin-3-ol (102 mg, 0.58 mmol),
Example 441D (154 mg, 0.53 mmol) and triphenylphosphine (208 mg,
0.793 mmol) in anhydrous THF (20 mL) was added DEAD (125 .mu.L,
0.79 mmol) and the reaction mixture stirred at room temperature for
2 hrs and concentrated. The residue was purified by flash column
chromatography on silica gel (0-15% CH.sub.3OH in 2:1 EtOAc/hexane)
to give the desired product (100 mg, 43%).
Example 441F
5-[5-(3-Benzoimidazol-1-yl-2-tert-butoxycarbonylamino-propoxy)-pyridin-3-y-
l]-3-methylindazole-1-carboxylic Acid Tert-Butyl Ester
[0908] The product was prepared by substituting Example 447E for
Example 202A in Example 203B.
Example 441G
(1S)-1-Benzoimidazol-1-ylmethyl-2-[5-(3-methyl-1H-indazol-5-yl)-pyridin-3--
yloxy]-ethylamine
[0909] The desired compound was prepared by as trifluoroacetic acid
salt by substituting Example 441F for Example 27B in Example 27C.
.sup.1H NMR (300 MHz, CD.sub.3OD) .delta. ppm 2.63 (m, 3H), 4.53
(m, 2H), 4.65 (m, 1H), 5.09 (d, J=6.78 Hz, 2H), 7.66 (m, 2H), 7.74
(d, J=1.70 Hz, 1H), 7.77 (d, J=1.70 Hz, 1H), 7.90 (m, 1H), 8.02 (m,
1H), 8.12 (m, 1H), 8.15 (d, J=2.37 Hz, 1H), 8.46 (d, J=2.71 Hz,
1H), 8.77 (d, J=1.70 Hz, 1H), 9.40 (s, 1H); Anal. Calcd for
C.sub.23H.sub.22N.sub.6O: C, 42.16; H, 2.93; N, 9.22. Found: C,
42.08; H, 3.24; N, 9.13.
EXAMPLE 442
3-{3-[(2S)-2-Amino-3-(1H-indol-3-yl)-propoxy]-5-isoquinolin-6-yl-pyridin-4-
-yl}-acrylonitrile
Example 442A
3-Chloro-5-(4-methoxy-benzyloxy)-pyridine
[0910] To a solution of 3-chloro-5-hydroxypyridine (2.0 g, 17.0
mmol), 4-methoxybenzyl alcohol (2.85 g, 25.5 mmol) and
triphenylphosphine (6.68 g, 25.5 mmol) in dry THF (100 ml) DEAD
(4.44 g, 25.5 mmol) was added dropwise. The resulting solution was
stirred 3 hours at room temperature. The reaction solution was
partitioned between ethyl acetate and water. The organic layer was
washed (brine), dried (Na.sub.2SO.sub.4), filtered and concentrated
under vacumm. Purification on silica gel with 20% ethyl
acetate/hexane to provide the title compound (1.9 g, 53%). MS
(DCI/NH.sub.3) m/e 250 (M+1).sup.+.
Example 442B
3-Chloro-5-(4-methoxy-benzyloxy)-pyridine-4-carbaldehyde
[0911] A solution of DIPA (1.73 g, 17.16 mmol) in THF (100 ml) was
treated dropwise with n-BuLi (6.86 ml, 17.16 mmol) at 0.degree. C.,
stirred for 30 min. at 0.degree. C. To the reaction Example 442A
(3.56 g, 14.3 mmol) in THF (10 ml) was added dropwise at
-78.degree. C. The resulting solution was stirred 1 hours at
-78.degree. C. The mixture was quenched with methyl formate (2.0
ml). The reaction solution was partitioned between ethylacetate and
water. The organic layer was washed (brine), dried
(Na.sub.2SO.sub.4), filtered and concentrated under vacumm.
Purification on silica gel with 20% ethyl acetate/hexane to provide
the title compound (2.2 g, 56%). MS (DCI/NH.sub.3) m/e 278
(M+1).sup.+.
Example 442C
3-[3-Chloro-5-(4-methoxy-benzyloxy)-pyridin-4-yl]-acrylonitrile
[0912] A solution of diethylmethylcyanophosponate (212 mg, 1.2
mmol) in THF (4 ml) was treated dropwise with LiHMDS (1.2 ml, 1.2
mmol) at 0.degree. C., stirred for 30 min. at 0.degree. C. treated
with Example 442B (277 mg, 1 mmol) in THF (1 ml). The resulting
solution was stirred 1 hours. The mixture was quenched with water.
The reaction solution was partitioned between ethylacetate and
water. The organic layer was washed (brine), dried
(Na.sub.2SO.sub.4), filtered and concentrated under vacumm.
Purification on silica gel with 20% ethyl acetate/hexane to provide
the title compound (210 mg, 70%). MS (DCI/NH.sub.3) m/e 301
(M+1).sup.+.
Example 442D
3-(3-Chloro-5-hydroxy-pyridin-4-yl)-acrylonitrile
[0913] To a solution of Example 442C (1.02 g, 3.4 mmol) in
dichloromethane (10 ml) THA (1 ml) was added. The resulting
solution was stirred for two hours. The reaction solution was
partitioned between ethylacetate and water. The organic layer was
washed (brine), dried (Na.sub.2SO.sub.4), filtered and concentrated
under vacumm. Purification on silica gel with 40% ethyl
acetate/hexane to provide the title compound (600 mg, 98%). MS
(DCI/NH.sub.3) m/e 181 (M+1).sup.+. 99
Example 442E
(1S)-[2-[5-Chloro-4-(2-cyano-vinyl)-pyridin-3-yloxy]-1-(1H-indol-3-ylmethy-
l)-ethyl]-carbamic Acid Tert-Butyl Ester
[0914] To a solution of Example 442D (430 mg, 2.39 mmol),
N-alpha-(tert-butoxycarbonyl)-L-tryptophanol (762 mg, 2.6 mmol) and
triphenylphosphine (1.38 g, 5.26 mmol) in dry THF (40 ml) DBAD (880
mg, 3.82 mmol) was added. The resulting solution was stirred 3
hours at room temperature. The reaction solution was partitioned
between ethylacetate and water. The organic layer was washed
(brine), dried (Na.sub.2SO.sub.4), filtered and concentrated under
vacumm. Purification on silica gel with 20% ethyl acetate/hexane to
provide the title compound (340 g, 32%). MS (DCI/NH.sub.3) m/e 453
(M+1).sup.+. 100
Example 442F
(1S)-[2-[4-(2-Cyano-vinyl)-5-isoquinolin-6-yl-pyridin-3-yloxy]-1-(1H-indol-
-3-ylmethyl)-ethyl]-carbamic Acid Tert-Butyl Ester
[0915] To a solution of Example 442E (330 mg, 0.73 mmol),
6-(1,1,1-trimethylstannyl)-isoquinoline(276 mg, 0.95 mmol),
tris(dibenzylideneacetone)-dipalladium (66.8 mg, 0.073 mmol) and
2-dicyclohexylphosphino-2'-dimethylamino-1,1'-biphenyl (57.3 mg,
0.146 mmol) in dry DMF (10 ml) triethyl amine was added under
N.sub.2. The resulting solution was stirred 3 hours at 100.degree.
C. The reaction solution was partitioned between ethylacetate and
water. The organic layer was washed (brine), dried
(Na.sub.2SO.sub.4), filtered and concentrated under vacumm.
Purification on silica gel with 60% ethyl acetate/hexane to provide
the title compound (61 mg, 17%).MS (DCI/NH.sub.3) m/e 546
(M+1).sup.+.
Example 442G
3-{3-[(2S)-2-Amino-3-(1H-indol-3-yl)-propoxy]-5-isoquinolin-6-yl-pyridin-4-
-yl}-acrylonitrile
[0916] MS (DCI/NH.sub.3) m/e 446 (M+1).sup.+; .sup.1H NMR (300 MHz,
D6-DMSO) .delta. 11.06 (s; 1H), 9.68 (s; 1H), 8.68 (d; 1H; J=6.0
Hz), 8.58 (s; 1H), 8.44 (d; 1H; J=8.4 Hz), 8.40 (s; 1H), 8.23 (d;
1H; J=6.0 Hz), 8.20 (s; 3H), 7.80 (d; 1H; J=8.4 Hz), 7.60 (d; 1H;
J=8.4 Hz), 7.44 (d; 1H; J=17.1 Hz), 7.40 (d; 1H; J=8.4 Hz), 7.30
(s; 1H), 7.11 (t; 1H; J=8.4 Hz), 7.01 (t; 1H; J=8.4 Hz), 6.24 (d;
1H; J=17.1 Hz), 4.48 (m; 1H), 4.31 (m; 1H), 3.97 (m; 1H), 3.17 (m;
2H)
EXAMPLE 443
(1S)-1-(1H-Indol-3-ylmethyl)-2-(5-isoquinolin-6-yl-4-methyl-pyridin-3-ylox-
y)-ethylamine
[0917] The desire product was prepared by substituting methyl
iodide for ethyl acetate in Example 442, omitting the step of
Example 442C. MS (DCI/NH.sub.3) m/e 409 (M+1).sup.+; .sup.1H NMR
(300 MHz, D6-DMSO) .delta. 11.06 (s; 1H), 9.72 (s; 1H), 8.68 (d;
1H; J=6.0 Hz), 8.47 (d; 1H; J=8.4 Hz), 8.37 (s; 1H), 8.32 (s; 1H),
8.22 (m; 4H), 7.91 (d; 1H; J=8.4 Hz), 7.61 (d; 1H; J=8.4 Hz), 7.40
(d; 1H; J=8.4 Hz), 7.30 (s; 1H), 7.12 (t; 1H; J=8.4 Hz), 7.02 (t;
1H; J=8.4 Hz), 4.37 (m; 1H), 4.22 (m; 1H), 3.89 (m; 1H), 3.20 (m;
2H), 2.29 (s; 3H).
EXAMPLE 444
5-{5-[(2S)-2-Amino-3-(1H-indol-3-yl)-propoxy]-pyridin-3-yl}-3-methyl-1,3-d-
ihydro-indol-2-one
Example 444A
3-Methyl-1,3-dihydro-indol-2-one
[0918] A solution of oxindole (665 mg, 5.0 mmol) in THF (10 ml) was
treated dropwise with n-BuLi (4.4 ml, 11.0 mmol) at -78.degree. C.,
stirred for 30 min. at -78.degree. C. To the reaction methyliodine
(2 ml) was added dropwise at -78.degree. C. The resulting solution
was warmed up to room temperature. The mixture was quenched with
water. The reaction solution was partitioned between ethylacetate
and water. The organic layer was washed (brine), dried
(Na.sub.2SO.sub.4), filtered and concentrated under vacumm.
Purification on silica gel with 30% ethyl acetate/hexane to provide
the title compound (630 mg, 86%). MS (DCI/NH.sub.3) m/e 148
(M+1).sup.+.
Example 444B
5-Bromo-3-methyl-1,3-dihydro-indol-2-one
[0919] To a solution of Example 444B (625 mg, 4.25 mmol) in
acetonitrile (10 ml) NBS (757 mg, 4.25 mmol) was added at
-10.degree. C. The mixture was stirred at -10.degree. C. for 1
hours and 0.degree. C. for 2 hours. The reaction solution was
partitioned between ethylacetate and water. The organic layer was
washed (brine), dried (Na.sub.2SO.sub.4), filtered and concentrated
under vacumm. Purification on silica gel with 30% ethyl
acetate/hexane to provide the title compound (640 mg, 66%). MS
(DCI/NH.sub.3) m/e 227 (M+1).sup.+.
Example 444C
5-{5-[(2S)-2-Amino-3-(1H-indol-3-yl)-propoxy]-pyridin-3-yl}-3-methyl-1,3-d-
ihydro-indol-2-one
[0920] The desired product was prepared by substituting Example 44B
for 6-bromophthalimide in Example 32. .sup.1H NMR (300 MHz,
D6-DMSO) .delta. 11.04 (s; 1H), 10.49 (s; 1H), 8.53 (s; 1H), 8.30
(s; 1H), 8.16 (s; 2H), 7.64 (s; 1H), 7.62 (d; 1H; J=7.5 Hz), 7.53
(d; 1H; J=7.5 Hz), 7.38 (d; 1H; J=8.7 Hz), 7.30 (s; 1H), 7.10 (t;
1H; J=8.7 Hz), 7.01 (t; 1H; J=8.7 Hz), 6.93 (d; 1H; J=8.7 Hz), 4.33
(m; 1H), 4.14 (m; 1H), 3.84 (m; 1H), 3.49 (q; 1H; J=7.5), 3.14 (m;
2H), 1.39 (d; 3H; J=7.5 Hz); MS (DCI/NH.sub.3) m/e 413
(M+1).sup.+.
EXAMPLE 445
5-{5-[(2S)-2-Amino-3-(1H-indol-3-yl)-propoxy]-pyridin-3-yl}-3,3-dimethyl-1-
,3-dihydro-indol-2-one
Example 445A
3,3-Dimethyl-1,3-dihydro-indol-2-one
[0921] A solution of Example 444A (500 mg, 3.4 mmol) in THF (10 ml)
was treated dropwise with n-BuLi (2.7 ml, 6.8 mmol) at -78.degree.
C., stirred for 30 min. at -78.degree. C. To the reaction
methyliodine (2 ml) was added dropwise at -78.degree. C. The
resulting solution was warmed up to room temperature. The mixture
was quenched with water. The reaction solution was partitioned
between ethylacetate and water. The organic layer was washed
(brine), dried (Na.sub.2SO.sub.4), filtered and concentrated under
vacumm. Purification on silica gel with 30% ethyl acetate/hexane to
provide the title compound (410 mg, 75%). MS (DCI/NH.sub.3) m/e 162
(M+).sup.+.
Example 445B
5-{5-[(2S)-2-Amino-3-(1H-indol-3-yl)-propoxy]-pyridin-3-yl}-3,3-dimethyl-1-
,3-dihydro-indol-2-one
[0922] The title compound was prepared by substituting Example 445A
for Example 444A in Example 444. .sup.1H NMR (300 MHz, D6-DMSO)
.delta. 11.03 (s; 1H), 10.49 (s; 1H), 8.56 (s; 1H), 8.31 (s; 1H),
8.18 (s; 2H), 7.70 (s; 1H), 7.64 (s; 1H), 7.61 (d; 1H; J=7.5 Hz),
7.57 (d; 1H; J=7.5 Hz), 7.38 (d; 1H; J=8.7 Hz), 7.27 (s; 1H), 7.10
(t; 1H; J=8.7 Hz), 7.01 (t; 1H; J=8.7 Hz), 6.96 (d; 1H; J=8.7 Hz),
4.33 (m; 1H), 4.17 (m; 1H), 3.84 (m; 1H), 3.17 (m; 2H), 1.31 (s;
6H); MS (DCI/NH.sub.3) m/e 427 (M+1).sup.+.
EXAMPLE 446
5-{5-[(2S)-2-Amino-3-(1H-indol-3-yl)-propoxy]-pyridin-3-yl}-1,3,3-trimethy-
l-1,3-dihydro-indol-2-one
Example 446A
1,3,3-Trimethyl-1,3-dihydro-indol-2-one
[0923] The title compound was prepared by substituting Example 445A
for Example 102A in Example 112. MS (DCI/NH.sub.3) m/e 176
(M+1).sup.+.
Example 446B
5-{5-[(2S)-2-Amino-3-(1H-indol-3-yl)-propoxy]-pyridin-3-yl}-1,3,3-trimethy-
l-1,3-dihydro-indol-2-one
[0924] The title compound was prepared by substituting Example 446A
for Example 444A in Example 444. .sup.1H NMR (300 MHz, D6-DMSO)
.delta. 11.03 (s; 1H), 8.60 (s; 1H), 8.32 (s; 1H), 8.20 (s; 2H),
7.78 (s; 1H), 7.67 (d; 1H; J=7.5 Hz), 7.62 (d; 1H; J=7.5 Hz), 7.39
(d; 1H; J=8.7 Hz), 7.29 (s; 1H), 7.14 (d; 1H; J=8.7 Hz), 7.10 (t;
1H; J=8.7 Hz), 7.01 (t; 1H; J=8.7 Hz), 4.35 (m; 1H), 4.28 (m; 1H),
3.83 (m; 1H), 3.19 (s; 3H), 3.17 (m; 2H), 1.33 (s; 6H); MS
(DCI/NH.sub.3) m/e 441 (M+1).sup.+.
EXAMPLE 447
5-{5-[(2S)-2-Amino-3-(1H-indol-3-yl)-propoxy]-pyridin-3-yl}-3-ethyl-1,3-di-
hydro-indol-2-one
[0925] The title compound was prepared by substituting iodoethane
for iodomethane in Example 444. .sup.1H NMR (300 MHz, D6-DMSO)
.delta. 11.04 (s; 1H), 10.51 (s; 1H), 8.53 (s; 1H), 8.30 (s; 1H),
8.16 (s; 2H), 7.64 (s; 1H), 7.62 (d; 1H; J=7.5 Hz), 7.53 (d; 1H;
J=7.5 Hz), 7.38 (d; 1H; J=8.7 Hz), 7.28 (s; 1H), 7.10 (t; 1H; J=8.7
Hz), 7.01 (t; 1H; J=8.7 Hz), 6.93 (d; 1H; J=8.7 Hz), 4.33 (m; 1H),
4.16 (m; 1H), 3.84 (m; 1H), 3.49 (t; 1H; J=7.5), 3.14 (m; 2H), 1.85
(m; 2H), 1.09 (d; 3H; J=7.5 Hz); MS (DCI/NH.sub.3) m/e 427
(M+1).sup.+.
EXAMPLE 448
5-{5-[(2S)-2-Amino-3-(1H-indol-3-yl)-propoxy]-pyridin-3-yl}-3-benzyl-1,3-d-
ihydro-indol-2-one
[0926] The title compound was prepared by substituting benzyl
chloride for iodomethane in Example 444. .sup.1H NMR (300 MHz,
D6-DMSO) .delta. 11.04 (s; 1H), 10.48 (s; 1H), 8.38 (s; 1H), 8.27
(s; 1H), 8.15 (s; 2H), 7.62 (d; 1H; J=7.5 Hz), 7.44 (d; 1H; J=7.5
Hz), 7.40 (s; 1H), 7.39 (d; 1H; J=8.7 Hz), 7.29 (s; 1H), 7.17 (m;
5H), 7.10 (t; 1H; J=8.7 Hz), 7.01 (t; 1H; J=8.7 Hz), 6.82 (d; 1H;
J=8.7 Hz), 4.30 (m; 1H), 4.12 (m; 1H), 3.86 (m; 1H), 3.40 (m; 1H),
3.17 (m; 2H), 3.01 (m; 1H); MS (DCI/NH.sub.3) m/e 489
(M+1).sup.+.
[0927] It will be evident to one skilled in the art that the
present invention is not limited to the foregoing illustrative
examples, and that it can be embodied in other specific forms
without departing from the essential attributes thereof. It is
therefore desired that the examples be considered in all respects
as illustrative and not restrictive, reference being made to the
appended claims, rather than to the foregoing examples, and all
changes which come within the meaning and range of equivalency of
the claims are therefore intended to be embraced therein.
* * * * *